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OMGE   Organisation Mondiale de Gastroenterologie 
OONO   Peroxynitrite 
PAB   Pancreatic Autoantibodies 
PAF   Platelet Activating Factor 
P-ANCA  Perinuclear Antineutrophil Cytoplasmic Antibodies 
PCA   Principle Component Analysis 
PCDAI   Perianal Crohn’s Disease Activity Index 
PE   Push Endoscopy 
PEG   Polyethylene Glycol 
PGA   Physician Global Assessment 
PGE2   Prostaglandin E2 
PHA   Phytohemagglutinin  
PID   Primary Immunodeficiency 
piRNA   Piwi-Interacting Ribonucleic Acid 
PLS-DA   Partial Least Squares Discriminant Analysis 
PMN-E   Polymorphonuclear Neutrophil Elastase  
PPARγ   Perioisome Proliferator-activated Receptor gamma 
PR-3   Proteinase 3 
PRR   Pattern Recognition Receptor 
PUFA   Polyunsaturated Fatty Acid 
RCT   Randomised Controlled Trial 
RF   Radio Frequency 
RNA   Ribonucleic Acid 
RR   Relative Risk 
RSD   Relative Standard Deviation 
SAA   Serum Amyloid A 
SCCAI   Simple Clinical Colitis Activity Index 
SCFA   Short Chain Fatty Acids 
SE   Spiral Enteroscopy 
SELDI   Surface-enhanced Desorption / Ionisation 
SES-CD   Simplified Endoscopic Activity Score for Crohn’s Disease  
SMRS    Standard Metabolic Reporting Structure 
SNP   Single Nucleotide Polymorphism 
SRB   Sulphate Reducing Bacteria 
STAT   Signal Transducer and Activation of Transcription 
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sTNFRII  Solid Tumour Necrosis Factor II 
TGFβ   Transforming Growth Factor Beta  
TGN   Thioguanine Nucleotide 
TLR   Toll-Like Receptor  
TMS   Trimethylsilyl 
TNF-α   Tumour Necrosis Factor Alpha 
ToF   Time of Flight 
TPMT   Thiopurine S-methyltransferase 
TSS   Transcription Start Site 
UC   Ulcerative Colitis 
UCCS   Ulcerative Colitis Clinical Score 
UCDAI   Ulcerative Colitis Disease Activity Index 
UHPLC   Ultra High Performance Liquid Chromatography 
UK   United Kingdom 
USA   United States of America 
VCAM   Vascular Cell Adhesion Molecule 
VEGF   Vascular Epithelial Growth Factor 
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Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder that encompasses two major 
subtypes; Crohn’s Disease (CD) and Ulcerative Colitis (UC). Our knowledge regarding disease 
pathogesis is rapidly increasing. However, these disease entities provide challenges in diagnosis, 
monitoring of disease activity and assessing individual response to treatment, because there is a lack 
of validated clinical biomarkers.  
Metabolomics involves the study of numerous analytes that have very diverse physical and chemical 
properties and occur in a wide concentration range. Early evidence suggests there is potential for 
metabolomic profiling to be used in the differentiation of CD and UC. However, knowledge is limited 




A metabolomics approach was taken to determine whether metabolomic profiles could distinguish 
between patients with CD or UC and healthy controls. We also aimed to define the relationship 
between metabolomic profile and disease activity, and to determine the effect of medical (anti-TNFα 
agents) and surgical treatment on the metabolome. 
 
Methods 
A metabolomics approach was undertaken. Serum and uri e sample sets were collected from a total of 
41 patients with ulcerative colitis, 43 patients with Crohn’s disease, and 62 healthy controls (HC). In 
order to allow a comparison of metablomic profile and disease activity, 4 sample sets were taken from 
the same patient at 3 monthly intervals over the period of one year. Those patients undergoing either 
surgical or biological treatment had sample sets taken pre and post intervention. Metabolomic analysis 
using gas chromatography time of flight mass spectrometry (GC-ToF-MS) and ultra-high performance 
liquid chromatography Fourier Transform mass spectrometry (UHPLC-FTMS) was carried out on 
both serum and urine. 
 
Results 
Serum and urine GC-ToF-MS and UHPLC-FTMS metabolomic analyses show differentiation 
between UC, CD and healthy controls, most significantly in urine analyses.  No significant 
differentiation was seen in pre- and post-surgical patients, or pre- and post-biological therapy patients.  
It was possible to differentiate surgical patients from healthy controls, especially in the urine analyses. 
Metabolite identification revealed consistently more dietary variation in the healthy controls than in 
the IBD patients. Significant differences (p<0.05) were seen between healthy controls and IBD 
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patients in classes of metabolites relating to the citric acid cycle and the uronic acid pathway, as well 
as amino acids, fatty acids and cholesterols. 
The behaviour or location of disease, or the disease activity score did not appear to influence the 
metabolome in either serum or urine analyses using GC-ToF-MS and UHPLC-FTMS.  
 
Conclusion 
Metabolomic profiling of urine and serum in IBD may provide a novel methodology aiding both 







Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the bowel. There are 
two main subtypes, Crohn’s disease (CD), and ulcerativ  colitis (UC). CD can affect any part of the 
digestive tract, from the mouth to the anus. UC affects the large bowel only. The reason that people 
get these diseases remains unclear, but the trigger s likely to be combination of factors. These are 
related to the genes a person has, the way in which t eir immune system fights infections, and the 
bacteria they carry in their bowel. These diseases ar  chronic, but tend to have periods of active 
inflammation in the bowel, and periods where the inflammation settles. IBD treatment essentially 
involves medication to reduce the inflammation in the bowel through suppression of the immune 
system. Surgical treatment is required if the bowel inflammation is very severe, is not responding to 
medical treatment, or is complicated by a perforatin or impending perforation of the bowel. 
CD and UC can be challenging to diagnose and differentiate. This usually requires an examination of 
the bowel using a flexible telescope, where small tissue samples are taken and examined carefully 
under a microscope. Even then the diagnosis can be u cl ar. This is an invasive test that is not without 
risk. Currently there are no less invasive tests that allow accurate diagnosis. 
The monitoring of response to treatment is also a difficult field, and the only proven method is again, 
a telescope examination of the bowel. It is simply not practical to subject patients to this recurrently 
and therefore the search for a simple test, or biomarker, such as a blood or urine test that could be used 
to aid the diagnosis or monitoring of a patients’ response to treatment, or the activity of their disease is 
necessary.  
Metabolomics is the measurement of all of the metabolites in a substance. Metabolites are the 
breakdown products produced during daily bodily activities. These are measured using mass 
spectroscopy. By measuring these we gain knowledge of biological reactions taking place within the 
body. These findings can be compared to healthy people, r patients can be compared to themselves in 
order to better understand the biological process occurring in different phases of disease.  
The aim of this study was to determine whether it is possible to differentiate between CD and UC 
patients, and healthy controls using metabolites measured in blood and urine samples. We also aimed 
to determine whether different medical and surgical treatments changed the metabolites we identified 
in IBD patients.  
We were able to differentiate between CD, UC and healt y controls by measuring metabolites in 
blood and urine. Urine appears to be better at differentiating than serum. We did not find metabolites 
that differentiated between the activity of the disea e, or where in the bowel it was affecting. It was 
possible to differentiate between IBD patients requiring surgery and healthy controls. 
This metabolomics study has allowed us to gain insight  into the biological pathways affected by IBD, 
and also differentiate between the subtypes. It maybe possible to develop biomarkers in the future to 










Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder that encompasses two major 
subtypes; Crohn’s Disease (CD) and Ulcerative Colitis (UC). In the UK, UC affects 146 000 people, 
the peak incidence of onset being between the ages of 15 and 25 years, with a second smaller peak 
between 55 and 65 years of age (National Clinical Guideline Centre (UK) 2013). Crohn’s Disease 
affects 115 000 people in the UK, with up to a third being diagnosed before the age of 21 years 
(National Clinical Guideline Centre (UK) 2012). 
Inflammatory bowel disease has been recognised since the 18th century, when in 1761 Morgagni 
described intestinal inflammation that we would now classify as Crohn’s Disease (Kirsner 2001). 
Despite multiple publications by Wilks (1859), Fenwick (1889) and Dalziel (1913) regarding 
inflammation of the gut in the meantime, it wasn’t until 1932 that Crohn, Ginzberg and Oppenheimer 
published the landmark paper describing terminal ileitis (Crohn, Ginzberg et al. 1932). In 1960, 
Lockart-Mummary and Morson described granulomatous colitis and it was understood that the 
condition now known as Crohn’s Disease could affect the large as well as the small intestine. 
Wilks is credited with the first pathological description of ulcerative colitis in a case report published 
in1859 (Wilks 1859). He and Moxon went on to furthe distinguish UC from infectious colitis in 1875 
(Wilks, Moxon 1875).  
 
1.1 Epidemiology of IBD 
In North America, incidence rates for IBD range from 2.3 (Stowe, Redmond et al. 1990) to 15.6 
(Blanchard, Bernstein et al. 2001) cases per 100 000 person-years for UC and from 3.6 (Kurata, 
Kantor-Fish et al. 1992) to 15.6 (Blanchard, Bernstein et al. 2001) per 100 000 person-years for CD. 
The prevalence is thought to range from 37.5 (Pinchbe k, Kirdeikis et al. 1988) to 246 (Loftus, Loftus 
et al. 2003) cases per 100 000 persons for UC and from 26 (Kurata, Kantor-Fish et al. 1992) to 198.5 
(Bernstein, Blanchard et al. 1999) cases per 100 000 persons for CD. It is caluclated that between 
7000 and 46 000 persons are newly diagnosed with UC per year, and 10 000 to 47 000 with CD per 
year (Loftus Jr 2004). 
Sonnenberg et al (Sonnenberg, McCarty et al. 1991) studied the geographical distribution of IBD in 
the USA by analysing 17.5 million hospital discharges of all US Medicare beneficiaries over a 2 year 
period. They found that both UC and CD were more frequent in the northern states than the southern 
states, and in urban areas as compared to rural parts. Pinchbeck et al (Pinchbeck, Kirdeikis et al. 1988) 
also showed that urban areas had a higher prevalence of IBD than rural areas. 
In Europe, the incidence rate of UC ranges from 1.5 (Vucelic, Korac et al. 1991b) to 20.3 (Roin, Roin 
1989) cases per 100 000 person-years and from 0.7 (Vucelic, Korac et al. 1991a) to 9.8 (Kyle 1992) 
cases per 100 000 person-years for CD. The prevalence of UC in Europe has been reported as ranging 
from 21.4 (Vucelic, Korac et al. 1991b) to 243 (Rubin, Hungin et al. 2000) cases per 100 000 persons, 
and as 8.3 (Vucelic, Korac et al. 1991a) to 214 (Montg mery, Morris et al. 1998) cases per 100 000 
persons in CD. 
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A recent European multicentre population based inception cohort of IBD patients has shown the 
median crude incidence rate per 100 000 in 2010 for CD to be 6.5 (range 0 – 10.7) in Western Europe 
and and 3.1 (range 0.4 – 11.5) in Eastern Europe, and for UC to be 10.8 (range 2.9 – 31.5) in Western 
Europe and 4.1 (range 2.4 – 10.3) in Eastern Europe (Burisch, Pedersen et al. 2014). The European 
collaborative study on inflammatory bowel disease reported on the apparent North-South divide in the 
distribution of IBD cases. They found that the highest rates of IBD come from the Scandinavian 
countries and the lowest from Mediterranean countries, that rates of UC in Northern centres were 40% 
higher than those in the South, and in CD rates in the North were 80% higher than those in the South 
(Shivananda, Lennard-Jones et al. 1996). 
Currently it is estimated that the prevalence of IBD in the UK (United Kingdom) is approximately 400 
per 100 000 people (Stone, Mayberry et al. 2003). Within Scotland itself the incidence of paediatric 
IBD is rising, with a statistically significant increase of 76% since the mid-1990s. The incidence of 
CD was 4.75/100 000/year, UC 2.06/100 000/year and IBD unclassified 1.01/100 000/year 
(Henderson, Hansen et al. 2012).  
 
1.2 Demographics of IBD 
In CD there appears to be a slight female preponderanc , especially in the late adolescent and early 
adulthood periods, potentially pointing towards a hormonal influence on disease expression (Loftus Jr 
2004). In UC, it seems that males are more affected (Loftus Jr 2004), and some studies actually 
suggest that although overall incidence is static, that male prevalence is increasing and female 
prevalence decreasing (Loftus, Silverstein et al. 2000). 
Both CD and UC are most commonly diagnosed in late adolescence and early adulthood, although 
diagnosis can occur at any age. The mean age at diagnosis of CD in North America is between 33.4 
and 45 years of age (Loftus, Schoenfeld et al. 2002). In UC, the mean age at diagnosis is 5 to 10 years 
later than in CD (Loftus, Silverstein et al. 2000, Bjornsson, Johannsson 2000). The classic bimodal 
distribution of diagnosis of IBD has recently been confirmed in a large population study of hospital 
admissions in England and Scotland with IBD. In both CD and UC the peaks were between 25 – 29 
years of age, and between 75 – 79 years of age. A more prominent first peak occurred in younger 
patients with CD, and a more prominent second peak in older patients with UC. During the two 
decades studied the rate of hospitalisation for both diseases increased in all age groups, although the 
increase was relatively more pronounced in the elderly and especially in UC (Sonnenberg 2010).  
 
1.3 Racial and Ethnic Implications on IBD 
Traditionally, IBD is thought of as a Western disea mainly impacting on Northern Europe and North 
America. However, more recently the prevalence and incidence of IBD, and especially UC, is 
increasing throughout central Europe, Asia, Africa and Latin America. In most of these regions CD 
still remains a rarity (Loftus Jr 2004). 
It is now suggested that the incidence of IBD amongst African Americans is similar to that of 
Caucasian Americans, with the prevalence of CD in African Americans being two thirds that of 
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Caucasian Americans. Paediatric IBD series from both North America (Ogunbi, Ransom et al. 1998) 
and the UK (Sawczenko, Sandhu et al. 2001) suggest that African Americans and Afro-Carribean 
Brits respectively have similar risks of IBD as their Caucasian counterparts. This was also shown to 
be the case in adults in the UK (Fellows, Freeman et al. 1990). 
The study of migrant populations has been of interest in determining the impact of lifestyle and 
environmental factors rather than genetic factors. South Asian immigrants to the UK, and their 
offspring, are at increased risk of UC relative to indigenous Caucasian peoples (Probert, Jayanthi et al.
1992, Probert, Jayanthi et al. 1993, Carr, Mayberry 1999, Montgomery, Morris et al. 1999). Those 
who immigrated to Singapore are also at increased ri k relative to the ethnic Chinese population (Lee, 
Fock et al. 2000). There is a higher prevalence of IBD in Jews from Europe and American when 
compared to those from Asia and Africa, although these differences may be decreasing (Fireman, 
Grossman et al. 1989, Odes, Locker et al. 1994). 
 
1.4 Cost Implications of Care 
During the last two decades hospital statistics from England and Scotland have shown a significant 
increase in the hospitalisation rates caused by CD and UC (Sonnenberg 2010). This has major 
economic implications. 
It has been proposed that the total economic impact of CD was up to $US15.5 billion in the US and 
€16.7 billion in Europe in 2006 (Yu, Cabanilla et al. 2008). There are no equivalent studies for UC, 
but based on previous work the cost is likely to be similar (Bodger 2011). 
The cost of IBD to the NHS (National Health Service) is thought to be £720 million per annum. This, 
again, is based on figures from 2006 and estimates an average of £3000 per patient per year (Luces, 
Bodger 2006, Cummings, Keshav et al. 2008).This has t e potential to increase due to new biological 
therapies becoming available and bringing with them a price tag of over £1500 per infusion (based on 
infliximab 5mg/kg for a 75kg adult) (Joint Formulary Committee. British National Formulary (online 
ed.) 2011). These therapies, however, may end up as cost effective by reducing the need for inpatient 
care including surgery (Rutgeerts, Feagan et al. 2004, Sands, Anderson et al. 2004, Lichtenstein, Yan 
et al. 2005, Colombel, Sandborn et al. 2007, Feagan, P accione et al. 2008, Jewell, Satsangi et al. 
2005).   
The total economic burden of the disease is difficult to measure but given that the peak onset of 
disease is in the 3rd decade of life, we must assume that there is significa t potential for employment 
prospects to be affected and earnings lost due to ill health. 
 
1.5 Gut Anatomy and Histology 
Ulcerative colitis is confined to the colon and rectum, usually progressing from the rectum 
proximally. Crohn’s Disease may affect any part of he gastrointestinal (GI) tract from mouth to anus. 
The GI tract arises initially in week 3 of embryological development, during the process of 
gastrulation from the endoderm of the trilaminar embryo, and extends from the buccopharyngeal 
membrane to the cloacal membrane. During week 4 of development, 3 distinct regions develop 
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extending throughout the length of the embryo: the for -, mid- and hind-gut. These 3 divisions are 
later defined by their vascular supply. Endodermal cells generate the lining of the digestive tube and
its glands; mesodermal mesenchyme cells will surround this tube to provide the muscles for 
peristalsis. The endodermal epithelium responds differently to different regionally specific 




The mucosa is the innermost layer of the gut. It surrounds the lumen and comes into direct contact 
with the chyme. It comprises 3 layers: 
• Epithelium: enterocytes, goblet cells, paneth cells (small intestine only), entero-endocrine 
cells, M cells. 
• Lamina propria: loose connective tissue, Peyer’s patches, lacteals 
• Muscularis mucosae: 2 layers of smooth muscle forming the boundary between mucosa and 
submucosa 
Submucosa: connective tissue, blood vessels, submucosal (Meissner’s) plexus, Brunner’s glands in 
the duodenum only 
Muscularis externa: 2 smooth muscle layers with myenteric (Auerbach’s) plexus between 
Adventitia: loose connective tissue 
 
The mucosae are highly specialised in each organ of the gastrointestinal tract to deal with the different 
conditions throughout. The most variation is seen in the epithelium.  
In the oesophagus, there is stratified, squamous, and non-keratinising epithelium, for protective 
purposes. There is an abrupt transition at the gastro-oesphageal junction from squamous to columnar 
epithelium. 
In the stomach the epithelium is simple columnar. It is organised into gastric pits and glands to deal 
with secretions.  
The epithelium of the small intestine is optimised for absorption. It is organised into plicae circulares 
and villi, and the enterocytes have microvilli, creating a brush border, greatly increasing the surface 
area for absorptive purposes. The epithelium is simple columnar with microvilli. In the ileum there are 
Peyer's patches in the lamina propria. 
The colon has simple columnar epithelium without villi but with goblet cells.  
The mucosa of the appendix resembles that of the colon but is heavily infiltrated with lymphocytes.  
At the ano-rectal junction, the pectinate line, there is a sharp transition from simple columnar to 







Figure 1.1: Cross-section his
 
 
Figure 1.2: GI tract histological slides
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tological diagram of the GI tract (OpenStax 04/06/2013)








1.6 Morphology of IBD 
1.6.1 Ulcerative Colitis 
UC is a chronic disease of the colon, spreading proximally from the rectum. It does not affect the 
small bowel, other than “backwash ileitis”. Endoscopi ally it is characterised by erythema, mucosa 
friability, loss of vascular pattern, and / or ulceration. The inflammatory process is limited to the 
mucosa and submucosa. Histologically there must be evidence of chronicity such as plasmacytosis in 
the lamina propria, eosinophilia, and distortion of the normal structures such as crypts and the surface 
mucosa. Regeneration and mucosal remodeling will result in a variety of altered shapes and sizes of 
crypts, and changes to the surface contours that vary from undulating to villiform. Acute active 
inflammation may accompany the chronic changes. Cryptitis, the invasion of crypt epithelium by 
neutrophils, can result in ulcers and crypt abscesses (Appleman 2008). 
 
1.6.2 Crohn’s Disease 
CD, whilst also a chronic relapsing and remitting disease, is characterised by skip lesions comprising 
focal, patchy erosions or ulcers, vertical fissures and fistulae, which can affect the whole 
gastrointestinal tract. Transmural inflammation with multiple lymphoid aggregates, granulomas, 
plasmocytosis and lymphocytosis of the lamina propria, chronic architectural distorsion, neurtophilic 
inflammation including neurtophilic crytpitis and crypt abscesses are common histoligical findings, as 
is submucosal fibrosis and neuromuscular hyperplasia of the submucosa.  
 
1.6.3 Indeterminate Colitis 
At the time of diagnosis of IBD, 10 – 15% of patiens will be diagnosed with indeterminate colitis 
(IC) or IBD-unclassified (IBDU). Currently we lack a diagnositic biomarker to specifiy IBD class and 
whilst with time > 50% of these patients will be given a formal diagnosis of CD or UC, with the 
majority being UC (Burakoff 2004), treatments are potentially delayed or suboptimal due to 
diagnostic uncertainty. The mean annual incidence of IC varies from 1.6/100 000 (Stewenius, 
Adnerhill et al. 1995) to 2.4/100 000 (Moum, Ekbom et al. 1997). 
In 1970, Kent et al (Kent, Ammon et al. 1970) performed the first retrospective study of clinical and 
pathological (colectomy) material from 222 patients with fulminant (n = 12) and chronic disease. The 
aim was to see whether the classical criteria could separate the 2 groups of ulcerative disease of the 
colon. Fourteen cases (15%) were categorised as “indeterminate” because of “overlapping features” 
(10%) and “data, insufficient to make a decision” (5%). One out of 12 fulminant cases was classified 
as indeterminate. “Overlapping features” were described as “severe mucosal and wall involvement.”  
In 1978, Price et al (Price 1978) went on to examine 30 colectomy specimens which had been 
designated “colitis indeterminate”. Features of thedisease included continuous or discontinuous 
disease with uneven distribution, fissures, nonaggre ated transmural inflammation and glandular 
irregularities. Following retrospective evaluation f pre- and post-operative biopsy samples and the 
surgical specimens 15 cases remained indeterminate. 
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In 1979, Lee et al (Lee, Medline et al. 1979) reported on 5 cases of IC in a series of 32 emergency 
colectomy specimens. Cardinal morphologic findings were extensive ulceration with sharp transition 
to normal adjacent mucosa and absence of lymphoid aggregates. Fissures reaching the muscularis 
propria were usually present (Geboes, Colombel et al. 2008). 
It was becoming apparent that, primarily in cases of fulminant colitis, a subgroup of resections had 
been characterised. This group was likely to have severe, often discontinuous, colitis with some 
degree of rectal sparing grossly. Histologically features included areas without architectural distortion 
to suggest long-standing disease, deep fissuring ulcers that often went into, and sometimes through, 
the muscularis propria, accompanied by transmural inflammation, although usually not with the 
typical lymphoid hyperplasia associated with CD, and without overt granulomas (Geboes, Colombel 
et al. 2008). 
Wells et al (Wells, McMillan et al. 1991) carried out a study of 46 patients who had a colectomy for 
fulminant colitis. After histological examination of the surgical specimens 16 patients were found to 
have IC. This group was followed for a median of 10 years, and during this time 12 remained with the 
diagnosis of IC, 1 was diagnosed with CD and 3 with UC. 
Moum et al (Moum, Ekbom et al. 1997) carried out a prospective incidence trial and found that of 36 
patients initially diagnosed with IC, 33% had been given a diagnosis of UC and 17% a diagnosis of 
CD within 1 to 2 years of initial diagnosis. 
Meucci et al (Meucci, Bortoli et al. 1999), in their retrospective observational study, showed that t e 
cumulative probability of having a definite diagnosis of either UC or CD was 80% 8 years after initial 
diagnosis of IC. 
Many of the features initially thought to be synonymous with IC, such as fissuring ulceration and 
transmural inflammation may in fact be those of fulminant colitis of any aetiology. In the accurate 
classification of fulminant colitis histopathological evaluation alone has its limitations (Guindi, 
Riddell 2004). Granulomas and transmural lymphoid hyperplasia/aggregates, especially when not in 
areas of ulceration, appear to be the two most specific indicators of CD in colectomy specimens from 
patients with fulminant colitis (Swan, Geoghegan et al. 1998). Poorly formed microgranulomas may 
be good indicators of CD, although when an aggregate of histiocytes becomes a granuloma is highly 
subjective. A figure of five histiocytes has been used to define microgranulomas in an attempt to 
provide objectivity (Mahadeva, Martin et al. 2002). Isolated giant cells and well defined epithelioid 
granulomas distant from crypts do not, as a rule, occur in UC, and hence their presence in a 
colonoscopic biopsy showing features of chronic IBD is a strong pointer towards the diagnosis of CD. 
However, crypt associated giant cells and granulomas c n occur in UC, and in themselves are 
unreliable features for the discrimination between CD and UC (Mahadeva, Martin et al. 2002). 
It has been hypothesised that treatment with steroids may lead to histological appearances consistent 
with IC (Rudolph, Uthoff et al. 2002), or that IC simply represents early IBD when the microscopic 
features required for diagnosis of UC or CD are not yet present (Schumacher, Kollberg et al. 1994). 
This made be especially relevant in children (Washington, Greenson et al. 2002). 
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IC in children is more marked than in adults, and can be further complicated by the presence of upper 
GI disease in patients clinically presenting as UC.pper GI disease however does tend to resolve, and 
is far less common in adults (6 – 12%) than in children (20 – 75%) (Geboes, Colombel et al. 2008). 
During initial diagnosis between 4 and 23% (Auvin, Molinie et al. 2005, Hildebrand, Fredrikzon et al. 
1991) of children are classified as having IC. In children diagnosed with IBD under the age of 2 years, 
33% are diagnosed with CD, 33% with UC and 33% with IC (Heyman, Kirschner et al. 2005). IC 
progressively decreases with increasing age, and is present in 9% of IBD patients aged 13 – 17 years 
(Heyman, Kirschner et al. 2005). Approximately 60% of paediatric patients with IC are reclassified 
(Bentsen, Moum et al. 2002), more often being UC (Stordal, Jahnsen et al. 2004, Antonioli 2005). 
The need to formally classify IC into either CD or UC is very relevant from a medical viewpoint when 
deciding on the most appropriate from of therapy or entry into clinical trials, and from a surgical 
standpoint in view of planning the most suitable procedure. It is generally accepted that patients with
CD have a poorer outcome than patients with UC when undergoing ileal pouch anal anastomosis 
(IPAA) due to a high risk of fistula incontinence, pouch failure and anastomotic leaks (Tekkis, Heriot 
et al. 2005). Reported rates of pouch failure in IC are very variable; Rudolph et al (Rudolph, Uthoff et 
al. 2002) reported 0% failure rate, McIntyre et al (McIntyre, Pemberton et al. 1995) and Yu et al (Yu, 
Pemberton et al. 2000), both from the Mayo Clinic, reported rates of 19% and 27% respectively 
compared to 8% (P=0.03) and 11% (p< 0.001) in their UC patients, and Koltum et al (Koltun, Schoetz 
et al. 1991) reported rates of 50% failure in IC patients compared with 3% in UC patients (p< 0.001).  
Interesting, Yu et al reported that at ten years of follow-up IC patients had significantly more episodes 
of pelvic sepsis (17% v 7% (p<0.001)) and pouch fistula (31% v 9% (p<0.001)) as well as the 
aforementioned pouch failure. However, during the course of their study 15% of IC patients had their 
diagnosis revised to one of CD, as did 2% of UC patients. When the outcomes of these patients newly 
diagnosed with CD were considered separately, the rate of complications for the remaining patients 
with IC was identical to that of patients with chronic UC. They concluded that after IPAA patients 
with IC who did not develop CD subsequently experienced long-term outcomes nearly identical to 
patients with chronic UC. CD, whether it develops after surgery for chronic UC or IC, is associated 
with poor long-term outcomes. 
The variability in outcomes of patients with IC following IPAA may be due to the heterogeneity of the 
patients included in the IC group of different studies, representing a mixture of CD and UC (Guindi, 
Riddell 2004). Functional outcomes appear to be similar in both IC and UC patients following IPAA 
(Rudolph, Uthoff et al. 2002, Pezim, Pemberton et al. 1989, Delaney, Dadvand et al. 2002). 
When considering indeterminate colitis we must stres  the requirement for new biomarker discovery 
to minimise diagnositic uncertainty and optimise trea ment regimens. 
 
1.6.4 Extraintestinal Manifestations of IBD 
In both CD and UC extrainstestinal manifestations of disease are common, occurring in 25-40% of 
IBD patients (Bernstein, Blanchard et al. 2001b). These can involve nearly any bodily system 
including musculoskeletal, ocular, dermatological, hepatopancreatobiliary, pulmonary and renal. 
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Table 1.1: Extraintestinal Manifestations of IBD (Levine, Burakoff 2011) 
Site Manifestation 
Musculoskeletal • Arthritis: colitic type, ankylosing spondylitis, isolated joint involvement  
• Hypertrophic osteoarthropathy: clubbing, periostitis 
• Miscellaneous manifestations: osteoporosis, aseptic necrosis, 
polymyositis 
Ocular • Uveitis/iritis, episcleritis, scleromalaci, corneal ulcers, retinal vascular 
disease 
Hepatopancreatobiliary • Primary sclerosing cholangitis, cholangiocarcinoma  
• Associated inflammation: autoimmune chronic active hepatitis, 
pericholangitis, portal fibrosis, cirrhosis, granulomatous disease  
• Metabolic manifestations: fatty liver, gallstones a sociated with ileal 
Crohn’s disease 
Dermatological and oral • Reactive lesions: erythema nodosum, pyoderma gangrenosum, aphthous 
ulcers, necrotising vasculitis 
• Specific lesions: fissures, fistulas, oral Crohn’s disease, drug rashes  
• Nutritional deficiencies: acrodermatitis enteropathica, purpura, glossitis, 
hair loss, brittle nails  
• Associated diseases: vitiligo, psoriasis, amyloidos s 
Metabolic • Growth retardation in children and adolescents, delayed sexual 
maturation 
Renal • Calcium oxalate stones 
 
Patients with UC are at higher risk of developing rectal carcinoma, and those with CD small bowel 
carcinoma and lymphoma. Both UC and CD hold equal risk of the development of hepatobiliary and 
colon carcinoma (Bernstein, Blanchard et al. 2001a).  
 
1.6.5 Colorectal Cancer and IBD 
The inflammatory bowel diseases, both CD and UC, have been associated with an increased risk of 
developing colorectal cancer (CRC). This is likely due to chronic inflammation promoting 
carcinogenesis (Ullman, Itzkowitz 2011).  
In UC, duration of disease, extensive mucosal involvement, concomitant primary sclerosing 
cholangitis (Brentnall, Haggitt et al. 1996, Broome, Lindberg et al. 1992, D'Haens, Lashner et al. 
1993), a family history of CRC (Nuako, Ahlquist et al. 1998) and early onset of UC (Devroede, 
Taylor et al. 1971) appear to increase the risk of developing CRC. In 2001 a landmark meta-analysis 
of over 54 000 patients was published by Eaden et al (E den, Abrams et al. 2001). The results 
suggested that in UC the cumulative risk of colorectal ancer is 2% at 10 years, 8% at 20 years and 
18% at 30 years irrespective of the extent of disease. Recently, Castanõ-Milla et al (Castano-Milla, 
Chaparro et al. 2014) have published an up-to-date meta-analysis, this time encompassing nearly 
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182000 UC patients. They estimate that the overall incidence rate of colorectal cancer in UC is 1.58 
per 1000 patient years, significantly lower than Eaden et al who reported 3 per 1000 patient years back
in 2001. Castanõ-Milla et al report an overall incidence rate of 0.91 per 1000 patient years in the first 
decade after the diagnosis of UC, 4.07 per 1000 patient years in the second decade and 4.55 per 1000 
patient years in the third decade. The apparent reduction in colorectal cancer in UC patients may be 
due to tighter control of inflammation, higher colectomy rates, the use of drugs with chemopreventive 
effects and a better adherence to endoscopic surveillance programmes in high-risk patients al 
(Castano-Milla, Chaparro et al. 2014).  
The risk of CRC in CD has been investigated less compared to UC. Pooled meta-analyses by Jess et al 
(Jess, Gamborg et al. 2005) and Lutgens et al (Lutgens, van Oijen et al. 2013) of population-based 
studies have shown increased risk of CRC in CD when compared to a healthy population, however the 
standardised incidence ratio was only 1.9 and 1.6 respectively. The risk appears to be higher in those 
with colonic or rectal involvement (Jess, Gamborg et al. 2005, Lutgens, van Oijen et al. 2013), those 
with stenosing colonic disease (Lovasz, Lakatos et al. 2013), and in those diagnosed under the age of 
30 years (Ekbom, Helmick et al. 1990). 
 
1.7 Treatment of IBD 
Due to the chronic relapsing and remitting nature of IBD, the mainstay of treatment involves the 
initiation of remission and then maintenance of this disease state with medical therapies with the aim 
of avoiding surgical intervention. Surgery is required to remove diseased segments of bowel, manage 
intra-abdominal sepsis, and to alleviate intestinal obstruction, fistulation or strictures.  
UC can be cured by proctocolectomy. There is no cure fo  CD and the aim is to maintain remission 
with medication. Widely utilised treatments are 5-aminosalicylic acid (5-ASA) drugs, corticosteroids, 
immunosuppressive agents, biological therapies, and antibiotics (Talley, Abreu et al. 2011).  
 
1.7.1 Aminosalicylates 
These drugs are believed to act as anti-inflammatory agents as they inhibit nuclear factor kappa B and 
chemoattractant leukotrienes and alter prostaglandin metabolism (Desreumaux, Ghosh 2006). The 
bioavailability of 5-ASA preparations is low (Sandborn, Hanauer 2003) and therefore adverse events 
are rare (Loftus, Kane et al. 2004), however the serious adverse effects include interstitial nephritis, 
pancreatitis, pneumonitis, pericarditis and hepatitis (Gisbert, Gonzalez-Lama et al. 2007).  
 
1.7.2 Corticosteroids 
Corticosteroids inhibit almost every aspect of the immune response (Talley, Abreu et al. 2011). This is 
through their interaction with glucocorticoid receptors in cell nuclei. They inhibit expression of 
adhesion molecules and trafficking of inflammatory cells to target tissues including the intestine. They 




Cortisone in UC was one of the first RCTs (randomised controlled trials) described in modern 
medicine in 1954 (Truelove, Witts 1954). Since then corticosteroids have been used for acute 
exacerbations of IBD. They are mainly used as short-term treatment to induce remission rather than a 
maintenance therapy. Although serious adverse effects such as increased risk of infection (Toruner, 
Loftus et al. 2008) and psychiatric disorders can occur in short-term use (Brown 2009), the long-term 
consequences of steroid use, such as loss of bone mineral density and diabetes mellitus, are even more 
serious (Irving, Gearry et al. 2007). 
 
1.7.3 Immunosuppressant Agents 
Thiopurine analogs (6-MP (6-mercaptopurine) and its pro-drug azathioprine), methotrexate, and the 
calcineurin inhibitors (ciclosporin and tacrolimus) are used in IBD management both as agents to 
induce and to maintain remission (Talley, Abreu et al. 2011). 
The thiopurine analogues are associated with nausea, all rgic reactions, acute pancreatitis, hepatitis, 
risk of infection, malignancy and bone marrow suppression.  
The adverse events associated with methotrexate are hepatotoxicity, pneumonitis, infection, 
malignancy alopecia, stomatitis and myelosuppression. 
The main adverse event associated with calcineurin inhibitors is renal toxicity, however hypertension, 
hirsutism, headache, infection, seizures and paraesthesia can occur (Aberra, Lichtenstein 2005). 
Thalidomide has many immundomodulatory properties; inhibiting TNF (tumour necrosis factor), IFN-
γ (interferon-γ) and IL-12 (interleukin-12), stimulating IL-4 (interleukin-4) and IL-5 (interleukin-5), 
and interfering with integrin expression, decreasing circulating helper T cells and inhibiting 
angiogenesis. It has previously been used in the treatment of IBD, however a recent systematic review 
has suggested that current evidence is insufficient to support its use to induce or maintain remission in 
UC or adult CD (Yang, Singh et al. 2015). 
 
1.7.4 Biologicals 
The use of anti-tumor necrosis factor alpha antibodies (anti-TNFα) was originally trialed 
unsuccessfully in the treatment of sepsis (Vilcek 2009). Following this, use in rheumatoid arthritis and 
IBD has occurred. Since 1998 anti-TNFα has been used IBD in both induction and maintenance of 
remission (Talley, Abreu et al. 2011). 
Infliximab is a chimeric monoclonal antibody to TNFα. It is widely used in the management of 
moderate to severely active and/or fistulating CD unresponsive to traditional anti-inflammatory agents 
or a single immunosuppressive agent (Hanauer, Feagan et al. 2002, Sands, Anderson et al. 2004). 
Adalimumab and Golimumab are recombinant human antibodies to TNFα and are effective for 
inducing and maintaining remission in CD and UC (Hanauer, Sandborn et al. 2006, Colombel, 
Sandborn et al. 2007, Sandborn, Feagan et al. 2014). Both have the advantage over infliximab of 
subcutaneous administration rather than intravenous, meaning that home administration is standard. 
Certolizumab pegol (CDP870) is an anti-TNFα with a unique structure. Unlike Infliximab and 
Adalimumab, which are based on the human immunoglobulin 1 Fc, certolizumab pegol does not 
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contain an Fc portion and therefore does not display Fc-mediated effects such as antibody-dependent 
cell-mediated cytotoxicity, apoptosis or necrosis of neutrophils. Certolizumab pegol is a human 
monoclonal antibody Fab′ conjugated with polyethylene glycol (PEG), an inert 40-kDa 
macromolecule used to enhance the pharmacokinetic properties of biologics. This improves the 
pharmokinetic behaviour of the drug, increasing solubility and stability, and decreasing 
immunogenicity. Currently certolizumab is not commercially available (Schreiber 2011). 
Vedolizumab is a humanized monoclonal antibody. It targets α4β7 integrin, which is expressed in gut-
homing lymphocytes. A key ligand for integrin α4β7 is mucosal addressin cell adhesion molecule 1 
(MAdCAM-1), which is expressed on the endothelium of venules in the lamina propria of the small 
intestine and the colon, as well as Peyer’s patches. V dolizumab disrupts the α4β7/MAdCAM-1 
interaction, hence blocking a key step in the infiltration of α4β7+ cells into the gut (Raine 2014). 
Vedolizumab has been shown to be of most clinical benefit in UC, although some patients with CD 
will gain benefit (Wang, Zhang et al. 2014). The most common adverse reactions are nasopharyngitis, 
headache and joint pain. 
Patients taking biological therapies are at risk of opportunistic infection (Irving, Gearry et al. 2007), 
lymphoma (Jones, Loftus 2007), and possibly demyelination disorders (Katsanos, Katsanos 2014).  
 
1.7.5 Antibiotics 
Several bacterial species may have a role in the pathogenesis of CD including Mycobacterium 
(Colemont, Pattyn et al. 1988, Feller, Huwiler et al. 2007), Listeria and Escherichia coli (Hugot, 
Alberti et al. 2003, Eckburg, Relman 2007, Darfeuill -Michaud, Boudeau et al. 2004). It has been 
shown that diverting the faecal stream though formation of ileostomy reduces the recurrence of CD in 
the colon (Janowitz, Croen et al. 1998). 
A systematic review of the use of antibiotics has shown that they can induce remission in active UC 
and prevent relapse in quiescent CD, however, the antibiotics evaluated were diverse and therefore it 
is not clear which antibiotic should be recommended (Talley, Abreu et al. 2011).  
 
1.8 Risk Factors for IBD 
1.8.1 Ethnicity 
Ethnicity is known to be a major risk factor for IBD. The Jewish population, especially the Ashkenazi, 
has been shown to be at significantly increased risk of developing IBD compared with Caucasians 
(Yang, McElree et al. 1993). In North America, Ashkenazi Jews have a significantly higher incidence 
of IBD than Sephardic Jews living in North America, indicating a genetic predisposition (Basu, Lopez 
et al. 2005). However, in Israel, Ashkenazi Jews have a lower incidence than those living in Northern 
Europe, or North America, suggesting an environmental component (Niv, Abuksis et al. 2000).  
Basu et al (Basu, Lopez et al. 2005) discovered significant differences in the subgroups of IBD, as 
well as serological markers and extraintestinal manifestations within varying racial groups. African 
and Caucasian Americans were more likely to have CD, whereas Mexican Americans were 
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predisposed to UC. All Mexican Americans tested with UC were positive for P-ANCA compared to 
only 40% of Caucasians. 
 
1.8.2 Perinatal and Childhood 
The expression of IBD may be influenced by perinatal nd childhood events. These include the 
method of feeding, domestic hygiene and perinatal infections. A Swedish group (Ekbom, Adami et al. 
1990) showed that those with a recorded “perinatal he lth event”, classified as infection or serious 
illness in the mother or child, had a 4-fold increas d risk for IBD than a control population. The same 
study also found those of low socioeconomic status to have a 3-fold increased risk of IBD than 
controls. 
However, the opposite has also been proposed, that a lack of exposure to childhood infections may be 
a risk factor for IBD, the so called “hygiene hypoth sis”. This hypothesis proposes that the rising 
frequency of immunological disorders can be attribued to lack of childhood exposure to enteric 
pathogens, leading to a greater susceptibility to develop an inappropriate immunological response 
upon exposure to new antigens later in life (Gent, Hellier et al. 1994, Bernstein, Shanahan 2008, 
Shanahan, Bernstein 2009). 
 
1.8.3 Breastfeeding  
Breastfeeding is known to have protective effects against autoimmune regulated diseases such as 
bronchial asthma (Gdalevich, Mimouni et al. 2001b), allergic rhinitis (Mimouni Bloch, Mimouni et al. 
2002), atopic dermatitis (Gdalevich, Mimouni et al.2001a) and type I diabetes mellitus (Mamun, 
O'Callaghan et al. 2014). However, in IBD, whilst some studies have shown a protective association, 
others have failed to show this effect. A meta-analysis of 17 studies did show a reduction in risk of 
both CD and UC in those who were breastfed; however th  evidence was not of high quality 
(Klement, Cohen et al. 2004). In a population based case control study, breastfeeding was found to be 
a risk factor for developing paediatric onset CD (Baron, Turck et al. 2005). Since then a further meta-
analysis of the role of breastfeeding in paedatric onset IBD did show protective effects, but again the 
studies were of poor quality (Barclay, Russell et al. 2009).  
In breast fed infants, there are higher concentrations of bifidobacteria and fewer anaerobic bacteria in 
faeces when compared to bottle fed infants (Fanaro, Chierici et al. 2003). Faecal flora can change up 
until 2 years of age, demonstrating the potential need for a longer duration of breastfeeding to impact 
a child’s risk of IBD development (Midtvedt, Midtvedt 1992). 
 
1.8.4 Antibiotic Usage 
Early and recurrent uses of antibiotics in childhood appear to be a risk factor for the development of 
IBD (Card, Logan et al. 2004, Shaw, Blanchard et al. 2010, Hviid, Svanstrom et al. 2011, Kronman, 
Zaoutis et al. 2012). 
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It is difficult to determine a causal effect as use of antibiotics may alter the gut microbiome but the 
effect seen may simply be due to the affected indivduals being genetically susceptible to infection 
and thus requiring courses of antibiotics (Ponder, Long 2013).  
 
1.8.5 Non-steroidal Anti-inflammatory Drugs (NSAIDs) 
NSAIDs can damage the mucosa of the stomach, small bowel and colon. They also increase intestinal 
permeability by inhibiting cyclooxygenase (Cipolla, Crema et al. 2002), which reduces prostaglandin 
production, leading to the inhibition of tumor necrosis factor and the induction of anti-inflammatory 
cytokines such as interleukin 10 (Berg, Zhang et al. 2002). These factors have been linked to the 
development of IBD.  
A large cohort study showed that regular use of NSAIDs, but not aspirin, was associated with an 
increased risk of both UC and CD (Ananthakrishnan, Higuchi et al. 2012). Another study showed that 
NSAID use in those with IBD is associated with frequ nt and early relapse of quiescent IBD 
(Takeuchi, Smale et al. 2006). 
 
1.8.6 Smoking 
In the early 1980s the first studies were carried out on smoking and IBD. Harries et al noticed that 
whilst smoking trends in patients with CD were similar to those of the general population, 42% adult 
males and 37% of adult females of the general population were smokers at the time, those with UC 
tended to be non-smokers. In their study they showed that 42% of patients with CD and 44% of 
healthy controls were current cigarette smokers, whereas only 8% of those with UC were (p<0.001) 
(Harries, Baird et al. 1982). 
Somerville et al (Somerville, Logan et al. 1984) later studied patients with CD and found that in 
comparison to a control group those with CD were significantly more likely to be smokers.  
In the late 1980s Calkins (Calkins 1989) carried out a meta-analysis and found that smoking and CD, 
and not smoking and UC and had a consistent association. Current smoking was associated with an 
OR of 2.0, 95%CI 1.65-2.47 for CD in comparison to non-smokers, and an OR of 1.8, 05%CI 1.33-
2.51 in comparison to ex-smokers. The OR for UC in current smokers was 0.41, 95%CI 0.34-0.48 
when compared to non-smokers.  
Mahid et al (Mahid, Minor et al. 2006) have shown in a recent meta-analysis that their data remain 
consistent. They showed an association between smoking and CD (OR 1.76, 95%CI 1.4-2.22) and 
former smoking and UC (OR 1.79, 95%CI 1.37-2.34). They also found that current smoking had a 
protective effect on the development of UC in comparison to controls (OR 0.58, 95%CI 0.45-0.75). 
UC patients that smoke usually have a more benign dsease course compared with non-smokers 
(Lakatos, Szamosi et al. 2007). They have been shown t  require hospitalisation for disease flares les
often than non-smokers (Boyko, Koepsell et al. 1987), require oral steroids for disease control less 
often (Mokbel, Carbonnel et al. 1998) and have lower colectomy rates than non-smokers (Mokbel, 
Carbonnel et al. 1998, Boyko, Perera et al. 1988). 
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In CD, smoking has been shown to influence disease phenotype. Those who smoke are at increased 
likelihood of having ileal than colonic or ileocolonic involvement (Lindberg, Jarnerot et al. 1992, 
Russel, Volovics et al. 1998). They are also more likely to have a disease type that progresses to 
penetrating, fistulating or stricturing when compared to a non smoking CD cohort (Lindberg, Jarnerot 
et al. 1992, Picco, Bayless 2003, Louis, Michel et al. 2003). Smokers are also more likely to require 
immunosuppressive agents (Cosnes, Carbonnel et al. 1999) and surgical resection (Lindberg, Jarnerot 
et al. 1992, Breuer-Katschinski, Hollander et al. 1996, Sutherland, Ramcharan et al. 1990) than non-
smokers. Patients who continue to smoke following surgical resection have been shown to be more 
likely to develop recurrent disease (Cosnes, Carbonnel et al. 1999, Breuer-Katschinski, Hollander et 
al. 1996, Sutherland, Ramcharan et al. 1990, Timmer, Sutherland et al. 1998) and to need further 
surgical intervention (Sutherland, Ramcharan et al. 1990). 
In patients with CD receiving anti-TNFα therapy, non-smokers have been shown to experience a 
higher response rate and a longer duration of response compared to smokers (Parsi, Achkar et al. 
2002). It has also been shown that patients who stop moking have fewer disease flares and require 
less steroids or immunosuppressants to control their symptoms than those who continue to smoke 
(Cosnes, Beaugerie et al. 2001).  
 
1.8.6.1 Mechanisms of Action of Smoke 
The exact mechanisms by which smoking influences IBD remain unclear. Tobacco had multiple 
constituents; however it has long been suspected that the metabolite of interest in disease course is 
nicotine (Birrenbach, Bocker 2004).  
Nicotine has been shown to decrease the synthesis of proinflammatory molecules, IL-1β and TNF-α, 
in murine colonic mucosa as well as the production of mucosal eicosanoids (Motley, Rhodes et al. 
1990). It has also been shown to decrease proinflammatory cytokines IL-2 (van Dijk, Meijssen et al. 
1998), IL-8 and TNF-α  (Wang, Yu et al. 2003) by human mononuclear cells through its action on the 
nicotinic acetylcholine receptor a7 subunit. 
Nicotinic acetylcholine receptors (nAChRs) are present in mucosal epithelial cells of the bowel and 
are also expressed on T-cells, thus indicating that nicotine may directly influence T-cell function. 
However, randomised placebo-controlled trials of nicotine patches for active UC have been carried 
out (Pullan, Rhodes et al. 1994, Sandborn, Tremaine et al. 1997) and although significant clinical 
improvement was noted in those receiving transdermal nicotine therapy, levels of remission were not 
shown to be significantly higher in either study. This was confirmed in a study by Thomas et al 
(Thomas, Rhodes et al. 1995) in which nicotine patches were compared to placebo for maintenance of 
remission. The nicotine group showed no benefit over placebo. It was also noted by Pullan et al that 
the side effects from nicotine, headache, nausea and dermatitis, were, in general, greater than the 
perceived clinical benefits (Pullan, Rhodes et al. 1994). 
 
1.8.6.2 Cytokine Levels 
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Dysregulated cytokine production is known to be a fe ture of IBD (Aldhous, Prescott et al. 2008). In 
CD excess production of IL-1β, IL-12 and TNF-α is noted (Cobrin, Abreu 2005), and in UC, excess 
IL-13 (Targan, Karp 2005). 
Increased levels of IL-4 has been found in smokers (Byron, Varigos et al. 1994), as well as decreased 
levels of IL-1β, IL-2, IL-8, IL-10, and TNF-α in peripheral blood mononuclear cells, and of IL-1β and 
IL-8 in colonic tissue of healthy controls and IBD patients who smoke. Sher et al (Sher, Bank et al. 
1999) found significantly lower levels of IL-1β and IL-8 in colonic mucosa of smokers with UC when 
compared to healthy controls, and lower levels of IL-8 in smokers with CD.  
Aldhous et al (Aldhous, Prescott et al. 2008) measured cytokine production from peripheral blood 
mononuclear cells stimulated with lipopolysaccaride (LPS) or phytohemagglutinin (PHA) +/- nicotine 
in CD and UC patients as well as healthy controls. Following stimulation with LPS and PHA, levels 
of IL-12/IL-23p40 were significantly higher in IBD patients than healthy controls. PHA stimulation 
increased IL-1β in UC patients and decreased TGFβ (Transforming growth factor beta) in IBD 
patients. In both IBD patients and healthy controls, nicotine decreased LPS and PHA induced 
production of IL-1β, IL-10, TGFβ, and TNF-α. In IBD patients, cell cycle analysis showed that PHA 
induced proliferation and decreased G0/G1 resting cells. Nicotine decreased PHA stimulated S-phase 
proliferation and increased G0/ 1 resting cells. They also showed independent associati ns between 
IL12/IL23p40 and apoptosis, IL-1β and resting cells, and TNF-α and proliferating cells. They 
concluded that dysregulated cytokine profiles in CDand UC are associated with specific cell cycle 
responses and that these effects may be modified by nicotine. 
 
1.8.6.3 Colonic Mucus Production 
In UC patients, Pullan et al (Pullan 1996) showed that a significantly thinner mucus layer was present 
in the colon in both smokers and non-smokers in comparison to healthy controls. This is in contrast to 
CD, where the mucus layer was shown to be thicker than in controls. A potential cause of this could 
be the skip lesions in CD facilitating areas with high levels of inflammatory mediators stimulating the 
release of mucin from adjacent “healthy” goblet cells (Birrenbach, Bocker 2004). Zijlstra et al 
(Zijlstra, Srivastava et al. 1994) showed that in rabbit rectal mucosa, mucus production is significantly 
increased with high dose nicotine therapy. Finnie et al (Finnie, Campbell et al. 1996) replicated these 
results in vitro in both left and right sided colonic epithelial biopsy specimens. Potentially this could 
explain the seemingly protective effects of nicotine  UC. 
 
1.8.6.4 Tissue Perfusion 
IBD patients with acute, severe episodes of inflammation have been shown to have increased gut 
perfusion, however chronic inflammation in both UC and CD has been shown to result in reduced gut 
perfusion (Tateishi, Arima et al. 1997, Hulten, Lindhagen et al. 1977, Angerson, Allison et al. 1993). 
Srivastava et al (Srivastava, Russell et al. 1990) showed that patients with UC have increased blood 
flow to the rectal mucosa.  We know that smoking decreases tissue perfusion and through increased 
CO (carbon monoxide) concentrations in the serum, may potentiate the impairment in vasodilatation 
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shown by Hatoum et al (Hatoum, Binion et al. 2003) to occur in chronically inflamed microvessels. 
This may be beneficial in acute UC but in chronic iflammation the resulting mucosal ischaemia can 
perpetuate ulceration and fibrosis (Hatoum, Binion et al. 2003).  
 
1.8.7 The Role of Appendicectomy  
1.8.7.1 Ulcerative Colitis 
In 1987, Gilat et al (Gilat, Hacohen et al. 1987) first reported the inverse relationship between the 
development of ulcerative colitis and appendicectomy. Their international case-control study of risk 
factors for IBD in childhood revealed only 3% of UC patients to have had an appendicectomy 
compared to 10% of control cases.  
In the 1990s multiple studies from both the Europe and the USA (United States of America) were in 
agreement, stating appendicectomy rates in those who ent on to develop UC to be 0.6 – 5%, 
compared to 14 – 25.4% in controls (Rutgeerts, D'Haens et al. 1994, Gent, Hellier et al. 1994, 
Smithson, Radford-Smith et al. 1995, Minocha, Raczkowski 1997, Parrello, Pavia et al. 1997, 
Duggan, Usmani et al. 1998).  
Koutroubakis et al (Koutroubakis, Vlachonikolis 2000) carried out a meta analysis of case-control 
studies in 2000 and showed that appendicectomy results in a 69% reduction in the risk of developing 
ulcerative colitis. These findings have been refined during the study of a large combined cohort of 
Scandinavian patients (Frisch, Pedersen et al. 2009) which showed a decreased risk of UC in patients 
who had an appendicectomy, but only if it was for appendicitis or mesenteric adenitis, and only in 
those < 20 yrs old, rather than in patients who had a negative appendicectomy. 
Swidsinski et al (Swidsinski, Dorffel et al. 2011) has shown that acute appendicitis is often caused by 
Fusobacterium nucleatum/necrophorum, and their presence positively correlated with disease 
severity. It was also evident in their study that the faecal microbiota represented by Bacteroides, 
Eubacterium rectale (Clostridium group XIVa), Faecalibacterium prausnitzii  groups and 
Akkermansia muciniphila were inversely related to the severity of the appendicitis. The relevance of 
this finding is that Faecalibacterium prausnitzii s known to have anti-inflammatory properties and is 
also known to be reduced in IBD, and this reduction is associated with CD recurrence after resection 
(Sokol, Pigneur et al. 2008). Roblin et al (Roblin, Neut et al. 2012) have since postulated that 
appendiceal dysbiosis may in fact be a trigger in the development of UC, based on previous 
correlations found between Fusobacterium, namely Fusobacterium varium, and UC (Ohkusa, Sato et 
al. 2002), and the improvement of UC symptoms when antibiotic therapy targeted at Fusobacterium 
varium is utilised (Ohkusa, Kato et al. 2010). 
 
 1.8.7.2 Crohn’s Disease 
The relationship between appendicectomy and the development of CD appears more difficult to 
define. Whilst there are numerous studies stating an increased risk of the development of CD post 
appendicectomy (Andersson, Olaison et al. 2003, Gearry, Richardson et al. 2010), large cohort studies 
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(Kaplan, Pedersen et al. 2007) and meta-analysis (Kaplan, Jackson et al. 2008) appear now to refute 
this phenomenon which may in fact be due to a difficulty in the initial diagnosis of CD. 
 
1.8.8 Measles 
During the study of the potential causative relationship between measles and IBD, three main areas 
have been studied; in utero exposure, infection in early life, and laboratory based tests to confirm past 
or present infection with the virus.  
 
1.8.8.1 In utero Infection 
Originally, in a Swedish cohort of 25 000 live births, 4 cases of maternal infection with measles virus 
were identified and 3 of the offspring went on to develop CD (Ekbom, Daszak et al. 1996). 
Subsequently a Danish study identified 33 cases of maternal measles between 1915 and 1966 and 
found that of the 26 offspring, 25 were available for follow-up and none had developed CD (Nielsen, 
Nielsen et al. 1998). A UK based study also showed that maternal exposure to measles did not seem to 
correlate to cases of CD or IBD in the offspring (Jones, Fine et al. 1997).  
 
1.8.8.2 Early Life Infection 
The British Cohort Study carried out by Montgomery t al (Montgomery, Morris et al. 1999) divided 
early life measles exposure into those infected under the age of 2 years, 2 – 5 years and 6 – 10 years. 
They found that out of the 20 individuals with CD, none were infected prior to age 2, 5 were infected 
aged 2 – 5 years (OR 1.06; 95% CI 0.37 to 3.06), and 4 were infected aged 6 – 10 years (OR 1.33; 
95% CI 0.42 to 4.19). The risk of UC was not significantly associated with early life measles 
infection. 
An American study (Pardi, Tremaine et al. 2000) followed 662 patients with measles infection under 
the age of 5 years, for 10 – 48 years. Of these 6 cases of CD and 6 cases of UC were identified, 
compared with an expected incidence of 1.9 and 2.0 respectively.   
In a further British study following two cohorts measles infection under the age of 7 years was not 
found to be associated with an increased risk of IBD (Thompson, Montgomery et al. 2000). 
Haslam et al (Haslam, Mayberry et al. 2000) combined data from 4 registers of patients with CD 
diagnosed from 1972 – 1989 and found that there was no association between being born in a year of 
measles epidemics and developing CD. 
 
1.8.8.3 Laboratory Testing of Present or Previous Infection 
Methods to confirm, or deny, a link between measles and CD have been extensively studied. It has 
been shown that hybridisation of measles virus RNA, immunohistochemical staining for measles virus 
nucleocapsid protein, and electron microscopy identfica ion of antibody labelled measles virus 
nucleocapsid are more common in CD than in a healthy population (Wakefield, Pittilo et al. 1993, 
Lewin, Dhillon et al. 1995, Daszak, Purcell et al. 1997). Miyamoto et al (Miyamoto, Tanaka et al. 
1995) detected a reaction to a monoclonal antibody derived from measles virus infected cells from 
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patients with CD and Kawashima et al (Kawashima, Mori et al. 2000) detected measles virus RNA in 
peripheral mononuclear cells in some patients with CD and UC. 
However, these results have failed to be replicated in both intestinal and peripheral blood 
mononuclear cells using PCR techniques (Iizuka, Nakagomi et al. 1995, Haga, Funakoshi et al. 1996, 
Afzal, Armitage et al. 1998, Chadwick, Bruce et al. 1998).  
 
1.8.8.4 Measles Vaccine 
In 1995, Thompson et al (Thompson, Montgomery et al. 1995) published a cohort study following 
children vaccinated against measles from 1964 to 1994. The incidence of IBD in this cohort was 
compared to a cohort of presumably unvaccinated children born in 1958 and showed that the 
vaccinated group had a 3-fold increased risk of CD and a 2.5- fold increased risk of UC. There were, 
however, considerable methodological concerns regarding this study (Patriarca, Beeler 1995) but still 
the possibility of a causal effect had been raised an therefore a number of studies were initiated. 
Feeney et al (Feeney, Ciegg et al. 1997) showed that there was no association between measles 
vaccination and CD, UC or IBD as a whole. However, Wakefield et al (Wakefield, Murch et al. 1998) 
again raised concerns regarding the vaccination by describing non-specific colitis, ileal-
lymphoidnodular hyperplasia, and developmental disor ers following the vaccination. Thus a large 
case-controlled study was initiated and no evidence was found the measles vaccine triggered IBD 
(Davis, Kramarz et al. 2001). This was confirmed by the 1970 British Cohort Study in which no 
association was found between measles vaccination and IBD (Morris, Montgomery et al. 2000).  
Hermon-Taylor et al plotted the course of increase of CD in the UK and found it have initiated 20 
years prior to the introduction of the measles vaccine (Hermon-Taylor, Ford et al. 1995), adding to the
evidence that the cause of CD or IBD does not stem fro the measles vaccine.  
It appears that the measles vaccine has been absolved f responsibility as a cause of IBD and in 
particular CD. The implication of early life measles virus infection however remains open to debate as 
conflicting evidence exists. This is also the case for the identifiable presence of measles virus in 
laboratory testing.  
 
1.8.9 The Oral Contraceptive Pill  
The oral contraceptive pill (OCP) has been implicated in the development of IBD with a potential 
mechanism being that the thrombotic properties of oestr gen exposure lead to a process of multifocal, 
microvascular gastrointestinal infarction (Wakefield, Sawyerr et al. 1991). A meta-analysis of over 75 
000 women calculated that the pooled relative risk (RR) for the development of CD in women taking 
the OCP was 1.51, and 1.46 when adjusted for smoking. The RR for UC in women taking the OCP 
was 1.53, and 1.28 when adjusted for smoking (Cornish, Tan et al. 2008).  
More recently a prospective cohort study compared users of the OCP with those who had never used 
the OCP. The multivariate-adjusted hazard ratios for CD were 2.82 (95% CI 1.65 to 4.82) among 
current users and 1.39 (95% CI 1.05 to 1.85) among past users. The association between OCP use and 




1.8.10 Diet  
It has been hypothesised that diet may have a role to play in the development of IBD. There has been 
an increase in the development of IBD in countries where it was previously rare, in parallel with the 
adoption of a western diet (Thia, Loftus et al. 2008).  Increasing intake of dietary fat, particularly n-6 
polyunsaturated fatty acids (PUFAs) and reduced intake of n-3 PUFAs is common in the Western diet. 
Through the arachidonic acid pathway, dietary n-3 PUFA competitively inhibits the formation of 
proinflammatory prostaglandins and leukotrienes (Marion-Letellier, Savoye et al. 2013). It also 
inhibits vascular adhesion and migration, angiogenesis, and adaptive immune responses through 
peroxisome proliferator-activated receptor γ (PPARγ) and nuclear factor κB (NFκB) mediated 
pathways (Hjerkinn, Seljeflot et al. 2005, Yang, Lu et al. 2012, Calder 2012). 
A large prospective study of over 170 000 women concluded that high intake of dietary long-chain n-3 
PUFAs may be associated with a reduced risk of UC (hazard ratio 0.72, 95% CI 0.51 to 1.01). 
However, high long-term intake of trans-unsaturated fats may be associated with a trend towards an 
increased incidence of UC (hazard ratio 1.34, 95% CI 0.94 to 1.92) (Ananthakrishnan, Khalili et al. 
2014). The same group also found that long-term intake of dietary fibre, particularly from fruit, is 
associated with lower risk of CD but not UC (Ananthakrishnan, Khalili et al. 2013).  
A recent literature review by Andersen et al (Andersen, Olsen et al. 2012) found that prospective 
studies suggest that a diet high in protein, particular animal protein, may be associated with increased 
risk of IBD and a higer risk of disease relapse, and that n-6 PUFAs may predispose to UC whilst a diet 
high in n-3 PUFA may protect from UC. These findings however were not replicated in the review by 
Spooren et al (Spooren, Pierik et al. 2013). They stated that although some studies report high intake 
of sugars and low intake of fruit and / or vegetables to be associated with increased risk of IBD, this
cannot be confirmed in other studies and thus the evidence is lacking. Currently the GEM Project 
(www.gemproject.ca) and the PREdiCCT Study are recruiting to investigate causes of IBD. 
 
1.9 Areas of Research Interest in IBD 
Over the past two decades, the majority of IBD research has been focused around microbiological, 
immunological and genetic studies. Thus I have chosen to focus on these areas of research interest 
whilst reviewing our current knowledge.  
 
1.9.1 Microbes in IBD 
At birth the human gut is sterile; however, bacterial colonisation begins within a few hours of life. 
Bacterial diversity increases rapidly in infancy, initially based on the method of birth and infant 
feeding (Penders, Thijs et al. 2006), eventually resulting in a distinct but relatively stable adult gut 
microbiome (Dominguez-Bello, Blaser et al. 2011).  
It is estimated that 1014 individual bacteria (Gill, Pop et al. 2006, Davis 1996) from >1000 species 
reside in the human gut, and that their genome is 150 times that of the human genome (Qin, Li et al. 
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2010). Within the human gut the majority of bacteria (98%) belong to four phyla; Firmicutes (64%), 
Bacteroidetes (23%), Proteobacteria (8%), and Actinobacteria (3%) (Frank, St Amand et al. 2007).  
 
Figure 1.3: Microbiota of the GI tract (Sartor 2008) 
 
 
In healthy people, the mucosal microbiome appears to form a stable ecosystem with the host immune 
system, whereas the luminal and faecal microbiome may alter with environment and diet (Eckburg, 
Bik et al. 2005).  
Current thinking denotes that in order for a chronic i flammatory reaction to be initiated, the host 
must either fail to identify and respond to pathogenic bacteria on initial contact, or must fail to initiate 
autophagic mechanisms of intracellular bacterial killing (Mukhopadhya, Hansen et al. 2012). Thus 
either the NOD2 (Nucleotide-binding Oligomerisation Domain-containing Protein 2) pathway or the 
ATG16L1 (Autophagy-related 16 Like 1) pathway is defective.   
Single bacteria have been studied in order to attempt to identify a causative agent for IBD. 
Mycobacterium avium subspecies paratuberculosis (MAP) has been extensively studied in both 
humans and in animal species; however despite a couple of meta-analyses recently published, a 
pathogenic effect has not been identified in CD (Feller, Huwiler et al. 2007, Abubakar, Myhill et al. 
2008).  
IBD patients appear to have a gut microbiome different in composition to healthy individuals. Studies 
have shown 10 – 100 fold decreases in abundances of bacteria beneficial to the host such as 
Firmicutes, specifically Faecalibacterium prausnitzii and Bacteroidetes, and an increase in the 
Gammaproteobacteria (Frank, St Amand et al. 2007, Sokol, Seksik et al. 2009, Frank, Robertson et al. 
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2011, Morgan, Tickle et al. 2012). It remains unclear, however, whether this dysbiosis in IBD is an 
effect of the disease or whether it is a contributory factor.  
 
Table 1.2: Alterations in Microbial Composition and Function Linked to IBD (Kostic, Xavier et al. 
2014) 
Microbial composition Decrease in α diversity 
Decrease in Bacteroides and Firmicutes 
Increase in Gammaproteobacteria 
Presence of E coli, specifically adherent invasive E coli 
Prescence of Fusobacterium 
Decrease in Clostridia, Ruminococcaceae, Bifidobacterium, 
Lactobacillus 
Decrease in F prausnitzii 
Microbial function Decrease in SCFAs, butyrate 
Decrease in butanoate and propanoate metabolism 
Decrease in amino acid biosynthesis 
Increase in auxotrophy 
Increase in amino acid transport 
Increase in sulfate transport 
Increased oxidative stress 
Increase in type II secretion systems, secretion of toxins 
 
In CD, proportions of the Clostridia are altered: the Roseburia and Faecalibacterium genera of the 
Lacchnospiracae and Ruminococcaceae families are decreased, whereas Ruminococcus gnavus i  
increased (Sokol, Seksik et al. 2009, Joossens, Huys et al. 2011, Sokol, Pigneur et al. 2008). 
Dysbiosis in UC is less well described, although increased sulphate-reducing Deltaproteobacteria 
have been reported (Gibson, Cummings et al. 1991, Roediger, Moore et al. 1997). 
Bacterial genes greater than 100 times that of the human gene set encode the normal gut microbiome 
(Eckburg, Bik et al. 2005, Qin, Li et al. 2010). Therefore the potential for treatments, diets and 
medications to affect the microbiome as well as the human host is great. Dietary fibre, the main 
energy source of the lower gastrointestinal tract microbiotia, is a prime example (Flint, Bayer et al. 
2008). Fibrolytic bacteria degrade polysaccharides into smaller carbohydrates, which are then 
fermented into short-chain fatty acids (SCFAs) such as acetate, propionate and butyrate. All of these 
have immunomodulatory properties, and butyrate, in particular, is a major source of energy for 
colonocytes (Tedelind, Westberg et al. 2007, Clausen, Mortensen 1995, Inan, Rasoulpour et al. 2000, 
Segain, Raingeard de la Bletiere et al. 2000, Saemann, Bohmig et al. 2000, Velazquez, Lederer et al. 
1997).  
Genetic studies in IBD pathogenesis have highlighted the role of host-microbe interactions (Khor, 
Gardet et al. 2011, Barrett, Hansoul et al. 2008, Franke, McGovern et al. 2010, McGovern, Gardet et 
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al. 2010), specifically the microbial responses in IBD of T-cell activation, the IL-23/T helper 17 
pathway, autophagy (Hampe, Franke et al. 2007), and Paneth cell function (Vaishnava, Behrendt et al. 
2008). This supports the theory of host-microbiotia interface for gut homeostasis and also for 
dysfunctional interactions between host and gut microbiome in IBD. 
Morgan et al (Morgan, Tickle et al. 2012) analysed the gut microbiome of CD and UC patients and 
healthy controls using multivariate metagenomic analysis and taking into account environmental 
factors such as treatments, age and smoking in order to measure compositional and functional 
differences in gut microbiota. Age was associated with a decrease in Bifidobacterium, as shown in 
previous studies (Agans, Rigsbee et al. 2011, Mariat, F rmesse et al. 2009), and disease activity was 
not independently associated with a specific shift in the microbiome composition. There was no 
significant association between microbiome composition and gender.  
Analysis of the microbiome showed Roseburia and Phascolarctobacterium to be significantly reduced 
in both UC and CD, whilst Clostridium was increased. Roseburia, which utilises acetate and produces 
butyrate (Duncan, Hold et al. 2002), is associated with anti-inflammatory T cell production in the gut 
(Atarashi, Tanoue et al. 2011). Phascolarctobacterium are succinate consumers, producing propionate 
when co-cultured with Paraprevotella (Watanabe, Nagai et al. 2012). Thus the decreases in Roseburia 
and Phascolarctobacterium seen in IBD may reflect a decrease in butyrate and propionate production.  
In CD, the Ruminococcaceae, which produce acetate (Chassard, Bernalier-Donadille 2006), were 
decreased, and in UC the L uconostocaceae, which produce acetate and lactate (Cogan, Jordan 1994), 
were decreased. In CD, the Enterobacteriaceae, specifically Escherichia / Shigella, which have 
previously been associated with intestinal inflammation (Baumgart, Dogan et al. 2007, Garrett, Gallini 
et al. 2010, Kleessen, Kroesen et al. 2002, Mylonaki, Rayment et al. 2005), were increased.  
Ileal CD was studied as a distinct microbiome phenotype. The Ruminococcaceae family was found to 
be dramatically reduced, especially Faecalibacterium. Faecalibacterium prausnitzii is able to 
metabolise diet-derived polysaccarides and host-derived substrates such as N-acetyl glucosamine from 
intestinal mucous (Lopez-Siles, Khan et al. 2012). It is also a major butyrate producer and inhibits 
anti-inflammatory effects in the setting of colitis (Sokol, Pigneur et al. 2008). The Ruminococcaceae 
consume hydrogen and produce acetate that can be utilis d by Roseburia produce butyrate (Duncan, 
Hold et al. 2002, Chassard, Bernalier-Donadille 2006). A reduction of these organisms may have 
functional consequences on the ability of the host t  repair the epithelium and regulate inflammation.  
 
1.9.1.1 The Faecal Microbiome 
Human infants have very heterogeneous, unstable and distinctive microbiota, whereas weaned 
children and adults show high functional uniformity (Kurokawa, Itoh et al. 2007, Palmer, Bik et al. 
2007). It is important to note that analysis of the microbiome based on faecal samples varies from that 
based on gut biopsies (Morgan, Tickle et al. 2012). 
Microbes in the human gut undergo selective pressur from the host as well as from microbial 
competitors leading to homeostasis of the ecosystem. Arumugam et al (Arumugam, Raes et al. 2011) 
identified three enterotypes, based on faecal samples, by variation in the levels of one of the three 
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genera: Bacteroides (enterotype 1), Prevotella (enterotype 2) and Ruminococcus (enterotype 3). The 
drivers of enterotype 1, enriched in Bacteroides and co-existing with Parabacteroides, derive energy 
primarily from carbohydrates and proteins through fermentation since these closely related genera 
have a broad saccharolytic potential and since genes coding enzymes involved in the degradation of 
these substrates (galactosidases, hexosaminidases, proteases) along with glycolysis and pentose 
phosphate pathways are enriched in this enterotype.  
Enterotype 2, enriched in Prevotella and co-existing with Desulfovibrio, can act in synergy to degrade 
mucin glycoproteins present in the mucosal layer of the gut. 
Enetrotype 3, the most common enterotype, is enriched in Ruminococcus and Akkermansia. Both are 
known to comprise species able to degrade mucins and are enriched in membrane transporters of 
sugars, suggesting the efficient binding of mucin and its subsequent hydrolysis as well as uptake of 
simple sugars by these genera.  
As well as conversion of complex carbohydrates into absorbable substrates, the gut microbiotia 
produces vitamins. Enterotypes 1 and 2 were enriched in biosynthesis of different vitamins: biotin, 
riboflavin, pantothenate and ascorbate in the former and thiamine and folate in the latter. 
With the exception of enterotype 1, which is most common in Japanese individuals, enterotypes do 
not seem to correlate with nationality, gender, age or BMI (body mass index). It may be however, that 
future analyses will allow enterotyping of individuals to determine responses to diet or medication 
strategies.  
 
1.9.1.2 E.coli and IBD 
Escherichia coli colonisation has been described in IBD patients (Mylonaki, Rayment et al. 2005, 
Conte, Schippa et al. 2006) and in abundance in those aving disease flares (Darfeuille-Michaud, Neut 
et al. 1998, Cooke, Ewins et al. 1974). E. coli strains are classified into four phylohenetic groups, A, 
B1, B2, and D. Groups A and B1 are commensal strains nd carry few virulence genes. Groups B2 
and D usually possess virulence genes which favours per istence, adhesion and extraintestinal 
infection (Johnson, Delavari et al. 2001).  
In 2007, Kotlowski et al (Kotlowski, Bernstein et al. 2007) described a link between E. coli of the 
phylogenetic groups B2 and D, and IBD. E coli of the serotype most commonly associated with 
urinary tract infections will often be found within phylogenetic group B2 whereas commensal faecal 
E. coli will not (Navidinia, Peerayeh et al. 2014). A recent meta-analysis (Petersen, Halkjaer et al. 
2015) has confirmed the relationship between group B2 E. coli colonisation and IBD. It was mainly in 
UC patients that this relationship was statistically significant, and these samples were from gut 
biopsies in the majority of cases rather than faecal cultures. The relationship between group D E. coli 
and IBD could not be confirmed as statistically significant in this study.  
E. coli is thought to be a trigger in the pathogenesis of IBD through toll-like receptor signalling (Cario 
2010). Lipopolysaccharides are produced by these gram-negative bacteria, which, in turn activate toll-
like receptor 4 (TLR4) signalling and cause intestinal inflammation through activation of two 
signalling pathways: the early myeloid differentiation primary response gene 88 (MyD88)-dependent, 
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and the delayed MyD88-independent response (Zughaier, Zimmer et al. 2005). The MyD88-
dependent cascade includes activation of the NF-κB pathway, involving recruitment of the IL-1R-
associated kinases (IRAKs), phosphorylation of IκB kinase (IKK) and subsequent phosphorylation 
and degradation of the family of IκB proteins, which allow phosphorylation of NF-κB followed by its 
translocation into the nucleus and transcription of pr -inflammatory cytokines such as TNF-α, IL-1β, 
IL-6 and IL-8 (Zeytun, Chaudhary et al. 2010, O'Neill, Bowie 2007, Haddad, Abdel-Karim 2011, 
Medvedev, Kopydlowski et al. 2000). 
Toll-like Receptor 4 (TLR4) has been shown to be strongly upregulated in both CD and UC (Cario, 
Podolsky 2000).  
 
1.9.1.2.1 Adherent Invasive E. Coli 
Adhesion allows bacteria to colonise the mucosa and resist mechanical removal from the intestine.  
Adhesive E. coli have been isolated from 68% of patients with UC, 62% of CD patients and only 6% 
of healthy controls (Giaffer, Holdsworth et al. 1992). More recently, Kotlowski et al  (Kotlowski, 
Bernstein et al. 2007) reported adhesive E. coli  were more likely to be associated with UC and CD 
tissues than controls. 
CD-associated E. coli preferentially adheres to differentiated Caco-2 cells, which represent a mature 
intestinal cell model (Rolhion, Darfeuille-Michaud 2007). This is consistent with crypt epithelial cells 
rarely being involved in early CD lesions (Sankey, Dhillon et al. 1993).  
Early CD lesions mainly occur in Peyer’s patches (Fujimura, Kamoi et al. 1996), induced by entero-
invasive pathogens, such as Shigella and Salmonella. The aphthous ulcer, the earliest lesion of CD, is 
a necrosis of M-cells of Peyer’s lymphoid follicles (Rickert, Carter 1980). The presence of 
intramucosal E. coli, or mucosa-associated E. coli with invasive properties has been reported in 29 – 
36% of CD patients, 12 – 19% of UC patients and only 3 – 9% of healthy controls (Martin, Campbell 
et al. 2004, Darfeuille-Michaud, Boudeau et al. 2004, Alpern, Sasaki et al. 2006). Strain LF82 invades 
multiple human epithelial cell lines including Hep-2 cells, and the intestinal cell lines Intestine-407, 
Caco-2 and HCT-8 (Boudeau, Glasser et al. 1999). The uptake of LF82, and of the invasive E. coli 
strains isolated from CD patients is dependent on both functioning host cell actin monofilaments and 
microtubules (Boudeau, Glasser et al. 1999).  
Adherent Invasive E. coli (AIEC) are a pathogenic group of E. coli. They have the ability to adhere to 
and invade intestinal epithelial cells with a macropin cytosis-like process of entry dependent on actin 
microfilaments and microtubules recruitment. They also have the ability to survive and replicate 
extensively in large vacuoles within macrophages without triggering host cell death, and the ability to 
induce the release of large amounts of TNF-α by infected macrophages (Rolhion, Darfeuille-Michaud 
2007). 
AIEC strains have been found to be highly associated with ileal mucosa in CD patients being found in 
36.4% of ileal specimens from CD patients, compared to 6% of healthy controls. In colonic specimens 
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AIEC was identified in 3.7% of CD patients, 0% of UC patients and 1.9% of healthy controls 
(Darfeuille-Michaud, Boudeau et al. 2004).  
Genetic studies have identified mutations in the NOD2/CARD15 encoding gene associated with the 
severity of ileal CD (Hugot, Chamaillard et al. 2001, Ogura, Bonen et al. 2001). The expression of 
functional NOD2 may play a role in the clearance of bacteria, even AIEC. Intestinal epithelial cells 
that do not express NOD2, or that express NOD2/CARD15 3020insC CD-associated variant, are 
unable to contain intracellular bacterial replication (Kobayashi, Chamaillard et al. 2005, Hisamatsu, 
Suzuki et al. 2003). Thus ileal CD could result from dysfunction of the NOD2 innate immune 
surveillance mechanism (Rolhion, Darfeuille-Michaud 2007). 
1.9.1.3 Ulcerative Colitis Microbiome 
Ulcerative colitis patients express lower biodiversity than healthy controls. In pancolitis patients 
Morgan et al (Morgan, Tickle et al. 2012) reported a reduced abundance of Odoribacter genus, which 
belongs to the Porphyromonadaceae family and the Bacteroides phylum. Odoribacter splanchnus 
produces acetate, propionate and butyrate (Goker, Gronow et al. 2011), thus decreased O oribacter 
may reduce SCFA availability and affect host inflammatory responses. 
 
1.9.1.3.1 Sulphate-reducing Bacteria in Ulcerative Colitis 
Sulphate-reducing bacteria (SRB) are Gram-negative, non-spore-forming, obligate anaerobes (Rowan, 
Docherty et al. 2009). SRB involved in bowel colonisat on are flagellate Vibrio bacteria. They can 
travel within bioflims such as the mucous layer of the colon (Devereux, Delaney et al. 1989). 
Helicobacter pylori is the equivalent in the stomach (Rowan, Docherty et al. 2009).  
SRB scavenge hydrogen and short-chain fatty acids with high affinity. They produce hydrogen 
sulphide (Pfennig, Widdel 1982). Hydrogen sulphide is freely permeable to the cell membrane. It does 
not have specific cell receptors and is known to affect adenosine 5’-triphosphate-dependent potassium 
channels, DNA integrity, and cytochrome c oxidase and carbonic anhydrase activity (Szabo 2007). 
Hydrgogen sulphide has been shown to impede butyrate oxidation in colonocytes (Roediger, Duncan 
et al. 1993). Colonisation with hydrogen-sulphide producing SRB, failed homeostasis of endogenous 
hydrogen sulphide production, and diminished clearance of excessive exogenous hydrogen sulphide 
are potential pathogenic pathways in UC (Rowan, Docherty et al. 2009). 
 
1.9.1.4 Amino Acid Biosynthesis and Carbohydrate Metabolism  
As described above, the basic gastrointestinal microb ome is altered in both CD and UC. Genes for 
the metabolism and biosynthesis of most amino acids, especially histine and lysine, are decreased, 
while arginine, histadine, and lysine transport genes are increased. 
In ileal CD, there is a decrease in gluatmine-related functional models. This leads to a lower amount 
of glutamate that is required for gamma-aminobutyric acid, ornithine, and arginine biosynthesis. 
Therefore, levels of these molecules are reduced. 
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Genes for the metabolism of the sulphur-containing amino acid cysteine are significantly increased in 
IBD, especially in ileal CD. This corresponds to an overrepresentation of genes related to sulphate 
transport in both UC and CD, and an increase in sulphur and nitrogen metabolism in CD. 
CD is associated with an increased abundance of many ge es related to carbohydrate transport. In ileal
CD, there are increases in the pentose phosphate pathway and an abundance of the fructose / mannose 
metabolism gene. There is also an increased abundance of transporter genes for glucose, hexoses, 
maltose and mono-, di-, and oligosaccharides, whereas butanoate and propanoate metabolism is 
decreased. The latter may be a result of decreased lev ls of Roseburia and Faecalibacterium resulting 
in decreased SCFA production (Morgan, Tickle et al. 2012). 
Glutathione transport gene abundance is increased in CD and UC, and in UC there is an increase in 
glutathione metabolism gene abundance. Glutathione, a tripeptide of cysteine and glutamate, is 
synthesised by Proteobacteria and a few streptococci and enterococci (Sherrill, Fahey 1998). It 
allows bacteria to maintain homeostasis during oxidative or acid stress. Inflammatory cascades 
include the production of highly reactive oxygen and nitrogen metabolites. These are greatly increased 
in IBD (Keshavarzian, Banan et al. 2003). 
During inflammation, lamina propria monocytes releas  homocysteine, contributing to oxidative 
stress. High levels of both mucosal and serum homocysteine have been identified in IBD (Danese, 
Sgambato et al. 2005). 
The increases in sulphate transport, cysteine metabolism and glutathione metabolism may reflect gut 
microbiome mechanisms addressing the oxidative stress caused by inflammation (Morgan, Tickle et 
al. 2012).  
 
1.9.1.5 Microorganisms as Pathogens in IBD 
Both UC and CD result from the inappropriate activation of intestinal mucosa immunity in genetically 
susceptible hosts. However, increasingly intestinal microbiota are deemed to have a role in the 
initiation, maintainance and phenotypical expression of IBD (Sartor 2008, Sartor 2010).  
Two hypotheses exist in relation to microbial pathogenesis of IBD: 
• Specific microorganisms have a role in induction. 
• Metabolites derived from the microbiotia can be medicators of injury and inflammation in a 
perpetuating inflammatory cycle. 
 
1.9.1.5.1 Microorganisms Linked to IBD Pathogenesis 
Multiple organisms have been linked to IBD including Mycobacterium paratuberculosis, Listeria 
monocytogenes, paramyxovirus, Chlamydia trachmatis, Shigella, Salmonella, Yersinia, 
Saccharomyces cerevisiae, Escherichia coli, Eubacteri , Pertostreptococcus, Coprococcus, and 
Bacteriodes vulgatus (Linskens, Huijsdens et al. 2001).  
I have concentrated on Mycobacterium paratuberculosis, which causes Johne’s disease, a 
granulomatous infectious ileitis in ruminants. This is very similar to ileal Crohn’s disease in humans 
and this hypothesis was first published in 1913 (Dalziel 1913). M. paratuberculosis has therefore been 
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investigated as a cause of CD, and was first cultured from the intestinal tissue of patients with Crohn’s 
disease by Chiodini et al (Chiodini, Van Kruiningen t al. 1984). However, there is now conflicting 
evidence with studies reporting detection rates of between 0 and 100% in CD patients (Frank, St 
Amand et al. 2007, Sartor 2005). In addition, some clinical studies of anti-mycobacterial therapy have 
failed to show a sustained response, suggesting that this pathogen is not involved in the initiation or 
progression of CD (Selby, Pavli et al. 2007, Thomas, Swift et al. 1998). However, evidence is slightly 
conflicted as a systematic review identified anti-mycobacterial therapy to be useful in the 
maintainence of remission when given with preceding corticosteroid therapy to induce remission 
(Borgaonkar, MacIntosh et al. 2000). 
 
1.9.1.5.2 Microbiotia Metabolic Mediators of Intestinal Injury or Inflammation 
The production of certain microbial metabolites may be mediators of mucosal injury.  
Significant alterations in microbial function have been identified between inflamed and non-
inflammed regions of UC patients, in comparison with CD patients. This is consistent with the theory 
that UC is a regionalised disease, whereas CD is a more systemic disease. In inflamed regions of UC 
patients, the metabolic activities of adherent bacteria have a reduced abundance of genes utilised for 
carbohydate and nucleotide metabolism, and an increased abundance of genes for lipid and amino acid 
metabolism. Bacteria that are highly dependent on nutrients from the host environment may have a 
reduced genome, lacking in genes specific for metabolic pathways (Davenport, Poles et al. 2014). In 
inflamed tissue, fewer carbohydatres are available, and therefore bacteria that are able to undergo 
amino acid and lipid metabolism dominate.  
Anaerobic degradation of undigested or endogenous protein in the colon results in the production of a 
wide range of metabolites that are in direct contact with the colonic mucosa. Products of protein 
fermatation such as ammonia, phenolic compounds and tryptophan metabolites have been found to be 
potentially carcinogenic, and thus high dietary meat intake has been linked to colorectal cancer (Chao, 
Thun et al. 2005). 
In the colon, protein degradation commences with hydrol sis of proteins to smaller peptides and 
amino acids by bacterial proteases and peptidases that are more active at neutral to alkaline pH. In the 
proximal colon the pH is more acidic due to the production of SCFAs from carbohydrate 
fermentation. Moving distally in the colon carbohydates levels become depleted, pH increases and 
protein fermentation becomes more efficient (Windey, De Preter et al. 2012). 
SCFAs are the major end product from carbohydate fermentation but they are also produced from 
many amino acids by reductive deamination. SCFAs are beneficial to the host and are rapidly 
absorbed from the colon. Butyrate is the most important energy source for colonocytes and plays a 
major role in proliferation and differentiation (Lupton 2004). Butyrate also inhibits colonic 
carcinogenesis and inflammation, reduces oxidative str ss and reinforces the colonic defense barrier 
(Hamer, Jonkers et al. 2008). Lack of SCFAs in UC stimulated the use of SCFAs as therapy in left 
sided UC. Recently the use of oral butyrate in DSS induced colitis in mice has shown promising 
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results in improving mucosal lesions and decreasing inflammatory profiles (Vieira, Leonel et al. 
2012).  
Branched chain fatty acids (BCFA) exclusively originate from fermentation of branched amino acids. 
Isobutyrate, isovalerate and 2-methylbutyrate are produced from the fermentation valine, leucine and 
isoleucine respectively (Smith, Macfarlane 1997). Increased levels of BCFAs signify limited 
carbohydrate levels.  
Ammonia is produced by bacteria through deamination of amino acids and through urea hydrolysis, 
catalysed by bacterial urease activity. Ammonia canbe utilised by bacteria in protein synthesis, or 
absorbed by colonocytes, metabolised in the liver and is excreted in the urine as urea (Blachier, 
Mariotti et al. 2007). 
Phenolic and indolic compounds are produced from the bacterial degradation of aromatic amino acids. 
BCFAs, phenols and indoles are unique colonic bacteri l metabolites and therefore can be considered 
markers of protein fermentation in the colon (Geypens, Claus et al. 1997). >90% of urinary phenolic 
compounds are excreted as p-cresol (Hughes, Magee et al. 2000). 
Exposure of human colonic epithelial cells to phenol reduces viability. Transepithelial resistance of 
Caco-2 cells is decreased after incubation with bot phenol and also ammonia (Pedersen, Brynskov et 
al. 2002, Hughes, Kurth et al. 2008, McCall, Betanzos et al. 2009). Permeability of endothelial cells is 
increased after exposure to p-cresol (Cerini, Dou et al. 2004).Thinning, or increased permeability of 
the mucous layer, is likely to increase the accessibility of potentially damaging agents to the colonic 
mucosa (Windey, De Preter et al. 2012).  
Fermentation of dietary and mucinous sulphate and sulphur amino acids such as methionine, cystine, 
cysteine and taurine by SRB leads to the production of hydrogen sulphide (H2S) (Lewis, Cochrane 
2007, Roediger, Moore et al. 1997).  
H2S is toxic to colonic cells. In human intestinal epithelial cells, the expression of genes involved in 
cell-cycle progression, inflammation and DNA repair response is modulated by sulphide (Attene-
Ramos, Nava et al. 2010). Sulphide also prevents the oxidation of butyrate in colonocytes, inducing an 
energy deficient state ultimately resulting in reduction of absorption of sodium, reduction of the 
secretion of mucin, and a reduced life span of colon cytes (Roediger, Moore et al. 1997). Cellular 
respiration is also inhibited by H2S. It acts as an inhibitor of cytochrome c oxidase, th  final step in the 
production adenosine triphosphate (Medani, Collins et al. 2011). 
Decarboxylation of amino acids results in amines in the gut. Monoamine and diamine oxidases 
detoxify the amines produced by gut microbiota. Amines also have a role in the formation of N-
nitrosamines by condensation of a secondary amine wth nitrite in an acidic environment or at neutral 
pH, when catalysed by bacterial enzymes (Tricker 1997). 
Bacterial sulphatase has a critical role in determining the rate of degradation of secreted mucous. 
There is significantly increased faecal mucin sulphatase activity in patients with UC, compared to 
healthy controls. CD patients also have increased levels but these are not significant. In UC, faecal 
sulphatase activities were highest in those with active disease. It is hypothesised that the increase in 
faecal sulphatase activity contributes to the coliti  process by increasing the mucin degradation and 
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therefore upsetting homestasis between mucous producti n and bacterial degradation, rather than an 
alteration in faecal flora causing increased faecal sulphatase activity (Tsai, Dwarakanath et al. 1995).  
The human microbiome remains an area requiring a gre t deal of research to aid our understanding 
and guide our knowledge with regards to IBD pathogenesis. It is likely that high throughput 
technologies, such as metabolomics, will greatly advance this field. Hopefully we will gain 
knowledge of a healthy metabolomic profile in relation to intrinsic properties such as human genetics, 
diurnal cycles, and age, and extrinsic factors such as diet, pharmacology and habitat (Goodacre 2007). 
We can then begin to assess the alterations manifested in the metabolite complement in relation to 
changes in the microbiome seen in diseases such as IBD.  
 
1.9.2 Gut Immunology  
The immune system has a major role to play in IBD pathogenesis. In intestinal health, there is 
symbiosis between the host and the gut microbiome maintained by autoregulatory pathways. However 
in IBD, dysregulation of this system occurs and chronic inflammation ensues.  
To provide defense against infection in the gut, secondary lympoid tissues and immune-system cells 
are present throughout the gut. Gut-associated lymphoid tissues (GALT) comprise two functional 
compartments: the inductive compartment and the effector compartment. 
The inductive compartment is where interactions betwe n antigen, dendritic cells and lymphocytes 
induce adaptive immune resposes. The effector compart ent, comprised of the lamina propria, is 
where plasma cells, effector T cells, macrophages, ma t cells and eosinophils reside (Parham 2015). 
In normal healthy intestine, the mucosal barrier comprises: 
• The mucous layer 
• The glycocalyx, a filamentous layer of branched carbohydrates 
• A layer of epithelial cells held together by tight junctions 
 
1.9.2.1 Mucous Layer 
The small bowel has a discontinuous layer of mucous. The colon has a continuous mucous layer 
comprised of two layers, the upper “sloppy” layer, and the lower adherent layer (Johansson, Phillipson 
et al. 2008, Johansson, Larsson et al. 2011). The physical properties of mucous are due to secreted 
mucins, or mucous glycoproteins. In both the small and large bowel, the MUC2 mucin, a large 
complex glycoprotein, predominates. MUC2 contains a protein core rich in proline, serine and 
threonine (Backstrom, Ambort et al. 2013, Johansson, Ambort et al. 2011). Other mucins (MUC3, 
MUC12, MUC13) attach to the epithelial layer via a cytoplasmic tail. This layer acts as a lubricant 




The glycocalyx is a layer of filamentous material coprised of glycoproteins and glycolipids integrated 
into the cell membrane. It has long branched polysaccaride chains forming a network covering the 
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epithelial layer. This layer is thinnest over the surface of M (microfold) cells. The glycocalyx provides 
a barrier to enteric pathogens, and a surface for the attachment of commensal bacteria (Merga, 
Campbell et al. 2014). 
 
1.9.2.3 Tight Junctions 
Desomosomes, adherent junctions and tight junctions h ld epithelial cells of the gut mucosa together. 
Tight junctions prevent intercellular ingress by pathogens.  They are composed of proteins from four 
junctional protein families: occluding, claudin, tricellulin and junctional adhesion molecules (Merga, 
Campbell et al. 2014). In IBD, tight junctions have b en shown to be damaged, although these 
changes may be secondary to the disease, rather than pathogonomic of it (Zeissig, Burgel et al. 2007).  
 
1.9.2.4 Defensins 
Defensins, a group of antimicrobial pepetides <100 amino acids in size, are found in most types of 
epithelial cells. Paneth cells produce large quantities to regulate small-bowel crypt microbiota (Merga, 
Campbell et al. 2014). In both adult and paediatric CD a reduction in human defensin 5 (HD5) and 
HD6 has been identified (Wehkamp, Salzman et al. 2005, Perminow, Beisner et al. 2010). 
 
1.9.2.5 Mucosal B Cells 
The adaptive immune effector mechanism throughout the gut is an immunoglobulin A (IgA)-
producing B-cell system giving rise to secretory IgA antibodies that function at the mucosal surface, 
inhibiting both microbial colonisation and antigen penetration through the epithelial barrier. The 
generation of secretory IgA antibodies in the gut depends on mucosal IgA-producing immunocytes, 
B-cell blasts and plasma cells that accumulate in the mucosal lamina propria by selective homing 
mechanisms after being primed by GALT (Brandtzaeg, Carlsen et al. ). As well as IgA antibodies, 
IgG, IgM, IgD and IgE antibodies are also produced. In IBD there is an increase in the number of 
plasma cells in a non-uniform picture; IgA, IgM, and IgG producing plasma cell increase 2-, 5-, and 
30-fold respectively (MacDermott, Nash et al. 1981). 
 
1.9.2.6 Mucosal T Cells 
Maintenance of the inflammatory response is mainly mediated by abnormally activated effector CD4+ 
T helper (Th) cells. In IBD, reduced rates of apoptosis of these cells have been reported (Bouma, 
Strober 2003). As a result there is upregulation of the synthesis and release of proinflammatory 
mediators including reactive oxygen and nitrogen metabolites, eicosanoids, chemokines and cytokines 
(Strober, Fuss 2011). 
The differentiations in specific T-cell types depends on the interactions of specific cytokines with 
signal transducer and activator of transcription (STAT) factors. The cytokines that promote Th cell 
polarisation are derived from innate immune cells that recognise microbe-associated molecular 
patterns (MAMPs).  
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Activated Th cells are divided into 2 subsets: Th-1 and Th-2. Th-1 cells secrete IFN-γ, a potent 
activator of intracellular killing by macrophages, with the main role of protecting the host against 
intracellular pathogens, some of which are capable of surviving and replicating within macrophages. 
Th1 cell development requires the sequential actions of STAT1 and STAT4, induced by IFN-γ and IL-
12 respectively, which promote an enhanced expression of the T-box transcription factor normally 
expressed in T cells, T-bet. Th-2 cells express the transcription factor GATA binding protein 3 
(GATA-3) and secrete IL-4, IL-5 and IL-13, collaborating to provide host defence against helminths 
(Galvez 2014). 
CD has traditionally been linked with Th1 cells, with a predominance of IL-12 and IFN-γ in the 
mucosa, whereas UC is linked to Th2 cells with an increased production of IL-5 and IL-13 (Pallone, 
Monteleone 1998). 
More recently Th17 cells have been described as a new subset of effector Th cells (Langrish, Chen et 
al. 2005). They are characterised by the expression of transcription factor retinoic acid orphan receptor 
(ROR)γt, but not T-bet or GATA-3, and by their ability toselectively produce high levels of IL-17A 
and IL-17F (Ivanov, McKenzie et al. 2006). 
 
1.9.2.7 Macrophages 
Macrophages are essential for intestinal homeostasis. The macrophage pool in the human intestine is 
heterogeneous, with its exact nature being determined by the presence or absence of inflammation. 
Despite being actively phagocytic and bacteriacidal, resident mucosal macrophages do not produce 
pro-inflammatory mediators in response to stimuli sch as TLR ligands. Instead they act as non-
inflammatory scavengers of bacteria, as well as assisting in the maintenance of regulatory T cells and
promoting epithelial cell renewal, via the production of IL-10 and PGE2 (Prostaglandin E2) 
respectively (Bain, Scott et al. 2013). 
In IBD, macrophages produce inflammatory mediators such as TNFα, IL-1, IL-6 and nitric oxide 
(MacDonald, Monteleone et al. 2011). It is thought that distinct populations of intestinal macrophages 
are responsible for their functional plasticity under different condictions: “resident” and 
“inflammatory” lineages of monocytes (Geissmann, Manz et al. 2010). In IBD, the number of 
macrophages of the colon is increased, partly from proliferation of the resident macrophage 
population, but more so from the recruitment of new monocytes / macrophages from peripheral blood 
(Rugtveit, Brandtzaeg et al. 1994). 
 
1.9.2.8 Epithelial Cells 
The oral cavity, oesophagus and anal canal are lined with stratified squamous epithelium. The 
remaining gut is lined with nonciliated coloumnar epithelium, which is involved in the absorption of 
water and nutrients, as well as acting as a barrier to luminal pathogens. 
The epitheilial monolayer is folded, producing crypts and villous protrusions. The crypts are the site 
of intestinal epithelial cell differentiation into Paneth cells, remaining at the base of the crypt, and 
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goblet, enteroendocrine, and absorptive cells that migrate to the tip of the villous. The epithelium is 
intermittently interrupted by Peyer’s patches, lymphoid aggregates, which are overlaid by microfold 
(M) cells, adept at sampling and transcytosing luminal antigen (Henderson, van Limbergen et al. 
2011).  
Enterocytes are hyperpolarised columnar epithelial cells. Not only do they produce a physical barrier 
to antigens, but also can act independently as antigen-presenting cells (APCs). In order to do this 
efficiently, intestinal epithelial cells express major histocompatibility complex (MHC) molecules class 
II (Bland 1988) and also class I molecules (Shao, Kamalu et al. 2005). 
The epithelium produces antimicrobial proteins such as lysozymes, secretory phospholipid A2, 
defensins, cathelicidins, RNases and C-type lectins in order to prevent microbial invasion (Henderson, 
van Limbergen et al. 2011). Cathelicidin LL-37 has been shown to be upregulated in UC (Schauber, 
Rieger et al. 2006) and C-type lectin MGL1/CD301has an anti-inflammatory role in murine 
explerimental colitis through the upregulation of IL-10 (Saba, Denda-Nagai et al. 2009). A SNP 
(Single Nucleotide Polymorphism ) in the region of CLEC16A that encodes a protein containing C-
type lectin domain, has been shown to be associated with CD patients lacking the NOD2/CARD15 
mutations (Marquez, Varade et al. 2009).  
 
1.9.2.9 Endothelial Cells 
Endothelial cells (ECs) are the major constituent of the microvasculature that line blood vessels and 
lymphatics.  
In health, ECs provide an anti-adhesive, selectively p rmeable exchange barrier (Cines, Pollak et al. 
1998). However, in IBD ECs undergo rapid changes in response to elevated levels of cytokines and 
growth factors related to gut injury. The endothelial microvasculature both expands and increases in 
permeability (Oshima, Laroux et al. 2001).  
ECs can produce IL-1β, IL-3 and IL-6 upon stimulation with inflammatory c tokines, TNFα, and IL-
1 (Nilsen, Johansen et al. 1998). ECs show distinct properties such as constitutive inducible nitric 
oxide synthase (iNOS) and unique adhesive determinants that may be altered in IBD (Binion, Rafiee 
et al. 2000). Endothelial-derived NO reduces leukocyte and platelet adhesion to the endothelium 
(Sessa 2009, Binion, Fu et al. 1998), mediates flow-dependent and agonist-dependent vasodilatation, 
and couples VEGF-A (vascular epithelial growth factor A) signalling with NO-dependent 
permeability (Petersson, Schreiber et al. 2007, Spyridopoulos, Luedemann et al. 2002). 
Endothelial nitric oxide synthase (eNOS)-derived NO is a radical scavenger that absorbs O2 and 
generates ONOO (perioxynitrite), a potent oxidant (Forstermann, Munzel 2006). eNOS expression is 
reduced in IBD, reducing endothelium-dependent vasodilatation, leading to ungoverned oxidant 
formation (Hatoum, Binion et al. 2003). NO may prevent development of endothelial inflammatory 
and hyper-adhesive phenotype in IBD by suppressing cytokine-induced EC adhesion molecules 
(ECAMs) and matrix mettaloproteinases (MMPs) (Oshima, Jordan et al. 2001). Increases in 
endothelial oxidant stress disturbs tight junctional organisation via p38, p42/44 MAPK (mitogen-
activated protein kinase) (Kevil, Oshima et al. 2000). 
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ECs from CD patients show a persistent loss of iNOS expression (Binion, Rafiee et al. 2000). iNOS 
can be decreased by injury to normal ECs, the opposite f most tissues, which mobilise iNOS in 
response to injury (Binion, Rafiee et al. 2000). Despite decreased iNOS however, IBD frequently 
exhibits increased leucocyte recruitment and activation of gut epithelial cells to increase overall NO 
production (Oshima, Jordan et al. 2001). Tissue-derived iNOS and leucocyte iNOS mediate colitis 
injury, and iNOS-dervived NO plays an important role in gut healing after injury through induction of 
VEGF, necessary for angiogenesis in wound healing (Aoi, Terashima et al. 2008). Excess NO may 
drive gut injury and thus exacerbate IBD (Elrod, Laroux et al. 2005).  
Endothelial cells of the gut microvasculature are activ ted by Toll-like receptor (TLR) signalling. 
Protease activated receptors activate transforming growth factor (TGF)-β to induce TLR4 and lead to 
increased IBD severity (Cromer, Mathis et al. 2011). TLR5, a receptor for flagellin, is expressed in all 
ECs (Maaser, Heidemann et al. 2004). TLR5 signalling induces endothelial intercellular adhesion 
molecule-1, TNFα production and leukocyte binding and emigration. Loss of TLR5 leads to 
infectious colitis due to deficent and improper responses to normal flora and pathological 
microorganisms (Vijay-Kumar, Aitken et al. 2008, Vijay-Kumar, Sanders et al. 2007). 
TLR3, mediated by interferon (IFN) type 1 induction f IL-10, a potent anti-inflammatory cytokine, is 
protective in the murine model of acute colitis (Vijay-Kumar, Wu et al. 2007). 
In IBD, plasma levels of inflammatory cytokines such as IL-6, IL-23, IL-12, and TNFα are increased 
(Cromer, Mathis et al. 2011). TNFα has pleiotropic effects of the endothelium in IBD, ranging from 
the induction of adhesion molecules (vascular cellular adhesion molecule (VCAM)-1, and mucosal 
addressin cellular adhesion molecule (MAdCAM)-1), the promotion of interaction of platelets with 
ECs, and inducing expression of pro-angiogenic growth factors such as VEGF-A (Oshima, Jordan et 
al. 2001, Haraldsen, Kvale et al. 1996). 
Defects in the activity of the anti-inflammatory cytokines such as IL-10 may play a role in 
establishing IBD. Pretreatment of ECs with IL-10 prevents IFN-γ mediated endothelial barrier 
disruption (Oshima, Laroux et al. 2001). Several ECadhesion molecules such as intercellular 
adhesion molecule (ICAM)-1, VCAM-1 (vascular cell adhesion molecule 1) and MAdCAM-1 are 
increased in IL-10-/- mouse colitis and may mediate leukocyte recruitment in this model (Kawachi, 
Jennings et al. 2000).  
In IBD, increases in both blood and lymphatic vessels in the intestine increases the endothelial surface 
area, increasing leukocyte recruitment with the mobilisation of ECAMS, including selectins (Binion, 
West et al. 1998). P and E-selectins, glycoproteins xpressed on the surface of platelets and other 
leukocytes, are also expressed on the surface of activated or inflammed endothelium in IBD. P-
selectin, a partial mediator of gut-infiltrating leukocytes, interacts with ECAMs such as VCAM-1 / 
ICAM-1, as well as O-glycans (Davenpeck, Gauthier et al. 1994, Kobayashi, Fukuda et al. 2009). 
Increased platelet P-selectin, with the enhanced prothrombotic surface of the gut EC in IBD, increases 
thrombus formation and tissue damage by ischaemic injury (Fagerstam, Whiss 2006). E-selectin is 
expressed solely on the surface of activated ECs during inflammation and is a major contributor to 
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leukocyte rolling injury. It is not stored but instead must be produced in response to inflammatory 
stimuli such as IL-1, TNFα, and VEGF-A (Rho, Chung et al. 2009, Zittermann, Issekutz 2006). 
Activation of the clotting cascade, as well as platelet and leukocyte activation in IBD reflect the loss 
of the non-thrombogenic EC phenotype. Thrombi aggravate inflammation by binding of micro 
infarcts to the endothelial surface leading to ischaemic inflammation in the intestinal microvasculature 
(Tabibian, Roth 2009). 
 
1.9.2.10 Enteroendocrine Cells 
Gut enteroendocrine cells (EEC) act as sensors of luminal content via G-protein coupled “taste” 
receptors (T1R2, T1R3 and T2R) and nutrient (SCFA) receptors (GPR40, GPR41, GPR43 and 
GPR120). They also express sensory receptors of the mucosal innate immune system. They function 
as transepithelial signal transduction conduits by releasing regulatory peptides and amines such as 
cholecystokinin (CCK, glucagon-like peptide-1 and -2 (GLP-1/2), and polypeptide YY. EECs via 
GLP-2 are involved in epithelial homeostatsis and repair (Moran, Pennock et al. 2012). Two EEC 
genes have been linked to CD: ubiquitination protein 4a (UbE4A) (Sakiyama, Fujita et al. 2008) and 
Phox2B (Rioux, Xavier et al. 2007). 
 
1.9.2.11 Development of Future Therapies 
Treatment of IBD to inhibit EC functions such as immune cell recruitment and inflammatory 
angiogenesis, and to improve beneficial lymphatic function may be developed. The use of endogenous 
inhibitors of leukocyte binding (sVCAM) and peptides (AJM300), as well as of angiogenesis 
(VEGF164b) may become novel therapies (Cromer, Mathis et al. 2011). 
 
1.9.3 Genetics 
In IBD, large quantities of research time and money have been utilised in genetic studies, which have 
lead to a greater understanding of both disease inheritance and susceptibility, and gut homeostasis.  
 
1.9.3.1 Twins Studies 
Twin studies have been carried out in IBD and have provided useful information regarding disease 
pathogenesis. If a disease has a purely genetic origin, concordance between monozygotic (MZ) twins 
should approach 100%. In dizygotic (DZ) twins you would expect the concordance to be 50%. Should 
a disease have a purely environmental origin, you wld expect the concordance to be similar in both 
sets of twins. 
Europeans studies have shown concordance in monozygotic twins to be 20-58% for CD, and 14-19% 
for UC, whereas in dizygotic twins concordance rates of ≤7% have been shown in both CD and UC 
(Tysk, Lindberg et al. 1988, Thompson, Driscoll et al. 1996, Orholm, Binder et al. 2000, Halfvarson, 
Bodin et al. 2003, Spehlmann, Begun et al. 2008).  Halfvarson has recently re-run the Swedish twin 
registry data with the Swedish hospital discharge register and found the concordance rate in 
monozygotic twins for CD to be 27% (Halfvarson 2011), previously thought to be 58% (Tysk, 
 
 70
Lindberg et al. 1988). Rates of CD in dizygotic twins was calculated at 2% (Halfvarson 2011), 
previously thought to be 6% (Tysk, Lindberg et al. 1988). Concordance for mono- and dizygotic twins 
with UC was 15% and 6% respectively, not representing a significant change from previous. This 
study suggests that the influence of genetics in CD may previously have been overestimated.  
 
1.9.3.2 Family Studies 
Familial clustering of IBD has been extensively studied. Patients with CD report a family history of 
CD in a first degree relative in 2 – 14% of cases (Orholm, Munkholm et al. 1991, Peeters, Nevens et 
al. 1996), and a relative with IBD in 5 – 16% of cases (Orholm, Munkholm et al. 1991, Halme, 
Turunen et al. 2002). Those with UC report a family h story in a first degree relative of UC in 7 – 11% 
(Halme, Turunen et al. 2002, Probert, Jayanthi et al. 1993, Yang, McElree et al. 1993) and IBD in 8 – 
14% of cases (Orholm, Munkholm et al. 1991, Halme, Turunen et al. 2002). 
Potentially these figures may be biased, as most published studies come from teaching hospitals that 
may see a more severe disease phenotype, and therefore have more family members affected than a 
population based study. The other confounder is that the longer studies go on, the more chance there is 
of a family member developing IBD. 
The use of age-adjusted figures is a method to establish the relative risk of developing IBD. The most 
commonly used method is Strömgren’s. Calculations are b sed on the assumption that everyone will 
live to 70 years of age. Based on work from Europe and North American (Orholm, Munkholm et al. 
1991, Peeters, Nevens et al. 1996, Yang, McElree et al. 1993), the approximated age-adjusted life-
time risk of developing IBD for a non-Jewish first-degree relative of a person with CD is 5 % and 
1.6% for UC (Halme, Paavola-Sakki et al. 2006). In Jewish populations these figures are calculated to 
be 8% and 5.2% respectively (Yang, McElree et al. 1993). 
Offspring of two parents with IBD are at increased risk of developing IBD with studies showing that 
up to 36% may be affected (Bennett, Rubin et al. 1991). 
Despite the different methodologies employed, it has been consistently shown that first degree 
relatives are at greatest risk of developing IBD, especially siblings, while parents are at lowest risk 
(Peeters, Nevens et al. 1996, Yang, McElree et al. 1993), and that a positive family history is seen 
more often in CD than in UC (Halme, Paavola-Sakki et al. 2006).  
 
1.9.3.3 Family-linkage Studies 
As previously discussed, twin studies demonstrated important genetic components to complex 
diseases such as IBD, however there was difficulty isolating the specific loci involved. Family-linkage 
studies, the study of large families with disease throughout multiple generations, are useful in the 
mapping of Mendelian disease genes, but were not optimal in the investigation of complex diseases 
such as IBD. With the exception of NOD2 and CD (Hugot, Chamaillard et al. 2001, Ogura, Bonen et 
al. 2001), it became apparent that these complex diseases are not caused by a few highly penetrant 
mutations, but were instead affected by a range of both common and rare mutations that only 




1.9.3.4 Association Studies 
Association studies, the comparison of a disease population with a healthy population in relation to 
genetic variations, allowed further progress to be made in the study of IBD, however it was not until 
genome-wide association studies became commonplace that knowledge of the genome rapidly 
evolved in IBD studies.  
 
1.9.3.5 Candidate Studies 
Candidate genetic studies allow researchers to focus on a single gene that has previously been 
identified through other study methodologies or prior knowledge. The advantage is that by either 
finding, or refuting an association, evidence for or against the functionality of the variant in a specific 
pathway can be clarified. The disadvantages of this method are that prior knowledge, which may be 
subjective, is required. Large study samples may be essential to identify the function of a single 
genetic variant in a complex disease, and because the search for variants is limited to a specific region, 
the influence of causative agents out with this region will be missed.  
 
1.9.3.6 Autophagy 
Autophagy is an essential process required for cellular homeostasis and organelle turnover (Rioux, 
Xavier et al. 2007) and occurs through the removal f waste products from the cellular cytoplasm. 
This occurs by encapsulation of the products to form an autophagosome, which eventually fuses with 
lysosomes causing degradation and recycling of the vesicle contents. The antigens are loaded on to 
major histocompatibility complex class II to activate T cell receptor-mediated adaptive immune 
responses (Plantinga, Crisan et al. 2011). This lysosomal degradation pathway is also used to degrade 
microorganisms that invade the cell such as bacteria, viruses and protozoa (Levine, Mizushima et al. 
2011).  
Autophagy is associated with most cellular stress-rponse pathways, including those involved in 
controlling immune responses and inflammation. This complex process also involves interactions 
between autophagy proteins and immune signalling molecules. An intricate relationship exists 
between the autophagy pathway and proteins, and immunity and inflammation.  Autophagy proteins 
function simultaneously in the induction and suppression of immune and inflammatory responses, and 
vice versa, and therefore defects in autophagy genes may lead to inflammatory conditions (Levine, 
Mizushima et al. 2011). 
Genetic variation in genes involving the recognitio f bacteria (NOD2), and also autophagy genes 
(ATG16L1 and IRGM) (Rioux, Xavier et al. 2007) invol ed in the processing and elimination of 
bacteria may provide insight into Crohn’s disease pathogenesis. 
 
1.9.3.7 NOD2/CARD15 
The first genome wide linkage study in CD was reported in 1996 and identified genomic sharing 
between CD relatives on chromosome 16, IBD1 (Hugot, Laurent-Puig et al. 1996). Since then there 
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has been mass replication of this finding with NOD (nucleotide oligomerisation domain) 2, also 
known as CARD (caspase-activation recruitment domain) 15 or IBD1 on chromosome 16 being 
confirmed as linking with CD but not UC (Hugot, Cham illard et al. 2001, Ogura, Bonen et al. 2001, 
Cavanaugh, IBD International Genetics Consortium 2001, Hampe, Cuthbert et al. 2001). 
The NOD2 gene was first characterised as belonging to a family of proteins sharing structural 
homologies to the plant R proteins that mediate host re istance to pathogens (Ogura, Inohara et al. 
2001). The NOD2 gene contains two N terminus caspase-activation recruitment domains, a central 
nucleotide oligomerisation domain  and a C terminus leucine- rich repeat (LRR) domain. The LRR 
domain mediates host response to microbial stimulation for both NOD and toll-like receptor (TLR) 
proteins (Khor, Gardet et al. 2011). NOD2 is expressed in intestinal epithelial cells, with particularly 
high expression in Paneth cells in the small intestin , intestinal myofibroblasts, endothelial cells, 
granulocytes, and monocyte-derived cells, including macrophages, osteoblasts, and dendritic cells 
(Cho, Abraham 2007). Activation of NOD2 results in activation of multiple signaling pathways, 
including the NF-κB and MAPK pathways, and ultimately leads to a variety of immune responses. 
Within NOD2, three coding region variants in or near the LRR domain, Arg702Trp, Gly908Arg, and 
the frameshift mutant Leu1007fsinsC, are each independently associated with CD. The frameshift 
mutant truncates the terminal 33 amino acids of the protein, resulting in a marked loss in the capacity 
to activate NF-κB (Ogura, Bonen et al. 2001). 
NOD2, a pattern recognition receptor (PRR), directly binds ATP (adenosine triphosphate) and 
muramyl dipeptide (MDP), a breakdown product of peptidoglycan derived from the cell wall of 
Gram-negative and Gram-positive bacteria. NOD2 recognises MDP, which modulates both innate and 
adaptive immune responses (Shaw, Kamada et al. 2011). MDP stimulation induces autophagy, which 
controls bacterial replication and antigen presentation, and acts on dendritic cells in conjunction with 
TLR ligands to promote TH17-cell differentiation (Cooney, Baker et al. 2010, Travassos, Carneiro et 
al. 2010). NOD2 may also contribute to immune tolerance. These effects are impaired in cells from 
patients with the Crohn's-disease-associated NOD2 mutation 3020insC. Furthermore, NOD2 can 
participate in distinct MDP-independent pathways such as regulation of the T-cell response and the 
type I IFN (interferon) response to single-stranded RNA (ssRNA) stimulation, indicating that gut 
microbial ssRNAs may exist and have immunomodulatory properties (Sabbah, Chang et al. 2009). 
Previously it was thought that carriers of either homozygous or compound heterozygous 
NOD2/CARD15 variant genotypes are associated with a severe, early onset disease phenotype 
consisting of stricturing and/or fistulating diseas (Lesage, Zouali et al. 2002, Laghi, Costa et al. 
2005), the requirement for early surgical intervention, and surgical recurrence (Alvarez-Lobos, 
Arostegui et al. 2005). However, the most recent, ad largest, genotype-phenotype IBD study 
encompassing phenotyping from nearly 30 000 IBD patients worldwide and matching genotypes from 
150 000 varients, has shown that in CD, NOD2 is not associated with stricturing disease after 
accounting for disease location (Cleynen, Boucher et al. 2016). Significant associations between ileal 





Autophagy-related 16-like 1 gene (ATG16L1) encodes for one of the main proteins involved in the 
formation of autophagosomes (Plantinga, Crisan et al. 2011). A mutation in ATG16L1 (non-
synonymous polymorphism T300A) has been implicated in susceptibility to Crohn’s disease (Rioux, 
Xavier et al. 2007, Hampe, Franke et al. 2007). As with NOD2 variants, dendritic cells from patients 
with the Crohn’s-disease-associated ATG16L1(T300A) risk variant are defective in presenting 
bacterial antigen to CD4+ T cells. In addition, ATG16L1 may have unique protective functions, 
including Paneth cell antimicrobial peptide release nd the negative regulation of pro-inflammatory 
cytokine production (Plantinga, Crisan et al. 2011).  
 
1.9.3.9 IRGM 
The IRGM (immunity-related GTPase family M) gene belongs to immunity-related GTPases, a family 
of genes induced by interferons and functioning as key mediators of IFN-regulated resistance to 
intracellular bacteria and protozoa (Singh, Davis et al. 2006). Genome-wide Association Studies 
(GWAS) have shown IRGM to be strongly associated with CD (Parkes, Barrett et al. 2007, Wellcome 
Trust Case Control Consortium 2007). In CD patients, autophagy has been demonstrated to limit the 
replication of intracellular adherent-invasive Escherichia coli (AIEC) associated with ileal CD. IRGM 
and ATG16L1-deficient cells have enhanced intracellular AIEC bacteria replication, suggesting a 
significant impact on the outcome of intestinal infammation (Lapaquette, Glasser et al. 2010). 
 
1.9.3.10 HLA 
The major histocompatibility complex (MHC), known ihumans as the human leukocyte antigen 
(HLA) region, was first reported on with regards to IBD in 1972 (Gleeson, Walker et al. 1972). Since 
then numerous studies have investigated the role HLA gene may play in IBD. HLA was one of the 
first multi-megabases regions to be sequenced (Complete sequence and gene map of a human major 
histocompatibility complex. The MHC sequencing consortium. 1999). HLA spans approximately 4 
megabases of DNA in the chromosome band 6p21.3. It is divided into 3 classes, and contains 224 
densely packed highly polymorphic gene loci, mainly relating to immunologic functions (Yap, Ahmad 
et al. 2004). Polymorphisms in key areas such as peptide binding regions and T cell receptor repertoire 
determination may affect these functions, possibly causing disease. A possible functional 
polymorphism is that of the association of the HLA DRB1*0103 allele with IBD. This allele encodes 
an HLA DR molecule with a unique sequence within the peptide-binding groove, thus allowing it to 
bind and present potentially disease-associated peptides (Coppin, Carmichael et al. 1993).  
HLA Class I and II genes have been extensively investigated through linkage studies to determine 
associations with IBD, however, results have been inconsistent. In UC evidence was found for linkage 
to HLA DRB1 (Satsangi, Welsh et al. 1996). 
Since then advances in technology and GWAS has allowed for the further investigation of HLA genes 
with regards to IBD. The focus has been on HLA Class II genes as they play a pivotal role in immune 
function. The class II molecules consist of an α chain and a β chain that form a groove in which the 
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antigenic peptide, after partial digestion of antigen by antigen presenting cells, is conferred to the T 
cell receptor (Brown, Jardetzky et al. 1993). Meta-an lysis has shown a positive association of HLA-
DR9, HLA-DR2 and allele 1502 of its split antigen HLA-DR15 with UC but a protective effect of 
HLA-DR4 against UC. HLA-DR7, HLA-DRB3*0301 and DQ4 (when Japanese populations 
included) are positively associated with CD, with HLA-DR2 and HLA-DR3 negatively associated 
with CD (Stokkers, Reitsma et al. 1999).The HLA-DRB1*0103 allele has been positively associated 
with UC, and has been shown to predispose to extensive disease (Roussomoustakaki, Satsangi et al. 
1997). Studies in CD have shown associations with DR1 (Toyoda, Wang et al. 1993, Danze, 
Colombel et al. 1996), DR4 (Matake, Okabe et al. 1992), and DR7 (Danze, Colombel et al. 1996, 
Reinshagen, Loeliger et al. 1996) with a protective effect of DR3 (Danze, Colombel et al. 1996, 
Reinshagen, Loeliger et al. 1996). The HLA-DRB1*0103 allele is also associated with CD and 
predisposes to later age at diagnosis and colonic disease compared to HLA-DRB1*0701 and HLA-
DRB1*04 predicting ileal disease (Newman, Silverberg t al. 2004).  
Most recently, the association between MHC and colonic CD has been confirmed, as has the 
association between MHC and both extensive and severe disease requiring colectomy in UC (Cleynen, 
Boucher et al. 2016). 
 
1.9.3.11 GWAS 
Conversely, genome-wide association studies are essentially a hypothesis-free methodology utilising 
high-throughput technology to genotype single nucleotide polymorphisms (SNPs) in large 
meticulously phenotyped patient cohorts, prompting he rapid discovery of complex disease genetics. 
Both CD and UC have been extensively investigated through international collaborative groups 
(International Inflammatory Bowel Disease Genetics Consortium, http://www.ibdgenetics.org/) 
amassing large datasets and thus huge statistical power (de Bakker, Ferreira et al. 2008). Most recently 
the number of confirmed IBD loci is 163, with each loci containing an average of 5 genes (Jostins, 
Ripke et al. 2012), the most in any complex disease. 110 of the 163 loci are associated with both CD 
and UC phenotypes, 30 are specific to CD and 23 to UC respectively. 43 of these 53 loci show the 
same direction of effect in the non-associated disease. Risk alleles at two CD loci, PTPN22 and 
NOD2, show significant protective effects in UC, potentially reflecting biological differences between 
the two diseases. In fact, the same coding variant of PTPN22 is a strong risk factor for type I diabetes 
and rheumatoid arthritis but is protective against CD (Wang, Baldassano et al. 2010) illustrating one 






Figure 1.4: IBD Susceptibility Loci (Lees, Barrett et al. 2011)
 
The loci (depicted by lead gene name) attaining genome-wide significance (p<5x10-8) are shown for 
CD (red), UC (blue) and IBD (black), where p<5x10-8 in CD and UC; red where p<5x10-8 in CD and 
p< 5x10-4 in UC; blue where p<5x10-8 in UC and p<5x10-4 in CD. 
 
In the most recent GWAS meta-analysis data, 113 of the 163 IBD loci identified are shared with other 
diseases or traits. Comparing the overlap with other diseases however is problematic as it depends on 
the power of other studies. Type I diabetes shares th  largest number of loci with IBD (20/39), 
however this is in part due to the large number of associations known in type I diabetes. Psoriasis 
(14/17) and ankylosing spondylitis (8/11) also show strong overlaps. IBD loci were shown to be 
enriched in genes involved with primary immunodefici ncies (PIDs), characterised by immune 
dysfunction resulting in severe infections. The genes involved in this overlap correlate with reduced 
circulating T-cell levels (ADA, CD40, TAP1/2, NBS1, BLM, DNMT3B), or with specific subsets such 
as Th17 (STAT3), memory (SP110), or regulatory T-cells (STAT5B). A group of PIDs genes leading to 
Mendelian susceptibility to mycobacterial disease (MSMD) was also shown to be enriched with six of 
the eight known autosomal genes linked to MSMD located within IBD loci (IL12B, IFNGR2, STAT1, 
IRF8, TYK2 and STAT3) and a seventh (IFNGR1) almost showing significance. Unsurprisingly 
perhaps, overlap with IBD is seen in complex mycobaterial disease and IBD associations were found 







Figure 1.5: Diseases Showing Genetic Overlap with IBD (Lees, Barrett et al. 2011) 
 
 
Genes that have attained genome-wide levels of significa ce in all diseases are depicted. IBD loci 




Table 1.3: Crohn’s Disease Loci (Jostins, Ripke et al. 2012) 
Crohn’s Disease 
Chromosome Position (Megabase) SNP Key genes (+ no.of 
additional loci genes) 
1 78.62 rs17391694 (5) 
1 114.3 rs6679677 || PTPN22 ¶ (8) 
1 120.45 rs3897478 ADAM30 (5) 
1 172.85 rs9286879 FASLG, TNFSF18 (0) 
2 27.63 rs1728918 UCN (23) 
2 62.55 rs10865331 (3) 
2 231.09 rs6716753 SP140 (5) 
2 234.15 rs12994997 ATG16L1 ¶  (8) 
4 48.36 rs6837335 (6) 
4 102.86 rs13126505 (1) 
5 55.43 rs10065637 IL6ST, IL31RA  (1) 
5 72.54 rs7702331 (4) 
5 173.34 rs17695092 CPEB4 (2) 
6 21.42 rs12663356 (3) 
6 31.27 rs9264942 (22) 
6 127.45 rs9491697 (3) 
6 128.24 rs13204742 (2) 
6 159.49 rs212388 TAGAP (5) 
7 26.88 rs10486483 (2) 
7 28.17 rs864745 CREB5, JAZF1 (1) 
8 90.87 rs7015630 RIPK2 (4) 
8 129.56 rs6651252 0 
13 44.45 rs3764147 LACC1 (3) 
15 38.89 rs16967103 RASGRP1, SPRED1 
(2) 
16 50.66 † rs2066847 || NOD2 ¶ (6) 
17 25.84 rs2945412 LGAS9, NOS2 (3) 
19 1.12 rs2024092 GPX4, HMHA1 (20) 
19 46.85 ‡ rs4802307 (9) 
19 49.2 rs516246 FUT2, (25) 





Table 1.4: Ulcerative Colitis Loci (Jostins, Ripke et al. 2012) 
Ulcerative Colitis 
Chromosome Position (Megabase) SNP Key genes (+ no.of 
additional loci genes) 
1 2.5 rs10797432 TNFRSF14 (10) 
1 20.15 † rs6426833 (9) 
1 200.09 rs2816958 (3) 
2 198.65 rs1016883 RFTN2, PLCL1 (7) 
2 199.70 * rs17229285 0 
3 53.05 rs9847710 PRKCD, ITIH4 (8) 
4 103.51 rs3774959 NFKB1, MANBA  (2) 
5 0.59 rs11739663 SLC9A3 (8) 
5 134.44 rs254560 (6) 
6 32.595 rs6927022 (15) 
7 2.78 rs798502 CARD11, GNA12 (5) 
7 27.22 ‡ rs4722672 (14) 
7 107.45 * rs4380874 DLD (9) 
7 128.57 rs4728142 IRF5 ¶ (13) 
11 96.02 rs483905 JRKL, MAML2 (2) 
11 114.38 rs561722 NXPE1, NXPE4 (5) 
15 41.55 rs28374715 (11) 
16 30.47 rs11150589 ITGAL (20) 
16 68.58 rs1728785 ZFP90 (6) 
17 70.64 rs7210086 (3) 
19 47.12 ‡ rs1126510 CALM3 (14) 
20 33.8 rs6088765 (11) 




Table 1.5: General IBD Loci (Jostins, Ripke et al. 2012) 
IBD 
Chromosome Position (Megabase) SNP Key genes (+ no.of 
additional loci genes) 
1 1.24 rs12103 TNFRSF18, TNFRSF4 
(30) 
1 8.02 rs35675666 TNFRSF9 (6) 
1 22.7 rs12568930 § (3) 
1 67.68 † rs11209026 § IL23R  ¶ (5) 
1 70.99 rs2651244 § (3) 
1 151.79 rs4845604 § RORC (14) 
1 155.67 rs670523 § (31) 
1 160.85 rs4656958 § CD48 (15) 
1 161.47 rs1801274 § FCGR2A, FCGR2B, 
FCGR3A (13) 
1 197.6 rs2488389 C1orf53 (2) 
1 200.87 rs7554511 KIF21B (6) 
1 206.93 rs3024505 § IL10 (10) 
2 25.12 rs6545800 § ADCY3 (6) 
2 28.61 rs925255 § FOSL2, BRE (1) 
2 43.81 rs10495903 § (5) 
2 61.2 rs7608910 REL (9) 
2 65.67 rs6740462 SPRED2 (1) 
2 102.86 * rs917997 § IL18RAP, IL1R1 (7) 
2 163.1 rs2111485 IFIH1 (5) 
2 191.92 rs1517352 STAT1, STAT4 (2) 
2 219.14 rs2382817 (15) 
2 241.57 * rs3749171 § GPR35 (12) 
3 18.76 rs4256159 § 0 
3 48.96 † rs3197999 MST1, PFKB4 (63) 
4 74.85 rs2472649 § (11) 
4 123.22 rs7657746 IL2, IL21 (2) 
5 10.69 rs2930047 DAP (2) 
5 40.38 † rs11742570 § PTGER4 (1) 
5 96.24 rs1363907 ERAP2, ERAP1 (3) 
5 130.01 rs4836519 § (1) 
5 131.19 * rs2188962 § IBD5 locus (18) 
5 141.51 rs6863411 § SPRY4, NDFIP1 (5) 
5 150.27 rs11741861 § IRGM ¶ (10) 
5 158.8 † rs6871626 § IL12B (3) 
5 176.79 rs12654812 DOK3 (17) 
6 14.71 rs17119 0 
6 20.77 * rs9358372 § (2) 
6 90.96 rs1847472 (1) 
6 106.43 rs6568421 § (2) 
6 111.82 rs3851228 TRAF3IP2 (4) 
6 138 rs6920220 § TNFAIP3 (1) 
6 143.9 rs12199775 PHACTR2 (5) 
6 167.37 rs1819333 § CCR6, RPS6KA1 (4) 
7 50.245 * rs1456896 ZPBP, IKZF1 (4) 
7 98.75 rs9297145 SMURF1 (6) 
7 100.34 rs1734907 § EPO (21) 
7 116.89 rs38904 § (6) 
8 126.53 rs921720 § TRIB1 (1) 
8 130.62 rs1991866 (2) 
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9 4.98 rs10759669 JAK2 (4) 
9 93.92 rs4743820 § NFIL3 (2) 
9 117.60 † rs4246905 TNFSF15 (4) 
9 139.32 * rs19781499 § CARD9 (22) 
10 6.08 rs12722515 § IL2RA, IL15RA (6) 
10 30.72 rs1042058 § MAP3K8 (3) 
10 35.3 rs11010067 § CREM (3) 
10 59.99 rs2790216 CISD1, IPMK (2) 
10 64.51 † rs10761659 § (3) 
10 75.67 rs2227564 § (13) 
10 81.03 rs1250546 § (5) 
10 82.25 rs6586030 § TSPAN14, C10orf58 
(4) 
10 94.43 rs7911264 (4) 
10 101.28 rs4409764 NKX2-3 (6) 
11 1.87 rs907611 TNNI2, LSP1 (17) 
11 58.33 rs10896794 CNTF, LPXN (8) 
11 60.77 rs11230563 CD6 (14) 
11 61.56 rs4246215 § (15) 
11 64.12 rs559928 CCDC88B (23) 
11 65.65 rs2231884 § RELA (25) 
11 76.29 rs2155219 § (5) 
11 87.12 rs6592362 (1) 
11 118.74 rs630923 § CXCR5 (17) 
12 12.65 rs11612508 § LOH12CR1 (8) 
12 40.77 * rs11564258 § MUC19 (1) 
12 48.2 rs11168249 § VDR (8) 
12 68.49 rs7134599 § IFNG (3) 
13 27.52 rs17085007 § (2) 
13 40.86 † rs941823 § (3) 
13 99.95 rs9557195 GPR183, GPR18 (6) 
14 69.27 rs194749 § ZFP36L1 (4) 
14 75.7 rs4899554 § FOS, MLH3 (6) 
14 88.47 rs8005161 GPR65, GALC (1) 
15 67.27 rs17293632 § SMAD3 (2) 
15 91.17 rs7495132 CRTC3 (3) 
16 11.54 * rs529866 § SOCS1, LITAF (11) 
16 23.86 rs7404095 PRKCB (5) 
16 28.6 rs26528 § IL27 (14) 
16 86 rs10521318 § IRF8 (4) 
17 32.59 rs3091316 § CCL13, CCL2 (5) 
17 37.91 rs12946510 ORMDL3 (16) 
17 40.53 rs12942547 § STAT3 (15) 
17 57.96 rs1292053 § TUBD1, RPS6KB1 (9) 
18 12.8 rs1893217 § (6) 
18 46.39 rs7240004 § SMAD9 (2) 
18 67.53 rs727088 CD226 (2) 
19 10.49 * rs11879191 TYK2 (27) 
19 33.73 rs17694108 CEBPG (8) 
19 55.38 rs11672983 (19) 
20 30.75 rs6142618 § HCK (10) 
20 31.37 rs4911259 DNMT3B (8) 
20 44.74 rs1569723 § CD40 (13) 
20 48.95 rs913678 CEBPB (5) 
20 57.82 rs259964 ZNF831, CTSZ (5) 
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20 62.34 rs6062504 TNFRSF6B (26) 
21 16.81 rs2823286 § 0 
21 40.46 rs2836878 § (3) 
21 45.62 rs7282490 ICOSLG (9) 
22 21.92 rs2266959 (13) 
22 30.43 rs2412970 LIF, OSM (9) 
22 39.69 * rs2413583 § TAB1 (18) 
 
In relation to tables 1.3-5, the position given is the middle of the locus window, with all positions 
relative to human reference genome GRCh37. Bolded rs numbers indicate SNPs with p values less 
than 1x10-13. Grey shading indicates newly discovered loci. Listed are genes implicated by one or 
more candidate gene approaches. Bolded genes have been implicated by two or more candidate gene 
approaches. For each locus, the top two candidate gen s are listed.  
* Additional genome-wide significant associated SNP in the region. 
† Two or more additional genome-wide significant associated SNPs in the region. 
‡ These regions have overlapping but distinct UC and CD signals. 
§ Hetrogeneity of odds ratios. 
|| CD risk allele is significantly protective in UC. 
¶ Gene for which functional studies of associated alleles have been reported.  
 
1.9.3.12 Epigenetics 
In humans, monozygotic (MZ) twins account for 1:250 live births (Fraga, Ballestar et al. 2005). 
Studies in MZ twins, considered genetically identical, have been used in the demonstration of the 
influence of environmental factors in complex diseases and human phenotypes (MacGregor, Snieder 
et al. 2000). However, significant discordance can occur in MZ twins for disease types and traits, and
the reason potentially could be explained by epigenetic differences. Epigenetic profiles may in fact 
represent the link between an environmental factor and phenotypic differences in MZ twins. 
 
A popular definition of epigenetics is “the study of mitotically and/or meiotically heritable changes in 
gene expression that occur without a change in DNA sequence” (Russo V.E.A., Martienssen R.A. et 
al. 1996). The epigenome of a cell is controlled by complex interactions between genetic and 
environmental factors (Rakyan, Down et al. 2011). In mammals, epigenetic information can be 
transferred in mitotically stable DNAm (DNA methylation), post-translational histone proteins and 
non-coding RNAs (ncRNAs) (Bernstein, Meissner et al. 2007). 
 
1.9.3.12.1 DNA Methylation 
DNA methylation is a mechanism for silencing gene expr ssion and maintaining stability during 
massive DNA replication, which if left unregulated, could allow illegitimate recombination events and 
cause transcriptional deregulation of nearby genes (Robertson 2005). For DNAm, the most common 
form of methylation is of cytosines in the context of cytosine-guanine dinucleotides (CpGs). CpG 
dinucleotides tend to cluster in areas called CpG islands, areas with more than 200 bases with a G+C 
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content of >50%.  Approximately 60% of human gene promoters are associated with CpG islands, 
which tend to be unmethylated in normal cells (Straussman, Nejman et al. 2009). CpH (where H = 
C/A/T) methylation also occurs but is less common, as is 5-hydroxymethylation of cytosines catalysed 
by ten-eleven translocation methycytosine dioxygenas s (Rakyan, Down et al. 2011). 
 
1.9.3.12.2 Histone Proteins 
Chromatin is a combination of DNA and proteins that form the nucleus of a cell. The nucleosome, the 
fundamental unit of chromatin, is composed of an octamer of the four core histones (H3, H4, H2A, 
H2B) around which 147 base pairs of DNA are wrapped. The core histones are predominantly 
globular except for their N-terminal ‘‘tails’’, which are unstructured and subject to modifications in 
the form of acetylation, methylation (lysines / arginines), phosphorylation, ubiquitylation, 
sumoylation, ADP (adenosine diphosphate) ribosylation, deimination or proline isomerisation to one 
or more of their amino-acids (Kouzarides 2007). Histone modifications play important roles in 
transcriptional regulation, DNA repair and replicaton (Huertas, Sendra et al. 2009), alternative 
splicing (Luco, Pan et al. 2010) and chromosome condensation (Kouzarides 2007). Histone 
modification levels are predictive for gene expression (Karlic, Chung et al. 2010). 
 
1.9.3.12.3 Nucleosome Positioning 
As discussed earlier, the nucleosome is a method of packaging a helical DNA polymer. Nucleosomes 
are positioned as a linear array along a DNA polymer. The exact position of the nucleosomes in 
relation to the transcription start sites (TSSs) is very influential on the initiation of transcription 
(Jiang, Pugh 2009, Portela, Esteller 2010). Small alterations in nucleosome position of only 30 base 
pairs at TSSs may change the activity of RNA polymeras  II. Loss of a nucleosome directly upstream 
of the TSS is associated with gene activation, and occlusion of the TSS by a nucleosome is associated 
with gene repression (Schones, Cui et al. 2008, Cairns 2009). 
 
1.9.3.12.4 ncRNA  
ncRNAs have been implicated in a variety of epigenetic mechanisms; small RNAs can direct cytosine 
methylation and histone modifications, microRNAs in gene expression control, large RNAs in X-
chromosome inactivation and imprinting, and piRNAs have been implicated in germ cell maintenance 
(Fabrício F. 2008).  
 
1.9.3.12.5 Epigenetics and IBD 
Epigenetic programming starts at fertilisation and continues throughout the lifespan of a being. 
Epigenetic information is stored as chemical modifications to cytosine bases and to the histone 
proteins that package the genome. These chemical alterations that regulate chromatin structure and 
DNA accessibility in turn influence how the genome is made and potentially how the genome 
interacts with the environment (Bernstein, Meissner et al. 2007). Animal models have shown the 
effects of epigenetic alterations due to environmental factors in pregnancy to be maintained for up to 
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two generations (Morgan, Sutherland et al. 1999, Schaible, Harris et al. 2011). This has raised interest 
in the scientific community where it was previously thought that epigenetic marks were reset during 
meiosis and therefore the crossing of generations is a novel phenomenon (Faulk, Dolinoy 2011). 
Factors such as smoking, diet and the microbiota that produce epimutations may now be implicated in 
the familial predisposition to certain diseases such as IBD (Ventham, Kennedy et al. 2013). 
 
1.10 Biomarkers 
Biomarkers are measurable substances in bodily fluids that can be used to diagnose pathology, 
monitor disease activity, predict disease phenotype, for individual therapeutic targeting, to measure 
outcomes in clinical trials, or a combination of all of the above (Sargent, Conley et al. 2005). IBD 
biomarkers include serological, faecal and gene polym rphisms. Their application in the diagnosis and 
monitoring of IBD is potentially cheaper, less laborious, less invasive and more objective compared to 
an endoscopy / biopsy based approach (Vermeire, Van Assche et al. 2006), however, currently none 
of the commercially available biomarkers can be used as stand-alone tools and are simply used as an 
adjunct to endoscopy. There is a great need for new biomarkers to be developed. 
1.10.1 Discovery and Development Challenges 
The discovery of biomarkers suitable for clinical use is challenging. Traditionally biomarkers were 
developed through a hypothesis driven understanding of disease pathophysiology. However, now the 
introduction of high throughput “omics” technologies not based on a priori hypotheses, whilst 
potentially providing new causal or mechanistic disease information, has also lead to the potential 
development of biomarkers ahead of the understanding of the biological basis of disease. Concerns 
have been raised regarding how to validate such markers. The two main areas of validation are 
technical (or analytical) validation, regarding intr sic measurement error and analytical sensitivity, 
and clinical (or field) validation relating to how a certain marker behaves in the population, depending 
on biological variability within the population (Vineis, Perera 2007).  
The areas of three major concerns are:  
1. Overfitting – the tendency of models trained on large numbers of variables measured on small 
numbers of samples to produce extraordinarily high sensitivity and specificity and then fail on 
independent validation sets  
2. Bias – are results due to differences between th disease and the control samples that do not exist in 
the disease and control populations?  
3. Robustness – can results be generalised to appropriate clinical populations? (Brenner, Normolle 
2007)  
The Early Detection Research Network (Pepe, Etzioni et al. 2001) has laid out five phases of 
validation to address “robustness”: 
Phase I. Preclinical / Exploratory – promising directions identified. 
Phase II. Clinical assay and validation – clinical assay detects established disease. 
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Phase III. Retrospective / Longitudinal – biomarker d tects disease early before it becomes clinical 
and a “screen positive” rule is defined. 
Phase IV. Prospective / Screening – extent and chara teristics of disease detected by the test and the 
false referral rate are identified. 
Phase V. Disease Control – Impact of screening on reducing the burden of disease on the population is 
quantified. 
The importance of robust studies and techniques to develop simple, sensitive, specific, inexpensive 
and reproducible tests for biomarkers that have a significant clinical utility cannot be underestimated 
(Newton, Newman et al. 2012). Further guidelines have been proposed to ensure accuracy and clinical 
applicability by utilising the prospective-specimen-collection, retrospective-blinded-evaluation 
(PRoBE) design (Pepe, Feng et al. 2008).  
In the UK, The Cancer Research UK Biomarker Discovery and Development Committee have defined 
the following groups of biomarkers, equally applicable to non-cancer processes (Newton, Newman et 
al. 2012): 
Risk assessment ⁄ predisposition biomarkers can be used to define individuals or populations at 
increased risk of developing a disease. The biomarker sample should be as non-invasive as possible, 
and the test must be sensitive, specific, reproducible, and able to diagnose the predisposition to a 
disease prior to the pathology developing. These biomarkers may be markers of a genetic 
predisposition or a measure of exposure to a substance that increases that individual’s risk. 
Screening ⁄ early detection biomarkers are used to aid early diagnosis of a condition, thus facilitating 
detection at a more treatable stage. Collection of these biomarkers must be acceptable to the screening 
population, and highly sensitive to avoid unnecessary anxiety and investigation with false positive 
results.  
Diagnostic biomarkers are used to define the type of cancer or disease present in the patient. These 
tend to be used alongside standard imaging techniques to further facilitate appropriate treatment. 
Prostate specific antigen, carcinoembryonic antigen and cancer antigen 125 are examples that can also 
be used to monitor disease and detect recurrence or relapse.  
Pharmacological biomarkers are used to assess pharmokinetics, measure the effects of drug treatment 
on a specific target (e.g. enzyme inhibition, receptor blockade, induction of apoptosis or reduction in 
angiogenesis), or to demonstrate clinical effects of that drug. These biomarkers can help to facilitate 
personalised treatment through dose optimisation and reduction of side effects. In Crohn’s disease, th 
thiopurine methyl- transferase (TMPT) gene has a role in identifying the 1:300 patients who are at risk 
of developing severe myelosuppression when treated with standard thiopurine dosages (Lennard 
2002).  
Predictive biomarkers can predict a subpopulation of patients who are likely to respond to a given 
therapy thus allowing more personalised targeting of treatment. Oestrogen and progesterone receptor 
status in breast cancer, and KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) and response to 




Prognostic biomarkers are used to predict the likely course of a disease. This may be the metastatic 
potential of a cancer and can be used to guide treatment and surveillance decisions, as well as survival 
prognosis.  
In IBD, the “omics” technologies and advances in geetic analyses have lead to the development of a 
range of putative biomarkers. However, to date, few have proven their clinical utility and validity in
the large prospective randomised trials required. In IBD, challenges remain in diagnosis and 
differentiation between CD and UC, as well as in the monitoring of disease activity and individual 
response to treatment. Advances in this field could lea  to earlier and more accurate diagnosis, as well 
as personalisation of treatment. 
1.10.2 Generic Serum Biomarkers 
1.10.2.1 C-Reactive Protein 
C-Reactive Protein (CRP) was first discovered in 1930 by Tillett and Francis (Tillett, Francis 1930), 
and is one of the most important acute phase proteins in humans (Vermeire, Van Assche et al. 2004). 
An acute phase reaction can be induced by stimuli of various origins: infectious (bacterial, fungal, 
mycobacterial, or severe viral), inflammatory, stres, tissue necrosis, trauma, childbirth, and neoplasia 
(Vermeire, Van Assche et al. 2004). 
CRP is a pentameric protein, the majority of which is produced by hepatocytes in response to IL-6, 
IL1-β and TNF-α originating at the site of inflammation or pathology. It consists of 5 identical 
subunits called protomers. Each protomer contains 2 binding sites for calcium. These allow CRP to 
bind to its main ligand, phosphocholine. After binding, the CRP-ligand complex will activate the 
complement cascade (C1 – C9) via C1q. This results in opsonisation and phagocytosis (Vermeire, 
Van Assche et al. 2004).  
Other minor sites of production have been described; p ripheral lymphocytes (Kuta, Baum 1986), 
neurons of patients with Alzheimer’s disease (Yasojima, Schwab et al. 2000) and in the thickened 
intima of atherosclerotic plaques (Yasojima, Schwab et al. 2001). 
When considering CRP as a potential biomarker in the diagnosis of IBD it must be taken into 
consideration that there is marked heterogeneity in CRP response among inflammatory diseases. CD 
and rheumatoid arthritis are associated with a strong CRP response, whereas others such as systemic 
lupus erythematosus, dermatomyositis, Sjögren’s syndrome, or UC have only a modest to absent CRP 
response, despite active inflammation (Vermeire, Van Assche et al. 2004). 
Shine et al (Shine, Berghouse et al. 1985) assessed gastrointestinal clinic patients, undergoing history, 
examination and rectal biopsy as well as routine blood tests including CRP and erythrocyte 
sedimentation rate (ESR). All patients diagnosed with CD had raised CRP and ESR measurements. Of 
those diagnosed with UC, 50% had raised CRP and ESR levels, and all were diagnosed by rectal 
biopsy. Of the patients eventually diagnosed with a functional bowel disorder none had raised CRP or 
ESR levels. It was concluded that the combination of rectal biopsy and measurement of CRP and ESR 
successfully differentiates between IBD and functional bowel syndrome.  
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Poullis et al (Poullis, Zar et al. 2002) used a new highly sensitive ELISA to measure CRP levels in 
patients attending a gastroenterology clinic. They found a cut off value of 2.3mg/l had a sensitivity of 
100% and a specificity of 67% in differentiating functional bowel disorders from new cases of IBD. 
CRP has also been evaluated as a marker of disease activity. The half-life of CRP is 19 hours, and this 
is independent of any physiological or pathophysiological factors or of the concentration of CRP in 
the serum. Thus, the synthesis rate of CRP by hepatocytes is the only factor determining the plasma 
CRP concentration. Consequently, only liver failure o  therapies affecting the acute phase stimulus 
may decrease CRP (Vermeire, Van Assche et al. 2004).  
Fagan et al (Fagan, Dyck et al. 1982) measured CRP and ESR in patients with CD and UC. CRP 
levels were found to be significantly higher in CD then in UC patients for all categories of disease; 
mild, moderate and severe. They also found that in CD, CRP levels corresponded closely with clinical 
and pathological indices of remission, relapse and response to therapy.  
Solem et al (Solem, Loftus et al. 2005) found that in CD patients, moderate to severe clinical activity, 
active disease at colonoscopy and histologically severe inflammation were all significantly associated 
with elevated CRP levels. In UC/IC patients, CRP elevation was significantly associated with severe 
clinical activity, increased ESR, anemia, hypoalbuminemia, and active disease at ileocolonoscopy, but 
not with histological inflammation. 
CRP has been used as a predictor of outcomes in IBD. Travis et al (Travis, Farrant et al. 1996) studied 
UC with severe colitis, all treated with intravenous and rectal hydrocortisone and 27% with 
cyclosporine. 41% had a complete response by day 7, 29% had a partial response by day 7, and 29% 
required a colectomy. During the first 5 days stool frequency and CRP level significantly 
distinguished between outcomes (p =0.00625). On day 3, 85% of patients with a stool frequency > 8 / 
day, or a stool frequency of 3 – 8 / day and a CRP of > 45mg/l required a colectomy.  
CRP has been evaluated as a marker of treatment response. Louis et al (Louis, Vermeire et al. 2002) 
showed that in patients receiving infliximab therapy, increased CRP at entry was significantly 
associated with response (p<0.004). 46% of patients without a raised CRP do however respond. 
In the ENACT-1 trial (Sandborn WJ. Colombel JF. Enns R. Feagan BG. Hanauer SB. Lawrance IC. 
Panaccione R. Sanders M. Schreiber S. Targan S. van Deventer S. Goldblum R. Despain D. Hogge 
GS. Rutgeerts P. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial 
Group. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group 2005) adults with 
moderate to severe CD were randomly assigned in a 4:1 ratio to receive an intravenous infusion of 
either 300 mg of natalizumab or placebo at weeks 0, 4, and 8 and were then followed through week 
12. This trial did not reach its endpoint due to a large placebo response in comparison with the 
natalizumab group (49% v 59%). However, the patients with an elevated CRP on entry showed 
significant benefit of natalizumab over placebo at both weeks 10 and 12. 
These trials raise the question as to whether patients with a normal CRP should be offered biological 
therapy, as those with a raised CRP appear more likely to respond. However, this inevitably would 
mean that a number of patients without a raised CRP would be denied a treatment that they may 




1.10.2.2 Erythrocyte Sedimentation Rate 
ESR is the rate at which erythrocytes migrate through the plasma. It is influenced by erythrocytes 
morphology and the plasma constituents such as immunoglobulins (Gabay, Kushner 1999). The 
concentration of many serum proteins varies, and some have long half-lives, therefore the ESR does 
not respond rapidly to alterations in clinical status. In UC, correlation between ESR and disease 
activity is good (Fagan, Dyck et al. 1982, Gabay, Kushner 1999, Dearing, McGuckin et al. 1969, 
Sachar, Smith et al. 1986, Sachar, Luppescu et al. 1990), however the ESR may be normal in proctitis 
and proctosigmoiditis (Desai, Faubion et al. 2007). In CD the ESR correlates less well with disease 
activity. The ESR does increase with increasing disease activity but this correlates more with colonic 
disease, and does not reflect the activity of small bowel disease (Fagan, Dyck et al. 1982, Dearing, 
McGuckin et al. 1969, Sachar, Smith et al. 1986, Sachar, Luppescu et al. 1990).  
 
1.10.2.3 Orosomucoid  
Orosomucoid (α1-acid glycoprotein) is another acute phase protein. As with CRP it is mainly 
produced by hepatocytes in response to potentially harmful stimuli (Desai, Faubion et al. 2007). 
Circulating levels of orosomucoid have been shown to correlate with disease activity in both CD and 
UC however; its 5 day half life means it cannot be reliably used as a measure of ongoing disease 
activity or response to treatment (Andre, Descos et al. 1981, Jensen, Jarnum et al. 1976).  
 
1.10.3 IBD Serum Biomarkers 
Anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic 
antibodies (P-ANCA) are autoantibodies to neutrophils and were the first extensively characterised 
serological IBD biomarkers (Sendid, Quinton et al. 1998, Satsangi, Landers et al. 1998).  
 
1.10.3.1 ANCA 
Anti-neutrophil cytoplasmic antibody (ANCA) tests were classically used in the diagnosis and 
monitoring of small vessel vasculitides (Papp, Norman et al. 2007). ANCA screening is carried out by 
indirect immunofluorescence (IIF) using ethanol-fixed neutrophils, as agreed in an international 
consensus (Savige, Gillis et al. 1999). IIF shows 2 major staining patterns: a cytoplasmic granular (C-
ANCA) and perinuclear (P-ANCA) pattern. The C-ANCA pattern shows granular cytoplasmic 
fluorescence, frequently accentuated between the nuclear lobes. C-ANCAs are seen in the sera of 
patients with Wegner’s granulomatosis and mainly recognise proteinase-3 (PR3) on enzyme-linked 
immunosorbent assays (ELISA) (Bossuyt 2006). The P-ANCA pattern results in a fine homogenous 
rim-like staining of the perinuclear cytoplasm. Nuclear extension can be present. P-ANCAs are 
present in patients with microscopic polyangiitis and recognise myeloperoxidase (MPO) on ELISA 
(Bossuyt 2006). It is recommended that ELISA should be performed on all serum samples since IFF 
alone detects only 90 – 95% of all ANCA positive samples (Savige J. Dimech W. Fritzler M. Goeken 
J. Hagen EC. Jennette JC. McEvoy R. Pusey C. Pollock W. Trevisin M. Wiik A. Wong R. 
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International Group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic 
Antibodies (ANCA) 2003). 
ANCAs have been identified in the sera of patients with chronic inflammatory disorders such as UC 
(40 – 80%) (Saxon, Shanahan et al. 1990, Rump, Scholmerich et al. 1990), primary sclerosing 
cholangitis (88%) (Terjung, Worman 2001), autoimmune hepatitis (81%) (Terjung, Bogsch et al. 
2004) and CD (5 – 25%) (Bossuyt 2006) but in only 1 – 3% of healthy controls (Papp, Norman et al. 
2007). In these disorders an atypical P-ANCA staining pattern is usually found and is recognised as a 
broad inhomogenous rim-like staining of the nuclear pe iphery often with multiple intranuclear foci 
(Terjung, Spengler et al. 2000). 
 
1.10.3.2 ASCA 
Anti-Saccharomyces cerevisiae antibodies (ASCAs) are antibodies primarily directed against a 200 
kDa phosphopeptidomannan cell wall component of thecommon baker’s or brewer’s yeast 
Saccharomyces cerevisiae (Main, McKenzie et al. 1988). It is not clear, however, whether ASCA are 
truly directed against this particular yeast or whether they represent cross-reactivity with other, yet-
unidentified microorganisms that also carry mannan sequences (Vermeire, Vermeulen et al. 2008). 
Both IgG and IgA antibodies are formed, and have ben demonstrated in 50 – 80% of patients with 
CD, 2 – 14% of patients with UC and1 – 7 % of healthy individuals (Quinton, Sendid et al. 1998, 
Peeters, Joossens et al. 2001). Approximately two-thirds of CD patients with ASCA IgG are also 
positive for ASCA IgA, but 0 – 19% of the patients have only ASCA IgA antibodies, suggesting that 
both ASCA IgG and IgA should be measured. In CD, up to 90% specificity has been reported in 
specimens positive for both ASCA IgG and IgA antibodies, especially when the magnitude of both the 
IgG and IgA ASCA antibodies is high (Norman 2001). ASCA has the best combined sensitivity (31 – 
45%) and specificity (90 – 100%) for diagnosing IBD, with a positive predictive value of 97 – 100% 
and a negative predictive value of 14 – 23% (Prideaux, De Cruz et al. 2012). 
Combining these two tests may be of higher clinical value in the differentiation of CD and UC. The 
combined pattern of ASCA positive / P-ANCA negative for CD and ASCA negative / P-ANCA 
positive in UC has been shown to have a specificity of 81 – 98% (Quinton, Sendid et al. 1998, Peeters, 
Joossens et al. 2001, Sandborn, Loftus et al. 2001) however this increased sensitivity was associated 
with reduced sensitivity. In patients with IBD, positive predictive values of a positive ASCA test with 
a negative P-ANCA test for UC has been reported as ~93% (Quinton, Sendid et al. 1998, 
Koutroubakis, Petinaki et al. 2001). 
 
1.10.3.3 Serological Biomarkers in IBDU/IC 
Serological biomarkers have been used in an attempt to differentiate characterise IC. In a multicentre 
study (Joossens, Reinisch et al. 2002) of 97 patients with IC ASCA and P-ANCA was analysed. After 
1 year a definitive diagnosis was reached in 31 patients. The combination of ASCA positive / P-
ANCA negative predicted CD in 80% of IC patients (sen itivity 67%, specificity 78%). The 
combination of ASCA negative / P-ANCA positive was predictive of UC in 64% of the IC patients 
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(sensitivity78%, specificity 67%). Interestingly, 47 patients (48.5%) did not have antibodies to either 
ASCAs or ANCAs, and of these seronegative patients o ly 7 (14.9%) became UC or CD, compared 
with 24 of 50 (48%) seropositive patients. These seron gative patients may represent an as yet 
undefined clinicoserological subgroup of IBD and may express not yet specified antibodies (Guindi, 
Riddell 2004). 
In the future wireless capsule endoscopy may provide another diagnostic tool for those with a 
diagnosis of IC, however whether the presence of small bowel lesions always represents a diagnosis 
of CD remains to be proven (Geboes, Colombel et al. 2008).  
At present the use of the term “indeterminate colitis” has evolved from one based on histological 
examination of colectomy specimens to one that includes patients suspected of having IBD based on 
biopsy specimens without features enabling a clear di gnosis. The Montreal Working Group 
(Silverberg, Satsangi et al. 2005) have recommended that the term “indeterminate colitis” is applied 
only to resected specimens, and that “inflammatory bowel disease unclassified” (IBDU) should be 
used in all other cases. The reason for this is that the original term, IC, was proposed for colectomy 
specimens and that not all diagnostic features can be identified on partial thickness biopsy specimens. 
Consequently, patients who appear to have IBD colitis but who cannot be readily classified when all 
clinical, radiological, endoscopic, histologic, and serologic data are taken into account should be 
classified as IBDU. 
Working towards biomarkers that can help in the classification of IC is vital for the future 
management of this condition. 
 
1.10.3.4 Markers of Disease Activity 
ASCA and P-ANCA have been studied with regard to developing a marker of disease activity or 
remission. In UC there has been shown to be no relationship between disease activity and the presence 
or titre of P-ANCA (Vasiliauskas, Plevy et al. 1996, Reumaux, Colombel et al. 2000), in fact the P-
ANCA titre has been shown to remain positive even after colectomy (Reumaux, Colombel et al. 
2000). In CD, the presence of ASCA has been shown t remain stable over time and is independent of 
activity, duration and usually remains stable after reatment (Vasiliauskas, Plevy et al. 1996, 
Vermeire, Peeters et al. 2001). 
Neither alone nor in combination do these biomarkers translate into clinical practice for the diagnosis 
or monitoring of IBD. They may simply be used as adjuncts to potentially aid in the diagnosis of 
complex indeterminate cases. 
A further 3 serological biomarkers were introduced to aim to solve this problem. These encompassed 
antibodies against the outer membrane porin C transport protein of Escherichia coli (anti-OmpC), 
Pseudomonas fluorescens bacterial sequence I2 (anti-I2), and bacterial flage lin (anti-CBir 1). 
 
1.10.3.4.1 Anti-OmpC 
Omp-C is a major outer membrane protein for which an excessive secretion of antibodies has been 
identified in IBD (Cohavy, Bruckner et al. 2000). The detection of IgA and IgG is carried out with 
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ELISA, and anti-ompC has been reported in 37 – 55% (Arnott, Landers et al. 2004, Landers, Cohavy 
et al. 2002) of CD patients. However, in children and young adults it appears to be less prevalent, only 
being identified in 24% of CD patients (Zholudev, Zurakowski et al. 2004). 
Anti-ompC has been identified 2 – 11% (Zholudev, Zurakowski et al. 2004, Peyrin-Biroulet, 
Standaert-Vitse et al. 2007) of UC patients. In children and young adults it has been reported in 11% 
(Zholudev, Zurakowski et al. 2004) of cases. 
In indeterminate colitis anti-ompC has been identified in 17 – 36% (Joossens, Colombel et al. 2006, 
Hui, Landers et al. 2005) of patients, and in 2 – 5% (Zholudev, Zurakowski et al. 2004, Peyrin-
Biroulet, Standaert-Vitse et al. 2007) of healthy controls. 
Mow et al (Mow, Vasiliauskas et al. 2004) found that patients expressing anti-ompC were 
significantly more likely to have internal perforating disease and require small bowel surgery than 
those in whom anti-ompC was negative. 
 
1.10.3.4.2 Anti-I2 
Microbical sequence I2 has been isolated in lamina propria mononuclear cells in colonic mucosa 
affected by CD (Sutton, Kim et al. 2000). This sequnce derives from Pseudomonas fluorescens (Wei, 
Huang et al. 2002). Sutton et al (Sutton, Kim et al. 2000) identified IgA anti-I2 antibodies in 54% of 
people with CD, 10% of people with UC, 19% of people with other inflammatory enteric diseases 
(infectious colitis, radiation proctitis, Shigella colitis, eosinophilic colitis and collagenous colitis), and 
4% of healthy controls. Joossens et al (Joossens, Colombel et al. 2006) found the prevalence of anti-I2 
to be 41.9% in IC, 17.2% in healthy controls and 31.3% in IBD patients. 
Patients with CD expressing anti-I2 are significantly more likely to have fibrostenosing disease and 




Using serologic expression cloning, Cbir1 has been id tified as an immunodominant and colitogenic 
antigen of the enteric microbial flora in C3H/HeJBir mice strain. Cbir1 is closely related to flagellin 
from Butyrivibrio, Roseburia, Thermagota, and Clostridium species, and appears in the Clostridium 
subphylum cluster XIVa of Gram-positive bacteria. Flagellins are molecules known to activate innate 
immunity via Toll-like receptor 5 (TLR5), and critical targets of the acquired immune system in host 
defence (Lodes, Cong et al. 2004). 
Targan et al (Targan, Landers et al. 2005) showed that 50% of patients with CD will express anti-
CBir1, compared with 6% of patients with UC, 8% of healthy individuals and 14% of patients with 
other inflammatory gastrointestinal diseases. 
Anti-CBir1 has been shown to be an independent marker of CD. It has no correlation with disease 
activity and usually remains stable following surgery or anti-TNFα therapy. It is associated with small 
bowel, internal-penetrating and fibro-stenosing disease features, but not with small bowel surgery 




1.10.3.5 Anti-glycan Antibodies 
Glycans are the predominant surface components of cells. They can be found on erythrocytes, immune 
cells, and microorganisms (Dotan, Fishman et al. 2006). They generate high levels of antiglycan 
antibodies of all classes, which have been demonstrated in a number of inflammatory and autoimmune 
diseases (Buonomano, Tinguely et al. 1999, McMorrow, Comrack et al. 1997, Willison, Yuki 2002). 
Dotan et al (Dotan, Fishman et al. 2006) investigated anti-glycan antibodies as markers of IBD. 
Initially, in the discovery phase, mono-, di-, and trisaccharides were used to characterise the anti-
glycan antibody profile in serum samples of patients with CD and UC, and in healthy controls. In the 
validation phase samples from IBD patients and healt y controls were screened to detect the presence 
of characteristic anti-glycan antibodies. After profiling anti-glycan antibodies by the glycan array 
using indirect immunofluorescence, an ELISA was established to determine the most discriminatory 
antibodies. These were gASCA, anti-Glc(β1,3)Glc(β) (laminaribioside) IgG and anti-GlcNAc(β 
1,4)GlcNAc(β) (chitobioside) IgA. These novel antibodies were dsignated anti-laminaribioside 
carbohydrate IgG antibody (ALCA), and anti-chitobioside IgA carbohydrate antibody (ACCA). 
gASCA is similar to conventional ASCA but is a measure of antibodies against mannan (IgG anti-
covalently attached anti-Saccharomyces cerevisiae ntibodies). 
In CD, ALCA and ACCA were positive in 37.5% and 36% of cases, compared to gASCA, which was 
positive in 65% of the discovery phase. In the validation phase ALCA, ACCA and gASCA were 
positive in 27%, 25% and 69% of CD patients; in 4%, 5  and 7% of UC patients; in 9%, 9% and 13% 
of the non-IBD gastrointestinal diseases group; andin 2%, 12% and 15% of healthy controls, 
respectively.   
Anti-mannobioside (Man(α1,3)Man(α)) carbohydrate IgG antibody (AMCA) is another anti-glycan 
antibody that has been investigated in the setting of IBD biomarkers. Malickova et al (Malickova, 
Lakatos et al. 2010) measured gASCA, ACCA, ALCA and AMCA in patients with CD, UC and in 
healthy controls to determine the role of these markers in IBD. They found that in CD patients 67% 
were positive for gASCA, 27% for ACCA, 25% for ALCA and 31% for AMCA. In the UC group 
14%, 45%, 22% and 36% were positive respectively. In the healthy control group 5.5% were positive 
to gASCA, 5.5% to ALCA, 11% to ACCA and 11% to AMCA. 
It was identified that the combination of gASCA, ACCA, ALCA and AMCA did not aid 
differentiation of CD from UC when compared to gASCA alone. The combination did however aid 
differentiation of CD from healthy controls, and sen itivity of immunological diagnosis of CD was 
85.5% when the markers were used in combination.   
In this study, ACCA, ALCA and AMCA levels did not vary with disease duration and were not 
associated with disease behaviour or location; however Ferrante et al (Ferrante, Henckaerts et al. 
2007) identified that ALCA is more often positive in the penetrating form of CD and ACCA in the 
stenosing form. 
Malickova et al (Malickova, Lakatos et al. 2010) found that over half (56.4%) of gASCA negative CD 
patients are seropositive for ACCA, ALCA or AMCA. This is in keeping with Ferrante et al (Ferrante, 
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Henckaerts et al. 2007) who identified anti-carbohydrate antibodies in 32% of gASCA negative CD 
patients, and allowed Malickova et al to formulate th hypothesis that ASCA negative CD patients 
may represent a distinct immunological phenotypic group compared to those with ASCA positivity 
(Malickova, Lakatos et al. 2010).  
Reider et al (Rieder, Schleder et al. 2010) evaluated a further two anti-glycan antibodies as novel 
markers in IBD; anti-laminarin IgA (Glc(β 1,3))3n(Glc(β 1,6))n carbohydrate antibody (Anti-L) and 
anti-chitin GlcNAc(β1,4)n IgA carbohydrate antibody (Anti-C). These were measured in conjunction 
with ACCA, ALCA, AMCA and gASCA.  
They found that the combination of gASCA/P-ANCA was the most accurate for the diagnosis of CD 
versus UC. The addition of anti-L and anti-C to gASCA significantly increased the discriminatory 
capacity for CD versus no CD compared to gASCA alone, and the addition of anti-L and anti-C to the 
combination of gASCA/P-ANCA significantly increased the discriminatory capacity for CD versus 
UC, compared to gASCA/P-ANCA alone. 
Overall, Reider et al (Rieder, Schleder et al. 2010) found that there was a poor correlation between th  
levels of the two new antibodies (anti-L and anti-C) and the established antibodies (ACCA, ALCA, 
AMCA and gASCA) suggesting distinct and independent serological responses. They did identify that 
anti-L had the strongest association with complications related to CD, and that anti-L and anti-C were 
strongly associated with the requirement for surgery. When multivariate analyses were carried out 
taking into account age, sex, BMI, disease location, age at time of diagnosis, and disease duration an 
independent association of gASCA, AMCA and anti-L was found with complicated CD behaviour, 
and gASCA, AMCA, anti-L and anti-C with the need for surgery. Patients with positivity for at least 
one serum marker had a higher likelihood of complicated disease behaviour, IBD-related surgery, 
early disease onset, and ileal and small bowel disease location compared to patients negative for all 
markers. Positivity for an increasing number of antibodies raised the likelihood for the occurrence of 
complicated disease behaviour, IBD-related surgery, arly disease onset, and ileal and small bowel 
involvement.  
These findings are in keeping with Seow et al (Seow, Stempak et al. 2009) who had also found that 
that adding anti-L and anti-C to gASCA/P-ANCA improved the differentiation between CD and UC. 
They also identified that adding anti-L to gASCA/P-ANCA differentiated colonic CD from UC, and 
that anti-L was associated with ileocolic CD. Seow et al (Seow, Stempak et al. 2009) also agreed with 
Rieder (Rieder, Schleder et al. 2010), Ferrante (Ferrante, Henckaerts et al. 2007) and Mow (Mow, 
Vasiliauskas et al. 2004), stating that an increasing number of positive antibodies is significantly 
(p<0.001) associated with an aggressive form of CD with early onset, penetrating phenotype, perianal 
disease and requirement for surgery.  
 
1.10.3.6 Anti-UBE4A 
Ubiquitination factor E4A (UBE4A) is a member of the of the U-box ubiquitin ligase family. The 
encoded protein is involved in multiubiquitin chain assembly and plays a critical role in chromosome 
condensation and separation through the polyubiquitination of securin, as well as cell cycle regulation, 
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cellular signaling in response to stress and to extracellular signals, morphogenesis, secretory 
pathways, DNA repair, and organelle biogenesis (Weissman 2001, Hershko, Ciechanover 1998). Anti-
UBE4A levels have been shown to be significantly correlated with the Crohn’s Disease Activity 
Index, as well as requirement of surgery and a stricturing or penetrating phenotype (Sakiyama, Fujita 
et al. 2008). 
 
1.10.3.7 Pancreatic Autoantibodies 
Pancreatic autoantibodies (PABs) have been considered as potential biomarkers in CD, since the 
1980s (Stocker, Otte et al. 1987). However, attempts to define the target of these antibodies have 
proved challenging (Stocker, Otte et al. 1987, Seibold, Weber et al. 1991, Fricke, Birkhofer et al. 
1999). Recently, Roggenbuck et al (Roggenbuck, Hausdorf et al. 2009) have shown that glycoprotein 
2 (GP2), the major zymogen granule membrane glycoprotein, is the major autoantigen of PABs 
expressed at mRNA and protein levels in colonic biopsies from patients with CD. Previously in 
animal models, GP2 has been associated with the cholesterol–glycosphingolipid-enriched 
microdomains (lipid rafts) of secretory granule membranes of the pancreatic acinar cells (Schmidt, 
Schrader et al. 2001), has been found in lipid rafts o  the brush-border membrane of small intestinal 
enterocytes (Nguyen, Amine et al. 2006), and has been shown to be specifically synthesised in murine 
M cells of Peyer’s patches (Terahara, Yoshida et al. 2008). PAB-positivity (type I and type II) can be
identified on the basis of indirect immunofluorescen  (IIF) patterns related to the location of specific 
IIF signals (Seibold, Mork et al. 1997). Type II does not seem to differentiate CD patients from UC 
patients whereas type I PAB appears to do so (Joossens, Vermeire et al. 2004).  
Anti-GP2 reactivity is not found in all PAB-positive patients thus revealing the potential for further 
autoantigenic PAB targets (Roggenbuck, Hausdorf et al. 2009, Roggenbuck, Reinhold et al. 2011, 
Roggenbuck, Bogdanos et al. 2013). Further investigation of these potential biomarkers may aid not 
only our diagnosis but also our understanding of CD.   
1.10.3.8 CXCL16 
CXCL16 is a transmembrane protein. It comprises an extracellular chemokine domain fused to a 
mucin stalk that extends through the cell membrane (Matloubian, David et al. 2000). CXCL16 is 
primarily expressed by macrophages (Wilbanks, Zondl et al. 2001), dendritic cells and vascular 
smooth muscle cells (Hofnagel, Luechtenborg et al. 2002, Wagsater, Olofsson et al. 2004) in various 
lymphoid tissues including the thymus, spleen, lymph nodes and Peyer’s patches, and in non-
lymphoid tissues including the lung, liver, kidney and small intestine, but not colonic tissue 
(Matloubian, David et al. 2000, Shimaoka, Kume et al. 2000). It combines the functionality of a 
pattern recognition receptor with the properties of an inflammatory chemokine (Matloubian, David et 
al. 2000).  
Lehrke et al (Lehrke, Konrad et al. 2008) investigated the association of CXCL16 with IBD and found 
that soluble serum levels of CXCL16 were significantly higher in patients with IBD than in healthy 
controls, although more so in CD than in UC. Levels were not found to be associated with disease 
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activity, and have been shown to be raised in other inflammatory disease processes (van der Voort, 
van Lieshout et al. 2005, Lehrke, Millington et al. 2007) thus potentially limiting the use of CXCL16 
as a biomarker. However, more recently Uza et al (Uza, Nakase et al. 2011) have shown soluble 
serum levels of CXCL16 correlate with disease activity in CD and UC, as well as being significantly 
raised in healthy controls compared to IBD patients. CXCL16 was also shown to have a critical role in 
the progression of colonic inflammation. Further investigation is clearly required. 
 
1.10.3.9 Apolipoprotein A-IV 
Apolipoprotein A-IV, expresed in the small intestine, is a component of intestine-derived, 
triglyceride-rich lipoproteins (Apfelbaum, Davidson et al. 1987). It is secreted on lymph chylomicrons 
and was initially thought to have roles in lipid transport and lipoprotein metabolism (Goldberg, 
Scheraldi et al. 1990), control of food intake (Fujimoto, Fukagawa et al. 1993) and gastric function 
(Okumura, Fukagawa et al. 1994), although these have not been proven in knock-out mice 
(Weinstock, Bisgaier et al. 1997). It has however ben shown to have anti-atherogenic, anti-oxidant 
and anti-inflammatory properties (Ostos, Conconi et al. 2001, Li, Conklin et al. 2008).  Vowinkel et al 
showed apolipoprotein A-IV to inhibit DSS-induced colitis in mice (Vowinkel, Mori et al. 2004). 
Following this investigation of apolipoprotein A-IV levels in human IBD patients was investigated. 
Broedl et al identified that apolipoprotein A-IV lev ls were inversely related to CRP and disease 
activity in CD but not in UC (Broedl, Schachinger et al. 2007). This has so far not been taken further 
with regards a biomarker or treatment discovery.  
 
1.10.3.10 Serum Calprotectin 
Faecal calprotectin is well established as a marker of disease activity in IBD (Desai, Faubion et al. 
2007), as well as having the potential to be used a a screening tool in the initial phase of investigation 
for IBD (van Rheenen, Van de Vijver et al. 2010). 
Serum calprotectin is a calcium- and zinc-binding protein complex composed of 8 and 14 kD subunits 
S100A8 and S100A9. It is also known as calgranulin A/B, S100A8/A9, MRP8/14 or 27E10 antigen.  
Calprotectin is mainly produced by neutrophils but is also present in macrophages. It is estimated to 
represent >40% and 5% of cytosolic and total proteins of neutrophils respectively (Yui, Nakatani et al. 
2003). 
The use of serum calprotectin as a biomarker has been investigated in other diseases such as cystic 
fibrosis (Gray, Imrie et al. 2010), diabetes mellitus type II (Ortega, Sabater et al. 2012), appendicitis 
(Kharbanda, Rai et al. 2012, Mills, Huckins et al. 2012), gynaecological cancers (Kostakis, Cholidou 
et al. 2010), and rheumatoid arthristis (Andres Cerezo, Mann et al. 2011) as it is a marker of 
inflammation. 
In IBD, Lugering et al showed that serum levels of MRP8/14 (calprotectin) are elevated in both CD 
(Lugering, Stoll et al. 1995a) and UC (Lugering, Stoll et al. 1995b).  More recently serum calprotectin 
has been shown to be elevated in children at diagnosis of IBD, and to correlate with paediatric disease 
activity scores (Leach, Yang et al. 2007), and Malíčková et al agreed with these findings and 
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themselves went on to show that serum calprotectin is significantly elevated in IBD patients prior to 
biological therapy, but in responders to therapy significantly reduces over a ten week period 
(Malickova, Kalousova et al. 2010).  
 
1.10.4 Faecal Biomarkers in IBD 
Faecal biomarkers have been strongly considered in IBD for a number of reasons. The faecal stream is 
in direct contact with the gut mucosa and therefore should contain specific markers of mucosal 
disease. The histological features of CD and UC include leucocyte infiltration into the gut wall and 
subsequent sloughing of the cells and their products into the bowel lumen and thus into the faecal 
stream. This is also associated with increased gut permeability and loss of the normal barrier function 
of the mucosa. As a result of these processes, potential faecal biomarkers include the faecal excretion 
of leucocytes, leucocyte products and serum proteins (Sutherland, Gearry et al. 2008).  
Several candidate leucocyte-derived proteins have be n identified, including faecal calprotectin, 
lactoferrin, myeloperoxidase, lysozyme, elastase, eosinophil cationic protein (ECP), eosinophil 
protein X (EPX), and human neutrophil lipocalin (HNL) (Klass, Neale 1978, Langhorst, Elsenbruch et 
al. 2005, Saiki 1998, Adeyemi, Hodgson 1992, van der Sluys Veer, Brouwer et al. 1998, Silberer, 
Kuppers et al. 2005, Peterson, Eklund et al. 2002).  
 
1.10.4.1 111Indium-labelled Leucocytes 
The faecal excretion of leucocytes is increased in IBD. The accurate measurement of excretion 
requires a radioactive-labelling method rather than a simple single faecal sample and is typically 
combined with abdominal scintigraphy to identify inflamed segments of intestine. The technique was 
initially described in 1981 (Segal, Ensell et al. 198 ) using mixed leucocytes and since has been 
refined to use pure granulocyte preparations (Saverymuttu, Camilleri et al. 1986).  
The faecal excretion of 111Indium-labelled leucocytes is considered the gold standard faecal marker of 
inflammation since strict correlations with intestinal inflammation were evidenced at colonoscopy and 
histology (Angriman, Scarpa et al. 2007). Saverymuttu e  al (Saverymuttu, Peters et al. 1985) reported 
a sensitivity of 97% for faecal 111Indium-labelled leucocyte excretion compared with 79% for 
radiology and 70% for rectal histology in the diagnosis of IBD. However, this technique has a number 
of limitations; specialist facilities are required to for abdominal scintigraphy and to carry out sterile 
labelling of leucocytes, patients are exposed to a dose of radiation (8.5–17 millisieverts (mSv)), and 
the cost of this investigation is ~ £300 / patient. The other drawback of this technique is that it requires 
a 4 day collection of faecal material, and the practic lities of this are somewhat limiting. It has 
therefore remained essentially a tool used in reseach, rather than translating into clinical practice 
(Tibble, Teahon et al. 2000). 
 
1.10.4.2 51Chromium-labelled Red Cells  
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Teahon et al (Teahon, Bjarnason 1993) compared the faecal excretion of 51Chromium-labelled red 
cells with 111Indium-labelled leucocytes in patients with IBD. Intestinal inflammation and blood loss 
were significantly correlated in patients with UC, but not in those with CD. 
As with measuring the faecal excretion of 111Indium-labelled leucocytes, this test is relatively 
expensive, involves an exposure to radiation, and a four day faecal collection, all of which make it a 
suboptimal faecal marker. 
 
1.10.4.3 Faecal Calprotectin  
Calprotectin is a heterocomplex protein consisting of 2 heavy (L1H) chains and 1 light (L1L) chain 
which are non-covalently linked (Bjerke, Halstensen et al. 1993). It was initially known as protein L1
(Fagerhol, Dale et al. 1980) and is a calcium-binding protein that exhibits antibacterial and antifungal 
activity, inhibits metalloproteinases, and induces apoptosis in malignant and non-malignant cell 
cultures (Steinbakk, Naess-Andresen et al. 1990). It has been found to represent approximately 60% 
of neutrophilic cytosolic protein (Fagerhol, Dale et al. 1980, Roseth, Fagerhol et al. 1992), is released 
from cells during cell activation or death (Desai, Faubion et al. 2007), and is stable in faeces for up to 
one week at room temperature (Roseth, Fagerhol et al. 1992). 
Faecal calprotectin (FC) is the most commonly used fa cal biomarker in IBD, and can be quantified 
using ELISA (Desai, Faubion et al. 2007). Single random stool samples of <5 g show FC 
concentrations equivalent to 24-hour homogenised spcimens, indicating that FC is evenly distributed 
through the faeces (Roseth, Fagerhol et al. 1992). These qualities increase the clinical utility of FC, 
allowing for potential delays in performing the assy, transport to a central laboratory, and the 
analysis of small samples (Sutherland, Gearry et al. 2008). 
The median FC level is 2 mg/L in healthy individuals with an upper limit of 10 mg/L (Desai, Faubion 
et al. 2007). In 2000, Ton et al (Ton, Brandsnes et al. 2000) developed an improved assay to measure 
FC. Since then the units have been changed to be measured in µg/g rather than mg/L. In order to 
convert from the older assays to the newer, figures need to be multiplied by a factor of 5. 
FC level has been shown to be a sensitive marker of activity in CD and to correlate well with 
endoscopic and histological activity in UC (Tibble, Teahon et al. 2000, Roseth, Fagerhol et al. 1992, 
Roseth, Aadland et al. 1997). Tibble et al also showed that FC normalises with endoscopic healing in 
CD (Tibble, Teahon et al. 2000). 
Roseth et al (Roseth, Schmidt et al. 1999) have shown that FC measurement correlates well with the 
more difficult and more expensive measurement of 111Indium-labelled leucocyte excretion in IBD. 
A recent meta-analysis (van Rheenen, Van de Vijver et al. 2010) has shown that FC is a useful 
screening tool in the identification of those who require endoscopic investigation for suspected IBD. 
This test however appears to be more useful in an adult population that in children or adolescents.  
 
1.10.4.4 Faecal Lactoferrin 
Lactoferrin is an iron-binding protein and a major c mponent of neutrophil secondary granules. It is 
secreted into the local environment upon neutrophil degranulation and can be found in many body 
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fluids (Buderus, Boone et al. 2004). During intestinal inflammation, polymorphonuclear neutrophils 
infiltrate the mucosa, resulting in an increase in the concentration of faecal lactoferrin (FL).  Its 
presence is proportional to neutrophil translocation o the gastrointestinal tract (Guerrant, Araujo et al. 
1992). The protein is resistant to proteolysis and u amaged by multiple freeze thaws, therefore 
providing a useful marker in faeces as an indicator of intestinal inflammation (Angriman, Scarpa et al. 
2007). 
A commercial ELISA has been developed for lactoferrin and is now widely available. It has been used 
extensively in the investigation of infectious diarrhoea and is highly sensitive for detecting faecal 
neutrophil infiltration (Sutherland, Gearry et al. 2008). 
The concentration of FL in healthy individuals is 1.45 ± 0.4 µg/g of faecal weight. In active IBD this 
value can rise to several hundred µg/g of faecal weight (Kane, Sandborn et al. 2003). FL is increased 
in patients with active IBD when compared to those with inactive IBD with specificity between 85% 
and 90%, and levels may rise significantly prior to a clinically evident relapse (van der Sluys Veer, 
Biemond et al. 1999, Walker, Land et al. 2004). 
Buderus et al (Buderus, Boone et al. 2004) reported on a study of five paediatric patients with CD 
undergoing infliximab therapy. FL levels were determined before and after infliximab treatment. It 
was determined that FL rapidly decreased after clinically successful treatment with infliximab in 
children with severe CD. They stated that FL was a ensitive and specific marker for intestinal 
inflammation that can be used for monitoring the thrapeutic response to infliximab in paediatric 
patients with CD. 
Parsi et al (Parsi, Shen et al. 2004) studied patients with an IPAA. The aim was to use FL to determine 
whether symptomatic patients had pouchitis, cuffitis or CD, or whether they had a non-inflammatory 
condition such as irritable pouch syndrome. Faecal samples were taken and analysed for FL, and these 
results were correlated with endoscopy / biopsy results. It was observed that symptomatic patients 
with an inflammatory condition had significantly hig er FL concentrations (median 176.0 µg/mL) 
than those with a non-inflammatory condition (median 4.8 µg/mL), or those who were asymptomatic 
(median 7.8 µg/mL), p<0.001. At a cut-off level of 7 µg/mL, FL could distinguish patients with 
irritable pouch syndrome from those with pouchitis, cuffitis, or CD with a sensitivity of 100% and 
specificity of 85%. Therefore this group felt that FL can serve as a sensitive and non-invasive initial 
screening test in the evaluation of symptomatic patients after restorative proctocolectomy for UC. 
Recent studies comparing FL and FC have suggested that both tests are similarly useful in the 
assessment of the disease activity of IBD. Faecal excretion of calprotectin has been shown to correlate 
with findings of colonic inflammation at endoscopic examination, whilst faecal excretion of 
lactoferrin correlates with histological inflammation (Langhorst, Elsenbruch et al. 2005, D'Inca, Dal 
Pont et al. 2007). 
Reference ranges between active and quiescent IBD for FL overlap. This restricts its use to that of 
diagnosing new cases of IBD, and despite the early promise of FL there have been limited further 




1.10.4.5 Faecal Lysozyme 
Lysozyme, also known as muramidase, is a polymorphonuclear neutrophil-derived enzyme which 
catalyses the hydrolysis of Gram-positive bacterial cel  walls (Angriman, Scarpa et al. 2007). Faecal 
lysozyme is elevated in patients with inactive and active CD, active UC, and non-inflammatory 
gastrointestinal diseases with diarrhoea, when compared to healthy controls (Klass, Neale 1978, van 
der Sluys Veer, Brouwer et al. 1998). It has been shown to correlate with excretion of 111Indium-
labelled leucocytes granulocytes in patients with colonic disease but not in those with small bowel 
disease (Crama-Bohbouth, Pena 1998). None of these factors make this a particularly useful 
biomarker in clinical practice, and faecal lysozyme has in fact been shown to be less effective than 
other markers in the diagnosis of IBD (Langhorst, Elsenbruch et al. 2005, Silberer, Kuppers et al. 
2005).  
 
1.10.4.6 Faecal Myeloperoxidase 
Myeloperoxidase is a constituent of neutrophil azure g anules (Angriman, Scarpa et al. 2007). It is 
released during inflammation and plays a role in the oxygen-dependent killing of micro-organisms 
and tumour cells. Its concentration within a suspenion has been found to be proportional to the 
number of neutrophils within that suspension (Saiki 1998, Peterson, Eklund et al. 2002, Sugi, Saitoh 
et al. 1996). 
Faecal levels of myeloperoxidase are elevated in active IBD compared with controls and correlate 
with laboratory parameters and endoscopic grade of inflammation (Saiki 1998), however this 
correlation has been shown to be less efficient that FL in the diagnosis of IBD (Silberer, Kuppers et al. 
2005). This may be due to the shorter half life of myeloperoxidase, but it means that it has not been 
established as a clinically useful faecal biomarker. 
 
1.10.4.7 Polymorphonuclear Neutrophil Elastase 
Polymorphonuclear Neutrophil Elastase (PMN-E) can be identified in the faeces of patients with IBD. 
It can be measured as either a complex bound to α1-antitrypsin (α1-AT), or as free faecal elastase 
(Adeyemi, Hodgson 1992, Sugi, Saitoh et al. 1996). PMN-E has been shown to correlate with the 
Crohn’s Disease Activity Index (CDAI) and a numerical disease activity index for UC (Adeyemi, 
Hodgson 1992).  However, PMN-E, when compared directly with FL, is an inferior biomarker in IBD 
(Langhorst, Elsenbruch et al. 2005, Sugi, Saitoh et al. 1996). 
 
1.10.4.8 Eosinophil Derived Protein 
In patients with a variety of intestinal diseases, including IBD, increased eosinophil levels and 
enhanced eosinophil activation have been seen in the in estinal mucosa (Heatley, James 1979, Talley, 
Kephart et al. 1992, Bischoff, Wedemeyer et al. 1996). The specific granules of the eosinophils 
contain a number of highly cationic proteins including ECP and EPX. These proteins have potent 
cytotoxic action and immunomodulatory properties, and re released from the cells after activation 
and stimulation of the cells (Gleich, Adolphson 1986).  
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The eosinophil may also be a major factor in the pathogenesis of IBD because biopsies from these 
patients have demonstrated an infiltration of eosinphils in the lamina propria (Bischoff, Wedemeyer 
et al. 1996, Sarin, Malhotra et al. 1987, Makiyama, K nzaki et al. 1995, Oshitani, Sawa et al. 1997, 
Raab, Hallgren et al. 1992) and marked extracellular deposits of ECP (Raab, Hallgren et al. 1992). 
There is also an excess release of the eosinophil proteins ECP and EPX in luminal fluid and feces of 
patients with active UC or CD (Berstad, Borkje et al. 1993, Bischoff, Grabowsky et al. 1997, Levy, 
Gleich et al. 1997, Saitoh, Kojima et al. 1999). 
ECP and EPX can be measured by radioimmunoassay, and are stable in faeces for at least three days 
when stored at 22°C (Peterson, Eklund et al. 2002), a key element for a useful biomarker. Saitoh et al 
(Saitoh, Kojima et al. 1999) found EPX to be more stable than ECP when stored at 25°C for 48 hours, 
and therefore postulated that EPX is a better marker.  
Peterson et al (Peterson, Eklund et al. 2002) showed that both ECP and EPX are elevated in CD and to 
a greater extent in UC when compared to healthy individuals, and that there seems to be an association 
in CD between disease activity and EPX concentration, but less so for ECP. No association was 
shown between EPX or ECP and disease activity in UC. 
Peterson’s (Peterson, Eklund et al. 2002) findings a ree with Saitoh et al (Saitoh, Kojima et al. 1999) 
who also showed that faecal ECP and EPX concentrations were significantly increased in both active 
UC and active CD compared to inactive UC and inactive CD, respectively. This study also reported 
that in the inactive phase CD patients who relapsed within 3 months had higher levels of ECP and 
EPX than those who remained in the inactive phase. Th refore Saitoh et al felt that ECP and EPX 
could be used as markers for evaluating disease activity and predicting relapse.  
Currently there is no defined clinical role for the routine clinical use of faecal EPX or ECP in the 
diagnosis or monitoring of IBD (Sutherland, Gearry et al. 2008). 
 
1.10.4.9 Human Neutrophil Lipocalin 
Human neutrophil lipocalin (HNL) is a neutrophil granule protein which is stored within secondary 
granules (Xu, Carlson et al. 1994). It is a specific marker of neutrophils (Seveus, Amin et al. 1997). 
Peterson et al (Peterson, Eklund et al. 2002) observed that faecal HNL concentrations are markedly 
increased in UC and moderately increased in CD compared to healthy individuals, and that the levels 
in UC are significantly higher than those seen in CD (p<0.0002). A correlation between faecal HNL 
and disease activity was unable to be established. 
 
1.10.4.10 Alpha 1-antitrypsin 
Alpha 1-antitrypsin (α1-AT) is a protease inhibitor produced by the liver, macrophages, and the 
intestinal epithelium (Angriman, Scarpa et al. 2007). It is present in blood and is excreted in the faeces 
in increased concentrations in a number of disease stat s causing increased intestinal permeability and 
therefore protein loss (Meyers, Wolke et al. 1985). It has in fact been shown to be a good marker of 
protein losing enteropathy (Bernier, Florent et al. 1978).  
 
 100 
α1-AT is relatively stable in faeces and can be measured using commercially available assays (van der 
Sluys Veer, Biemond et al. 1999, Wilson, McGilligan et al. 1988). Random stool samples can be used 
to measure faecal α1-antitrypsin concentration or alternatively α1-antitrypsin clearance can be 
calculated from a 24-hour faecal collection and measurement of total faecal α1-AT and serum α1-AT 
(Meyers, Wolke et al. 1985). Becker et al (Becker, Berger et al. 1999) showed that random faecal α1-
AT levels are as useful as long collections in measuring CD activity, but the same is not true in UC 
patients. 
Faecal excretion is increased in active CD and correlates well with clinical disease activity scores and 
the extent of small bowel disease in CD (Meyers, Wolke et al. 1985, Grill, Hillemeier et al. 1984). 
However, this is not a marker widely used in clinical practice as the method is not routinely available. 
There is also some controversy regarding conflicting evidence on the efficacy of faecal α1-AT as a 
diagnostic and monitoring tool in IBD (Angriman, Scarpa et al. 2007, Poullis, Foster et al. 2002). 
Furthermore, data about the efficiency in the follow-up after medical or surgical therapy, such as in 
case of pouchitis, are lacking (Parsi, Shen et al. 2004, Poullis, Foster et al. 2002) and other markers 
were demonstrated more accurate or cost-effective than faecal α1-AT in the assessment of patients 
with IBD (van der Sluys Veer, Biemond et al. 1999). 
 
1.10.4.11 Alpha 2-macroglobulin 
Alpha 2-macroglobulin (AMG) is a serum anti-proteinase (Angriman, Scarpa et al. 2007). In healthy 
subjects it is excreted in the faeces in small quantities (Poullis, Foster et al. 2002); however Becker et 
al (Becker, Niederau et al. 1999) have shown that in CD and UC it is present in elevated levels, and 
that in active disease it is far more prevalent than in quiescent disease. They also observed that faecal 
AMG correlated to the CDAI in subjects with CD but not to the CAI in subjects with UC. This 
method is not available in clinical practice (Angriman, Scarpa et al. 2007).    
 
1.10.4.12 Tumour Necrosis Factor Alpha 
Tumour necrosis factor alpha (TNF-α) is a proinflammatory cytokine produced by polymorphonuclear 
neutrophils. Braegger et al (Braegger, Nicholls et al. 1992) studied faecal TNF-α in children with IBD 
and found it to be a useful marker of disease activity. Kapel et al (Kapel, Roman et al. 2005) showed 
that the use of aecal TNF-α in diagnosing IBD was of equal value to the use of FC. Faecal TNF-α 
returns to normal levels in the quiescent disease phase or after curative surgery (Poullis, Foster et al. 
2002).  
Given that faecal TNF-α requires to be kept frozen where other faecal biomarkers do not (Peterson, 
Eklund et al. 2002), this technique does not translate well into clinical practice. Large inter-individual 
variations of levels in both serum and faeces have also limited also its routine use (Konikoff, Denson 
2006), and it has not been fully evaluated in an adult population (Poullis, Foster et al. 2002). 
 
1.10.4.13 Faecal Lactate 
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DL-Lactate is an intermediary metabolite in the bacterial fermentation of carbohydrates in the colon 
(Hove, Nordgaard-Andersen et al. 1994). The faecal concentration is normally less than 2-3 mmol/l 
(Mortensen, Hove et al. 1991). The combined large-bowel flora produces both stereoisomers, L- and 
D-lactate, which are further metabolised to shortchain fatty acids, the principal end-products of 
bacterial fermentation (Mortensen, Hove et al. 1991). In patients with IBD (Vernia, Caprilli et al. 
1988, Vernia, Gnaedinger et al. 1988), as well as patients with severe malabsorption after extensive 
gastrointestinal resections (Oh, Phelps et al. 1979, Schoorel, Giesberts et al. 1980, Stolberg, Rolfe et 
al. 1982, Traube, Bock et al. 1983), an increased level of faecal lactate has been observed. 
It is hypothesised that intestinal malabsorption increases the bacterial production of both D- and L-
lactate from the non-digested luminal carbohydrates pr ent in the contents of the large bowel (Hove, 
Nordgaard-Andersen et al. 1994). The production of intestinal lactate in inflammatory bowel diseases 
(IBD) may, however, derive from the anaerobicity of the inflamed mucosa, which probably forms the 
L-isomer, since D-lactate is not normally produced by mammalian cells (Christopher, Eckfeldt et al. 
1990). 
Hove et al (Hove, Nordgaard-Andersen et al. 1994) studied faecal DL-lactate in 100 patients with 
severe gastrointestinal diseases. It was observed that faecal L-lactate is elevated in IBD associated 
with proctitis, but not in quiescent IBD, IBD without proctitis or Crohn's ileitis. As proctitis is easily 
visible using rigid or flexible sigmoidoscopy, measuring faecal lactate does not add relevant clinical 
information (Poullis, Foster et al. 2002).  
 
1.10.4.14 Platelet Activating Factor 
Platelet activating factor (PAF) is a potent endogenous mediator in the inflammatory process (Poullis, 
Foster et al. 2002). It induces microvascular leakage, vasodilatation, smooth muscle contraction, and 
both platelet and leucocyte aggregation (Oshimoto, Okamura et al. 2005). Faecal PAF has been shown 
to correlate with the endoscopic extent of bowel inflammation in UC and CD, but not with disease 
activity scores or systemic inflammatory markers (CRP and ESR) (Hocke, Richter et al. 1999). 
 
1.10.4.15 Cytokines 
It is postulated that cytokines appear in the stool as they are produced locally in the diseased bowel 
and leak into the bowel lumen, or that IBD affected epithelial cells and immune-system cells, both 
capable of producing cytokines (Eckmann, Jung et al. 1993, Casini-Raggi, Kam et al. 1995), may be 
extruded into the bowel lumen and appear in the stool. The theory that the cytokines in the stool arise 
from leakage from the blood vessels within the gut wall is excluded by previous data showing 100-
fold higher levels of various cytokines in stool than in plasma of patients with acute shigellosis 
(Raqib, Wretlind et al. 1995). 
Saiki et al (Saiki, Mitsuyama et al. 1998) carried out a study to identify and quantify cytokines with 
pro- and anti-inflammatory properties in the stools of IBD patients. Stool concentrations of IL-1β and 
its natural antagonist IL-1ra (receptor antagonist) were significantly higher in patients with active IBD 
than in patients with inactive disease and normal controls. Stool concentrations of IL-4 and IL-10 in 
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active disease were not statistically different to h se of patients with inactive disease or controls, as 
were TNF-α levels. In a paired analysis of the same individual, stool concentrations of TNF-α, IL-1β 
and IL-1ra were shown to decrease after the clinical resolution of disease exacerbation, and levels of 
IL-4 and IL-10 to increase. The reason for this is unclear. It is however conceivable that IL-4 and IL-
10 may play a down-regulatory role in the acute inflammatory process. 
 
1.10.4.16 Faecal S100A12 
S100A12, is a calcium-binding protein, previously known as calgranulin C or EN-RAGE 
(extracellular newly identified receptor for advanced glycation end products). It is expressed as a 
cytoplasmatic protein in activated neutrophils with proinflammatory properties. The S100A12 
activates the nuclear factor-кB signal transduction pathway and induces proinflammatory cytokine 
release, including TNF-α (Angriman, Scarpa et al. 2007). Elevated serum S100A 2 levels are seen in 
inflammatory diseases such as rheumatoid arthritis (Marenholz, Heizmann et al. 2004, Foell, Kane et 
al. 2003) and cystic fibrosis (Foell, Seeliger et al. 2003), as well as in the serum and mucosa of 
children (Leach, Messina et al. 2004) with IBD and i  the serum of adults with IBD (Foell, Kucharzik 
et al. 2003). De Jong et al (de Jong, Leach et al. 2006) studied in children and found that faecal 
S100A12 is distributed evenly in faeces and remains stable for 7 days, desirable characteristics for a 
potential biomarker. Faecal S100A12 was elevated in ch ldren at the time of diagnosis of IBD and 
could distinguish IBD children from normal healthy control subjects with 96% sensitivity and 92% 
specificity. Faecal S100A12 levels were shown to correlate closely with the PCDAI and standard 
serum inflammatory markers, specifically when there is lower gut involvement, and induction of 
clinical and biological remission in children leads to reduced faecal levels of S100A12.  
It was proposed that at present faecal S100A12 could not replace colonoscopy and biopsy in the 
diagnosis of IBD in children, but that it may form a useful screening tool in deciding whether 
colonoscopy and biopsy is warranted. It may also be a useful non-invasive monitor of disease activity.  
 
1.10.4.17 Nitric Oxide 
Nitric oxide (NO) is an endogenously produced gas. In response to acute proinflammatory cytokines 
leucocytes and epithelial cells express iNOS leading to the production and accumulation of significant 
quantities of NO (Lundberg, Hellstrom et al. 2005). 
Lundberg et al (Lundberg, Hellstrom et al. 1994) directly measured luminal NO in 12 controls and 6 
patients with acute UC by a chemiluminescence technique. The gas was aspirated from different areas 
of the colon at colonoscopy. In the UC patients NO concentrations were found to be >100 times 
higher than in the controls. 
Perner et al (Perner, Nordgaard et al. 2002) showed that in acute UC patients the production of NO in 
the colon is 10 times higher than controls (p<0.001), and that the results positively correlated with 
disease activity scores (p<0.01). 
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Although this technique can be carried out using a silicone catheter in the rectum to aspirate NO rather 
than having to use a colonoscope, it remains an invas ve technique that is technically challenging and
is not in routine clinical practice at present (Sutherland, Gearry et al. 2008). 
 
1.11 Proteomics  
The National Human Genome Research Institute and the US Department of Energy launched the 
human genome project in 1990 (National Human Genome Research, Institutes of Health et al. 2003). 
The objective was to sequence the entire human genetic code. From this the first CD gene (IBD1 locus 
on chromosome 16) was identified (Hugot, Laurent-Puig et al. 1996) and many others were to follow. 
However, this information does not elucidate the physiological processes ongoing during which 
millions of molecules resulting from an unknown number of post-translational modifications interact 
at varying time points (Yau, Leong et al. 2013). 
Other molecular biology technologies therefore develop d with the aim of understanding transcription 
and the resulting protein activity, and identifying physiological pathways. These have been termed 
“functional genomics”, “systems biology” or “omics” encompassing genomics, transcriptomics, 
proteomics and metabolomics. 
Proteomics has revolutionised the way in which biomarker discovery can be carried out as it allows 
large scale, high throughput identification and analysis of proteins in different biological fluids with 
the potential for elucidation of biological pathways affected in disease, the identification of 
individuals at high risk of disease, the assessment of prognosis and prediction of response to 
treatment, as well as the personalisation of therapeutic interventions and the prediction of those who 
may develop side-effects of a therapeutic intervention (Guest, Gottschalk et al. 2013).  
 
1.11.1 Analytical Platforms for Proteomics 
Mass spectrometry (MS) has become the method of choice f r analysis of complex protein samples. 
MS-based proteomics is made possible by the availability of gene and genome sequence databases, 
and the development of protein ionisation methods.  
A mass spectrometer consists of an ion source, a mass analyser that measures the mass-to-charge ratio 
(m/z) of the ionised analytes, and a detector that regist rs the number of ions at each mass 
spectrometric measurements are carried out in the gas phase on ionised analytes m/zvalue (Aebersold, 
Mann 2003). 
Electrospray ionisation (ESI) ionises the analytes out of a solution. It is coupled with liquid-based 
separation tools such as chromatography or electrophoresis (Fenn, Mann et al. 1989). 
Matrix-assisted laser desorption / ionisation (MALDI) sublimates and ionises the samples out of a dry, 
crystalline matrix via laser pulses (Karas, Hillenkamp 1988). MALDI-MS is usually utilised in the 
analysis of simple peptide mixtures whereas ESI-MS is preferred in the analysis of more complex 
samples (Aebersold, Mann 2003).  
There are four basic types of mass analyser currently used in proteomics: 
• Ion trap 
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• Time-of-flight (ToF) 
• Quadropole 
• Fourier transform ion cyclotron (FT) 
These can be used as stand-alone analysers or in tandem to maximise the strengths of each. 
 
Table 1.6: Advantages and Disadvantages of Mass Analysers (Aebersold, Mann 2003) 
Platform Advantages Disadvantages 
Ion trap Robust, sensitive, inexpensive Low mass accuracy 
ToF High sensitivity, high resolution, high 
mass accuracy, well suited for pulsed 
ionisation methods 
Requires pulsed ionisation method or ion 
beam switching, limited dynamic range, 
limited precursor-ion selectivity 
Quadropole High sensitivity, high resolution, high 
mass accuracy, can be used with ESI 
ionisation source 
Peak heights variable as a function of 
mass (mass discrimination), not well 
suited for pulsed ionisation methods 
FT High sensitivity, high mass accuracy, 
high resolution, dynamic range 
Expensive, operational complexity, low 
peptide-fragmentation efficiency 
 
High-resolution two dimensional gel electophoresis (2-DE) is used in combination with MS to allow 
the differentiation of all of the protein species. The commonly applied 2-DE methods separate the 
complex protein mixture by: 
1. Charge separation employing isoelectic focusing (IEF) 
a. IPG (immobilised pH gradient) strips 
b. NEPHGE (Nonequilibrium pH Gel Electrophoresis) technique 
2. Size separation involving SDS-PAGE (Sodium Dodecyl Sulfate – PolyAcrylamide Gel 
Electrophoresis) (Wittmann-Liebold, Graack et al. 2006) 
 
1.11.2 Proteomics in IBD 
In 2002 the first hypothesis-free proteomics research in IBD was published, and examined protein 
changes in human intestinal epithelial cells exposed to IL-γ, IL-1β, and IL-6. High levels of 
indoleamine-2,3-dioxygenase was found in IBD subjects compared with controls and the authors 
hypothesised an involvement of the kynurenine pathwy of tryptophan metabolism in IBD  (Barcelo-
Batllori, Andre et al. 2002). 
The first serum proteomic study of IBD was carried out in 2007 using surface-enhanced desorption 
ionisation (SELDI)-TOF MS  for the initial proteome scan, followed by MALDI MS/MS, Western 
blotting and ELISA assay analysis of the proteins of interest. The profiles of subjects with CD, UC, 
nonspecific inflammation, and healthy controls were analysed and four biomarker candidates were 
validated (Meuwis, Fillet et al. 2007).  
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The follow-up to the previous study compared CD subjects before and after infliximab treatment, 
comparing the responeders with the non-responders. The previously identified candidate biomarker 
platelet factor 4 was found to be significantly higher in non-responders than in responders (Meuwis, 
Fillet et al. 2008). 
More recently, Presley et al (Presley, Ye et al. 2012) have defined the metaproteome, protein 
expression on the mucosal-luminal interface of the int stine. The contents of this intestinal layer wee 
analysed using SELDI-TOF MS and the results correlated bacterial phylotypes with specific 
immunological protein features. This work has the potential to discover host-microbe interactions in 
IBD pathogenesis.  
 
1.11.3 Combining Proteomics and Metabolomics 
The ability to explore both genetic and environmental factors in the pathogenesis of IBD is exciting. 
Proteomics and metabolomics offer the potential to study both endogenous and exogenous processes 
of the phenotypic manifestations of disease, and whilst these technologies are still in their relative 
infancies, they are progressing rapidly and are likly to offer valuable insights in the future.  
 
1.12 Metabolomics 
The phrase “the metabolome” was coined in the late 1990s (Oliver, Winson et al. 1998, Tweeddale, 
Notley-McRobb et al. 1998) and was initially defined as the total quantitative collection of low 
molecular weight compounds present in a cell or organism which participate in metabolic reactions 
required for growth, maintenance and normal function (Oliver, Winson et al. 1998). Nicholson et al 
(Nicholson, Wilson 2003) went on to further clarify this definition as “the measurement of metabolite 
concentrations and fluxes and secretion in cells and tissues in which there is a direct connection 
between the genetic activity, protein activity and the metabolic activity itself”.  
The metabolome consists of thousands of organic and inorganic species, generally of weight < 1500 
Daltons (Da) (Dunn 2008) or < 3000 m/z (Hollywood, Brison et al. 2006). The symbol m/z is used to 
denote the dimensionless quantity formed by dividing the mass of an ion in unified atomic mass units 
by its charge number, giving the mass-to-change ratio (McNaught, Wilkinson 1997).  
The “omics” technologies primary aim is the non-targeted identification of all of the products of gene 
expression in order for us to understand the biologcal system as a whole. Information flow is from the 
genome via transcriptomics (the measurement of mRNA levels for quantifying gene expression) and 
proteomics (protein translation, including post-transl tional modifications) to metabolomics 
(Weckwerth 2003). The metabolome is the furthest “downstream” and is therefore can be thought of 








Figure 1.6: The “omics” cascade 
  
Measuring the metabolites of patients with IBD is not a new concept. In 1980, Roediger and Truelove 
(Roediger, Truelove 1979) identified luminal n-butyrate as the major respiratory fuel of isolated 
colonocytes, and identified that colonocytes taken from patients with UC have an impaired ability to 
metabolise butyrate (Roediger 1980). In 1982, Roediger et al (Roediger, Heyworth et al. 1982) 
reported on the measurement of short chain fatty acids (SCFA), ammonia, sodium and potassium 
concentrations in the colon of patients with UC. They identified increased levels of luminal SCFA in 
patients with severe UC. In particular, butyrate leve s were found to be increased in all UC patients, a 
finding independent of the disease severity. This confirmed that butyrate utilisation by the colonic 
mucosa is impaired in UC. It was thought that in the short term this deficiency lead to mucosal 
hypoplasia, and in the long term colitis (Scheppach, C ristl et al. 1997). Therefore, SCFA enemas 
were used to attempt to reduce colonic inflammation, but were not shown to be successful (Breuer, 
Soergel et al. 1997, Scheppach 1996, Steinhart, Hiruki et al. 1996). This lead to the hypothesis that e 
inflammatory process is responsible for the decrease in colonic mucosal cell metabolism, or that the 
decrease in metabolism may be the result of a primary or acquired mucosal enzymatic defect, rather 
than unavailability of the mucosal substrate (Duffy, Regan et al. 1998). Duffy et al (Duffy, Regan et 
al. 1998) reported that mucosal metabolic fluxes of butyrate and glutamine are reduced in both UC 
and CD in comparison to healthy individuals. They showed that the differences were most marked in 
those with moderate to severe mucosal inflammation, and are not a result of a panenteric metabolic 
disorder in either condition, but simply a result of the inflammatory process. This is supported by 
Finnie et al (Finnie, Taylor et al. 1993) who found that patients with longstanding quiescent UC had 














The introduction of mass spectrometry in relation t metabolomic profiling has meant that vast 
numbers of metabolites can be identified from tissue, bodily fluids, plants and microbes. The mass 
spectrometer was first invented in 1912 (Dunn 2008) by J.J Thompson, and in 1922 Francis William 
Ashton won the Nobel Prize for Chemistry for his design and use of the mass spectrograph. Mass 
spectrometers operate by ion formation, separation of ions according to their mass-to-charge (m/z) 
ratio and detection of separated ions (Dunn, Ellis 2005). 
In 2005, the Metabolomics Standards Initiative (MSI) was formed to oversee the standardisation of 
techniques in this rapidly expanding field. In 2001, a group from Imperial College London (Lindon, 
Nicholson et al. 2003) was working on metabonomic toxicity. This involved generating databases of 
1H NMR spectra of body fluids from animals. Six major pharmaceutical corporations were involved 
and due to the collaborative nature of the project standards were needed to exchange data and 
communicate results. The Standard Metabolic Reporting Structure (SMRS) initiative was formed at 
this time and reported in 2005 (Lindon, Nicholson et al. 2005). Simultaneously a consortium focused 
on the metabolomic profiling of plants was working on a generic data model to provide a basis for the 
design of systems for data storage and exchange, call d Architecture for Metabolomics (ArMet) 
(Jenkins, Hardy et al. 2004). These two groups merged to form the MSI (Castle, Fiehn et al. 2006) and 
aim to provide a common mechanism for describing the work so that the data can be made available to 
others for evaluation, or to support an extension or repeat of the work as desired, or published in a 
public repository (Fiehn, Robertson et al. 2007). 
The metabolome has been studied in relation to microbes (Khoo, Al-Rubeai 2007, Koek, Muilwijk et 
al. 2006, Mashego, Rumbold et al. 2007), plants (Kopka, Fernie et al. 2004, Hall 2006), fruits (Biais, 
Allwood et al. 2009), the environment (Lim, Viant et al. 2006, Viant 2007), and mammals (Sellick, 
Hansen et al. 2009). With regards to the medical world the study of health and nutrition (Fava, 
Lovegrove et al. 2006, German, Watkins et al. 2005, Zeisel, Freake et al. 2005) as well as the potential 
for the discovery of metabolites (biomarkers) that are indicative of disease (Ackermann, Hale et al. 
2006, Kenny, Broadhurst et al. 2008), and the ability to monitor pharmacological therapies (Chen, 
Gonzalez et al. 2007) is very exciting.  
Metabolomics involves the study of numerous analytes that have very diverse physical and chemical 
properties and occur in a wide concentration range. Currently there is no single instrument platform 
that can analyse all metabolites, and this may represent part of the reason that metabolomics lags 
behind genomics, transcriptomics and proteomics (Dettmer, Aronov et al. 2007). To further 
complicate the analysis of the metabolome, it must be aken into account that metabolite distributions 
are subject to high temporal and spatial variability e.g. circadian fluctuations in mammals (Dettmer, 
Aronov et al. 2007) and diet-dependent biological vriability (Vigneau-Callahan, Shestopalov et al. 
2001). Due to this complexity a number of different strategies are employed when considering the 
metabolome (Dunn 2008). 
Tang et al (Tang, Wang 2006) have conjectured that t e ideal detection method for metabolomic 
analysis would have to be objective, have high sensitivity and reproducibility, good signal resolution, 
not require pre-knowledge to assist biomarker discovery, have good quantification capability for 
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complex mixtures, be able to provide in depth molecular information such as structure, concentration, 
dynamics, interactions, pH and compartmentation, be holistic rather than selective, be inexpensive and 
have high throughput, require little or no sample pr paration, be non-invasive and non-destructive to 
facilitate in vivo and in situ studies, and have low recurrent expenditure. In reality this analytical 
platform does not exist but the available techniques attempt to meet as many of these criteria as 
possible. 
Most metabolomic analyses are carried out by mass spectrometry (MS), and nuclear magnetic 
resonance (NMR) spectroscopy (Fiehn, Kind 2007). MSrequires pre-separation of the metabolic 
components, usually by either gas chromatography after chemical derivatisation, or liquid 
chromatography (Beckonert, Keun et al. 2007).  
 
1.12.1 Mass Spectrometry 
Mass Spectrometry is an established technique and is a potent platform for metabolomics due to its 
ability to detect metabolites at µM concentrations (Werner, Heilier et al. 2008). Atmospheric pressure 
ionisation (API) includes common soft ionisation techniques that generally produce protonated 
molecules [M+H]+ or deprotonated molecules [M–H]-. Some metabolites can only be observed in one 
ionisation mode, therefore acquisition should be performed in both positive and negative ion mode to 
maximise the metabolome coverage (Boccard, Veuthey et al. 2010).  
The high mass accuracy of MS provides structural information, as an exact molecular mass can be 
indicative of the molecular formula or fragments of the molecular structure (Dunn, Ellis 2005). 
Direct Injection MS (DIMS) is the simplest form of MS technology. It allows high throughput 
screening and is mainly used for sample classification. Quantification and metabolite identification is 
limited in this technique due its susceptibility to ion suppression, especially when performed on 
complex biological matrices (Boccard, Veuthey et al. 2010). An effective chromatographic separation 
prior to MS will reduce these effects (Cubbon, Antonio et al. 2010). 
 
1.12.2 Gas Chromatography Mass Spectrometry 
Combined Gas Chromatography Mass Spectrometry (GC-MS) is a system where volatile and 
thermally stable compounds are first separated by GC and then eluting compounds are detected 
traditionally by electron-impact mass spectrometers (Dunn, Ellis 2005). GC-MS provides 
reproducible and accurate measurements of volatile compounds and the fragmentation pattern of these 
molecules (Jonsson, Gullberg et al. 2004, Veriotti, Sacks 2001). The chemical derivatisation of semi-
volatile compounds is required to increase the volatility and produces ions that can be separated in the 
GC column (Halket, Zaikin 2003, Halket, Waterman et al. 2005, Zaikin, Halket 2003). GC-MS has 
been called the “gold standard” in metabolomic analyses (Harrigan, Goodacre 2003) and libraries 
have been built to allow the identification of compounds (Schauer, Steinhauser et al. 2005). 
Comprehensive two-dimensional gas chromatography (GC x GC) is a novel separation technique as 
conventional GC cannot resolve all analytes. Initially  heart-cut technique was used in which one or a
limited number of fractions of the first column eluate was transferred to a second column with 
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different characteristics to obtain an improved separation (GC – GC). The technique was not useful 
for samples in which the analytes of interest are scattered throughout the first-dimension 
chromatogram, or in which attention has to be devoted to unknowns more than to target analytes. 
Therefore a comprehensive technique has evolved in which the entire sample is subjected to 2 
independent separations. The 2 dimensional (2D) separation is completed in the run time of the first 
separation thus providing more information and reducing the time of GC – GC (Beens, Brinkman 
2005). This technique is linked to MS in metabolomic analyses (GC x GC-MS). 
 
1.12.3 Liquid Chromatography Mass Spectrometry 
Liquid Chromatography Mass Spectrometry (LC-MS) is another combined technique in which 
metabolites are separated by liquid chromatography nd then detected by electrospray ionisation (ESI) 
or less commonly API. This technique does not require samples to be volatile and is carried out at 
lower temperatures than GC-MS, thus simplifying sample preparation (Dunn, Ellis 2005). Although 
sample derivatisation is generally not required, it can be beneficial to improve chromatographic 
resolution and sensitivity or to provide ionisable groups on metabolites otherwise undetectable by 
ESI-MS (Leavens, Lane et al. 2002). 
ESI does not result in fragmentation of molecular ions as observed in electron impact mass 
spectrometers, and therefore does not allow direct metabolite identification by comparison of ESI 
mass spectra (Dunn, Ellis 2005). However, with the us  of accurate mass measurements and/or 
tandem MS (MS/MS) to provide collisional induced dissociation (CID) and related mass spectra 
(MS/MS), metabolite identification can be performed (Lenz, Bright et al. 2004). 
The introduction of capillary LC (Dear, Ayrton et al. 1999, Ding, Sorensen et al. 2007) and ultra-high 
pressure LC (Swartz 2005) has great potential for metabolomic analyses on complex samples by 
improving the chromatographic performance. 
 
1.12.4 Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance (NMR) Spectroscopy is a rapid, quantitative, non-destructive, non-
invasive, non-equilibrium perturbing technique with high throughput that requires minimal sample 
preparation. It provides detailed information on soluti n-state molecular structures, based on atom 
centred nuclear interactions and properties (Dunn, Ellis 2005, Beckonert, Keun et al. 2007). It is not
however as sensitive as MS (Lenz, Wilson 2007). 
NMR spectroscopy operates by the application of strng magnetic fields and radio frequency pulses to 
the nuclei of atoms. In atoms with an odd atomic number (e.g., 1H) or odd mass number (e.g., 13C), the 
presence of a magnetic field will cause the nucleus to possess spin, termed nuclear spin. Absorption of 
RF energy will promote the nuclei from low-energy to high-energy spin states, and the subsequent 
emission of radiation during the relaxation process is detected (Dunn, Ellis 2005). 
It tends to be 1H NMR spectroscopy that is employed in clinical studies (Dunn, Ellis 2005), which has 





Table 1.7: Advantages and Limitations of Mass Spectrometry versus NMR in Metabolomic Analysis 
(Lin, Helsby et al. 2011) 




Sensitivity Higher Lower 
Detection Range Wider 
• Couple with 
chromatographic 
separation (e.g. LC, 
GC) 
Narrower 
• Bias towards high 
abundance metabolites 
• Restricted to specific 
resonances 
• Overlapping signals 
not easily resolved 
Samples Cannot be reused May be nondestructive 
 
1.12.5 Orbitrap 
The Orbitrap, a mass spectrometer, operates by radially trapping ions about a spindle-like central 
electrode, kept at high voltage. An outer barrel-like electrode, kept at ground potential, is coaxial w th 
the inner electrode and mass/charge values are measured from the frequency of the harmonic ion 
oscillations, along the axis of the electric field, undergone by orbitally trapped ions. The electrodes ar  
shaped in such a way that the quadro-logarithmic potential distribution is formed with very high 
accuracy. Ion frequencies are measured non-destructively by acquisition of time-domain image 
current transients; with subsequent fast Fourier transforms (FFTs) being used to obtain mass spectra 
(Hu, Noll et al. 2005).  
 
1.12.6 The Application and Reporting of the Metabolome in Biomarker Discovery  
The “omics” technologies lend themselves to the possibility of biomarker discovery, especially using 
multiple biomarkers simultaneously to diagnose or predict disease. Statistically there are three steps in 
biomarker analysis; biomarker selection, performance evaluation, and model creation.  
Biomarker selection involves the identification of an optimal subset of feature that will provide the 
maximal discriminating power between diseased and healt y samples. Performance evaluation 
involves the assessment and validation of the panel of biomarkers proposed. The final model creation 
involves developing a fixed mathematical model, which combines the panel of biomarkers into a 
single test score with the aim of accurately predicting a particular clinical outcome, given the 
measured biomarker responses from a particular target population. 
Metabolomic studies can be placed into two general categories, those evaluating biological process, 
and those aiming to develop biomarkers. Studies aimed at biological understanding tend to utilise 
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multivariate statistical methods such as principal component analysis (PCA) or partial least squares 
discriminant analysis (PLS-DA). The results are accompanied by a long list of compounds selected 
based on a given model’s loading values, variable projection scores, or p-values derived from 
parametric univariate hypothesis testing, or their non-parametric equivalent performed on each 
measure metabolite in turn. These compounds may be labeled “putative biomarkers”, but may not be 
useful in clinical practice. 
Studies focused on biomarker discovery should be performed a priori rather than post hoc. That is, 
biomarker selection must be performed before deriving a definitive multivariate predictive model. A 
short list of up to ten metabolites is mathematically more robust and more practical for clinical testing 
purposes. Supervised machine learning algorithms, or multivariate regression models should be used 
to build the predictive models for biomarker analysis. 
Whilst metabolomic biomarkers screening for inborn e rors of metabolism in neonates are in clinical 
practice, as they can often be diagnosed using a single metabolic marker (Scolamiero, Cozzolino et al. 
2015), other chronic diseases exhibit smaller concentration changes spread across potentially dozens 
of metabolites, making the development of a single compound test very challenging. Compound 
quantification is another important area when considering metabolites as biomarkers, as it can be 
difficult and time-consuming (Xia, Broadhurst et al. 2013).  
The standardisation of metabolomic profiling techniques, and the manner in which they are reported, 
is of utmost importance.  There are many challenges starting with the vast number of samples types 
available for analysis, and the significant number of analytical platforms available, with MS and NMR 
being the most utilised. The complexity of the stati ical processes required to analyse data, and the 
need for standardisation of both the experimental and reporting techniques, as well as validation of 
said techniques, lead to the publication of proposed minimum reporting stardards related to the 
chemical analysis aspects of metabolomics experiments including; sample preparation, experimental 
analysis, quality control, metabolite identification, and data pre-processing (Sumner, Amberg et al. 
2007).  
In metabolomics experiments, the numbers of samples is far fewer than the number of metabolites or 
variables measured. Statistical analysis (univariate or multivariate), or machine learning analysis, as 
well as informatic analyses, is therefore required to produce knowledge that can be useful in the 
generation of hypotheses and biological understanding. The Framework Programme 7 EU Initiative 
“COordination of Standards in MetabOlomicS” (COSMOS) is developing a robust data infrastructure 
and exchange standards for metabolomics data and metadata (Salek, Neumann et al. 2015). The 
development of metabolomics repositories, such as Metabolomics Workbench or MetaboLights, are 
an example of using standardised legacy data to demonstrate new, or compare existing data analysis 
approaches, where data standards and sharing excel. These repositories also facilitate computational 






Figure 1.7: Information flow in a metabolomics 
 
1.12.6.1 Data Reduction and Deconvolution
The data produced from metabolomic profiling produces multiple measurements of multiple 
metabolites at different concentrations. These large volumes of raw data need to be transformed into 
an appropriate data format that can be statistically analysed. This involves the extraction of relevant 
signals from the data, and correcting for confounding factors that may bias the data, including bioflud 
characteristics and analytical processing techniques. In m
the separation of overlapping signals into individual chemical peaks, is used in hyphenated 
chromatography / mass spectrometry, where the raw 3D matrices (time vs. mass vs. intensity) are 
especially complex. In NMR,
individual resonances or into metabolite identification lists, and the term “data transformation” is 
preferred (Goodacre, Broadhurst et al. 2007)
 
1.12.6.2 Pre-processing and Pre
Pre-processing is a generic term for methods used to convert raw instrumental data to clean data to 
allow data processing. Pre
processing. 
There are many methods for pre
these, including the order in which they were performed, and the software utilised, should be reported. 
Order-independent pre-processing methods are more difficult to report as they may require assessment 
or interpretation by the reader prior to the analysis moving on the the next stage, such as outlier 
detection by principal component analysis 
   




etabolomic terms, deconvolution, meaning 
 deconvolution describes the separation of overlapping peaks into 
. 
-treatment 
-treatment involves transforming the clean data to make them ready for data 
-processing data matrices produced by metabolomic studies, and 











Metabolomics experiments produce multivariate data, however, univariate methods can be utilised to 
test individually for metabolites that are increased or decreased significantly between different groups. 
These tests include parametric methods for data that are normally distributed, such as ANOVA 
(analysis of variance), t-tests, and z-tests. When the data is not normally distributed, or cannot be 
assumed to be so, non-parametric methods can be used s ch as the Kruskal-Wallis test (Goodacre, 
Broadhurst et al. 2007). 
 
1.12.6.4 Multivariate Analysis 
The volume of “outputs” created from a metabolomics experiment is vast, thousands from a few 
subjects. The initial data analysis starts from a single matrix N x D, where N is the number of 
samples, and D is the number of variables (metabolomics / masses / retention times etc.). Each 
independent variable may be thought of as a single geometric dimension, such that each sample may 
be considered to exist as a single point in an abstr ct entity referred to as D-dimensional hyperspace. 
In order to determine the underlying properties of the data points in this hyperspace, methods such as 
unsupervised dimensionality reduction (usually projection into a space of significantly smaller 
dimensionality whilst trying to minimise information loss), clustering (identifying groups of points 
that are more similar to each other than the rest of the data), correlation analysis, or supervised pattern 
recognition / machine learning (including multivariate regression and discriminant analysis) may be 
employed (Goodacre, Broadhurst et al. 2007). 
 
1.12.6.5 Unsupervised Methods 
Unsupervised methods can be split into dimension reduction and cluster analysis. Dimension 
reduction, typified by principal component analysis (PCA), is essentially a multivariate linear 
transformation, and is often used as a pre-processing step prior to application of a supervised method 
such as partial least squares and discriminate analysis (PLS-DA). When reporting this method, 
reference to the software used or the theoretical source of the mathematical algorithm should be made, 
as well as stating any assumptions made about the chara teristics of the dataset before transformation. 
Cluster analysis utilises an algorithm attempting to “find” clusters of similarly characterised samples. 
Once found they may be used to classify each sample and similarities between clusters may be 
assessed. When reporting this method, details of the software or algorithm must be given, as well as 
the similarity measure used. It is also possible to determine correlations between the metabolites or 
variables by conducting Correlation Analysis, and creating correlation matrix pseudomaps or 
confusion matrices as the first step in data explorati n (Goodacre, Broadhurst et al. 2007). 
 
1.12.6.6 Supervised Methods 
When one knows the classes or value of the responses that one is trying to predict (Y-data) associated 
with each of the sample inputs (X-data), supervised methods can be used. The aim is to find a model 
that will correctly associate all of the X-data with the target Y-data. Usually supervised methods 
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require meta-parameterisation (meta-parameters are parameters that help to define the structure and 
optimisation of the model) (Goodacre, Broadhurst et al. 2007).  
 
1.12.6.7 Model Validation 
Should the results of a metabolomics study indicate a g neral model, or general biomarker discovery, 
reports must be verified by a model validation. This is required in both supervised and unsupervised 
analysis. Internal validation is used in supervised methods to optimise meta-parameters such as the 
number of latent variables in PLS. Even if internal v lidation appears to improve the predictive 
capability of the final model chosen, this model’s generalisation capability tends to be overoptimistic 
(overfitting); hence it is not a replacement for extrinsic model validation. 
Simple model validation involves splitting the data into three sets: training, monitoring, and test. The 
training data are used to build one or more possible models, the monitoring data are then used to 
assess and optimise the quality of every “trained” model, and the independent test data are used to 
measure the generalisation / predictive expectation of the final published “optimal” model.  There are 
several validation methods in which the training and monitoring sets are initially combined and then 
subsequently dynamically partitioned into temporary training / monitoring dataset (e.g. bootstrapping 
and K-fold cross-validation). 
Importantly, in all cases, the test set is “blind” to the model building and selection process. The test 
procedure involves applying the test data to the “optimal” model with subsequent model predictions 
being compared to known responses. These models are known to be overoptimistic. 
For unsupervised methods sush as PCA, the monitoring dataset is not required. However, care must be 
taken not to make claims regarding data clustering when plotting the principal component y against 
principal component x when x and y are anything other than 1 and 2 respectively. Searching all 
possible component axes is a form of multiple testing (supervised analysis) and therefore requires the 
application of proper corrections to the clustering statistic (e.g. Bonferroni) (Goodacre, Broadhurst et 
al. 2007). 
 
1.13 Metabolomic Studies  
1.13.1 Human Diseases 
Metabolomic studies have been carried out in numerous human diseases in an aim to aid both 
diagnosis and disease monitoring, as well as personali ing treatments. Many metabolomic studies into 
malignancies (e.g. liver (Wei, Suryani et al. 2012, Gao, Lu et al. 2009, Yang, Xu et al. 2004), bladder 
(Issaq, Nativ et al. 2008), prostate (Serkova, Gamito et al. 2008, Sreekumar, Poisson et al. 2009), oral 
(Zhou, Xu et al. 2009, Tiziani, Lopes et al. 2009, Yan, Wei et al. 2008), stomach (Hirayama, Kami et 
al. 2009), renal (Kim, Aronov et al. 2009, Kind, Tolstikov et al. 2007), brain (Chen, Lou et al. 2011, 
Monleon, Morales et al. 2008), lung (Chen, Ma et al. 2015), colorectal (Hirayama, Kami et al. 2009, 
Monleon, Morales et al. 2009, Mal, Koh et al. 2009, Denkert, Budczies et al. 2008, Chan, Koh et al. 
2009) and breast / gynaecological cancers (Denkert, Budczies et al. 2006, Woo, Kim et al. 2009, 
Frickenschmidt, Frohlich et al. 2008)) have been undertaken in a search for biomarkers of disease and 
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disease activity. None, however, are currently in cl ical use. Metabolomic profiling has also been 
undertaken in diabetes (Sas, Karnovsky et al. 2015), cardiovascular diseases (Basak, Varshney et al. 
2015, Kordalewska, Markuszewski 2015) and neurological diseases (Zhang, Sun et al. 2013, Hassan-
Smith, Wallace et al. 2012) with the aim of gaining knowledge of disease pathogenesis as well as 
searching for biomarkers. As yet this has not been translated into clinical practice either. 
 
1.13.2 Animal Models of IBD 
Varma et al (Varma, Bird et al. 2007) studied 30 male Sprague-Dawley rats. These were divided into 
three groups of ten rats each. The first group was fed a regular diet for 2 weeks, the second group was 
fed a regular diet for one week and 2% carrageenan by weight for the second week, and the third 
group was fed 2% carrageenan by weight for the two week duration. Degraded lambda-carrageenan 
has been shown to cause inflammation similar to human IBD in a rodent model (Moyana, Xiang et al. 
1994).  
After the two week period all rats were sacrificed, their colons were excised and the mucosal layer 
scraped off using a glass slide. 1H NMR Spectroscopy experiments were carried out on the samples. 
After correlating the spectroscopy results with histology results and performing a multivariate 
analysis, the accuracy with which these samples were assigned to their respective groups was 82%. 
Four regions of the spectra were identified as being the most discriminatory. These included spectral 
resonances due to the -CH2HC= group in fatty acyl chain of triglycerides (2.79–2.83 ppm), creatine 
(3.00 ppm), phosphocholine (3.56–3.60 ppm) and glycerol backbone of lipids (4.03–4.05 ppm). 
Martin et al (Martin, Wang et al. 2007) have characterised the metabolic profile of normal rodent 
intestinal tissue including proximal and distal colon using high resolution 1H NMR Spectroscopy. 
They observed significant levels of phosphatidylchoine, creatine, glycerol and triglycerides. 
Phosphatidylcholine is the predominant phospholipid resent in the cell membranes (Cullis, Hope 
1992) including colonic mucosal cells (White 1973), and is an important constituent of PAF. PAF has 
been shown to increase significantly in mucosal biopsies from ulcerative colitis patients (Thyssen, 
Turk et al. 1996), and PAF levels in stool can be used to estimate the severity of mucosal 
inflammation in patients with IBD (Hocke, Richter et al. 1999). 
Creatine is a metabolite present in normal tissues and serves as an energy reservoir. Colonic 
inflammation causes cellular damage and increases energy requirements therefore creatine 
concentrations may be increased during periods of inflammation. 
Varma et al (Varma, Bird et al. 2007) concluded that 1H NMR Spectroscopy is a sensitive tool to 
detect early colonic inflammation in an animal model of IBD. 
Murdoch et al (Murdoch, Fu et al. 2008) studied urina y metabolomic profiles in IL-10 gene deficient 
(IL-10-/-) mice, and compared them to wild-type mice using NMR Spectroscopy. IL-10-/- mice are 
genetically susceptible to develop enterocolitis when colonised with enteric mouse microbiota (Kuhn, 
Lohler et al. 1993). The urinary metabolic fingerprint of IL-10-/- and wild-type mice was found to be 
similar at 4 weeks, before development of IBD in the IL-10-/- mouse model. Those metabolites that 
showed significant differences when data were analysed by two-way analysis of variance (ANOVA) 
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(with p < 0.01) with onset of IBD at approximately 12 weeks and older were fucose (p < 0.0001); 
trimethylamine (p < 0.0001); dimethylamine (p < 0.0001); fumarate (p < 0.0001); N-
isovaleroylglycine (p < 0.0001); 2-oxoglutarate (p = 0.0008); trimethylamine-N-oxide (p = 0.0011); 
butyrate (p = 0.0025); citrate (p = 0.0027); succinate (p = 0.0035); 3-indoxylsulfate (p = 0.0036); 
valine (p = 0.0058); and phenylacetylglycine (p = 0.0087). 
This study was the first to demonstrate urinary metabolic differences in an IBD mouse model as the 
disease develops over time through serial metabolic profiling. It also demonstrates significant 
differences between the urinary metabolites of wild-type mice and IL-10-/- mice, however the 
significance if these findings is yet to be clarified. Potentially these findings could lead to a non-
invasive urinary biomarker of IBD. 
Lin et al (Lin, Edmunds et al. 2009, Lin, Barnett et al. 2010) also performed urinary metabolomic 
analyses on IL-10-/- mice, however the GC-MS platform was used in these studies.  
Elevated urinary levels of xanthurenic acid and fucose were identified indicating upregulation of 
tryptophan catabolism and perturbed fucosylation in IL-10-/- mice. Three short-chain dicarboxylic acid 
metabolites (glutaric acid, 2-hydroxyglutaric acid, and 2-hydroxyadipic acid) were decreased in IL-10-
/- mice relative to wildtype, suggesting the downregulation of fatty acid oxidation (Lin, Edmunds et al. 
2009). 
Martin et al (Martin, Rezzi et al. 2009) studied 20wild-type mice and 20 IL-10-/- mice using a 
combination of histopathological analysis of intestinal sections, metabolic profiling of blood plasma 
using 1H NMR Spectroscopy, and measurement of plasma inflammatory biomarkers.  
Histology of the colon and caecum showed inflammatory changes in all IL-10-/- mice at the age of 8, 
16 and 24 weeks, the grade of which increased with age. Concentrations of serum amyloid A (SAA) 
and soluble tumour necrosis factor II (sTNFRII) were measured. Expression of SAA showed an 
upward trend in IL-10-/- mice compared to the wild-type, however the difference never reached 
significance. Blood levels of sTNFRII were significantly increased in IL-10-/- mice from the age of 8 
weeks onwards. 
On metabolic analysis, IL-10-/- mice showed a marked reduction of global levels of creatinine, 
dimethylglycine, glucose, leucine, methionine, trimethylamine, tyrosine and very low density 
lipoprotein (VLDL). These changes were associated with an increase in alanine, arginine, choline in 
phospholipids, citrate, fumarate, high density lipoprotein (HDL), isoleucine, lactate, low density 
lipoprotein (LDL), phenylalanine, polyunsaturated lipids and pyruvate. 
The relative decrease of the level of VLDL particles in IL-10-/- mice can be associated with an 
increased activity of lipoprotein lipase in the capill ry beds in adipose tissue and skeletal muscles to 
remove triglycerides.  
Inflammatory processes in IL-10-/- mice were characterised by increased blood levels of secretory 
phospholipase A2, which promotes hydrolysis of phoslipids in LDL and VLDL and generates 
PUFAs that can be oxidised and promote inflammation. 
Elevated levels of lactate, citrate and pyruvate and decreased plasma glucose level in the IL-10-/- mice 
are suggestive of increased fatty acid oxidation and extensive glycolysis to accommodate a higher 
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energy demand or decreased energy availability due to decreased nutrient absorption through the 
compromised alimentary system. 
Elevation of alanine and glutamine in plasma was associated with decreased levels of the branched-
chain amino acids valine and leucine, which reflected both breakdown of proteins and increased 
gluconeogenesis and carbon flux through the anapleurotic pathway to support ATP production.  
Schicho et al (Schicho, Nazyrova et al. 2010) used 1H NMR Spectroscopy to perform quantitative 
metabolomic analysis of metabolites in urine and blood serum of mice in which experimental 
ulcerative colitis has been induced with dextran sulfate sodium (DSS). DSS induced colitis is one of 
the most widely used and reproducible animal models for UC (Okayasu, Hatakeyama et al. 1990). 
During DSS colitis in urine samples increases in cocentrations were observed for the amino acids 
creatine, carnitine, glycine and phenylalanine, for allantoin and for methylamines such as 
dimethyamine, trimethylamine and trimethylamine-N-oxide while urea (a terminal metabolite of 
catabolic processes), methionine, nicotinamide and ascorbate were decreased. 
In serum, large increases in concentration are shown f r ketone bodies (acetoacetate, acetone and 3-
hydroxybutyrate), hypoxanthine, inosine and tryptophan, while glucose, Krebs cycle intermediates 
(fumarate, 2-oxoglutarate, citrate), and several amino acids are decreased. 
Methylamines are produced by gut bacteria (Smith, Wishnok et al. 1994), which are known to have a 
role in IBD pathogenesis (Takaishi, Matsuki et al. 2008). 
Overall, urine samples revealed mostly changes in bacterial metabolites and metabolites associated 
with oxidative stress, while serum samples showed changes in metabolites associated with the 
regulation of the organism’s energy level.  
Chen et al also studied (Chen, Shah et al. 2008) DSS induced colitic mice, however they used LC-MS 
to perform metabolomic analysis of serum. They showed that DSS-treated mice have increased serum 
levels of stearoyl lysophosphatidiylcholine and decreased levels of oleoyl lysophosphatidiylcholine. 
The alterations in the levels of these lipids led to the discovery that these levels were caused by DSS 
inhibition of stearoyl-coA desaturase 1 (SCD1)-mediated olecic acid biogenesis in the liver, resulting 
in exacerbation of proinflammatory responses. The findings of the study implied that SCD1 and 
associated lipids could be potential drug targets for treating IBD (Lin, Helsby et al. 2011). 
These animal models help to understand more about the pathogenesis of IBD but do not provide 
complete answers at present.  
 
1.13.3 Human IBD Studies 
Marchesi et al (Marchesi J.R., Holmes E. et al. 2007) used 1H NMR Spectroscopy to study faecal 
extracts obtained from patients with CD and UC, as well as healthy controls. In the CD and UC 
patients levels of short chain fatty acids (SCFAs) butyrate, acetate, methylamine, and trimethylamine 
were reduced when compared to the control population. The changes were more marked in the CD 
group than the UC group. 
Several studies (Seksik, Rigottier-Gois et al. 2003, Sokol, Seksik et al. 2006, Scanlan, Shanahan et al.
2006) of the diversity of microbiota associated with IBD have shown that members of the Clostridium 
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coccoides and Clostridium leptum groups are significantly reduced when compared to healt y 
subjects. These bacterial groups are involved in SCFA production, and therefore these findings would 
be consistent with Marchesi’s results. 
Jansson et al (Jansson, Willing et al. 2009) used ion cyclotron resonance-Fourier transform mass 
spectrometry (ICR-FT/MS) to study the metabolites in 17 identical twin pairs including healthy twin 
pairs, concordant pairs (both twins have CD) and discordant pairs (one twin is healthy and the 
matched twin has CD). ICR-FT/MS with an ultrahigh mass resolution enables differentiation of very 
subtle variations in thousands of mass signals, including higher molecular weight metabolites 
(Rossello-Mora, Lucio et al. 2008).  
Siffledeen et al (Siffledeen, Fu et al. 2008) were th first to use NMR Spectroscopy to observe 
differences in the urinary metabolomic profile betwen patients with IBD and healthy controls (78% 
sensitivity and 89% specificity on a blinded test set). They also found that patients with CD could be 
differentiated from those with UC.  
Williams (Williams, Cox et al. 2009) analysed samples of urine from patients with CD, UC and 
healthy controls. 1H NMR Spectroscopy was used to carry our urinary metabolomic profiling. 
Hippurate levels were found to be significantly lower in CD patients than in the other groups 
(p<0.0001) as were 4-cresol sulphate levels (p<0.0002). Formate levels were found to be significantly 
higher in CD patients than in UC patients or healthy controls (p<0.0005).  
Urinary hippurate is a product of the microbial metabolism of various dietary aromatic compounds 
(e.g. purines) and aromatic amino acids (e.g. tyrosine) to benzoic acid with subsequent renal and 
hepatic conjugation of benzoic acid with glycine (Williams, Cox et al. 2009). The concentration of 
urinary hippurate has been shown to be modulated according to gut microbes (Nicholls, Mortishire-
Smith et al. 2003, Williams, Eyton-Jones et al. 2002). A reduction in Clostridia spp. has been shown 
in IBD (Sartor 2008), and Li et al (Li, Wang et al. 2008) found a positive association between 
Clostridia spp and hippurate levels. This leads us to believe that there is an inherent difference in the 
gut microbiotia between patients with IBD and healthy controls. 
Mammalian formate may be generated endogenously as the result of one-carbon metabolism (Case, 
Benevenga 1977), however it is also a major fermentative microbial metabolite (Leonhartsberger, 
Korsa et al. 2002). It is a characteristic product in the mixed-acid fermentation of the 
Enterobacteriaceae. The result of increased formate in the CD group is consistent with previous 
findings of an increase in Enterobacteriacea and particularly in E. coli, in CD patients (Seksik, 
Rigottier-Gois et al. 2003, Sartor 2008).  
Urinary 4-cresol sulphate is the product of the bacterial metabolism of tyrosine (Folin, Denis 1915) 
and is only synthesized by few bacterial species, particularly by Clostridia spp. and, to a lesser extent, 
by Bacteroidetes (Bone, Tamm et al. 1976, Smith, Macfarlane 1996). Clostridia spp. As previously 
discussed Clostridia spp. has been shown to be reduced in CD, and to a cert in extent the same has 
been suggested about Bacteroidetes (Ott, Musfeldt et al. 2004, Baumgart, Dogan et al. 2007). This 




Balasubramanian et al (Balasubramanian, Kumar et al. 2009) recruited patients with CD and UC, as 
well as healthy controls to study the metabolism of the colonic mucosa using 1H NMR Spectroscopy. 
In the active phase of UC and CD, significantly lower (p≤0.05) concentrations of amino acids 
(isoleucine, leucine, valine, alanine, glutamate and glutamine), membrane components (choline, 
glycerophosphorylcholine and myo-inositol), lactate nd succinate were observed compared to normal 
mucosa of controls. An increased level of α-glucose was found in the colonic mucosa of active IBD
patients when compared to the controls. These findings essentially translate into lower carbohydrate 
and protein metabolism in the active phase of IBD leading to loss of mucosal integrity.  
In normal intestinal mucosa glucose serves as an energy source (Roediger 1982, Ardawi, Newsholme 
1985). Its utilisation and, consequently, lactate production are reduced during malnutrition and 
starvation, a common symptom observed in IBD (Firmansy h, Penn et al. 1989, Faintuch 2002, Al-
Jaouni, Hebuterne et al. 2000). Low levels of lactate nd high levels of α-glucose observed in this 
study indicate the inability of the colonic mucosal ce ls to utilise glucose for its energy needs in UC
and CD. In the remission phase of UC and CD, the concentration of most of the metabolites was 
similar to the controls except for lower values of lactate, glycerophosphorylcholine and myo-inositol 
in UC and lactate in CD. Formate levels were found to be significantly lower in patients with the 
active phase of UC compared to patients with the active phase of CD. This raises the potential to use 
formate as a biomarker in distinguishing between CD and UC in the active phase. 
Bjerrum et al (Bjerrum, Nielsen et al. 2010) studied mucosal colonic biopsies, colonocytes, 
lymphocytes, and urine of patients with active UC, quiescent UC and healthy controls. Metabolomic 
analyses were performed using 1H NMR Spectroscopy. In the biopsies from patients with active UC 
higher levels of antioxidants, ascorbate and glutathione, and of amino acids, glutamate, glutamine, 
taurine and asparate, but lower levels of lipid, glycerophosphocholine, myo-inositol, and betaine were 
found, whereas the colonocytes only displayed low levels of glycerophosphocholine, myo-inositol and 
choline. The increased levels of glutamine and glutathione found in the biopsies from patients with 
active UC are most likely due to activated lymphocytes in the lamina propria as these metabolites 
were also found to be prominent features of the metabolic profile of peripheral lymphocytes. The 
results of this study lead to a hypothesis of an imbalanced antioxidant response in the lamina propria 
and colonocytes of patients with UC.  
Unfortunately at present there are inconsistencies within the literature regarding amino acid profiles 
and their part in the pathogenesis of IBD. Glutamine and glutathione have been studied previously 
however Balasubramanian et al (Balasubramanian, Kumar et al. 2009) in fact found levels to be lower 
than normal, rather than raised as found in this study. Finnie et al (Finnie, Taylor et al. 1993) observed 
increased glutamine metabolism in the distal colon of patients with quiescent UC, whereas Chapman 
et al (Chapman, Grahn et al. 1994) and Duffy et al (Duffy, Regan et al. 1998) found no such 
difference. Similar inconsistencies have been found with respect to glutathione (Ruan, Rao et al. 1997, 
Holmes, Yong et al. 1998). This is potentially due to the heterogeneity of these studies. 
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The metabolic profiles of lymphocytes and urine didnot allow a differentiation between active UC, 
inactive UC, and controls, which means that the inflammation in the large bowel is not reflected 
systemically in a cohort with moderate UC. 
Bezabeh et al (Bezabeh, Somorjai et al. 2001) used 1H NMR Spectroscopy to analyse colonic biopsies 
from IBD patients and normal healthy controls. The aim was to determine whether it was possible to 
differentiate between CD, UC and healthy controls. A classification accuracy between UC and CD of 
98.6% was achieved, with only one case of CD and no cases of UC misclassified. The classification 
accuracy between normal controls and IBD was 97.9%. They felt that there is strong potential for 
NMR Spectroscopy to be used in the accurate diagnosis of indeterminate colitis; however this method 
does require colonic biopsies. 
Johnston et al (Johnston 2014) were the first group to use an UPLC-MS platform to study the 
metabolomic profiles of serum from patients with CD and UC, and compare them to healthy controls. 
In their study, the majority of metabolic differences were observed in Vitamin D and its metabolites, 
steroids and their derivatives, fatty acids, bile acids, phospholipids and phosphocholine. A number of 
metabolites were uniquely altered in one or other IBD subclass versus control comparisons. 
Sphingolipids were exclusively decreased within theCD cohort compared to the control group. 
Isoprenoids were decreased in the UC cohort compared to controls. A comparison of UC and CD 
profiles showed that the quinone, ubiquinone was significantly greater in the UC group. All of these 
findings were of statistical significance at the discovery stage and replicated through a validation 
study.  
1.13.4 Metabolomics and Personalised Medicine in IBD 
Metabolomic profiling has the potential to be used to etermine responders from non-responders when 
considering drug therapies. In IBD, immunosuppressant drugs such as thiopurines (azathioprine or 
mercaptopurine) are used to induce and maintain long-term remission. However there is the risk of 
significant adverse effects such as myelosupression w th these drugs, which can occur through the 
accumulation of mercaptopurine derived thioguanine ucleotide (TGN) cytotoxic metabolites that are 
linked to a lack of red blood cell thiopurine S-methyl ransferase (TPMT) activity. Prior to 
commencing treatment with thiopurines, TPMT activity is measured to identify the 1:300 patients 
who are at risk of severe myelosuppression. Despite monitoring, myelotoxicity can still occur with 
normal TPMT activity, indicating a role for TPMT in the prediction of early events rather than in 











2.1 Hypothesis  
Currently there is little in the literature studying metabolomic profiles of patients with IBD. As 
previously discussed, Johnston et al (Johnston 2014) studied both serum and urinary metabolomic 
profiles in both CD and UC and compared them to healt y controls. During discovery and validation 
studies important metabolomic differences were defined between CD, UC and matched controls. 
Univariate analysis demonstrated greater than 50 metabolites that varied in their relative concentration 
when comparing CD or UC versus control patients, whilst only 6 metabolites were shown to change 
when comparing CD versus UC. The greatest perturbation to metabolism was between healthy and 
disease subjects as would be expected, with a significa tly lower level of differences observed 
between the two diseases. This may highlight similar pathophysiological mechanisms of both diseases 
with spatial differences in symptoms.  
 
Using metabolomic profiles measured on GC-ToF-MS and UHPLC-FTMS platforms to analyse 
serum and urine samples from healthy controls, CD and UC patients we hypothesise that: 
1. The work of Johnston et al (Johnston 2014) can be replicated with regards to metabolite 
identification and differentiation between healthy controls and IBD 
2. Metabolomic profile will alter with disease activity, anatomical location and treatment 
 
2.2 Principle Research Objectives 
1. To determine whether it is possible to differentiate between the metabolmic profiles of 
healthy controls, ulcerative colitis patients and Crohn’s disease patients. 
2. The identification of biologically relevant metabolites in IBD. 
3. To determine whether metablomic profile in IBD is affected by disease activity, anatomical 






Materials and Methods  
 
 
3.1 Patients, Materials and Methods
 
Figure 3.1: Study Design 
 
The design of the study, in association with Professor Roy Goodacre and Dr Warwick Dunn, was 
based around the IBD cohort being treated in NHS Highland
40 new patients are diagnosed with 
surgery for IBD. These were the figures decided upon for attempted recruitment, as shown in
3.1 in white. The number of patients successfully recruited into each group is shown in
red. This correlates with the recommendations made by Lancaster et al for the number of participants 
required for a pilot study 
Throughout the study it was feasible for patients to cross from the longitudinal sampling group into 
either or both of the biological and surgical groups, depending on the treatment that they required. It 
was also possible for patients initially recruited 
longitudinal sampling group, unless they had potentially curative surgery. 
The treatment naïve group of IBD patients was a cohort we felt may give the “purest” metabolomic 
profile as we hoped not to see d
This was a challenging group to recruit, resulting in low numbers, however due to the percieved value 
of this uncontaminated profile we chose to continue with analysis.





 (Appendix 8.1). Each year approximately 
IBD, 40 patients commenced biological therapy and 30 underwent 
(Lancaster, Dodd et al. 2004). 
into the surgical or biological groups to join the 
 




 Figure 3.1 in 
-invasive and simple 
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3.2 Ethical Approval  
Ethical approval was granted on 17/06/11 by the North f Scotland Research Ethics Committee; 
Reference Number 11\AL\0238. The approved documentatio  is attached in Appendix 8.1.1. 
 
3.3 Patient Recruitment  
Patients with IBD in the Highlands and Islands Scotland were approached to take part in the study by 
means of a letter of invitation with a routine clinic or endoscopy appointment, or were approached by 
the clinician in charge of their care in either thein- or out-patient setting. 
Each participant in the study was recruited by me. Those willing to discuss potential recruitment were 
given information sheets detailing the project, and the opportunity to ask questions regarding the 
project of myself. Exclusion criteria were those under the age of 16 years, and those unable to give 
informed consent. Those willing to participate in the study gave written informed consent to me 
(Appendix 8.1.2-8.1.14). A detailed interview and review of the case notes was carried out by me to 
establish relevant demographic and clinical data. This included classification of diet, although a 
formal food diary was not undertaken. A review of clini al data as well as disease activity scoring was 
carried out for each patient every time samples were collected. In view of their simplicity and use in 
routine clinical practice, the Harvey Bradshaw Index (Harvey, Bradshaw 1980) was used in patients 
with CD, and the Simple Clinical Colitis Activity Index (Walmsley, Ayres et al. 1998) was used in 
patients with UC. Disease phenotyping was carried out using relevant clinical investigations and 
pathological results available, by means of the Montreal Classification (Satsangi, Silverberg et al. 
2006) in CD, and in UC, disease location / extent was recorded using the Paris Classification (Levine, 




3.4 Harvey-Bradshaw Index  
In 1980, Harvey and Bradshaw developed and validated  simplified index of CD activity based on 5 
items; general well being, abdominal pain, number of liquid stools per day, the presence of an 
abdominal mass and the presence of complications (Harvey, Bradshaw 1980). They compared the 
simplified index (the Harvey-Bradshaw Index (HBI)) with the CDAI in a prospective study of 112 
patients and found that there was significant correlation between the 2 despite not weighting the 
simple index and not averaging symptoms over one week. They did however state that symptoms and 
stool frequency should be scored from the day previous as a visit to the clinic may alter symptoms. 
This simple index is reproducible and easy to use in a clinical setting; however it is reasonably 
subjective and is heavily biased by the number of liquid stools per day. 
 
Table 3.1: Harvey-Bradshaw Index (Harvey, Bradshaw 1980) 
General well-being 
0 = very well 
1 = slightly below par 
2 = poor 
3 = very poor 
4 = terrible 
Abdominal pain 
0 = none 
1 = mild 
2 = moderate 
3 = severe 
Number of liquid stools per day 
Abdominal mass 
0 = none 
1 = dubious 
2 = definite 
3 = definite and tender 
Complications: arthralgia, uveitis, erythema nodosum, aphthous ulcers, pyoderma gangrenosum, anal 




3.5 Simple Clinical Colitis Activity Index 
In 1998, Walmsley et al (Walmsley, Ayres et al. 1998) described a simple clinical index to aid in the 
evaluation of UC exacerbations. They aimed for an index that could be calculated in an outpatient 
setting and that did not require physical examination, endoscopic examination or laboratory test 
results. The Simple Clinical Colitis Activity Index (SCCAI) was established by correlating criteria in 
the Powell-Tuck Index as well as nocturnal stool frequency, urgency of defaecation and the general 
well being factor from the Harvey-Bradshaw Index. On testing this score showed a highly significant 
correlation with both the Powell-Tuck score (p<0.0001) as well as all laboratory markers (p=0.0003 to 
p<0.0001) (Walmsley, Ayres et al. 1998).  
Clinical remission or response to medication did not have scores allocated in the original paper, 
however a score of <2.5 points has been shown to correlate with Patient-Defined Remission (Higgins, 
Schwartz et al. 2005). This score has not been formally validated (Cooney, Warren et al. 2007). 
 
Table 3.2: Simple Clinical Colitis Activity Index (Walmsley, Ayres et al. 1998) 
Symptom Score 
Bowel frequency (day)  
1 – 3 0 
4 – 6 1 
7 – 9 2 
>9 3 
Bowel frequency (night)  
1 – 3 1 
4 – 6 2 




Blood in stool  
Trace 1 
Occasionally frank 2 
Usually frank 3 
General well being  
Very well 0 
Slightly below par 1 
Poor 2 
Very poor 3 
Terrible 4 




3.6 The Montreal Classification 
The Montreal Classification of CD accounts for age t onset of disease, disease location and disease 
behaviour to be taken into consideration in both clinical practice as well as for research purposes 
(Satsangi, Silverberg et al. 2006).  
 
Table 3.3: The Montreal Classification (Satsangi, Silverberg et al. 2006) 
Age at Diagnosis • A1 below 16 years 
• A2 between 17 and 40 years 
• A3 above 40 years 
Location • L1 ileal 
• L2 colonic 
• L3 ileocolonic 
• L4 isolated upper disease * 
Behaviour • B1 non-stricturing, non-penetrating 
• B2 stricturing 
• B3 penetrating 
• p perianal disease modifier ‡ 
* L4 is a modifier that can be added to L1 – L3 when concomitant upper gastrointestinal disease is 
present. 
‡ “p” is added to B1 – B3 when concomitant perianal disease is present. 
 
3.7 The Paris Classification 
The Paris Classification of UC records the extent of c lonic involvement. In paediatrics this 
classification also accounts for whether or not the patient has ever had a severe episode (as defined by 
the Paediatric Ulcerative Colitis Activity Index score ≥ 65) (Levine, Griffiths et al. 2011). This part of 
the score was not utilised in our adult population. 
 
Table 3.4: The Paris Classification (Levine, Griffiths et al. 2011) 
Extent • E1: ulcerative proctitis 
• E2: Left-sided UC (distal to splenic flexure) 
• E2+: Left-sided UC (extending beyond the limitation of the 
endoscopic examination) 
• E3: Extensive (hepatic flexure distally) 
• E4: Pancolitis (proximal to hepatic flexure) 
Severity • S0: never severe 




3.8 Healthy Control Recruitment 
Healthy controls attending clinics for non-gastrointestinal operative procedures were approached 
initially by the clinician in charge of their care and then by a member of the research team if they were 
willing. 
They were given information sheets detailing the project and the opportunity to ask any questions. 
Informed consent was gained and a detailed interview and review of the case notes was carried out to 
establish relevant demographic and clinical data. As previously exclusion criteria were under the age 
of 16 years, and unable to give informed consent.  
 
3.9 Metadata  
All relevant clinical data for the IBD patients and the healthy controls was stored on a secure 
Microsoft Access 2003 database on the NHS server. This database contained details of age, sex, body 
mass index, ethnicity, disease activity score (HBI / SCCAI), disease classification (Montreal / Paris), 
past medical and surgical history, current medications and family history of immunological diseases. 
 
3.10 Sample Collection 
Blood samples (up to 20ml) were taken by means of peripheral venesection using two Greiner Z-
serum clot activator tubes. 
Urine samples (20ml) were collected by means of a midstream clean catch urine specimen into a 
sterile universal container.  
All samples were taken in the fasting state (> 6 hours). Patients were allowed to drink water only in 
this timeframe. 
 
3.10.1 Surgery Group 
Samples of blood and urine were taken on the morning of surgery, and repeat samples were taken 
when patients attended for routine follow-up at thesurgical out patient clinic ~ 8 weeks after their 
procedure.  
 
3.10.2 Biological Therapy Group 
Samples of blood and urine were taken immediately prior to the first dose of biological therapy, and 
repeated immediately prior to their second dose 2 weeks later. 
 
3.10.3 Treatment Naïve Group 
Samples were taken immediately prior to commencing medical therapy. Patients then joined the 
longitudinal sampling group and had 3 monthly samples taken for the duration of 1 year. 
 
3.10.4 Longitudinal Sampling Group 




3.10.5 Healthy Control Group 
Samples were taken on the morning of elective non-gastrointestinal surgery. 
 
3.11 Sample Preparation 
Initial sample preparation and storage prior to transfer was carried out in the Department of Diabetes 
& Cardiovascular Science at the University of the Highlands and Islands in Inverness. 
  
3.11.1 Blood Samples 
Samples were allowed to clot at 4°C on ice for >60 mins but <120mins. Centrifugation was then 
carried out at 2500g for 15 minutes at 4°C. The cap of the tube was removed and, without disturbing 
the pellet, 0.5ml aliquots of serum were transferred, using a Pastor pipette into labelled 2ml Greiner 
cryovials. Care was taken to ensure that no red blood cells were carried over with the serum. The 
cryovials were placed in cryoboxes and stored immediat ly at -80°C. 
 
3.11.2 Urine Samples 
Samples were centrifuged at 5000g for 10 minutes at 4°C and then, without disturbing any precipitate, 
0.5ml aliquots were transferred, using a Pastor pipette into labelled 2ml Greiner cryovials. The 
cryovials were placed in cryoboxes and stored immediat ly at -80°C. 
 
3.12 Sample Transfer 
Samples were transferred on dry ice to the Biochemistry Department of Manchester Institute of 
Biotechnology, where metabolomic profiling was performed on these samples under the supervision 
of Dr N Rattray, Dr D Trivedi and Professor R Goodacre. Here samples were analysed using both an 
Ultra High Performance Liquid chromatography-Fourier Transform Mass spectrometry process 
(UHPLC-FTMS) and a Gas chromatography-Time of Flight-Mass spectrometry process (GC-ToF-
MS). 
 
3.13 Established Methodology Utilised 
In this metabolomics study established workflow protoc ls created by the Manchester Centre for 
Integrative Systems Biology, School of Chemisty, Manchester Institute of Biotechnology were used. 
The quality assurance protocols and sample processing teps were followed as previously defined by 
this expert group, thus there was no requirement for preliminary experiments to check the protocols 
(Dunn, Broadhurst et al. 2011). 
 
3.14 Materials 
All materials were purchased from Sigma-Aldrich (Gillingham, U.K.) unless otherwise stated. 
Pyridine (extra dry), hexane, methoxylamine hydrochl ride, and N-methyl-N-trimethylsilyl- 
trifluoroacetamide (MSTFA) were obtained from Acros Organics (Loughborough, U.K.).  The 
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internal standards lysine-d4, succinic acid-d4, andglycine-d5 were purchased from Sigma-Aldrich 
(Gillingham, U.K.). HPLC-MS grade Methanol was purchased from Fisher Scientific, UK. 
 
3.15.1 Serum Sample Pre-treatment 
Serum samples were thawed on ice (4°C) and thereafter 200µl of sample deproteinised by adding 
600µl of methanol and vortex mixed for 15 secs and the centrifuged for 15 minutes at 13,500 g. Two 
aliquots of supernatant were transferred to pre-labl ed eppendorf tubes - one each for GC-ToF-MS 
and UHPLC-FTMS analysis. Prior to drying down, all samples had 10 µL removed and pooled to 
provide a quality control (QC) sample whilst those only allocated for GC-ToF-MS analysis had 
100µL of a 30mg mL-1 internal standard solution containing lysine-d4, succinic acid-d4, and glycine-d5 
added. Samples were then lyophilised (Centrifugal vacuum evaporator (Eppendorf 5301)) for 16hrs 
and sample pellets stored at -80°C until analysis. 
 
3.15.2 Urine Sample Pre-treatment 
Urine samples were thawed on ice at (4°C) and two aliquots of 100 µl were transferred to pre-labelled 
Eppendorf tubes – one each for GC-ToF-MS and UHPLC-FTMS analysis. From GC-ToF-MS aliquot 
high urea content was removed via enzymatic degradation using 150 µL urease (Urease from 
Canavalia ensiformis, Sigma Aldrich, U1501; 20mg mL-1, 37°C for 30mins). Subsequent addition of 
400µL of methanol in both aliquots (vortexed for 15s and centrifuged at 13500 g for 15 minutes) 
resulted in protein precipitation. 
100 µl supernatant was then transferred to pre-labelled Eppendorf tubes – one each for GC-ToF-MS 
and UHPLC-FTMS analysis. Prior to drying down, all samples had 10µL removed and pooled to 
provide a QC sample whilst those only allocated for GC-ToF-MS analysis had 100 µL of a 30mg mL-1 
internal standard solution containing lysine-d4, succinic acid-d4, and glycine-d5 added. Samples were 
then lyophilised (Centrifugal vacuum evaporator (Eppendorf 5301)) for 16hrs and sample pellets 
stored at -80°C until analysis. 
 
3.16.1 Sample Preparation Prior to UHPLC-FTMS Analysis 
Prior to analysis samples were reconstituted in HPLC grade water (free from organic and inorganic 
compounds, with no ultraviolet absorbance) (100µl per sample), vortex mixed and centrifuged for 15 
minutes at 13,500 g. Each sample extract was transferred to a single analytical vial with 200 µL fixed 
insert, caped, stored in the autos ampler at 5 °C. Samples were analysed within 48h of reconstitution 
in positive ionisation mode. The samples were analysed over four separate analytical blocks each 
completely randomised. 
 
3.16.2 UHPLC-FTMS Conditioning, Calibration and Tuning 
All samples were analysed on the Accela UHPLC system (Thermo-Fisher Ltd. Hemel Hempsted, 
U.K.) coupled to an electrospray LTQ-Orbitrap XL hybrid mass spectrometry system (ThermoFisher, 
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Bremen, Germany). UHPLC columns were conditioned with solvent B (HPLC-MS grade methanol 
and 0.1% formic acid) at 50°C, gradually increasing the flow rate to 400 µL.min-1 over 30 mins. 
Thereafter a 50:50 solution solvent A (HPLC water and 0.1% formic acid) and solvent B was used for 
3 hours in order to condition column. The column was maintained at 95:5 Water: MeOH composition 
until analysis begun. 
Prior to sample analysis, the LTQ-Orbitrap MS was tuned to optimise detection of ions in the m/z 50-
1000 range and calibrated according to the manufacturers predefined methods using ultra mark and 
caffeine mixture. Data were acquired in the Orbitrap mass analyser operating at a mass resolution of 
30,000 (FWHM defined at m/z 400) and a scan speed of 0.4 s. Prior to and in-between each analytical 
block the ESI ion tube and spray deflector were cleaned using 8:2 HPLC grade methanol: water 
acidified with 1 % formic acid and ultra-sonication for 15 minutes. 
 
3.16.3 UHPLC-FTMS Parameters 
Analysis was carried out on an Accela UHPLC auto sampler system using a Hypersil Gold C18 reverse 
phase column (L = 100mm, D = 2.1 mm, particle size 1.9 µm) coupled to an electrospray LTQ-
Orbitrap XL hybrid mass spectrometry system (ThermoFisher, Bremen, Germany). Excalibur and 
TunePlus software were used for instrument operation and tuning and calibration was carried out as 
per the manufactures instruction. 10 µL of each sample was injected on to the column and a 
methanol/water solvent gradient below was used for metabolite separation over the column. 
 
Table 3.5: UHPLC-FTMS Solvent Gradient for Reverse Phase Analysis 
Time  
(min) 
Flow Rate  
(µLmin-1) 
Mobile Phase A 
(H2O%) 
Mobile Phase A 
(MeOH%) 
Initial 400 100 0 
5 400 100 0 
15 400 0 100 
25 400 0 100 
30 400 100 0 
 
3.16.4 Orbitrap Parameters 
• 1 micro scan per 400ms, 100-1000 m/zrange 
• ESI ion source transfer tube set at 275°C 
• Tube lens voltage = 100V (-90V in negative mode) 
• Capillary V = - 30V (-28V in negative mode) 
• Sheath Gas = 40, Aux Gas =5, Sweep Gas = 1 




3.16.5 Processing of Raw UHPLC-FTMS Profiles and Analyte Identification 
The UHPLC-FTMS raw data profiles were converted into a NetCDF format within the Xcalibur 
software's file conversion programme. Peak deconvolution was performed using XCMS software 
(http://masspec.scripps.edu/xcms/xcms.php) with in-house script. The XCMS deconvolution produced 
an MS Excel based XY matrix of mass spectral features (with related accurate m/z and retention time 
variable pairs) x sample, with peak area input where the mass spectral feature was detected in each 
sample. 
Peaks that failed quality control (greater than 20% RSD (relative standard deviation) within analytical 
QCs) were removed and not analysed further. The putative identification of features detected on the 
UHPLC-FTMS platform was performed by accurate mass match (m/z tolerance of 0.01) with Human 
Metabolome Database (www.hmdb.ca) 
 
3.17.1 Sample Preparation Prior to GC-ToF-MS Analysi  
Prior to analysis via GC-ToF-MS, a two-stage chemical derivatisation process was carried out to 
impart volatility to non-volatile metabolites. Methods are briefly summarised as follows: 
The process of derivatisation modifies metabolites not volatile enough to be analysed within a GC-
ToF-MS system with methoxy and trimethylsilyl groups (TMS). These groups help analytes to remain 
in the gas phase and enable separation on a GC column. The methoxy group is used to protect 
carbonyl moieties, such as ketones, and to reduce sgar  in order to open cyclic ring structures. The 
relative chemical inertness and lack of presence within nature allows the TMS grouping to act as an 
efficient GC derivatisation agent within the two step process: 
 







The first reaction, oxymation, was performed by heating previously prepared sample pellets in the 
presence of 50 µL of O-methoxyamine (20mg/mL in pyridine) for 40 mins at 65°C. Then the second 
stage trimethylsilyation was performed where samples w re reacted with 50 µL of MSTFA (N-acetyl-
N-(trimethylsilyl)-trifluoroacetamide) for 40mins at 65°C. Derivatised samples then had 20 µL of a 
retention index mixture added (30mg/mL dodecane, pentadecane, nonadecane, docosane at 30mg/mL 
dissolved in hexane and diluted 1:10 in pyridine), were centrifuged for 15 minutes at 13500 g with the 
resultant supernatant added to appropriately labelled GC-MS amber vial with fitted 200 µL insert. To 
minimise degradation of sample at room temperature while sitting in the auto sampler, each sample 
was analysed within a 48h window. 
For each analytical block, initially 10 injections of pooled QC sample were performed for column 
conditioning, after which 5 injections of experimental samples were made, followed by a QC 
injection. This was repeated until all samples within the block were analysed. Finally three QC 
injections were made at the end of the block run. 
 
3.17.2 GC-TOF-MS Analysis  
All samples were analysed on an Agilent 6890 GC (Agilent Technologies, Stockport, UK) coupled to 
a LECO Pegasus III electron impact mass spectrometer (LECO Corp., St. Joseph, MO) with 
appropriate instrument pre-operation checks. 
Initially 10 QC samples were run before any sample inj ction to condition the column. Samples were 
injected through injector into inlet 280°C helium carrier flow at a rate of 1ml min-1. A DB5-MS 
column (Supelco, Gillingham, UK, 30m x 0.25mm x 0.25µm film thickness) was used with the 
transfer line held at 230°C. Samples were analysed within a mass range of 30-600 Da at a detector 
voltage of 1550 V. Temperature programme was as follows: 4 minute hold at 70 °C, then 20 °C/min 
increase to reach 300°C, followed by a 4 min hold. Experimental samples were interspersed with 
regular pooled QC samples to assess drift. 
 
3.17.3 Processing of Raw GC-TOF-MS Profiles and Metabolite Identification 
The raw data profiles were converted into a NetCDF format within LECO ChromaTof v2.32. Peak 
deconvolution was performed using XCMS software (http://masspec.scripps.edu/xcms/xcms.php) 
with in-house script. The XCMS deconvolution produced an MS Excel based XY matrix of mass 
spectral features (with related accurate m/z and retention time variable pairs) x sample, with peak area 
input where the mass spectral feature was detected in ach sample. Peaks that failed quality control 
(greater than 30% RSD within analytical QCs) were removed and not analysed further. Putative 
identification was carried out by matching spectra and retention times with in-house library spectra 





3.18 Data Pre-processing 
Deconvolved data was normalised by total ion count followed by log transformation (glog) and auto 
scaling (mean-centered and divided by the standard eviation of each variable). For various research 
questions of interest, the data was re-organised using one-way analysis of variance (ANOVA), and 
then Mann-Whitney U test as well as Wilcoxon rank sum test were performed. Metabolites with p-
values < 0.05 were considered significant. These p-values were then corrected using Bonferroni 
correction (q value). The resultant variables identified with p-value and q-value < 0.05 were 
considered to be truly significant without any bias. 
When considering large data sets with multiple testing, such as the longitudinal sampling group, 
Bonferroni correction can be too conservative, reducing the number of false positives, but also the 
number of true discoveries, and therefore p values w re corrected using an optimised False Discovery 
Rate (FDR) approach. This approach is designed to control the expected proportion of rejected null 
hypotheses that were incorrect rejections, and was used in correlation analysis where fewer features 
are significantly correlated. When considering comparisons between two conditions where hundreds 
of metabolites are significant, Bonferroni tends to be a stricter criteria leading to fewer significant 
features that stand the correction procedure. Through t the results it is stated when Bonferroni or 
FDR corrections are utilised. 
PCA correlation analysis was performed with diseases cores and patient metabolite profiles. 
Classification of samples into groups was tested using PLS-DA analysis validated by bootstrapping.  
Metabolite lists thus obtained, were then assigned biologically relevant IDs, and box-plots were 
created to visualise the difference.  
When utilising paired samples, differences in the variables deemed significant were visualised by 
calculating the numeric difference between process p ak areas and plotting bar charts. 
 
3.19 Power Calculation 
This is the first study in the UK of its kind in view of the logitundinal sampling taking place. No 
power calculation was required as part of this novel project, as this is a hypothesis generating study 
and thus no sample size can be reliably determined. It has been suggested that 20-30 participants is 
appropriate to control for variance between samples in a feasibility or pilot study (Lancaster, Dodd et 
al. 2004). Johnston et al (Johnston 2014) sampled 30 CD patients, 30 UC patients and 30 healthy 
controls in their study. These numbers allowed the generation of metabolomic data that was able to 
differentiate between the groups studied. Based on these observations and the numbers of patients 
thought to be available for recruitment we designed th  study. 
 
3.20 Declaration of Assigned Work 
Due to the specialised nature of metabolomic profiling, assistance was required for data analysis of 
samples utilising both the UHPLC-FTMS and GC-ToF-MS platforms. Bioinformatic analysis of raw 
data to identifiy differentiation of metabolomic profiles between the study groups, as well as the 
identification of significant differentiating metabolites was carried out by the team at MIB.  
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The study design, patient recruitment, data collection, sample collection and sample preparation were 
performed by me. I carried out the work on interpretation and relevance of identified metabolites, and











4.1 Recruitment Data 
In total, 84 patients with IBD were recruited over an 18 month period; 41 with UC, 43 with CD, and 
62 HC. All were from Raigmore Hospital, Inverness. All of the IBD patients were recruited by me. 
The HC were recruited by me and Natasha Ross, Clinica  Research Fellow. 
Sample sets of blood and urine were taken as previously discussed. During the study it was not 
possible to take blood from 1 IBD patient, and 2 IBD patients and 2 healthy controls failed to pass 
urine during the required timeframe.  
 
4.2 Participant Demographics 
A total of 255 samples sets were taken from IBD patients by me. Of the IBD patients analysed, 164 
sample sets were from females, and 91 sample sets from males. The median age at the time of 
sampling was 44 years (range 19 – 77, IQR 33 - 58). The median age in the UC group was 46 years 
(IQR 33 – 58), and the median age was 42 years (IQR34 – 53.8) in the Crohn’s Disease group. 
 All of the IBD participants were of Caucasian origin, however, of these there was one Australasian 
participant who moved to the UK in 2010, and one Southern European participant who had lived in 
Scotland for >10 years.  
The IBD participants had a mean BMI of 26.17 (range 15.45 – 38.67), with a median of 25.2 (IQR 
23.2 – 28.9). UC participants had a median BMI of 25.6 (IQR 24.4 – 28.4) and CD participants a 
median BMI of 24.3 (IQR 22.0 – 30.2). 
17% of IBD sample sets were taken from current smokers, 41% from ex-smokers, and 42% from 
those who have never smoked. In UC, 11% of samples were taken from current smokers compared to 
23% of CD samples (p<0.05). In UC, 48% of samples wre from ex-smokers and 41% from non-
smokers. In CD, 33% of samples were from ex-smokers, and 43% from non-smokers. 
92% of samples were taken from those eating a normal diet, 4% of samples were taken from 
vegetarians, 2% of samples were taken from participants who do not eat red meat, 1% from 
participants on a low residue diet, 1 sample set from a gluten free patient and 1 sample set from a 
participant receiving total parental nutrition.  
During the study three patients died, one in the surgical group, and one in the biological and 
longitudinal groups. One other patient, from the surgical group, withdrew from the study following a 
diagnosis of cholangiocarcinoma, and died during the study period. One patient withdrew from the 
longitudinal group, one was not contactable following the second set of longitudinal samples, and one 
was withdrawn when she became pregnant. 
A total of 62 sample sets were taken from healthy controls. Of the HCs 48 sample sets were from 
males and 14 from females. The median age at the tim  of sampling was 53 years (range 28 – 83 
years). The mean BMI was 27.3 (range 18.5 – 43.6), median BMI 26.3 (IQR 24.1 – 29.9). All of the 
HCs were British Caucasian apart from one Eastern European Caucasian. 72% were non-smokers, 





4.2.1 Surgery Group 
A total of 30 participants undergoing surgical procedures for the management of IBD were recruited 
by me. Both elective and emergency patients were included. Of the 30 patients recruited, 15 had UC 
and 15 had CD. 10 patients underwent a colectomy, 6 small bowel resections, 4 completion 
proctectomy, 3 perianal procedures, 3 ileocaecal resections +/- stoma formation, 2 
panproctocolectomy and 2 right hemicolectomy. 28 complete serum samples sets and 27 complete 
urine sample sets were available for paired sample analysis. 
 
4.2.2 Biological Group 
 A total of 24 patients receiving biological therapy were recruited to the study. 14 patients had Crohn’s 
disease and 10 patients had UC. 21 complete samples sets were available for paired sample analysis.  
 
4.2.3 Treatment Naïve Group 
Six treatment naïve patients were recruited. One was excluded from the study when he was found to 
have he was identified as having a diverticular mass r ther than a new diagnosis of Crohn’s disease.   
Of the five remaining patients 3 had CD and 2 had UC.
 
4.2.4 Longitudinal Group 
Forty patients were recruited. 22 patients had UC and 18 had CD.  
 
4.2.5 Healthy Controls 
In total, 63 patients were recruited and 62 patient samples were analysed. One patient was excluded as 
they were found to have a daughter with IBD, which was only established after sampling. 


















Table 4.1: Participant Demographics 
 UC (n=41) CD (n=43) HC (n=62) p value 
Sample sets 127 129 62  
Median Age in 
years (range) 
46 (19 – 77) 43 (20 – 73) 53 (40 – 62) 0.001*** 
Sex M:F ratio 2.26:1 1.43:1 3.42:1 <0.0001** 















BMI (median) 25.6 (IQR 24.4 – 
28.4) 
24.3 (IQR 22.0 – 
30.2) 
















Diet 1 no red meat 
3 vegetarian 
 
2 low residue 
1 TPN 
1 gluten free 
1 no red meat 
1 vegetarian 
1 vegetarian 0.64** 
Alcohol excess* 1 2 1 0.64** 
*Alcohol excess defined as > 14 units for a female or > 21 units for a male per week. 
** Fisher’s exact test 
*** Independent t-test 
 
The complete table of metadata from the study participants is presented in appendix 8.2. 
The sample collection details for the IBD patients are presented in appendix 8.3. 
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4.3 Experiment 1: Differentiation HC v UC v CD 
 
4.3.1 Experiment 1 Aims 
To determine whether it is possible to differentiate between the metabolomic profiles of healthy 
controls, ulcerative colitis patients and Crohn’s Di ease patients. 
 
Analyses are carried out on serum and urine samples, and using GC-ToF-MS, and UHPLC-FTMS 
platforms. 
 
Table 4.2 Experiment 1 number of samples analysed 
 Heathly Controls UC CD 
Serum samples 62 127 128 
Urine samples 60 125 127 
 
Confusion matrices and bar charts are used to visualise the results. Identification of metabolites and 
their biological relevance is considered in future experiements. 
 
A confusion matrix is a table used to describe the performance of a classification model on a set of 
test data.  
 
Table 4.3: Example of a confusion matrix 
 Predicted 
No Yes 
Actual No 60 40 
Yes 25 75 
 
There are two possible predicted classes in the tabl : “yes” and “no”. A total of 200 predictions are 
made in this example (e.g. 200 patients being tested for a disease), and of these the classifier predict  
“yes” 115 times, and “no” 85 times. The actual number of “yes” is 100, and “no” is 100, therefore in 
reality 100 patients have the disease and 100 do not. The true positives are the cases predicted “yes” 
that have the disease. The true negatives and thosepredicted “no” that do not have the disease. False 
positives are those predicted “yes” that do not have the disease (type I error), and false negatives ar  
those predicted “no” who do have the disease (type II rror). The percentage of cases correctly 
classified, the correct classification rate (CCR) is recorded. The confusion matrix is visualised using a 
colour map with the rows representing the x-axis representing the predicted label and the y-axis 
representing the actual label. 
 
Bar charts are used to compare the null hypothesis, that there is no discerable difference between HCs, 
CD and UC, and the observed profile. 
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4.3.2 Experiment 1.1 Results 
 
Figure 4.1: Visualisation of Confusion Matrix of GS-ToF-MS Serum Analysis HC v UC v CD 
Table 4.4: Confusion Matrix of GS-ToF-MS Serum Analysis HC v UC v CD 
 Predicted 
1 (HC) 2 (UC) 3 (CD) 
 
Actual 
1 (HC) 20.0% 37.0% 43.0% 
2 (UC) 9.6% 50.9% 39.5% 
3 (CD) 11.4% 39.5% 49.1% 
Averaged CCR% = 43.7% 
 
The averaged correct classification rate is 43.7%, with UC being the correctly identified as UC most 
frequently: in 50.9% of cases. CD is correctly identified as CD in 49.1% of cases. It appears difficult 
to differentiate HCs from IBD as in 37% of actual HC cases UC is predicted, and in 43% of cases CD 
is predicted. However, it is less common for actual cases of UC or CD to be predicted as a healthy 
control (9.6% and 11.4% of cases respectively). Differentiating between UC and CD is challenging in 
this experiment with 39.5% of actual UC cases being predicted as CD, and 39.1% of actual CD cases 
being predicted as UC. 
 
The bar chart shows that the observed distribution of the profile is not significantly different to the 



















Figure 4.2: Bar Chart of GS-ToF-MS Serum Analysis HC v UC v CD Observed and Null 
Distributions 
 
p-value > 0.1 
 
In this dataset, using serum samples analysed by GS-ToF-MS, it is not possible to differentiate 
between HCs, CD and UC.  

















4.3.3 Experiment 1.2: Results 
 
Figure 4.3: Visualisation of Confusion Matrix of UHPLC-FTMS Serum Analysis HC v UC v CD 
Table 4.5: Confusion Matrix of UHPLC-FTMS Serum Analysis HC v UC v CD 
 Predicted 
1 (HC) 2 (UC) 3 (CD) 
 
Actual 
1 (HC) 16.9% 42.0% 41.0% 
2 (UC) 14.2% 43.1% 42.7% 
3 (CD) 14.6% 42.4% 43.0% 
Averaged CCR% = 38.6% 
 
The averaged correct classification rate is 38.6%. Actual cases of HCs are only correctly classified in 
16.9% of cases in this analysis. Whilst actual cases of UC and CD are only predicted as HCs in 14.2% 
and 14.6% of cases respectively, it is not possible to correctly differentiate between UC and CD, with 
true positives in UC in only 43.1% of cases, and in CD in 43% of cases. 
 
The bar chart shows that the observed distribution of the profile is not significantly different to the 


















Figure 4.4: Bar Chart of UHPLC-FTMS Serum Analysis HC v UC v CD Observed and Null 
Distributions
 
p-value > 0.1 
 
In this dataset, using serum samples analysed by UHPLC-FTMS, it is not possible to differentiate 
between HCs, CD and UC.  
 





















4.3.4 Experiment 1.3: Results 
 
Figure 4.5: Visualisation of Confusion Matrix of GC-ToF-MS Urine Analysis HC v UC v CD 
Table 4.6: Confusion Matrix of GC-ToF-MS Urine Analysis HC v UC v CD 
 Predicted 
1 (HC) 2 (UC) 3 (CD) 
 
Actual 
1 (HC) 16.8% 45.3% 37.9% 
2 (UC) 12.3% 56.3% 31.4% 
3 (CD) 11.6% 35.7% 52.6% 
Averaged CCR = 46.9% 
 
The averaged correct classification rate is 46.9%. In this dataset it is possible to correctly predict UC 
in 56.3% of cases and CD in 52.6% of cases. Actual cases of UC and CD are only predicted as HC in 
12.3% and 11.6% of cases respectively, however, actual HCs are predicted to be UC in 45.3% of 
cases, and CD in 37.9% of cases. 
 
The bar chart shows that the observed distribution of the profile is not significantly different to the 
null distribution; however, it shows more differentio  from the null distribution than in Experiment 




















Figure 4.6: Bar Chart of GC-ToF-MS Urine Analysis HC v UC v CD Observed and Null Distributions
 
p-value < 0.1 
 
In this dataset, using urine samples analysed by GC-ToF-MS, it is not possible to differentiate 
between HCs, CD and UC. However, this dataset on this platform shows more differentiation than 
seen in the serum analyses.  
 
 





















4.3.5 Experiment 1.4: Results 
 
Figure 4.7: Visualisation of Confusion Matrix of UHPLC-FTMS Urine Analysis HC v UC v CD 
 
Table 4.7: Confusion Matrix of UHPLC-FTMS Urine Analysis HC v UC v CD 
 Predicted 
1 (HC) 2 (UC) 3 (CD) 
 
Actual 
1 (HC) 39.2% 31.1% 29.7% 
2 (UC) 25.4% 47.0% 27.6% 
3 (CD) 23.0% 29.1% 47.9% 
Averaged CCR = 45.7% 
 
The averaged correct classification rate is 45.7%. It is possible to correctly predict HCs in 39.2% of 
cases, UC in 47% of cases and CD in 47.9% of cases. The differentiation in this dataset appears 
greater between UC and CD, with only 27.6% of UC cases being predicted as CD, and only 29.1% of 
CD cases being predicted as UC. 
 
The bar chart shows that the observed distribution of the profile is not significantly different to the 
null distribution; however, it shows more differentio  from the null distribution than in Experiment 















Figure 4.8: Bar Chart of UHPLC-FTMS Urine Analysis HC v UC v CD Observed and Null 
Distributions 
 
p-value < 0.1 
 
In this dataset, using urine samples analysed by UHPLC-FTMS, it is not possible to differentiate 
between HCs, CD and UC. However, this dataset on this platform shows more differentiation than 






4.3.6 Experiment 1 Summary  
• No significant differentiation was seen between healt y controls, ulcerative colitis patients and 
Crohn’s Disease patients when comparing either serum or urine samples on either UHPLC-FTMS 
(pos) or GC-ToF-MS platforms 
• Urine samples appear to give greater differentiation between the groups than serum samples on 
both UHPLC-FTMS (pos) and GC-ToF-MS platforms 
• Samples of urine analysed by GC-ToF-MS have the greatest correct classification rate (46.9%) 
• Overall ulcerative colitis has the highest true positve predictive rate  





















4.4 Experiment 2: Pre- and Post-Surgery  
 
4.4.1 Experiment 2 Aims 
To determine whether it is possible to differentiate between the metabolomic profiles of IBD patients 
immediately prior to surgery and 8 weeks after surgery. 
 
Analyses are carried out on serum and urine samples, and using GC-ToF-MS, and UHPLC-FTMS 
platforms. 
 
Table 4.8 Experiment 2 number of samples analysed 
 Pre-surgery Post-surgery 
Serum samples 30 28 
Urine samples 30 28 
 
 
Confusion matrices and bar charts are used to visualise the results.  
 
Bar charts are used to compare the null hypothesis, that there is no discerable difference between the 


















4.4.2 Experiment 2.1: Results 
 
Figure 4.9: Visualisation of Confusion Matrix of GC-ToF-MS Serum Analysis Pre- and Post-Surgery 
 
Table 4.9: Confusion Matrix of GC-ToF-MS Serum Analysis Pre- and Post-Surgery 
 Predicted 
Pre Surgery Post Surgery 
Actual Pre Surgery 58.1% 41.9% 
Post Surgery 34.0% 66.0% 
Averaged CCR% = 60.3% 
 
The averaged correct classification rate is 60.3%. In pre-surgery cases the true positive rate is 58.1% 
and in post-surgery cases it is 66.0%. 
 
The bar chart shows that the observed distribution, f pre-surgery versus post-surgery, is not 
















Figure 4.10: Bar Chart of GC-ToF-MS Serum Analysis Pre- and Post-Surgery Observed and Null 
Distributions
 
p-value > 0.1 
 
In this dataset, using serum samples from pre- and post-surgery IBD patients, analysed by GC-ToF-
MS, it is not possible to differentiate between pre-and post-surgery profiles. 





















4.4.3 Experiment 2.2: Results 
 
Figure 4.11: Visualisation of Confusion Matrix of UHPLC-FTMS Serum Analysis Pre- and Post-
Surgery 
 
Table 4.10: Confusion Matrix of UHPLC-FTMS Serum Analysis Pre- and Post-Surgery 
 Predicted 
Pre Surgery Post Surgery 
Actual Pre Surgery 45.9% 54.1% 
Post Surgery 64.4% 35.6% 
Averaged CCR% = 39.7% 
 
The averaged correct classification rate is 39.7%. It is only possible to correctly predict the pre- and 
post-surgery groups in 45.9% and 35.6% of cases respectively. 
 
The bar chart shows that the observed distribution, f pre-surgery versus post-surgery, is not 















Figure 4.12: Bar Chart of UHPLC-FTMS Serum Analysis Pre- and Post-Surgery Observed and Null 
Distributions 
 
p-value > 0.1 
 
In this dataset, using serum samples from pre- and post-surgery IBD patients, analysed by UHPLC-
FTMS, it is not possible to differentiate between pre-and post-surgery profiles.  






















4.4.4 Experiment 2.3: Results 
 
Figure 4.13: Visualisation of Confusion Matrix of GC-ToF-MS Urine Analysis Pre- and Post-Surgery 
 
 
Table 4.11: Confusion Matrix of GC-ToF-MS Urine Analysis Pre- and Post-Surgery 
 Predicted 
Pre Surgery Post Surgery 
Actual Pre Surgery 49.6% 50.4% 
Post Surgery 59.0% 41.0% 
Averaged CCR% = 43.8% 
 
The averaged correct classification rate is 43.8%. It is only possible to correctly predict the pre- and 
post-surgery groups in 49.5% and 41.0% of cases respectively. 
 
The bar chart shows that the observed distribution, f pre-surgery versus post-surgery, is not 






















Figure 4.14: Bar Chart of GC-ToF-MS Urine Analysis Pre- and Post-Surgery Observed and Null 
Distributions 
 
p-value > 0.1 
 
In this dataset, using urine samples from pre- and post-surgery IBD patients, analysed by GC-ToF-
MS, it is not possible to differentiate between pre-and post-surgery profiles.  






















4.4.5 Experiment 2.4: Results 
 
Figure 4.15: Visualisation of Confusion Matrix of UHPLC-FTMS Urine Analysis Pre- and Post-
Surgery 
Table 4.12: Confusion Matrix of UHPLC-FTMS Urine Analysis Pre- and Post-Surgery 
 Predicted 
Pre Surgery Post Surgery 
Actual Pre Surgery 64.9% 35.1% 
Post Surgery 52.4% 47.6% 
Averaged CCR% = 55.2% 
 
The averaged correct classification rate is 55.2%. It is possible to correctly predict the pre-surgery 
group in 64.9% of cases. However, it is only possible to predict the post-surgery group correctly in 
47.6% of cases. 
 
The bar chart shows that the observed distribution, f pre-surgery versus post-surgery, is not 















Figure 4.16: Bar Chart of UHPLC-FTMS Urine Analysis Pre- and Post-Surgery Observed and Null 
Distributions
 
p-value > 0.1 
 
In this dataset, using urine samples from pre- and post-surgery IBD patients, analysed by UHPLC-





4.4.6 Experiment 2 Summary  
• There was no significant differentiation between the metabolomic profiles of pre- and post-
surgery IBD patients when comparing either serum or urine samples on either UHPLC-FTMS 
(pos) or GC-ToF-MS platforms 
• Serum analysis on the GC-ToF-MS platform had the greatest averaged correct classification rate 
(60.9% of cases) 
• The post-surgical group in the serum analysis on the GC-ToF-MS platform has the highest true 
positive predictive rate (66.0%) 
• The lowest rate of positive prediction was seen in serum analysis on the UHPLC-FTMS (pos) 
platform, with an averaged correct classification rate of only 39.7% 
























4.5 Experiment 3: Surgical IBD v HC 
 
4.5.1 Experiment 3 Aims 
In experiment 2 we were unable to differentiate betwe n the metabolomic profiles of pre- and post-
surgery IBD patients. In view of this we aimed to determine whether it is possible to differentiate 
between the metabolomic profiles of IBD patients who required surgical intervention, and healthy 
controls. Samples from the pre- and post-surgical groups were considered as one group in this 
experiment. 
 
Analyses are carried out on serum and urine samples, and using GC-ToF-MS, and UHPLC-FTMS 
platforms. 
 
Table 4.13 Experiment 3 number of samples analysed 
 Surgical IBD Healthy Contols 
Serum samples 58 62 
Urine samples 58 60 
 
Confusion matrices and bar charts are used to visualise the results.  
 
Bar charts are used to compare the null hypothesis, that there is no discerable difference between the 
profile of surgical IBD patients and healthy controls. 
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4.5.2 Experiment 3.1: Results 
 
Figure 4.17: Visualisation of Confusion Matrix of GC-ToF-MS Serum Analysis Surgical IBD v HC 
 
 
Table 4.14: Confusion Matrix of GC-ToF-MS Serum Analysis Surgical IBD v HC 
 Predicted 
Surgical HC 
Actual Surgical 65.6% 34.4% 
HC 28.1% 71.9% 
Averaged CCR% = 68.3% 
 
The averaged correct classification rate is 68.3%. It is possible to correctly predict the surgical IBD 
patients in 65.6% of cases, and in 71.9% of healthy controls. 
 
The bar chart shows that the observed distribution, of surgical IBD patients versus healthy controls, is 





















Figure 4.18: Bar Chart of GC-ToF-MS Serum Analysis Surgical IBD v HC Observed and Null 
Distributions
 
p-value < 0.05 
 
In this dataset, using serum samples from surgical IBD patients and HCs, analysed by GC-ToF-MS, 
differentiation between the profiles is possible. 

















4.5.3 Experiment 3.2: Results 
 
Figure 4.19: Visualisation of Confusion Matrix of UHPLC-FTMS Serum Analysis Surgical IBD v HC 
 
 
Table 4.15: Confusion Matrix of UHPLC-FTMS Serum Analysis Surgical IBD v HC 
 Predicted 
Surgical HC 
Actual Surgical 45.0% 55.0% 
HC 49.5% 50.5% 
Averaged CCR% = 47.2% 
 
The averaged correct classification rate is 47.2%. It is only possible to correctly predict the surgical 
IBD group and the healthy controls in 45.0% and 50.5% of cases. 
 
The bar chart shows that the observed distribution, of surgical IBD versus HCs, is not significantly 



















Figure 4.20: Bar Chart of UHPLC-FTMS Serum Analysis Surgical IBD v HC Observed and Null 
Distributions
 
p-value > 0.1 
 
In this dataset, using serum samples from surgical IBD patients and HCs, analysed by UHPLC-FTMS, 
it is not possible to differentiate between the groups. 

















4.5.4 Experiment 3.3: Results 
 
Figure 4.21: Visualisation of Confusion Matrix of GC-ToF-MS Urine Analysis Surgical IBD v HC 
 
 
Table 4.16: Confusion Matrix of GC-ToF-MS Urine Analysis Surgical IBD v HC 
 Predicted 
Surgical HC 
Actual Surgical 71.9% 28.1% 
HC 18.0% 82.0% 
Averaged CCR% = 77.2% 
 
The averaged correct classification rate is 77.2%. It is possible to correctly predict the surgical IBD 
patients in 71.9% of cases, and in 82.0% of healthy controls. 
 
The bar chart shows that the observed distribution, of surgical IBD patients versus healthy controls, is 




















Figure 4.22: Bar Chart of GC-ToF-MS Urine Analysis Surgical IBD v HC Observed and Null 
Distributions
 
p-value < 0.01 
 
In this dataset, using urine samples from surgical IBD patients and HCs, analysed by GC-ToF-MS, 
differentiation between the profiles is very possible. 






















4.5.5 Experiment 3.4: Results 
 
Figure 4.23: Visualisation of Confusion Matrix of UHPLC-FTMS Urine Analysis Surgical IBD v HC 
 
 
Table 4.17: Confusion Matrix of UHPLC-FTMS Urine Analysis Surgical IBD v HC 
 Predicted 
Surgical HC 
Actual Surgical 80.1% 19.9% 
HC 8.5% 91.5% 
Averaged CCR% = 86.2% 
 
The averaged correct classification rate is 86.2%. It is possible to correctly predict the surgical IBD 
patients in 80.1% of cases, and in 91.5% of healthy controls. 
 
The bar chart shows that the observed distribution, of surgical IBD patients versus healthy controls, is 





















Figure 4.24: Bar Chart of UHPLC-FTMS Urine Analysis Surgical IBD v HC Observed and Null 
Distributions
 
p-value < 0.001 
 
In this dataset, using urine samples from surgical IBD patients and HCs, analysed by GC-ToF-MS, 








4.5.6 Experiment 3 Summary  
• Differentiation between the metabolomic profiles of surgical IBD patients and healthy controls is 
possible using serum and urine samples on both GC-ToF-MS and UHPLC-FTMS 
• Urine samples show a greater level of significance of differentiation between surgical IBD 
patients than serum samples 
• The most significant differentiation between surgical IBD samples and HCs is seen in urine 
samples analysed on the UHPLC-FTMS (pos) platform 

















4.6 Experiment 4: Pre- and Post- Biological Therapy  
 
4.6.1 Experiment 4 Aims 
To determine whether it is possible to differentiate between the metabolomic profiles of IBD patients 
immediately prior to commencing biological therapy for IBD (infliximab or adalimumab), and 2 
weeks post initial treatment. 
 
Analyses are carried out on serum and urine samples, and using GC-ToF-MS, and UHPLC-FTMS 
platforms. 
 
Table 4.18 Experiment 4 number of samples analysed 
 Pre-biological Therapy Post-biological Therapy 
Serum samples 24 24 
Urine samples 24 23 
 
Confusion matrices and bar charts are used to visualise the results.  
 
Bar charts are used to compare the null hypothesis, that there is no discerable difference between the 
profile of pre and post biological therapy patients. 
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4.6.2 Experiment 4.1: Results 
 
Figure 4.25: Visualisation of Confusion Matrix of GC-ToF-MS Serum Analysis Pre- and Post-
Biological Therapy 
 
Table 4.19: Confusion Matrix of GC-ToF-MS Serum Analysis Pre- and Post-Biological Therapy 
 Predicted 
Pre biological Post biological 
Actual Pre biological 51.5% 48.5% 
Post biological 55.2% 44.8% 
Averaged CCR% = 43.7% 
 
The averaged correct classification rate is 43.7%. It is possible to correctly predict the pre biological 
IBD patients in 51.5% of cases, but only in 44.8% of post biological patients. 
 
The bar chart shows that the observed distribution, of pre-biological versus post-biological IBD 
























Figure 4.26: Bar Chart of GC-ToF-MS Serum Analysis Pre- and Post-Biological Therapy 




In this dataset, using serum samples from pre- and post-biological IBD patients, analysed by GC-ToF-
MS, it is not possible to differentiate between pre-and post-biological therapy profiles.  
 






















4.6.3 Experiment 4.2: Results 
 




Table 4.20: Confusion Matrix of UHPLC-FTMS Serum Analysis Pre- and Post-Biological Therapy 
 Predicted 
Pre biological Post biological 
Actual Pre biological 48.9% 51.1% 
Post biological 48.9% 51.1% 
Averaged CCR% = 46.1% 
 
The averaged correct classification rate is 46.1%. It is possible to correctly predict the post biological 
IBD patients in 51.1% of cases, but only in 48.9% of pre biological patients. 
 
The bar chart shows that the observed distribution, of pre-biological versus post-biological IBD 























Figure 4.28: Bar Chart of UHPLC-FTMS Serum Analysis Pre- and Post-Biological Therapy 
Observed and Null Distributions 
 
p-value > 0.1 
 
In this dataset, using serum samples from pre- and post-biological IBD patients, analysed by UHPLC-
FTMS (pos), it is not possible to differentiate betw en pre-and post-biological therapy profiles.  
 






















4.6.4 Experiment 4.3: Results 
 




Table 4.21: Confusion Matrix of GC-ToF-MS Urine Analysis Pre- and Post-Biological Therapy 
 Predicted 
Pre biological Post biological 
Actual Pre biological 41.0% 59.0% 
Post biological 44.0% 56.0% 
Averaged CCR% = 46.1% 
 
The averaged correct classification rate is 46.1%. It is possible to correctly predict the post biological 
IBD patients in 56.0% of cases, but only in 41.0% of pre biological patients. 
 
The bar chart shows that the observed distribution, of pre-biological versus post-biological IBD 





















Figure 4.30: Bar Chart of GC-ToF-MS Urine Analysis Pre- and Post-Biological Therapy 
Observed and Null Distributions 
 
p-value > 0.1 
 
In this dataset, using urine samples from pre- and post-biological IBD patients, analysed by GC-ToF-
MS, it is not possible to differentiate between pre-and post-biological therapy profiles.  























4.6.5 Experiment 4.4: Results 
 
Figure 4.31: Visualisation of Confusion Matrix of UHPLC-FTMS Urine Analysis Pre- and Post-
Biological Therapy 
 
Table 4.22: Confusion Matrix of UHPLC-FTMS Urine Analysis Pre- and Post-Biological Therapy 
 Predicted 
Pre biological Post biological 
Actual Pre biological 43.4% 56.6% 
Post biological 37.4% 62.6% 
Averaged CCR% = 45.2% 
 
The averaged correct classification rate is 45.2%. It is possible to correctly predict the post biological 
IBD patients in 62.6% of cases, but only in 43.4% of pre biological patients. 
 
The bar chart shows that the observed distribution, of pre-biological versus post-biological IBD 























Figure 4.32: Bar Chart of UHPLC-FTMS Urine Analysis Pre- and Post-Biological Therapy Observed 
and Null Distributions 
 
p-value > 0.1 
 
In this dataset, using urine samples from pre- and post-biological IBD patients, analysed by UHPLC-





4.6.6 Experiment 4 Summary  
• There was no significant differentiation between the metabolomic profiles of pre- and post-
biological therapy IBD patients when comparing eithr serum or urine samples on either UHPLC-
FTMS (pos) or GC-ToF-MS platforms 
• UHPLC-FTMS (pos) Serum samples and GC-ToF-MS urine samples showed the highest average 
correct classification rate (46.1%) 
• The lowest rate of positive prediction was seen in serum analysis on the GC-ToF-MS platform, 
with an averaged correct classification rate of only 43.7% 
• Post-biological samples appear to have higher positive predictive rates than pre-biological 
samples 























4.7 Experiment 5: Biological IBD v HC 
 
4.7.1 Experiment 5 Aims 
In experiment 4 we were unable to differentiate betwe n the metabolomic profiles of pre- and post-
biological therapy IBD patients. In view of this, we aimed to determine whether it is possible to 
differentiate between the metabolomic profiles of IBD patients who required biological therapy, and 
healthy controls. Samples from the pre- and post-biolog cal groups were considered as one group in 
this experiment. 
 
Analyses are carried out on serum and urine samples, and using GC-ToF-MS, and UHPLC-FTMS 
platforms. 
 
Table 4.23 Experiment 5 number of samples analysed 
 Biological IBD Healthy Controls 
Serum samples 48 62 
Urine samples 47 60 
 
Confusion matrices and bar charts are used to visualise the results.  
 
Bar charts are used to compare the null hypothesis, that there is no discerable difference between the 
profile of surgical IBD patients and healthy controls. 
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4.7.2 Experiment 5.1: Results 
 
Figure 4.33: Visualisation of Confusion Matrix of GC-ToF-MS Serum Analysis Biological Therapy 
IBD Patients v HC 
 
Table 4.24: Confusion Matrix of GC-ToF-MS Serum Analysis Biological Therapy IBD Patients v HC 
 Predicted 
Biological IBD HC 
Actual Biological IBD 35.8% 64.2% 
HC 21.3% 78.7% 
Averaged CCR% = 64.8% 
 
The averaged correct classification rate is 64.8%. It is possible to correctly predict the biological IBD 
patients in only 35.8% of cases, however, in 78.7% of cases HC are correctly identified as HC. 
 
The bar chart shows that the observed distribution, of biological IBD versus HC, is not significantly 























Figure 4.34: Bar Chart of GC-ToF-MS Serum Analysis Biological Therapy IBD Patients v HC 
Observed and Null Distributions 
 
p-value > 0.1 
 
In this dataset, using serum samples from biological IBD patients and healthy controls analysed by 
GC-ToF-MS, it is not possible to differentiate betwen the profiles of IBD patients requiring 
biological therapy and healthy controls.  
 






















4.7.3 Experiment 5.2: Results 
 
Figure 4.35: Visualisation of Confusion Matrix of UHPLC-FTMS Serum Analysis Biological Therapy 
IBD Patients v HC 
 
Table 4.25: Confusion Matrix of UHPLC-FTMS Serum Analysis Biological Therapy IBD Patients v 
HC 
 Predicted 
Biological IBD HC 
Actual Biological IBD 40.4% 59.6% 
HC 34.4% 65.6% 
Averaged CCR% = 57.1% 
 
The averaged correct classification rate is 57.1%. It is possible to correctly predict the biological IBD 
patients in only 40.4% of cases, however, in 65.5% of cases HC are correctly identified as HC. 
 
The bar chart shows that the observed distribution, of biological IBD versus HC, is not significantly 



















Figure 4.36: Bar Chart of UHPLC-FTMS Serum Analysis B ological Therapy IBD Patients v HC 
Observed and Null Distributions 
 
p-value > 0.1 
 
In this dataset, using serum samples from biological IBD patients and healthy controls analysed by 
UHPLC-FTMS (pos), it is not possible to differentiate between the profiles of IBD patients requiring 
biological therapy and healthy controls.  
 





















4.7.4 Experiment 5.3: Results 
 
Figure 4.37: Visualisation of Confusion Matrix of GC-ToF-MS Urine Analysis Biological Therapy 
IBD Patients v HC 
 
Table 4.26: Confusion Matrix of GC-ToF-MS Urine Analysis Biological Therapy IBD Patients v HC 
 Predicted 
Biological IBD HC 
Actual Biological IBD 31.8% 68.2% 
HC 20.1% 79.9% 
Averaged CCR% = 66.4% 
 
The averaged correct classification rate is 66.4%. It is possible to correctly predict the biological IBD 
patients in only 31.8% of cases, however, in 79.9% of cases HC are correctly identified as HC. 
 
The bar chart shows that the observed distribution, of biological IBD versus HC, is not significantly 























Figure 4.38: Bar Chart of GC-ToF-MS Urine Analysis Biological Therapy IBD Patients v HC 
Observed and Null Distributions 
 
p-value > 0.1 
 
In this dataset, using urine samples from biological IBD patients and healthy controls analysed by 
GC-ToF-MS, it is not possible to differentiate betwen the profiles of IBD patients requiring 
biological therapy and healthy controls.  

















4.7.5 Experiment 5.4: Results 
 
Figure 4.39: Visualisation of Confusion Matrix of UHPLC-FTMS Urine Analysis Biological Therapy 
IBD Patients v HC 
 
Table 4.27: Confusion Matrix of UHPLC-FTMS Urine Analysis Biological Therapy IBD Patients v 
HC 
 Predicted 
Biological IBD HC 
Actual Biological IBD 43.8% 56.2% 
HC 11.5% 88.5% 
Averaged CCR% = 75.8% 
 
The averaged correct classification rate is 75.8%. It is possible to correctly predict the biological IBD 
patients in 43.8% of cases, however, in 88.5% of cases HC are correctly identified as HC. 
 
The bar chart shows that the observed distribution, of biological IBD versus HC, is not significantly 























Figure 4.40: Bar Chart of UHPLC-FTMS Urine Analysis Biological Therapy IBD Patients v HC 
Observed and Null Distributions 
 
0.1 > p-value > 0.05 
 
In this dataset, using urine samples from biological IBD patients and healthy controls analysed by 
GC-ToF-MS, it is not possible to differentiate betwen the profiles of IBD patients requiring 




4.7.6 Experiment 5 Summary  
• It is not possible to differentiate between the metabolomic profiles of biological IBD patients and 
healthy controls using either serum and urine samples on either GC-ToF-MS or UHPLC-FTMS 
platforms 
• Urine samples analysed on the UHPLC-FTMS (pos) platform show the highest averaged correct 
classification rate (75.8%) 
• Urine samples analysed on the UHPLC-FTMS (pos) platform show HC to have the highest 
postive predictability (88.5%)  
• Serum samples analysed on the UHPLC-FTMS (pos) platform have the lowest averaged correct 
classification rate (57.1%)  






















4.8 Metabolite Identification 
 
4.8.1 Important Metabolites 
For each of the groups studied significant metabolites were identified for both urine and serum 
samples, and using both the UHPLC-FTMS and GC-ToF-MS platforms. In each of the experiments, 
the differentiating variables (metabolites) between the groups being interrogated are studied. As 
previously discussed, classification of metabolites s carried out using their mass spectral features, and 
identification using the Human Metabolome Database (www.hmdb.ca) for UHPLC-FTMS samples, 
and with in-house library spectra with the help of retention indices as well as the NIST libraries for 
GC-ToF-MS samples. 
Using KEGG (Kyoto Encyclopedia of Genes and Genomes) (www.kegg.jp), PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), PubChem (https://pubchem.ncbi.nlm.nih.gov/), DrugBank 
(www.drugbank.ca), and LIPID MAPS (Lipid Metabolites and Pathways Strategy) 
(www.lipidmaps.org), metabolites were considered with regards to their biological relevance in IBD.  
 
Box plots are used to visualise the differences seen in statistically significant metabolites after 
Bonferroni correction for group in each experiment.  
 
In paired samples, the differences seen between pre and post intervention samples in an important 
variable are visualised using bar charts. 
  





4.8.2 Experiment 6: Metabolite Identification UC v CD v HC 
 
In this experiment we aim to identify metabolites that differentiate between UC, CD and healthy 
controls. 
For each of the variables identified below a search of the mass spectra relating to the specific mass / 
charge ratio is carried out. The ten metabolites with the smallest Delta (i.e. the ten metabolites which 
are closest to the exact m/z figure), are identified and each one investigated to determine biological 
relevance in the clinical setting described (in this experiment considering the differences between UC, 
CD and HC).   
 
4.8.3 Experiment 6.1: Metabolite Identification UC v CD v HC UHPLC-FTMS 
 
Table 4.28: Experiment 6 number of samples analysed 
 Heathly Controls UC CD 
Serum samples 62 127 128 
Urine samples 60 125 127 
 
Table 4.29: Important Variables Identified UC v CD v HC UHPLC-FTMS 
Variable ID Biofluid m/z Retention 
time 
p value q value 








12 Urine 106.0362854 240.0221 7.96E-05 0.0066068 
148 Urine 149.011087 1321.0958 0.00042576 0.03533808 
562 Urine 243.1580154 502.09675 4.20E-05 0.003486 
727 Urine 296.1481922 181.38205 0.00033741 0.02800503 
743 Urine 302.1587031 143.3935 2.38E-05 0.0019754 
800 Urine 334.0909909 299.601 1.03E-05 0.0008549 
 
Table 4.29.1: Mass spectra search for 337.1867552 m/z 



















































































In this experiment, serum peak intensities of variable ID 422 are higher in CD than in UC or HCs. The 
metabolites pyridoxamine and soyasapogenol B 3-O-b-D-glucuronide have been identified as 


























Pyridoxamine is the 4-aminomethyl form of vitamin B6. The biologically active form of vitamin B6 is 
pyridoxal-5-phosphate (PLP). Whilst a relationship between vitamin B6 and inflammation has been 
postulated, it is yet to be defined. Plasma PLP concentrations have been shown to be reduced in 
rheumatoid arthritis patients, inversely related to the severity of disease (Roubenoff, Roubenoff et al. 
1995). Saibeni et al (Saibeni, Cattaneo et al. 2003) report that plasma PLP concentrations are 
significantly lower in IBD patients than in healthy controls, and that the prevalence of low PLP 
(<20nmol/L) was significantly higher amongst patiens with active disease compared to quiescent 
disease (26.9% v 2.9% ; p≤0.001). Selhub et al (Selhub, Byun et al. 2013) have shown that, in a rodent 
model, both low and high plasma PLP concentrations significantly reduce histological and molecular 
features of colonic inflammation. The findings of deficiency are in keeping with previous work 
(Benight, Stoll et al. 2011), however, this study raises the possibility of vitamin B6 modulation as a 
therapy in IBD.   
 
Soyasapogenol B 3-O-b-D-glucuronide 
Soyasapogenols, aglycones of soyasaponins, do not occur in soyabean naturally but can be formed by 
acid or alkaline hydrolysis of soyasaponins and therefore may exist in processed soy products. 
Soyasaponins and soyasapogenols have been reported t  possess anti-inflammatory, anticarcinogen, 
antiviral and antioxidant activities, as well as hepatoprotective and cardiovascular protective effects. 
Soyasaponins may inhibit NF-κB activation thus exerting anti-inflammatory effects, however, 
soyasapogenols exhibit no inhibitory effect on the production of NO, iNOS, and TNF-α, or on the 
iNOS enzyme activity in LPS-stimulated macrophages, indicating that sugar chains in the structures 
of soyasaponins are critical to their anti-inflammatory activities (Guang, Chen et al. 2014). 
In 2,4,6-trinitrobenzenesulfonic acid (TNBS)- induced colitic mice, orally administered soyasaponins 
Ab and I potently ameliorated body weight reduction, colon shortening, macroscopic score, and 
myeloperoxidase activity, the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide 
synthase (iNOS), and activation of the transcription factor nuclear factor-κB (NF-κB) (Lee, Park et al. 
2011, Lee, Park et al. 2010). Soyasaponin I suppresses the expression of PGE2 and IL-6, and also 
suppresses the activation of NF-κB, reducing the levels of the lipid peroxides malondialdehyde 
(MDA) and 4-hydroxy-2-nonenal and increasing the glutathione content as well as the superoxide 
dismutase (SOD) and catalase activities (Lee, Park et al. 2010). This suggests that soyasaponin I may 
ameliorate colitis by inhibiting NF-κB activation and consequently diminishing its ability to scavenge 
the lipid peroxides produced by TNBS. Soyasaponin Ab also inhibits the expression of TLR4 and the 
phosphorylation of IRAK1, the inhibitor of NF-κB kinase (IKK)-β, and the NF-κB subunit p65 in the 
colon of TNBS- induced colitic mice (Lee, Park et al. 2011). 
Soyasaponin I has also been shown to have moderate activities against Escherichia coli and Candida 
albicans, and soysapogenol A has shown moderate anti-HSV-1 activity (Guang, Chen et al. 2014).  
 
The findings in this experiment, showing raised pyridoxamine or soyasapogenol B 3-O-b-D-
glucuronide levels in CD patients, in comparison to UC and healthy controls, may be due to dietary 
 
 190 
factors. However, raised soyasapogenol B 3-O-b-D-glucuronide levels in the serum of CD patients 
may be diagnostic of anti-inflammatory processes occurring in this patient group. 
 
Table 4.29.2: Mass spectra search for 106.0362854 m/z 











































M+Na 106.037565 83.048347 0.0012796 Azoles 
HMDB298
62 

































In this experiment, urinary peak intensities of variable ID 12 are higher in HCs than in UC or CD. The 
following metabolites are deemed biologically relevant; N-Acetylglutamine, Ethyl 1-
(propylthio)propyl disulfide, Butyl 1-(methylthio)propyl disulfide, 4-Thiocyanatophenol and 5-
Aminoimidazole. 
 
N-Acetylglutamine, Ethyl 1-(propylthio)propyl disul fide, Butyl 1-(methylthio)propyl disulfide 
and 4-Thiocyanatophenol 
A recent study investigating the effects of the Mediterranean diet, a diet considered beneficial for 
health, on the urinary metabolome, has shown increased levels of N-Acetylglutamine when compared 
to a low fat control diet (Vazquez-Fresno, Llorach et al. 2015). In our study, interestingtly, we see 
lower levels of N-Acetylglutamine in both disease states when compared to HCs. This is also true for 
Ethyl 1-(propylthio)propyl disulfide, Butyl 1-(methylthio)propyl disulfide and 4-Thiocyanatophenol, 
all of which are metabolites from fruits and vegetables. It has been proposed that the typical 
“Western” diet, low in fruit and vegetables, and high n fat and protein may be associated with IBD. A 
large systematic review encompassing nineteen studies and 2609 patients revealed that a high intake 
of fruits is associated with a decreased risk of CD, and a high vegetable intake with a decreased risk of 




























restrictions upon themselves and up to 45% avoid specifics foods including fruit and vegetables 
(Limdi, Aggarwal et al. 2015). 
 
5-Aminoimidazole  
5-Aminoimidazole belongs to the class of organic compounds known as aminoimidazoles. 5-
aminoimidazole-4-carboxamide ribonucleoside induces AMP-activated protein kinase activation and 
has been shown to have a therapeutic effect in ameliorating acute and chronic DSS-induced murine 
colitis as shown by reduced body weight, loss and significant attenuation in clinical symptoms, and 
histological inflammation. Also, 5-aminoimidazole-4-carboxamide ribonucleoside treatment inhibits 
NF-kB activation in macrophages, reduces levels of Th1- and Th17-type cytokines in colon tissues, 
and down-regulates Th1 and Th17 cell responses during the progress of acute and chronic 
experimental murine colitis (Bai, Yong et al. 2010). Higher levels in the urine of healthy controls than 
IBD patients may represent IBD patients not excreting in an attempt to utilise, or higher overall levels 
in healthy controls. 
 
Table 4.29.3: Mass spectra search for 149.011087 m/z 








































































Isogentisin M+H+K 149.011629 258.052823 0.000542 Benzopyran
s 
 
Figure 4.43: Boxplot Urinary variable ID 148 UC v CD v HC UHPLC-FTMS 
p=0.00042576 
 
In this experiment, urinary peak intensities of variable ID 148 are higher in UC than in HCs or CD. 
Imidazole-4-acetaldehyde and alternariol are deemed biologically relevant. 
 
Imidazole-4-acetaldehyde  
Imidazole-4-acetaldehyde is a naturally occurring aldehyde metabolite of histamine formed by the 
action of histaminase, and can be synthesised by oxidation of histidine. There are four histamine 
receptors known, which all belong to the class of G-protein coupled receptors: histamine H1 receptor 
(H1R), H2R, H3R and H4R. The H4R is expressed mainly on immune cells such as mast cells, 
dendritic cells, T-cells and eosinophils, and receptor stimulation leads to a Gi-mediated activation of 
these cells via phospholipase C activation and subsequent intracellular calcium mobilisation and 
inhibition of membrane-bound adenylyl cyclase (Schirmer, Rezniczek et al. 2015). Histamine is 
known to act as a proinflammatory mediator in IBD, with colonic tissues of IBD patients showing 

























Matek et al. 1995). H4R blockade is beneficial in TNBS-induced colitis in rats (Varga, Horvath et al. 
2005), and in DSS-induced colitis in mice (Schirmer, Rezniczek et al. 2015). 
This may explain the raised levels of Imidazole-4-acet ldehyde in UC patients in comparison to CD 
patients and HCs, in whom colonic disease is not as prevalent.  
 
Alternariol  
Alternariol, a mycotoxin produced by Alternaria fungi, has been shown to change the cell morphology 
of human macrophages, and to increase the secretion of TNFα and IL-6, as well as reducing 
macrophage endocytic activity and autophagosomes throug  the induction of DNA damage (Solhaug, 
Wisbech et al. 2015).  This metabolite may be relevant in the inflammatory and autophagy cycles in 
IBD patients. 
 
Table 4.29.4: Mass spectra search for 243.1580154 m/z 


























































































These compounds represent metabolites found in tea, fruits, herbs and spices, milk and milk products, 
flavouring agents in orange drinks, and mushrooms. This wide range of dietary products is likely to be 
the cause of the wide ranges of intensities of metabolites seen throughout these groups. 
 
Table 4.29.5: Mass spectra search for 296.1481922m/z 

































































































M+H+Na 296.142428 568.288362 0.0057642 Prenol 
lipids 
 




These compounds represent metabolites found in milkprotein, bile acid, tea, fruits, and in the 
























Table 4.29.6: Mass spectra search for 302.1587031 m/z 
















































































In this experiment, urinary peak intensities of variable ID 743 are increased in HCs compared to UC 
and CD. Interestingly, the majority of metabolites here are found in drugs, yet in the HC group the 
peak intensity of this group of compounds is increased in relation to IBD groups. However, Hordatine 
B, found in barley, may be more prevalent in the HCgroup in keeping with the theory that in IBD 
there is reduced dietary variance and increased fat and sugar intake compared to natural fibre intake.  
 
Hydroxy-alpha-sanshool 
Hydroxy-alpha-sanshool, naturally found in Japanese pepper, and one of the main active compounds 
in TU-100, a pharmaceutical grade traditional Japanese medicine, has been shown to accelerate 
colonic emptying (Manabe, Camilleri et al. 2010), esp cially in post-operative ileus (Tokita, 
Yuzurihara et al. 2007) and adhesive intestinal obstruction (Tokita, Yamamoto et al. 2011). At present 
there are trials underway in the United States of America and Japan on the use of TU-100 in patients 
with post-operative ileus, functional constipation, irritable bowel disease, and Crohn’s Disease 




























Table 4.29.7: Mass spectra search for 334.0909909 m/z 




























































M+2K+H 334.097004 257.177964 0.0060131 Morphinans 
HMDB390
87 
Sudachiin B M+2H 334.097076 666.1796 0.0060851 Flavonoids 
HMDB390
88 









In this experiment, urinary peak intensities of variable ID 800 are increased in HCs compared to UC 
and CD. Taxiphyllin, dhurrin and N-(1-Deoxy-1-fructosyl)methionine are carbohydrate derivatives 
from plants. Sudachiin B and C are found in citrus fruits. These are seen to be more abundant in 

























4.8.4 Experiment 6.2: Metabolite Identification UC v CD v HC GC-ToF-MS 
 
In this experiment using the GC-ToF-MS platform, in-house library spectra with the help of retention 
indices, as well as the NIST libraries are used to identify putative matches of metabolites. As in 
Experiment 6.1, each identified metabolite is investigated to determine biological relevance in the 
clinical setting described (in this experiment considering the differences between UC, CD and HC).  
Where variable IDs repetitively match to the same mtabolite, only one blox plot is shown to 
represent the diffences seen between groups. 
 









p value q value 




8 Serum 47 573.478 Unknown 2.38E-05 0.0075684 
14 Serum 49 577.428 Unknown 1.14E-05 0.0036252 
27 Serum 52 571.628 Threonine 
or urea 
1.55E-05 0.004929 
30 Serum 53 575.774 Unknown 1.27E-05 0.0040386 
45 Serum 56 574.878 Unknown 3.99E-06 0.00126882 
60 Serum 60 570.318 Urea 1.14E-05 0.0036252 
64 Serum 61 575.528 Unknown 4.76E-05 0.0151368 
69 Serum 63 576.428 Unknown 6.82E-06 0.00216876 
74 Serum 64 570.778 Urea 3.18E-06 0.00101124 
76 Serum 65 571.903 Threonine 
or urea 
9.70E-07 0.00030846 
81 Serum 66 571.278 Threonine 
or urea 
2.69E-06 0.00085542 
86 Serum 67 572.201 Unknown 1.99E-06 0.00063282 
93 Serum 69 571.028 Threonine 
or urea 
2.25E-06 0.0007155 




106 Serum 71 571.978 Threonine 
or urea 
3.35E-06 0.0010653 
107 Serum 72 572.378 Unknown 4.00E-06 0.001272 
121 Serum 75 574.929 Unknown 5.13E-05 0.0163134 
133 Serum 78 572.928 Unknown 3.90E-06 0.0012402 
137 Serum 79 570.426 Urea 5.90E-05 0.018762 
142 Serum 80 570.674 Urea 8.32E-06 0.00264576 
157 Serum 84 575.428 Unknown 6.72E-05 0.0213696 
218 Serum 99 570.728 Urea 1.30E-06 0.0004134 













279 Serum 115 572.628 Unknown 1.70E-05 0.005406 
334 Serum 127 571.479 Threonine 
or urea 
1.45E-05 0.004611 
355 Serum 132 576.428 Unknown 1.03E-05 0.0032754 
390 Serum 141 570.928 Urea 4.04E-06 0.00128472 
424 Serum 150 579.278 Unknown 4.11E-05 0.0130698 
428 Serum 151 580.351 Unknown 0.00014196 0.04514328 
446 Serum 155 570.524 Urea 1.94E-06 0.00061692 
455 Serum 157 570.478 Urea 3.97E-06 0.00126246 
507 Serum 171 570.474 Urea 2.96E-06 0.00094128 
509 Serum 172 570.678 Urea 3.81E-06 0.00121158 
513 Serum 173 570.328 Urea 2.47E-06 0.00078546 
563 Serum 186 570.728 Urea 1.24E-05 0.0039432 
569 Serum 187 571.628 Threonine 
or urea 
2.63E-05 0.0083634 
574 Serum 189 570.078 Urea 2.33E-06 0.00074094 
576 Serum 190 569.928 Urea 2.60E-06 0.0008268 
582 Serum 191 569.826 Urea 1.94E-05 0.0061692 
614 Serum 198 954.428 Unknown 0.00012029 0.03825222 
844 Serum 265 845.578 Fructose 3.60E-05 0.011448 
921 Serum 292 657.578 Aminomalo
nic acid 
3.94E-05 0.0125292 
960 Serum 305 825.874 Eicosane 1.38E-06 0.00043884 
990 Serum 318 829.026 Glucuronic 
acid 
1.51E-06 0.00048018 
1056 Serum 347 795.178 Pentanoic 
acid 
0.00010806 0.03436308 















In this experiment, urinary peak intensities of variable ID 347 (Propanetricarboxylic acid) are 
increased in CD compared to HCs and UC. 
 
Propanetricarboxylic acid  
Propanetricarboxylic acid, belonging to the class Carboxylic Acids and Derivatives, is an inhibitor of 
the enzyme aconitase, which catalyses the conversion of cirtic acid into isocitric acid in the citric acid 
or tricarboxylic acid (TCA) cycle (Kreb’s cycle). It has been shown that in UC patients reduced levels 
of amino acids are seen in both sera and colonic tissue, resulting in reduced TCA cycle-related 
































In this experiment, all of the serum variables identified as threonine or urea show increased peak 
intensities in HCs compared to IBD patients.  
 
Threonine 
Threonine is an essential amino acid, belonging to the class Fatty Acyls, is abundant in human plasma, 
especially in the newborn. It is an immunostimulant, promoting thymus gland growth and promoting 
cell immune defence function. Threonine is required for the production and maintenance of mucin in 
the gut, and the rate of mucin synthesis has been shown to be dircectly related to the availability of 
dietary threonine in both rats (Faure, Moennoz et al. 2005) and piglets (Law, Bertolo et al. 2007). In a 
rat model of sepsis, threonine utilisation for the synthesis of intesitinal mucins was 70% greater than 
in healthy controls (Faure, Chone et al. 2007). In ileitis and colitis models, intestinal mucin production 
is not stimulated in pair-fed animals and only dietary supply of threonine, serine, proline and cysteine 
was effective in promoting colonic mucin synthesis, with threonine being shown to be the rate 
limiting amino-acid for mucin synthesis in the intestinal mucosa (Faure, Mettraux et al. 2006, 
Remond, Buffiere et al. 2009). Our IBD groups show reduced threonine levels compared to HCs. 
Currently there is a study recruiting with the aim of identifying threonine requirement in those with 
































Urea is a highly soluble organic compound formed in the liver from ammonia produced by the 
deamination of amino acids. It is excreted in urine by the kidney. During the study all participants 
were fasted for a minimum of six hours. However, they were allowed to drink water during this 
period. The individual states of hydration were notmeasured or standardised and therefore we do not 


































In this experiment all of the serum variables identified as Dihydroxybutanoic acid or Serine have peak 
intensities greater in HCs than in IBD patients. 
 
Dihydroxybutanoic acid 
Dihydroxybutanoic acid, belonging to the class Fatty Acyls, an organic acid that is a major component 
of cerebrospinal fluid (CSF), has been investigated as a potential biomarker in Alzheimer’s Disease 
(Oresic, Hyotylainen et al. 2011, Mousavi, Jonsson et al. 2014). This metabolite has been shown to be 
overproduced under low oxygen conditions from D-galacturonic acid, a uronic acid, which is a 
stereoisomer of glucoronic acid.  D-galacturonic acid, a sugar acid, is the main component of pectin. 
Dietary pectin has been shown to down regulate colonic inflammatory responses by moderating the 
production of proinflammatory cytokines and immunoglobulins (Ye, Lim 2010). 
 
Serine 
Serine, belonging to the class Carboxylic Acids and Derivatives, has also been investigated as a 
biomarker in Alzheimer’s Disease (Madeira, Lourenco et al. 2015). Recently theories regarding the 

























considered. Irritable bowel syndrome (IBS) and the associated alteration of the gut microbiome 
enhance gut inflammation, intestinal barrier dysfunction, and systemic to neuroinflammation may 
provide key insights. Hence, gut dysbiosis is now beginning to be considered as a potential therapeutic 
target for prevention of IBS related conditions including congnitive decline (Daulatzai 2014).  
Whilst links with IBD and dementia have not yet been stablished, there are reports of rapidly 
progressive dementia as a presenting feature in IBD (Papathanasiou, Nikakis et al. 2014).  
 




In this experiment the serum variables identified as fructose have higher peak intensities in HCs than
in IBD patients. 
 
Fructose 
Fructose, a simple monosaccharide in the class Carbohydrates and Carbohydrate Conjugates, is found 
in fruits and berries, root vegetables and honey. A high level of fructose is negatively associated with 
IBD (Reif, Klein et al. 1997, Mahmud, Weir 2001). In our study HC have higher serum fructose levels 
than IBD patients, as would be expected.  
Prebiotic oliogsaccharides are not sensitive to gastric acid, and remain intact when they reach the 























and Lactobacilli (Bouhnik, Raskine et al. 2004) and have a positive effect in maintaining intestinal 
homeostasis (Cherbut 2002, Nyman 2002). Fermentatio of these carbohydrates produces SCFAs, 
mainly acetate, propionate, and butyrate (Sanderson 2007). Fructose-based oligo- and polysaccharides 
have been reported as promising candidates in IBD management (Lara-Villoslada, de Haro et al. 
2006).  
 




In this experiment, similar serum levels of the variable identified as aminomalonic acid are seen in 
HCs and UC, with lower peak intensities in CD. 
 
Aminomalonic acid 
Aminomalonic acid, a dicarboxylic acid in the class Carboxylic Acids and Derivatives, has been 
isolated from proteins of Escherichia coli and human atherosclerotic plaque (Van Buskirk, Kirsch et 
al. 1984). Its potential origins are errors of protein synthesis and oxidative damage to amino acid 
residues in proteins. Aminomalonic acid metabolism i  not fully understood. 
Aminomalonic acid has been proposed as a potential biomarker in hepatocellular carcinoma as the 
conversion of cysteine into acidic aminomalonate could induce conformational changes that are 






















post-transcriptionsal expression of mRNA-encoding proteins involved in iron homeostasis and 
utilisation, and potentially in tumour cell metabolism and proliferation in HCC (Xue, Lin et al. 2008). 
In renal transplant patients with acute allograft rejection, aminomalonic acids levels have been found 
to be low. When taken in conjuncation with other metabolites this can be ulitised in the diagnosis of 
acute rejection and also stable function with reason ble accuracy (Mao, Bai et al. 2008). 
In the serum of patients with large abdominal aortic aneurysms, aminomalonic acid has been shown to 
be 800% higher than in control patients (Ruperez, Ramos-Mozo et al. 2012). This may be related to 
atherosclerosis, however, interestingly a study in patients with acute coronary syndrome has shown 
low levels of aminomalonic acid (Teul, Garcia et al. 2011).  
Recently, reduced levels of aminomalonic acid have be n reported in canine IBD (Minamoto, Otoni et 
al. 2015). In our study, aminomalonic acid is reduced in the serum of CD patients, but increased in the 
serum of UC patients when compared to HCs. Clearly this metabolite requires further investigation 
with regards to not only its mechanism of action and metabolic pathways, but also its utilisation as a 
potential biomarker in many fields.  
 




In this experiment higher peak intensities of the serum variable identified as eicosane are seen in HCs





























Eicosane is an acyclic hydrocarbon in the Alkane class. There is no known relationship to IBD.  
 




In this experiment the serum variable identified as glucuronic acid has higher peak intensities in HCs 
than in UC or CD. 
 
Glucuronic acid 
Glucuronic acid, or glucuronate, belongs to the Carbohydrate and Carbohydrate Conjugate class. It is 
synthesised in the uronic acid pathway, an alternative pathway for the oxidation of glucose that does 
not provide ATP. Instead, the activated form of glucuronate, uridine diphosphate-glucuronate is 
formed, and is mainly used for detoxification of foreign chemicals and in the synthesis of 
mucopolysaccharides. Glucuronate is hydrolysed to form glucaronic acid. In certain species this can 
be synthesised into ascorbic acid (vitamin C). However, in humans, the required enzyme L-
gluconolate oxidase is absent and vitamin C must come from the diet. The excess glucaronic acid is 
utilised by the pentose phosphate pathway. Interestingly, the pentose phosphate pathway is known to 






















reason for the low levels of glucaronic acid seen in serum of both UC and especially CD in relation to 
HCs in our study. 
 




In this experiment lower peak intensities of the serum variable identified as pentanoic acid are seen in 
CD than in UC and HCs. 
 
Pentanoic acid  
Pentanoic acid, also known as valeric acid, is a naturally occurring micronutrient in the Fatty Acyls 
class, which is synthesised in small amounts by plants and animals, including humans. It has 
antioxidant and chemoprotective properties, acting as a free radical scavenger, assisting in repairing 
oxidative damage and regenerating endogenous antioxidants including vitamin C, E and glutathione. 
Glutathione,a key biomarker of oxidative stress, reduces intracellular reactive oxygen species and 
plays an important role in the detoxification of xenobiotics. This has previously been shown to be 
reduced in IBD (Iantomasi, Marraccini et al. 1994, Karp, Koch 2006). Recently pentanoate levels 
































In this experiment lower peak intensities of the serum variable identified as either galactose or 
cellobiose are seen in CD than in UC and HCs. 
 
Galactose 
Galactose, belonging to the Carbohydrate and Carbohydrate Conjugates class, is an aldohexose that 
occurs naturally in the D-form in lactose, cerebroside , gangliosides, and mucoproteins. D-Galactose 
is an energy-providing nutrient and also a necessary b sic substrate for the biosynthesis of many 
macromolecules in the body. 
IgG, the most abundant class of antibody in human pl sma, provides the majority of antibody-based 
immunity against pathogens. IgG can demonstrate both pro and anti-inflammatory activity depending 
on the glycosylation status (Theodoratou, Campbell et al. 2014). The anti-inflammatory activity of 
IgG is mediated by Fc galactosylation, and decreased IgG galatosylation has been observed in the sera 
of IBD patients (Dube, Rook et al. 1990, Shinzaki, Iijima et al. 2008).  The extent of IgG 
galactosylation, measured by HPLC, has been considered as a potential biomarker in IBD (Shinzaki, 





























Cellobiose, belonging to the Carbohydrate and Carbohydrate Conjugates class, is produced from 
cellulose using bacterial enzymes, and is hydrolysed into two glucose molecules by cellobiosidase and 
cellulase. In mice with DSS induced colitis, cellobiose appears to have a protective effect (Nishimura, 
Andoh et al. 2010). It has been suggested that cellobiose fermented by the intestinal microflora acts as 
a prebiotic (van Zanten, Sparding et al. 2015), but also that it inhibits proinflammatory cytokine 
expression via the anti-inflammatory actions of SCFAs, especially butyrate (Nishimura, Andoh et al. 
2010). 
 
Low levels of these metabolites seen in our study in CD are in keeping with previous studies. These 
metabolites may aid in the development of biomarkers and therapies in the future.  
 




In this experiment the serum variable identified as myo-inositol has higher peak intensities in HCs 
























Myo-inositol, belonging to the class Alcohols and Polyols, is a product of glycerophospholipid 
metabolism and is a substrate of D-glucaronate. Lower levels of myo-insitol seen in IBD patients may 


































4.8.5 Experiment 6 Summary 
Metabolites in the classes Fatty Acyls, Carboxylic A ids and Derivatives, Carbohydrate and 
Carbohydrate Conjugates, appear reduced in IBD compared to HCs. 
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4.9 Experiment 7: Metabolite Identification Pre Biological v Post Biological (Grouped) 
 
In this experiment, the IBD patients pre biological treatment are compared to those post biological 
treatment. The samples are grouped as pre and post biological therapy. Future experiments will study 
paired samples. 
 
Table 4.31 Experiment 7and 8 number of samples analysed 
 Pre Biological Post Biological 
Serum samples 24 24 
Urine samples 24 23 
 
4.9.1 Experiment 7.1: Metabolite Identification Pre Biological v Post Biological (Grouped) 
UHPLC-FTMS 
 
Table 4.32: Important Variables Identified Pre Biological Therapy v Post Biological Therapy 
(Grouped) UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
Time 
p value q value 
208 Urine 160.0959935 222.1519 0.0034846 0.0313614 
 
Table 4.32.1: Mass spectra search for 160.0959935 m/z 








































































M+H 160.096819 159.089543 0.0008255 Not 
classified 
 





In this experiment the urine variable ID 208 has higher peak intensities in pre biological therapy 
patients than in post biological therapy patients. Calystegine A3, 3-Dehydrocarnitine and N-
acetylvaline are considered biologically relevant.  
 
Calystegine A3 
Calystegines, organic tropane alkaloids, which occur in plant families, are classified into three groups; 
A, B, and C, on the basis of the number of hydroxyl group substitutes on the nortropane ring. 
Calystegine A3, B1, B2 and C1 inhibit rat liver lysosomal β-glucosidase (Asano, Kato et al. 1997). β-
glucosidase is involved in cellulose hydrolysis, eventually converting cellobiose to glucose. As 
discussed previously, cellobiose is potentially protective against DSS-induced colitis and has anti-
inflammatory properties. In our study we see potentially lower levels of calystengine A3 post 
biological treatment. This may represent less inhibition of β-glucosidase, and thus more conversion of 
cellobiose to glucose in the post biological group. Also, anti-TNFα therapy is known to decrease 















unlikely that the differences seen in pre- and post-biological therapy groups purely represent the 
effects of calystegine A3. 
 
3-Dehydrocarnitine 
3-Dehydrocarnitine, a member of the carnitine family, is an intermediate in carnitine degradation. It 
can be formed from either D-carnitine (biologically inactive) or L-carnitine (biologically active). 
Carnitine is a quaternary ammonium compound biosynthesised from lysine and methionine. In living 
cells, carnitine is required for the transport of fatty acids from the cytosol into the mitochondria during 
the breakdown of lipids. L-carnitine has anti-oxidant activity through the reduction of 
myeloperoxidase (MPO) and malondialdehyde (MDA), the inhibition of the accumulation of lipid 
peroxides, the up-regulation of superoxide dismutase and the prevention of glutathione reduction. This 
suppresses the formation and activation of reactive oxygen species, resulting in NF-κB pathway 
inhibition (Moeinian, Farnaz Ghasemi-Niri et al. 2013).  
However, L-carnitine, which is adundant in red meat, is processed by the enteric microbiota into 
trimethylamine, the human metabolite of which is trmethylamine-N-oxide. Trimethylamine-N-oxide 
is a pro-atherosclerotic metabolite and plasma levels of L-carnitine have infact been associated with 
cardiovascular disease (Koeth, Wang et al. 2013). Broad-spectrum antibiotics have been shown to 
reduce the metabolic conversions of L-carnitine to trimethylamine-N-oxide (Koeth, Wang et al. 2013), 
indicating that the gut microbiome is significant i non-GI disease processes such as carnitine-
associated atherosclerosis.  
In IL-10 gene deficient mice, urinary trimethylamine has been shown to parallel the progression of 
IBD (Murdoch, Fu et al. 2008) and thus may have potential as a biomarker in the future.  
In our study we saw lower levels of urinary 3-Dehydrocarnitine after biological treatment. This may 
represent less carnitine degradation and excretion, as less is present due to the NF-κB pathway being 
successfully inhibited by TNF-α blockade instead of the body utilising carnitine i this way.  
 
N-acetylvaline  
N-acetylvaline is a derivative of valine. Whilst nodirect links are seen with this amino acid carrying a 
N-acylated aliphatic chain, γ-glutamyl carrying valine and cysteine have been investigated with 
regards to GI homeostasis. The extra-cellular calcium sensing receptor (CaSR) is distributed 
throughout the GI tract, and its activation has been shown to promote intestinal homeostasis. The γ-
glutamyl dipeptides, γ-glutamyl cysteine, and γ-glutamyl valine, are dietary flavour enhancing 
compounds that can activate CaSR via allosteric ligand binding to exert anti-inflammatory effects in 
the GI tract by blocking the activation of the TNF-α-dependent pro-inflammatory signalling cascade 
(Zhang, Kovacs-Nolan et al. 2015). In our study we saw lower levels of urinary N-acetylvaline after 
biological treatment. This may represent less excretion of valine derivatives, which promote anti-
inflammatory effects in the gastrointestinal tract. 
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4.9.2 Experiment 7.2: Metabolite Identification Pre Biological v Post Biological (Grouped) GC-
ToF-MS 
 
As in Experiment 7.1, the samples are grouped as pre and post biological therapy. Future experiments 
will study paired samples. 
 










p value q value 
339 Urine 265 882.328 Acetamide 0.023985 0.023985 
 
Figure 4.60: Boxplot Urinary Variable ID 339 Acetamide Pre Biological Therapy v Post Biological 




In this experiment lower peak intensities of the urinary variable identified as acetamide were 
identified in post biological therapy patients than in pre biological therapy patients.  
 
Acetamide 
























Acetamide, the amide of acetic acid (commonly used to induce murine colitis (Randhawa, Singh et al. 
2014) ), is found in red beetroot. Belonging to the family of primary carboxylic acid amides, is known 
to exhibit a broad spectrum of biological activity including antimicrobial, antioxidant, anti-
inflammatory, tranquiliser and antagonist properties (Jayadevappa, Nagendrappa et al. 2012).  
Metronidazole, a commonly used antibiotic in IBD, is metabolised to acetamide, mediated by the gut 
flora (Koch, Chrystal et al. 1979). In our study wesee less urinary acetamide excreted post biological 






























4.9.3 Experiment 7 Summary 
Metabolites in the carboxylic acids and derivatives class are increased in the urine of pre biological 
therapy IBD patients compared to post biological therapy IBD patients.
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4.10 Experiment 8: Metabolite Identification Pre Biological v Post Biological Therapy (Paired) 
 
In this experiment we interogate paired samples from the IBD patients undergoing biological therapy. 
The aim of using a paired analysis is to minimise background noise and to allow a direct comparison 
of a patient with themselves pre and post intervention (in this experiment the administration of anti 
TNFα therapy). 
 
4.10.1 Experiment 8.1: Metabolite Identification Pre Biological v Post Biological Therapy 
(Paired) UHPLC-FTMS  
In the UHPLC-FTMS analyses of both serum and urine th re were no significant metabolites 
identified that differentiated between paired patient samples pre- and post-biological therapy.  
 
4.10.2 Experiment 8.2: Metabolite Identification Pre Biological v Post Biological Therapy 
(Paired) GC-ToF-MS 
 










p value q value 
51 Urine 69 312.326 Unknown 0.011347 0.022694 
374 Urine 321 1023.428 Lactose 0.021571 0.043142 
 
Figure 4.61: Barchart Urinary Variable ID 374 Paired Sample Comparison of Post Biological 




In this experiment utilising paired samples, we cansee that 14 patients have lower urinary lactose 


















Alpha-Lactose is the major sugar present in milk. Persons with lactose intolerance are unable to digest 
significant amounts of lactose. Common symptoms include abdominal pain and bloating, excessive 
flatus, and watery stool following the ingestion of f ods containing lactose. Whilst lactose intolerance 
is common in IBD (Eadala, Matthews et al. 2011), this experiment utilises paired samples and 




























4.10.3 Experiment 8 Summary 
In experiment 8, little differentiation is seen betw en the paired samples analysed. Using the patients 
as their own controls should minimise background noise and allow for an accurate representation of 
the change in metabolites related to disease state, and effect of treatment only.  These results suggest 
that the metabolites identified in experiment 7 may simply represent background noise rather than 
truly significant findings. 
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4.11 Experiment 9: Metabolite Identification Pre Biological v Healthy Controls 
 
In this experiment we aim to determine if differentiation between the group of pre biological therapy 
IBD patients and healthy controls is possible, in view of the small number of relevant metabolites 
identified in Experiments 7 and 8.  
 
Table 4.35 Experiment 9 number of samples analysed 
 Pre Biological Healthy Controls 
Serum samples 24 62 
Urine samples 24 60 
 
4.11.1 Experiment 9.1: Metabolite Identification Pre Biological v Healthy Controls UHPLC-
FTMS 
 
Table 4.36: Important Variables Identified Pre Biological Therapy v Healthy Controls UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
Time 
p value q value 
455 Urine 211.0567871 217.2532 0.00034964 0.01713236 
544 Urine 237.1222813 180.762 0.0002237 0.0109613 
726 Urine 295.1872401 709.07225 0.00097519 0.04778431 
743 Urine 302.1587031 143.3935 0.0003303 0.0161847 
784 Urine 322.075723 65.84785 0.00078133 0.03828517 
800 Urine 334.0909909 299.601 3.74E-05 0.0018326 
 
Table 4.36.1: Mass spectra search for 211.0567871 m/z 





























M+H+K 211.056036 382.141638 0.0007511 Flavanoids 
HMDB337
12 












M+Na 211.057691 188.068473 0.0009039 Dicarboxyli



























M+2Na 211.057691 376.136947 0.0009039 Not 
classified 
 
Table 4.36.2: Mass spectra search for 237.1222813 m/z 


















































































Table 4.36.3: Mass spectra search for 295.1872401 m/z 



































2M+H 295.186363 147.089543 0.0008771 Fatty acyls 
HMDB334
53 












2M+Na 295.189315 136.100048 0.0020749 Diazines 
HMDB149
18 













2M+Na 295.189315 136.100048 0.0020749 Diazines 
 
Table 4.36.4: Mass spectra search for 302.1587031 m/z 








































































Doxepin M+Na 302.151532 279.162314 0.0071711 Benzoxepin
es 
 
Table 4.36.5: Mass spectra search for 322.075723 m/z 














































































Table 4.36.6: Mass spectra search for 334.0909909 m/z 




























































M+2K+H 334.097004 257.177964 0.0060131 Morphinans 
HMDB390
87 
Sudachiin B M+2H 334.097076 666.1796 0.0060851 Flavanoids 
HMDB390
88 
Sudachiin C M+2H 334.097076 666.1796 0.0060851 Not 
classified 
 









However, 8-hydroxyguanosine and myricetin 3,3'-digalactoside, identified under variable ID 784, may 
be of relevance in future biomarker and pathogenesis r earch. 
 
8-hydroxyguanosine  
8-hydroxyguanosine is a nucleoside that is an oxidative derivative of guanosine. It is a marker for 
measuring the rate of oxidative damage to nucleic ac ds and lipids. 8-hydroxydeoxyguanosine (8-
OHdG) is formed when deoxyguanosine is oxidatively modified by reactive oxygen species. Although 
8-hydroxyguanosine has never been considered as a biomarker in IBD, 8-OHdG has been 
(Thorsteinsdottir, Gudjonsson et al. 2011). The accumulation of 8-OHdG in colonic epithelial cells 
has been shown to increase with the duration of ulcerative colitis and the development of dysplasia. 
High levels of 8-OHdG are also found in ulcerative colitis-associated neoplasia. The major 
disadvantage of using 8-OHdG as a biomarker is that deoxyguanosine is rapidly oxidised to 8-OHdG 
during sample preparation and analysis, leading to the formation of artifacts, which can interfere with 
























Myricetin 3,3'-digalactoside, a flavanoid, is found i  herbs and spices. Flavanoids are known to have 
both anti-oxidant, anti-inflammatory, anti-carcinogenic and analgesia properties. Myricetin 
administered orally to mice with DSS induced colitis has been shown to reduced weight loss and 
reduce severity of colitis. It decreases the production of nitric oxide, myeloperoxidase and 
malondialdehyde, whilst increasing the activity of superoxide dismutase and glutathione peroxidise, as 
well as significantly reducing IL-1β and IL-6 levels (Zhao, Hong et al. 2013). Further investigation is 
required into its mechanisms of action but it may prove a useful therapy in IBD management, and 





4.11.2 Experiment 9.2: Metabolite Identification Pre Biological v Healthy Controls GC-ToF-MS 
 









p value q value 
1109 Serum 368 954.378 Unknown 0.00016476 0.03641196 
1113 Serum 369 957.078 Unknown 0.00015623 0.03452683 
1146 Serum 382 954.428 Unknown 0.00017955 0.03968055 
1344 Serum 441 954.628 Unknown 0.00010545 0.02330445 
1347 Serum 442 954.478 Unknown 9.25E-05 0.0204425 
1395 Serum 456 954.578 Unknown 0.00013387 0.02958527 
1396 Serum 457 954.378 Unknown 0.00018582 0.04106622 




353 Urine 285 315.029 Glycine 0.0060148 0.0360888 
 
Figure 4.63: Boxplot Urinary Variable ID 337 Propanetricarboxylic acid Pre Biological Therapy v 




Variable ID 337, identified as propanetricarboxylic a id from the carboxylic acid and derivatives 
class, has been discussed in detail in experiment 6.2. Here, urinary levels are seen to be higher in pre 
biological therapy IBD patients than in HCs. This may be due to increased secretion and thus lower 































Glycine is a simple amino acid belonging to the metabolite class of carboxylic acids and derviatives. It 
is synthesised from serine, threonine, choline, and hy roxyproline via inter-organ metabolism 
involving primarily the liver and kidneys. It is degraded through 3 pathways: the glycine cleavage 
system (forming ammonia and CO2), serine hydroxymethytransferase, and conversion to glyoxylate 
by perioxisomal D-amino acid oxidase. Glycine is utilised for the biosynthesis of glutathione, heme, 
creatine, nucleic acids and uric acid. It is also a significant component of bile acid secretions and plays 
an important role in metabolic regulation, anti-oxidative reactions, and neurological function. Glycine 
has been shown to inhibit the production of proinflammatory cytokines (TNF-α, IL-1b and IL-6) and 
enhance IL-10.  It can also exert anti-inflammatory effects during endothelial inflammation through 
inhibiting activation of NF-κB, degradation of inhibitor κBα, and expression of E-selectin. Therefore, 
this nutrient has been used to prevent tissue injury, enhance anti-oxidative capacity, promote protein 
synthesis and wound healing, improve immunity, and treat metabolic disorders in obesity, diabetes, 
cardiovascular disease, ischaemia-reperfusion injuries, cancers and inflammatory diseases (Wang, Wu 
et al. 2013). In our study we see higher levels of urinary glycine in pre biological therapy IBD patients 






















glycine levels in the serum of patients with an ongoi  inflammatory process, as part of the inhibition 
of proinflammatory cytokine described above, or reduced levels allowing an uninhibited inflammatory 


































4.11.3 Experiment 9 Summary 
Metabolites in the carboxylic acids and derivatives class are increased in the urine of pre biological 
therapy IBD patients compared to healthy controls. 
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4.12 Experiment 10: Metabolite Identification Post Biological v Healthy Controls 
 
In this experiment we aim to determine whether differentiation between the group of post biological 
therapy IBD patients and healthy controls is possible.  
 
Table 4.38 Experiment 10 number of samples analysed 
 Post Biological Healthy Controls 
Serum samples 23 62 
Urine samples 22 60 
 
4.12.1 Experiment 10.1: Metabolite Identification Post Biological v Healthy Controls UHPLC-
FTMS 
 
Table 4.39: Important Variables Identified Post Biological v Healthy Controls UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
Time 
p value q value 
75 Urine 130.0491589 291.87825 0.00083544 0.0334176 
590 Urine 250.0923999 110.4985 0.00036714 0.0073428 
710 Urine 288.1252366 524.0685 0.00071216 0.0284864 
 
Table 4.39.1: Mass spectra search for 130.0491589 m/z 




























































M+H 130.049869 129.042593 0.0007101 Azolines 
HMDB023 Imidazoleac M+2H 130.049869 258.085186 0.0007101 Imidazole 
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The variable ID 75 is shown to be higher in the urine of post biological therapy patients compared to 
healthy controls. The following metabolites may be of clinical relevance to IBD. 
 





S-aminomethyldihydrolipoamide, belonging to the class of organic compounds known as fatty acyls, 
is an intermediate in the transfer of a methylamine group from gylcine via the glycine cleavage 
system. The enzyme glycine dehydrogenase catalyses the production, and consumption, of S-
aminomethyldihydrolipoamide in the mitochondria. Interestingly we have previously see higher 
urinary levels of glycine in pre biological therapy IBD patient than in healthy controls, and this result 
may collaborate that finding, although the significan e remains unclear. 
 























Phenylalanyl-Arginine and Arginyl-Phenylalanine are dipeptides composed of phenylalanine and 
arginine. It is an incomplete breakdown product of protein digestion or protein catabolism.  
Serum levels of phenylalanine have been identified n UC in both human (Zhang, Lin et al. 2013) and 
murine (Schicho, Nazyrova et al. 2010) models althoug  this is as yet unexplained.  
Serum levels of L-arginine are increased in murine DSS induced colitis, and dietary supplementation 
is associated with improvement in clinincal measure, duced colonic permeability and number of 
myeloperoxidase-positive neutrophils and reduced proinflammatory cytokine and chemokine 
expression (Coburn, Gong et al. 2012). This would be in keeping with the findings in our study. 
 
Pyrrolidonecarboxylic acid and pyroglutamic acid 
Pyrrolidonecarboxylic acid and pyroglutamic acid are cyclic derivatives of glutamic acid, and belong 
to the class of organic compounds known as alpha amino acids and derivatives. Poly-γ-glutamic acid 
has been shown to attenuate weight loss, disease activity index and colonic shortening in DSS induced 
murine colitis, as well as reduce vascular endothelial growth factor-A and vascular endothelial growth 
factor receptor 2 expression and recruitment of leukocytes to the inflamed colon (Davaatseren, Hwang 
et al. 2013). Increased levels in the urine of post biological therapy patients may relate to a respone to 
treatment. 
 
Imidazoleacetic acid riboside 
Imidazoleacetic acid riboside is a metabolite of imidazoleacetic acid. In kidney glomeruli, histamine s 
predominantly catabolised to acid metabolites of the diamine oxidase (histaminase) pathway, 
imidazoleacetic acid and imidazoleacetic acid riboside. In a murine model, histamine has been shown 
to have a proinflammatory role via histamine H4 receptor (Schirmer, Rezniczek et al. 2015), however 
a recent study in CD and UC in humans revealed no difference in histamine levels between IBD 
patients and healthy controls (Hagel, de Rossi et al. 2015). It is difficult to interpret our results in light 
of this finding. 
 
Table 4.39.2: Mass spectra search for 250.0923999m/z 



































































































































None of the urinary metabolites identified have anyrelation to IBD. They are all dietary or medication 
related, and the medication related metabolites mayaccount for higher urinary levels seen in post 

























Table 4.39.3: Mass spectra search for 288.1252366 m/z 































M+H 288.123034 287.115758 0.0022026 Morphinans 
HMDB340
75 



























































The variable ID 710 is shown to be higher in the urine of post biological therapy patients compared to 
healthy controls. This is likely to be accounted for by medications. 
 
Ortho-hydroxyatorvastatin and Para-hydroxyatorvastatin  
Ortho-hydroxyatorvastatin and Para-hydroxyatorvastatin are metabolites of atorvastatin. Statins are 
known to reduce chemokine expression in coronary artery disease. CXCL10 is a ligand for the 
CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the 
perpetuation of mucosal inflammation. Atorvastatin has been shown to reduce plasma CXCL10 levels 

























4.12.2 Experiment 10.2: Metabolite Identification Post Biological v Healthy Controls GC-ToF-
MS 
 









p value q value 
2 Serum 45 354.576 Unknown 9.93E-06 0.00303858 
21 Serum 51 355.301 Unknown 2.09E-05 0.0063954 
26 Serum 52 355.584 Unknown 8.42E-06 0.00257652 
33 Serum 53 353.773 Isotridecano
l 
6.55E-05 0.020043 
58 Serum 59 354.938 Unknown 1.03E-05 0.0031518 
80 Serum 66 355.789 Unknown 3.29E-05 0.0100674 
87 Serum 67 354.848 Unknown 3.89E-05 0.0119034 
109 Serum 72 355.624 Unknown 2.73E-05 0.0083538 
112 Serum 73 355.538 Unknown 4.11E-05 0.0125766 
169 Serum 87 355.848 Unknown 2.12E-05 0.0064872 
171 Serum 88 355.468 Unknown 2.96E-05 0.0090576 
177 Serum 89 355.368 Unknown 8.77E-06 0.00268362 
198 Serum 94 357.848 Unknown 4.70E-05 0.014382 
226 Serum 101 356.236 Unknown 6.18E-06 0.00189108 
283 Serum 115 356.848 Unknown 4.30E-05 0.013158 
290 Serum 117 355.488 Unknown 3.15E-05 0.009639 
293 Serum 118 355.451 Unknown 2.79E-05 0.0085374 
344 Serum 129 355.924 Unknown 1.90E-05 0.005814 
352 Serum 131 356.183 Unknown 1.40E-05 0.004284 
360 Serum 133 355.593 Unknown 2.46E-05 0.0075276 
367 Serum 135 355.638 Unknown 1.99E-05 0.0060894 
417 Serum 147 355.621 Unknown 3.00E-05 0.00918 
420 Serum 148 355.588 Unknown 2.17E-05 0.0066402 
423 Serum 149 355.524 Unknown 1.94E-05 0.0059364 
522 Serum 175 355.768 Unknown 3.75E-05 0.011475 
577 Serum 190 355.338 Unknown 2.20E-05 0.006732 
581 Serum 191 355.326 Unknown 1.93E-05 0.0059058 
585 Serum 192 355.298 Unknown 1.51E-05 0.0046206 
590 Serum 193 356.103 Unknown 1.48E-05 0.0045288 
635 Serum 203 355.328 Unknown 2.68E-05 0.0082008 
690 Serum 219 355.371 Unknown 1.45E-05 0.004437 
697 Serum 220 355.596 Unknown 1.54E-05 0.0047124 
700 Serum 221 355.586 Unknown 1.22E-05 0.0037332 









In this experiment, the only identified substance is isotridecanol, a fatty alcohol. No relation to 
inflammation or IBD has been identified. We see higher levels in the post biological therapy group 









4.12.3 Experiment 10 Summary 
Metabolites in the carboxylic acids and derivatives class, the fatty acyls class, and the imidazole 
ribonucleosides and ribonucleotides class are increased in the urine of post biological therapy IBD 
patients compared to healthy controls. Metabolites in the fatty alcohols class are increased in the 


























4.13 Experiment 11: Metabolite Identification Pre Surgery v Post Surgery (Grouped) 
 
In experiment 11 we consider the IBD patients undergoing surgery, and aim to determine whether 
differentiation between the pre and post surgery groups is possible. In this experiment the samples ar 
grouped as pre and post surgery. Future experiments will consider paired samples. 
 
Table 4.41 Experiment 11 number of samples analysed 
 Pre-surgery Post-surgery 
Serum samples 30 28 
Urine samples 30 28 
 
4.13.1 Experiment 11.1: Metabolite Identification Pre Surgery v Post Surgery (Grouped) 
UHPLC-FTMS 
 
Table 4.42: Important Variables Identified Pre Surgery v Post Surgery (Grouped) UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
time 
p value q value 
579 Serum 425.3168199 1033.3427 0.0045059 0.0360472 
 
Table 4.42.1: Mass spectra search for 425.3168199 m/z 










































































2M+H 425.312232 212.152478 0.0045879 Piperidines 
 




In this experiment, peak intensities of serum variable ID 579 are higher in the post surgery group than 
in the pre-surgery group. Cholesterol, 5-beta-cholestan-3-one and lathosterol are considered relevant. 
 
Cholesterol  
Cholesterol, belonging to the class of organic compunds known as steroids and steroid derivatives, is 
a sterol (a combination steroid and alcohol) and a lipid found in the cell membranes of all body 
tissues, and transported in the blood plasma of all animals. IBD patients exhibit lower levels of low-
density lipoprotein cholesterol and total cholesterol than healthy controls, with this effect being more 
profound in CD than UC. These findings are independent of disease activity and are also observed 
post operatively (Agouridis, Elisaf et al. 2011). In our study, cholesterol levels are seen to be lower in 
the pre-operative group than the post-operative group. This may be due to malabsorption in the pre-

























operative group or the presence of pro-inflammatory cytokines and autoantibodies against lipoprotein 
lipase altering lipoprotein metabolism (Sappati Biyyani, Putka et al. 2010). 
 
5-beta-cholestan-3-one   
5-beta-cholestan-3-one is part of the primary bile acid biosynthesis and steroid hormone biosynthesis 
pathways. It belongs to the class of organic compounds known as cholesterols and derivatives. It has 
been postulated that IBD-associated dysbiosis leads to modifications in bile acid pool composition and 
can affect gut homeostasis (Duboc, Rajca et al. 2013). Bile acids are known to be anti-inflammatory 
molecules able to decrease the synthesis of proinflammatory cytokines such as TNF-α in monocytes 
and macrophages through NF-κB inhibition. In our study we see lower levels of 5-beta-cholestan-3-
one in pre-operative patients compared to post-operativ  patients. This may alter bile acid composition 
and thus start the cycle of bile acid dysmetabolism, and lack of anti-inflammatory effect. In post-
operative patients it may be that we are seeing more n mal levels of 5-beta-cholestan-3-one when gut 
homeostasis should be improved. 
 
Lathosterol 
Lathosterol is a sterol and a lipid found in the cell membranes of all body tissues, and transported in 
the blood plasma of all animals. It belongs to the class of organic compounds known as cholesterols 
and derivatives, and is used as an indicator of whole-b dy cholesterol synthesis. Plasma lathosterol 
levels are significantly lower in patients with active CD than in healthy controls (Agouridis, Elisaf et 
al. 2011). This finding is replicated in our pre- and post-operative analyses. 
 
Lathosterol 
Lathosterol is a sterol and a lipid found in the cell membranes of all body tissues, and transported in 
the blood plasma of all animals. It belongs to the class of organic compounds known as cholesterols 
and derivatives, and is used as an indicator of whole-b dy cholesterol synthesis. Plasma lathosterol 
levels are significantly lower in patients with active CD than in healthy controls (Agouridis, Elisaf et 





4.13.2 Experiment 11.2: Metabolite Identification Pre Surgery v Post Surgery (Grouped) GC-
ToF-MS 
 









p value q value 
1145 Serum 381 953.529 Unknown 0.00037018 0.03923908 
324 Urine 233 593.988 Erythritol 0.0015129 0.0090774 










In this experiment, higher peak intensities of variable ID 324, erythritol, are seen in the pre-operative 
group than in the post-operative group. 
 
Erythritol 
Erythritol belongs to the class of organic compounds known as sugar alcohols. It is used as a food 
additive and occurs naturally in some fruit and ferm nted foods. In our study we see higher urinary 
























levels in pre-operative compared to post-operative patients, however, no links with IBD have been 
identified and this result is unexplained but may purely be dietary. 
 





In this experiment higher peak intensities of variable ID 337, propanetricarboxylic acid, are seen in 
the pre-operative group than in the post-operative group. 
 
Propanetricarboxylic acid  
Propanetricarboxylic acid has previously been described in detail in experiment 6.2. In this 
experiment we see higher levels of propanetricarboxylic acid in the urine of the pre-operative group 
compared to the post-operative group. This may mean th t pre-operatively less TCA cycle-related 
downstream molecules are available due to inhibition of aconitase, and post-operatively less inhibition 





























































4.13.3 Experiment 11 Summary 
Metabolites in the class steroids and steroid derivatives are increased in the serum of post surgery IBD 
patients compared to pre surgery IBD patients. Metabolites in the classes carbohydrates and 
carbohydrate conjugates, and carboxylic acids and derivatives are increased in the urine of pre surgery 
IBD patients compared to post surgery IBD patients. 
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4.14 Experiment 12: Metabolite Identification Pre Surgery v Post Surgery (Paired) 
 
In this experiment we utilise paired samples in IBD patients undergoing surgery. This allows each 
patients to act as their own control pre and post intervention (in this case surgery). 
 
Table 4.44 Experiment 12 number of samples analysed 
 Pre-surgery Post-surgery 
Serum samples 30 28 
Urine samples 30 28 
 
4.14.1 Experiment 12.1: Metabolite Identification Pre Surgery v Post Surgery (Paired) UHPLC-
FTMS 
 
Table 4.45: Important Variables Identified Pre Surgery v Post Surgery (Paired) UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
time 
p value q value 
579 Serum 425.3168199 1033.3427 0.0090494 0.0361976 
750 Urine 303.1256521 327.27085 0.0020453 0.040906 
 
Table 4.45.1: Mass spectra search for 425.3168199 m/z 










































































2M+H 425.312232 212.152478 0.0045879 Piperidines 
 
These metabolites have previously been discussed in xperiment 11.1. Those of biological relevance 
are cholesterol, 5-beta-cholestan-3-one and lathosterol. 
 
Figure 4.72: Barchart Serum Variable ID 579 paired sample comparison of post surgery to pre 




Variable ID 579 shows increased serum levels in post surgery patients compared to pre surgery 
patients in 19 of the 28 sample sets.  
 
Table 4.45.2: Mass spectra search for 303.1256521 m/z 






































M+H 303.1227 302.115424 0.0029521 Isoflavanoi
ds 
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579 (Post Surgery - Pre Surgery)
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28 Sphaerosin classified 
HMDB010
08 
























Figure 4.73: Barchart Urinary Variable ID 750 UHPLC-FTMS paired sample comparison of post 




Variable ID 750 shows increased urinary levels in post surgery patients compared to pre surgery 
patients in 17 of the 27 sample sets. The following metabolites are potentially biologically relevant. 
 
3'-Hydroxy-3,4,5,4'-tetramethoxystilbene 
3'-Hydroxy-3,4,5,4'-tetramethoxystilbene, a polyphenol belonging to the stilbenes class of organic 
compounds, has no links with IBD. However, resveratrol (3,5,40-trihydroxy-trans-stilbene) has been 
shown to down-regulate inflammatory pathways of MAPK and NF-κB, lessen COX-2, modify 
cytokines, diminish leucocytes, alter intestinal microflora and decrease clinical symptoms in animal 
models of IBD (Farzaei, Rahimi et al. 2015). 
 
Biliverdin 
Biliverdin belongs to the class of organic compounds known as bilirubins and is formed as a 
byproduct of haemoglobin breakdown. Heme is catabolised by heme oxygenase into biliverdin, free 
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750 (Post Surgery - Pre Surgery)
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cytoprotective and has anti-inflammatory effects (Wegiel, Otterbein 2012). Heme oxygenase-1, an 
isoenzyme of heme oxygenase, is transcriptionally induced in response to oxidative stress and may 
play a protective role in intestinal damage. Both carbon monoxide and biliverdin have been implicated 
as mediators in this response (Naito, Takagi et al. 2004). More recently, heme oxygenase-1 and 
carbon monoxide may be novel therapeutic molecules in patients with IBD (Takagi, Naito et al. 2010, 
Takagi, Uchiyama et al. 2015).  
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4.14.2 Experiment 12.2: Metabolite Identification Pre Surgery v Post Surgery (Paired) GC-ToF-
MS 
 









p value q value 
221 Urine 164 755.278 Sorbitol 0.0035504 0.0213024 
324 Urine 233 593.988 Erythritol 0.0020453 0.0122718 
 
 
Figure 4.74: Barchart Urinary Variable ID 221 GC-ToF-MS paired sample comparison of post 




Variable ID 221 identified as sorbitol, shows increas d urinary levels in post surgery patients 
compared to pre surgery patients in 16 of the 27 sample sets.  
 
Figure 4.75: Barchart Urinary Variable ID 324 GC-ToF-MS paired sample comparison of post 
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Variable ID 324 identified as erythritol, shows reduced urinary levels in post surgery patients 
compared to pre surgery patients in 15 of the 27 sample sets.  
 
Neither of the urinary metabolites identified in this experiment are of biological relevance in IBD. 






















4.14.3 Experiment 12 Summary 
On the UHPLC-FTMS platform, cholesterol, 5-beta-cholestan-3-one and lathosterol appear to be 
increased in the serum of the majority of post-operative patients, compared to their pre-operative 
samples. These compounds all belong to the steroid and steroid derivatives class. 
In the urine of post-operative patients compared to their pre-operative samples, 3'-Hydroxy-3,4,5,4'-
tetramethoxystilbene, from the stilbenes class, and Biliverdin, from the tetrapyrroles and derivatives 
class, are biologically relevant metabolites that have increased levels in the majority of patients. 
On the GS-ToF-MS platform, the metabolites identifed, sorbitol and erythritol from the carbohydrates 
and carbohydrate conjugates class, are not of biological relevance. However, sorbitol apprears to be 
increased and erythritol decreased in the urine of the majority of patients post surgery compared to 
when they are in the pre-operative period.  
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4.15 Experiment 13: Metabolite Identification Pre Surgery v Healthy Controls 
 
Experiment 13 aims to determine whether differentiation between the profiles of pre surgery IBD 
patients, and HCs is possible. 
 
Table 4.47 Experiment 13 number of samples analysed 
 Pre-surgery Healthy Controls 
Serum samples 30 62 
Urine samples 30 60 
 
4.15.1 Experiment 13.1: Metabolite Identification Pre Surgery v Healthy Controls UHPLC-
FTMS 
 
Table 4.48: Important Variables Identified Pre Surgery v Healthy Controls UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
time 
p value q value 
12 Urine 106.0362854 240.0221 8.53E-07 4.69E-05 
174 Urine 153.0727774 228.6984 0.00026143 0.01437865 
258 Urine 169.1213976 500.2978 2.81E-05 0.0015455 
407 Urine 200.1999862 697.53385 0.00067961 0.03737855 
597 Urine 253.0654594 62.4078 0.00079279 0.04360345 
610 Urine 257.1488092 361.4173 6.65E-05 0.0036575 
743 Urine 302.1587031 143.3935 0.00040501 0.02227555 
784 Urine 322.075723 65.84785 6.19E-05 0.0034045 
800 Urine 334.0909909 299.601 1.02E-06 5.61E-05 
 
Table 4.48.1: Mass spectra search for 106.0362854 m/z 











































M+Na 106.037565 83.048347 0.0012796 Azoles 


































In this experiment, as previously discussed in Experim nt 6.1 results, urinary peak intensities of 
variable ID 12 are higher in HCs than IBD patients, in this case those pre surgery.  
 
Table 4.48.2: Mass spectra search for 153.0727774 m/z 


















































































M+H+Na 153.071609 282.146724 0.0011684 Prenol 
lipids 
 




In this experiment, peak intensities of urinary variable 174 are higher in healthy controls than in pre




























are dietary and therefore the increased levels in HCs may be related to greater dietary variablitity in 
healthy controls when compared to IBD patients, as previously discussed. 
 
Table 4.48.3: Mass spectra search for 169.1213976 m/z 














































































In this experiment, a higher peak intensity in urina y variable ID 258 is seen in healthy controls when 
compared to pre surgical IBD patients. 12,13-DHOME and 9,10-DHOME are identified as potentially 
biologically relevant. The other metabolites in this search are predominantly dietary. 
 
12,13-DHOME and 9,10-DHOME 
12,13-DHOME (dihydroxy-octadecenoic acid) and 9,10-DHOME are derivatives of linoleic acid diol 
that have been reported to be toxic in human tissue preparations. They are epoxide hydrolase 
metabolites of the leukotoxin12,13-EpOME (epoxy-octadecenoic acid) and 9,10-EpOME 
respectively. They belong to the class of organic compounds known as hydroxy fatty acids. Linoleic 
acid metabolites in this pathway are regarded as biologically active compounds. Leukotoxin (9(10)-
epoxy-12Z-octadecenoic acid, 9,10 EpOME) and its regioisomer have been associated with multiple 
organ failure and adult respiratory distress syndrome seen in severe burn patients while the 
corresponding diols (9,10-DHOME and 12,13-DHOME) are lso known to be cytotoxic. In healthy 
individuals, these metabolites may be endogenous chemical mediators regulating vascular 
permeability and inflammation (Yang, Schmelzer et al. 2009) In our study we see higher urinary 


























healthy controls. No direct links have been previously identified with IBD as yet but further 
investigation may be warranted. 
 
Table 4.48.4: Mass spectra search for 200.1999862 m/z 












































































In this experiment, a higher peak intensity in urina y variable ID 407 is seen in healthy controls when 
compared to pre surgical IBD patients. None of the metabolites identified have biological links to 
IBD. The difference identified may be dietary.  
 
Table 4.48.5: Mass spectra search for 253.0654594 m/z 






































































































2M+Na 253.068256 115.039519 0.0027966 Not 
classified 
 




In this experiment, a higher peak intensity in urina y variable ID 597 is seen in healthy controls when 
compared to pre surgical IBD patients. Methionyl-Cysteine, Cysteinyl-Methionine and 


























Methionyl-Cysteine and Cysteinyl-Methionine 
Methionyl-Cysteine and Cysteinyl-Methionine are dipeptides composed of methionine and cysteine. 
They are incomplete breakdown products of protein digestion or protein catabolism. Metabolism of 
the sulfur-containing amino acid cysteine is increased in both UC and CD, and metabolism of cysteine 
and methionine is increased in ileal CD. This is accompanied by increases in riboflavin metabolism, 
glutathione transporters, and the N-acetylgalactosamine phosphotransferase system. Mucin, which is 
rich in cysteine and glycosylated sugars, is abundant in the intestinal epithelium, and it is upregulated 
during inflammation. The increases in cysteine metabolism and N-acetylgalactosamine transporters 
may reflect a shift in the microbiome towards greater abundance of microbes that use mucin as a 
primary energy source. This functionality suggests activity at the mucosa and this may be problematic 
for a damaged IBD epithelium with compromised barrier function (Morgan, Tickle et al. 2012). In our 
study we see less Methionyl-Cysteine and Cysteinyl-Methionine in the urine of IBD patients. This 
may reflect the upregulated metabolism resulting in less excretion. 
 
Oxytetracycline 
Oxytetracycline, a broad-spectrum antibiotic, belongs to the class of organic compounds known as 
tetracyclines. Some evidence suggests that there may be  link between oral tetracycline usage and the 
development of IBD, particularly CD (Margolis, Fanelli t al. 2010). This metabolite would only be 
identified from the urine of those taking this drug during the study therefore we cannot derive any 
causal effect from this data. 
 
Table 4.48.6: Mass spectra search for 257.1488092 m/z 






































































Coniferan M+2Na-H 257.14879 212.17763 0.0000192 Not 
classified 
 




In this experiment, a higher peak intensity in urina y variable ID 610 is seen in healthy controls when 
compared to pre surgical IBD patients. None of the urinary metabolites identified are relevant in IBD, 
and the differences between the groups are likely to be dietary in nature. 
 
Table 4.48.7: Mass spectra search for 302.1587031 m/z 









































































































In this experiment, a higher peak intensity in urina y variable ID 743 is seen in healthy controls when 
compared to pre surgical IBD patients. None of the urinary metabolites identified are relevant in IBD 
as previously discussed in experiment 9.1. 
 
Table 4.48.8: Mass spectra search for 322.075723 m/z 




































































































M+Na 322.071758 299.08254 0.003965 Benzodiaze
pines 
 
As previously discussed in experiment 9.1 none of the urinary metabolites identified are of biological 
relevance in IBD but 8-hydroxyguanosine and Myricetin 3,3'-digalactoside may warrent further 
investigation as potential biomarkers.  
 
Table 4.48.9: Mass spectra search for 334.0909909 m/z 




























































M+2K+H 334.097004 257.177964 0.0060131 Morphinans 
HMDB390
87 
Sudachiin B M+2H 334.097076 666.1796 0.0060851 Flavonoids 









In this experiment, higher peak intensities of urina y variable ID 800 are in seen in healthy controls 
than in pre-surgery IBD patients. This was identified and discussed previously in experiment 6.1, and 




























4.15.2 Experiment 13.2: Metabolite Identification Pre-Surgery v Healthy Controls GC-ToF-MS 
 









p value q value 
8 Serum 47 573.478 Unknown 7.03E-08 1.91E-05 
14 Serum 49 577.428 Unknown 4.48E-05 0.0121856 
22 Serum 51 575.128 Unknown 3.88E-05 0.0105536 
27 Serum 52 571.628 Threonine 
or urea 
1.74E-09 4.73E-07 
30 Serum 53 575.774 Unknown 4.25E-08 1.16E-05 
34 Serum 54 577.453 Unknown 8.69E-09 2.36E-06 
45 Serum 56 574.878 Unknown 1.18E-08 3.21E-06 
60 Serum 60 570.318 Urea 8.74E-10 2.38E-07 
64 Serum 61 575.528 Unknown 4.60E-08 1.25E-05 
69 Serum 63 576.428 Unknown 8.14E-07 0.00022140
8 
74 Serum 64 570.778 Urea 3.15E-09 8.57E-07 
76 Serum 65 571.903 Threonine 
or urea 
1.12E-09 3.05E-07 
81 Serum 66 571.278 Threonine 
or urea 
4.55E-10 1.24E-07 
86 Serum 67 572.201 Unknown 3.81E-09 1.04E-06 
93 Serum 69 571.028 Threonine 
or urea 
2.52E-09 6.85E-07 




106 Serum 71 571.978 Threonine 
or urea 
1.22E-09 3.32E-07 
107 Serum 72 572.378 Unknown 2.19E-09 5.96E-07 
121 Serum 75 574.929 Unknown 6.90E-07 0.00018768 
133 Serum 78 572.928 Unknown 9.13E-09 2.48E-06 
137 Serum 79 570.426 Urea 3.19E-08 8.68E-06 
142 Serum 80 570.674 Urea 2.07E-09 5.63E-07 
157 Serum 84 575.428 Unknown 6.23E-08 1.69E-05 
218 Serum 99 570.728 Urea 4.52E-10 1.23E-07 









266 Serum 111 571.579 Threonine 
or urea 
7.15E-09 1.94E-06 
279 Serum 115 572.628 Unknown 1.04E-08 2.83E-06 
334 Serum 127 571.479 Threonine 
or urea 
5.89E-09 1.60E-06 
355 Serum 132 576.428 Unknown 1.37E-08 3.73E-06 
383 Serum 139 570.378 Urea 0.00015774 0.04290528 
390 Serum 141 570.928 Urea 3.15E-09 8.57E-07 
394 Serum 141 793.553 Galactose 4.14E-05 0.0112608 
404 Serum 144 532.088 Octanoic 
acid 
2.25E-06 0.000612 
446 Serum 155 570.524 Urea 3.66E-09 9.96E-07 
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455 Serum 157 570.478 Urea 3.25E-10 8.84E-08 
507 Serum 171 570.474 Urea 6.33E-10 1.72E-07 
509 Serum 172 570.678 Urea 9.12E-10 2.48E-07 
513 Serum 173 570.328 Urea 9.02E-11 2.45E-08 
516 Serum 174 568.138 Urea 2.10E-09 5.71E-07 
549 Serum 183 795.628 Citric acid 5.93E-06 0.0016129  
554 Serum 184 792.678 Galactose 4.80E-05 0.013056 
563 Serum 186 570.728 Urea 1.35E-08 3.67E-06 
569 Serum 187 571.628 Threonine 
or urea 
7.15E-08 1.94E-05 
574 Serum 189 570.078 Urea 5.09E-11 1.38E-08 
576 Serum 190 569.928 Urea 8.01E-11 2.18E-08 
582 Serum 191 569.826 Urea 1.78E-08 4.84E-06 
622 Serum 200 537.679 Unknown 3.51E-05 0.0095472 
637 Serum 204 568.779 Urea 3.74E-08 1.02E-05 
642 Serum 206 575.028 Unknown 3.38E-05 0.0091936 
754 Serum 237 902.428 Linoleic 
acid 
3.00E-05 0.00816 
819 Serum 257 794.778 Galactose 1.20E-06 0.0003264 
823 Serum 259 794.828 Galactose 1.40E-05 0.003808 
831 Serum 261 570.453 Urea 4.50E-06 0.001224 
844 Serum 265 845.578 Fructose 2.77E-06 0.00075344 
864 Serum 272 798.856 Unknown 0.00012309 0.03348048 
867 Serum 273 795.729 Citric acid 3.36E-05 0.0091392 
883 Serum 280 864.078 Tyrosine 0.00016737 0.04552464 
990 Serum 318 829.026 Glucuronic 
acid 
1.45E-06 0.0003944 
1000 Serum 324 967.778 Oleic acid 0.00017291 0.04703152 
1056 Serum 347 795.178 Pentanoic 
acid 
9.34E-05 0.0254048 
1059 Serum 349 794.328 Galactose 4.55E-05 0.012376 
1072 Serum 353 954.878 Unknown 6.13E-05 0.0166736 
1099 Serum 363 795.678 Citric acid 6.55E-05 0.017816 
1113 Serum 369 957.078 Unknown 5.67E-05 0.0154224 
1146 Serum 382 954.428 Unknown 8.94E-05 0.0243168 
1149 Serum 383 956.728 Unknown 2.37E-05 0.0064464 
1151 Serum 384 957.378 Unknown 1.00E-04 0.0272 
1325 Serum 432 841.678 myo-
inositol 
0.00013905 0.0378216 
1344 Serum 441 954.628 Unknown 0.00016304 0.04434688 
1392 Serum 455 954.528 Unknown 0.00017072 0.04643584 
1395 Serum 456 954.578 Unknown 0.0001677 0.0456144 
82 Urine 77 915.078 Unknown 0.0017361 0.0486108 














In this experiment, variable ID 404, identified as octanoic acid, is increased in the serum of pre 
surgery IBD patients compared to healthy controls. It belongs to the class of organic compounds 
known as fatty acid esters. It is a medium chain fatty cids and has been shown to be significantly 
decreased in patients with CD, UC and pouchitis compared with healthy controls (De Preter, Machiels 
et al. 2015). Our findings are not in keeping with this, showing increased levels in the serum of pre 



















































Citric Acid  
The variable IDs 867 and 1099, identified as citric acid, are reduced in the serum of pre surgery IBD 
patients compared to healthy controls. Citric acid is a weak acid that is an intermediate in the 
tricarboxylic acid cycle or that may be introduced with diet. Acute colitis has been shown to result in 
depletion in the levels of gut microbial cometabolites in urine along with an increase in citric 
acid cycle intermediates. These findings suggest that DSS-induced acute colitis causes a disturbance 
of lipid and energy metabolism, damage to the colon and liver, a promoted antioxidative and anti-
inflammatory response, and perturbed gut microbiotal communities (Dong, Zhang et al. 2013). Our 
results show reduced levels of citric acid in the serum of pre surgery IBD patients. This may be due to 





























Oleic Acid  
The variable ID 1000 identified as oleic acid, is reduced in the serum of pre surgery IBD patients 
compared to healthy controls. Oleic acid, a fatty ac l, is an unsaturated fatty acid that is the most 
widely distributed and abundant fatty acid in nature. It belongs to the class of organic compounds 
known as long-chain fatty acids, and has been shown t  be decreased in the colonic mucosa of IBD 
patients (Ramakers, Mensink et al. 2007). Our results show reduced levels in the serum of pre surgery 



























Increased urinary levels of variable ID 320, Malonic Acid or Oxalic Acid, are seen in pre surgery IBD 
patients compared to HCs. Both compounds belong to the class of carboxylic acids and derivatives. 
Oxalic acid is found in plants and vegeteables and these finding may be dietary in nature. Malonic 





























As previously discussed, urinary erythritol levels seen here to be higher in pre surgery IBD patients 











4.15.3 Experiment 13 Summary 
Metabolites in the classes organic disulphides, benzene and substituted benzene derivatives, 
carboxylic acids and derivatives, azoles, and fatty cyls have been shown to be decreased in both urine
and serum samples of pre surgery IBD patients in comparison to healthy controls. Metabolites in the 
class carbohydrates and carbohydrate conjugates are increased in the urine of pre surgery IBD patients 
























4.16 Experiment 14: Metabolite Identification: Post Surgery v Healthy Controls 
 
In this experiment we aim to determine whether we can identify metabolites that differentiate between 
post surgery IBD patients and HCs. 
 
Table 4.50 Experiment 14 number of samples analysed 
 Post-surgery Healthy Controls 
Serum samples 28 62 
Urine samples 28 60 
 
4.16.1 Experiment 14.1 Metabolite Identification: Post Surgery v Healthy Controls UHPLC-
FTMS 
 
Table 4.51: Important Variables Identified Post Surgery v Healthy Controls UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
time 
p value q value 
12 Urine 106.0362854 240.0221 0.00024696 0.0111132 
125 Urine 143.1058707 371.7795 0.00030249 0.01361205 
450 Urine 209.1244076 168.6093 2.66E-05 0.001197 
544 Urine 237.1222813 180.762 0.00029484 0.0132678 
548 Urine 239.088045 336.9686 0.00063886 0.0287487 
751 Urine 303.2348021 502.1351 0.00040589 0.01826505 
800 Urine 334.0909909 299.601 0.00012066 0.0054297 
 
The variables that have been previously identified an  discussed (variable ID 12 and 800) are not 
repeated, although the relevant boxplots are displayed to show the difference between the groups (post 








In this study urinary variable ID 12 is seen to be reduced in post surgical IBD patients compared to 
healthy controls. These metabolites have been discussed previously. 
 
Table 4.51.1: Mass spectra search for 143.1058707 m/z 






























































































M+H 143.106656 142.09938 0.0007853 Fatty acyls 
 
 
Figure 4.91: Boxplot Urinary Variable ID 125 Post Surgery v Healthy Controls UHPLC- FTMS 
p=0.00030249 
 
In this study urinary variable ID 125 is seen to be increased in post surgical IBD patients compared to 
healthy controls. All of the above metabolites are dietary in nature.  
 
Table 4.51.2: Mass spectra search for 209.1244076m/z 












































































































In this study urinary variable ID 450 is found to be increased in post surgery IBD patients compared 
to healthy controls. Metabolites considered biologically relevant are listed below. 
 
MG(20:4(8Z,11Z,14Z,17Z)/0:0/0:0), MG(0:0/20:4(8Z,11Z,14Z,17Z)/0:0, 
MG(20:4(5Z,8Z,11Z,14Z)/0:0/0:0)) and 2-Arachidonylglycerol  
These metabolites are from the glycerolipid class. They are monoacylglycerides, a glyceride 
consisting of one fatty acid chain covalently bonded to a glycerol molecule through ester linkage. 
Monoacylglycerols are formed biochemically via releas  of a fatty acid from diacylglycerol by 
diacylglycerol lipase or hormone sensitive lipase.  
Endocannabinoids, N-acylethanolamine N-arachidonoylglycerol and monacylglycerol 2-
arachidonoylglycerol, are lipid mediators expressed in the GI tract. The endocannabinoid system is 
implicated in gut homeostasis, modulating gastrointestinal motility, visceral sensation, and 
inflammation, as well as being recently implicated in IBD pathogenesis (Alhouayek, Muccioli 2012). 
In our study these urinary metabolites are found to be raised in comparison to healthy controls. This 























Table 4.51.3: Mass spectra search for 237.1222813m/z 






















































































Urinary variable ID 544 is found to be reduced in post surgery IBD patients compared to healthy 
controls. All of the metabolites identified are dietary in nature. The findings may be reflective of pst 
surgery IBD patients not yet returning to a diet comparable with healthy controls. 
 
Table 4.51.4: Mass spectra search for 239.088045 m/z 




































































































































In this study urinary variable 548 is reduced in post surgery IBD patients compared to healthy 
controls. The metabolites identified are predominantly dietary in nature. The findings may be 
reflective of post surgery IBD patients not yet retu ning to a diet comparable with healthy controls. 
 
Table 4.51.5: Mass spectra search for 303.2348021m/z 




















































































In this study urinary variable 751 is increased in post surgical IBD patients compared to healthy 
controls. Most of the variables identified are dietary in nature. Retinyl esther may be of biological 
interest.  
 
Retinyl Ester  
Retinyl ester, from the prenol lipid class, is the storage form of vitamin A. In IBD the absorption of 
vitamin A is normal, however serum levels have been shown to be reduced in active disease phases, 
returning to normal following treatment, withour supplementation (Janczewska, Bartnik et al. 1991). 
In our study we see increased urinary levels of retinyl ester in the post surgery IBD patients compared 
to healthy controls. This is difficult to explain, but may represent increased excretion following 





























In this study urinary variable 800 is decreased in post surgical IBD patients compared to healthy 




























4.16.2 Experiment 14.2: Metabolite Identification Post Surgery v Healthy Controls 
GC-ToF-MS 
 









p value q value 
82 Urine 77 915.078 Unknown 0.00076565 0.02220385 
231 Urine 172 945.828 Uric acid -
tetrakis 
0.001411 0.040919 
394 Urine 375 788.078 Unknown 0.0011832 0.0343128 
401 Urine 442 946.478 Unknown 0.00011248 0.00326192 
8 Serum 47 573.478 Unknown 6.80E-06 0.001122 
14 Serum 49 577.428 Unknown 6.48E-05 0.010692 
22 Serum 51 575.128 Unknown 0.00012231 0.02018115 
27 Serum 52 571.628 Threonine 
or urea 
7.98E-06 0.0013167 
30 Serum 53 575.774 Unknown 1.32E-05 0.002178 
34 Serum 54 577.453 Unknown 2.09E-05 0.0034485 
45 Serum 56 574.878 Unknown 5.98E-06 0.0009867 
64 Serum 61 575.528 Unknown 3.04E-05 0.005016 
69 Serum 63 576.428 Unknown 6.81E-05 0.0112365 
74 Serum 64 570.778 Urea 3.18E-06 0.0005247 
76 Serum 65 571.903 Threonine 
or urea 
1.26E-06 0.0002079 
81 Serum 66 571.278 Threonine 
or urea 
5.40E-07 8.91E-05 
86 Serum 67 572.201 Unknown 6.39E-07 0.00010543
5 
93 Serum 69 571.028 Threonine 
or urea 
2.35E-06 0.00038775 




106 Serum 71 571.978 Threonine 
or urea 
1.88E-06 0.0003102 
107 Serum 72 572.378 Unknown 1.53E-06 0.00025245 
121 Serum 75 574.929 Unknown 2.24E-06 0.0003696 
133 Serum 78 572.928 Unknown 9.85E-06 0.00162525 
137 Serum 79 570.426 Urea 1.98E-06 0.0003267 
142 Serum 80 570.674 Urea 4.65E-06 0.00076725 
157 Serum 84 575.428 Unknown 1.17E-05 0.0019305 
177 Serum 89 355.368 Unknown 0.00028811 0.04753815 
190 Serum 92 580.328 Unknown 0.0001573 0.0259545 
218 Serum 99 570.728 Urea 6.91E-07 0.00011401
5 








266 Serum 111 571.579 Threonine 
or urea 
1.69E-06 0.00027885 
279 Serum 115 572.628 Unknown 1.70E-05 0.002805 
 
 286 
291 Serum 117 578.178 Unknown 4.32E-05 0.007128 
334 Serum 127 571.479 Threonine 
or urea 
2.73E-06 0.00045045 
355 Serum 132 576.428 Unknown 9.79E-06 0.00161535 
383 Serum 139 570.378 Urea 9.24E-05 0.015246 
389 Serum 140 574.228 Unknown 6.90E-05 0.011385 
390 Serum 141 570.928 Urea 4.17E-06 0.00068805 
428 Serum 151 580.351 Unknown 0.00023489 0.03875685 
446 Serum 155 570.524 Urea 1.63E-06 0.00026895 
455 Serum 157 570.478 Urea 1.72E-06 0.0002838 
490 Serum 166 487.164 Glycerol 7.37E-11 1.22E-08 
500 Serum 169 797.528 Citric acid 0.00025658 0.0423357 
507 Serum 171 570.474 Urea 2.04E-06 0.0003366 
509 Serum 172 570.678 Urea 1.91E-06 0.00031515 
513 Serum 173 570.328 Urea 1.09E-06 0.00017985 
563 Serum 186 570.728 Urea 8.37E-06 0.00138105 
569 Serum 187 571.628 Threonine 
or urea 
7.30E-06 0.0012045 
574 Serum 189 570.078 Urea 3.73E-07 6.15E-05 
576 Serum 190 569.928 Urea 5.27E-07 8.70E-05 
582 Serum 191 569.826 Urea 2.74E-07 4.52E-05 
637 Serum 204 568.779 Urea 0.00011918 0.0196647 
990 Serum 318 829.026 Glucuronic 
acid 
7.71E-05 0.0127215 




The metabolites previously discussed are not repeatd. Biologically relevant metabolites are 










The variable ID 231, identified as uric acid is reduced in the urine of post surgery IBD patients 
compared to healthy controls. Uric acid is a heterocyclic purine derivative that is the final oxidation 
product of purine metabolism. Thiopurines are known to induce and maintain remission of IBD, and 
the methyl thioinosine monophosphate / 6-thioguanine nucleotide concentration ratio has been 
associated with drug efficacy. Most genes that correlate with thiopurine metabolite levels have been 
shown to correlate with disease activity or to participate in networks with candidate IBD susceptibility 
genes involved in processes such as purine metabolism, cytokine signaling, and functioning of 
invariant natural killer T cells, T cells and B cells (Haglund, Almer et al. 2013). Interestingly, levels of 
uric acid in the urine of post surgery IBD patients are lower than in healthy controls. This may be du





























The variable ID identified as glycerol is reduced in the serum of post surgery IBD patients compared 
to healthy controls. Glycerol is an important component of triglycerides and of phospholipids. It 
belongs to the class of organic compounds known as sugar alcohols. When the body uses stored fat as 
a source of energy, glycerol and fatty acids are released into the bloodstream. The glycerol component 
can be converted to glucose by the liver and provides energy for cellular metabolism. Elevated 
glycerol levels have been identified in the faeces of CD when compared to both UC and HC 
(Marchesi J.R., Holmes E. et al. 2007). The reason for this is unknown. In our study we see reduced 
levels of glycerol in the serum of post surgery IBD patients when compared to HCs. This has never 
been investigated in IBD patients, however, in patients undergoing abdominal hysterectomy, increased 
rate of glycerol turnover has been noted postoperativ ly, and increased glycerol concentration in the 
perioperative period (Schricker, Berroth et al. 1997). Our samples were taken 8 weeks post 





























































4.16.3 Experiment 14 Summary 
Urinary metabolites belonging to the super class alkaloids and derivatives, and the classes organic 
disulphides, benzene and substituted derivatives, carboxylic acids and derivatives, azoles, and 2-
arylbenzofuran flavonoids are reduced in post surgical IBD patients when compared to healthy 
controls. Metabolites in the class prenol lipids and glycerolipids are increased in the urine of post 
surgical IBD patients when compared to healthy controls. 
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4.17 Experiment 15: Metabolite Identification Treatment Naïve  v Post Treatment (Paired) 
 
In this experiment we aim to identify metabolites that allow differentiation between treatment naïve 
IBD patients, and those who have undergone treatment. 
 
Table 4.53 Experiment 15 number of samples analysed 
 Treatment Naive Post Treatment 
Serum samples 6 110 
Urine samples 6 109 
 
4.17.1 Experiment 15.1: Metabolite Identification Treatment Naïve  v Post Treatment (Paired) 
UHPLC-FTMS 
 
Table 4.54: Important Variables Identified Treatment Naïve v Post Treatment (Paired) 
UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
time 
p value q value 
302 Serum 272.9491301 45.6825 0.0014647 0.0497998 
  
Table 4.54.1: Mass spectra search for 272.9491301 m/z 



























































































M+2Na+H 272.957349 317.928509 0.0082189 Azobenzene
s 
 
Figure 4.99: Barchart Serum Variable ID 302 UHPLC-FTMS paired sample comparison of treatment 




Variable ID 302 shows reduced serum levels post trea m nt when compared patients are compared to 
their pre treatment drug naïve samples. All of the m tabolites identified are dietary or drug related, 
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302 (After Treatment - Before Treatment)
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4.17.2 Experiment 15.2: Metabolite Identification Treatment Naïve v Post Treatment (Grouped 
Results) GC-ToF-MS 
 
Table 4.55: Putative Metabolites Table 4.41: Putative Metabolites Treatment Naïve v Post Treatment 









p value q value 
589 Serum 193 545.928 Phosphate 0.0001098 0.014823 
 
Figure 4.100: Boxplot Serum Variable ID 589 Phosphate Treatment Naïve v Post Treatment 




In this experiment, the serum variable ID 589 identified as phosphate is lower in treatment naïve 
patients than in those who have been commenced on treatment for IBD. 
 
Phosphate 
Phosphate is from the class non-metal oxoanionic compounds. Hypophosphataemia is associated with 
low albumin, malnutrition and refeeding syndrome (Imel, Econs 2012). In our study, serum phosphate 





























































4.17.3 Experiment 15 Summary 
Metabolites in the class non-metal oxoanionic compounds were found to be increased in the serum of 
drug naïve IBD patients pre treatment compared to post treatment.  
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4.18 Experiment 16: Metabolite Identification Treatment Naïve v Healthy Controls 
 
In this experiment we aim to identify metabolites differentiating between treatment naïve IBD patients 
and HCs. 
 
Table 4.56 Experiment 16 number of samples analysed 
 Treatment Naive Healthy Controls 
Serum samples 6 62 
Urine samples 28 60 
 
4.18.1 Experiment 16.1: Metabolite Identification Treatment Naïve v Healthy Controls UHPLC-
FTMS 
 
Table 4.57: Important Variables Identified Treatment Naïve v Healthy Controls UHPLC-FTMS 
Variable ID Biofluid M/z Retention 
time 
p value q value 
28 Serum 124.9759098 67.42955 0.00036218 0.00796796 
493 Serum 386.7679997 992.1447 0.0021199 0.0466378 
529 Serum 404.2888825 998.1519 0.00013426 0.0029537 
12 Urine 106.0362854 240.0221 0.00011055 0.01006005 
75 Urine 130.0491589 291.87825 0.00018568 0.01689688 
212 Urine 161.0399971 822.8008 4.27E-05 0.0038857 
214 Urine 161.0799605 276.0668 1.07E-06 9.74E-05 
265 Urine 171.0758451 50.5109 0.0002354 0.0214214 
373 Urine 194.9948803 1269.253 0.00015633 0.01422603 
501 Urine 224.0294257 244.16795 4.60E-05 0.004186 
680 Urine 279.1330075 177.2557 5.31E-05 0.0048321 
706 Urine 287.099141 258.5507 0.00019558 0.01779778 
800 Urine 334.0909909 299.601 1.08E-05 0.0009828 
 
Table 4.57.1: Mass spectra search for 124.9759098 m/z 

























hate K salt 
(1:2) 







M+K 124.982179 86.019021 0.0062692 Dihydrothio
phenes 



















M+H+K 124.968484 209.966533 0.0074258 Sulfenyl 
compounds 
 




In this experiment, peak intensities in serum variable ID 28 are higher in treatment naïve IBD patients 
than in healthy controls. Peroxynitrite is a metabolite of biological interest. The rest of the metabolites 
identified are dietary. 
 
Peroxynitrite  
Peroxynitrite belongs to the class of inorganic comp unds known as non-metal peroxynitrites and is a 
potent oxidant synthesised by the cell during its normal metabolism. The peroxynitrite anion (ONOO-
) is a reactive species produced in the reaction between the superoxide anion (O2*-) and nitric oxide 
(*NO). Peroxynitrite (ONOO-) is a strong oxidation and nitration agent, which damages DNA, 



























inflammation, arteriosclerosis, and neurodegenerative and cardiovascular disorders. The 
immunoreactivity of both peroxynitrite-mediated protein nitration and nitric oxide synthase are 
significantly higher in UC than in CD (Kruidenier, Kuiper et al. 2003). 
 
Table 4.57.2: Mass spectra search for 386.7679997 m/z 
















































































In this experiment, peak intensities of serum variable ID 493 were lower in treatment naïve IBD 
patients than in HCs. All of the metabolites identified are dietary in nature. 
 
Table 4.57.3: Mass spectra search for 404.2888825 m/z 




































M+H+K 404.298612 768.62679 0.0097295 Not 
classified 






















































M+H+K 404.298612 768.62679 0.0097295 Not 
classified 
 




In this experiment, peak intensities of serum variable ID 529 were lower in treatment naïve IBD 

























Table 4.57.4: Mass spectra search for 106.0362854m/z 











































M+Na 106.037565 83.048347 0.0012796 Azoles 
HMDB298
62 

































In this experiment, lower peak intensities of urinay variable ID 12 were seen in treatment naïve IBD 
patients compared to HCs. These metabolites have been discussed previously.  
 
Table 4.57.5: Mass spectra search for 130.0491589 m/z 












































































































In this experiment, higher peak intensities of urina y variable ID 75 were seen in treatment naïve IBD


























Table 4.57.6: Mass spectra search for 161.0399971 m/z 



















M+H+Na 161.040309 298.084124 0.0003119 Flavonoids 
HMDB388
11 





























































In this experiment, lower peak intensities of urinay variable ID 212 were seen in treatment naïve IBD
patients compared to HCs. All of the metabolites identified are dietary in nature. 
 
Table 4.57.7: Mass spectral search for 161.0799605 m/z 



































M+H 161.080835 160.073559 0.0008745 Fatty acyls 






























































M+H 161.080835 160.073559 0.0008745 Not 
classified 
 




In this experiment, higher peak intensities of urina y variable ID 214 were seen in treatment naïve 
























Table 4.57.8: Mass spectra search for 171.0758451 m/z 

























M+2Na-H 171.075625 126.104465 0.0002201 Fatty acyls 
HMDB397
69 












































In this experiment, peak intensities of urinary variable 265 are lower in treatment naïve IBD patients 
than in HCs. All of the metabolites identified are di tary or medication related. However, fluvoxamine 
is of interest. 
 
Fluvoxamine 
Fluvoxamine is a selective serotonin reuptake inhibitor antidepressant medication. Recently, its anti-
inflammatory and anti-colitic effects have been shown in colitic rats, and based upon this study 
fluvoxamine has been suggested as the anti-depressant medication of choice in IBD (Minaiyan, 
Hajhashemi et al. 2015). This is not currently clini al practice. 
 
Table 4.57.9: Mass spectra search for 194.9948803 m/z 









































































hate Mg salt 
(1:1) 



















M+H+Na 195.000523 366.004553 0.0056427 Flavonoids 
 
Figure 4.109: Boxplot Urinary Variable ID 373 Treatment Naïve v Healthy Controls UHPLC-FTMS 
 
p=0.00015633 
In this experiment, peak intensities of urinary variable ID 373 are lower in treatment naïve IBD 



























Nucleoside Triphosphate  
Nucleoside triphosphate (NTP) belongs to the class of organic compounds known as c-glycosyl 
compounds. NTPs generally provide energy and a phosphate group f r hosphorylations. Adenosine 
triphosphate is an example of a natural nucleoside triphosphate that is an essential activator of 
inflammasomes (Cauwels, Rogge et al. 2014). Anti-inflammatory medications such as salicylates, 
methotrexate and purine analogs like 6-MP and cyclosporine, exert their therapeutic actions in 
inflammatory diseases by decreasing intracellular adenosine 5’-triphosphate concentrations and 
increasing extracellular adenosine levels. Adenosine contributes to the resolution of inflammation, 
both by down-regulating macrophage activation and by advancing Th2- vs Th1-cell response (Ye, 
Rajendran 2009). In our study we see lower levels of NTP (potentially ATP) in the urine of treatment 




Indane, a hydrocarbon petrochemical compound, belongs to the class of organic compounds known as 
indanes. The indane skeleton is found in therapeutic molecules in medicinal chemistry. A novel 
indane, PH46A, optimised for anti-inflammatory and bioavailability, has been shown to reduce reduce 
histological damage in murine colitis models (Frankish, Sheridan 2012). This compound may have 
potential as a treatment in the future.  
 
Table 4.57.10: Mass spectra search for 224.0294257 m/z 


















































































M+Na 224.025286 201.036068 0.0041397 Benzimidaz
oles 
 




In this experiment, lower peak intensities of urinay variable 501 are seen in treatment naïve IBD 
patients than in HCs. Hippuric acid and adenochrome are identified as metabolites of interest. 
 
Hippuric Acid  
Hippuric acid is an acyl glycine formed by the conjugation of benzoic acid with glycine. It is a gut-
bacteria regulated metabolite that has been show to be reduced in IBD. This is likely due to alteration 
in the gut microbiota rather than dietary benzoate in ake, although the specific gut flora remain 





























Adrenochrome is a pigment obtained by the oxidation of adrenaline. This metabolite was identified as 
being less abundant in CD patients than in HCs in a previous study (Johnston 2014), and although the 
reason remains unclear, we have duplicated these results in our study. 
 
Table 4.57.11: Mass spectra search for 279.1330075 m/z 








































































In this experiment, peak intensities of urinary variable ID 680 are lower in treatment naïve IBD 
patients than in healthy controls. All of the metabolites identified in this group are dietary in nature.  
 
Table 4.57.12: Mass spectra search for 287.099141 m/z 










































































































In this experiment, reduced peak intensities of urinary variable ID 706 are seen in treatment naïve IBD 
patients compared to healthy controls. Di-Hydroxymelatonin, Acetyl-N-formyl-5-































Di-Hydroxymelatonin, a metabolite of melatonin, belongs to the class of organic compounds known 
as serotonins. Melatonin is a powerful antioxidant d free radical scavenger. It also decreases levels 
of TNF-α and can inhibit NF-κB. Melatonin can prevent DSS-induced coltis in mice and rat models. 
In these models, melatonin reversed both the increase in intestinal permeability and influx of bacterial 
endotoxins, and decreased myeloperoxidase and TNF-α activity (Swanson, Burgess et al. 2011). In 
our study, lower levels of a melatonin metabolite ar seen in treatment naïve IBD patients than in 
healthy controls.  
 
Acetyl-N-formyl-5-methoxykynurenamine  
Acetyl-N-formyl-5-methoxykynurenamine, belonging to the class of organic compounds known as 
phenylpropylamines, results from the oxidative cleavage of the pyrrole ring during melatonin 




Tracheloside, found in fats and oils, belongs to the family of lignan glycosides. Trachelogenin, an 
aglycone of tracheloside (Shin, Bae et al. 2015), has been shown to enhance intestinal barrier functio, 
and is seen in greater levels in HCs than in IBD in our study. 
 
Table 4.57.13: Mass spectra search for 334.0909909 m/z 






























































M+2K+H 334.097004 257.177964 0.0060131 Morphinans 
HMDB390
87 
Sudachiin B M+2H 334.097076 666.1796 0.0060851 Flavanoids 
HMDB390
88 
Sudachiin C M+2H 334.097076 666.1796 0.0060851 Not 
classified 
 




In this experiment increased peak intensities of urinary variable ID 800 are seen in healthy controls 
compared to treatment naïve IBD patients. This group f metabolites have been discussed previously, 




























4.18.2 Experiment 16.2: Metabolite Identification Treatment Naïve v Healthy Controls GC-ToF-
MS 
 







Putative match p value q value 
105 Urine 91 1222.228 Hydroxylamine 0.0020794 0.0374292 
186 Urine 143 1024.129 Cellobiose 0.00046286 0.00833148 
338 Urine 259 1024.928 Cellobiose 0.0018524 0.0333432 
 





In this experiment, increased peak intensities of hydroxylamine are seen in the urine of treatment 































Hydroxylamine, utilised in the preparation of oximes and as an intermediate in biological nitrification, 
belongs to the class of inorganic compounds known as homogeneous other non-metal compounds. No 
pathogonomic links are to IBD are identified and these findings are unexplained. 
 






























In our study we see higher peak intensities of cellobiose in the urine of treatment naïve patients than in 
HCs. Cellobiose has been previously discussed. In this treatment naïve IBD patient group, this may 








4.18.3 Experiment 16 Summary 
Serum metabolites in the class benzenes and substituted derivatives, and urinary metabolites in the 
class carbohydrates and carbohydrate conjugates, indoles and derivatives, and benzene and derivatives 
are reduced in drug naïve IBD patients compared to healthy controls. Metabolites in the class 
homogenous other non-metal compounds are increased in the urine of treatment naïve IBD patients 



























4.19 Crohn’s Disease Behaviour, Location, Age at Diagnosis and HBI 
The following experiments, based upon the longitudinal group, aim to determine whether the variables 
identified in the Montreal Classification, and the disease activity score (HBI), have discernable 
metabolomic profiles. 
 
Table 4.59 Experiment 17-20 number of samples analysed 
 Crohn’s Disease 
Serum samples 128 
Urine samples 127 
 
4.19.1 Experiment 17: Crohn’s Disease Behaviour Differentiation 
In experiment 17 we consider the group of patients with Crohn’s disease, and aim to determine 
whether disease behaviour can be differentiated by the metabolic profile. The variables have been 
collected as part of the Montreal Classification;  
B1 non-stricturing non-penetrating,  
B2 stricturing,   
B3 penetrating,  
p concomintant perianal disease.  
The label B4 was allocated to a patient with strictu ing and penetrating disease. 
 
Results are presented by means of principle component analysis plots. PCA allows us to find patterns 
in data of high dimensions, and expressing the datain such a way to highlight the similarities and 
differences. The advantage of using PCA is that once patterns are identified, data is compressed by 
reducing the number of dimensions, without much loss f information. When plotting PCA, each axis 
has an eigenvalue associated with it. The eigenvalue is the amount of variation explained by the axis, 




4.19.2 Experiment 17.1: Crohn’s Disease Behaviour Differentiation Urine Analysis UHPLC-
FTMS 
 
Figure 4.117: PCA Plot UHPLC-FTMS Urine Analysis Grouped by Disease Behaviour 
 
No differentiation is seen between the metabolomic profiles of urine samples from patients with 















4.19.3 Experiment 17.2: Crohn’s Disease Behaviour Differentiation Urine Analysis GC-ToF-MS 
 
Figure 4.118: PCA Plot GC-ToF-MS Urine Analysis Grouped by Disease Behaviour 
 
 
No differentiation is seen between the metabolomic profiles of urine samples from patients with 














4.19.4 Experiment 17.3: Crohn’s Disease Behaviour Differentiation Serum Analysis UHPLC-
FTMS  
 
Figure 4.119: PCA Plot UHPLC-FTMS Serum Analysis Grouped by Disease Behaviour 
 
No differentiation is seen between the metabolomic profiles of serum samples from patients with 
















4.19.5 Experiment 17.4: Crohn’s Disease Behaviour Differentiation Serum Analysis GC-ToF-
MS 
 
Figure 4.120: PCA Plot GC-ToF-MS Serum Analysis Grouped by Disease Behaviour 
 
No differentiation is seen between the metabolomic profiles of serum samples from patients with 










4.19.6 Experiment 17 Summary 
In our study we have not been able to show differentiation between the metabolomic profiles of 
Crohn’s Disease patients in relation to the disease behaviour they are displaying, using either serum or 
urine samples, on UHPLC-FTMS or GC-ToF-MS platforms. 
 
 323 
4.20 Experiment 18: Crohn’s Disease Location Differentiation 
In experiment 18 we consider the group of patients with Crohn’s disease, and aim to determine 
whether disease location can be differentiated by the metabolic profile. The variables have been 
collected as part of the Montreal Classification;  
L1 ileal, 
L2 colonic,   
L3 ileocolonic,  
L4 isolated upper GI diease*.  
*L4 is a modified that can be added to L1–L3 when co cominant upper GI disease is present. 
 
As in experiment 17, the results are presented by means of PCA plots.  
 
4.20.1 Experiment 18.1: Crohn’s Disease Location Differentiation Urine Analysis UHPLC-
FTMS 
 
Figure 4.121: PCA Plot UHPLC-FTMS Urine Analysis Grouped by Disease Location 
 
No differentiation is seen between the metabolomic profiles of urine samples from patients with 
Crohn’s Disease in relation to disease location on the UHPLC-FTMS platform. 
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4.20.2 Experiment 18.2: Crohn’s Disease Location Differentiation Urine Analysis GC-ToF-MS 
 
Figure 4.122: PCA Plot GC-ToF-MS Urine Analysis Grouped by Disease Location 
 
No differentiation is seen between the metabolomic profiles of urine samples from patients with 

















4.20.3 Experiment 18.3: Crohn’s Disease Location Differentiation Serum Analysis UHPLC-
FTMS 
 
Figure 4.123: PCA Plot UHPLC-FTMS Serum Analysis Grouped by Disease Location 
 
No differentiation is seen between the metabolomic profiles of serum samples from patients with 

















4.20.4 Experiment 18.4: Crohn’s Disease Location Differentiation Serum Analysis GC-ToF-MS 
 
Figure 4.124: PCA Plot GC-ToF-MS Serum Analysis Grouped by Disease Location 
 
No differentiation is seen between the metabolomic profiles of serum samples from patients with 










4.20.5 Experiment 18 Summary 
In our study we have not been able to show differentiation between the metabolomic profiles of 
Crohn’s Disease patients in relation to the disease location, using either serum or urine samples, on 
UHPLC-FTMS or GC-ToF-MS platforms. 
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4.21 Experiment 19: Crohn’s Disease Age at Diagnosis Differentiation 
In experiment 19 we consider the group of patients with Crohn’s disease, and aim to determine 
whether age at diagnosis can be differentiated by the metabolic profile. The variables have been 
collected as part of the Montreal Classification;  
A1 below 16 years, 
A2 between 17 and 40 years,   
A3 above 40 years,  
 
As in experiment 17 and 18, the results are presentd by means of PCA plots.  
 
4.21.1 Experiment 19.1: Crohn’s Disease Age at Diagnosis Differentiation Urine Analysis 
UHPLC-FTMS 
 





4.21.2 Experiment 19.2: Crohn’s Disease Age at Diagnosis Differentiation Urine Analysis GC-
ToF-MS 
 




4.21.3 Experiment 19.3: Crohn’s Disease Age at Diagnosis Differentiation Serum Analysis 
UHPLC-FTMS 
 




4.21.4 Experiment 19.4: Crohn’s Disease Age at Diagnosis Differentiation Serum Analysis GC-
ToF-MS 
 













4.21.5 Experiment 19 Summary 
In our study we have not been able to show differentiation between the metabolomic profiles of 
Crohn’s Disease patients in relation to the age at disease diagnosis, using either serum or urine 
samples, on UHPLC-FTMS or GC-ToF-MS platforms. 
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4.22 Experiment 20: Crohn’s Disease Differentiation by HBI 
 
In Experiment 20 we consider the group of patients with Crohn’s disease, and aim to determine 
whether the disease activity score (HBI) can be differentiated by the metabolic profile. 
 
Spearman’s rank correlation coefficient (rs) is a nonparametric measure of statistical dependence 
between two variables. The sign of the Spearman correlation indicates the direction of association 
between x (the independent variable) and y (the dependent variable). If y tends to increase when x 
increases, the Spearman correlation coefficient is positive. If y tends to decrease when x increases, it 
is negative. When x and y are perfectly monotonically related, the Spearman correlation coefficient 
becomes +1 or -1. Correlation is an effect size, thus we can describe the strength of the correlation. 
 
Table 4.60: Strength of the Spearman’s rank correlation coefficient 
r s Strength of the correlation 
0.00 – 0.19 Very Weak 
0.20 – 0.39 Weak 
0.40 – 0.59 Moderate 
0.60 – 0.79 Strong 
0.80 – 1.0 Very Strong 
 
As previously discussed, due to the complexity of the data analysed in the longitudinal group with 
multiple testing, FDR correction rather than Bonferroni is used in the following experiments.  
In this experiment, variables were deemed significant if both the p and the q value were <0.05. 
 
4.22.1 Experiment 20.1: Crohn’s Disease Differentiation by HBI Urine Analysis UHPLC-FTMS 
 
Table 4.61: Important Variables Identified UHPLC-FTMS Urine Analysis by HBI 
Variable ID Spearman Rank p value q value 
646 0.2443 0.0063 0.946268605 
667 -0.2339 0.0089 0.946268605 
60 0.216 0.016 0.946268605 
446 -0.197 0.0283 0.946268605 
111 0.1965 0.0287 0.946268605 
471 0.1954 0.0297 0.946268605 
617 0.1915 0.0331 0.946268605 
180 0.1912 0.0334 0.946268605 
194 0.1895 0.035 0.946268605 
566 0.1856 0.039 0.946268605 
622 0.1844 0.0403 0.946268605 
407 -0.1788 0.0469 0.946268605 
371 0.1785 0.0473 0.946268605 
 
All of the variables identified were very weakly orweakly associated with the HBI. None of the 
variables identified maintained significance in relation to the HBI following FDR correction (q value). 
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4.22.2 Experiment 20.2: Crohn’s Disease Differentiation by HBI Urine Analysis GC-ToF-MS 
 
Table 4.62: Important Variables Identified GC-ToF-MS Urine Analysis by HBI 
Variable ID Spearman Rank p value q value 
208 0.2178 0.0143 0.926296678 
44 0.2085 0.0192 0.926296678 
29 0.1826 0.0407 0.926296678 
24 0.1802 0.0435 0.926296678 
 
All of the variables identified were very weakly orweakly associated with the HBI. None of the 





4.22.3 Experiment 20.3: Crohn’s Disease Differentiation by HBI Serum Analysis UHPLC-FTMS 
 
Table 4.63: Important Variables Identified UHPLC-FTMS Serum Analysis by HBI 
Variable ID Spearman Rank p value q value 
178 0.2535 0.004 0.353871429 
23 -0.2514 0.0044 0.353871429 
443 0.2483 0.0049 0.353871429 
105 0.2423 0.0061 0.353871429 
318 -0.2412 0.0063 0.353871429 
396 -0.2414 0.0063 0.353871429 
436 -0.2384 0.0069 0.353871429 
163 0.2259 0.0107 0.381845455 
174 0.2255 0.0108 0.381845455 
496 -0.2256 0.0108 0.381845455 
55 -0.2232 0.0117 0.381845455 
442 0.2143 0.0155 0.463708333 
399 -0.21 0.0178 0.470923529 
9 -0.2077 0.0191 0.470923529 
16 -0.2033 0.0219 0.470923529 
27 0.2027 0.0223 0.470923529 
341 -0.2027 0.0223 0.470923529 
235 -0.1957 0.0274 0.521494737 
226 -0.1955 0.0276 0.521494737 
15 -0.1906 0.0318 0.547047619 
354 -0.1904 0.032 0.547047619 
548 -0.1877 0.0346 0.564609091 
195 -0.1855 0.0368 0.567872727 
30 0.1843 0.0381 0.567872727 
462 -0.1819 0.0407 0.567872727 
299 -0.1768 0.0468 0.567872727 
482 -0.1755 0.0484 0.567872727 
 
All of the variables identified were very weakly orweakly associated with the HBI. None of the 




4.22.4 Experiment 20.4: Crohn’s Disease Differentiation by HBI Serum Analysis GC-ToF-MS 
 
Table 4.64: Important Variables Identified GC-ToF-MS Serum Analysis by HBI 
Variable ID Spearman Rank p value q value 
985 -0.3114 0.0004 0.7632 
1018 -0.2815 0.0013 0.776613486 
1468 -0.246 0.0053 0.776613486 
197 -0.2437 0.0058 0.776613486 
1464 -0.2347 0.0079 0.776613486 
1742 -0.2302 0.0092 0.776613486 
1009 -0.2294 0.0095 0.776613486 
1227 -0.228 0.0099 0.776613486 
487 0.2261 0.0106 0.776613486 
320 -0.2213 0.0124 0.776613486 
1284 -0.2199 0.013 0.776613486 
1641 -0.2183 0.0137 0.776613486 
560 -0.2181 0.0138 0.776613486 
622 -0.2114 0.017 0.776613486 
394 -0.2098 0.0179 0.776613486 
1368 0.2069 0.0196 0.776613486 
1532 0.2054 0.0205 0.776613486 
1059 -0.2041 0.0214 0.776613486 
1206 -0.2033 0.0219 0.776613486 
1764 0.2024 0.0225 0.776613486 
1629 -0.2013 0.0232 0.776613486 
983 -0.2002 0.0241 0.776613486 
1421 -0.2001 0.0241 0.776613486 
849 -0.1999 0.0242 0.776613486 
1013 -0.1987 0.0252 0.776613486 
1329 -0.1985 0.0252 0.776613486 
1760 -0.1983 0.0255 0.776613486 
1064 -0.198 0.0257 0.776613486 
1292 0.1955 0.0276 0.776613486 
493 -0.1935 0.0293 0.776613486 
1460 0.1899 0.0325 0.776613486 
619 -0.1896 0.0327 0.776613486 
1182 -0.1894 0.033 0.776613486 
1280 -0.1887 0.0336 0.776613486 
1155 -0.1883 0.034 0.776613486 
727 -0.1876 0.0347 0.776613486 
1371 -0.1874 0.0349 0.776613486 
755 -0.187 0.0353 0.776613486 
1004 -0.1864 0.0359 0.776613486 
534 -0.1859 0.0364 0.776613486 
1750 0.1843 0.038 0.776613486 
1504 0.1843 0.0381 0.776613486 
338 -0.183 0.0394 0.776613486 
688 -0.183 0.0394 0.776613486 
769 -0.1828 0.0397 0.776613486 
1225 -0.1827 0.0398 0.776613486 
951 -0.1824 0.0401 0.776613486 
1023 -0.1819 0.0406 0.776613486 
1113 -0.182 0.0406 0.776613486 
1179 0.1818 0.0408 0.776613486 
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1591 -0.1815 0.0411 0.776613486 
1820 -0.181 0.0417 0.776613486 
954 -0.1803 0.0425 0.776613486 
1199 -0.1802 0.0427 0.776613486 
1859 0.1801 0.0427 0.776613486 
864 -0.1792 0.0438 0.776613486 
1756 -0.1785 0.0446 0.776613486 
1461 -0.1784 0.0448 0.776613486 
1523 0.1781 0.0451 0.776613486 
245 -0.178 0.0452 0.776613486 
1050 -0.1769 0.0466 0.776613486 
1223 0.1767 0.0469 0.776613486 
352 -0.1762 0.0475 0.776613486 
621 -0.1762 0.0475 0.776613486 
1374 -0.1757 0.0481 0.776613486 
1443 0.1753 0.0487 0.776613486 
157 -0.1745 0.0497 0.776613486 
 
All of the variables identified were very weakly orweakly associated with the HBI. None of the 






















4.22.5 Experiment 20 Summary 
HBI analysis did not reveal any significant associations between disease activity score and identified 
variables on either UHPLC-FTMS or GC-ToF-MS platforms for both urine and serum samples. 
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4.23 Ulcerative Colitis Extent of Disease and SCCAI 
The following experiments, based upon the longitudinal group, aim to determine whether the extent of 
disease identified in the Paris Classification, andthe disease activity score (SCCAI), have discernable 
metabolomic profiles. 
 
4.23.1 Experiment 21: Ulcerative Colitis Extent of Disease Differentiation 
In experiment 21 we consider the group of patients wi h ulcerative colitis, and aim to determine 
whether the extent of disease can be differentiated by the metabolic profile. The variables have been 
collected as part of the Paris Classification;  
E1 ulcerative proctitis,  
E2 Left-sided UC (distal to splenic flexure), 
E2+ Left-sided UC (extending beyond the limitation of the endoscopic examination),   
E3 Extensive (hepatic flexure distally),  
E4 Pancolitis (proximal to hepatic flexure). 
 
As in experiment 17 – 19, results are presented by means of principle component analysis plots.  
 
Table 4.65 Experiment 21-22 number of samples analysed 
 Ulcerative Colitis 
Serum samples 127 




4.23.2 Experiment 21.1: Ulcerative Colitis Extent of Disease Differentiation Urine Analysis 
UHPLC-FTMS 
 




4.23.3 Experiment 21.2: Ulcerative Colitis Extent of Disease Differentiation Urine Analysis GC-
ToF-MS 
 




4.23.4 Experiment 21.3: Ulcerative Colitis Extent of Disease Differentiation Serum Analysis 
UHPLC-FTMS 
 




4.23.5 Experiment 21.4: Ulcerative Colitis Extent of Disease Differentiation Serum Analysis GC-
ToF-MS 
 













4.23.6 Experiment 21 Summary 
In our study we have not been able to show differentiation between the metabolomic profiles of 
ulcerative colitis patients in relation to the disea  extent, using either serum or urine samples, on 
UHPLC-FTMS or GC-ToF-MS platforms. 
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4.24 Experiment 22: Ulcerative Colitis Differentiation by SCCAI 
 
In Experiment 22 we consider the group of patients with Ulcerative Colitis, and aim to determine 
whether the disease activity score (SCCAI) can be diff rentiated by the metabolic profile. As in 
experiment 19, Spearman’s rank correlation coefficint is used to determine association, and  FDR 
correction rather than Bonferroni is used.  
In this experiment, variables were deemed significant if both the p value and the q value (FDR 
corrected) were <0.05. 
 
4.24.1 Experiment 22.1: Ulcerative Colitis Differentiation by SCCAI Urine Analysis UHPLC-
FTMS 
 
Table 4.66: Important Variables Identified UHPLC-FTMS Urine Analysis by SCCAI 
Variable ID Spearman Rank p value q value 
188 -0.29629 0.001592 0.464688 
334 -0.29046 0.001984 0.28969 
2 -0.28521 0.002412 0.234749 
232 0.274366 0.003568 0.260406 
277 -0.27252 0.003808 0.222351 
15 -0.27116 0.003994 0.194335 
187 0.266453 0.004702 0.196107 
176 0.265454 0.004866 0.177579 
304 -0.25685 0.006503 0.210944 
90 0.255876 0.006717 0.196091 
72 -0.24401 0.009856 0.261587 
261 0.242461 0.010349 0.251786 
178 0.23933 0.011412 0.256281 
81 -0.23748 0.012082 0.251965 
191 0.233673 0.013576 0.26423 
308 -0.22895 0.015647 0.285505 
245 0.22869 0.015769 0.270815 
314 -0.22846 0.01588 0.257567 
54 0.221457 0.019498 0.299612 
25 0.217558 0.021807 0.31833 
28 0.216799 0.022283 0.309787 
173 -0.20936 0.027438 0.364114 
315 -0.20822 0.028308 0.359333 
250 0.204725 0.031132 0.378718 
155 -0.2039 0.03183 0.371714 
107 0.199955 0.035369 0.397154 
125 0.196776 0.038454 0.415809 
168 0.195812 0.039433 0.411162 
123 -0.1945 0.040801 0.41076 
31 -0.19446 0.040843 0.397479 
249 0.193916 0.041419 0.390081 
104 -0.1914 0.044181 0.403084 
180 0.189023 0.046935 0.41524 
189 0.188983 0.046983 0.403434 
278 0.188525 0.047529 0.39646 
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327 -0.18792 0.048263 0.3914 
 
All of the variables identified were very weakly orweakly associated with the SCCAI. None of the 





4.24.2 Experiment 22.2: Ulcerative Colitis Differentiation by SCCAI Urine Analysis GC-ToF-
MS 
 
Table 4.67: Important Variables Identified GC-ToF-MS Urine Analysis by SCCAI 
Variable ID Spearman Rank p value q value 
133 -0.43547 1.78E-06 6.79E-04 
30 -0.3442 0.000216 0.041225 
326 -0.31263 0.000836 0.060962 
281 -0.3068 0.001056 0.060962 
204 -0.3046 0.001152 0.060962 
36 -0.30093 0.00133 0.060962 
113 -0.29793 0.001494 0.060962 
223 -0.29766 0.00151 0.060962 
82 -0.29636 0.001587 0.060962 
14 -0.29615 0.0016 0.060962 
70 -0.28874 0.002117 0.073309 
184 -0.281 0.002814 0.089332 
283 -0.2747 0.003526 0.091106 
39 -0.27291 0.003757 0.091106 
174 -0.27205 0.003871 0.091106 
3 -0.27099 0.004017 0.091106 
249 -0.27065 0.004065 0.091106 
220 -0.26629 0.004728 0.100073 
236 -0.26278 0.00533 0.100678 
260 -0.26264 0.005356 0.100678 
310 -0.26159 0.005549 0.100678 
91 -0.25078 0.007936 0.131286 
101 -0.24796 0.008691 0.131286 
275 -0.24711 0.00893 0.131286 
149 -0.24658 0.009083 0.131286 
394 -0.24605 0.009239 0.131286 
205 -0.24514 0.00951 0.131286 
393 -0.24332 0.010074 0.131286 
397 -0.24306 0.010157 0.131286 
37 -0.2425 0.010337 0.131286 
391 -0.23829 0.011785 0.136868 
103 -0.23729 0.012155 0.136868 
50 -0.23649 0.012456 0.136868 
130 -0.23647 0.012465 0.136868 
44 -0.23594 0.01267 0.136868 
7 -0.23439 0.013282 0.136868 
74 -0.23429 0.013322 0.136868 
239 -0.23349 0.013651 0.136868 
305 -0.2308 0.014808 0.144659 
388 -0.22799 0.016102 0.14879 
131 -0.22614 0.017008 0.14879 
173 -0.22562 0.017268 0.14879 
27 -0.22506 0.017554 0.14879 
330 -0.22439 0.017902 0.14879 
235 -0.22399 0.018113 0.14879 
344 -0.223 0.018646 0.14879 
68 -0.2229 0.018699 0.14879 
222 -0.22216 0.019106 0.14879 
 
 344 
278 -0.22211 0.019136 0.14879 
264 -0.22087 0.019831 0.149815 
98 -0.21961 0.020565 0.149815 
215 -0.21887 0.021006 0.149815 
323 -0.21833 0.021334 0.149815 
398 -0.2174 0.021904 0.149815 
43 -0.21689 0.022227 0.149815 
52 -0.21613 0.02271 0.149815 
200 -0.21599 0.022796 0.149815 
261 -0.21575 0.022957 0.149815 
160 -0.21486 0.023537 0.149815 
309 -0.21337 0.024544 0.149815 
42 -0.21236 0.025248 0.149815 
234 -0.21216 0.025386 0.149815 
338 -0.21195 0.02554 0.149815 
401 -0.21147 0.02588 0.149815 
116 -0.21141 0.025921 0.149815 
38 -0.2112 0.026072 0.149815 
300 -0.21065 0.026473 0.149815 
245 -0.2099 0.027028 0.149815 
288 -0.20932 0.027468 0.149815 
77 -0.20919 0.027565 0.149815 
53 -0.2085 0.028088 0.149815 
399 -0.2081 0.028401 0.149815 
356 -0.20732 0.029015 0.149815 
21 -0.20707 0.029209 0.149815 
241 -0.20667 0.029536 0.149815 
221 -0.20623 0.029884 0.149815 
5 -0.20541 0.030562 0.150146 
364 -0.20506 0.03085 0.150146 
315 -0.20443 0.031384 0.150146 
78 -0.20426 0.031527 0.150146 
20 -0.20296 0.032649 0.153573 
2 -0.20081 0.034578 0.158321 
343 -0.20067 0.034704 0.158321 
23 -0.20045 0.034905 0.158321 
216 -0.1994 0.035892 0.158577 
154 -0.19876 0.036503 0.158577 
318 -0.19869 0.036571 0.158577 
118 -0.19863 0.036627 0.158577 
167 -0.19617 0.039065 0.163111 
231 -0.19554 0.039712 0.163111 
363 -0.19521 0.040052 0.163111 
402 -0.19428 0.041036 0.163111 
279 -0.19426 0.041055 0.163111 
54 -0.19404 0.041291 0.163111 
327 -0.19397 0.041358 0.163111 
161 -0.1932 0.04219 0.163111 
151 -0.19308 0.042325 0.163111 
121 -0.19272 0.042713 0.163111 
304 -0.19247 0.042992 0.163111 
11 -0.19209 0.04341 0.163111 
317 -0.19162 0.043931 0.163111 
166 -0.19152 0.044046 0.163111 




Only variable ID 133 (moderately associated) and variable ID 30 (weakly associated) are significantly 
related to the SCCAI following FDR correction. They are both unknown metabolites. 
 
292 -0.19071 0.044968 0.164739 
163 -0.1899 0.045902 0.165824 
90 -0.1897 0.046135 0.165824 
203 -0.1889 0.047078 0.166565 
126 -0.18879 0.047215 0.166565 
66 -0.18825 0.04786 0.16708 
320 -0.18784 0.048354 0.16708 
319 -0.18745 0.048837 0.16708 
259 -0.18722 0.049115 0.16708 
117 -0.18674 0.049709 0.167604 
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4.24.3 Experiment 22.3: Ulcerative Colitis Differentiation by SCCAI Serum Analysis UHPLC-
FTMS 
 
Table 4.68: Important Variables Identified UHPLC-FTMS Serum Analysis by SCCAI 
 
All of the variables identified were very weakly orweakly associated with the SCCAI. None of the 
variables identified maintain significance in relation to the SCCAI following FDR correction (q 
value). 
 
Variable ID Spearman Rank p value q value 
115 -0.2539 0.006414 1 
123 0.236886 0.011161 1 
81 -0.23646 0.011314 0.868529 
142 -0.23407 0.01219 0.70187 
336 -0.22619 0.015526 0.715166 
35 0.216186 0.020878 0.801372 
138 -0.21071 0.024427 0.803659 
90 0.210203 0.024784 0.713479 
79 -0.20179 0.031317 0.801374 
247 -0.19449 0.03812 0.877929 
169 -0.19369 0.038934 0.815163 
170 -0.18929 0.043689 0.83848 
243 -0.18587 0.047702 0.845082 
93 -0.18429 0.049661 0.816937 
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4.24.4 Experiment 22.4: Ulcerative Colitis Differentiation by SCCAI Serum Analysis GC-ToF-
MS 
 
Table 4.69: Important Variables Identified GC-ToF-MS Serum Analysis by SCCAI 
Variable ID Spearman Rank p value q value 
904 -0.32232 0.00047 0.636686 
886 0.295282 0.001426 0.965727 
1788 -0.29281 0.001569 0.70884 
1189 0.280751 0.002481 0.840365 
1648 -0.27798 0.002749 0.74484 
1731 -0.27369 0.003214 0.725826 
907 -0.26672 0.004124 0.798165 
606 -0.26238 0.0048 0.813013 
1814 -0.25861 0.005466 0.822821 
759 0.250557 0.007172 0.971701 
723 0.249251 0.007489 0.922439 
501 0.24355 0.009023 1 
567 0.241833 0.009536 0.993891 
23 -0.24057 0.009931 0.96109 
387 0.238057 0.010756 0.971585 
969 0.237242 0.011037 0.934626 
1570 0.236747 0.011211 0.893497 
892 0.231676 0.013131 0.988392 
1589 -0.22956 0.014014 0.999351 
264 -0.22704 0.015131 1 
199 0.226184 0.015528 1 
903 0.225791 0.015714 0.967772 
438 0.225279 0.015958 0.940084 
1482 0.222854 0.01716 0.968773 
1787 0.222072 0.017564 0.951927 
1475 -0.21929 0.019068 0.993702 
1371 -0.21788 0.019874 0.997344 
571 0.217276 0.020227 0.978769 
1479 -0.21291 0.022948 1 
802 -0.21239 0.023289 1 
1004 0.207581 0.026682 1 
664 0.207544 0.02671 1 
1291 -0.20614 0.027782 1 
816 0.205263 0.028463 1 
1079 -0.20476 0.02886 1 
658 -0.20451 0.029064 1 
902 -0.20449 0.029077 1 
613 -0.20339 0.029974 1 
975 0.203006 0.030293 1 
186 0.20256 0.030667 1 
859 0.202417 0.030787 1 
624 0.202273 0.030909 0.997113 
1880 0.202179 0.030988 0.97644 
974 0.201704 0.031394 0.966731 
1761 0.201507 0.031563 0.950338 
1196 -0.20068 0.032279 0.950777 
1869 0.199689 0.033163 0.956039 




All of the variables identified were very weakly orweakly associated with the SCCAI. None of the 







4.24.5 Experiment 22 Summary 
In this experiment only 2 statistically significant variables were identified, both during analysis of 
urine samples on the GC-ToF-MS platform. Unfortunately they are both unknown metabolites. 
Analysis of serum and urine on the UHPLC-FTMS platform and serum on the GC-ToF-MS platform 
did not identify any significant metabolites in relation to the SCCAI. 
998 0.199529 0.033307 0.920994 
622 0.199492 0.03334 0.903475 
429 0.199357 0.033463 0.889006 
682 -0.19893 0.033854 0.882106 
451 0.198821 0.033951 0.867955 
534 -0.19702 0.035638 0.894189 
900 0.196572 0.036066 0.888485 
1387 0.196089 0.036535 0.883959 
57 0.195913 0.036707 0.87254 
737 -0.19564 0.036976 0.863791 
611 0.194946 0.037663 0.864928 
1241 -0.19467 0.037943 0.856823 
586 -0.19459 0.038021 0.844518 
835 0.193525 0.039107 0.854639 
1713 -0.19331 0.039328 0.845813 
945 0.191588 0.041151 0.871187 
923 0.191432 0.041318 0.861284 
1360 -0.19132 0.041438 0.850692 
1610 0.191199 0.041571 0.840691 
159 0.190506 0.042329 0.843425 
1571 -0.18751 0.045741 0.898191 
1667 0.187472 0.045789 0.886293 
906 0.187349 0.045934 0.876575 
1491 0.186812 0.046571 0.876389 
30 0.186276 0.047215 0.876345 
1642 0.18603 0.047513 0.869951 
548 0.185825 0.047762 0.862854 
714 0.185416 0.048264 0.860444 
1893 0.185207 0.048521 0.853801 
256 -0.18512 0.048633 0.84479 
1228 0.184957 0.048831 0.837494 
316 0.184895 0.048907 0.828318 









5.1 Results Overview 
This is the first study in human IBD in which paired and longitudinal sampling methodologies have 
been employed to investigate metabolomic profiles in various disease states and in relation to certain 
treatments. The utilisation of two biofluids, serum and urine, on UHPLC-FTMS and GC-ToF-MS 
analytical platforms allows us significant insight in o the human metabolome in IBD, and is therefore 
a useful discovery study. 
 
5.2 Comparison to Previous Work: UC v CD v HC 
The initial experiments carried out in our study allow us to make a comparison with previous work 
carried out by the group working under Professor Goodacre in Manchester Institute of Biotechnology 
(Johnston 2014). By following the same rigourous sample collection and preparation procedures, it is 
possible to draw comparisons between their study and my own, although the previous study was 
carried out purely on a male population to avoid hormonal variation, and used single sample sets 
rather than paired or multiple sets of samples. Johnst n et al identified the following classes to show 
most differentiation between healthy controls and IBD patients; Vitamin D and its metabolites, 
steroids and their derivatives, fatty acids, bile acids, phospholipids and phosphocholine. They 
specifically found that sphingolipids were exclusively decreased within the CD cohort compared to 
the control group and isoprenoids were decreased in the UC cohort compared to controls.  
Interestingly, despite my cohort of patients being from a region significantly further North in the UK 
than the cohort studied by the Manchester group, vitamin D and its metabolites was not identified as a 
significant descriminant between IBD patients and HCs. A feasible explanation for this may be 
reduced levels throughout the entire study population including the HCs, thus no differentiation was 
identified. There is growing evidence that vitamin D may play a role in IBD pathogenesis, and 
potentially may have a therapeutic function (Hlavaty, Krajcovicova et al. 2015). An interesting follow 
up to both of these studies would be a direct comparison of the metabolomic profiles of IBD patients 
in the North of Scotland and IBD patients in the North of England, specifically searching for vitamin 
D and its metabolites. 
In our study, we identified metabolites in the classes; fatty acyls, carboxylic acids and derivatives, 
carbohydrate and carbohydrate conjugates to be reduced in IBD compared to HCs. 
The following specific metabolites have been identified as of biological relevance in our study: N-
Acetylglutamine, Ethyl 1-(propylthio)propyl disulfide, Butyl 1-(methylthio)propyl disulfide, 4-
Thiocyanatophenol, 5-aminoimidazole, imidazole-4-acet ldehyde, alternariol, hydroxyl-alpha-
sanshool, propanetricarboxylic acid, threonine, dihy roxybutanoic acid, serine, fructose, 
aminomalonic acid, glucaronic acid, pentanoic acid, galactose, cellobiose and myo-insitol. 
 
5.3 IBD Surgery Patients 
This is the first study in human IBD metabolomics to consider patients undergoing surgical 
management of their disease, and the effects that may be translated into their profile. During the 
various experiments carried out on this patient group, we were able to utilise both grouped and paired 
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sample analyses.  
Initially we compared pre and post surgical patients, and found that we were unable to differentiate 
between their profiles using either serum or urine samples, on either the GC-ToF-MS, or the UHPLC-
FTMS platforms. We were, however, able to differentiate between surgical IBD patients and healthy 
controls. Urine samples showed more significant differentiation than serum samples, and urine 
samples analysed on the UHPLC-FTMS platform were the most significantly differential of all. 
Specific metabolite identification revealed cholesterol, 5-beta-cholestan-3-one, lathosterol, erythritol, 
propanetricarboxylic acid, 3’-hydroxy-3,4,5,4’-tetramethoxystilbene, biliverdin, N-Acetylglutamine, 
ethyl 1-(propylthio)propyl disulfide, butyl 1-(methylthio)propyl disulfide and 4-thiocyanatophenol, 5-
aminoimidazole, 12,13-DHOME, 9,10-DHOME, methyl-cysteine, cysteinyl-methionine, 8-
hydroxyguanosine, myricetine 3,3’-digalactoside, octanoic acid, citric acid, oleic acid, uric acid, 
retinyl ester, 2-arachidonylglycerol, monoacylglycerid s and glycerol to be of relevance.  
Metabolite identification experiments showed metabolites in the classes organic disulphides, benzene 
and substituted derivatives, carboxylic acids and derivatives, azoles, and fatty acyls to be decreased in 
both urine and serum samples of pre surgery IBD patients in comparison to healthy controls. 
Metabolites in the class carbohydrates and carbohydrate conjugates are increased in the urine of pre 
surgery IBD patients compared to healthy controls. 
In post surgery IBD patients, urinary metabolites belonging to the super class alkaloids and 
derivatives, and the classes organic disulphides, bnzene and substituted derivatives, carboxylic acids 
and derivatives, azoles, and 2-arylbenzofuran flavonoids are reduced when compared to healthy 
controls. Metabolites in the class prenol lips and glycerolipids are increased in the urine of post 
surgical IBD patients when compared to healthy controls. 
 
5.4 Biological Therapy Patients 
Again, this is a novel study in human IBD metabolomics, to consider patients undergoing biological 
therapy for their disease, and how their metabolomic profile may be affected by this treatment. During 
the various experiments carried out on this patient group, we were able to utilise both grouped and 
paired sample analyses. Initially we aimed to determine whether we could differentiate between pre 
and post biological therapy patients. We did not find any significant difference between the 
metabolomic profiles of pre- and post-biological therapy IBD patients when comparing either serum 
or urine samples on either UHPLC-FTMS  or GC-ToF-MS platforms. We also found that we were not 
able to differentiate IBD patients undergoing biological therapy from healthy controls using either 
biofluid on either analytic platform. 
Metabolite identification experiments showed higher l vels of urinary metabolites in the class 
carboxylic acid and derivatives in pre biological therapy IBD patients compared to both post 
biological therapy IBD patients and healthy controls. In the post biological therapy IBD patients, 
higher levels of urinary fatty acyls and imidazole ribonucleosides and nucleotides were identified, as 
well as increased serum fatty alcohols, in comparison to healthy controls. 
Specific metabolite identification revealed calystegin  A3, 3-dehydrocarnitine, N-acetylvaline, 
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acetamide, lactose, 8-hydroxyguanosine, myricetin 3,3’-digalactoside, propanetricarboxylic acid, 
glycine, s-aminomethylduhydrolipoamide, phenylalany-arginine, arginyl-phenylalanine, 
pyrrolidonecarboylic acid, pyroglutamic acid, imidazoleacetic acid riboside, and ortho- and para-
hydroxyatorvastatin to be of biological interest in IBD.  
Interesting, Johnston at el (Johnston 2014) showed lower levels of carnitine in CD patients compared 
to healthy controls. In this study we showed increased levels of urinary 3-dehydrocarnitine, an 
intermediate in carnitine degradation, in pre biological therapy IBD patients compared to post 
biological therapy patients. Carnitine has anti-oxidant properties, reducing myeloperoxidase and 
malondialdehyde, and upregulating superoxide dismutase preventing the reduction of glutathione. It 
inhibits lipid peroxidation of phospholipid membranes therefore suppressing the formation and 
activation of reactive oxygen species, and inhibiting the NF-κB pathway. Carnitine is required for β-
oxidation and therefore carnitine transporters, coded for by OCTN genes, have been implicated in IBD 
susceptibility, with reduced carnitine absorption leading to impaired fatty acid oxidation in intestinal 
epithelial cells, and cell injury (Moeinian, Farnaz Ghasemi-Niri et al. 2013). The increased urinary 
secrection in pre biological therapy IBD patients we have identified may be an indication that 
carnitine is not being utilised well in patients with active IBD.  
Recently, in a rat IBD model, the combined effects of treatment with butyrate, Lactobacillus casei and 
L-carnitine showed a significantly beneficial effect in the alleviation of colitis (Moeinian, Ghasemi-
Niri et al. 2014). Further investigation of this sub tance in relation to IBD is warrented in view of its 
significance in two separate metabolomic IBD studies, and its potential to translate into therapeutic 
clinical practice.  
 
5.5 Treatment Naïve Patients 
In this study, the group of treatment naïve patients was very small and thus any conclusions drawn 
must be interpreted with care. Specific metabolite id ntification deemed phosphate, peroxynitrite, 
nucleoside triphosphate, indane, di-hydroxymelatonin, acetyl-N-formyl-5-methoxykynurenamine, 
tracheloside, hippuric acid, adrenochrome, hydroxylamine and cellobiose of biological importance. 
Metabolites in the class non-metal oxoanionic compounds were found to be increased in the serum of 
drug naïve IBD patients pre treatment compared to post treatment. Serum metabolites in the class 
benzenes and substituted derivatives, and urinary metabolites in the class carbohydrates and 
carbohydrate conjugates, indoles and derivatives, and benzene and derivatives are reduced in drug 
naïve IBD patients compared to healthy controls. Metabolites in the class homogenous other non-
metal compounds are increased in the urine of treatm nt naïve IBD patients compared to healthy 
controls.  
 
5.6 Longitudinal Sampling Patients 
This is the first study in IBD and metabolomic profiling to collect longitudinal biofluid samples and 
use participants as their own internal controls. Meticulous collection of patient phenotype, and disease 
activity score at each sampling episode was imperativ  to allow appropriate comparisons to be drawn. 
 
 353 
This research methodology, which was carefully constructed in collaboration with Professor Roy 
Goodacre and Dr Warwick Dunn, has allowed the opportunity to study the effects on the metabolomic 
profile of disease behaviour, location and age at di gnosis in Crohn’s disease patients (Montreal 
Classification), and of disease extent in ulcerative colitis patients (Paris Classification). In both CD 
and UC patients, disease activity scores, HBI and SCCAI respectively, were calculated at each 
sampling episode, and the effects on the metabolome established.  
In Crohn’s disease patients, it was not possible to sh w differentiation between the metabolomic 
profiles in relation to the disease behaviour displayed, the location of disease, or the age at diagnosis, 
using either serum or urine samples, on UHPLC-FTMS or GC-ToF-MS platforms. In relation to the 
disease activity score, it was not possible to identifiy any significant associations between metabolite 
variables and HBI. 
In ulcerative colitis patients, we did not show any differentiation between the metabolomic profiles in 
relation to the disease extent, using either serum or urine samples, on UHPLC-FTMS or GC-ToF-MS 
platforms. In relation to the disease activity score, only two metabolite variables identified were 
significantly associated with the SCCAI. These were both identified in urine analysis on the GC-ToF-
MS platform. Unfortunately, both of these metabolites are unknown variables. 
It is not surprising that non-localised biofluids do not show alterations in the metabolome when 
considering potentially systematic factors such as disease behaviour and location. Further work on this 
subject could involve metabolomic analysis of location specific and behaviour specific tissue in order 
to determine potential alterations in the metabolome in relation to these factors. 
 
5.7 Study Strengths  
This study was designed in collaboration with the team from MIB, who have a plethora of experience 
and knowledge in the design and completion of metabolomics experiments. The study was designed to 
minimise bias and confounding factors, within the limitations of a clinical setting, whilst upholding 
the ethical requirements set. The strengths of this study are that it is case-controlled, and also uses 
participants as their own internal controls in certain experiments. A strict participant recruitment ad 
sampling process was adhered to throughout the study, and all samples were taken in a single centre. 
The samples were prepared and analysed using validated protocols from MIB. Sample preparation 
was carried out by me under the supervision of Dr Drupad Trivedi and Dr Nicholas Rattray. Sample 
analysis on the GC-ToF-MS and UHPLC-FTMS platforms was carried out by the above experienced 
members of the MIB team to minimise experimental error. 
All meta-data was collected prospectively by me to minimise reporting bias. The bioinformatics 
analysis was carried out by Dr Drupad Trivedi and Dr Yun Xu at MIB. I met with them on a regular 
basis to direct the clinical relevance of the analysis.  
 
5.8 Study Limitations 
As previously discussed, metabolomics involves the study of numerous analytes that have very 
diverse physical and chemical properties, and occur in a wide concentration range. Therefore, 
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currently no single analytical platform exists that allows for analysis of a complete profile. The 
metabolomic profile is also potentially very susceptible to alterations in environment and diet, and 
whilst patient and disease phenotype can be recorded, th se variables are challenging to identify and 
correct for during studies. 
Throughout this study, dietary and drug metabolites were identified. Whilst in the setting of IBD 
dietary variability may have some relevance, it is potentially a confounding factor. We attempt to 
minimise these effects by taking samples in the fasting state (>6 hours), and by recording dietary 
variations.  
In this study most of the patients were receiving out-patient treatment. Those who were inpatients in 
the hospital will have had different dietary intakes from those eating in their own home. Similarly, 
patients requiring emergency surgery for conditions such as obstructive strictures will not have had 
the same pre-operative diet to those having an elective surgical procedure such as a completion 
proctectomy. 
The medications taken throughout the study are identified in metabolomic profiles. Whilst a detailed 
drug history was taken from each of the participants, these findings are potentially confounding 
factors. It is challenging to control for medications as patients will be prescribed them for good reason 
and it is not ethical to stop them. In order to try and assess the profiles of treatment naïve IBD patients 
without drug contamination of their metabolomic profile, we attempted to recruit treatment naïve 
patients. The practicality of this was very challenging, as most patients identified with a possible new 
diagnosis of IBD were commenced on treatment in the primary care setting prior to contact with 
hospital services. Those who were identified as “treatment naïve” may have been on other non-IBD 
medications such as analgesics, anti-spasmodics, or may have received bowel preparation prior to 
their diagnostic endoscopic procedure.  
The other recruitment challenge with this group of patients was that following a diagnosis of IBD 
being made, medical treatment should be commenced immediately. It was not ethical to delay 
treatment to allow for the 6 hour fasting window required to take samples for metabolomic analysis. 
This lead to a very small number of treatment naïve patients being recruited. A larger study population 
would be required to confidently assess the metabolomic profiles of treatment naïve IBD patients. The 
paediatric IBD population potentially offers a “cleaner” profile due to less confounding factors such as 
coexisting diseases and medication use, and the ability to evaluate the environment in which the child 
has spent most of their life.   
In the surgical group, patients underwent different procedures for different conditions, ranging from 
perianal procedures, to colectomies. It is unknown how the physiological effects of major surgical 
intervention affect the metabolomic profile. We chose to sample patients 8 weeks post procedure as 
we would expect them to be back to near normal by then, and also to fit in with clinical appointments; 
however this time frame has not been evaluated in the metabolomics setting.  
Ideally, standardisation of the surgical group would have involved chosing either CD or UC patients, 
and selecting one procedure to study. Investigation of patients with severe UC requiring colectomy 
would be a good group to study, as the operative procedure should rid the patient of the majority of 
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their disease burden, and thus allow useful comparison of a profile in the presence of severe disease 
compared to a profile that theoretically should be normalising. 
Similarly, patients undergoing biological therapy combined both CD and UC patients, and treatment 
with both Infliximab and Adalimumab.  
Standardisation of both the surgical and biological groups in future studies would allow a more 
homogenous group of profiles to be studied.  
Both disease activity scoring systems (HBI and SCCAI) have limitations. They both rely on a score 
being created from the stool frequency reported by the patient. Should a patient have a stoma, the 
score is difficult to interpret. In these cases we simply used the patients’ normal bowel frequency to 
correlate with a minimum score, and extrapolated the score from the extra frequency of stoma 
movement they reported. 
Both scoring indices are reasonably subjective, with a score for “general well being” contributing 
significantly to the final result. It is well documented that levels of anxiety and depression are higher 
in IBD patients than in HCs (Mikocka-Walus, Knowles t al. 2016). Subjective scoring systems are at 
risk of reporting bias, and may not correlate well with physiological disease activity.  
 
5.9 Advantages of UHPLC-FTMS and GC-ToF-MS  
As previously discussed, the human metabolome is vast. The diversity encountered does not lend itslf 
to a single platform method of analysis. The use of tw  platforms, GS-ToF-MS, and UHPLC-FTMS 
allows a more complete spectrum of metabolites to be analysed, as does the use of more than one 
biofluid. This is especially relevant in this discovery type study, where we aimed to identify a 
quantitive compliment of metabolites in relation to each disease, and disease course. 
One of the limitations of GC-MS is that only volatie compounds, or those that can be made volatile 
by chemical derivatisation, can be analysed. The derivatisation process has the potential to be a 
confounding factor in the present study. GC, however, can identify up to 200 metabolic features in a 
serum or plasma sample, and provides separation of molecules at low molecular weight (18 – 350Da), 
allowing identification of metabolite classes such as amino acids, amines, amides, and sugars.  
The UHPLC-FTMS platform used within this study allows for high mass resolution and high mass 
accuracy (typically 5 p.p.m), and provides high chromatographic resolution with high mass accuracy, 
that is used for putative metabolite identification. 
Unlike GC-MS, which uses capillary columns that provides appropriate chromatographic resolution 
with peak widths of 2 – 5 seconds and reproducible ret ntion times, in LC-MS retention time and 
collision-induced dissociation mass spectra are not reproducible between systems due to differences in 
LC column chemistries, and therefore mass transferabl  mass spectral libraries are not available. 
In UHPLC-FTMS, samples are analysed in positive and negative ion mode as they provide 
completentary data, and some metabolites will only be detected in a single-ion mode, dependent on 
their charge. 
The combination of GC-ToF-MS and reversed phase UHPLC-FTMS is well accepted, and provides 
the opportunity to detect low-molecular weight molecul s with a boiling point low enough to allow 
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elution through a GC column, and higher molecular weight compounds including many lipid classes, 
at very low concentrations respectively. Unfortunately, as many of the variables identified using 
chromatography and mass spectroscopy are as yet “unknow ”, putative metabolite identification is 
challenging, and will remain this way until the human metabolome is more fully, if not completely, 
characterised.   
The use of NMR may be able to provide better quantitative accuracy of targeted metabolites, and is 
worth considering in future studies. 
 
5.10 Optimisation and Planning of Future Studies 
This is a small study, and the results are potentially limited by low sample numbers and patient 
heterogeneity within each of the groups analysed.  
 
5.10.1 Patient Selection 
In order to optimise results patient cohorts should be as closely grouped as possible, including sex 
(ideally male to avoid changes in hormone levels), age, social and dietary habits, area of habitation, 
past medical history, and medication usage. In clinical studies these variables are difficult to contrl 
for and therefore potentially need to be taken intoaccount.  
 
5.10.2 Patients Undergoing Biological Therapy 
A longitudinal study with biofluid samples taken at each drug administration out to 1 year, rather than 
just the initial loading of the medication, may show alterations in profile. Comparing patients with one 
biological therapy and either UC or CD, rather than a combination of both, would provide a more 
homogenous study group.  
 
5.10.3 Patients Undergoing Surgery 
Ideally as many confounding factors as possible should be alleviated in order to achieve as pure a 
profile as possible. In order to do this, future studies could focus on one disease process and one 
operative treatment. UC is less heterogeneous than CD as it only affects the large bowel. The surgical 
procedure of choice is also more standardised than in CD and therefore UC patients undergoing 
subtotal colectomy would be a sensible study medium. In order to reduce “background noise” the 
group selected should ideally have had the same treatment for their disease and over a similar 
timeframe. It may be that selecting patients with an acute flare of severe colitis that come to require 
surgery is optimal. If pre-operative medical management is standardised and these patients are 
identified at first presentation, metabolomic profiles should be the most homogeneous. Of course in 
clinical practice this is unlikely to be achievable and therefore meticulous recording of disease 
activity, medications, and if possible diet, should be mandatory when carrying out ‘omics studies. 
 
5.10.4 Biofluid Choice 
Blood and urine are readily available biofluids amenable to metablomic analysis. Sample collection 
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is minimally invasive for blood and non-invasive for urine, and therefore these integrative biofluids 
that incorporate the functions and phenotypes of many different parts of the body in a single sample, 
are attractive biofluids to study. However, the “metabolomic footprint” identified is a complex 
combination of many bodily functions, and hence teasing out relevant information from potentially 
thousands of metabolites can be challenging (Dunn, Broadhurst et al. 2011). 
Faecal samples provide another non-invasive sampling methodology, with the advantage over urine 
and serum that the sample has been in the gut lumen and in contact with the mucin layer on the gut 
mucosa. Therefore faecal samples may provide insights into the gut microbiome and disease 
pathogenesis not offered by other biofluids. However, the collection of faecal samples, and the 
transportation and storage, as well as processing provides more challenges than serum and urine.  
Tissue samples are considered the gold standard in clin cal practice in the diagnosis of IBD, however 
the collection of tissue samples is an invasive procedure and few metabolomic studies using human 
IBD gut tissue have been carried out. Groups have however shown differentiation between IBD and 
HCs (Balasubramanian, Kumar et al. 2009), active and quiescent UC (Bjerrum, Nielsen et al. 2010), 
although other authors have reported similarities btween these groups (Sharma, Singh et al. 2010).  
When considering future studies the utilisation of faecal samples and tissue samples must be 
considered. However, it is likely that a combination f biofluids and tissue samples may in fact 
provide the most robust and accurate profile, althoug  the analysis of such a large group of variables 
would be extremely challenging. 
 
5.10.5 Focus on Specific Metabolite Classes 
Throughout our experiments, biologically relevant metabolites from the classes carboxylic acids and 
derivatives, benzene and substituted derivatives, fatty acyls, and azoles appear to be the most 
prevalent. A focused study of these particular metabolite groups may yeald interesting results with 
regards to disease pathogenesis and biomarker discovery.  
 
5.11 Future IBD Studies 
To allow a complete analysis of the human metabolome in IBD, a systems-wide approach utilising 
multiple biological samples, ideally taken at a single sitting, could be undertaken. Sampling of blood, 
urine, tissue, faeces and colonic mucus may lead to futher understanding of disease pathogenesis. 
Ideally multiple platforms (GC-MS / LC-MS +/- NMR) would be utilised to gain knowledge of as 
wide a metabolome as possible. 
In the search for biomarkers to assess and monitor d sease activity, using patients as their own 
controls seems important. It may be that a more objctive measure of disease severity is required, than 
the subjective disease activity scores that we use at present, to identify metabolites that differentiate 
disease severity. Objective findings such as histological results in resectional specimens or tissue 
biopsies may prove useful in identifiying corresponding differentiating metabolites in biofluid 
samples. 
In all metabolomics studies, environmental factors can prove be very challenging to both control for 
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and consider during analysis. The paediatric population may offer an opportunity to study patients 
with less confounding factors than adults. Many paedi tric IBD patients will be treatment naïve prior 
to diagnosis, and will not have the underlying disease processes present in large numbers of the adult 
population, such as atherolscleortic disease or diabetes. They are also less likely than an adult 
population to have been exposed to social factors such as tobacco and alcohol, and are more likely 
than adults to have lived in one place for their whole life. Studying this population may give a 
“cleaner” metabolomic profile than in an adult, although other factors such as growth hormones and 
their effect on the metabolome would have to be considered.  
Finally, there is great potential gain knowledge of disease pathogenesis from treatment naïve patients. 
In this study it proved incredibly challenging to rec uit and sample these patients prior to a treatment 
regimen commencing. Larger numbers than were studied here are required to draw any conclusions 
regarding metabolomic profile. It may be that recruitment in the primary care setting would be 
necessary; however, logistically this would be a very difficult study.  
 
5.12 Challenges Faced 
This study was the first of its kind carried out from Raigmore Hospital, which lead to a number of 
challenges. I was heavily involved in the initial set-up of my work area within the Centre for Health 
Science. This involved the networking of computers onto the NHS system, and the procurement of a -
80ºC freezer and all of the equipment required for the preparation and storage of biofluid samples.  
As there was not a longstanding research network in this area I spent time discussing the project with 
both the general surgical and gastroenterology teams in Raigmore Hospital. I also sent information to 
all of the general practitioners in the region, and visited those who requested a meeting or further 
information about the project. 
In a setting new to the recruitment of patients into clinical studies, I found that altering the mindset of 
clinicians to consider everyone as a potential participant into the study was challenging. This required 
a near constant presence from me at clinics and within the department of gastroenterology to ensure 
the potential for recruitment was optimised. There w re similar difficulties with healthy controls, 
where clinical staff were sometimes unwilling for a p tient to have the opportunity to spend time with 
me to take samples in case it delayed their journey to theatre.  
Working on a project that required complete recruitment and sample collection before it was 
possibleto start the experiments was frustrating at times. Whilst the expertise from the team at MIB is 
invaluable and this project could not have succeeded without collaboration, I found it difficult to wait 
for my time on the analysers, and the delays seen with machine failures and then complex data 
analysis were reasonably lengthy. This lead to a prolonged project duration, with results only 









Inflammatory bowel disease comprises two main disease subtypes; Crohn’s Disease, and ulcerative 
colitis. Both are relapsing, remitting conditions, with significant socioeconomic implications. 
The diagnosis and monitoring of these disease processes can be challenging, and currently there are no 
biomarkers in routine clinical practice. 
The pathogenesis of IBD is complex and is not fully understood. Genetic, immunological and 
microbiological studies have provided great insights, and the use of the “omics” technologies have the 
potential to further advance our understanding.  
This thesis describes a novel metabolomics profiling study. I aimed to identify urinary and serum 
metabolites that differentiate between IBD and healt y controls, and also to interrogate the differences 
in metabolomic profiles during different phases of disease, with special consideration given to the 
effects of medical and surgical treatments. In order to do this, patients were recruited into a 
longitudinal sampling group, a surgical group and a biological therapy group.  
To optimise of the metabolomic profile identified, serum and urine samples were studied on both GC-
ToF-MS and UHPLC-FTMS platforms. The biofluid selected were chosen as samples can be obtained 
using minimally invasive methods, and as such they have the potential to be utilised in future clinical 
practice. 
The study carried out identified metabolites in the classes; benzene and substituted derivatives, 
carboxylic acids and derivatives, organic disuplphides, azoles, and fatty acyls to be of most relevance 
in delineating between the disease phenotypes. Analysis of the specific metabolites identified has 
given insights into the metabolic disturbances thatoccur in these diseases, and the effects of medical 
and surgical treatments. 
It was not possible to identify specific metabolites that would differentiate disease activity score o 
disease behaviour or location in either CD or UC in th s relatively small discovery study. 
Future research should include larger population studies, ideally of the most hetrogenous groups 
possible. Utilising paired or longitudinal sampling techniques allows patients to act as their own 
internal controls, and is important when considering technologies such as metabolomics, which are 
strongly affected by environmental factors. Drug naïve IBD patients are a specific group that should 
be concentrated on as they may give the truest repres ntation of the IBD metabolome, without the 
contamination of treatment regimens. Focus on specific metabolite classes that seem to differentiate 










ABERRA, F.N. and LICHTENSTEIN, G.R., 2005. Review article: monitoring of immunomodulators 
in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 21(4), pp. 307-319. 
ABUBAKAR, I., MYHILL, D., ALIYU, S.H. and HUNTER, P.R., 2008. Detection of 
Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic 
acid-based techniques: a systematic review and meta-analysis. Inflammatory bowel diseases, 14(3), 
pp. 401-410. 
ACKERMANN, B.L., HALE, J.E. and DUFFIN, K.L., 2006. The role of mass spectrometry in 
biomarker discovery and measurement. Current Drug Metabolism, 7(5), pp. 525-539. 
Activity Related Abnormalities in Inflammatory Bowel Disease. Woerden-Huybregts Press, pp. 89-
103. 
ADEYEMI, E.O. and HODGSON, H.J., 1992. Faecal elastase reflects disease activity in active 
ulcerative colitis. Scandinavian journal of gastroenterology, 27(2), pp. 139-142. 
AEBERSOLD, R. and MANN, M., 2003. Mass spectrometry-based proteomics. Nature, 422(6928), 
pp. 198-207. 
AFZAL, M.A., ARMITAGE, E., BEGLEY, J., BENTLEY, M.L., MINOR, P.D., GHOSH, S. and 
FERGUSON, A., 1998. Absence of detectable measles viru genome sequence in inflammatory bowel 
disease tissues and peripheral blood lymphocytes. Journal of medical virology, 55(3), pp. 243-249. 
AGANS, R., RIGSBEE, L., KENCHE, H., MICHAIL, S., KHAMIS, H.J. and PALIY, O., 2011. 
Distal gut microbiota of adolescent children is different from that of adults. FEMS microbiology 
ecology, 77(2), pp. 404-412. 
AGOURIDIS, A.P., ELISAF, M. and MILIONIS, H.J., 2011. An overview of lipid abnormalities in 
patients with inflammatory bowel disease. Annals of gastroenterology : quarterly publication of the 
Hellenic Society of Gastroenterology, 24(3), pp. 181- 7. 
ALDHOUS, M.C., PRESCOTT, R.J., ROBERTS, S., SAMUEL, K., WATERFALL, M. and 
SATSANGI, J., 2008. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic 
responses in inflammatory bowel disease?. Inflammatory bowel diseases, 14(11), pp. 1469-1482. 
ALHOUAYEK, M. and MUCCIOLI, G.G., 2012. The endocannabinoid system in inflammatory 
bowel diseases: from pathophysiology to therapeutic opportunity. Trends in molecular medicine, 
18(10), pp. 615-625. 
AL-JAOUNI, R., HEBUTERNE, X., POUGET, I. and RAMPAL, P., 2000. Energy metabolism and 
substrate oxidation in patients with Crohn's disease. Nutrition, 16(3), pp. 173-178. 
ALPERN, J.A., SASAKI, M., SITARAMAN, S.V., RUTHERFORD, R.E., OLEJEME, H.C., CAI, Q. 
and KLAPPROTH, J.A., 2006. Invasive E. Coli Strains Are Increased in Crohn’s Disease.  
ALVAREZ-LOBOS, M., AROSTEGUI, J.I., SANS, M., TASSIES, D., PLAZA, S., DELGADO, S., 
LACY, A.M., PIQUE, J.M., YAGUE, J. and PANES, J., 2005. Crohn's disease patients carrying 
Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing 
disease and higher rate of surgical recurrence. Annals of Surgery, 242(5), pp. 693-700. 
ANANTHAKRISHNAN, A.N., HIGUCHI, L.M., HUANG, E.S., KHALILI, H., RICHTER, J.M., 
FUCHS, C.S. and CHAN, A.T., 2012. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for 
Crohn disease and ulcerative colitis: a cohort study. Annals of Internal Medicine, 156(5), pp. 350-359. 
ANANTHAKRISHNAN, A.N., KHALILI, H., KONIJETI, G.G., HIGUCHI, L.M., DE SILVA, P., 
FUCHS, C.S., WILLETT, W.C., RICHTER, J.M. and CHAN, A.T., 2014. Long-term intake of 
dietary fat and risk of ulcerative colitis and Crohn's disease. Gut, 63(5), pp. 776-784. 
ANANTHAKRISHNAN, A.N., KHALILI, H., KONIJETI, G.G., HIGUCHI, L.M., DE SILVA, P., 
KORZENIK, J.R., FUCHS, C.S., WILLETT, W.C., RICHTER, J.M. and CHAN, A.T., 2013. A 
prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. 
Gastroenterology, 145(5), pp. 970-977. 
ANDERSEN, V., OLSEN, A., CARBONNEL, F., TJONNELAND, A. and VOGEL, U., 2012. Diet 
and risk of inflammatory bowel disease. Digestive and liver disease : official journal of the Italian 
Society of Gastroenterology and the Italian Association for the Study of the Liver, 44(3), pp. 185-194. 
ANDERSSON, R.E., OLAISON, G., TYSK, C. and EKBOM, A., 2003. Appendectomy is followed 
by increased risk of Crohn's disease. Gastroenterology, 124(1), pp. 40-46. 
ANDRE, C., DESCOS, L., LANDAIS, P. and FERMANIAN, J., 1981. Assessment of appropriate 
laboratory measurements to supplement the Crohn's disease activity index. Gut, 22(7), pp. 571-574. 
ANDRES CEREZO, L., MANN, H., PECHA, O., PLESTILOVA, L., PAVELKA, K., 
VENCOVSKY, J. and SENOLT, L., 2011. Decreases in serum levels of S100A8/9 (calprotectin) 
correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid 
arthritis. Arthritis research & therapy, 13(4), pp. R122. 
 
 363 
ANGERSON, W.J., ALLISON, M.C., BAXTER, J.N. and RUSSELL, R.I., 1993. Neoterminal ileal 
blood flow after ileocolonic resection for Crohn's di ease. Gut, 34(11), pp. 1531-1534. 
ANGRIMAN, I., SCARPA, M., D'INCA, R., BASSO, D., RUFFOLO, C., POLESE, L., 
STURNIOLO, G.C., D'AMICO, D.F. and PLEBANI, M., 2007. Enzymes in feces: useful markers of 
chronic inflammatory bowel disease. Clinica Chimica Acta, 381(1), pp. 63-68. 
ANTONIOLI, D.A., 2005. Pediatric inflammatory bowel disease. Pediatric & Developmental 
Pathology, 8(1), pp. 2-19. 
AOI, Y., TERASHIMA, S., OGURA, M., NISHIO, H., KATO, S. and TAKEUCHI, K., 2008. Roles 
of nitric oxide (NO) and NO synthases in healing of dextran sulfate sodium-induced rat colitis. 
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 
59(2), pp. 315-336. 
APFELBAUM, T.F., DAVIDSON, N.O. and GLICKMAN, R.M., 1987. Apolipoprotein A-IV 
synthesis in rat intestine: regulation by dietary triglyceride. The American Journal of Physiology, 
252(5 Pt 1), pp. G662-6. 
APPLEMAN, H.D., 2008. What are the critical histologic features in the diagnosis of ulcerative 
colitis? Inflammatory bowel diseases, 14 Suppl 2, pp. S164-5. 
ARDAWI, M.S. and NEWSHOLME, E.A., 1985. Fuel utilization in colonocytes of the rat. 
Biochemical Journal, 231(3), pp. 713-719. 
ARNOTT, I.D., LANDERS, C.J., NIMMO, E.J., DRUMMOND, H.E., SMITH, B.K., TARGAN, 
S.R. and SATSANGI, J., 2004. Sero-reactivity to microbial components in Crohn's disease is 
associated with disease severity and progression, but not NOD2/CARD15 genotype. American 
Journal of Gastroenterology, 99(12), pp. 2376-2384. 
ARUMUGAM, M., RAES, J., PELLETIER, E., LE PASLIER, D., YAMADA, T., MENDE, D.R., 
FERNANDES, G.R., TAP, J., BRULS, T., BATTO, J.M., BERTALAN, M., BORRUEL, N., 
CASELLAS, F., FERNANDEZ, L., GAUTIER, L., HANSEN, T., HATTORI, M., HAYASHI, T., 
KLEEREBEZEM, M., KUROKAWA, K., LECLERC, M., LEVENEZ, F., MANICHANH, C., 
NIELSEN, H.B., NIELSEN, T., PONS, N., POULAIN, J., QIN, J., SICHERITZ-PONTEN, T., TIMS, 
S., TORRENTS, D., UGARTE, E., ZOETENDAL, E.G., WANG, J., GUARNER, F., PEDERSEN, 
O., DE VOS, W.M., BRUNAK, S., DORE, J., METAHIT CONSORTIUM, ANTOLIN, M., 
ARTIGUENAVE, F., BLOTTIERE, H.M., ALMEIDA, M., BRECHOT, C., CARA, C., 
CHERVAUX, C., CULTRONE, A., DELORME, C., DENARIAZ, G., DERVYN, R., FOERSTNER, 
K.U., FRISS, C., VAN DE GUCHTE, M., GUEDON, E., HAIMET, F., HUBER, W., VAN 
HYLCKAMA-VLIEG, J., JAMET, A., JUSTE, C., KACI, G., KNOL, J., LAKHDARI, O., LAYEC, 
S., LE ROUX, K., MAGUIN, E., MERIEUX, A., MELO MINARDI, R., M'RINI, C., MULLER, J., 
OOZEER, R., PARKHILL, J., RENAULT, P., RESCIGNO, M., SANCHEZ, N., SUNAGAWA, S., 
TORREJON, A., TURNER, K., VANDEMEULEBROUCK, G., VARELA, E., WINOGRADSKY, 
Y., ZELLER, G., WEISSENBACH, J., EHRLICH, S.D. and BORK, P., 2011. Enterotypes of the 
human gut microbiome. Nature, 473(7346), pp. 174-180. 
ASANO, N., KATO, A., MIYAUCHI, M., KIZU, H., TOMIMORI, T., MATSUI, K., NASH, R.J. and 
MOLYNEUX, R.J., 1997. Specific alpha-galactosidase inhibitors, N-methylcalystegines--
structure/activity relationships of calystegines from Lycium chinense. European journal of 
biochemistry / FEBS, 248(2), pp. 296-303. 
ATARASHI, K., TANOUE, T., SHIMA, T., IMAOKA, A., KUWAHARA, T., MOMOSE, Y., 
CHENG, G., YAMASAKI, S., SAITO, T., OHBA, Y., TANIGUCHI, T., TAKEDA, K., HORI, S., 
IVANOV, I.I., UMESAKI, Y., ITOH, K. and HONDA, K., 2011. Induction of colonic regulatory T 
cells by indigenous Clostridium species. Science (Nw York, N.Y.), 331(6015), pp. 337-341. 
ATTENE-RAMOS, M.S., NAVA, G.M., MUELLNER, M.G., WAGNER, E.D., PLEWA, M.J. and 
GASKINS, H.R., 2010. DNA damage and toxicogenomic analyses of hydrogen sulfide in human 
intestinal epithelial FHs 74 Int cells. Environmental and molecular mutagenesis, 51(4), pp. 304-314. 
AUVIN, S., MOLINIE, F., GOWER-ROUSSEAU, C., BRAZIER, F., MERLE, V., 
GRANDBASTIEN, B., MARTI, R., LEREBOURS, E., DUPAS, J.L., COLOMBEL, J.F., 
SALOMEZ, J.L., CORTOT, A. and TURCK, D., 2005. Incidence, clinical presentation and location 
at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in 
northern France (1988-1999). Journal of Pediatric Gastroenterology & Nutrition, 41(1), pp. 49-55. 
BACKSTROM, M., AMBORT, D., THOMSSON, E., JOHANSSON, M.E. and HANSSON, G.C., 
2013. Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming 




BAI, A., YONG, M., MA, A.G., MA, Y., WEISS, C.R., GUAN, Q., BERNSTEIN, C.N. and PENG, 
Z., 2010. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with 
protective effect in dextran sulfate sodium-induced acute and chronic colitis. The Journal of 
pharmacology and experimental therapeutics, 333(3), pp. 717-725. 
BAIN, C.C., SCOTT, C.L., URONEN-HANSSON, H., GUDJONSSON, S., JANSSON, O., GRIP, 
O., GUILLIAMS, M., MALISSEN, B., AGACE, W.W. and MOWAT, A.M., 2013. Resident and pro-
inflammatory macrophages in the colon represent alternative context-dependent fates of the same 
Ly6Chi monocyte precursors. Mucosal immunology, 6(3), pp. 498-510. 
BALASUBRAMANIAN, K., KUMAR, S., SINGH, R.R., SHARMA, U., AHUJA, V., MAKHARIA, 
G.K. and JAGANNATHAN, N.R., 2009. Metabolism of the colonic mucosa in patients with 
inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magnetic 
resonance imaging, 27(1), pp. 79-86. 
BARCELO-BATLLORI, S., ANDRE, M., SERVIS, C., LEVY, N., TAKIKAWA, O., MICHETTI, 
P., REYMOND, M. and FELLEY-BOSCO, E., 2002. Proteomic analysis of cytokine induced proteins 
in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics, 2(5), 
pp. 551-560. 
BARCLAY, A.R., RUSSELL, R.K., WILSON, M.L., GILMOUR, W.H., SATSANGI, J. and 
WILSON, D.C., 2009. Systematic review: the role of breastfeeding in the development of pediatric 
inflammatory bowel disease. The Journal of pediatrics, 155(3), pp. 421-426. 
BARON, S., TURCK, D., LEPLAT, C., MERLE, V., GOWER-OUSSEAU, C., MARTI, R., YZET, 
T., LEREBOURS, E., DUPAS, J.L., DEBEUGNY, S., SALOMEZ, J.L., CORTOT, A. and 
COLOMBEL, J.F., 2005. Environmental risk factors in paediatric inflammatory bowel diseases: a 
population based case control study. Gut, 54(3), pp. 357-363. 
BARRETT, J.C., HANSOUL, S., NICOLAE, D.L., CHO, J.H., DUERR, R.H., RIOUX, J.D., 
BRANT, S.R., SILVERBERG, M.S., TAYLOR, K.D., BARMADA, M.M., BITTON, A., 
DASSOPOULOS, T., DATTA, L.W., GREEN, T., GRIFFITHS, A.M., KISTNER, E.O., MURTHA, 
M.T., REGUEIRO, M.D., ROTTER, J.I., SCHUMM, L.P., STEINHART, A.H., TARGAN, S.R., 
XAVIER, R.J., NIDDK IBD GENETICS, C., LIBIOULLE, C., SANDOR, C., LATHROP, M., 
BELAICHE, J., DEWIT, O., GUT, I., HEATH, S., LAUKENS, D., MNI, M., RUTGEERTS, P., VAN 
GOSSUM, A., ZELENIKA, D., FRANCHIMONT, D., HUGOT, J.P., DE VOS, M., VERMEIRE, S., 
LOUIS, E., BELGIAN-FRENCH IBD, C., WELLCOME TRUST CASE CONTROL, C., CARDON, 
L.R., ANDERSON, C.A., DRUMMOND, H., NIMMO, E., AHMAD, T., PRESCOTT, N.J., ONNIE, 
C.M., FISHER, S.A., MARCHINI, J., GHORI, J., BUMPSTEAD, S., GWILLIAM, R., 
TREMELLING, M., DELOUKAS, P., MANSFIELD, J., JEWELL, D., SATSANGI, J., MATHEW, 
C.G., PARKES, M., GEORGES, M. and DALY, M.J., 2008. Genome-wide association defines more 
than 30 distinct susceptibility loci for Crohn's disease. Nature genetics, 40(8), pp. 955-962. 
BASAK, T., VARSHNEY, S., AKHTAR, S. and SENGUPTA, S., 2015. Understanding different 
facets of cardiovascular diseases based on model syst ms to human studies: A proteomic and 
metabolomic perspective. Journal of proteomics, . 
BASU, D., LOPEZ, I., KULKARNI, A. and SELLIN, J.H., 2005. Impact of race and ethnicity on 
inflammatory bowel disease. The American Journal of Gastroenterology, 100(10), pp. 2254-2261. 
BAUMGART, M., DOGAN, B., RISHNIW, M., WEITZMAN, G., BOSWORTH, B., YANTISS, R., 
ORSI, R.H., WIEDMANN, M., MCDONOUGH, P., KIM, S.G., BERG, D., SCHUKKEN, Y., 
SCHERL, E. and SIMPSON, K.W., 2007. Culture independent analysis of ileal mucosa reveals a 
selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales 
in Crohn's disease involving the ileum. The Isme Journal, 1(5), pp. 403-418. 
BECKER, K., BERGER, M., NIEDERAU, C. and FRIELING, T., 1999. Individual fecal alpha 1-
antitrypsin excretion reflects clinical activity inCrohn's disease but not in ulcerative colitis. Hepato-
gastroenterology, 46(28), pp. 2309-2314. 
BECKER, K., NIEDERAU, C. and FRIELING, T., 1999. Fecal excretion of alpha 2-macroglobulin: a 
novel marker for disease activity in patients with inflammatory bowel disease. Zeitschrift fur 
Gastroenterologie, 37(7), pp. 597-605. 
BECKONERT, O., KEUN, H.C., EBBELS, T.M., BUNDY, J., HOLMES, E., LINDON, J.C. and 
NICHOLSON, J.K., 2007. Metabolic profiling, metabolomic and metabonomic procedures for NMR 
spectroscopy of urine, plasma, serum and tissue extracts. Nature Protocols, 2(11), pp. 2692-2703. 
BEENS, J. and BRINKMAN, U.A., 2005. Comprehensive two-dimensional gas chromatography--a 
powerful and versatile technique. Analyst, 130(2), pp. 123-127. 
 
 365 
BENIGHT, N.M., STOLL, B., CHACKO, S., DA SILVA, V.R., MARINI, J.C., GREGORY, 
J.F.,3RD, STABLER, S.P. and BURRIN, D.G., 2011. B-vitamin deficiency is protective against DSS-
induced colitis in mice. American journal of physiology.Gastrointestinal and liver physiology, 301(2), 
pp. G249-59. 
BENNETT, R.A., RUBIN, P.H. and PRESENT, D.H., 1991. Frequency of inflammatory bowel 
disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology, 
100(6), pp. 1638-1643. 
BENTSEN, B.S., MOUM, B. and EKBOM, A., 2002. Incidence of inflammatory bowel disease in 
children in southeastern Norway: a prospective population-based study 1990-94. Scandinavian journal 
of gastroenterology, 37(5), pp. 540-545. 
BERG, D.J., ZHANG, J., WEINSTOCK, J.V., ISMAIL, H.F., EARLE, K.A., ALILA, H., 
PAMUKCU, R., MOORE, S. and LYNCH, R.G., 2002. Rapid development of colitis in NSAID-
treated IL-10-deficient mice. Gastroenterology, 123(5), pp. 1527-1542. 
BERNIER, J.J., FLORENT, C., DESMAZURES, C., AYMES, C. and L'HIRONDEL, C., 1978. 
Diagnosis of protein-losing enteropathy by gastroinestinal clearance of alpha1-antitrypsin. Lancet, 
2(8093), pp. 763-764. 
BERNSTEIN, B.E., MEISSNER, A. and LANDER, E.S., 2007. The mammalian epigenome. Cell, 
128(4), pp. 669-681. 
BERNSTEIN, C.N. and SHANAHAN, F., 2008. Disorders of a modern lifestyle: reconciling the 
epidemiology of inflammatory bowel diseases. Gut, 57(9), pp. 1185-1191. 
BERNSTEIN, C.N., BLANCHARD, J.F., KLIEWER, E. and WAJDA, A., 2001a. Cancer risk in 
patients with inflammatory bowel disease: a population-based study. Cancer, 91(4), pp. 854-862. 
BERNSTEIN, C.N., BLANCHARD, J.F., RAWSTHORNE, P. and WAJDA, A., 1999. Epidemiology 
of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. 
American Journal of Epidemiology, 149(10), pp. 916-924. 
BERNSTEIN, C.N., BLANCHARD, J.F., RAWSTHORNE, P. and YU, N., 2001b. The prevalence of 
extraintestinal diseases in inflammatory bowel disease: a population-based study. The American 
Journal of Gastroenterology, 96(4), pp. 1116-1122. 
BERSTAD, A., BORKJE, B., RIEDEL, B., ELSAYED, S. and BERSTAD, A., 1993. Increased fecal 
eosinophil cationic protein in inflammatory bowel disease. Hepato-gastroenterology, 40(3), pp. 276-
278. 
BEZABEH, T., SOMORJAI, R.L., SMITH, I.C., NIKULIN, A.E., DOLENKO, B. and BERNSTEIN, 
C.N., 2001. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: 
distinguishing ulcerative colitis from Crohn's disea . American Journal of Gastroenterology, 96(2), 
pp. 442-448. 
BIAIS, B., ALLWOOD, J.W., DEBORDE, C., XU, Y., MAUCOURT, M., BEAUVOIT, B., DUNN, 
W.B., JACOB, D., GOODACRE, R., ROLIN, D. and MOING, A., 2009. 1H NMR, GC-EI-TOFMS, 
and data set correlation for fruit metabolomics: application to spatial metabolite analysis in melon. 
Analytical Chemistry, 81(8), pp. 2884-2894. 
BINION, D.G., FU, S., RAMANUJAM, K.S., CHAI, Y.C., DWEIK, R.A., DRAZBA, J.A., WADE, 
J.G., ZIATS, N.P., ERZURUM, S.C. and WILSON, K.T., 1998. iNOS expression in human intestinal 
microvascular endothelial cells inhibits leukocyte adhesion. The American Journal of Physiology, 
275(3 Pt 1), pp. G592-603. 
BINION, D.G., RAFIEE, P., RAMANUJAM, K.S., FU, S., FISHER, P.J., RIVERA, M.T., 
JOHNSON, C.P., OTTERSON, M.F., TELFORD, G.L. and WILSON, K.T., 2000. Deficient iNOS in 
inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte 
adhesion. Free radical biology & medicine, 29(9), pp. 881-888. 
BINION, D.G., WEST, G.A., VOLK, E.E., DRAZBA, J.A., ZIATS, N.P., PETRAS, R.E. and 
FIOCCHI, C., 1998. Acquired increase in leucocyte binding by intestinal microvascular endothelium 
in inflammatory bowel disease. Lancet, 352(9142), pp. 1742-1746. 
Biochemistry of lipids, lipoproteins and membranes . Amsterdam: Elsevier Science Publishers, pp. 1-
41. 
BIRRENBACH, T. and BOCKER, U., 2004. Inflammatory bowel disease and smoking: a review of 
epidemiology, pathophysiology, and therapeutic implcations. Inflammatory bowel diseases, 10(6), 
pp. 848-859. 
BISCHOFF, S.C., GRABOWSKY, J. and MANNS, M.P., 1997. Quantification of inflammatory 
mediators in stool samples of patients with inflammatory bowel disorders and controls. Digestive 
Diseases & Sciences, 42(2), pp. 394-403. 
 
 366 
BISCHOFF, S.C., WEDEMEYER, J., HERRMANN, A., MEIER, P.N., TRAUTWEIN, C., CETIN, 
Y., MASCHEK, H., STOLTE, M., GEBEL, M. and MANNS, M.P., 1996. Quantitative assessment of 
intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology, 28(1), pp. 1-13. 
BJERKE, K., HALSTENSEN, T.S., JAHNSEN, F., PULFORD, K. and BRANDTZAEG, P., 1993. 
Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's 
patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut, 34(10), pp. 
1357-1363. 
BJERRUM, J.T., NIELSEN, O.H., HAO, F., TANG, H., NICHOLSON, J.K., WANG, Y. and 
OLSEN, J., 2010. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and 
insight into the pathophysiology. Journal of Proteom  Research, 9(2), pp. 954-962. 
BJORNSSON, S. and JOHANNSSON, J.H., 2000. Inflammatory bowel disease in Iceland, 1990-
1994: a prospective, nationwide, epidemiological study. European journal of gastroenterology & 
hepatology, 12(1), pp. 31-38. 
BLACHIER, F., MARIOTTI, F., HUNEAU, J.F. and TOME, D., 2007. Effects of amino acid-derived 
luminal metabolites on the colonic epithelium and physiopathological consequences. Amino acids, 
33(4), pp. 547-562. 
BLANCHARD, J.F., BERNSTEIN, C.N., WAJDA, A. and RAWSTHORNE, P., 2001. Small-area 
variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. 
American Journal of Epidemiology, 154(4), pp. 328-335. 
BLAND, P., 1988. MHC class II expression by the gutepithelium. Immunology today, 9(6), pp. 174-
178. 
Blue Histology - Gastrointestinal Tract05/08, 2009-last update [Homepage of School of Anatomy and 
Human Biology - The University of Western Australia], [Online]. Available: 
http://www.lab.anhb.uwa.edu.au/mb140/CorePages/GIT/git.htm [31/01, 2015]. 
BOCCARD, J., VEUTHEY, J.L. and RUDAZ, S., 2010. Knowledge discovery in metabolomics: an 
overview of MS data handling. Journal of Separation Science, 33(3), pp. 290-304. 
BODGER, K., 2011. Cost effectiveness of treatments for inflammatory bowel disease. 
PharmacoEconomics, 29(5), pp. 387-401. 
BONE, E., TAMM, A. and HILL, M., 1976. The production of urinary phenols by gut bacteria and 
their possible role in the causation of large bowel cancer. American Journal of Clinical Nutrition, 
29(12), pp. 1448-1454. 
BORGAONKAR, M.R., MACINTOSH, D.G. and FARDY, J.M., 2000. A meta-analysis of 
antimycobacterial therapy for Crohn's disease. The Am rican Journal of Gastroenterology, 95(3), pp. 
725-729. 
BOSSUYT, X., 2006. Serologic markers in inflammatory bowel disease. Clinical chemistry, 52(2), 
pp. 171-181. 
BOUDEAU, J., GLASSER, A.L., MASSERET, E., JOLY, B. and DARFEUILLE-MICHAUD, A., 
1999. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with 
Crohn's disease. Infection and immunity, 67(9), pp. 4499-4509. 
BOUHNIK, Y., RASKINE, L., SIMONEAU, G., VICAUT, E., NEUT, C., FLOURIE, B., BROUNS, 
F. and BORNET, F.R., 2004. The capacity of nondigest ble carbohydrates to stimulate fecal 
bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, 
dose-response relation study. The American Journal of C inical Nutrition, 80(6), pp. 1658-1664. 
BOUMA, G. and STROBER, W., 2003. The immunological and genetic basis of inflammatory bowel 
disease. Nature reviews.Immunology, 3(7), pp. 521-533. 
BOYKO, E.J., KOEPSELL, T.D., PERERA, D.R. and INUI, T.S., 1987. Risk of ulcerative colitis 
among former and current cigarette smokers. New England Journal of Medicine, 316(12), pp. 707-
710. 
BOYKO, E.J., PERERA, D.R., KOEPSELL, T.D., KEANE, E.M. and INUI, T.S., 1988. Effects of 
cigarette smoking on the clinical course of ulcerative colitis. Scandinavian Journal of 
Gastroenterology, 23(9), pp. 1147-1152. 
BRAEGGER, C.P., NICHOLLS, S., MURCH, S.H., STEPHENS, S. and MACDONALD, T.T., 1992. 
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339(8785), pp. 
89-91. 
BRANDTZAEG, ,PER, CARLSEN, ,HEGES. and HALSTENSEN, ,TRONDS., The B-Cell System 
in Inflammatory Bowel Disease.  
BRENNER, D.E. and NORMOLLE, D.P., 2007. Biomarkers for cancer risk, early detection, and 
prognosis: the validation conundrum. Cancer epidemiology, biomarkers & prevention : a publication 
 
 367 
of the American Association for Cancer Research, cosponsored by the American Society of 
Preventive Oncology, 16(10), pp. 1918-1920. 
BRENTNALL, T.A., HAGGITT, R.C., RABINOVITCH, P.S., KIMMEY, M.B., BRONNER, M.P., 
LEVINE, D.S., KOWDLEY, K.V., STEVENS, A.C., CRISPIN, D.A., EMOND, M. and RUBIN, 
C.E., 1996. Risk and natural history of colonic neoplasia in patients with primary sclerosing 
cholangitis and ulcerative colitis. Gastroenterology, 110(2), pp. 331-338. 
BREUER, R.I., SOERGEL, K.H., LASHNER, B.A., CHRIST, M.L., HANAUER, S.B., 
VANAGUNAS, A., HARIG, J.M., KESHAVARZIAN, A., ROBINSON, M., SELLIN, J.H., 
WEINBERG, D., VIDICAN, D.E., FLEMAL, K.L. and RADEMAKER, A.W., 1997. Short chain 
fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut, 
40(4), pp. 485-491. 
BREUER-KATSCHINSKI, B.D., HOLLANDER, N. and GOEBELL, H., 1996. Effect of cigarette 
smoking on the course of Crohn's disease. European jour al of gastroenterology & hepatology, 8(3), 
pp. 225-228. 
BROEDL, U.C., SCHACHINGER, V., LINGENHEL, A., LEHRKE, M., STARK, R., SEIBOLD, F., 
GOKE, B., KRONENBERG, F., PARHOFER, K.G. and KONRAD-ZERNA, A., 2007. 
Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory 
bowel disease. Inflammatory bowel diseases, 13(4), pp. 391-397. 
BROOME, U., LINDBERG, G. and LOFBERG, R., 1992. Primary sclerosing cholangitis in ulcerative 
colitis--a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology, 102(6), 
pp. 1877-1880. 
BROWN, E.S., 2009. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment 
and preventive therapy. Annals of the New York Academy of Sciences, 1179, pp. 41-55. 
BROWN, J.H., JARDETZKY, T.S., GORGA, J.C., STERN, L.J., URBAN, R.G., STROMINGER, 
J.L. and WILEY, D.C., 1993. Three-dimensional structure of the human class II histocompatibility 
antigen HLA-DR1. Nature, 364(6432), pp. 33-39. 
BUDERUS, S., BOONE, J., LYERLY, D. and LENTZE, M.J., 2004. Fecal lactoferrin: a new 
parameter to monitor infliximab therapy. Digestive Diseases & Sciences, 49(6), pp. 1036-1039. 
BUONOMANO, R., TINGUELY, C., RIEBEN, R., MOHACSI, P.J. and NYDEGGER, U.E., 1999. 
Quantitation and characterization of anti-Galalpha1-3Gal antibodies in sera of 200 healthy persons. 
Xenotransplantation, 6(3), pp. 173-180. 
BURAKOFF, R., 2004. Indeterminate colitis: clinical spectrum of disease. Journal of clinical 
gastroenterology, 38(5 Suppl 1), pp. S41-3. 
BURISCH, J., PEDERSEN, N., CUKOVIC-CAVKA, S., BRINAR, M., KAIMAKLIOTIS, I., 
DURICOVA, D., SHONOVA, O., VIND, I., AVNSTROM, S., THORSGAARD, N., ANDERSEN, 
V., KRABBE, S., DAHLERUP, J.F., SALUPERE, R., NIELSEN, K.R., OLSEN, J., MANNINEN, P., 
COLLIN, P., TSIANOS, E.V., KATSANOS, K.H., LADEFOGED, K., LAKATOS, L., 
BJORNSSON, E., RAGNARSSON, G., BAILEY, Y., ODES, S.CHWARTZ, D., MARTINATO, 
M., LUPINACCI, G., MILLA, M., DE PADOVA, A., D'INCA, R., BELTRAMI, M., KUPCINSKAS, 
L., KIUDELIS, G., TURCAN, S., TIGHINEANU, O., MIHU, I., MAGRO, F., BARROS, L.F., 
GOLDIS, A., LAZAR, D., BELOUSOVA, E., NIKULINA, I., HERNANDEZ, V., MARTINEZ-
ARES, D., ALMER, S., ZHULINA, Y., HALFVARSON, J., AREBI, N., SEBASTIAN, S., 
LAKATOS, P.L., LANGHOLZ, E., MUNKHOLM, P. and EPICOM-GROUP, 2014. East-West 
gradient in the incidence of inflammatory bowel disea e in Europe: the ECCO-EpiCom inception 
cohort. Gut, 63(4), pp. 588-597. 
BYRON, K.A., VARIGOS, G.A. and WOOTTON, A.M., 1994. IL-4 production is increased in 
cigarette smokers. Clinical & Experimental Immunology, 95(2), pp. 333-336. 
CAIRNS, B.R., 2009. The logic of chromatin architecture and remodelling at promoters. Nature, 
461(7261), pp. 193-198. 
CALDER, P.C., 2012. Mechanisms of action of (n-3) fatty acids. The Journal of nutrition, 142(3), pp. 
592S-599S. 
CALKINS, B.M., 1989. A meta-analysis of the role of smoking in inflammatory bowel disease. 
Digestive Diseases & Sciences, 34(12), pp. 1841-1854. 
CARD, T., LOGAN, R.F., RODRIGUES, L.C. and WHEELER, J.G., 2004. Antibiotic use and the 
development of Crohn's disease. Gut, 53(2), pp. 246-250. 
CARIO, E. and PODOLSKY, D.K., 2000. Differential alteration in intestinal epithelial cell expression 
of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infection & Immunity, 
68(12), pp. 7010-7017. 
 
 368 
CARIO, E., 2010. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflammatory 
bowel diseases, 16(9), pp. 1583-1597. 
CARR, I. and MAYBERRY, J.F., 1999. The effects of migration on ulcerative colitis: a three-year 
prospective study among Europeans and first- and second- generation South Asians in Leicester 
(1991-1994). The American Journal of Gastroenterology, 94(10), pp. 2918-2922. 
CASE, G.L. and BENEVENGA, N.J., 1977. Significance of formate as an intermediate in the 
oxidation of the methionine, S-methyl-L-cysteine and sarcosine methyl carbons to CO2 in the rat. 
Journal of Nutrition, 107(9), pp. 1665-1676. 
CASINI-RAGGI, V., KAM, L., CHONG, Y.J., FIOCCHI, C., PIZARRO, T.T. and COMINELLI, F., 
1995. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A 
novel mechanism of chronic intestinal inflammation. Journal of Immunology, 154(5), pp. 2434-2440. 
CASTANO-MILLA, C., CHAPARRO, M. and GISBERT, J.P., 2014. Systematic review with meta-
analysis: the declining risk of colorectal cancer in ulcerative colitis. Alimentary Pharmacology & 
Therapeutics, 39(7), pp. 645-659. 
CASTLE, L.A., FIEHN, O., KADDURAH-DAOUK, R. and LINDON, J.C., 2006. Metabolomics 
standards workshop and the development of internatio l standards for reporting metabolomics 
experimental results. Briefings in Bioinformatics, 7(2), pp. 159-165. 
CAUWELS, A., ROGGE, E., VANDENDRIESSCHE, B., SHIVA, S. and BROUCKAERT, P., 2014. 
Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell death & disease, 
5, pp. e1102. 
CAVANAUGH, J. and IBD INTERNATIONAL GENETICS CONSORTIUM, 2001. International 
collaboration provides convincing linkage replication in complex disease through analysis of a large 
pooled data set: Crohn disease and chromosome 16. American Journal of Human Genetics, 68(5), pp. 
1165-1171. 
CERINI, C., DOU, L., ANFOSSO, F., SABATIER, F., MOAL, V., GLORIEUX, G., DE SMET, R., 
VANHOLDER, R., DIGNAT-GEORGE, F., SAMPOL, J., BERLAND, Y. and BRUNET, P., 2004. 
P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thrombosis and 
haemostasis, 92(1), pp. 140-150. 
CHADWICK, N., BRUCE, I.J., SCHEPELMANN, S., POUNDER, .E. and WAKEFIELD, A.J., 
1998. Measles virus RNA is not detected in inflammatory bowel disease using hybrid capture and 
reverse transcription followed by the polymerase chain reaction. Journal of medical virology, 55(4), 
pp. 305-311. 
CHAN, E.C., KOH, P.K., MAL, M., CHEAH, P.Y., EU, K.W., BACKSHALL, A., CAVILL, R., 
NICHOLSON, J.K. and KEUN, H.C., 2009. Metabolic profiling of human colorectal cancer using 
high-resolution magic angle spinning nuclear magnetic r sonance (HR-MAS NMR) spectroscopy and 
gas chromatography mass spectrometry (GC/MS). Journal of proteome research, 8(1), pp. 352-361. 
CHAO, A., THUN, M.J., CONNELL, C.J., MCCULLOUGH, M.L , JACOBS, E.J., FLANDERS, 
W.D., RODRIGUEZ, C., SINHA, R. and CALLE, E.E., 2005. Meat consumption and risk of 
colorectal cancer. Jama, 293(2), pp. 172-182. 
CHAPMAN, M.A., GRAHN, M.F., BOYLE, M.A., HUTTON, M., ROGERS, J. and WILLIAMS, 
N.S., 1994. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative 
colitis. Gut, 35(1), pp. 73-76. 
CHASSARD, C. and BERNALIER-DONADILLE, A., 2006. H2 and acetate transfers during xylan 
fermentation between a butyrate-producing xylanolytic species and hydrogenotrophic microorganisms 
from the human gut. FEMS microbiology letters, 254(1), pp. 116-122. 
CHEN, C., GONZALEZ, F.J. and IDLE, J.R., 2007. LC-MS-based metabolomics in drug metabolism. 
Drug metabolism reviews, 39(2-3), pp. 581-597. 
CHEN, C., SHAH, Y.M., MORIMURA, K., KRAUSZ, K.W., MIYAZAKI, M., RICHARDSON, 
T.A., MORGAN, E.T., NTAMBI, J.M., IDLE, J.R. and GONZALEZ, F.J., 2008. Metabolomics 
reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute 
colitis. Cell Metabolism, 7(2), pp. 135-147. 
CHEN, W., LOU, H., ZHANG, H., NIE, X., LAN, W., YANG, Y., XIANG, Y., QI, J., LEI, H., 
TANG, H., CHEN, F. and DENG, F., 2011. Grade classification of neuroepithelial tumors using high-
resolution magic-angle spinning proton nuclear magnetic resonance spectroscopy and pattern 
recognition. Science China.Life sciences, 54(7), pp. 606-616. 
CHEN, Y., MA, Z., LI, A., LI, H., WANG, B., ZHONG, J., MIN, L. and DAI, L., 2015. Metabolomic 
profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole 
 
 369 
time-of-flight mass spectrometry and gas chromatography/mass spectrometry. Journal of cancer 
research and clinical oncology, 141(4), pp. 705-718. 
CHERBUT, C., 2002. Inulin and oligofructose in the di tary fibre concept. The British journal of 
nutrition, 87 Suppl 2, pp. S159-62. 
CHIODINI, R.J., VAN KRUININGEN, H.J., MERKAL, R.S., THAYER, W.R.,JR and COUTU, J.A., 
1984. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's 
disease. Journal of clinical microbiology, 20(5), pp. 966-971. 
CHO, J.H. and ABRAHAM, C., 2007. Inflammatory bowel disease genetics: Nod2. Annual Review 
of Medicine, 58, pp. 401-416. 
CHRISTOPHER, M.M., ECKFELDT, J.H. and EATON, J.W., 1990. Propylene glycol ingestion 
causes D-lactic acidosis. Laboratory Investigation, 62(1), pp. 114-118. 
CINES, D.B., POLLAK, E.S., BUCK, C.A., LOSCALZO, J., ZIMMERMAN, G.A., MCEVER, R.P., 
POBER, J.S., WICK, T.M., KONKLE, B.A., SCHWARTZ, B.S , BARNATHAN, E.S., MCCRAE, 
K.R., HUG, B.A., SCHMIDT, A.M. and STERN, D.M., 1998. Endothelial cells in physiology and in 
the pathophysiology of vascular disorders. Blood, 91(10), pp. 3527-3561. 
CIPOLLA, G., CREMA, F., SACCO, S., MORO, E., DE PONTI, F. and FRIGO, G., 2002. 
Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. 
Pharmacological research : the official journal of the Italian Pharmacological Society, 46(1), pp. 1-6. 
CLAUSEN, M.R. and MORTENSEN, P.B., 1995. Kinetic studies on colonocyte metabolism of short 
chain fatty acids and glucose in ulcerative colitis. Gut, 37(5), pp. 684-689. 
CLEYNEN, I., BOUCHER, G., JOSTINS, L., SCHUMM, L.P., ZEISSIG, S., AHMAD, T., 
ANDERSEN, V., ANDREWS, J.M., ANNESE, V., BRAND, S., BRANT, S.R., CHO, J.H., DALY, 
M.J., DUBINSKY, M., DUERR, R.H., FERGUSON, L.R., FRANKE, A., GEARRY, R.B., 
GOYETTE, P., HAKONARSON, H., HALFVARSON, J., HOV, J.R., HUANG, H., KENNEDY, 
N.A., KUPCINSKAS, L., LAWRANCE, I.C., LEE, J.C., SATSANGI, J., SCHREIBER, S., 
THEATRE, E., VAN DER MEULEN-DE JONG, A.E., WEERSMA, R.K., WILSON, D.C., 
INTERNATIONAL INFLAMMATORY BOWEL DISEASE GENETICS CONSORTIUM, 
PARKES, M., VERMEIRE, S., RIOUX, J.D., MANSFIELD, J., SILVERBERG, M.S., RADFORD-
SMITH, G., MCGOVERN, D.P., BARRETT, J.C. and LEES, C.W., 2016. Inherited determinants of 
Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (London, 
England), 387(10014), pp. 156-167. 
COBRIN, G.M. and ABREU, M.T., 2005. Defects in mucosal immunity leading to Crohn's disease. 
Immunological reviews, 206, pp. 277-295. 
COBURN, L.A., GONG, X., SINGH, K., ASIM, M., SCULL, B.P., ALLAMAN, M.M., WILLIAMS, 
C.S., ROSEN, M.J., WASHINGTON, M.K., BARRY, D.P., PIAZUELO, M.B., CASERO, R.A.,JR, 
CHATURVEDI, R., ZHAO, Z. and WILSON, K.T., 2012. L-arginine supplementation improves 
responses to injury and inflammation in dextran sulfate sodium colitis. PloS one, 7(3), pp. e33546. 
COGAN, T.M. and JORDAN, K.N., 1994. Metabolism of Leuconostoc Bacteria. Journal of dairy 
science, 77(9), pp. 2704-2717. 
COHAVY, O., BRUCKNER, D., GORDON, L.K., MISRA, R., WEI, B., EGGENA, M.E., 
TARGAN, S.R. and BRAUN, J., 2000. Colonic bacteria express an ulcerative colitis pANCA-related 
protein epitope. Infection & Immunity, 68(3), pp. 1542-1548. 
COLEMONT, L.J., PATTYN, S.R., MICHIELSEN, P.P., PEN, J.H., PELCKMANS, P.A., VAN 
MAERCKE, Y.M. and PORTAELS, F., 1988. Acid-fast bacilli in Crohn's disease. Lancet, 1(8580), 
pp. 294-295. 
COLOMBEL, J., SANDBORN, W.J., RUTGEERTS, P., ENNS, R. HANAUER, S.B., 
PANACCIONE, R., SCHREIBER, S., BYCZKOWSKI, D., LI, J., KENT, J.D. and POLLACK, P.F., 
2007. Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s 
Disease: The CHARM Trial. Gastroenterology, 132(1), pp. 52-65. 
CONTE, M.P., SCHIPPA, S., ZAMBONI, I., PENTA, M., CHIARINI, F., SEGANTI, L., OSBORN, 
J., FALCONIERI, P., BORRELLI, O. and CUCCHIARA, S., 2006. Gut-associated bacterial 
microbiota in paediatric patients with inflammatory bowel disease. Gut, 55(12), pp. 1760-1767. 
COOKE, E.M., EWINS, S.P., HYWEL-JONES, J. and LENNARD-JONES, J.E., 1974. Properties of 
strains of Escherichia coli carried in different phases of ulcerative colitis. Gut, 15(2), pp. 143-146. 
COONEY, R., BAKER, J., BRAIN, O., DANIS, B., PICHULIK, T., ALLAN, P., FERGUSON, D.J., 
CAMPBELL, B.J., JEWELL, D. and SIMMONS, A., 2010. NOD2 stimulation induces autophagy in 




COONEY, R.M., WARREN, B.F., ALTMAN, D.G., ABREU, M.T. and TRAVIS, S.P.L., 2007. 
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials, 8(17),. 
COPPIN, H.L., CARMICHAEL, P., LOMBARDI, G., L'FAQIHI, F.E., SALTER, R., PARHAM, P., 
LECHLER, R.I. and DE PREVAL, C., 1993. Position 71 in the alpha helix of the DR beta domain is 
predicted to influence peptide binding and plays a central role in allorecognition. European journal of 
immunology, 23(2), pp. 343-349. 
CORNISH, J.A., TAN, E., SIMILLIS, C., CLARK, S.K., TEARE, J. and TEKKIS, P.P., 2008. The 
risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. The 
American Journal of Gastroenterology, 103(9), pp. 2394-2400. 
COSNES, J., BEAUGERIE, L., CARBONNEL, F. and GENDRE, J.P., 2001. Smoking cessation and 
the course of Crohn's disease: an intervention study. Gastroenterology, 120(5), pp. 1093-1099. 
COSNES, J., CARBONNEL, F., CARRAT, F., BEAUGERIE, L. CATTAN, S. and GENDRE, J., 
1999. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. 
Alimentary Pharmacology & Therapeutics, 13(11), pp. 1403-1411. 
CRAMA-BOHBOUTH, G.E.B.I. and  PENA, A.S., 1998. 
CROHN, B.B., GINZBERG, L. and OPPENHEIMER, G.D., 1932. REGIONAL ILEITIS A 
PATHOLOGIC AND CLINICAL ENTITY. The Journal of the American Medical Association, 
99(16), pp. 1323-1329. 
CROMER, W.E., MATHIS, J.M., GRANGER, D.N., CHAITANYA, G.V. and ALEXANDER, J.S., 
2011. Role of the endothelium in inflammatory bowel diseases. World journal of gastroenterology : 
WJG, 17(5), pp. 578-593. 
CUBBON, S., ANTONIO, C., WILSON, J. and THOMAS-OATES, J., 2010. Metabolomic 
applications of HILIC-LC-MS. Mass spectrometry reviws, 29(5), pp. 671-684. 
CULLIS, P.R. and  HOPE, M.J., 1992. Physical properties and functional roles of lipids in 
membranes. In: D.E. VANCE, ed,  
CUMMINGS, J.R., KESHAV, S. and TRAVIS, S.P., 2008. Medical management of Crohn's disease. 
BMJ (Clinical research ed.), 336(7652), pp. 1062-1066. 
DALZIEL, T.K., 1913. Chronic intestinal enteritis. British medical journal, 2, pp. 1068-1070. 
DANESE, S., SGAMBATO, A., PAPA, A., SCALDAFERRI, F., POLA, R., SANS, M., 
LOVECCHIO, M., GASBARRINI, G., CITTADINI, A. and GASBARRINI, A., 2005. Homocysteine 
triggers mucosal microvascular activation in inflammatory bowel disease. The American Journal of 
Gastroenterology, 100(4), pp. 886-895. 
DANZE, P.M., COLOMBEL, J.F., JACQUOT, S., LOSTE, M.N., HERESBACH, D., ATEGBO, S., 
KHAMASSI, S., PERICHON, B., SEMANA, G., CHARRON, D. and CEZARD, J.P., 1996. 
Association of HLA class II genes with susceptibility to Crohn's disease. Gut, 39(1), pp. 69-72. 
DARFEUILLE-MICHAUD, A., BOUDEAU, J., BULOIS, P., NEUT, C., GLASSER, A.L., 
BARNICH, N., BRINGER, M.A., SWIDSINSKI, A., BEAUGERIE, L. and COLOMBEL, J.F., 2004. 
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. 
Gastroenterology, 127(2), pp. 412-421. 
DARFEUILLE-MICHAUD, A., NEUT, C., BARNICH, N., LEDERMAN, E., DI MARTINO, P., 
DESREUMAUX, P., GAMBIEZ, L., JOLY, B., CORTOT, A. and COLOMBEL, J.F., 1998. Presence 
of adherent Escherichia coli strains in ileal mucosa f patients with Crohn's disease. Gastroenterology, 
115(6), pp. 1405-1413. 
DASZAK, P., PURCELL, M., LEWIN, J., DHILLON, A.P., POUNDER, R.E. and WAKEFIELD, 
A.J., 1997. Detection and comparative analysis of persistent measles virus infection in Crohn's disease 
by immunogold electron microscopy. Journal of clinial pathology, 50(4), pp. 299-304. 
DAULATZAI, M.A., 2014. Chronic functional bowel syndrome enhances gut-brain axis dysfunction, 
neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochemical research, 
39(4), pp. 624-644. 
DAVAATSEREN, M., HWANG, J.T., PARK, J.H., KIM, M.S., WANG, S. and SUNG, M.J., 2013. 
Poly-gamma-glutamic acid attenuates angiogenesis and inflammation in experimental colitis. 
Mediators of inflammation, 2013, pp. 982383. 
DAVENPECK, K.L., GAUTHIER, T.W., ALBERTINE, K.H. and LEFER, A.M., 1994. Role of P-
selectin in microvascular leukocyte-endothelial interaction in splanchnic ischemia-reperfusion. The 
American Journal of Physiology, 267(2 Pt 2), pp. H622-30. 
DAVENPORT, M., POLES, J., LEUNG, J.M., WOLFF, M.J., ABIDI, W.M., ULLMAN, T., 
MAYER, L., CHO, I. and LOKE, P., 2014. Metabolic alterations to the mucosal microbiota in 
inflammatory bowel disease. Inflammatory bowel diseases, 20(4), pp. 723-731. 
 
 371 
DAVIS, C.P., 1996. Normal Flora. In: S. BARON, ed, Medical Microbiology. 4th edn. Galveston 
(TX): The University of Texas Medical Branch at Galveston, . 
DAVIS, R.L., KRAMARZ, P., BOHLKE, K., BENSON, P., THOMPSON, R.S., MULLOOLY, J., 
BLACK, S., SHINEFIELD, H., LEWIS, E., WARD, J., MARCY, S.M., ERIKSEN, E., 
DESTEFANO, F., CHEN, R. and VACCINE SAFETY DATALINK TEAM, 2001. Measles-mumps-
rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel 
disease: a case-control study from the Vaccine Safety Datalink project. Archives of Pediatrics & 
Adolescent Medicine, 155(3), pp. 354-359. 
DE BAKKER, P.I., FERREIRA, M.A., JIA, X., NEALE, B.M., RAYCHAUDHURI, S. and 
VOIGHT, B.F., 2008. Practical aspects of imputation-driven meta-analysis of genome-wide 
association studies. Human molecular genetics, 17(R2), pp. R122-8. 
DE JONG, N.S., LEACH, S.T. and DAY, A.S., 2006. Fecal S100A12: a novel noninvasive marker in 
children with Crohn's disease. Inflammatory bowel diseases, 12(7), pp. 566-572. 
DE PRETER, V., MACHIELS, K., JOOSSENS, M., ARIJS, I., MATTHYS, C., VERMEIRE, S., 
RUTGEERTS, P. and VERBEKE, K., 2015. Faecal metabolite profiling identifies medium-chain fatty 
acids as discriminating compounds in IBD. Gut, 64(3), pp. 447-458. 
DEAR, G.J., AYRTON, J., PLUMB, R. and FRASER, I.J., 1999. The rapid identification of drug 
metabolites using capillary liquid chromatography coupled to an ion trap mass spectrometer. Rapid 
Communications in Mass Spectrometry, 13(5), pp. 456- 63. 
DEARING, W.H., MCGUCKIN, W.F. and ELVEBACK, L.R., 1969. Serum alpha 1-acid 
glycoprotein in chronic ulcerative colitis. Gastroent rology, 56(2), pp. 295-303. 
DELANEY, C.P., DADVAND, B., REMZI, F.H., CHURCH, J.M. and FAZIO, V.W., 2002. 
Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected 
septuagenarians. Diseases of the Colon & Rectum, 45(7), pp. 890-894. 
DELZENNE, N.M., 2003. Oligosaccharides: state of the art. The Proceedings of the Nutrition 
Society, 62(1), pp. 177-182. 
DENKERT, C., BUDCZIES, J., KIND, T., WEICHERT, W., TABLACK, P., SEHOULI, J., 
NIESPOREK, S., KONSGEN, D., DIETEL, M. and FIEHN, O., 2006. Mass spectrometry-based 
metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian 
borderline tumors. Cancer research, 66(22), pp. 10795-10804. 
DENKERT, C., BUDCZIES, J., WEICHERT, W., WOHLGEMUTH, G., SCHOLZ, M., KIND, T., 
NIESPOREK, S., NOSKE, A., BUCKENDAHL, A., DIETEL, M. and FIEHN, O., 2008. Metabolite 
profiling of human colon carcinoma--deregulation of TCA cycle and amino acid turnover. Molecular 
cancer, 7, pp. 72-4598-7-72. 
DESAI, D., FAUBION, W.A. and SANDBORN, W.J., 2007. Review article: biological activity 
markers in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 25(3), pp. 247-
255. 
DESREUMAUX, P. and GHOSH, S., 2006. Review article: mode of action and delivery of 5-
aminosalicylic acid - new evidence. Alimentary Pharm cology & Therapeutics, 24 Suppl 1, pp. 2-9. 
Detection of inflammatory bowel disease by proton magnetic resonance spectroscopy (1H MRS) 
using an animal model. Journal of Inflammation, 4(24),. 
DETTMER, K., ARONOV, P.A. and HAMMOCK, B.D., 2007. Mass spectrometry-based 
metabolomics. Mass spectrometry reviews, 26(1), pp. 51-78. 
DEVEREUX, R., DELANEY, M., WIDDEL, F. and STAHL, D.A., 1989. Natural relationships 
among sulfate-reducing eubacteria. Journal of Bacteriology, 171(12), pp. 6689-6695. 
DEVROEDE, G.J., TAYLOR, W.F., SAUER, W.G., JACKMAN, R.J. and STICKLER, G.B., 1971. 
Cancer risk and life expectancy of children with ulcerative colitis. The New England journal of 
medicine, 285(1), pp. 17-21. 
D'HAENS, G.R., LASHNER, B.A. and HANAUER, S.B., 1993. Pericholangitis and sclerosing 
cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. The American Journal of 
Gastroenterology, 88(8), pp. 1174-1178. 
D'INCA, R., DAL PONT, E., DI LEO, V., FERRONATO, A., FRIES, W., VETTORATO, M.G., 
MARTINES, D. and STURNIOLO, G.C., 2007. Calprotectin and lactoferrin in the assessment of 
intestinal inflammation and organic disease. International journal of colorectal disease, 22(4), pp. 429-
437. 
DING, J., SORENSEN, C.M., ZHANG, Q., JIANG, H., JAITLY, N., LIVESAY, E.A., SHEN, Y., 
SMITH, R.D. and METZ, T.O., 2007. Capillary LC coupled with high-mass measurement accuracy 
mass spectrometry for metabolic profiling. Analytical Chemistry, 79(16), pp. 6081-6093. 
 
 372 
DOMINGUEZ-BELLO, M.G., BLASER, M.J., LEY, R.E. and KNIGHT, R., 2011. Development of 
the human gastrointestinal microbiota and insights from high-throughput sequencing. 
Gastroenterology, 140(6), pp. 1713-1719. 
DONG, F., ZHANG, L., HAO, F., TANG, H. and WANG, Y., 2013. Systemic responses of mice to 
dextran sulfate sodium-induced acute ulcerative colitis using 1H NMR spectroscopy. Journal of 
proteome research, 12(6), pp. 2958-2966. 
DOTAN, I., FISHMAN, S., DGANI, Y., SCHWARTZ, M., KARBAN, A., LERNER, A., 
WEISHAUSS, O., SPECTOR, L., SHTEVI, A., ALTSTOCK, R.T., DOTAN, N. and HALPERN, Z., 
2006. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's 
disease. Gastroenterology, 131(2), pp. 366-378. 
DUBE, R., ROOK, G.A., STEELE, J., BREALEY, R., DWEK, R., RADEMACHER, T. and 
LENNARD-JONES, J., 1990. Agalactosyl IgG in inflammatory bowel disease: correlation with C-
reactive protein. Gut, 31(4), pp. 431-434. 
DUBOC, H., RAJCA, S., RAINTEAU, D., BENAROUS, D., MAUBERT, M.A., QUERVAIN, E., 
THOMAS, G., BARBU, V., HUMBERT, L., DESPRAS, G., BRIDONNEAU, C., DUMETZ, F., 
GRILL, J.P., MASLIAH, J., BEAUGERIE, L., COSNES, J., CHAZOUILLERES, O., POUPON, R., 
WOLF, C., MALLET, J.M., LANGELLA, P., TRUGNAN, G., SOKOL, H. and SEKSIK, P., 2013. 
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. 
Gut, 62(4), pp. 531-539. 
DUFFY, M.M., REGAN, M.C., RAVICHANDRAN, P., O'KEANE, C., HARRINGTON, M.G., 
FITZPATRICK, J.M. and O'CONNELL, P.R., 1998. Mucosal metabolism in ulcerative colitis and 
Crohn's disease. Diseases of the Colon & Rectum, 41(11), pp. 1399-1405. 
DUGGAN, A.E., USMANI, I., NEAL, K.R. and LOGAN, R.F., 1998. Appendicectomy, childhood 
hygiene, Helicobacter pylori status, and risk of inflammatory bowel disease: a case control study. Gut,
43(4), pp. 494-498. 
DUMAS, M.E., MAIBAUM, E.C., TEAGUE, C., UESHIMA, H., ZHOU, B., LINDON, J.C., 
NICHOLSON, J.K., STAMLER, J., ELLIOTT, P., CHAN, Q. and HOLMES, E., 2006. Assessment 
of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale 
epidemiological research: the INTERMAP Study. Analytical Chemistry, 78(7), pp. 2199-2208. 
DUNCAN, S.H., HOLD, G.L., BARCENILLA, A., STEWART, C.S. and FLINT, H.J., 2002. 
Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human 
faeces. International Journal of Systematic and Evolutionary Microbiology, 52(Pt 5), pp. 1615-1620. 
DUNN, W.B. and ELLIS, D.I., 2005. Metabolomics: Current analytical platforms and methodologies. 
TrAC Trends in Analytical Chemistry, 24(4), pp. 285-294. 
DUNN, W.B., 2008. Current trends and future requirements for the mass spectrometric investigation 
of microbial, mammalian and plant metabolomes. Physical Biology, 5(1), pp. 011001. 
DUNN, W.B., BROADHURST, D., BEGLEY, P., ZELENA, E., FRANCIS-MCINTYRE, S., 
ANDERSON, N., BROWN, M., KNOWLES, J.D., HALSALL, A., HASELDEN, J.N., NICHOLLS, 
A.W., WILSON, I.D., KELL, D.B., GOODACRE, R. and THE HUMAN SERUM METABOLOME 
(HUSERMET) CONSORTIUM, 2011. Procedures for large-scale metabolic profiling of serum and 
plasma using gas chromatography and liquid chromatogr phy coupled to mass spectrometry. Nature 
protocols, 6(7), pp. 1060-1083. 
EADALA, P., MATTHEWS, S.B., WAUD, J.P., GREEN, J.T. and CAMPBELL, A.K., 2011. 
Association of lactose sensitivity with inflammatory bowel disease--demonstrated by analysis of 
genetic polymorphism, breath gases and symptoms. Alimentary Pharmacology & Therapeutics, 34(7), 
pp. 735-746. 
EADEN, J.A., ABRAMS, K.R. and MAYBERRY, J.F., 2001. The risk of colorectal cancer in 
ulcerative colitis: a meta-analysis. Gut, 48(4), pp. 526-535. 
ECKBURG, P.B. and RELMAN, D.A., 2007. The role of microbes in Crohn's disease. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America, 44(2), pp. 
256-262. 
ECKBURG, P.B., BIK, E.M., BERNSTEIN, C.N., PURDOM, E., DETHLEFSEN, L., SARGENT, 
M., GILL, S.R., NELSON, K.E. and RELMAN, D.A., 2005. Diversity of the human intestinal 
microbial flora. Science (New York, N.Y.), 308(5728), pp. 1635-1638. 
ECKMANN, L., JUNG, H.C., SCHURER-MALY, C., PANJA, A., MORZYCKA-WROBLEWSKA, 
E. and KAGNOFF, M.F., 1993. Differential cytokine expression by human intestinal epithelial cell 
lines: regulated expression of interleukin 8. Gastroenterology, 105(6), pp. 1689-1697. 
 
 373 
EKBOM, A., ADAMI, H.O., HELMICK, C.G., JONZON, A. and ZACK, M.M., 1990. Perinatal risk 
factors for inflammatory bowel disease: a case-control s udy. American Journal of Epidemiology, 
132(6), pp. 1111-1119. 
EKBOM, A., DASZAK, P., KRAAZ, W. and WAKEFIELD, A.J., 1996. Crohn's disease after in-
utero measles virus exposure. Lancet, 348(9026), pp. 515-517. 
EKBOM, A., HELMICK, C., ZACK, M. and ADAMI, H.O., 1990. Increased risk of large-bowel 
cancer in Crohn's disease with colonic involvement. Lancet, 336(8711), pp. 357-359. 
ELROD, J.W., LAROUX, F.S., HOUGHTON, J., CARPENTER, A.  ANDO, T., JENNINGS, M.H., 
GRISHAM, M., WALKER, N. and ALEXANDER, J.S., 2005. DSS-induced colitis is exacerbated in 
STAT-6 knockout mice. Inflammatory bowel diseases, 11(10), pp. 883-889. 
FABRÍCIO F., C., 2008. Non-coding RNAs, epigenetics and complexity. Gene, 410(1), pp. 9-17. 
FAGAN, E.A., DYCK, R.F., MATON, P.N., HODGSON, H.J., CHADWICK, V.S., PETRIE, A. and 
PEPYS, M.B., 1982. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. 
European journal of clinical investigation, 12(4), pp. 351-359. 
FAGERHOL, M.K., DALE, I. and ANDERSON, T., 1980. Release and Quantitation of a Leucocyte 
Derived Protein (L1). Scandinavian journal of haematology, 24(5), pp. 393-398. 
FAGERSTAM, J.P. and WHISS, P.A., 2006. Higher platelet P-selectin in male patients with 
inflammatory bowel disease compared to healthy males. World journal of gastroenterology : WJG, 
12(8), pp. 1270-1272. 
FAINTUCH, J., 2002. Nutritional abnormalities in inflammatory bowel disease. Revista do Hospital 
das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo, 57(4), pp. 129-130. 
FANARO, S., CHIERICI, R., GUERRINI, P. and VIGI, V., 2003. Intestinal microflora in early 
infancy: composition and development. Acta paediatric  (Oslo, Norway : 1992).Supplement, 91(441), 
pp. 48-55. 
FARZAEI, M.H., RAHIMI, R. and ABDOLLAHI, M., 2015. The role of dietary polyphenols in the 
management of inflammatory bowel disease. Current Pharmaceutical Biotechnology, 16(3), pp. 196-
210. 
FAULK, C. and DOLINOY, D.C., 2011. Timing is everything: the when and how of environmentally 
induced changes in the epigenome of animals. Epigenetics: Official Journal of the DNA Methylation 
Society, 6(7), pp. 791-797. 
FAURE, M., CHONE, F., METTRAUX, C., GODIN, J.P., BECHEREAU, F., VUICHOUD, J., 
PAPET, I., BREUILLE, D. and OBLED, C., 2007. Threonine utilization for synthesis of acute phase 
proteins, intestinal proteins, and mucins is increased during sepsis in rats. The Journal of nutrition, 
137(7), pp. 1802-1807. 
FAURE, M., METTRAUX, C., MOENNOZ, D., GODIN, J.P., VUICHOUD, J., ROCHAT, F., 
BREUILLE, D., OBLED, C. and CORTHESY-THEULAZ, I., 2006. Specific amino acids increase 
mucin synthesis and microbiota in dextran sulfate sodium-treated rats. The Journal of nutrition, 
136(6), pp. 1558-1564. 
FAURE, M., MOENNOZ, D., MONTIGON, F., METTRAUX, C., BREUILLE, D. and BALLEVRE, 
O., 2005. Dietary threonine restriction specifically reduces intestinal mucin synthesis in rats. The 
Journal of nutrition, 135(3), pp. 486-491. 
FAVA, F., LOVEGROVE, J.A., GITAU, R., JACKSON, K.G. and TUOHY, K.M., 2006. The gut 
microbiota and lipid metabolism: implications for human health and coronary heart disease. Current 
medicinal chemistry, 13(25), pp. 3005-3021. 
FEAGAN, B.G., PANACCIONE, R., SANDBORN, W.J., D'HAENS, G.R., SCHREIBER, S., 
RUTGEERTS, P.J., LOFTUS, E.V.,JR, LOMAX, K.G., YU, A.P., WU, E.Q., CHAO, J. and 
MULANI, P., 2008. Effects of adalimumab therapy on incidence of hospitalization and surgery in 
Crohn's disease: results from the CHARM study. Gastroenterology, 135(5), pp. 1493-1499. 
FEENEY, M., CIEGG, A., WINWOOD, P. and SNOOK, J., 1997. A case-control study of measles 
vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet, 
350(9080), pp. 764-766. 
FELLER, M., HUWILER, K., STEPHAN, R., ALTPETER, E., SHANG, A., FURRER, H., 
PFYFFER, G.E., JEMMI, T., BAUMGARTNER, A. and EGGER, M., 2007. Mycobacterium avium 
subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. The Lancet 
Infectious Diseases, 7(9), pp. 607-613. 
FELLOWS, I.W., FREEMAN, J.G. and HOLMES, G.K., 1990. Crohn's disease in the city of Derby, 
1951-85. Gut, 31(11), pp. 1262-1265. 
 
 374 
FENN, J.B., MANN, M., MENG, C.K., WONG, S.F. and WHITEHOUSE, C.M., 1989. Electrospray 
ionization for mass spectrometry of large biomolecus. Science (New York, N.Y.), 246(4926), pp. 
64-71. 
FERRANTE, M., HENCKAERTS, L., JOOSSENS, M., PIERIK, M., JOOSSENS, S., DOTAN, N., 
NORMAN, G.L., ALTSTOCK, R.T., VAN STEEN, K., RUTGEERTS, P., VAN ASSCHE, G. and 
VERMEIRE, S., 2007. New serological markers in inflammatory bowel disease are associated with 
complicated disease behaviour. Gut, 56(10), pp. 1394-1403. 
FIEHN, O. and KIND, T., 2007. Metabolite profiling in blood plasma. Methods in Molecular Biology, 
358, pp. 3-17. 
FIEHN, O., ROBERTSON, D., GRIFFIN, J., VAN DER WERF, M., NIKOLAU, B., MORRISON, 
N., SUMNER, L.W., GOODACRE, R., HARDY, N.W., TAYLOR, C., FOSTEL, J., KRISTAL, B., 
KADDURAH-DAOUK, R., MENDES, P., VAN OMMEN, B., LINDON, J.C. and SANSONE, S.A., 
2007. The metabolomics standards initiative (MSI). Metabolomics, 3, pp. 175-178. 
FINNIE, I.A., CAMPBELL, B.J., TAYLOR, B.A., MILTON, J.D., SADEK, S.K., YU, L.G. and 
RHODES, J.M., 1996. Stimulation of colonic mucin synthesis by corticosteroids and nicotine. 
Clinical science, 91(3), pp. 359-364. 
FINNIE, I.A., TAYLOR, B.A. and RHODES, J.M., 1993. Ileal and colonic epithelial metabolism in 
quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate 
metabolism. Gut, 34(11), pp. 1552-1558. 
FIREMAN, Z., GROSSMAN, A., LILOS, P., ESHCHAR, Y., THEODOR, E. and GILAT, T., 1989. 
Epidemiology of Crohn's disease in the Jewish population of central Israel, 1970-1980. The American 
Journal of Gastroenterology, 84(3), pp. 255-258. 
FIRMANSYAH, A., PENN, D. and LEBENTHAL, E., 1989. Isolated colonocyte metabolism of 
glucose, glutamine, n-butyrate, and beta-hydroxybutyrate in malnutrition. Gastroenterology, 97(3), pp.
622-629. 
FLINT, H.J., BAYER, E.A., RINCON, M.T., LAMED, R. and WHITE, B.A., 2008. Polysaccharide 
utilization by gut bacteria: potential for new insights from genomic analysis. Nature 
reviews.Microbiology, 6(2), pp. 121-131. 
FOELL, D., KANE, D., BRESNIHAN, B., VOGL, T., NACKEN, W., SORG, C., FITZGERALD, O. 
and ROTH, J., 2003. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in 
rheumatoid and psoriatic arthritis. Rheumatology, 42(11), pp. 1383-1389. 
FOELL, D., KUCHARZIK, T., KRAFT, M., VOGL, T., SORG, C., DOMSCHKE, W. and ROTH, J., 
2003. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active 
inflammatory bowel disease. Gut, 52(6), pp. 847-853. 
FOELL, D., SEELIGER, S., VOGL, T., KOCH, H.G., MASCHEK, H., HARMS, E., SORG, C. and 
ROTH, J., 2003. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax, 58(7), pp. 613-617. 
FOLIN, O. and DENIS, W., 1915. The excretion of free and conjugated phenols and phenol 
derivatives. Journal of Biological Chemistry, 22, pp. 309-320. 
Form and function of phospholipids. Amsterdam: Elsevier Scienctific Publishing Co., pp. 441-482. 
FORSTERMANN, U. and MUNZEL, T., 2006. Endothelial nitric oxide synthase in vascular disease: 
from marvel to menace. Circulation, 113(13), pp. 1708-1714. 
FRAGA, M.F., BALLESTAR, E., PAZ, M.F., ROPERO, S., SETIEN, F., BALLESTAR, M.L., 
HEINE-SUNER, D., CIGUDOSA, J.C., URIOSTE, M., BENITEZ, J., BOIX-CHORNET, M., 
SANCHEZ-AGUILERA, A., LING, C., CARLSSON, E., POULSEN, P., VAAG, A., STEPHAN, Z., 
SPECTOR, T.D., WU, Y.Z., PLASS, C. and ESTELLER, M.2005. Epigenetic differences arise 
during the lifetime of monozygotic twins. Proceedings of the National Academy of Sciences of the 
United States of America, 102(30), pp. 10604-10609. 
FRANK, D.N., ROBERTSON, C.E., HAMM, C.M., KPADEH, Z., ZHANG, T., CHEN, H., ZHU, 
W., SARTOR, R.B., BOEDEKER, E.C., HARPAZ, N., PACE, N.R. and LI, E., 2011. Disease 
phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory 
bowel diseases. Inflammatory bowel diseases, 17(1), pp. 179-184. 
FRANK, D.N., ST AMAND, A.L., FELDMAN, R.A., BOEDEKER, E.C., HARPAZ, N. and PACE, 
N.R., 2007. Molecular-phylogenetic characterization of microbial community imbalances in human 
inflammatory bowel diseases. Proceedings of the Nation l Academy of Sciences of the United States 
of America, 104(34), pp. 13780-13785. 
FRANKE, A., MCGOVERN, D.P., BARRETT, J.C., WANG, K., RADFORD-SMITH, G.L., 
AHMAD, T., LEES, C.W., BALSCHUN, T., LEE, J., ROBERTS, R., ANDERSON, C.A., BIS, J.C., 
BUMPSTEAD, S., ELLINGHAUS, D., FESTEN, E.M., GEORGES, M., GREEN, T., 
 
 375 
HARITUNIANS, T., JOSTINS, L., LATIANO, A., MATHEW, C.G., MONTGOMERY, G.W., 
PRESCOTT, N.J., RAYCHAUDHURI, S., ROTTER, J.I., SCHUMM, P., SHARMA, Y., SIMMS, 
L.A., TAYLOR, K.D., WHITEMAN, D., WIJMENGA, C., BALDASSANO, R.N., BARCLAY, M., 
BAYLESS, T.M., BRAND, S., BUNING, C., COHEN, A., COLOMBEL, J.F., COTTONE, M., 
STRONATI, L., DENSON, T., DE VOS, M., D'INCA, R., DUBINSKY, M., EDWARDS, C., 
FLORIN, T., FRANCHIMONT, D., GEARRY, R., GLAS, J., VAN GOSSUM, A., GUTHERY, S.L., 
HALFVARSON, J., VERSPAGET, H.W., HUGOT, J.P., KARBAN, A., LAUKENS, D., 
LAWRANCE, I., LEMANN, M., LEVINE, A., LIBIOULLE, C., LOUIS, E., MOWAT, C., 
NEWMAN, W., PANES, J., PHILLIPS, A., PROCTOR, D.D., REGUEIRO, M., RUSSELL, R., 
RUTGEERTS, P., SANDERSON, J., SANS, M., SEIBOLD, F., STEINHART, A.H., STOKKERS, 
P.C., TORKVIST, L., KULLAK-UBLICK, G., WILSON, D., WALTERS, T., TARGAN, S.R., 
BRANT, S.R., RIOUX, J.D., D'AMATO, M., WEERSMA, R.K., KUGATHASAN, S., GRIFFITHS, 
A.M., MANSFIELD, J.C., VERMEIRE, S., DUERR, R.H., SILVERBERG, M.S., SATSANGI, J., 
SCHREIBER, S., CHO, J.H., ANNESE, V., HAKONARSON, H., DALY, M.J. and PARKES, M., 
2010. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease 
susceptibility loci. Nature genetics, 42(12), pp. 1118-1125. 
FRANKISH, N. and SHERIDAN, H., 2012. 6-(methylamino)hexane-1,2,3,4,5-pentanol 4-(((1S,2S)-
1-hydroxy-2,3-dihydro-1H,1'H-[2,2-biinden]-2-yl)methyl)benzoate (PH46A): a novel small molecule 
with efficacy in murine models of colitis. Journal of medicinal chemistry, 55(11), pp. 5497-5505. 
FRICKE, H., BIRKHOFER, A., FOLWACZNY, C., MEISTER, W. and SCRIBA, P.C., 1999. 
Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target 
antigens for autoantibodies in Crohn's disease. European journal of clinical investigation, 29(1), pp. 
41-45. 
FRICKENSCHMIDT, A., FROHLICH, H., BULLINGER, D., ZELL, A., LAUFER, S., GLEITER, 
C.H., LIEBICH, H. and KAMMERER, B., 2008. Metabonomics in cancer diagnosis: mass 
spectrometry-based profiling of urinary nucleosides from breast cancer patients. Biomarkers, 13(4), 
pp. 435-449. 
FRISCH, M., PEDERSEN, B.V. and ANDERSSON, R.E., 2009. Appendicitis, mesenteric 
lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. BMJ, 
338, pp. b716. 
FUJIMOTO, K., FUKAGAWA, K., SAKATA, T. and TSO, P., 1993. Suppression of food intake by 
apolipoprotein A-IV is mediated through the central nervous system in rats. The Journal of clinical 
investigation, 91(4), pp. 1830-1833. 
FUJIMURA, Y., KAMOI, R. and IIDA, M., 1996. Pathogen sis of aphthoid ulcers in Crohn's disease: 
correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. 
Gut, 38(5), pp. 724-732. 
GABAY, C. and KUSHNER, I., 1999. Acute-phase proteins and other systemic responses to 
inflammation. New England Journal of Medicine, 340(6), pp. 448-454. 
GALVEZ, J., 2014. Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN inflammation, 
2014, pp. 928461. 
GAO, H., LU, Q., LIU, X., CONG, H., ZHAO, L., WANG, H. and LIN, D., 2009. Application of 1H 
NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and 
liver cirrhosis. Cancer science, 100(4), pp. 782-785. 
GARRETT, W.S., GALLINI, C.A., YATSUNENKO, T., MICHAUD, M., DUBOIS, A., DELANEY, 
M.L., PUNIT, S., KARLSSON, M., BRY, L., GLICKMAN, J.N., GORDON, J.I., ONDERDONK, 
A.B. and GLIMCHER, L.H., 2010. Enterobacteriaceae act in concert with the gut microbiota to 
induce spontaneous and maternally transmitted colitis. Cell host & microbe, 8(3), pp. 292-300. 
GDALEVICH, M., MIMOUNI, D. and MIMOUNI, M., 2001b. Breast-feeding and the risk of 
bronchial asthma in childhood: a systematic review with meta-analysis of prospective studies. The 
Journal of pediatrics, 139(2), pp. 261-266. 
GDALEVICH, M., MIMOUNI, D., DAVID, M. and MIMOUNI, M., 2001a. Breast-feeding and the 
onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies. 
Journal of the American Academy of Dermatology, 45(4), pp. 520-527. 
GEARRY, R.B., RICHARDSON, A.K., FRAMPTON, C.M., DODGSHUN, A.J. and BARCLAY, 
M.L., 2010. Population-based cases control study of inflammatory bowel disease risk factors. Journal 
of gastroenterology and hepatology, 25(2), pp. 325-33. 
GEBOES, K., COLOMBEL, J.F., GREENSTEIN, A., JEWELL, D.P., SANDBORN, W.J., VATN, 
M.H., WARREN, B., RIDDELL, R.H. and PATHOLOGY TASK FORCE OF THE 
 
 376 
INTERNATIONAL ORGANIZATION OF INFLAMMATORY BOWEL,DISEASES, 2008. 
Indeterminate colitis: a review of the concept--what's in a name? Inflammatory bowel diseases, 14(6), 
pp. 850-857. 
GEISSMANN, F., MANZ, M.G., JUNG, S., SIEWEKE, M.H., MERAD, M. and LEY, K., 2010. 
Development of monocytes, macrophages, and dendritic cells. Science (New York, N.Y.), 327(5966), 
pp. 656-661. 
GENT, A.E., HELLIER, M.D., GRACE, R.H., SWARBRICK, E.T. and COGGON, D., 1994. 
Inflammatory bowel disease and domestic hygiene in infancy. Lancet, 343(8900), pp. 766-767. 
GERMAN, J.B., WATKINS, S.M. and FAY, L.B., 2005. Metabolomics in practice: emerging 
knowledge to guide future dietetic advice toward inividualized health. Journal of the American 
Dietetic Association, 105(9), pp. 1425-1432. 
GEYPENS, B., CLAUS, D., EVENEPOEL, P., HIELE, M., MAES, B., PEETERS, M., 
RUTGEERTS, P. and GHOOS, Y., 1997. Influence of dietary protein supplements on the formation 
of bacterial metabolites in the colon. Gut, 41(1), pp. 70-76. 
GIAFFER, M.H., HOLDSWORTH, C.D. and DUERDEN, B.I., 1992. Virulence properties of 
Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut, 33(5), pp. 646-
650. 
GIBSON, G.R., CUMMINGS, J.H. and MACFARLANE, G.T., 1991. Growth and activities of 
sulphate-reducing bacteria in gut contents of healty subjects and patients with ulcerative colitis. 
FEMS microbiology ecology, 9(2), pp. 103-111. 
GILAT, T., HACOHEN, D., LILOS, P. and LANGMAN, M.J., 1987. Childhood factors in ulcerative 
colitis and Crohn's disease. An international cooperative study. Scandinavian Journal of 
Gastroenterology, 22(8), pp. 1009-1024. 
GILBERT, S.F., 2000. Endoderm. In: M.A. SUNDERLAND, ed, Developmental Biology. 6th edition 
edn. Sinauer Associates, . 
GILL, S.R., POP, M., DEBOY, R.T., ECKBURG, P.B., TURNBAUGH, P.J., SAMUEL, B.S., 
GORDON, J.I., RELMAN, D.A., FRASER-LIGGETT, C.M. and NELSON, K.E., 2006. 
Metagenomic analysis of the human distal gut microbiome. Science (New York, N.Y.), 312(5778), 
pp. 1355-1359. 
GISBERT, J.P., GONZALEZ-LAMA, Y. and MATE, J., 2007. 5-Aminosalicylates and renal function 
in inflammatory bowel disease: a systematic review. Inflammatory bowel diseases, 13(5), pp. 629-
638. 
GLEESON, M.H., WALKER, J.S., WENTZEL, J., CHAPMAN, J.A. and HARRIS, R., 1972. Human 
leucocyte antigens in Crohn's disease and ulcerativ colitis. Gut, 13(6), pp. 438-440. 
GLEICH, G.J. and ADOLPHSON, C.R., 1986. The eosinophilic leukocyte: structure and function. 
Advances in Immunology, 39, pp. 177-253. 
GOKER, M., GRONOW, S., ZEYTUN, A., NOLAN, M., LUCAS, S., LAPIDUS, A., HAMMON, 
N., DESHPANDE, S., CHENG, J.F., PITLUCK, S., LIOLIOS, K., PAGANI, I., IVANOVA, N., 
MAVROMATIS, K., OVCHINIKOVA, G., PATI, A., TAPIA, R., HAN, C., GOODWIN, L., CHEN, 
A., PALANIAPPAN, K., LAND, M., HAUSER, L., JEFFRIES, C.D., BRAMBILLA, E.M., ROHDE, 
M., DETTER, J.C., WOYKE, T., BRISTOW, J., MARKOWITZ, V., HUGENHOLTZ, P., EISEN, 
J.A., KYRPIDES, N.C. and KLENK, H.P., 2011. Complete genome sequence of Odoribacter 
splanchnicus type strain (1651/6). Standards in genomic sciences, 4(2), pp. 200-209. 
GOLDBERG, I.J., SCHERALDI, C.A., YACOUB, L.K., SAXENA, U. and BISGAIER, C.L., 1990. 
Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. The Journal 
of biological chemistry, 265(8), pp. 4266-4272. 
GOODACRE, R., 2007. Metabolomics of a superorganism. Journal of Nutrition, 137(1 Suppl), pp. 
259S-266S. 
GOODACRE, R., BROADHURST, D., SMILDE, A.K., KRISTAL, B.S., BAKER, J.D., BEGER, R., 
BESSANT, C., CONNOR, S., CAPUANI, G., CRAIG, A., EBBELS, T., KELL, D.B., MANETTI, C., 
NEWTON, J., PATERNOSTRO, G., SOMORJAI, R., SJOSTROM, M., TRYGG, J. and WULFERT, 
F., 2007. Proposed minimum reporting standards for data analysis in  metabolomics. Metabolomics, 3, 
pp. 231-241. 
GOULDING, N.J., 2004. The molecular complexity of glucocorticoid actions in inflammation - a 
four-ring circus. Current opinion in pharmacology, 4(6), pp. 629-636. 
GRAY, R.D., IMRIE, M., BOYD, A.C., PORTEOUS, D., INES, J.A. and GREENING, A.P., 2010. 
Sputum and serum calprotectin are useful biomarkers du ing CF exacerbation. Journal of cystic 
fibrosis : official journal of the European Cystic Fibrosis Society, 9(3), pp. 193-198. 
 
 377 
GRILL, B.B., HILLEMEIER, A.C. and GRYBOSKI, J.D., 1984. Fecal alpha 1-antitrypsin clearance 
in patients with inflammatory bowel disease. Journal of Pediatric Gastroenterology & Nutrition, 3(1), 
pp. 56-61. 
GRIP, O. and JANCIAUSKIENE, S., 2009. Atorvastatin reduces plasma levels of chemokine 
(CXCL10) in patients with Crohn's disease. PloS one, 4(5), pp. e5263. 
GUANG, C., CHEN, J., SANG, S. and CHENG, S., 2014. Biological functionality of soyasaponins 
and soyasapogenols. Journal of Agricultural and Food Chemistry, 62(33), pp. 8247-8255. 
GUERRANT, R.L., ARAUJO, V., SOARES, E., KOTLOFF, K., LIMA, A.A., COOPER, W.H. and 
LEE, A.G., 1992. Measurement of fecal lactoferrin as a marker of fecal leukocytes. Journal of clinical 
microbiology, 30(5), pp. 1238-1242. 
GUEST, P.C., GOTTSCHALK, M.G. and BAHN, S., 2013. Proteomics: improving biomarker 
translation to modern medicine? Genome medicine, 5(2), pp. 17. 
GUINDI, M. and RIDDELL, R.H., 2004. Indeterminate colitis. Journal of clinical pathology, 57(12), 
pp. 1233-1244. 
HADDAD, J.J. and ABDEL-KARIM, N.E., 2011. NF-kappaB cellular and molecular regulatory 
mechanisms and pathways: therapeutic pattern or pseudor gulation? Cellular immunology, 271(1), pp. 
5-14. 
HAGA, Y., FUNAKOSHI, O., KUROE, K., KANAZAWA, K., NAKAJIMA, H., SAITO, H., 
MURATA, Y., MUNAKATA, A. and YOSHIDA, Y., 1996. Absence of measles viral genomic 
sequence in intestinal tissues from Crohn's disease by nested polymerase chain reaction. Gut, 38(2), 
pp. 211-215. 
HAGEL, A.F., DE ROSSI, T., KONTUREK, P.C., ALBRECHT, H., WALKER, S., HAHN, E.G. and 
RAITHEL, M., 2015. Plasma histamine and tumour necrosis factor-alpha levels in Crohn's disease 
and ulcerative colitis at various stages of disease. Journal of physiology and pharmacology : an 
official journal of the Polish Physiological Society, 66(4), pp. 549-556. 
HAGLUND, S., ALMER, S., PETERSON, C. and SODERMAN, J., 2013. Gene expression and 
thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and 
disease mechanisms? PloS one, 8(2), pp. e56989. 
HALFVARSON, J., 2011. Genetics in twins with Crohn's disease: less pronounced than previously 
believed?. Inflammatory bowel diseases, 17(1), pp. 6-12. 
HALFVARSON, J., BODIN, L., TYSK, C., LINDBERG, E. and JARNEROT, G., 2003. 
Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and 
clinical characteristics. Gastroenterology, 124(7), pp. 1767-1773. 
HALKET, J.M. and ZAIKIN, V.G., 2003. Derivatization i  mass spectrometry--1. Silylation. 
European Journal of Mass Spectrometry, 9(1), pp. 1-21. 
HALKET, J.M., WATERMAN, D., PRZYBOROWSKA, A.M., PATEL, R.K., FRASER, P.D. and 
BRAMLEY, P.M., 2005. Chemical derivatization and mass spectral libraries in metabolic profiling by 
GC/MS and LC/MS/MS. Journal of experimental botany, 56(410), pp. 219-243. 
HALL, R.D., 2006. Plant metabolomics: from holistic hope, to hype, to hot topic. New Phytologist, 
169(3), pp. 453-468. 
HALME, L., PAAVOLA-SAKKI, P., TURUNEN, U., LAPPALAINEN, M., FARKKILA, M. and 
KONTULA, K., 2006. Family and twin studies in inflammatory bowel disease. World Journal of 
Gastroenterology, 12(23), pp. 3668-3672. 
HALME, L., TURUNEN, U., HELIO, T., PAAVOLA, P., WAL E, T., MIETTINEN, A., 
JARVINEN, H., KONTULA, K. and FARKKILA, M., 2002. Familial and sporadic inflammatory 
bowel disease: comparison of clinical features and serological markers in a genetically homogeneous 
population. Scandinavian Journal of Gastroenterology, 37(6), pp. 692-698. 
HAMER, H.M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F.J. and BRUMMER, 
R.J., 2008. Review article: the role of butyrate on c lonic function. Alimentary Pharmacology & 
Therapeutics, 27(2), pp. 104-119. 
HAMPE, J., CUTHBERT, A., CROUCHER, P.J., MIRZA, M.M, MASCHERETTI, S., FISHER, S., 
FRENZEL, H., KING, K., HASSELMEYER, A., MACPHERSON, A.J., BRIDGER, S., VAN 
DEVENTER, S., FORBES, A., NIKOLAUS, S., LENNARD-JONES, J.E., FOELSCH, U.R., 
KRAWCZAK, M., LEWIS, C., SCHREIBER, S. and MATHEW, C.G., 2001. Association between 
insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet, 
357(9272), pp. 1925-1928. 
HAMPE, J., FRANKE, A., ROSENSTIEL, P., TILL, A., TEUBER, M., HUSE, K., ALBRECHT, M., 
MAYR, G., DE LA VEGA, F.M., BRIGGS, J., GUNTHER, S., PRESCOTT, N.J., ONNIE, C.M., 
 
 378 
HASLER, R., SIPOS, B., FOLSCH, U.R., LENGAUER, T., PLATZER, M., MATHEW, C.G., 
KRAWCZAK, M. and SCHREIBER, S., 2007. A genome-wide association scan of nonsynonymous 
SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature genetics, 39(2), pp. 
207-211. 
HANAUER, S.B., FEAGAN, B.G., LICHTENSTEIN, G.R., MAYER, L.F., SCHREIBER, S., 
COLOMBEL, J.F., RACHMILEWITZ, D., WOLF, D.C., OLSON, A., BAO, W., RUTGEERTS, P. 
and ACCENT I STUDY, G., 2002. Maintenance infliximab for Crohn's disease: the ACCENT I 
randomised trial. Lancet, 359(9317), pp. 1541-1549. 
HANAUER, S.B., SANDBORN, W.J., RUTGEERTS, P., FEDORAK, R.N., LUKAS, M., 
MACINTOSH, D., PANACCIONE, R., WOLF, D. and POLLACK, P., 2006. Human Anti–Tumor 
Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial. 
Gastroenterology, 130(2), pp. 323-333. 
HARALDSEN, G., KVALE, D., LIEN, B., FARSTAD, I.N. and BRANDTZAEG, P., 1996. 
Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and 
vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. Journal of 
immunology (Baltimore, Md.: 1950), 156(7), pp. 2558-2565. 
HARRIES, A.D., BAIRD, A. and RHODES, J., 1982. Non-smoking: a feature of ulcerative colitis. 
British Medical Journal Clinical Research Ed, 284(6317), pp. 706. 
HARRIGAN, G.G. and GOODACRE, R., eds,  2003. Metabolic Profiling: Its Role in Biomarker 
Discovery and Gene Function Analysis. London: Kluwer Academic Publishers. 
HARVEY, R.F. and BRADSHAW, J.M., 1980. A simple index of Crohn's-disease activity. Lancet, 
1(8167), pp. 514. 
HASLAM, N., MAYBERRY, J.F., HAWTHORNE, A.B., NEWCOMBE, R.G., HOLMES, G.K. and 
PROBERT, C.S., 2000. Measles, month of birth, and Crohn's disease. Gut, 47(6), pp. 801-803. 
HASSAN-SMITH, G., WALLACE, G.R., DOUGLAS, M.R. and SINCLAIR, A.J., 2012. The role of 
metabolomics in neurological disease. Journal of neuroimmunology, 248(1-2), pp. 48-52. 
HATOUM, O.A., BINION, D.G., OTTERSON, M.F. and GUTTERMAN, D.D., 2003. Acquired 
microvascular dysfunction in inflammatory bowel disea e: Loss of nitric oxide-mediated vasodilation. 
Gastroenterology, 125(1), pp. 58-69. 
HEATLEY, R.V. and JAMES, P.D., 1979. Eosinophils in the rectal mucosa. A simple method of 
predicting the outcome of ulcerative proctocolitis?. Gut, 20(9), pp. 787-791. 
HENDERSON, P., HANSEN, R., CAMERON, F.L., GERASIMIDIS, K., ROGERS, P., BISSET, 
W.M., REYNISH, E.L., DRUMMOND, H.E., ANDERSON, N.H., VAN LIMBERGEN, J., 
RUSSELL, R.K., SATSANGI, J. and WILSON, D.C., 2012. Rising incidence of pediatric 
inflammatory bowel disease in Scotland. Inflammatory bowel diseases, 18(6), pp. 999-1005. 
HENDERSON, P., VAN LIMBERGEN, J.E., SCHWARZE, J. and WILSON, D.C., 2011. Function 
of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflammatory bowel 
diseases, 17(1), pp. 382-395. 
HERMON-TAYLOR, J., FORD, J., SUMAR, N., MILLAR, D., DORAN, T. and TIZARD, M., 1995. 
Measles virus and Crohn's disease. Lancet, 345(8954), pp. 922-923. 
HERSHKO, A. and CIECHANOVER, A., 1998. The ubiquitin system. Annual Review of 
Biochemistry, 67, pp. 425-479. 
HEYMAN, M.B., KIRSCHNER, B.S., GOLD, B.D., FERRY, G., BALDASSANO, R., COHEN, 
S.A., WINTER, H.S., FAIN, P., KING, C., SMITH, T. and EL-SERAG, H.B., 2005. Children with 
early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. 
Journal of Pediatrics, 146(1), pp. 35-40. 
HIGGINS, P.D., SCHWARTZ, M., MAPILI, J., KROKOS, I., LEUNG, J. and ZIMMERMANN, 
E.M., 2005. Patient defined dichotomous end points for remission and clinical improvement in 
ulcerative colitis. Gut, 54(6), pp. 782-788. 
HILDEBRAND, H., FREDRIKZON, B., HOLMQUIST, L., KRISTIANSSON, B. and LINDQUIST, 
B., 1991. Chronic inflammatory bowel disease in children and adolescents in Sweden. Journal of 
Pediatric Gastroenterology & Nutrition, 13(3), pp. 293-297. 
HIRAYAMA, A., KAMI, K., SUGIMOTO, M., SUGAWARA, M., TOKI, N., ONOZUKA, H., 
KINOSHITA, T., SAITO, N., OCHIAI, A., TOMITA, M., ESUMI, H. and SOGA, T., 2009. 
Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary 
electrophoresis time-of-flight mass spectrometry. Cancer research, 69(11), pp. 4918-4925. 
 
 379 
HISAMATSU, T., SUZUKI, M., REINECKER, H.C., NADEAU, W.J., MCCORMICK, B.A. and 
PODOLSKY, D.K., 2003. CARD15/NOD2 functions as an antibacterial factor in human intestinal 
epithelial cells. Gastroenterology, 124(4), pp. 993-1000. 
HJERKINN, E.M., SELJEFLOT, I., ELLINGSEN, I., BERSTAD, P., HJERMANN, I., SANDVIK, L. 
and ARNESEN, H., 2005. Influence of long-term intervention with dietary counseling, long-chain n-3 
fatty acid supplements, or both on circulating markers of endothelial activation in men with long-
standing hyperlipidemia. The American Journal of Clinical Nutrition, 81(3), pp. 583-589. 
HLAVATY, T., KRAJCOVICOVA, A. and PAYER, J., 2015. Vitamin D therapy in inflammatory 
bowel diseases: who, in what form, and how much? Journal of Crohn's & colitis, 9(2), pp. 198-209. 
HOCKE, M., RICHTER, L., BOSSECKERT, H. and EITNER, K. 1999. Platelet activating factor in 
stool from patients with ulcerative colitis and Crohn's disease. Hepato-gastroenterology, 46(28), pp. 
2333-2337. 
HOFNAGEL, O., LUECHTENBORG, B., PLENZ, G. and ROBENK, H., 2002. Expression of the 
novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial 
cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 22(4), pp. 710-711. 
HOLLYWOOD, K., BRISON, D.R. and GOODACRE, R., 2006. Metabolomics: Current technologies 
and future trends. Proteomics, 6(17), pp. 4716-4723. 
HOLMES, E.W., YONG, S.L., EIZNHAMER, D. and KESHAVARZIAN, A., 1998. Glutathione 
content of colonic mucosa: evidence for oxidative damage in active ulcerative colitis. Digestive 
Diseases & Sciences, 43(5), pp. 1088-1095. 
HOU, J.K., ABRAHAM, B. and EL-SERAG, H., 2011. Dietary intake and risk of developing 
inflammatory bowel disease: a systematic review of the literature. The American Journal of 
Gastroenterology, 106(4), pp. 563-573. 
HOVE, H., NORDGAARD-ANDERSEN, I. and MORTENSEN, P.B., 1994. Faecal DL-lactate 
concentration in 100 gastrointestinal patients. Scandinavian journal of gastroenterology, 29(3), pp. 
255-259. 
HU, Q., NOLL, R.J., LI, H., MAKAROV, A., HARDMAN, M. and GRAHAM COOKS, R., 2005. 
The Orbitrap: a new mass spectrometer. Journal of mass spectrometry : JMS, 40(4), pp. 430-443. 
HUERTAS, D., SENDRA, R. and MUNOZ, P., 2009. Chromatin dynamics coupled to DNA repair. 
Epigenetics : official journal of the DNA Methylation Society, 4(1), pp. 31-42. 
HUGHES, R., KURTH, M.J., MCGILLIGAN, V., MCGLYNN, H. and ROWLAND, I., 2008. Effect 
of colonic bacterial metabolites on Caco-2 cell paracellular permeability in vitro. Nutrition and cancer, 
60(2), pp. 259-266. 
HUGHES, R., MAGEE, E.A. and BINGHAM, S., 2000. Protein degradation in the large intestine: 
relevance to colorectal cancer. Current Issues in Intestinal Microbiology, 1(2), pp. 51-58. 
HUGOT, J.P., ALBERTI, C., BERREBI, D., BINGEN, E. and CEZARD, J.P., 2003. Crohn's disease: 
the cold chain hypothesis. Lancet, 362(9400), pp. 2012-2015. 
HUGOT, J.P., CHAMAILLARD, M., ZOUALI, H., LESAGE, S., CEZARD, J.P., BELAICHE, J., 
ALMER, S., TYSK, C., O'MORAIN, C.A., GASSULL, M., BINDER, V., FINKEL, Y., CORTOT, 
A., MODIGLIANI, R., LAURENT-PUIG, P., GOWER-ROUSSEAU, C., MACRY, J., COLOMBEL, 
J.F., SAHBATOU, M. and THOMAS, G., 2001. Association f NOD2 leucine-rich repeat variants 
with susceptibility to Crohn's disease. Nature, 411(6837), pp. 599-603. 
HUGOT, J.P., LAURENT-PUIG, P., GOWER-ROUSSEAU, C., OLSON, J.M., LEE, J.C., 
BEAUGERIE, L., NAOM, I., DUPAS, J.L., VAN GOSSUM, A., ORHOLM, M., BONAITI-PELLIE, 
C., WEISSENBACH, J., MATHEW, C.G., LENNARD-JONES, J.E., CORTOT, A., COLOMBEL, 
J.F. and THOMAS, G., 1996. Mapping of a susceptibility locus for Crohn's disease on chromosome 
16. Nature, 379(6568), pp. 821-823. 
HUI, T., LANDERS, C., VASILIAUSKAS, E., ABREU, M., DUBINSKY, M., PAPADAKIS, K.A., 
PRICE, J., LIN, Y.C., HUIYING, Y., TARGAN, S. and FLESHNER, P., 2005. Serologic responses in 
indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for 
continuous pouch inflammation. Diseases of the Colon & Rectum, 48(6), pp. 1254-1262. 
HULTEN, L., LINDHAGEN, J., LUNDGREN, O., FASTH, S. and AHREN, C., 1977. Regional 
intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology, 72(3), pp. 388-396. 
HVIID, A., SVANSTROM, H. and FRISCH, M., 2011. Antibiotic use and inflammatory bowel 
diseases in childhood. Gut, 60(1), pp. 49-54. 
IANTOMASI, T., MARRACCINI, P., FAVILLI, F., VINCENZINI, M.T., FERRETTI, P. and 
TONELLI, F., 1994. Glutathione metabolism in Crohn's disease. Biochemical medicine and metabolic 
biology, 53(2), pp. 87-91. 
 
 380 
IIZUKA, M., NAKAGOMI, O., CHIBA, M., UEDA, S. and MASAMUNE, O., 1995. Absence of 
measles virus in Crohn's disease. Lancet, 345(8943), pp. 199. 
IMEL, E.A. and ECONS, M.J., 2012. Approach to the hypophosphatemic patient. The Journal of 
clinical endocrinology and metabolism, 97(3), pp. 696-706. 
INAN, M.S., RASOULPOUR, R.J., YIN, L., HUBBARD, A.K., ROSENBERG, D.W. and 
GIARDINA, C., 2000. The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a 
human colonic epithelial cell line. Gastroenterology, 118(4), pp. 724-734. 
IRVING, P.M., GEARRY, R.B., SPARROW, M.P. and GIBSON, P.R., 2007. Review article: 
appropriate use of corticosteroids in Crohn's disease. Alimentary Pharmacology & Therapeutics, 
26(3), pp. 313-329. 
ISSAQ, H.J., NATIV, O., WAYBRIGHT, T., LUKE, B., VENSTRA, T.D., ISSAQ, E.J., 
KRAVSTOV, A. and MULLERAD, M., 2008. Detection of bladder cancer in human urine by 
metabolomic profiling using high performance liquid chromatography/mass spectrometry. The 
Journal of urology, 179(6), pp. 2422-2426. 
IVANOV, I.I., MCKENZIE, B.S., ZHOU, L., TADOKORO, C.E., LEPELLEY, A., LAFAILLE, J.J., 
CUA, D.J. and LITTMAN, D.R., 2006. The orphan nuclear receptor RORgammat directs the 
differentiation program of proinflammatory IL-17+ T helper cells. Cell, 126(6), pp. 1121-1133. 
JANCZEWSKA, I., BARTNIK, W., BUTRUK, E., TOMECKI, R., KAZIK, E. and OSTROWSKI, J., 
1991. Metabolism of vitamin A in inflammatory bowel disease. Hepato-gastroenterology, 38(5), pp. 
391-395. 
JANOWITZ, H.D., CROEN, E.C. and SACHAR, D.B., 1998. The role of the fecal stream in Crohn's 
disease: an historical and analytic review. Inflammatory bowel diseases, 4(1), pp. 29-39. 
JANSSON, J., WILLING, B., LUCIO, M., FEKETE, A., DICKSVED, J., HALFVARSON, J., TYSK, 
C. and SCHMITT-KOPPLIN, P., 2009. Metabolomics reveals metabolic biomarkers of Crohn's 
disease. PLoS ONE [Electronic Resource], 4(7), pp. e6386. 
JAYADEVAPPA, H.P., NAGENDRAPPA, G., UMESHA, S. and CHANDRASHEKAR, S., 2012. 
Synthesis and antimicrobial study of N-[4-(2-  piper dine-1-yl-ethoxy) phenyl] acetamide analogues. 
Journal of Applied Pharmaceutical Science, 2(3), pp. 192-196. 
JENKINS, H., HARDY, N., BECKMANN, M., DRAPER, J., SMITH, A.R., TAYLOR, J., FIEHN, 
O., GOODACRE, R., BINO, R.J., HALL, R., KOPKA, J., LANE, G.A., LANGE, B.M., LIU, J.R., 
MENDES, P., NIKOLAU, B.J., OLIVER, S.G., PATON, N.W., RHEE, S., ROESSNER-TUNALI, 
U., SAITO, K., SMEDSGAARD, J., SUMNER, L.W., WANG, T., WALSH, S., WURTELE, E.S. 
and KELL, D.B., 2004. A proposed framework for the description of plant metabolomics experiments 
and their results. Nature biotechnology, 22(12), pp. 1601-1606. 
JENSEN, K.B., JARNUM, S., KOUDAHL, G. and KRISTENSEN, M., 1976. Serum orosomucoid in 
ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG. 
Scandinavian Journal of Gastroenterology, 11(2), pp. 177-183. 
JESS, T., GAMBORG, M., MATZEN, P., MUNKHOLM, P. and SORENSEN, T.I., 2005. Increased 
risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. The 
American Journal of Gastroenterology, 100(12), pp. 2724-2729. 
JEWELL, D.P., SATSANGI, J., LOBO, A., PROBERT, C., FORBES, A., GHOSH, S., SHAFFER, J., 
FRENZ, M., DRUMMOND, H., TROY, G., TURNER, S., YOUNGE, L., EVANS, L., MOOSA, M., 
RODGERS-GRAY, B. and BUCHAN, S., 2005. Infliximab use in Crohn's disease: impact on health 
care resources in the UK. European journal of gastroen erology & hepatology, 17(10), pp. 1047-1052. 
JIANG, C. and PUGH, B.F., 2009. Nucleosome positioning and gene regulation: advances through 
genomics. Nature reviews.Genetics, 10(3), pp. 161-172. 
JOHANSSON, M.E., AMBORT, D., PELASEYED, T., SCHUTTE, A., GUSTAFSSON, J.K., 
ERMUND, A., SUBRAMANI, D.B., HOLMEN-LARSSON, J.M., THOMSSON, K.A., 
BERGSTROM, J.H., VAN DER POST, S., RODRIGUEZ-PINEIRO, A.M., SJOVALL, H., 
BACKSTROM, M. and HANSSON, G.C., 2011. Composition and functional role of the mucus layers 
in the intestine. Cellular and molecular life sciens : CMLS, 68(22), pp. 3635-3641. 
JOHANSSON, M.E., LARSSON, J.M. and HANSSON, G.C., 2011. The two mucus layers of colon 
are organized by the MUC2 mucin, whereas the outer lay r is a legislator of host-microbial 
interactions. Proceedings of the National Academy of Sciences of the United States of America, 108 
Suppl 1, pp. 4659-4665. 
JOHANSSON, M.E., PHILLIPSON, M., PETERSSON, J., VELCICH, A., HOLM, L. and 
HANSSON, G.C., 2008. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid 
 
 381 
of bacteria. Proceedings of the National Academy of Sciences of the United States of America, 
105(39), pp. 15064-15069. 
JOHNSON, J.R., DELAVARI, P., KUSKOWSKI, M. and STELL, A.L., 2001. Phylogenetic 
distribution of extraintestinal virulence-associated raits in Escherichia coli. The Journal of infectious 
diseases, 183(1), pp. 78-88. 
JOHNSTON, C., 2014. Metabolomic Profiling in Inflammatory Bowel Disease, Doctor of Medicine. 
Joint Formulary Committee. British National Formulary (online ed.) 09/2011, 2011-last update 
[Homepage of BMJ Group and Pharmaceutical Press], [Online]. Available: www.bnf.org12/2011]. 
JONES, J.L. and LOFTUS, E.V.,JR, 2007. Lymphoma risk in inflammatory bowel disease: is it the 
disease or its treatment? Inflammatory bowel diseases, 13(10), pp. 1299-1307. 
JONES, P., FINE, P. and PIRACHA, S., 1997. Crohn's disease and measles. Lancet, 349(9050), pp. 
473. 
JONSSON, P., GULLBERG, J., NORDSTROM, A., KUSANO, M., KOWALCZYK, M., 
SJOSTROM, M. and MORITZ, T., 2004. A strategy for identifying differences in large series of 
metabolomic samples analyzed by GC/MS. Analytical Chemistry, 76(6), pp. 1738-1745. 
JOOSSENS, M., HUYS, G., CNOCKAERT, M., DE PRETER, V., ERBEKE, K., RUTGEERTS, 
P., VANDAMME, P. and VERMEIRE, S., 2011. Dysbiosis of the faecal microbiota in patients with 
Crohn's disease and their unaffected relatives. Gut, 60(5), pp. 631-637. 
JOOSSENS, S., COLOMBEL, J.F., LANDERS, C., POULAIN, D.  GEBOES, K., BOSSUYT, X., 
TARGAN, S., RUTGEERTS, P. and REINISCH, W., 2006. Anti-outer membrane of porin C and anti-
I2 antibodies in indeterminate colitis. Gut, 55(11), pp. 1667-1669. 
JOOSSENS, S., REINISCH, W., VERMEIRE, S., SENDID, B., POULAIN, D., PEETERS, M., 
GEBOES, K., BOSSUYT, X., VANDEWALLE, P., OBERHUBER, G., VOGELSANG, H., 
RUTGEERTS, P. and COLOMBEL, J.F., 2002. The value of serologic markers in indeterminate 
colitis: a prospective follow-up study. Gastroenterology, 122(5), pp. 1242-1247. 
JOOSSENS, S., VERMEIRE, S., VAN STEEN, K., GODEFRIDIS, G., CLAESSENS, G., PIERIK, 
M., VLIETINCK, R., AERTS, R., RUTGEERTS, P. and BOSSUYT, X., 2004. Pancreatic 
autoantibodies in inflammatory bowel disease. Inflammatory bowel diseases, 10(6), pp. 771-777. 
JOSTINS, L., RIPKE, S., WEERSMA, R.K., DUERR, R.H., MCGOVERN, D.P., HUI, K.Y., LEE, 
J.C., SCHUMM, L.P., SHARMA, Y., ANDERSON, C.A., ESSERS, J., MITROVIC, M., NING, K., 
CLEYNEN, I., THEATRE, E., SPAIN, S.L., RAYCHAUDHURI, S., GOYETTE, P., WEI, Z., 
ABRAHAM, C., ACHKAR, J.P., AHMAD, T., AMININEJAD, L., ANANTHAKRISHNAN, A.N., 
ANDERSEN, V., ANDREWS, J.M., BAIDOO, L., BALSCHUN, T., BAMPTON, P.A., BITTON, A., 
BOUCHER, G., BRAND, S., BUNING, C., COHAIN, A., CICHON, S., D'AMATO, M., DE JONG, 
D., DEVANEY, K.L., DUBINSKY, M., EDWARDS, C., ELLINGHAUS, D., FERGUSON, L.R., 
FRANCHIMONT, D., FRANSEN, K., GEARRY, R., GEORGES, M., GIEGER, C., GLAS, J., 
HARITUNIANS, T., HART, A., HAWKEY, C., HEDL, M., HU, X., KARLSEN, T.H., 
KUPCINSKAS, L., KUGATHASAN, S., LATIANO, A., LAUKENS, D., LAWRANCE, I.C., LEES, 
C.W., LOUIS, E., MAHY, G., MANSFIELD, J., MORGAN, A.R., MOWAT, C., NEWMAN, W., 
PALMIERI, O., PONSIOEN, C.Y., POTOCNIK, U., PRESCOTT, N.J., REGUEIRO, M., ROTTER, 
J.I., RUSSELL, R.K., SANDERSON, J.D., SANS, M., SATSANGI, J., SCHREIBER, S., SIMMS, 
L.A., SVENTORAITYTE, J., TARGAN, S.R., TAYLOR, K.D., TREMELLING, M., VERSPAGET, 
H.W., DE VOS, M., WIJMENGA, C., WILSON, D.C., WINKELMANN, J., XAVIER, R.J., 
ZEISSIG, S., ZHANG, B., ZHANG, C.K., ZHAO, H., INTERNATIONAL IBD GENETICS 
CONSORTIUM (IIBDGC), SILVERBERG, M.S., ANNESE, V., HAKONARSON, H., BRANT, 
S.R., RADFORD-SMITH, G., MATHEW, C.G., RIOUX, J.D., SCHADT, E.E., DALY, M.J., 
FRANKE, A., PARKES, M., VERMEIRE, S., BARRETT, J.C. and CHO, J.H., 2012. Host-microbe 
interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 
pp. 119-124. 
KANE, S.V., SANDBORN, W.J., RUFO, P.A., ZHOLUDEV, A., BOONE, J., LYERLY, D., 
CAMILLERI, M. and HANAUER, S.B., 2003. Fecal lactoferrin is a sensitive and specific marker in 
identifying intestinal inflammation. American Journal of Gastroenterology, 98(6), pp. 1309-1314. 
KAPEL, N., ROMAN, C., CALDARI, D., SIEPRATH, F., CANIONI, D., KHALFOUN, Y., 
GOULET, O. and RUEMMELE, F.M., 2005. Fecal tumor necrosis factor-alpha and calprotectin as 
differential diagnostic markers for severe diarrhea of small infants. Journal of Pediatric 
Gastroenterology & Nutrition, 41(4), pp. 396-400. 
 
 382 
KAPLAN, G.G., JACKSON, T., SANDS, B.E., FRISCH, M., ANDERSSON, R.E. and KORZENIK, 
J., 2008. The risk of developing Crohn's disease after n appendectomy: a meta-analysis. American 
Journal of Gastroenterology, 103(11), pp. 2925-2931. 
KAPLAN, G.G., PEDERSEN, B.V., ANDERSSON, R.E., SANDS, B.E., KORZENIK, J. and 
FRISCH, M., 2007. The risk of developing Crohn's diease after an appendectomy: a population-
based cohort study in Sweden and Denmark. Gut, 56(10), pp. 1387-1392. 
KARAS, M. and HILLENKAMP, F., 1988. Laser desorption ionization of proteins with molecular 
masses exceeding 10,000 daltons. Analytical Chemistry, 60(20), pp. 2299-2301. 
KARLIC, R., CHUNG, H.R., LASSERRE, J., VLAHOVICEK, K. and VINGRON, M., 2010. Histone 
modification levels are predictive for gene expression. Proceedings of the National Academy of 
Sciences of the United States of America, 107(7), pp. 2926-2931. 
KARP, S.M. and KOCH, T.R., 2006. Oxidative stress and ntioxidants in inflammatory bowel 
disease. Disease-a-month : DM, 52(5), pp. 199-207. 
KATSANOS, A.H. and KATSANOS, K.H., 2014. Inflammatory bowel disease and demyelination: 
more than just a coincidence? Expert review of clinical immunology, 10(3), pp. 363-373. 
KAWACHI, S., JENNINGS, S., PANES, J., COCKRELL, A., LAROUX, F.S., GRAY, L., PERRY, 
M., VAN DER HEYDE, H., BALISH, E., GRANGER, D.N., SPECIAN, R.A. and GRISHAM, M.B., 
2000. Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. 
American journal of physiology.Gastrointestinal and liver physiology, 278(5), pp. G734-43. 
KAWASHIMA, H., MORI, T., KASHIWAGI, Y., TAKEKUMA, K ., HOSHIKA, A. and 
WAKEFIELD, A., 2000. Detection and sequencing of measl s virus from peripheral mononuclear 
cells from patients with inflammatory bowel disease nd autism. Digestive diseases and sciences, 
45(4), pp. 723-729. 
KENNY, L.C., BROADHURST, D., BROWN, M., DUNN, W.B., REDMAN, C.W., KELL, D.B. and 
BAKER, P.N., 2008. Detection and identification of novel metabolomic biomarkers in preeclampsia. 
Reproductive Sciences, 15(6), pp. 591-597. 
KENT, T.H., AMMON, R.K. and DENBESTEN, L., 1970. Differentiation of ulcerative colitis and 
regional enteritis of colon. Archives of Pathology & Laboratory Medicine, 89(1), pp. 20-29. 
KESHAVARZIAN, A., BANAN, A., FARHADI, A., KOMANDURI , S., MUTLU, E., ZHANG, Y. 
and FIELDS, J.Z., 2003. Increases in free radicals and cytoskeletal protein oxidation and nitration in 
the colon of patients with inflammatory bowel disea. Gut, 52(5), pp. 720-728. 
KEVIL, C.G., OSHIMA, T., ALEXANDER, B., COE, L.L. and ALEXANDER, J.S., 2000. H(2)O(2)-
mediated permeability: role of MAPK and occludin. American journal of physiology.Cell physiology, 
279(1), pp. C21-30. 
KHALILI, H., HIGUCHI, L.M., ANANTHAKRISHNAN, A.N., RICHTER, J.M., FESKANICH, D., 
FUCHS, C.S. and CHAN, A.T., 2013. Oral contraceptives, reproductive factors and risk of 
inflammatory bowel disease. Gut, 62(8), pp. 1153-1159. 
KHARBANDA, A.B., RAI, A.J., COSME, Y., LIU, K. and DAYAN, P.S., 2012. Novel serum and 
urine markers for pediatric appendicitis. Academic emergency medicine : official journal of the 
Society for Academic Emergency Medicine, 19(1), pp. 56-62. 
KHOO, S.H. and AL-RUBEAI, M., 2007. Metabolomics as  complementary tool in cell culture. 
Biotechnology & Applied Biochemistry, 47(Pt 2), pp. 71-84. 
KHOR, B., GARDET, A. and XAVIER, R.J., 2011. Genetics and pathogenesis of inflammatory 
bowel disease. Nature, 474(7351), pp. 307-317. 
KIM, K., ARONOV, P., ZAKHARKIN, S.O., ANDERSON, D., PERROUD, B., THOMPSON, I.M. 
and WEISS, R.H., 2009. Urine metabolomics analysis for kidney cancer detection and biomarker 
discovery. Molecular & cellular proteomics : MCP, 8(3), pp. 558-570. 
KIND, T., TOLSTIKOV, V., FIEHN, O. and WEISS, R.H., 2007. A comprehensive urinary 
metabolomic approach for identifying kidney cancerr. Analytical Biochemistry, 363(2), pp. 185-195. 
KIRSNER, J.B., 2001. Historical origins of current IBD concepts. World journal of gastroenterology : 
WJG, 7(2), pp. 175-184. 
KLASS, H.J. and NEALE, G., 1978. Serum and faecal lysozyme in inflammatory bowel disease. Gut, 
19(3), pp. 233-239. 
KLEESSEN, B., KROESEN, A.J., BUHR, H.J. and BLAUT, M., 2002. Mucosal and invading 
bacteria in patients with inflammatory bowel disease compared with controls. Scandinavian Journal of 
Gastroenterology, 37(9), pp. 1034-1041. 
 
 383 
KLEMENT, E., COHEN, R.V., BOXMAN, J., JOSEPH, A. and REIF, S., 2004. Breastfeeding and 
risk of inflammatory bowel disease: a systematic review with meta-analysis. The American Journal of 
Clinical Nutrition, 80(5), pp. 1342-1352. 
KOBAYASHI, K.S., CHAMAILLARD, M., OGURA, Y., HENEGARIU, O., INOHARA, N., 
NUNEZ, G. and FLAVELL, R.A., 2005. Nod2-dependent regulation of innate and adaptive immunity 
in the intestinal tract. Science (New York, N.Y.), 307(5710), pp. 731-734. 
KOBAYASHI, M., FUKUDA, M. and NAKAYAMA, J., 2009. Role of sulfated O-glycans expressed 
by high endothelial venule-like vessels in pathogenesis of chronic inflammatory gastrointestinal 
diseases. Biological & pharmaceutical bulletin, 32(5), pp. 774-779. 
KOCH, R.L., CHRYSTAL, E.J., BEAULIEU, B.B.,JR and GOLDMAN, P., 1979. Acetamide--a 
metabolite of metronidazole formed by the intestinal flora. Biochemical pharmacology, 28(24), pp. 
3611-3615. 
KOEK, M.M., MUILWIJK, B., VAN DER WERF, M.J. and HANKEMEIER, T., 2006. Microbial 
metabolomics with gas chromatography/mass spectromey. Analytical Chemistry, 78(4), pp. 1272-
1281. 
KOETH, R.A., WANG, Z., LEVISON, B.S., BUFFA, J.A., ORG, E., SHEEHY, B.T., BRITT, E.B., 
FU, X., WU, Y., LI, L., SMITH, J.D., DIDONATO, J.A., CHEN, J., LI, H., WU, G.D., LEWIS, J.D., 
WARRIER, M., BROWN, J.M., KRAUSS, R.M., TANG, W.H., BUSHMAN, F.D., LUSIS, A.J. and 
HAZEN, S.L., 2013. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes 
atherosclerosis. Nature medicine, 19(5), pp. 576-585. 
KOLTUN, W.A., SCHOETZ, D.J.,JR, ROBERTS, P.L., MURRAY, J.J., COLLER, J.A. and 
VEIDENHEIMER, M.C., 1991. Indeterminate colitis predisposes to perineal complications after ileal 
pouch-anal anastomosis. Diseases of the Colon & Rectum, 34(10), pp. 857-860. 
KONIKOFF, M.R. and DENSON, L.A., 2006. Role of fecal lprotectin as a biomarker of intestinal 
inflammation in inflammatory bowel disease. Inflammatory bowel diseases, 12(6), pp. 524-534. 
KOPKA, J., FERNIE, A., WECKWERTH, W., GIBON, Y. and STITT, M., 2004. Metabolite 
profiling in plant biology: platforms and destinations. Genome biology, 5(6), pp. 109. 
KORDALEWSKA, M. and MARKUSZEWSKI, M.J., 2015. Metabolomics in cardiovascular 
diseases. Journal of pharmaceutical and biomedical analysis, . 
KOSTAKIS, I.D., CHOLIDOU, K.G., KALLIANIDIS, K., PERREA, D. and ANTSAKLIS, A., 2010. 
The role of calprotectin in obstetrics and gynecology. European journal of obstetrics, gynecology, and 
reproductive biology, 151(1), pp. 3-9. 
KOSTIC, A.D., XAVIER, R.J. and GEVERS, D., 2014. The microbiome in inflammatory bowel 
disease: current status and the future ahead. Gastroente ology, 146(6), pp. 1489-1499. 
KOTLOWSKI, R., BERNSTEIN, C.N., SEPEHRI, S. and KRAUSE, D.O., 2007. High prevalence of 
Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut, 
56(5), pp. 669-675. 
KOUTROUBAKIS, I.E. and VLACHONIKOLIS, I.G., 2000. Appendectomy and the development of 
ulcerative colitis: results of a metaanalysis of published case-control studies. The American Journal of 
Gastroenterology, 95(1), pp. 171-176. 
KOUTROUBAKIS, I.E., PETINAKI, E., MOUZAS, I.A., VLACHONIKOLIS, I.G., 
ANAGNOSTOPOULOU, E., CASTANAS, E., MANIATIS, A.N. and KOUROUMALIS, E.A., 2001. 
Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in 
Greek patients with inflammatory bowel disease. American Journal of Gastroenterology, 96(2), pp. 
449-454. 
KOUZARIDES, T., 2007. Chromatin modifications and their function. Cell, 128(4), pp. 693-705. 
KRONMAN, M.P., ZAOUTIS, T.E., HAYNES, K., FENG, R. and COFFIN, S.E., 2012. Antibiotic 
exposure and IBD development among children: a population-based cohort study. Pediatrics, 130(4), 
pp. e794-803. 
KRUIDENIER, L., KUIPER, I., LAMERS, C.B. and VERSPAGET, H.W., 2003. Intestinal oxidative 
damage in inflammatory bowel disease: semi-quantifica ion, localization, and association with 
mucosal antioxidants. The Journal of pathology, 201(1), pp. 28-36. 
KUBOTA, K., OHTAKE, N., OHBUCHI, K., MASE, A., IMAMURA, S., SUDO, Y., MIYANO, K., 
YAMAMOTO, M., KONO, T. and UEZONO, Y., 2015. Hydroxy-alpha sanshool induces colonic 
motor activity in rat proximal colon: a possible involvement of KCNK9. American journal of 
physiology.Gastrointestinal and liver physiology, 308(7), pp. G579-90. 
KUHN, R., LOHLER, J., RENNICK, D., RAJEWSKY, K. and MULLER, W., 1993. Interleukin-10-
deficient mice develop chronic enterocolitis. Cell, 75(2), pp. 263-274. 
 
 384 
KURATA, J.H., KANTOR-FISH, S., FRANKL, H., GODBY, P. and VADHEIM, C.M., 1992. 
Crohn's disease among ethnic groups in a large health m intenance organization. Gastroenterology, 
102(6), pp. 1940-1948. 
KUROKAWA, K., ITOH, T., KUWAHARA, T., OSHIMA, K., TOH, H., TOYODA, A., TAKAMI, 
H., MORITA, H., SHARMA, V.K., SRIVASTAVA, T.P., TAYLOR, T.D., NOGUCHI, H., MORI, 
H., OGURA, Y., EHRLICH, D.S., ITOH, K., TAKAGI, T., SAKAKI, Y., HAYASHI, T. and 
HATTORI, M., 2007. Comparative metagenomics revealed commonly enriched gene sets in human 
gut microbiomes. DNA research : an international journal for rapid publication of reports on genes 
and genomes, 14(4), pp. 169-181. 
KUTA, A.E. and BAUM, L.L., 1986. C-reactive protein is produced by a small number of normal 
human peripheral blood lymphocytes. Journal of Experim ntal Medicine, 164(1), pp. 321-326. 
KYLE, J., 1992. Crohn's disease in the northeastern and northern Isles of Scotland: an 
epidemiological review. Gastroenterology, 103(2), pp. 392-399. 
LAGHI, L., COSTA, S., SAIBENI, S., BIANCHI, P., OMODEI, P., CARRARA, A., SPINA, L., 
CONTESSINI AVESANI, E., VECCHI, M., DE FRANCHIS, R. and MALESCI, A., 2005. Carriage 
of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn's ileal 
disease. Alimentary Pharmacology & Therapeutics, 22(6), pp. 557-564. 
LAKATOS, P.L., SZAMOSI, T. and LAKATOS, L., 2007. Smoking in inflammatory bowel diseases: 
good, bad or ugly? World Journal of Gastroenterology, 13(46), pp. 6134-6139. 
LANCASTER, G.A., DODD, S. and WILLIAMSON, P.R., 2004. Design and analysis of pilot 
studies: recommendations for good practice. Journal of evaluation in clinical practice, 10(2), pp. 307-
312. 
LANDERS, C.J., COHAVY, O., MISRA, R., YANG, H., LIN, Y.C., BRAUN, J. and TARGAN, 
S.R., 2002. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to 
auto- and microbial antigens. Gastroenterology, 123(3), pp. 689-699. 
LANGHORST, J., ELSENBRUCH, S., MUELLER, T., RUEFFER, A., SPAHN, G., MICHALSEN, 
A. and DOBOS, G.J., 2005. Comparison of 4 neutrophil-derived proteins in feces as indicators of 
disease activity in ulcerative colitis. Inflammatory bowel diseases, 11(12), pp. 1085-1091. 
LANGRISH, C.L., CHEN, Y., BLUMENSCHEIN, W.M., MATTSON, J., BASHAM, B., 
SEDGWICK, J.D., MCCLANAHAN, T., KASTELEIN, R.A. and CUA, D.J., 2005. IL-23 drives a 
pathogenic T cell population that induces autoimmune inflammation. The Journal of experimental 
medicine, 201(2), pp. 233-240. 
LAPAQUETTE, P., GLASSER, A.L., HUETT, A., XAVIER, R.J. and DARFEUILLE-MICHAUD, 
A., 2010. Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired 
autophagy to replicate intracellularly. Cellular microbiology, 12(1), pp. 99-113. 
LARA-VILLOSLADA, F., DE HARO, O., CAMUESCO, D., COMALADA, M., VELASCO, J., 
ZARZUELO, A., XAUS, J. and GALVEZ, J., 2006. Short-chain fructooligosaccharides, in spite of 
being fermented in the upper part of the large intestin , have anti-inflammatory activity in the TNBS 
model of colitis. European journal of nutrition, 45(7), pp. 418-425. 
LAW, G.K., BERTOLO, R.F., ADJIRI-AWERE, A., PENCHARZ, P.B. and BALL, R.O., 2007. 
Adequate oral threonine is critical for mucin production and gut function in neonatal piglets. 
American journal of physiology.Gastrointestinal and liver physiology, 292(5), pp. G1293-301. 
LEACH, S., MESSINA, I. and YANG, Z., 2004. 
LEACH, S.T., YANG, Z., MESSINA, I., SONG, C., GECZY, C.L., CUNNINGHAM, A.M. and 
DAY, A.S., 2007. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, 
are elevated at diagnosis in children with inflammatory bowel disease. Scandinavian Journal of 
Gastroenterology, 42(11), pp. 1321-1331. 
LEAVENS, W.J., LANE, S.J., CARR, R.M., LOCKIE, A.M. and WATERHOUSE, I., 2002. 
Derivatization for liquid chromatography/electrospray mass spectrometry: synthesis of 
tris(trimethoxyphenyl)phosphonium compounds and their d rivatives of amine and carboxylic acids. 
Rapid Communications in Mass Spectrometry, 16(5), pp. 433-441. 
LEE, I.A., PARK, Y.J., JOH, E.H. and KIM, D.H., 2011. Soyasaponin Ab ameliorates colitis by 
inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages. 
Journal of Agricultural and Food Chemistry, 59(24), pp. 13165-13172. 
LEE, I.A., PARK, Y.J., YEO, H.K., HAN, M.J. and KIM, D.H., 2010. Soyasaponin I attenuates 
TNBS-Induced colitis in mice by inhibiting NF-kappaB pathway. Journal of Agricultural and Food 
Chemistry, 58(20), pp. 10929-10934. 
 
 385 
LEE, K.S., MEDLINE, A. and SHOCKEY, S., 1979. Indeterminate colitis in the spectrum of 
inflammatory bowel disease. Archives of Pathology & Laboratory Medicine, 103(4), pp. 173-176. 
LEE, Y.M., FOCK, K., SEE, S.J., NG, T.M., KHOR, C. and TEO, E.K., 2000. Racial differences in 
the prevalence of ulcerative colitis and Crohn's disease in Singapore. Journal of gastroenterology and 
hepatology, 15(6), pp. 622-625. 
LEES, C.W., BARRETT, J.C., PARKES, M. and SATSANGI, J., 2011. New IBD genetics: common 
pathways with other diseases. Gut, . 
LEHRKE, M., KONRAD, A., SCHACHINGER, V., TILLACK, C., SEIBOLD, F., STARK, R., 
PARHOFER, I.G. and BROEDL, U.C., 2008. CXCL16 is a urrogate marker of inflammatory bowel 
disease. Scandinavian Journal of Gastroenterology, 43(3), pp. 283-288. 
LEHRKE, M., MILLINGTON, S.C., LEFTEROVA, M., CUMARANATUNGE, R.G., SZAPARY, 
P., WILENSKY, R., RADER, D.J., LAZAR, M.A. and REILLY, M.P., 2007. CXCL16 is a marker of 
inflammation, atherosclerosis, and acute coronary syndromes in humans. Journal of the American 
College of Cardiology, 49(4), pp. 442-449. 
LENNARD, L., 2002. TPMT in the treatment of Crohn's di ease with azathioprine. Gut, 51(2), pp. 
143-146. 
LENZ, E.M. and WILSON, I.D., 2007. Analytical strategies in metabonomics. Journal of Proteome 
Research, 6(2), pp. 443-458. 
LENZ, E.M., BRIGHT, J., KNIGHT, R., WILSON, I.D. and MAJOR, H., 2004. Cyclosporin A-
induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 
1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. Journal of Pharmaceutical & Biomedical 
Analysis, 35(3), pp. 599-608. 
LEONHARTSBERGER, S., KORSA, I. and BOCK, A., 2002. The molecular biology of formate 
metabolism in enterobacteria. Journal of Molecular Microbiology & Biotechnology, 4(3), pp. 269-
276. 
LESAGE, S., ZOUALI, H., CEZARD, J.P., COLOMBEL, J.F., BELAICHE, J., ALMER, S., TYSK, 
C., O'MORAIN, C., GASSULL, M., BINDER, V., FINKEL, Y., MODIGLIANI, R., GOWER-
ROUSSEAU, C., MACRY, J., MERLIN, F., CHAMAILLARD, M., JANNOT, A.S., THOMAS, G., 
HUGOT, J.P., EPWG-IBD GROUP, EPIMAD GROUP and GETAID GROUP, 2002. 
CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with 
inflammatory bowel disease. American Journal of Human Genetics, 70(4), pp. 845-857. 
LEVINE, A., GRIFFITHS, A., MARKOWITZ, J., WILSON, D.C., TURNER, D., RUSSELL, R.K., 
FELL, J., RUEMMELE, F.M., WALTERS, T., SHERLOCK, M., DUBINSKY, M. and HYAMS, 
J.S., 2011. Pediatric modification of the Montreal cl ssification for inflammatory bowel disease: the 
Paris classification. Inflammatory bowel diseases, 17(6), pp. 1314-1321. 
LEVINE, B., MIZUSHIMA, N. and VIRGIN, H.W., 2011. Autophagy in immunity and inflammation. 
Nature, 469(7330), pp. 323-335. 
LEVINE, J.S. and BURAKOFF, R., 2011. Extraintestinal manifestations of inflammatory bowel 
disease. Gastroenterology & hepatology, 7(4), pp. 235- 41. 
LEVY, A.M., GLEICH, G.J., SANDBORN, W.J., TREMAINE, W.J., STEINER, B.L. and 
PHILLIPS, S.F., 1997. Increased eosinophil granule proteins in gut lavage fluid from patients with 
inflammatory bowel disease. Mayo Clinic proceedings, 72(2), pp. 117-123. 
LEWIN, J., DHILLON, A.P., SIM, R., MAZURE, G., POUNDER, R.E. and WAKEFIELD, A.J., 
1995. Persistent measles virus infection of the intstine: confirmation by immunogold electron 
microscopy. Gut, 36(4), pp. 564-569. 
LEWIS, S. and COCHRANE, S., 2007. Alteration of sulfate and hydrogen metabolism in the human 
colon by changing intestinal transit rate. The American Journal of Gastroenterology, 102(3), pp. 624-
633. 
LI, M., WANG, B., ZHANG, M., RANTALAINEN, M., WANG, S., ZHOU, H., ZHANG, Y., SHEN, 
J., PANG, X., ZHANG, M., WEI, H., CHEN, Y., LU, H., ZUO, J., SU, M., QIU, Y., JIA, W., XIAO, 
C., SMITH, L.M., YANG, S., HOLMES, E., TANG, H., ZHAO, G., NICHOLSON, J.K., LI, L. and 
ZHAO, L., 2008. Symbiotic gut microbes modulate human metabolic phenotypes. Proceedings of the 
National Academy of Sciences of the United States of America, 105(6), pp. 2117-2122. 
LI, X., CONKLIN, L. and ALEX, P., 2008. New serological biomarkers of inflammatory bowel 
disease. World Journal of Gastroenterology, 14(33), pp. 5115-5124. 
LICHTENSTEIN, G.R., YAN, S., BALA, M., BLANK, M. and SANDS, B.E., 2005. Infliximab 
maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's 
disease. Gastroenterology, 128(4), pp. 862-869. 
 
 386 
LIM, C.Y., VIANT, M.R. and TJEERDEMA, R.S., 2006. Metabolomics: methodologies and 
application in the environmental sciences. Journal of Pesticide Science, 31, pp. 245-251. 
LIMDI, J.K., AGGARWAL, D. and MCLAUGHLIN, J.T., 2015. Dietary Practices and Beliefs in 
Patients with Inflammatory Bowel Disease. Inflammatory bowel diseases, . 
LIN, H., HELSBY, N.A., ROWAN, D.D. and FERGUSON, L.R , 2011. Using metabolomic analysis 
to understand inflammatory bowel diseases. Inflammatory bowel diseases, 17(4), pp. 1021-1029. 
LIN, H.M., BARNETT, M.P., ROY, N.C., JOYCE, N.I., ZHU, S., ARMSTRONG, K., HELSBY, 
N.A., FERGUSON, L.R. and ROWAN, D.D., 2010. Metabolomic analysis identifies inflammatory 
and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. 
Journal of Proteome Research, 9(4), pp. 1965-1975. 
LIN, H.M., EDMUNDS, S.I., HELSBY, N.A., FERGUSON, L.R. and ROWAN, D.D., 2009. 
Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. Journal of Proteome 
Research, 8(4), pp. 2045-2057. 
LINDBERG, E., JARNEROT, G. and HUITFELDT, B., 1992. Smoking in Crohn's disease: effect on 
localisation and clinical course. Gut, 33(6), pp. 779-782. 
LINDON, J.C., NICHOLSON, J.K., HOLMES, E., ANTTI, H., BOLLARD, M.E., KEUN, H., 
BECKONERT, O., EBBELS, T.M., REILY, M.D., ROBERTSON, D., STEVENS, G.J., LUKE, P., 
BREAU, A.P., CANTOR, G.H., BIBLE, R.H., NIEDERHAUSER, U., SENN, H., 
SCHLOTTERBECK, G., SIDELMANN, U.G., LAURSEN, S.M., TYMIAK, A., CAR, B.D., 
LEHMAN-MCKEEMAN, L., COLET, J.M., LOUKACI, A. and THOMAS, C., 2003. Contemporary 
issues in toxicology the role of metabonomics in toxic logy and its evaluation by the COMET project. 
Toxicology & Applied Pharmacology, 187(3), pp. 137-146. 
LINDON, J.C., NICHOLSON, J.K., HOLMES, E., KEUN, H.C , CRAIG, A., PEARCE, J.T., 
BRUCE, S.J., HARDY, N., SANSONE, S.A., ANTTI, H., JONSSON, P., DAYKIN, C., 
NAVARANGE, M., BEGER, R.D., VERHEIJ, E.R., AMBERG, A., BAUNSGAARD, D., CANTOR, 
G.H., LEHMAN-MCKEEMAN, L., EARLL, M., WOLD, S., JOHANSSON, E., HASELDEN, J.N., 
KRAMER, K., THOMAS, C., LINDBERG, J., SCHUPPE-KOISTINEN, I., WILSON, I.D., REILY, 
M.D., ROBERTSON, D.G., SENN, H., KROTZKY, A., KOCHHAR, S., POWELL, J., VAN DER 
OUDERAA, F., PLUMB, R., SCHAEFER, H., SPRAUL, M. and STANDARD METABOLIC 
REPORTING STRUCTURES WORKING,GROUP, 2005. Summary recommendations for 
standardization and reporting of metabolic analyses. Nature biotechnology, 23(7), pp. 833-838. 
LINSKENS, R.K., HUIJSDENS, X.W., SAVELKOUL, P.H., VANDENBROUCKE-GRAULS, C.M. 
and MEUWISSEN, S.G., 2001. The bacterial flora in inflammatory bowel disease: current insights in 
pathogenesis and the influence of antibiotics and probiotics. Scandinavian journal of 
gastroenterology.Supplement, (234)(234), pp. 29-40. 
LODES, M.J., CONG, Y., ELSON, C.O., MOHAMATH, R., LANDERS, C.J., TARGAN, S.R., 
FORT, M. and HERSHBERG, R.M., 2004. Bacterial flagellin is a dominant antigen in Crohn disease. 
Journal of Clinical Investigation, 113(9), pp. 1296-1306. 
LOFTUS JR, E.V., 2004. Clinical epidemiology of inflammatory bowel disease: incidence, 
prevalence, and environmental influences. Gastroenterology, 126(6), pp. 1504-1517. 
LOFTUS JR, E.V., KANE, S.V. and BJORKMAN, D., 2004. Systematic review: short-term adverse 
effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Alimentary Pharmacology 
& Therapeutics, 19(2), pp. 179-189. 
LOFTUS JR, E.V., SCHOENFELD, P. and SANDBORN, W.J., 2002. The epidemiology and natural 
history of Crohn's disease in population-based patient cohorts from North America: a systematic 
review. Alimentary Pharmacology & Therapeutics, 16(1), pp. 51-60. 
LOFTUS, C.G., LOFTUS JR, E.V., SANDBORN, W.J., TREMAINE, W.J., HARMSEN, W.S. and 
ZINSMEISTER, A.R., 2003. Update on incidence and prevalence of Crohn's disease and ulcerative 
colitis in Olmsted Country, Minnesota. Gastroenterology, 124, pp. A36. 
LOFTUS, E.V.,JR, SILVERSTEIN, M.D., SANDBORN, W.J., TREMAINE, W.J., HARMSEN, W.S. 
and ZINSMEISTER, A.R., 2000. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: 
incidence, prevalence, and survival. Gut, 46(3), pp. 336-343. 
LOPEZ-SILES, M., KHAN, T.M., DUNCAN, S.H., HARMSEN, H.J., GARCIA-GIL, L.J. and 
FLINT, H.J., 2012. Cultured representatives of two major phylogroups of human colonic 
Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. 
Applied and Environmental Microbiology, 78(2), pp. 420-428. 
LOUIS, E., MICHEL, V., HUGOT, J.P., REENAERS, C., FONTAINE, F., DELFORGE, M., EL 
YAFI, F., COLOMBEL, J.F. and BELAICHE, J., 2003. Early development of stricturing or 
 
 387 
penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking 
but not by NOD2/CARD15 genotype. Gut, 52(4), pp. 552- 7. 
LOUIS, E., VERMEIRE, S., RUTGEERTS, P., DE VOS, M., VAN GOSSUM, A., PESCATORE, P., 
FIASSE, R., PELCKMANS, P., REYNAERT, H., D'HAENS, G., MALAISE, M. and BELAICHE, J., 
2002. A positive response to infliximab in Crohn disease: association with a higher systemic 
inflammation before treatment but not with -308 TNF gene polymorphism. Scandinavian journal of 
gastroenterology, 37(7), pp. 818-824. 
LOVASZ, B.D., LAKATOS, L., GOLOVICS, P.A., DAVID, G., PANDUR, T., ERDELYI, Z., 
BALOGH, M., SZITA, I., MOLNAR, C., KOMAROMI, E., VEGH, Z., MANDEL, M.D., KISS, L.S. 
and LAKATOS, P.L., 2013. Risk of colorectal cancer in Crohn's disease patients with colonic 
involvement and stenosing disease in a population-based cohort from Hungary. Journal of 
gastrointestinal and liver diseases : JGLD, 22(3), pp. 265-268. 
LUCES, C. and BODGER, K., 2006. Economic burden of inflammatory bowel disease: a UK 
perspective. Expert review of pharmacoeconomics & outcomes research, 6(4), pp. 471-482. 
LUCO, R.F., PAN, Q., TOMINAGA, K., BLENCOWE, B.J., PEREIRA-SMITH, O.M. and 
MISTELI, T., 2010. Regulation of alternative splicing by histone modifications. Science (New York, 
N.Y.), 327(5968), pp. 996-1000. 
LUGERING, N., STOLL, R., KUCHARZIK, T., SCHMID, K.W., ROHLMANN, G., 
BURMEISTER, G., SORG, C. and DOMSCHKE, W., 1995a. Immunohistochemical distribution and 
serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in 
Crohn's disease. Digestion, 56(5), pp. 406-414. 
LUGERING, N., STOLL, R., SCHMID, K.W., KUCHARZIK, T., STEIN, H., BURMEISTER, G., 
SORG, C. and DOMSCHKE, W., 1995b. The myeloic related protein MRP8/14 (27E10 antigen)--
usefulness as a potential marker for disease activity in ulcerative colitis and putative biological 
function. European journal of clinical investigation, 25(9), pp. 659-664. 
LUNDBERG, J.O., HELLSTROM, P.M., FAGERHOL, M.K., WEITZBERG, E. and ROSETH, 
A.G., 2005. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of 
inflammatory bowel disease. Nature Clinical Practice Gastroenterology & Hepatology, 2(2), pp. 96-
102. 
LUNDBERG, J.O., HELLSTROM, P.M., LUNDBERG, J.M. and ALVING, K., 1994. Greatly 
increased luminal nitric oxide in ulcerative colitis. Lancet, 344(8938), pp. 1673-1674. 
LUPTON, J.R., 2004. Microbial degradation products influence colon cancer risk: the butyrate 
controversy. The Journal of nutrition, 134(2), pp. 479-482. 
LUTGENS, M.W., VAN OIJEN, M.G., VAN DER HEIJDEN, G.J., VLEGGAAR, F.P., SIERSEMA, 
P.D. and OLDENBURG, B., 2013. Declining risk of colorectal cancer in inflammatory bowel disease: 
an updated meta-analysis of population-based cohort studies. Inflammatory bowel diseases, 19(4), pp. 
789-799. 
MAASER, C., HEIDEMANN, J., VON EIFF, C., LUGERING, A., SPAHN, T.W., BINION, D.G., 
DOMSCHKE, W., LUGERING, N. and KUCHARZIK, T., 2004. Human intestinal microvascular 
endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. Journal of 
immunology (Baltimore, Md.: 1950), 172(8), pp. 5056- 062. 
MACDERMOTT, R.P., NASH, G.S., BERTOVICH, M.J., SEIDEN, M.V., BRAGDON, M.J. and 
BEALE, M.G., 1981. Alterations of IgM, IgG, and IgA Synthesis and secretion by peripheral blood 
and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. 
Gastroenterology, 81(5), pp. 844-852. 
MACDONALD, T.T., MONTELEONE, I., FANTINI, M.C. and MONTELEONE, G., 2011. 
Regulation of homeostasis and inflammation in the int stine. Gastroenterology, 140(6), pp. 1768-
1775. 
MACGREGOR, A.J., SNIEDER, H., SCHORK, N.J. and SPECTOR, T.D., 2000. Twins. Novel uses 
to study complex traits and genetic diseases. Trends in genetics : TIG, 16(3), pp. 131-134. 
MADEIRA, C., LOURENCO, M.V., VARGAS-LOPES, C., SUEMOTO, C.K., BRANDAO, C.O., 
REIS, T., LEITE, R.E., LAKS, J., JACOB-FILHO, W., PASQUALUCCI, C.A., GRINBERG, L.T., 
FERREIRA, S.T. and PANIZZUTTI, R., 2015. d-serine levels in Alzheimer's disease: implications for 
novel biomarker development. Translational psychiatry, 5, pp. e561. 
MAHADEVA, U., MARTIN, J.P., PATEL, N.K. and PRICE, A.B., 2002. Granulomatous ulcerative 
colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative 
colitis. Histopathology, 41(1), pp. 50-55. 
 
 388 
MAHID, S.S., MINOR, K.S., SOTO, R.E., HORNUNG, C.A. and GALANDIUK, S., 2006. Smoking 
and inflammatory bowel disease: a meta-analysis. Mayo Clinic proceedings, 81(11), pp. 1462-1471. 
MAHMUD, N. and WEIR, D.G., 2001. The urban diet and Crohn's disease: is there a relationship? 
European journal of gastroenterology & hepatology, 13(2), pp. 93-95. 
MAIN, J., MCKENZIE, H., YEAMAN, G.R., KERR, M.A., ROBSON, D., PENNINGTON, C.R. and 
PARRATT, D., 1988. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ, 
297(6656), pp. 1105-1106. 
MAKIYAMA, K., KANZAKI, S., YAMASAKI, K., ZEA-IRIART E, W. and TSUJI, Y., 1995. 
Activation of eosinophils in the pathophysiology of ulcerative colitis. Journal of gastroenterology, 
30(Suppl 8), pp. 64-69. 
MAL, M., KOH, P.K., CHEAH, P.Y. and CHAN, E.C., 2009. Development and validation of a gas 
chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid 
communications in mass spectrometry : RCM, 23(4), pp. 487-494. 
MALICKOVA, K., KALOUSOVA, M., FUCIKOVA, T., BORTLIK , M., DURICOVA, D., 
KOMAREK, V., ZIMA, T., JANATKOVA, I. and LUKAS, M., 2010. Anti-inflammatory effect of 
biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do 
not correspond to sRAGE changes. Scandinavian Journal of Clinical & Laboratory Investigation, 
70(4), pp. 294-299. 
MALICKOVA, K., LAKATOS, P.L., BORTLIK, M., KOMAREK, V., JANATKOVA, I. and 
LUKAS, M., 2010. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a 
Central European cohort. European journal of gastroen erology & hepatology, 22(2), pp. 144-150. 
MAMUN, A.A., O'CALLAGHAN, M.J., WILLIAMS, G.M., NAJMAN, J.M., CALLAWAY, L. and 
MCINTYRE, H.D., 2014. Breastfeeding is protective to diabetes risk in young adults: a longitudinal 
study. Acta Diabetologica, . 
MANABE, N., CAMILLERI, M., RAO, A., WONG, B.S., BURTON, D., BUSCIGLIO, I., 
ZINSMEISTER, A.R. and HARUMA, K., 2010. Effect of daikenchuto (TU-100) on gastrointestinal 
and colonic transit in humans. American journal of physiology.Gastrointestinal and liver physiology, 
298(6), pp. G970-5. 
MAO, Y.Y., BAI, J.Q., CHEN, J.H., SHOU, Z.F., HE, Q., WU, J.Y., CHEN, Y. and CHENG, Y.Y., 
2008. A pilot study of GC/MS-based serum metabolic profiling of acute rejection in renal 
transplantation. Transplant immunology, 19(1), pp. 74-80. 
MARCHESI J.R., HOLMES E., KHAN F., KOCHHAR S., SCANLAN P., SHANAHAN F., 
WILSON I.D. and WANG Y., 2007. Rapid and noninvasive metabonomic characterization of 
inflammatory bowel disease.  
MARENHOLZ, I., HEIZMANN, C.W. and FRITZ, G., 2004. S100 proteins in mouse and man: from 
evolution to function and pathology (including an update of the nomenclature). Biochemical & 
Biophysical Research Communications, 322(4), pp. 1111- 122. 
MARGOLIS, D.J., FANELLI, M., HOFFSTAD, O. and LEWIS, J.D., 2010. Potential association 
between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel 
disease. The American Journal of Gastroenterology, 105(12), pp. 2610-2616. 
MARIAT, D., FIRMESSE, O., LEVENEZ, F., GUIMARAES, V., SOKOL, H., DORE, J., 
CORTHIER, G. and FURET, J.P., 2009. The Firmicutes/Bacteroidetes ratio of the human microbiota 
changes with age. BMC microbiology, 9, pp. 123-2180-9-123. 
MARION-LETELLIER, R., SAVOYE, G., BECK, P.L., PANACIONE, R. and GHOSH, S., 2013. 
Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic 
approaches. Inflammatory bowel diseases, 19(3), pp. 650-661. 
MARQUEZ, A., VARADE, J., ROBLEDO, G., MARTINEZ, A., MENDOZA, J.L., TAXONERA, 
C., FERNANDEZ-ARQUERO, M., DIAZ-RUBIO, M., GOMEZ-GARCIA, M., LOPEZ-NEVOT, 
M.A., DE LA CONCHA, E.G., MARTIN, J. and URCELAY, E., 2009. Specific association of a 
CLEC16A/KIAA0350 polymorphism with NOD2/CARD15(-) Crohn's disease patients. European 
journal of human genetics : EJHG, 17(10), pp. 1304-1308. 
MARTIN, F.P., REZZI, S., PHILIPPE, D., TORNIER, L., MESSLIK, A., HOLZLWIMMER, G., 
BAUR, P., QUINTANILLA-FEND, L., LOH, G., BLAUT, M., BLUM, S., KOCHHAR, S. and 
HALLER, D., 2009. Metabolic assessment of gradual development of moderate experimental colitis 
in IL-10 deficient mice. Journal of Proteome Research, 8(5), pp. 2376-2387. 
MARTIN, F.P., WANG, Y., SPRENGER, N., HOLMES, E., LINDON, J.C., KOCHHAR, S. and 
NICHOLSON, J.K., 2007. Effects of probiotic Lactobacillus paracasei treatment on the host gut tissue 
 
 389 
metabolic profiles probed via magic-angle-spinning NMR spectroscopy. Journal of Proteome 
Research, 6(4), pp. 1471-1481. 
MARTIN, H.M., CAMPBELL, B.J., HART, C.A., MPOFU, C., NAYAR, M., SINGH, R., 
ENGLYST, H., WILLIAMS, H.F. and RHODES, J.M., 2004. Enhanced Escherichia coli adherence 
and invasion in Crohn's disease and colon cancer. Gastroenterology, 127(1), pp. 80-93. 
MASHEGO, M.R., RUMBOLD, K., DE MEY, M., VANDAMME, E., SOETAERT, W. and 
HEIJNEN, J.J., 2007. Microbial metabolomics: past, present and future methodologies. Biotechnology 
Letters, 29(1), pp. 1-16. 
MATAKE, H., OKABE, N., NAITO, S. and YAO, T., 1992. An HLA study on 149 Japanese patients 
with Crohn's disease. Gastroenterologia Japonica, 27(4), pp. 496-501. 
MATLOUBIAN, M., DAVID, A., ENGEL, S., RYAN, J.E. and CYSTER, J.G., 2000. A 
transmembrane CXC chemokine is a ligand for HIV-core eptor Bonzo. Nature immunology, 1(4), pp. 
298-304. 
MCCALL, I.C., BETANZOS, A., WEBER, D.A., NAVA, P., MILLER, G.W. and PARKOS, C.A., 
2009. Effects of phenol on barrier function of a human intestinal epithelial cell line correlate with 
altered tight junction protein localization. Toxicology and applied pharmacology, 241(1), pp. 61-70. 
MCGOVERN, D.P., GARDET, A., TORKVIST, L., GOYETTE, P., ESSERS, J., TAYLOR, K.D., 
NEALE, B.M., ONG, R.T., LAGACE, C., LI, C., GREEN, T., STEVENS, C.R., BEAUCHAMP, C., 
FLESHNER, P.R., CARLSON, M., D'AMATO, M., HALFVARSON, J., HIBBERD, M.L., 
LORDAL, M., PADYUKOV, L., ANDRIULLI, A., COLOMBO, E., LATIANO, A., PALMIERI, O., 
BERNARD, E.J., DESLANDRES, C., HOMMES, D.W., DE JONG, D.J., STOKKERS, P.C., 
WEERSMA, R.K., NIDDK IBD GENETICS, C., SHARMA, Y., SILVERBERG, M.S., CHO, J.H., 
WU, J., ROEDER, K., BRANT, S.R., SCHUMM, L.P., DUERR, R.H., DUBINSKY, M.C., 
GLAZER, N.L., HARITUNIANS, T., IPPOLITI, A., MELMED, G.Y., SISCOVICK, D.S., 
VASILIAUSKAS, E.A., TARGAN, S.R., ANNESE, V., WIJMENGA, C., PETTERSSON, S., 
ROTTER, J.I., XAVIER, R.J., DALY, M.J., RIOUX, J.D. and SEIELSTAD, M., 2010. Genome-wide 
association identifies multiple ulcerative colitis susceptibility loci. Nature genetics, 42(4), pp. 332-
337. 
MCINTYRE, P.B., PEMBERTON, J.H., WOLFF, B.G., DOZOIS, R.R. and BEART, R.W.,JR, 1995. 
Indeterminate colitis. Long-term outcome in patients after ileal pouch-anal anastomosis. Diseases of 
the Colon & Rectum, 38(1), pp. 51-54. 
MCMORROW, I.M., COMRACK, C.A., SACHS, D.H. and DERSIMONIAN, H., 1997. 
Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose 
epitope. Transplantation, 64(3), pp. 501-510. 
MCNAUGHT, A.D. and WILKINSON, A., 1997. IUPAC. Compendium of Chemical Terminology. 
2nd (the "Gold Book") edn. Oxford: Blackwell Scientific Publications. 
MEDANI, M., COLLINS, D., DOCHERTY, N.G., BAIRD, A.W., O'CONNELL, P.R. and WINTER, 
D.C., 2011. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. 
Inflammatory bowel diseases, 17(7), pp. 1620-1625. 
MEDVEDEV, A.E., KOPYDLOWSKI, K.M. and VOGEL, S.N., 2000. Inhibition of 
lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: 
dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. Journal of 
immunology (Baltimore, Md.: 1950), 164(11), pp. 5564-5574. 
MERGA, Y., CAMPBELL, B.J. and RHODES, J.M., 2014. Mucosal barrier, bacteria and 
inflammatory bowel disease: possibilities for therapy. Digestive diseases (Basel, Switzerland), 32(4), 
pp. 475-483. 
MEUCCI, G., BORTOLI, A., RICCIOLI, F.A., GIRELLI, C.M., RADAELLI, F., RIVOLTA, R. and 
TATARELLA, M., 1999. Frequency and clinical evolution of indeterminate colitis: a retrospective 
multi-centre study in northern Italy. GSMII (Gruppo di Studio per le Malattie Infiammatorie 
Intestinali). European journal of gastroenterology & hepatology, 11(8), pp. 909-913. 
MEUWIS, M.A., FILLET, M., GEURTS, P., DE SENY, D., LUTTERI, L., CHAPELLE, J.P., 
BOURS, V., WEHENKEL, L., BELAICHE, J., MALAISE, M., LOUIS, E. and MERVILLE, M.P., 
2007. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. 
Biochemical pharmacology, 73(9), pp. 1422-1433. 
MEUWIS, M.A., FILLET, M., LUTTERI, L., MAREE, R., GEURTS, P., DE SENY, D., MALAISE, 
M., CHAPELLE, J.P., WEHENKEL, L., BELAICHE, J., MERVILLE, M.P. and LOUIS, E., 2008. 
Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot 
study. Clinical biochemistry, 41(12), pp. 960-967. 
 
 390 
MEYERS, S., WOLKE, A., FIELD, S.P., FEUER, E.J., JOHNSON, J.W. and JANOWITZ, H.D., 
1985. Fecal alpha 1-antitrypsin measurement: an indicator of Crohn's disease activity. 
Gastroenterology, 89(1), pp. 13-18. 
MIDTVEDT, A.C. and MIDTVEDT, T., 1992. Production of short chain fatty acids by the intestinal 
microflora during the first 2 years of human life. Journal of pediatric gastroenterology and nutrition, 
15(4), pp. 395-403. 
MIKOCKA-WALUS, A., KNOWLES, S.R., KEEFER, L. and GRAFF, L., 2016. Controversies 
Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory 
Bowel Diseases. Inflammatory bowel diseases, 22(3), pp. 752-762. 
MILLS, A.M., HUCKINS, D.S., KWOK, H., BAUMANN, B.M., RUDDY, R.M., ROTHMAN, R.E., 
SCHROCK, J.W., LOVECCHIO, F., KRIEF, W.I., HEXDALL, A., CASPARI, R., COHEN, B. and 
LEWIS, R.J., 2012. Diagnostic characteristics of S100A8/A9 in a multicenter study of patients with 
acute right lower quadrant abdominal pain. Academic emergency medicine : official journal of the 
Society for Academic Emergency Medicine, 19(1), pp. 48-55. 
MIMOUNI BLOCH, A., MIMOUNI, D., MIMOUNI, M. and GDALEVICH, M., 2002. Does 
breastfeeding protect against allergic rhinitis during childhood? A meta-analysis of prospective 
studies. Acta Paediatrica (Oslo, Norway : 1992), 91(3), pp. 275-279. 
MINAIYAN, M., HAJHASHEMI, V., RABBANI, M., FATTAHIA N, E. and MAHZOUNI, P., 2015. 
Evaluation of anti-colitic effect of fluvoxamine aginst acetic acid-induced colitis in normal and 
reserpinized depressed rats. European journal of pharmacology, 746, pp. 293-300. 
MINAMOTO, Y., OTONI, C.C., STEELMAN, S.M., BUYUKLEBLEBICI, O., STEINER, J.M., 
JERGENS, A.E. and SUCHODOLSKI, J.S., 2015. Alteration of the fecal microbiota and serum 
metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut microbes, 6(1), pp. 33-
47. 
MINOCHA, A. and RACZKOWSKI, C.A., 1997. Role of appendectomy and tonsillectomy in 
pathogenesis of ulcerative colitis. Digestive Diseases & Sciences, 42(7), pp. 1567-1569. 
MIYAMOTO, H., TANAKA, T., KITAMOTO, N., FUKUDA, Y. and SHIMOYAMA, T., 1995. 
Detection of immunoreactive antigen, with a monoclona  antibody to measles virus, in tissue from a 
patient with Crohn's disease. Journal of gastroenterology, 30(1), pp. 28-33. 
MOEINIAN, M., FARNAZ GHASEMI-NIRI, S., MOZAFFARI, S. and ABDOLLAHI, M., 2013. 
Synergistic effect of probiotics, butyrate and l-Carnitine in treatment of IBD. Journal of Medical 
Hypotheses and Ideas, 7(2), pp. 50-53. 
MOEINIAN, M., GHASEMI-NIRI, S.F., MOZAFFARI, S., ABDOLGHAFFARI, A.H., BAEERI, 
M., NAVAEA-NIGJEH, M. and ABDOLLAHI, M., 2014. Beneficial effect of butyrate, Lactobacillus 
casei and L-carnitine combination in preference to ach in experimental colitis. World journal of 
gastroenterology, 20(31), pp. 10876-10885. 
MOKBEL, M., CARBONNEL, F., BEAUGERIE, L., GENDRE, J.P. and COSNES, J., 1998. [Effect 
of smoking on the long-term course of ulcerative colitis]. Gastroenterologie clinique et biologique, 
22(11), pp. 858-862. 
MONLEON, D., MORALES, J.M., BARRASA, A., LOPEZ, J.A, VAZQUEZ, C. and CELDA, B., 
2009. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR in 
biomedicine, 22(3), pp. 342-348. 
MONLEON, D., MORALES, J.M., GONZALEZ-DARDER, J., TALAMANTES, F., CORTES, O., 
GIL-BENSO, R., LOPEZ-GINES, C., CERDA-NICOLAS, M. and CELDA, B., 2008. Benign and 
atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular 
profiling. Journal of proteome research, 7(7), pp. 2882-2888. 
MONTGOMERY, S.M., MORRIS, D.L., POUNDER, R.E. and WAKEFIELD, A.J., 1999. Asian 
ethnic origin and the risk of inflammatory bowel disease. European journal of gastroenterology & 
hepatology, 11(5), pp. 543-546. 
MONTGOMERY, S.M., MORRIS, D.L., POUNDER, R.E. and WAKEFIELD, A.J., 1999. 
Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. 
Gastroenterology, 116(4), pp. 796-803. 
MONTGOMERY, S.M., MORRIS, D.L., THOMPSON, N.P., SUBHANI, J., POUNDER, R.E. and 
WAKEFIELD, A.J., 1998. Prevalence of inflammatory bowel disease in British 26 year olds: national 
longitudinal birth cohort. BMJ, 316(7137), pp. 1058-1059. 
MORAN, G.W., PENNOCK, J. and MCLAUGHLIN, J.T., 2012. Enteroendocrine cells in terminal 
ileal Crohn's disease. Journal of Crohn's & colitis, 6(9), pp. 871-880. 
 
 391 
MORGAN, H.D., SUTHERLAND, H.G., MARTIN, D.I. and WHITELAW, E., 1999. Epigenetic 
inheritance at the agouti locus in the mouse. Nature genetics, 23(3), pp. 314-318. 
MORGAN, X.C., TICKLE, T.L., SOKOL, H., GEVERS, D., DEVANEY, K.L., WARD, D.V., 
REYES, J.A., SHAH, S.A., LELEIKO, N., SNAPPER, S.B., OUSVAROS, A., KORZENIK, J., 
SANDS, B.E., XAVIER, R.J. and HUTTENHOWER, C., 2012. Dysfunction of the intestinal 
microbiome in inflammatory bowel disease and treatment. Genome biology, 13(9), pp. R79-2012-13-
9-r79. 
MORRIS, D.L., MONTGOMERY, S.M., THOMPSON, N.P., EBRAHIM, S., POUNDER, R.E. and 
WAKEFIELD, A.J., 2000. Measles vaccination and inflammatory bowel disease: a national British 
Cohort Study. The American Journal of Gastroenterology, 95(12), pp. 3507-3512. 
MORTENSEN, P.B., HOVE, H., CLAUSEN, M.R. and HOLTUG, K., 1991. Fermentation to short-
chain fatty acids and lactate in human faecal batch cultures. Intra- and inter-individual variations 
versus variations caused by changes in fermented saccharides. Scandinavian journal of 
gastroenterology, 26(12), pp. 1285-1294. 
MOTLEY, R.J., RHODES, J., WILLIAMS, G., TAVARES, I.A  and BENNETT, A., 1990. Smoking, 
eicosanoids and ulcerative colitis. Journal of Pharmacy & Pharmacology, 42(4), pp. 288-289. 
MOUM, B., EKBOM, A., VATN, M.H., AADLAND, E., SAUAR, J., LYGREN, I., SCHULZ, T., 
STRAY, N. and FAUSA, O., 1997. Inflammatory bowel disease: re-evaluation of the diagnosis in a 
prospective population based study in south eastern No way. Gut, 40(3), pp. 328-332. 
MOUSAVI, M., JONSSON, P., ANTTI, H., ADOLFSSON, R., NORDIN, A., BERGDAHL, J., 
ERIKSSON, K., MORITZ, T., NILSSON, L.G. and NYBERG, L., 2014. Serum metabolomic 
biomarkers of dementia. Dementia and geriatric cognitive disorders extra, 4(2), pp. 252-262. 
MOW, W.S., VASILIAUSKAS, E.A., LIN, Y.C., FLESHNER, P.R., PAPADAKIS, K.A., TAYLOR, 
K.D., LANDERS, C.J., ABREU-MARTIN, M.T., ROTTER, J.I., YANG, H. and TARGAN, S.R., 
2004. Association of antibody responses to microbial antigens and complications of small bowel 
Crohn's disease. Gastroenterology, 126(2), pp. 414-424. 
MOYANA, T.N., XIANG, J., QI, Y. and KALRA, J., 1994. Development of the early mucosal lesions 
in experimental inflammatory bowel disease--implications for pathogenesis. Experimental & 
Molecular Pathology, 60(2), pp. 119-129. 
MUKHOPADHYA, I., HANSEN, R., EL-OMAR, E.M. and HOLD, G.L., 2012. IBD-what role do 
Proteobacteria play? Nature reviews.Gastroenterology & hepatology, 9(4), pp. 219-230. 
MURDOCH, T.B., FU, H., MACFARLANE, S., SYDORA, B.C., FEDORAK, R.N. and SLUPSKY, 
C.M., 2008. Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-
deficient mice. Analytical Chemistry, 80(14), pp. 5524-5531. 
MYLONAKI, M., RAYMENT, N.B., RAMPTON, D.S., HUDSPITH, B.N. and BROSTOFF, J., 
2005. Molecular characterization of rectal mucosa-asociated bacterial flora in inflammatory bowel 
disease. Inflammatory bowel diseases, 11(5), pp. 481-487. 
NAITO, Y., TAKAGI, T. and YOSHIKAWA, T., 2004. Heme oxygenase-1: a new therapeutic target 
for inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 20 Suppl 1, pp. 177-184. 
NATIONAL CLINICAL GUIDELINE CENTRE (UK), 2012.  
NATIONAL CLINICAL GUIDELINE CENTRE (UK), 2013.  
NATIONAL HUMAN GENOME RESEARCH, INSTITUTES OF HEALTH, DEPARTMENT OF 
HEALTH AND HUMAN SERVICES, OFFICE OF SCIENCE and  U.S. DEPARTMENT OF 
ENERGY, 2003-last update, International Consortium Completes Human Genome Project. Available: 
https://www.genome.gov/11006929 [05/15, 2015]. 
NAVIDINIA, M., PEERAYEH, S.N., FALLAH, F., BAKHSHI, B. and SAJADINIA, R.S., 2014. 
Phylogenetic grouping and pathotypic comparison of urine and fecal Escherichia coli isolates from 
children with urinary tract infection. Brazilian journal of microbiology : [publication of the Brazilian 
Society for Microbiology], 45(2), pp. 509-514. 
NEWMAN, B., SILVERBERG, M.S., GU, X., ZHANG, Q., LAZARO, A., STEINHART, A.H., 
GREENBERG, G.R., GRIFFITHS, A.M., MCLEOD, R.S., COHEN, Z., FERNANDEZ-VINA, M., 
AMOS, C.I. and SIMINOVITCH, K., 2004. CARD15 and HLA DRB1 alleles influence susceptibility 
and disease localization in Crohn's disease. The Amrican Journal of Gastroenterology, 99(2), pp. 
306-315. 
NEWTON, K.F., NEWMAN, W. and HILL, J., 2012. Review of biomarkers in colorectal cancer. 
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and 
Ireland, 14(1), pp. 3-17. 
 
 392 
NGUYEN, H.T., AMINE, A.B., LAFITTE, D., WAHEED, A.A., NICOLETTI, C., VILLARD, C., 
LETISSE, M., DEYRIS, V., ROZIERE, M., TCHIAKPE, L., DANIELLE, C.D., COMEAU, L. and 
HIOL, A., 2006. Proteomic characterization of lipid rafts markers from the rat intestinal brush border. 
Biochemical and biophysical research communications, 342(1), pp. 236-244. 
NICHOLLS, A.W., MORTISHIRE-SMITH, R.J. and NICHOLSON, J.K., 2003. NMR spectroscopic-
based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chemical 
research in toxicology, 16(11), pp. 1395-1404. 
NICHOLSON, J.K. and WILSON, I.D., 2003. Opinion: understanding 'global' systems biology: 
metabonomics and the continuum of metabolism. Nature Reviews.Drug Discovery, 2(8), pp. 668-676. 
NIELSEN, L.L., NIELSEN, N.M., MELBYE, M., SODERMANN, M., JACOBSEN, M. and AABY, 
P., 1998. Exposure to measles in utero and Crohn's disease: Danish register study. BMJ, 316(7126), 
pp. 196-197. 
NILSEN, E.M., JOHANSEN, F.E., JAHNSEN, F.L., LUNDIN, K.E., SCHOLZ, T., BRANDTZAEG, 
P. and HARALDSEN, G., 1998. Cytokine profiles of cultured microvascular endothelial cells from 
the human intestine. Gut, 42(5), pp. 635-642. 
NISHIMURA, T., ANDOH, A., HASHIMOTO, T., KOBORI, A., TSUJIKAWA, T. and 
FUJIYAMA, Y., 2010. Cellobiose Prevents the Development of Dextran Sulfate Sodium (DSS)-
Induced Experimental Colitis. Journal of Clinical Biochemistry and Nutrition, 46(2), pp. 105-110. 
NIV, Y., ABUKSIS, G. and FRASER, G.M., 2000. Epidemiology of ulcerative colitis in Israel: a 
survey of Israeli kibbutz settlements. The American Journal of Gastroenterology, 95(3), pp. 693-698. 
NORMAN, G.L., 2001. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease. 
Clinical and Applied Immunology Reviews, 2(1), pp. 45-63. 
NUAKO, K.W., AHLQUIST, D.A., MAHONEY, D.W., SCHAID, D.J., SIEMS, D.M. and LINDOR, 
N.M., 1998. Familial predisposition for colorectal c ncer in chronic ulcerative colitis: a case-control 
study. Gastroenterology, 115(5), pp. 1079-1083. 
NYMAN, M., 2002. Fermentation and bulking capacity of indigestible carbohydrates: the case of 
inulin and oligofructose. The British journal of nutrition, 87 Suppl 2, pp. S163-8. 
ODES, H.S., LOCKER, C., NEUMANN, L., ZIRKIN, H.J., WEIZMAN, Z., SPERBER, A.D., 
FRASER, G.M., KRUGLIAK, P., GASPAR, N. and EIDELMAN, L., 1994. Epidemiology of Crohn's 
disease in southern Israel. The American Journal of Gastroenterology, 89(10), pp. 1859-1862. 
OGUNBI, S.O., RANSOM, J.A., SULLIVAN, K., SCHOEN, B.T. and GOLD, B.D., 1998. 
Inflammatory bowel disease in African-American children living in Georgia. The Journal of 
pediatrics, 133(1), pp. 103-107. 
OGURA, Y., BONEN, D.K., INOHARA, N., NICOLAE, D.L., CHEN, F.F., RAMOS, R., 
BRITTON, H., MORAN, T., KARALIUSKAS, R., DUERR, R.H., ACHKAR, J.P., BRANT, S.R., 
BAYLESS, T.M., KIRSCHNER, B.S., HANAUER, S.B., NUNEZ, G. and CHO, J.H., 2001. A 
frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 411(6837), pp. 
603-606. 
OGURA, Y., INOHARA, N., BENITO, A., CHEN, F.F., YAMAOKA, S. and NUNEZ, G., 2001. 
Nod2, a Nod1/Apaf-1 family member that is restricted o monocytes and activates NF-kappaB. The 
Journal of biological chemistry, 276(7), pp. 4812-4818. 
OH, M.S., PHELPS, K.R., TRAUBE, M., BARBOSA-SALDIVAR, J.L., BOXHILL, C. and 
CARROLL, H.J., 1979. D-lactic acidosis in a man with the short-bowel syndrome. New England 
Journal of Medicine, 301(5), pp. 249-252. 
OHKUSA, T., KATO, K., TERAO, S., CHIBA, T., MABE, K., MURAKAMI, K., MIZOKAMI, Y., 
SUGIYAMA, T., YANAKA, A., TAKEUCHI, Y., YAMATO, S., YOKOYAMA, T., OKAYASU, I., 
WATANABE, S., TAJIRI, H., SATO, N. and JAPAN UC ANTIBIOTIC THERAPY STUDY 
GROUP, 2010. Newly developed antibiotic combination herapy for ulcerative colitis: a double-blind 
placebo-controlled multicenter trial. The American Journal of Gastroenterology, 105(8), pp. 1820-
1829. 
OHKUSA, T., SATO, N., OGIHARA, T., MORITA, K., OGAWA, M. and OKAYASU, I., 2002. 
Fusobacterium varium localized in the colonic mucosa f patients with ulcerative colitis stimulates 
species-specific antibody. Journal of gastroenterology and hepatology, 17(8), pp. 849-853. 
OKAYASU, I., HATAKEYAMA, S., YAMADA, M., OHKUSA, T. , INAGAKI, Y. and NAKAYA, 
R., 1990. A novel method in the induction of reliabe experimental acute and chronic ulcerative colitis 
in mice. Gastroenterology, 98(3), pp. 694-702. 
 
 393 
OKUMURA, T., FUKAGAWA, K., TSO, P., TAYLOR, I.L. and PAPPAS, T.N., 1994. Intracisternal 
injection of apolipoprotein A-IV inhibits gastric secretion in pylorus-ligated conscious rats. 
Gastroenterology, 107(6), pp. 1861-1864. 
OLIVER, S.G., WINSON, M.K., KELL, D.B. and BAGANZ, F., 1998. Systematic functional analysis 
of the yeast genome. Trends in biotechnology, 16(9), pp. 373-378. 
O'NEILL, L.A. and BOWIE, A.G., 2007. The family of five: TIR-domain-containing adaptors in Toll-
like receptor signalling. Nature reviews.Immunology, 7(5), pp. 353-364. 
OOI, M., NISHIUMI, S., YOSHIE, T., SHIOMI, Y., KOHASHI, M., FUKUNAGA, K., 
NAKAMURA, S., MATSUMOTO, T., HATANO, N., SHINOHARA, M., IRINO, Y., TAKENAWA, 
T., AZUMA, T. and YOSHIDA, M., 2011. GC/MS-based profiling of amino acids and TCA cycle-
related molecules in ulcerative colitis. Inflammation research : official journal of the European 
Histamine Research Society ...[et al.], 60(9), pp. 831-840. 
OPENSTAX, 04/06/2013-last update, Overview of the Digestive System [Homepage of OpenStax 
CNX], [Online]. Available: http://cnx.org/contents/94fbc1ca-dcaa-47ad-94be-
2cfeb168c347@3/Overview_of_the_Digestive_Syst#fig-ch24_01_02 [31/01, 2015]. 
ORESIC, M., HYOTYLAINEN, T., HERUKKA, S.K., SYSI-AHO, M., MATTILA, I., SEPPANAN-
LAAKSO, T., JULKUNEN, V., GOPALACHARYULU, P.V., HALLIKAINEN, M., 
KOIKKALAINEN, J., KIVIPELTO, M., HELISALMI, S., LOTJONEN, J. and SOININEN, H., 2011. 
Metabolome in progression to Alzheimer's disease. Translational psychiatry, 1, pp. e57. 
ORHOLM, M., BINDER, V., SORENSEN, T.I., RASMUSSEN, L.P. and KYVIK, K.O., 2000. 
Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. 
Scandinavian Journal of Gastroenterology, 35(10), pp. 1075-1081. 
ORHOLM, M., MUNKHOLM, P., LANGHOLZ, E., NIELSEN, O.H., SORENSEN, T.I. and 
BINDER, V., 1991. Familial occurrence of inflammatory bowel disease. New England Journal of 
Medicine, 324(2), pp. 84-88. 
ORTEGA, F.J., SABATER, M., MORENO-NAVARRETE, J.M., PUEYO, N., BOTAS, P., 
DELGADO, E., RICART, W., FRUHBECK, G. and FERNANDEZ-REAL, J.M., 2012. Serum and 
urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. European 
journal of endocrinology / European Federation of Endocrine Societies, . 
OSHIMA, T., JORDAN, P., GRISHAM, M.B., ALEXANDER, J.S., JENNINGS, M., SASAKI, M. 
and MANAS, K., 2001. TNF-alpha induced endothelial MAdCAM-1 expression is regulated by 
exogenous, not endogenous nitric oxide. BMC gastroen erology, 1, pp. 5. 
OSHIMA, T., LAROUX, F.S., COE, L.L., MORISE, Z., KAWACHI, S., BAUER, P., GRISHAM, 
M.B., SPECIAN, R.D., CARTER, P., JENNINGS, S., GRANGER, D.N., JOH, T. and 
ALEXANDER, J.S., 2001. Interferon-gamma and interleukin-10 reciprocally regulate endothelial 
junction integrity and barrier function. Microvascular research, 61(1), pp. 130-143. 
OSHIMOTO, H., OKAMURA, S., IIDA, T., ISHIKAWA, T., HOSAKA, K. and MORI, M., 2005. 
Diagnostic value of the serum platelet-activating factor acetylhydrolase activity in inflammatory 
bowel disease. Tohoku Journal of Experimental Medicine, 207(1), pp. 65-71. 
OSHITANI, N., SAWA, Y., HARA, J., ADACHI, K., NAKAMURA, S., MATSUMOTO, T., 
ARAKAWA, T. and KUROKI, T., 1997. Functional and phenotypical activation of leucocytes in 
inflamed human colonic mucosa. Journal of Gastroenterology & Hepatology, 12(12), pp. 809-814. 
OSTOS, M.A., CONCONI, M., VERGNES, L., BAROUKH, N., RIBALTA, J., GIRONA, J., 
CAILLAUD, J.M., OCHOA, A. and ZAKIN, M.M., 2001. Antioxidative and antiatherosclerotic 
effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 21(6), pp. 1023-1028. 
OTT, S.J., MUSFELDT, M., WENDEROTH, D.F., HAMPE, J.BRANT, O., FOLSCH, U.R., 
TIMMIS, K.N. and SCHREIBER, S., 2004. Reduction in diversity of the colonic mucosa associated 
bacterial microflora in patients with active inflammatory bowel disease. Gut, 53(5), pp. 685-693. 
PALLONE, F. and MONTELEONE, G., 1998. Interleukin 12 and Th1 responses in inflammatory 
bowel disease. Gut, 43(6), pp. 735-736. 
PALMER, C., BIK, E.M., DIGIULIO, D.B., RELMAN, D.A. and BROWN, P.O., 2007. Development 
of the human infant intestinal microbiota. PLoS biology, 5(7), pp. e177. 
PAPATHANASIOU, A., NIKAKIS, P., BONAKIS, A., KILIDIREAS, K., DIMITRAKOPOULOS, 
A., MICHOPOULOS, S., KALFAKIS, N. and PAPAGEORGIOU, S.G., 2014. Rapidly progressive 
dementia as presenting feature in inflammatory bowel dis ase. Alzheimer Disease and Associated 
Disorders, 28(3), pp. 294-295. 
 
 394 
PAPP, M., NORMAN, G.L., ALTORJAY, I. and LAKATOS, P.L., 2007. Utility of serological 
markers in inflammatory bowel diseases: gadget or magic? World Journal of Gastroenterology, 
13(14), pp. 2028-2036. 
PARDI, D.S., TREMAINE, W.J., SANDBORN, W.J., LOFTUS, E.V.,JR, POLAND, G.A., 
HARMSEN, W.S., ZINSMEISTER, A.R. and MELTON, L.J.,3RD, 2000. Early measles virus 
infection is associated with the development of inflammatory bowel disease. The American Journal of 
Gastroenterology, 95(6), pp. 1480-1485. 
PARHAM, P., 2015. Preventing Infection at Mucosal Surfaces. The Immune System. Fourth Edition 
edn. New York, USA: Garland Science, pp. 267-294. 
PARKES, M., BARRETT, J.C., PRESCOTT, N.J., TREMELLING, M., ANDERSON, C.A., 
FISHER, S.A., ROBERTS, R.G., NIMMO, E.R., CUMMINGS, F.R., SOARS, D., DRUMMOND, 
H., LEES, C.W., KHAWAJA, S.A., BAGNALL, R., BURKE, D.A., TODHUNTER, C.E., AHMAD, 
T., ONNIE, C.M., MCARDLE, W., STRACHAN, D., BETHEL, G., BRYAN, C., LEWIS, C.M., 
DELOUKAS, P., FORBES, A., SANDERSON, J., JEWELL, D.P., SATSANGI, J., MANSFIELD, 
J.C., WELLCOME TRUST CASE CONTROL CONSORTIUM, CARDON, L. and MATHEW, C.G., 
2007. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to 
Crohn's disease susceptibility. Nature genetics, 39(7), pp. 830-832. 
PARMENTIER-DECRUCQ, E., DUHAMEL, A., ERNST, O., FERMONT, C., LOUVET, A., 
VERNIER-MASSOUILLE, G., CORTOT, A., COLOMBEL, J.F., DESREUMAUX, P. and PEYRIN-
BIROULET, L., 2009. Effects of infliximab therapy on abdominal fat and metabolic profile in 
patients with Crohn's disease. Inflammatory bowel diseases, 15(10), pp. 1476-1484. 
PARRELLO, T., PAVIA, M., ANGELILLO, I.F., MONTELEONE, G., RIEGLER, G., PAPI, G., 
D'INCA, R., ANNESE, V., TONELLI, F., CAPRILLI, R. and PALLONE, F., 1997. Appendectomy is 
an independent protective factor for ulcerative colitis: results of a multicentre case control study. The 
Italian Group for the Study of the Colon and Rectum (GISC). Italian Journal of Gastroenterology & 
Hepatology, 29(3), pp. 208-211. 
PARSI, M.A., ACHKAR, J.P., RICHARDSON, S., KATZ, J., HAMMEL, J.P., LASHNER, B.A. and 
BRZEZINSKI, A., 2002. Predictors of response to infliximab in patients with Crohn's disease. 
Gastroenterology, 123(3), pp. 707-713. 
PARSI, M.A., SHEN, B., ACHKAR, J.P., REMZI, F.F., GOLDBLUM, J.R., BOONE, J., LIN, D., 
CONNOR, J.T., FAZIO, V.W. and LASHNER, B.A., 2004. Fecal lactoferrin for diagnosis of 
symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology, 126(5), pp. 1280-1286. 
PATRIARCA, P.A. and BEELER, J.A., 1995. Measles vaccination and inflammatory bowel disease. 
Lancet. 
PEDERSEN, G., BRYNSKOV, J. and SAERMARK, T., 2002. Phenol toxicity and conjugation in 
human colonic epithelial cells. Scandinavian Journal of Gastroenterology, 37(1), pp. 74-79. 
PEETERS, M., JOOSSENS, S., VERMEIRE, S., VLIETINCK, R.  BOSSUYT, X. and 
RUTGEERTS, P., 2001. Diagnostic value of anti-Sacchromyces cerevisiae and antineutrophil 
cytoplasmic autoantibodies in inflammatory bowel disease. American Journal of Gastroenterology, 
96(3), pp. 730-734. 
PEETERS, M., NEVENS, H., BAERT, F., HIELE, M., DE MEYER, A.M., VLIETINCK, R. and 
RUTGEERTS, P., 1996. Familial aggregation in Crohn's disease: increased age-adjusted risk and 
concordance in clinical characteristics. Gastroenterology, 111(3), pp. 597-603. 
PENDERS, J., THIJS, C., VINK, C., STELMA, F.F., SNIJDERS, B., KUMMELING, I., VAN DEN 
BRANDT, P.A. and STOBBERINGH, E.E., 2006. Factors influencing the composition of the 
intestinal microbiota in early infancy. Pediatrics, 118(2), pp. 511-521. 
PEPE, M.S., ETZIONI, R., FENG, Z., POTTER, J.D., THOMPSON, M.L., THORNQUIST, M., 
WINGET, M. and YASUI, Y., 2001. Phases of biomarker d velopment for early detection of cancer. 
Journal of the National Cancer Institute, 93(14), pp. 1054-1061. 
PEPE, M.S., FENG, Z., JANES, H., BOSSUYT, P.M. and POTTER, J.D., 2008. Pivotal evaluation of 
the accuracy of a biomarker used for classification or prediction: standards for study design. Journal of 
the National Cancer Institute, 100(20), pp. 1432-1438. 
PERMINOW, G., BEISNER, J., KOSLOWSKI, M., LYCKANDER, L.G., STANGE, E., VATN, 
M.H. and WEHKAMP, J., 2010. Defective paneth cell-mediated host defense in pediatric ileal 
Crohn's disease. The American Journal of Gastroenterology, 105(2), pp. 452-459. 
PERNER, A., NORDGAARD, I., MATZEN, P. and RASK-MADSEN, J., 2002. Colonic production 
of nitric oxide gas in ulcerative colitis, collagenous colitis and uninflamed bowel. Scandinavian 
journal of gastroenterology, 37(2), pp. 183-188. 
 
 395 
PETERSEN, A.M., HALKJAER, S.I. and GLUUD, L.L., 2015. Intestinal colonization with 
phylogenetic group B2 Escherichia coli related to inflammatory bowel disease: a systematic review 
and meta-analysis. Scandinavian Journal of Gastroenterology, , pp. 1-9. 
PETERSON, C.G., EKLUND, E., TAHA, Y., RAAB, Y. and CARLSON, M., 2002. A new method 
for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal 
levels and clinical application in patients with inflammatory bowel disease. American Journal of 
Gastroenterology, 97(7), pp. 1755-1762. 
PETERSSON, J., SCHREIBER, O., STEEGE, A., PATZAK, A., HELLSTEN, A., PHILLIPSON, M. 
and HOLM, L., 2007. eNOS involved in colitis-induced mucosal blood flow increase. American 
journal of physiology.Gastrointestinal and liver physiology, 293(6), pp. G1281-7. 
PEYRIN-BIROULET, L., STANDAERT-VITSE, A., BRANCHE, J. and CHAMAILLARD, M., 
2007. IBD serological panels: facts and perspectives. Inflammatory bowel diseases, 13(12), pp. 1561-
1566. 
PEZIM, M.E., PEMBERTON, J.H., BEART, R.W.,JR, WOLFF, B.G., DOZOIS, R.R., 
NIVATVONGS, S., DEVINE, R. and ILSTRUP, D.M., 1989. Outcome of "indeterminant" colitis 
following ileal pouch-anal anastomosis. Diseases of the Colon & Rectum, 32(8), pp. 653-658. 
PFENNIG, N. and WIDDEL, F., 1982. The bacteria of the sulphur cycle. Philosophical transactions of 
the Royal Society of London.Series B, Biological scien es, 298(1093), pp. 433-441. 
PICCO, M.F. and BAYLESS, T.M., 2003. Tobacco consumption and disease duration are associated 
with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. American Journal of 
Gastroenterology, 98(2), pp. 363-368. 
PINCHBECK, B.R., KIRDEIKIS, J. and THOMSON, A.B., 1988. Inflammatory bowel disease in 
northern Alberta. An epidemiologic study. Journal of clinical gastroenterology, 10(5), pp. 505-515. 
PLANTINGA, T.S., CRISAN, T.O., OOSTING, M., VAN DE VEERDONK, F.L., DE JONG, D.J., 
PHILPOTT, D.J., VAN DER MEER, J.W., GIRARDIN, S.E., JOOSTEN, L.A. and NETEA, M.G., 
2011. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine 
responses selectively upon activation of NOD2. Gut, 60(9), pp. 1229-1235. 
PONDER, A. and LONG, M.D., 2013. A clinical review of recent findings in the epidemiology of 
inflammatory bowel disease. Clinical epidemiology, 5, pp. 237-247. 
PORTELA, A. and ESTELLER, M., 2010. Epigenetic modifications and human disease. Nature 
biotechnology, 28(10), pp. 1057-1068. 
POULLIS, A., FOSTER, R., NORTHFIELD, T.C. and MENDALL, M.A., 2002. Review article: 
faecal markers in the assessment of activity in inflammatory bowel disease. Alimentary Pharmacology 
& Therapeutics, 16(4), pp. 675-681. 
POULLIS, A.P., ZAR, S., SUNDARAM, K.K., MOODIE, S.J., RISLEY, P., THEODOSSI, A. and 
MENDALL, M.A., 2002. A new, highly sensitive assay for C-reactive protein can aid the 
differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant 
functional bowel disorders. European journal of gastroenterology & hepatology, 14(4), pp. 409-412. 
PRESLEY, L.L., YE, J., LI, X., LEBLANC, J., ZHANG, Z., RUEGGER, P.M., ALLARD, J., 
MCGOVERN, D., IPPOLITI, A., ROTH, B., CUI, X., JESKE, D.R., ELASHOFF, D., GOODGLICK, 
L., BRAUN, J. and BORNEMAN, J., 2012. Host-microbe relationships in inflammatory bowel 
disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface. 
Inflammatory bowel diseases, 18(3), pp. 409-417. 
PRICE, A.B., 1978. Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis 
indeterminate'. Journal of clinical pathology, 31(6), pp. 567-577. 
PRIDEAUX, L., DE CRUZ, P., NG, S.C. and KAMM, M.A., 2012. Serological antibodies in 
inflammatory bowel disease: A systematic review. Inflammatory bowel diseases, 18(7), pp. 1340-
1355. 
PROBERT, C.S., JAYANTHI, V., HUGHES, A.O., THOMPSON, J.R., WICKS, A.C. and 
MAYBERRY, J.F., 1993. Prevalence and family risk of ulcerative colitis and Crohn's disease: an 
epidemiological study among Europeans and south Asians in Leicestershire. Gut, 34(11), pp. 1547-
1551. 
PROBERT, C.S., JAYANTHI, V., PINDER, D., WICKS, A.C and MAYBERRY, J.F., 1992. 
Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of 
Leicestershire. Gut, 33(5), pp. 687-693. 
PULLAN, R.D., 1996. Colonic mucus, smoking and ulcerative colitis. Annals of the Royal College of 
Surgeons of England, 78(2), pp. 85-91. 
 
 396 
PULLAN, R.D., RHODES, J., GANESH, S., MANI, V., MORRIS, J.S., WILLIAMS, G.T., 
NEWCOMBE, R.G., RUSSELL, M.A., FEYERABEND, C. and THOMAS, G.A., 1994. Transdermal 
nicotine for active ulcerative colitis. New England Journal of Medicine, 330(12), pp. 811-815. 
QIN, J., LI, R., RAES, J., ARUMUGAM, M., BURGDORF, K.S., MANICHANH, C., NIELSEN, T., 
PONS, N., LEVENEZ, F., YAMADA, T., MENDE, D.R., LI, J., XU, J., LI, S., LI, D., CAO, J., 
WANG, B., LIANG, H., ZHENG, H., XIE, Y., TAP, J., LEPAGE, P., BERTALAN, M., BATTO, 
J.M., HANSEN, T., LE PASLIER, D., LINNEBERG, A., NIELSEN, H.B., PELLETIER, E., 
RENAULT, P., SICHERITZ-PONTEN, T., TURNER, K., ZHU, H., YU, C., LI, S., JIAN, M., 
ZHOU, Y., LI, Y., ZHANG, X., LI, S., QIN, N., YANG, H., WANG, J., BRUNAK, S., DORE, J., 
GUARNER, F., KRISTIANSEN, K., PEDERSEN, O., PARKHILL, J., WEISSENBACH, J., 
METAHIT, C., BORK, P., EHRLICH, S.D. and WANG, J., 2010. A human gut microbial gene 
catalogue established by metagenomic sequencing. Nature, 464(7285), pp. 59-65. 
QUINTON, J.F., SENDID, B., REUMAUX, D., DUTHILLEUL, P., CORTOT, A., 
GRANDBASTIEN, B., CHARRIER, G., TARGAN, S.R., COLOMBEL, J.F. and POULAIN, D., 
1998. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic 
autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut, 42(6), pp. 788-
791. 
RAAB, Y., HALLGREN, R., KNUTSON, L., KROG, M. and GERDIN, B., 1992. A technique for 
segmental rectal and colonic perfusion in humans. American Journal of Gastroenterology, 87(10), pp. 
1453-1459. 
RAINE, T., 2014. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the 
same? United European Gastroenterology Journal, 2(5), pp. 333-344. 
RAITHEL, M., MATEK, M., BAENKLER, H.W., JORDE, W. and HAHN, E.G., 1995. Mucosal 
histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic 
enteropathy. International archives of allergy and immunology, 108(2), pp. 127-133. 
RAKYAN, V.K., DOWN, T.A., BALDING, D.J. and BECK, S., 2011. Epigenome-wide association 
studies for common human diseases. Nature reviews.Genetics, 12(8), pp. 529-541. 
RAMAKERS, J.D., MENSINK, R.P., SCHAART, G. and PLAT, J., 2007. Arachidonic acid but not 
eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in 
Caco-2 cells. Lipids, 42(8), pp. 687-698. 
RANDHAWA, P.K., SINGH, K., SINGH, N. and JAGGI, A.S, 2014. A review on chemical-induced 
inflammatory bowel disease models in rodents. The Korean journal of physiology & pharmacology : 
official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 18(4), 
pp. 279-288. 
RAQIB, R., WRETLIND, B., ANDERSSON, J. and LINDBERG, A.A., 1995. Cytokine secretion in 
acute shigellosis is correlated to disease activity and directed more to stool than to plasma. Journal of 
Infectious Diseases, 171(2), pp. 376-384. 
REIF, S., KLEIN, I., LUBIN, F., FARBSTEIN, M., HALLAK, A. and GILAT, T., 1997. Pre-illness 
dietary factors in inflammatory bowel disease. Gut, 40(6), pp. 754-760. 
REINSHAGEN, M., LOELIGER, C., KUEHNL, P., WEISS, U., MANFRAS, B.J., ADLER, G. and 
BOEHM, B.O., 1996. HLA class II gene frequencies in Crohn's disease: a population based analysis 
in Germany. Gut, 38(4), pp. 538-542. 
REMOND, D., BUFFIERE, C., GODIN, J.P., MIRAND, P.P., OBLED, C., PAPET, I., DARDEVET, 
D., WILLIAMSON, G., BREUILLE, D. and FAURE, M., 2009. Intestinal inflammation increases 
gastrointestinal threonine uptake and mucin synthesis in enterally fed minipigs. The Journal of 
nutrition, 139(4), pp. 720-726. 
REUMAUX, D., COLOMBEL, J.F., MASY, E., DUCLOS, B., HERESBACH, D., BELAICHE, J., 
CORTOT, A., DUTHILLEUL, P., GETAID and GROUPE D'ETUDE DES AFFECTIONS 
INFLAMMATOIRES DU TUBE,DIGESTIF, 2000. Anti-neutrophil cytoplasmic auto-antibodies 
(ANCA) in ulcerative colitis (UC): no relationship with disease activity. Inflammatory bowel 
diseases, 6(4), pp. 270-274. 
RHO, Y.H., CHUNG, C.P., OESER, A., SOLUS, J., ASANUMA, Y., SOKKA, T., PINCUS, T., 
RAGGI, P., GEBRETSADIK, T., SHINTANI, A. and STEIN, C.M., 2009. Inflammatory mediators 
and premature coronary atherosclerosis in rheumatoid rthritis. Arthritis and Rheumatism, 61(11), pp. 
1580-1585. 
RICKERT, R.R. and CARTER, H.W., 1980. The "early" ulcerative lesion of Crohn's disease: 




RIEDER, F., SCHLEDER, S., WOLF, A., DIRMEIER, A., STRAUCH, U., OBERMEIER, F., 
LOPEZ, R., SPECTOR, L., FIRE, E., YARDEN, J., ROGLER, G., DOTAN, N. and KLEBL, F., 
2010. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with 
complicated Crohn's disease behavior. Inflammatory b wel diseases, 16(2), pp. 263-274. 
RIOUX, J.D., XAVIER, R.J., TAYLOR, K.D., SILVERBERG, M.S., GOYETTE, P., HUETT, A., 
GREEN, T., KUBALLA, P., BARMADA, M.M., DATTA, L.W., SHUGART, Y.Y., GRIFFITHS, 
A.M., TARGAN, S.R., IPPOLITI, A.F., BERNARD, E.J., MEI, L., NICOLAE, D.L., REGUEIRO, 
M., SCHUMM, L.P., STEINHART, A.H., ROTTER, J.I., DUERR, R.H., CHO, J.H., DALY, M.J. 
and BRANT, S.R., 2007. Genome-wide association study identifies new susceptibility loci for Crohn 
disease and implicates autophagy in disease pathogenesis. Nature genetics, 39(5), pp. 596-604. 
ROBERTSON, K.D., 2005. DNA methylation and human disease. Nature reviews.Genetics, 6(8), pp. 
597-610. 
ROBLIN, X., NEUT, C., DARFEUILLE-MICHAUD, A. and COLOMBEL, J.F., 2012. Local 
appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis? Gut, 61(4), pp. 
635-636. 
ROCCA-SERRA, P., SALEK, R.M., ARITA, M., CORREA, E., DAYALAN, S., GONZALEZ-
BELTRAN, A., EBBELS, T., GOODACRE, R., HASTINGS, J., HAUG, K., KOULMAN, A., 
NIKOLSKI, M., ORESIC, M., SANSONE, S.A., SCHOBER, D., SMITH, J., STEINBECK, C., 
VIANT, M.R. and NEUMANN, S., 2016. Data standards can boost metabolomics research, and if 
there is a will, there is a way. Metabolomics : Official journal of the Metabolomic Society, 12(1), pp. 
14. 
ROEDIGER, W.E. and TRUELOVE, S.C., 1979. Method of preparing isolated colonic epithelial cells 
(colonocytes) for metabolic studies. Gut, 20(6), pp. 484-488. 
ROEDIGER, W.E., 1980. The colonic epithelium in ulcerative colitis: an energy-deficiency disease?. 
Lancet, 2(8197), pp. 712-715. 
ROEDIGER, W.E., 1982. Utilization of nutrients by isolated epithelial cells of the rat colon. 
Gastroenterology, 83(2), pp. 424-429. 
ROEDIGER, W.E., DUNCAN, A., KAPANIRIS, O. and MILLARD, S., 1993. Reducing sulfur 
compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. 
Gastroenterology, 104(3), pp. 802-809. 
ROEDIGER, W.E., HEYWORTH, M., WILLOUGHBY, P., PIRIS, J., MOORE, A. and 
TRUELOVE, S.C., 1982. Luminal ions and short chain f tty acids as markers of functional activity of 
the mucosa in ulcerative colitis. Journal of clinical pathology, 35(3), pp. 323-326. 
ROEDIGER, W.E., MOORE, J. and BABIDGE, W., 1997. Colonic sulfide in pathogenesis and 
treatment of ulcerative colitis. Digestive diseases and sciences, 42(8), pp. 1571-1579. 
ROGGENBUCK, D., BOGDANOS, D. and CONRAD, K., 2013. Loss of tolerance to one or two 
major targets in Crohn's disease or just cross-reactivity? Journal of Crohn's & colitis, 7(7), pp. e273-4. 
ROGGENBUCK, D., HAUSDORF, G., MARTINEZ-GAMBOA, L., REINHOLD, D., BUTTNER, 
T., JUNGBLUT, P.R., PORSTMANN, T., LAASS, M.W., HENKER, J., BUNING, C., FEIST, E. and 
CONRAD, K., 2009. Identification of GP2, the major zymogen granule membrane glycoprotein, as 
the autoantigen of pancreatic antibodies in Crohn's disease. Gut, 58(12), pp. 1620-1628. 
ROGGENBUCK, D., REINHOLD, D., WEX, T., GOIHL, A., VON ARNIM, U., 
MALFERTHEINER, P., BUTTNER, T., PORSTMANN, T., PORSTMANN, S., LIEDVOGEL, B., 
BOGDANOS, D.P., LAASS, M.W. and CONRAD, K., 2011. Autoantibodies to GP2, the major 
zymogen granule membrane glycoprotein, are new markers in Crohn's disease. Clinica chimica acta; 
international journal of clinical chemistry, 412(9-10), pp. 718-724. 
ROIN, F. and ROIN, J., 1989. Inflammatory bowel disea e of the Faroe Islands, 1981-1988. A 
prospective epidemiologic study: primary report. Scandinavian Journal of Gastroenterology - 
Supplement, 170, pp. 44-46. 
ROLHION, N. and DARFEUILLE-MICHAUD, A., 2007. Adhernt-invasive Escherichia coli in 
inflammatory bowel disease. Inflammatory bowel diseases, 13(10), pp. 1277-1283. 
ROSETH, A.G., AADLAND, E., JAHNSEN, J. and RAKNERUD, N., 1997. Assessment of disease 
activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion, 
58(2), pp. 176-180. 
ROSETH, A.G., FAGERHOL, M.K., AADLAND, E. and SCHJONSBY, H., 1992. Assessment of the 
neutrophil dominating protein calprotectin in feces. A methodologic study. Scandinavian journal of 
gastroenterology, 27(9), pp. 793-798. 
 
 398 
ROSETH, A.G., SCHMIDT, P.N. and FAGERHOL, M.K., 1999. Correlation between faecal 
excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in 
patients with inflammatory bowel disease. Scandinavian journal of gastroenterology, 34(1), pp. 50-54. 
ROSSELLO-MORA, R., LUCIO, M., PENA, A., BRITO-ECHEVERRIA, J., LOPEZ-LOPEZ, A., 
VALENS-VADELL, M., FROMMBERGER, M., ANTON, J. and SCHMITT-KOPPLIN, P., 2008. 
Metabolic evidence for biogeographic isolation of the extremophilic bacterium Salinibacter ruber. The 
Isme Journal, 2(3), pp. 242-253. 
ROUBENOFF, R., ROUBENOFF, R.A., SELHUB, J., NADEAU, M.R., CANNON, J.G., 
FREEMAN, L.M., DINARELLO, C.A. and ROSENBERG, I.H., 1995. Abnormal vitamin B6 status 
in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and 
markers of inflammation. Arthritis and Rheumatism, 38(1), pp. 105-109. 
ROUSSOMOUSTAKAKI, M., SATSANGI, J., WELSH, K., LOUIS, E., FANNING, G., TARGAN, 
S., LANDERS, C. and JEWELL, D.P., 1997. Genetic markers may predict disease behavior in 
patients with ulcerative colitis. Gastroenterology, 112(6), pp. 1845-1853. 
ROWAN, F.E., DOCHERTY, N.G., COFFEY, J.C. and O'CONNELL, P.R., 2009. Sulphate-reducing 
bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. The British journal of surgery, 
96(2), pp. 151-158. 
RUAN, E.A., RAO, S., BURDICK, J.S., STRYKER, S.J., TELFORD, G.L., OTTERSON, M.F., 
OPARA, E.C. and KOCH, T.R., 1997. Glutathione levels in chronic inflammatory disorders of the 
human colon. Nutrition Research, 17(3), pp. 463-473. 
RUBIN, G.P., HUNGIN, A.P., KELLY, P.J. and LING, J., 2000. Inflammatory bowel disease: 
epidemiology and management in an English general practice population. Alimentary Pharmacology 
& Therapeutics, 14(12), pp. 1553-1559. 
RUDOLPH, W.G., UTHOFF, S.M., MCAULIFFE, T.L., GOODE, .T., PETRAS, R.E. and 
GALANDIUK, S., 2002. Indeterminate colitis: the real story. Diseases of the Colon & Rectum, 
45(11), pp. 1528-1534. 
RUGTVEIT, J., BRANDTZAEG, P., HALSTENSEN, T.S., FAUSA, O. and SCOTT, H., 1994. 
Increased macrophage subset in inflammatory bowel dis ase: apparent recruitment from peripheral 
blood monocytes. Gut, 35(5), pp. 669-674. 
RUMP, J.A., SCHOLMERICH, J., GROSS, V., ROTH, M., HELFESRIEDER, R., RAUTMANN, A., 
LUDEMANN, J., GROSS, W.L. and PETER, H.H., 1990. A new type of perinuclear anti-neutrophil 
cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. 
Immunobiology, 181(4-5), pp. 406-413. 
RUPEREZ, F.J., RAMOS-MOZO, P., TEUL, J., MARTINEZ-PINNA, R., GARCIA, A., MALET-
MARTINO, M., CAMAFEITA, E., LOPEZ, J.A., PASTOR-VARGAS, C., EGIDO, J., 
BALAYSSAC, S., GILARD, V., BARBAS, C. and MARTIN-VENTURA, J.L., 2012. Metabolomic 
study of plasma of patients with abdominal aortic aneurysm. Analytical and bioanalytical chemistry, 
403(6), pp. 1651-1660. 
RUSSEL, M.G., VOLOVICS, A., SCHOON, E.J., VAN WIJLICK, E.H., LOGAN, R.F., 
SHIVANANDA, S. and STOCKBRUGGER, R.W., 1998. Inflammatory bowel disease: is there any 
relation between smoking status and disease presentation? European Collaborative IBD Study Group. 
Inflammatory bowel diseases, 4(3), pp. 182-186. 
RUSSO V.E.A., MARTIENSSEN R.A. and RIGGS A.D., eds,  1996. Epigenetic Mechanisms of 
Gene Regulation. New York: Cold Spring Harbour Labor t ry Press. 
RUTGEERTS, P., D'HAENS, G., HIELE, M., GEBOES, K. and VANTRAPPEN, G., 1994. 
Appendectomy protects against ulcerative colitis. Gastroenterology, 106(5), pp. 1251-1253. 
RUTGEERTS, P., FEAGAN, B.G., LICHTENSTEIN, G.R., MAYER, L.F., SCHREIBER, S., 
COLOMBEL, J.F., RACHMILEWITZ, D., WOLF, D.C., OLSON, A., BAO, W. and HANAUER, 
S.B., 2004. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's 
disease. Gastroenterology, 126(2), pp. 402-413. 
SABA, K., DENDA-NAGAI, K. and IRIMURA, T., 2009. A C-type lectin MGL1/CD301a plays an 
anti-inflammatory role in murine experimental colitis. The American journal of pathology, 174(1), pp. 
144-152. 
SABBAH, A., CHANG, T.H., HARNACK, R., FROHLICH, V., TOMINAGA, K., DUBE, P.H., 
XIANG, Y. and BOSE, S., 2009. Activation of innate immune antiviral responses by Nod2. Nature 
immunology, 10(10), pp. 1073-1080. 
 
 399 
SACHAR, D.B., LUPPESCU, N.E., BODIAN, C., SHLIEN, R.D., FABRY, T.L. and GUMASTE, 
V.V., 1990. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in 
ileitis versus colitis. Journal of clinical gastroent rology, 12(6), pp. 643-646. 
SACHAR, D.B., SMITH, H., CHAN, S., COHEN, L.B., LICHTIGER, S. and MESSER, J., 1986. 
Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. 
Journal of clinical gastroenterology, 8(6), pp. 647-650. 
SAEMANN, M.D., BOHMIG, G.A., OSTERREICHER, C.H., BURTSCHER, H., PAROLINI, O., 
DIAKOS, C., STOCKL, J., HORL, W.H. and ZLABINGER, G.J., 2000. Anti-inflammatory effects of 
sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 
production. FASEB journal : official publication ofthe Federation of American Societies for 
Experimental Biology, 14(15), pp. 2380-2382. 
SAIBENI, S., CATTANEO, M., VECCHI, M., ZIGHETTI, M.L., LECCHI, A., LOMBARDI, R., 
MEUCCI, G., SPINA, L. and DE FRANCHIS, R., 2003. Low vitamin B(6) plasma levels, a risk 
factor for thrombosis, in inflammatory bowel diseas: role of inflammation and correlation with acute 
phase reactants. The American Journal of Gastroenterology, 98(1), pp. 112-117. 
SAIKI, T., 1998. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory 
bowel disease. Kurume Medical Journal, 45(1), pp. 69-73. 
SAIKI, T., MITSUYAMA, K., TOYONAGA, A., ISHIDA, H. and TANIKAWA, K., 1998. Detection 
of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. 
Scandinavian journal of gastroenterology, 33(6), pp. 616-622. 
SAITOH, O., KOJIMA, K., SUGI, K., MATSUSE, R., UCHIDA, K., TABATA, K., NAKAGAWA, 
K., KAYAZAWA, M., HIRATA, I. and KATSU, K., 1999. Fecal eosinophil granule-derived proteins 
reflect disease activity in inflammatory bowel disea . American Journal of Gastroenterology, 94(12), 
pp. 3513-3520. 
SAKIYAMA, T., FUJITA, H. and TSUBOUCHI, H., 2008. Autoantibodies against ubiquitination 
factor E4A (UBE4A) are associated with severity of Crohn's disease. Inflammatory bowel diseases, 
14(3), pp. 310-317. 
SALEK, R.M., NEUMANN, S., SCHOBER, D., HUMMEL, J., BILLIAU, K., KOPKA, J., 
CORREA, E., REIJMERS, T., ROSATO, A., TENORI, L., TURANO, P., MARIN, S., DEBORDE, 
C., JACOB, D., ROLIN, D., DARTIGUES, B., CONESA, P., HAUG, K., ROCCA-SERRA, P., 
O'HAGAN, S., HAO, J., VAN VLIET, M., SYSI-AHO, M., LUDWIG, C., BOUWMAN, J., 
CASCANTE, M., EBBELS, T., GRIFFIN, J.L., MOING, A., NIKOLSKI, M., ORESIC, M., 
SANSONE, S.A., VIANT, M.R., GOODACRE, R., GUNTHER, U.L., HANKEMEIER, T., 
LUCHINAT, C., WALTHER, D. and STEINBECK, C., 2015. COordination of Standards in 
MetabOlomicS (COSMOS): facilitating integrated metabolomics data access. Metabolomics : Official 
journal of the Metabolomic Society, 11(6), pp. 1587-1597. 
SANDBORN WJ. COLOMBEL JF. ENNS R. FEAGAN BG. HANAUER SB. LAWRANCE IC. 
PANACCIONE R. SANDERS M. SCHREIBER S. TARGAN S. VAN DEVENTER S. GOLDBLUM 
R. DESPAIN D. HOGGE GS. RUTGEERTS P. INTERNATIONAL EFFICACY OF 
NATALIZUMAB AS ACTIVE CROHN'S THERAPY (ENACT-1) TRIAL GROUP. EVALUATION 
OF NATALIZUMAB AS CONTINUOUS THERAPY (ENACT-2) TRIAL GROUP, 2005. 
Natalizumab induction and maintenance therapy for Cr hn's disease. New England Journal of 
Medicine, 353(18), pp. 1912-1925. 
SANDBORN, W.J. and HANAUER, S.B., 2003. Systematic review: the pharmacokinetic profiles of 
oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. 
Alimentary Pharmacology & Therapeutics, 17(1), pp. 29-42. 
SANDBORN, W.J., FEAGAN, B.G., MARANO, C., ZHANG, H., STRAUSS, R., JOHANNS, J., 
ADEDOKUN, O.J., GUZZO, C., COLOMBEL, J.F., REINISCH, W., GIBSON, P.R., COLLINS, J., 
JARNEROT, G., RUTGEERTS, P. and PURSUIT-MAINTENANCE STUDY GROUP, 2014. 
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative 
colitis. Gastroenterology, 146(1), pp. 96-109.e1. 
SANDBORN, W.J., LOFTUS, E.V.,JR, COLOMBEL, J.F., FLEMING, K.A., SEIBOLD, F., 
HOMBURGER, H.A., SENDID, B., CHAPMAN, R.W., TREMAINE, W.J., KAUL, D.K., 
WALLACE, J., HARMSEN, W.S., ZINSMEISTER, A.R. and TARGAN, S.R., 2001. Evaluation of 
serologic disease markers in a population-based cohort f patients with ulcerative colitis and Crohn's 
disease. Inflammatory bowel diseases, 7(3), pp. 192-201. 
SANDBORN, W.J., TREMAINE, W.J., OFFORD, K.P., LAWSON, G.M., PETERSEN, B.T., 
BATTS, K.P., CROGHAN, I.T., DALE, L.C., SCHROEDER, D.R. and HURT, R.D., 1997. 
 
 400 
Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, 
placebo-controlled trial. Annals of Internal Medicine, 126(5), pp. 364-371. 
SANDERSON, I.R., 2007. Dietary modulation of GALT. he Journal of nutrition, 137(11 Suppl), pp. 
2557S-2562S. 
SANDS, B.E., ANDERSON, F.H., BERNSTEIN, C.N., CHEY, W.Y., FEAGAN, B.G., FEDORAK, 
R.N., KAMM, M.A., KORZENIK, J.R., LASHNER, B.A., ONKEN, J.E., RACHMILEWITZ, D., 
RUTGEERTS, P., WILD, G., WOLF, D.C., MARSTERS, P.A., TRAVERS, S.B., BLANK, M.A. and 
VAN DEVENTER, S.J., 2004. Infliximab maintenance thrapy for fistulizing Crohn's disease. New 
England Journal of Medicine, 350(9), pp. 876-885. 
SANKEY, E.A., DHILLON, A.P., ANTHONY, A., WAKEFIELD, A.J., SIM, R., MORE, L., 
HUDSON, M., SAWYERR, A.M. and POUNDER, R.E., 1993. Early mucosal changes in Crohn's 
disease. Gut, 34(3), pp. 375-381. 
SAPPATI BIYYANI, R.S., PUTKA, B.S. and MULLEN, K.D., 2010. Dyslipidemia and lipoprotein 
profiles in patients with inflammatory bowel diseas. Journal of clinical lipidology, 4(6), pp. 478-482. 
SARGENT, D.J., CONLEY, B.A., ALLEGRA, C. and COLLETTE, L., 2005. Clinical trial designs 
for predictive marker validation in cancer treatment trials. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology, 23(9), pp. 2020-2027. 
SARIN, S.K., MALHOTRA, V., SEN GUPTA, S., KAROL, A., GAUR, S.K. and ANAND, B.S., 
1987. Significance of eosinophil and mast cell counts i  rectal mucosa in ulcerative colitis. A 
prospective controlled study. Digestive Diseases & Sciences, 32(4), pp. 363-367. 
SARTOR, R.B., 2005. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's 
disease? Gut, 54(7), pp. 896-898. 
SARTOR, R.B., 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology, 
134(2), pp. 577-594. 
SARTOR, R.B., 2010. Genetics and environmental interactions shape the intestinal microbiome to 
promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology, 139(6), pp. 
1816-1819. 
SAS, K.M., KARNOVSKY, A., MICHAILIDIS, G. and PENNATHUR, S., 2015. Metabolomics and 
diabetes: analytical and computational approaches. Diabetes, 64(3), pp. 718-732. 
SATSANGI, J., LANDERS, C.J., WELSH, K.I., KOSS, K., TARGAN, S. and JEWELL, D.P., 1998. 
The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within 
inflammatory bowel disease. Inflammatory bowel diseases, 4(1), pp. 18-26. 
SATSANGI, J., SILVERBERG, M.S., VERMEIRE, S. and COL MBEL, J.F., 2006. The Montreal 
classification of inflammatory bowel disease: contrversies, consensus, and implications. Gut, 55(6), 
pp. 749-753. 
SATSANGI, J., WELSH, K.I., BUNCE, M., JULIER, C., FARRANT, J.M., BELL, J.I. and JEWELL, 
D.P., 1996. Contribution of genes of the major histocompatibility complex to susceptibility and 
disease phenotype in inflammatory bowel disease. Lancet, 347(9010), pp. 1212-1217. 
SAVERYMUTTU, S.H., CAMILLERI, M., REES, H., LAVENDER, J.P., HODGSON, H.J. and 
CHADWICK, V.S., 1986. Indium 111-granulocyte scanning n the assessment of disease extent and 
disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal 
indium 111-granulocyte excretion. Gastroenterology, 90(5 Pt 1), pp. 1121-1128. 
SAVERYMUTTU, S.H., PETERS, A.M., CROFTON, M.E., REES, H., LAVENDER, J.P., 
HODGSON, H.J. and CHADWICK, V.S., 1985. 111Indium autologous granulocytes in the detection 
of inflammatory bowel disease. Gut, 26(9), pp. 955-60. 
SAVIGE J. DIMECH W. FRITZLER M. GOEKEN J. HAGEN EC. JENNETTE JC. MCEVOY R. 
PUSEY C. POLLOCK W. TREVISIN M. WIIK A. WONG R. INTERNATIONAL GROUP FOR 
CONSENSUS STATEMENT ON TESTING AND REPORTING OF ANTINEUTROPHIL 
CYTOPLASMIC ANTIBODIES (ANCA), 2003. Addendum to the International Consensus 
Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control 
guidelines, comments, and recommendations for testing in other autoimmune diseases. American 
Journal of Clinical Pathology, 120(3), pp. 312-318. 
SAVIGE, J., GILLIS, D., BENSON, E., DAVIES, D., ESNAULT, V., FALK, R.J., HAGEN, E.C., 
JAYNE, D., JENNETTE, J.C., PASPALIARIS, B., POLLOCK, W., PUSEY, C., SAVAGE, C.O., 
SILVESTRINI, R., VAN DER WOUDE, F., WIESLANDER, J. and WIIK, A., 1999. International 
Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). 
American Journal of Clinical Pathology, 111(4), pp.507-513. 
 
 401 
SAWCZENKO, A., SANDHU, B.K., LOGAN, R.F., JENKINS, H., TAYLOR, C.J., MIAN, S. and 
LYNN, R., 2001. Prospective survey of childhood inflammatory bowel disease in the British Isles. 
Lancet, 357(9262), pp. 1093-1094. 
SAXON, A., SHANAHAN, F., LANDERS, C., GANZ, T. and TARGAN, S., 1990. A distinct subset 
of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. Journal of 
Allergy & Clinical Immunology, 86(2), pp. 202-210. 
SCANLAN, P.D., SHANAHAN, F., O'MAHONY, C. and MARCHESI, J.R., 2006. Culture-
independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial 
subgroups in Crohn's disease. Journal of clinical microbiology, 44(11), pp. 3980-3988. 
SCHAIBLE, T.D., HARRIS, R.A., DOWD, S.E., SMITH, C.W. and KELLERMAYER, R., 2011. 
Maternal methyl-donor supplementation induces prolonged murine offspring colitis susceptibility in 
association with mucosal epigenetic and microbiomic changes. Human molecular genetics, 20(9), pp. 
1687-1696. 
SCHAUBER, J., RIEGER, D., WEILER, F., WEHKAMP, J., ECK, M., FELLERMANN, K., 
SCHEPPACH, W., GALLO, R.L. and STANGE, E.F., 2006. Heterogeneous expression of human 
cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. European journal of gastroenterology & 
hepatology, 18(6), pp. 615-621. 
SCHAUER, N., STEINHAUSER, D., STRELKOV, S., SCHOMBURG, D., ALLISON, G., 
MORITZ, T., LUNDGREN, K., ROESSNER-TUNALI, U., FORBES, M.G., WILLMITZER, L., 
FERNIE, A.R. and KOPKA, J., 2005. GC-MS libraries for the rapid identification of metabolites in 
complex biological samples. FEBS letters, 579(6), pp. 1332-1337. 
SCHEPPACH, W., 1996. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A 
placebo-controlled trial. German-Austrian SCFA Study Group. Digestive Diseases & Sciences, 
41(11), pp. 2254-2259. 
SCHEPPACH, W., CHRISTL, S.U., BARTRAM, H.P., RICHTER, F. and KASPER, H., 1997. 
Effects of short-chain fatty acids on the inflamed colonic mucosa. Scandinavian Journal of 
Gastroenterology - Supplement, 222, pp. 53-57. 
SCHICHO, R., NAZYROVA, A., SHAYKHUTDINOV, R., DUGGAN, G., VOGEL, H.J. and 
STORR, M., 2010. Quantitative metabolomic profiling of serum and urine in DSS-induced ulcerative 
colitis of mice by (1)H NMR spectroscopy. Journal of Proteome Research, 9(12), pp. 6265-6273. 
SCHIRMER, B., REZNICZEK, T., SEIFERT, R. and NEUMANN, D., 2015. Proinflammatory role of 
the histamine H receptor in dextrane sodium sulfate-induced acute colitis. Biochemical pharmacology, 
. 
SCHMIDT, K., SCHRADER, M., KERN, H.F. and KLEENE, R., 2001. Regulated apical secretion of 
zymogens in rat pancreas. Involvement of the glycoslphosphatidylinositol-anchored glycoprotein 
GP-2, the lectin ZG16p, and cholesterol-glycosphingolipid-enriched microdomains. The Journal of 
biological chemistry, 276(17), pp. 14315-14323. 
SCHONES, D.E., CUI, K., CUDDAPAH, S., ROH, T.Y., BARSKI, A., WANG, Z., WEI, G. and 
ZHAO, K., 2008. Dynamic regulation of nucleosome positi ning in the human genome. Cell, 132(5), 
pp. 887-898. 
SCHOOREL, E.P., GIESBERTS, M.A., BLOM, W. and VAN GELDEREN, H.H., 1980. D-Lactic 
acidosis in a boy with short bowel syndrome. Archives of Disease in Childhood, 55(10), pp. 810-812. 
SCHREIBER, S., 2011. Certolizumab pegol for the treatment of Crohn's disease. Therapeutic 
advances in gastroenterology, 4(6), pp. 375-389. 
SCHRICKER, T., BERROTH, A., PFEIFFER, U., SCHREIBER, M., GEISSER, W., GOERTZ, A. 
and GEORGIEFF, M., 1997. Assessment of perioperative glycerol metabolism by stable isotope 
tracer technique. Nutrition (Burbank, Los Angeles County, Calif.), 13(3), pp. 191-195. 
SCHUMACHER, G., KOLLBERG, B. and SANDSTEDT, B., 1994. A prospective study of first 
attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year 
after presentation. Scandinavian journal of gastroenterology, 29(4), pp. 318-332. 
SCOLAMIERO, E., COZZOLINO, C., ALBANO, L., ANSALONE, A., CATERINO, M., CORBO, 
G., DI GIROLAMO, M.G., DI STEFANO, C., DURANTE, A., FRANZESE, G., FRANZESE, I., 
GALLO, G., GILIBERTI, P., INGENITO, L., IPPOLITO, G., MALAMISURA, B., MAZZEO, P., 
NORMA, A., OMBRONE, D., PARENTI, G., PELLECCHIA, S., PECCE, R., PIERUCCI, I., 
ROMANELLI, R., ROSSI, A., SIANO, M., STODUTO, T., VILLANI, G.R., ANDRIA, G., 
SALVATORE, F., FRISSO, G. and RUOPPOLO, M., 2015. Targeted metabolomics in the expanded 
newborn screening for inborn errors of metabolism. Molecular bioSystems, 11(6), pp. 1525-1535. 
 
 402 
SEGAIN, J.P., RAINGEARD DE LA BLETIERE, D., BOURREILLE, A., LERAY, V., GERVOIS, 
N., ROSALES, C., FERRIER, L., BONNET, C., BLOTTIERE, H.M. and GALMICHE, J.P., 2000. 
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's 
disease. Gut, 47(3), pp. 397-403. 
SEGAL, A.W., ENSELL, J., MUNRO, J.M. and SARNER, M., 1981. Indium-111 tagged leucocytes 
in the diagnosis of inflammatory bowel disease. Lancet, 2(8240), pp. 230-232. 
SEIBOLD, F., MORK, H., TANZA, S., MULLER, A., HOLZHUTER, C., WEBER, P. and 
SCHEURLEN, M., 1997. Pancreatic autoantibodies in Crohn's disease: a family study. Gut, 40(4), pp. 
481-484. 
SEIBOLD, F., WEBER, P., JENSS, H. and WIEDMANN, K.H., 1991. Antibodies to a trypsin 
sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup 
of patients with Crohn's disease. Gut, 32(10), pp. 1192-1197. 
SEKSIK, P., RIGOTTIER-GOIS, L., GRAMET, G., SUTREN, M., POCHART, P., MARTEAU, P., 
JIAN, R. and DORE, J., 2003. Alterations of the dominant faecal bacterial groups in patients with 
Crohn's disease of the colon. Gut, 52(2), pp. 237-242. 
SELBY, W., PAVLI, P., CROTTY, B., FLORIN, T., RADFORD-SMITH, G., GIBSON, P., 
MITCHELL, B., CONNELL, W., READ, R., MERRETT, M., E, H., HETZEL, D. and 
ANTIBIOTICS IN CROHN'S DISEASE STUDY GROUP, 2007. Two-year combination antibiotic 
therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology, 132(7), 
pp. 2313-2319. 
SELHUB, J., BYUN, A., LIU, Z., MASON, J.B., BRONSON, R.T. and CROTT, J.W., 2013. Dietary 
vitamin B6 intake modulates colonic inflammation in the IL10-/- model of inflammatory bowel 
disease. The Journal of nutritional biochemistry, 24(1 ), pp. 2138-2143. 
SELLICK, C.A., HANSEN, R., MAQSOOD, A.R., DUNN, W.B, STEPHENS, G.M., GOODACRE, 
R. and DICKSON, A.J., 2009. Effective quenching processes for physiologically valid metabolite 
profiling of suspension cultured Mammalian cells. Analytical Chemistry, 81(1), pp. 174-183. 
SENDID, B., QUINTON, J.F., CHARRIER, G., GOULET, O., CORTOT, A., GRANDBASTIEN, B., 
POULAIN, D. and COLOMBEL, J.F., 1998. Anti-Saccharomyces cerevisiae mannan antibodies in 
familial Crohn's disease. American Journal of Gastroenterology, 93(8), pp. 1306-1310. 
SEOW, C.H., STEMPAK, J.M., XU, W., LAN, H., GRIFFITHS, A.M., GREENBERG, G.R., 
STEINHART, A.H., DOTAN, N. and SILVERBERG, M.S., 2009. Novel anti-glycan antibodies 
related to inflammatory bowel disease diagnosis and phenotype. American Journal of 
Gastroenterology, 104(6), pp. 1426-1434. 
SERKOVA, N.J., GAMITO, E.J., JONES, R.H., O'DONNELL, C., BROWN, J.L., GREEN, S., 
SULLIVAN, H., HEDLUND, T. and CRAWFORD, E.D., 2008. The metabolites citrate, myo-
inositol, and spermine are potential age-independent markers of prostate cancer in human expressed 
prostatic secretions. The Prostate, 68(6), pp. 620-628. 
Serum and mucosal calprotectin (S100A8/A9) and S100A 2 are elevated in children with 
inflammatory bowel disease (IBD). Journal of Gastroenterology and Hepatology, 19, pp. A278. 
SESSA, W.C., 2009. Molecular control of blood flow and angiogenesis: role of nitric oxide. Journal 
of thrombosis and haemostasis : JTH, 7 Suppl 1, pp. 35-37. 
SEVEUS, L., AMIN, K., PETERSON, C.G., ROOMANS, G.M. and VENGE, P., 1997. Human 
neutrophil lipocalin (HNL) is a specific granule constituent of the neutrophil granulocyte. Studies in 
bronchial and lung parenchymal tissue and peripheral blood cells. Histochemistry & Cell Biology, 
107(5), pp. 423-432. 
SHANAHAN, F. and BERNSTEIN, C.N., 2009. The evolving epidemiology of inflammatory bowel 
disease. Current opinion in gastroenterology, 25(4), pp. 301-305. 
SHAO, L., KAMALU, O. and MAYER, L., 2005. Non-classical MHC class I molecules on intestinal 
epithelial cells: mediators of mucosal crosstalk. Immunological reviews, 206, pp. 160-176. 
SHARMA, U., SINGH, R.R., AHUJA, V., MAKHARIA, G.K. and JAGANNATHAN, N.R., 2010. 
Similarity in the metabolic profile in macroscopically involved and un-involved colonic mucosa in 
patients with inflammatory bowel disease: an in vitro proton ((1)H) MR spectroscopy study. Magnetic 
resonance imaging, 28(7), pp. 1022-1029. 
SHAW, M.H., KAMADA, N., WARNER, N., KIM, Y.G. and NUNEZ, G., 2011. The ever-expanding 




SHAW, S.Y., BLANCHARD, J.F. and BERNSTEIN, C.N., 2010. Association between the use of 
antibiotics in the first year of life and pediatric inflammatory bowel disease. The American Journal of 
Gastroenterology, 105(12), pp. 2687-2692. 
SHER, M.E., BANK, S., GREENBERG, R., SARDINHA, T.C., WEISSMAN, S., BAILEY, B., 
GILLILAND, R. and WEXNER, S.D., 1999. The influence of cigarette smoking on cytokine levels in 
patients with inflammatory bowel disease. Inflammatory bowel diseases, 5(2), pp. 73-78. 
SHERRILL, C. and FAHEY, R.C., 1998. Import and metabolism of glutathione by Streptococcus 
mutans. Journal of Bacteriology, 180(6), pp. 1454-1459. 
SHIMAOKA, T., KUME, N., MINAMI, M., HAYASHIDA, K., KATAOKA, H., KITA, T. and 
YONEHARA, S., 2000. Molecular cloning of a novel scavenger receptor for oxidized low density 
lipoprotein, SR-PSOX, on macrophages. The Journal of biological chemistry, 275(52), pp. 40663-
40666. 
SHIN, H.S., BAE, M.J., JUNG, S.Y., SEE, H.J., KIM, Y.T., DO, J.R., BACK, S.Y., CHOI, S.W. and 
SHON, D.H., 2015. Enhancing Effect of Trachelogenin from Trachelospermi caulis Extract on 
Intestinal Barrier Function. Biological & pharmaceutical bulletin, . 
SHINE, B., BERGHOUSE, L., JONES, J.E. and LANDON, J., 1985. C-reactive protein as an aid in 
the differentiation of functional and inflammatory bowel disorders. Clinica Chimica Acta, 148(2), pp. 
105-109. 
SHINZAKI, S., IIJIMA, H., NAKAGAWA, T., EGAWA, S., NAKAJIMA, S., ISHII, S., IRIE, T., 
KAKIUCHI, Y., NISHIDA, T., YASUMARU, M., KANTO, T., TSUJII, M., TSUJI, S., 
MIZUSHIMA, T., YOSHIHARA, H., KONDO, A., MIYOSHI, E. and HAYASHI, N., 2008. IgG 
oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of 
inflammatory bowel disease. The American Journal of Gastroenterology, 103(5), pp. 1173-1181. 
SHIVANANDA, S., LENNARD-JONES, J., LOGAN, R., FEAR, N., PRICE, A., CARPENTER, L. 
and VAN BLANKENSTEIN, M., 1996. Incidence of inflamatory bowel disease across Europe: is 
there a difference between north and south? Results of the European Collaborative Study on 
Inflammatory Bowel Disease (EC-IBD). Gut, 39(5), pp. 690-697. 
SIFFLEDEEN, J.S., FU, H., SLUPSKY, C.M. and FEDORAK, R.N., 2008. Urinary Metabolomic 
Profiles Differ Between Patients With And Without Inflammatory Bowel Disease. Gastroenterology, 
134(4), pp. A203. 
Significance of faecal lysozme excretion and alph-1-antitrypsin clearance in the assessment of activity 
of inflammatory bowel disease. In: B. GE, ed,  
SILBERER, H., KUPPERS, B., MICKISCH, O., BANIEWICZ, W., DRESCHER, M., TRABER, L., 
KEMPF, A. and SCHMIDT-GAYK, H., 2005. Fecal leukocyte proteins in inflammatory bowel 
disease and irritable bowel syndrome. Clinical labor tory, 51(3-4), pp. 117-126. 
SILVERBERG, M.S., SATSANGI, J., AHMAD, T. and ET AL., 2005. 
SINGH, S.B., DAVIS, A.S., TAYLOR, G.A. and DERETIC, V., 2006. Human IRGM induces 
autophagy to eliminate intracellular mycobacteria. Science (New York, N.Y.), 313(5792), pp. 1438-
1441. 
SMITH, E.A. and MACFARLANE, G.T., 1996. Enumeration f human colonic bacteria producing 
phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on 
dissimilatory aromatic amino acid metabolism. Journal of Applied Bacteriology, 81(3), pp. 288-302. 
SMITH, E.A. and MACFARLANE, G.T., 1997. Dissimilatory amino Acid metabolism in human 
colonic bacteria. Anaerobe, 3(5), pp. 327-337. 
SMITH, J.L., WISHNOK, J.S. and DEEN, W.M., 1994. Metabolism and excretion of methylamines 
in rats. Toxicology & Applied Pharmacology, 125(2), pp. 296-308. 
SMITHSON, J.E., RADFORD-SMITH, G. and JEWELL, G.P., 1995. Appendectomy and 
tonsillectomy in patients with inflammatory bowel disease. Journal of clinical gastroenterology, 21(4), 
pp. 283-286. 
SOKOL, H., PIGNEUR, B., WATTERLOT, L., LAKHDARI, O., BERMUDEZ-HUMARAN, L.G., 
GRATADOUX, J.J., BLUGEON, S., BRIDONNEAU, C., FURET, J.P., CORTHIER, G., 
GRANGETTE, C., VASQUEZ, N., POCHART, P., TRUGNAN, G., THOMAS, G., BLOTTIERE, 
H.M., DORE, J., MARTEAU, P., SEKSIK, P. and LANGELLA, P., 2008. Faecalibacterium 
prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of 
Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of 
America, 105(43), pp. 16731-16736. 
 
 404 
SOKOL, H., SEKSIK, P., FURET, J.P., FIRMESSE, O., NIO -LARMURIER, I., BEAUGERIE, L., 
COSNES, J., CORTHIER, G., MARTEAU, P. and DORE, J., 2009. Low counts of Faecalibacterium 
prausnitzii in colitis microbiota. Inflammatory bowel diseases, 15(8), pp. 1183-1189. 
SOKOL, H., SEKSIK, P., RIGOTTIER-GOIS, L., LAY, C., LEPAGE, P., PODGLAJEN, I., 
MARTEAU, P. and DORE, J., 2006. Specificities of the fecal microbiota in inflammatory bowel 
disease. Inflammatory bowel diseases, 12(2), pp. 106-111. 
SOLEM, C.A., LOFTUS, E.V.,JR, TREMAINE, W.J., HARMSEN, W.S., ZINSMEISTER, A.R. and 
SANDBORN, W.J., 2005. Correlation of C-reactive protein with clinical, endoscopic, histologic, and 
radiographic activity in inflammatory bowel disease. Inflammatory bowel diseases, 11(8), pp. 707-
712. 
SOLHAUG, A., WISBECH, C., CHRISTOFFERSEN, T.E., HULT, L.O., LEA, T., ERIKSEN, G.S. 
and HOLME, J.A., 2015. The mycotoxin alternariol induces DNA damage and modify macrophage 
phenotype and inflammatory responses. Toxicology letters, 239(1), pp. 9-21. 
SOMERVILLE, K.W., LOGAN, R.F., EDMOND, M. and LANGMAN, M.J., 1984. Smoking and 
Crohn's disease. British Medical Journal Clinical Research Ed, 289(6450), pp. 954-956. 
SONNENBERG, A., 2010. Temporal changes in the age distribution of inflammatory bowel disease 
hospitalization: data from England and Scotland. European journal of gastroenterology & hepatology, 
22(1), pp. 95-101. 
SONNENBERG, A., MCCARTY, D.J. and JACOBSEN, S.J., 199 . Geographic variation of 
inflammatory bowel disease within the United States. Gastroenterology, 100(1), pp. 143-149. 
SPEHLMANN, M.E., BEGUN, A.Z., BURGHARDT, J., LEPAGE, P., RAEDLER, A. and 
SCHREIBER, S., 2008. Epidemiology of inflammatory bowel disease in a German twin cohort: 
results of a nationwide study. Inflammatory bowel diseases, 14(7), pp. 968-976. 
SPOOREN, C.E., PIERIK, M.J., ZEEGERS, M.P., FESKENS, E.J., MASCLEE, A.A. and 
JONKERS, D.M., 2013. Review article: the association of diet with onset and relapse in patients with 
inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 38(10), pp. 1172-1187. 
SPYRIDOPOULOS, I., LUEDEMANN, C., CHEN, D., KEARNEY, M., CHEN, D., MUROHARA, 
T., PRINCIPE, N., ISNER, J.M. and LOSORDO, D.W., 200 . Divergence of angiogenic and vascular 
permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced 
angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 22(6), pp. 901-906. 
SREEKUMAR, A., POISSON, L.M., RAJENDIRAN, T.M., KHAN, A.P., CAO, Q., YU, J., 
LAXMAN, B., MEHRA, R., LONIGRO, R.J., LI, Y., NYATI, M.K., AHSAN, A., KALYANA-
SUNDARAM, S., HAN, B., CAO, X., BYUN, J., OMENN, G.S , GHOSH, D., PENNATHUR, S., 
ALEXANDER, D.C., BERGER, A., SHUSTER, J.R., WEI, J.T., VARAMBALLY, S., BEECHER, 
C. and CHINNAIYAN, A.M., 2009. Metabolomic profiles delineate potential role for sarcosine in 
prostate cancer progression. Nature, 457(7231), pp. 910-914. 
SRIVASTAVA, E.D., RUSSELL, M.A., FEYERABEND, C. and RHODES, J., 1990. Effect of 
ulcerative colitis and smoking on rectal blood flow. Gut, 31(9), pp. 1021-1024. 
STEINBAKK, M., NAESS-ANDRESEN, C.F., LINGAAS, E., DALE, I., BRANDTZAEG, P. and 
FAGERHOL, M.K., 1990. Antimicrobial actions of calcium binding leucocyte L1 protein, 
calprotectin. Lancet, 336(8718), pp. 763-765. 
STEINHART, A.H., HIRUKI, T., BRZEZINSKI, A. and BAKER, J.P., 1996. Treatment of left-sided 
ulcerative colitis with butyrate enemas: a controlled trial. Alimentary Pharmacology & Therapeutics, 
10(5), pp. 729-736. 
STEWENIUS, J., ADNERHILL, I., EKELUND, G., FLOREN, C.H., FORK, F.T., JANZON, L., 
LINDSTROM, C., MARS, I., NYMAN, M. and ROSENGREN, J.E., 1995. Ulcerative colitis and 
indeterminate colitis in the city of Malmo, Sweden. A 25-year incidence study. Scandinavian journal 
of gastroenterology, 30(1), pp. 38-43. 
STOCKER, W., OTTE, M., ULRICH, S., NORMANN, D., FINKBEINER, H., STOCKER, K., 
JANTSCHEK, G. and SCRIBA, P.C., 1987. Autoimmunity to pancreatic juice in Crohn's disease. 
Results of an autoantibody screening in patients wih chronic inflammatory bowel disease. 
Scandinavian journal of gastroenterology.Supplement, 139, pp. 41-52. 
STOKKERS, P.C., REITSMA, P.H., TYTGAT, G.N. and VAN DEVENTER, S.J., 1999. HLA-DR 
and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut, 45(3), pp. 395-401. 
STOLBERG, L., ROLFE, R., GITLIN, N., MERRITT, J., MANN, L.,JR, LINDER, J. and 
FINEGOLD, S., 1982. d-Lactic acidosis due to abnormal gut flora: diagnosis and treatment of two 
cases. New England Journal of Medicine, 306(22), pp. 1344-1348. 
 
 405 
STONE, M.A., MAYBERRY, J.F. and BAKER, R., 2003. Prevalence and management of 
inflammatory bowel disease: a cross-sectional study from central England. European journal of 
gastroenterology & hepatology, 15(12), pp. 1275-1280. 
STORDAL, K., JAHNSEN, J., BENTSEN, B.S. and MOUM, B., 2004. Pediatric inflammatory bowel 
disease in southeastern Norway: a five-year follow-up study. Digestion, 70(4), pp. 226-230. 
STOWE, S.P., REDMOND, S.R., STORMONT, J.M., SHAH, A.N., CHESSIN, L.N., SEGAL, H.L. 
and CHEY, W.Y., 1990. An epidemiologic study of inflammatory bowel disease in Rochester, New 
York. Hospital incidence. Gastroenterology, 98(1), pp. 104-110. 
STRAUSSMAN, R., NEJMAN, D., ROBERTS, D., STEINFELD, I., BLUM, B., BENVENISTY, N., 
SIMON, I., YAKHINI, Z. and CEDAR, H., 2009. Developmental programming of CpG island 
methylation profiles in the human genome. Nature Stuctural & Molecular Biology, 16(5), pp. 564-
571. 
STROBER, W. and FUSS, I.J., 2011. Proinflammatory cytokines in the pathogenesis of inflammatory 
bowel diseases. Gastroenterology, 140(6), pp. 1756-67. 
SUGI, K., SAITOH, O., HIRATA, I. and KATSU, K., 1996. Fecal lactoferrin as a marker for disease 
activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. American 
Journal of Gastroenterology, 91(5), pp. 927-934. 
SUMNER, L.W., AMBERG, A., BARRETT, D., BEALE, M.H., BEGER, R., DAYKIN, C.A., FAN, 
T.W., FIEHN, O., GOODACRE, R., GRIFFIN, J.L., HANKEMEIER, T., HARDY, N., HARNLY, J., 
HIGASHI, R., KOPKA, J., LANE, A.N., LINDON, J.C., MARRIOTT, P., NICHOLLS, A.W., 
REILY, M.D., THADEN, J.J. and VIANT, M.R., 2007. Proposed minimum reporting standards for 
chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative 
(MSI). Metabolomics : Official journal of the Metabolomic Society, 3(3), pp. 211-221. 
SUTHERLAND, A.D., GEARRY, R.B. and FRIZELLE, F.A., 2008. Review of fecal biomarkers in 
inflammatory bowel disease. Diseases of the Colon & Rectum, 51(8), pp. 1283-1291. 
SUTHERLAND, L.R., RAMCHARAN, S., BRYANT, H. and FICK, G., 1990. Effect of cigarette 
smoking on recurrence of Crohn's disease. Gastroenterology, 98(5 Pt 1), pp. 1123-1128. 
SUTTON, C.L., KIM, J., YAMANE, A., DALWADI, H., WEI, B., LANDERS, C., TARGAN, S.R. 
and BRAUN, J., 2000. Identification of a novel bacterial sequence associated with Crohn's disease. 
Gastroenterology, 119(1), pp. 23-31. 
SWAN, N.C., GEOGHEGAN, J.G., O'DONOGHUE, D.P., HYLAND, J.M. and SHEAHAN, K., 
1998. Fulminant colitis in inflammatory bowel disea: detailed pathologic and clinical analysis. 
Diseases of the Colon & Rectum, 41(12), pp. 1511-155. 
SWANSON, G.R., BURGESS, H.J. and KESHAVARZIAN, A., 2011. Sleep disturbances and 
inflammatory bowel disease: a potential trigger for disease flare? Expert review of clinical 
immunology, 7(1), pp. 29-36. 
SWARTZ, M.E., 2005. UPLC: An Introduction and Review. Journal of Liquid Chromatography & 
Related Technologies, 28(7&8), pp. 1253-1263. 
SWIDSINSKI, A., DORFFEL, Y., LOENING-BAUCKE, V., THEISSIG, F., RUCKERT, J.C., 
ISMAIL, M., RAU, W.A., GASCHLER, D., WEIZENEGGER, M., KUHN, S., SCHILLING, J. and 
DORFFEL, W.V., 2011. Acute appendicitis is characterised by local invasion with Fusobacterium 
nucleatum/necrophorum. Gut, 60(1), pp. 34-40. 
SZABO, C., 2007. Hydrogen sulphide and its therapeutic potential. Nature reviews.Drug discovery, 
6(11), pp. 917-935. 
TABIBIAN, J.H. and ROTH, B.E., 2009. Local thrombolysis: a newer approach to treating 
inflammatory bowel disease-related thromboembolism. Journal of clinical gastroenterology, 43(5), pp. 
391-398. 
TAKAGI, T., NAITO, Y., UCHIYAMA, K. and YOSHIKAWA, T., 2010. The role of heme 
oxygenase and carbon monoxide in inflammatory bowel disease. Redox Report: Communications In 
Free Radical Research, 15(5), pp. 193-201. 
TAKAGI, T., UCHIYAMA, K. and NAITO, Y., 2015. The therapeutic potential of carbon monoxide 
for inflammatory bowel disease. Digestion, 91(1), pp. 13-18. 
TAKAISHI, H., MATSUKI, T., NAKAZAWA, A., TAKADA, T. , KADO, S., ASAHARA, T., 
KAMADA, N., SAKURABA, A., YAJIMA, T., HIGUCHI, H., INOUE, N., OGATA, H., IWAO, Y., 
NOMOTO, K., TANAKA, R. and HIBI, T., 2008. Imbalance in intestinal microflora constitution 
could be involved in the pathogenesis of inflammatory bowel disease. Ijmm International Journal of 
Medical Microbiology, 298(5-6), pp. 463-472. 
 
 406 
TAKEUCHI, K., SMALE, S., PREMCHAND, P., MAIDEN, L., SHERWOOD, R., 
THJODLEIFSSON, B., BJORNSSON, E. and BJARNASON, I., 2006. Prevalence and mechanism of 
nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel 
disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the 
American Gastroenterological Association, 4(2), pp. 196-202. 
TALLEY, N.J., ABREU, M.T., ACHKAR, J.P., BERNSTEIN, C.N., DUBINSKY, M.C., 
HANAUER, S.B., KANE, S.V., SANDBORN, W.J., ULLMAN, T.A., MOAYYEDI, P. and 
AMERICAN COLLEGE OF GASTROENTEROLOGY IBD TASK FORCE, 2011. An evidence-
based systematic review on medical therapies for inlammatory bowel disease. The American Journal 
of Gastroenterology, 106 Suppl 1, pp. S2-25; quiz S26. 
TALLEY, N.J., KEPHART, G.M., MCGOVERN, T.W., CARPENTER, H.A. and GLEICH, G.J., 
1992. Deposition of eosinophil granule major basic protein in eosinophilic gastroenteritis and celiac 
disease. Gastroenterology, 103(1), pp. 137-145. 
TANG, H. and WANG, Y., 2006. Metabonomics: A revolution in progress. Progress in Biochemistry 
and Biophysics, 33(5), pp. 401-417. 
TARGAN, S.R. and KARP, L.C., 2005. Defects in mucosal immunity leading to ulcerative colitis. 
Immunological reviews, 206, pp. 296-305. 
TARGAN, S.R., LANDERS, C.J., YANG, H., LODES, M.J., CONG, Y., PAPADAKIS, K.A., 
VASILIAUSKAS, E., ELSON, C.O. and HERSHBERG, R.M., 2005. Antibodies to CBir1 flagellin 
define a unique response that is associated indepenntly with complicated Crohn's disease. 
Gastroenterology, 128(7), pp. 2020-2028. 
TATEISHI, S., ARIMA, S. and FUTAMI, K., 1997. Assessment of blood flow in the small intestine 
by laser Doppler flowmetry: comparison of healthy small intestine and small intestine in Crohn's 
disease. Journal of gastroenterology, 32(4), pp. 457-463. 
TEAHON, K. and BJARNASON, I., 1993. Comparison of leukocyte excretion and blood loss in 
inflammatory disease of the bowel. Gut, 34(11), pp. 1535-1538. 
TEDELIND, S., WESTBERG, F., KJERRULF, M. and VIDAL, A., 2007. Anti-inflammatory 
properties of the short-chain fatty acids acetate and propionate: a study with relevance to 
inflammatory bowel disease. World journal of gastroenterology : WJG, 13(20), pp. 2826-2832. 
TEKKIS, P.P., HERIOT, A.G., SMITH, O., SMITH, J.J., WINDSOR, A.C. and NICHOLLS, R.J., 
2005. Long-term outcomes of restorative proctocolect my for Crohn's disease and indeterminate 
colitis. Colorectal Disease, 7(3), pp. 218-223. 
TERAHARA, K., YOSHIDA, M., IGARASHI, O., NOCHI, T., PONTES, G.S., HASE, K., OHNO, 
H., KUROKAWA, S., MEJIMA, M., TAKAYAMA, N., YUKI, Y ., LOWE, A.W. and KIYONO, H., 
2008. Comprehensive gene expression profiling of Peyer's patch M cells, villous M-like cells, and 
intestinal epithelial cells. Journal of immunology (Baltimore, Md.: 1950), 180(12), pp. 7840-7846. 
TERJUNG, B. and WORMAN, H.J., 2001. Anti-neutrophil antibodies in primary sclerosing 
cholangitis. Best Practice & Research in Clinical Gstroenterology, 15(4), pp. 629-642. 
TERJUNG, B., BOGSCH, F., KLEIN, R., SOHNE, J., REICHEL, C., WASMUTH, J.C., BEUERS, 
U., SAUERBRUCH, T. and SPENGLER, U., 2004. Diagnostic accuracy of atypical p-ANCA in 
autoimmune hepatitis using ROC- and multivariate regression analysis. European journal of medical 
research, 9(9), pp. 439-448. 
TERJUNG, B., SPENGLER, U., SAUERBRUCH, T. and WORMAN, H.J., 2000. "Atypical p-
ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of 
neutrophils and myeloid cell lines. Gastroenterology, 119(2), pp. 310-322. 
TEUL, J., GARCIA, A., TUNON, J., MARTIN-VENTURA, J.L., TARIN, N., BESCOS, L.L., 
EGIDO, J., BARBAS, C. and RUPEREZ, F.J., 2011. Targeted and non-targeted metabolic time 
trajectory in plasma of patients after acute coronay syndrome. Journal of pharmaceutical and 
biomedical analysis, 56(2), pp. 343-351. 
The phospholipid composition of mammalian tissue. In: G.B. ANSELL, J.N. HAWTHORNE and  
R.M.C. DAWSON, eds,  
THEODORATOU, E., CAMPBELL, H., VENTHAM, N.T., KOLARICH, D., PUCIC-BAKOVIC, 
M., ZOLDOS, V., FERNANDES, D., PEMBERTON, I.K., RUDAN, I., KENNEDY, N.A., 
WUHRER, M., NIMMO, E., ANNESE, V., MCGOVERN, D.P., SATSANGI, J. and LAUC, G., 




THIA, K.T., LOFTUS, E.V.,JR, SANDBORN, W.J. and YANG, S.K., 2008. An update on the 
epidemiology of inflammatory bowel disease in Asia. The American Journal of Gastroenterology, 
103(12), pp. 3167-3182. 
THOMAS, G., SWIFT, G., GREEN, J., NEWCOMBE, R., BRANIFF-MATHEWS, C., RHODES, J., 
WILKINSON, S., STROHMEYER, G. and KREUZPAINTER, G., 1998. Controlled trial of 
antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut, 42(4), pp. 497-500. 
THOMAS, G.A., RHODES, J., MANI, V., WILLIAMS, G.T., NEWCOMBE, R.G., RUSSELL, M.A. 
and FEYERABEND, C., 1995. Transdermal nicotine as mintenance therapy for ulcerative colitis. 
New England Journal of Medicine, 332(15), pp. 988-992. 
THOMPSON, N.P., DRISCOLL, R., POUNDER, R.E. and WAKEFIELD, A.J., 1996. Genetics 
versus environment in inflammatory bowel disease: results of a British twin study. BMJ, 312(7023), 
pp. 95-96. 
THOMPSON, N.P., MONTGOMERY, S.M., POUNDER, R.E. and WAKEFIELD, A.J., 1995. Is 
measles vaccination a risk factor for inflammatory bowel disease? Lancet, 345(8957), pp. 1071-1074. 
THOMPSON, N.P., MONTGOMERY, S.M., WADSWORTH, M.E., POUNDER, R.E. and 
WAKEFIELD, A.J., 2000. Early determinants of inflammatory bowel disease: use of two national 
longitudinal birth cohorts. European journal of gastroenterology & hepatology, 12(1), pp. 25-30. 
THORSTEINSDOTTIR, S., GUDJONSSON, T., NIELSEN, O.H., VAINER, B. and SEIDELIN, J.B., 
2011. Pathogenesis and biomarkers of carcinogenesis i  ulcerative colitis. Nature 
reviews.Gastroenterology & hepatology, 8(7), pp. 395-404. 
THYSSEN, E., TURK, J., BOHRER, A. and STENSON, W.F., 1996. Quantification of distinct 
molecular species of platelet activating factor in ulcerative colitis. Lipids, 31(Suppl), pp. S255-9. 
TIBBLE, J., TEAHON, K., THJODLEIFSSON, B., ROSETH, A., SIGTHORSSON, G., BRIDGER, 
S., FOSTER, R., SHERWOOD, R., FAGERHOL, M. and BJARNASON, I., 2000. A simple method 
for assessing intestinal inflammation in Crohn's disease. Gut, 47(4), pp. 506-513. 
TILLETT, W.S. and FRANCIS, T., 1930. SEROLOGICAL REACTIONS IN PNEUMONIA WITH 
A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. The Journal of experimental 
medicine, 52(4), pp. 561-571. 
TIMMER, A., SUTHERLAND, L.R. and MARTIN, F., 1998. Oral contraceptive use and smoking are 
risk factors for relapse in Crohn's disease. The Canadi n Mesalamine for Remission of Crohn's 
Disease Study Group. Gastroenterology, 114(6), pp. 1143-1150. 
TIZIANI, S., LOPES, V. and GUNTHER, U.L., 2009. Early stage diagnosis of oral cancer using 1H 
NMR-based metabolomics. Neoplasia (New York, N.Y.), 11(3), pp. 269-76, 4p following 269. 
TOKITA, Y., YAMAMOTO, M., SATOH, K., NISHIYAMA, M., IIZUKA, S., IMAMURA, S. and 
KASE, Y., 2011. Possible involvement of the transiet receptor potential vanilloid type 1 channel in 
postoperative adhesive obstruction and its prevention by a kampo (traditional Japanese) medicine, 
daikenchuto. Journal of pharmacological sciences, 115(1), pp. 75-83. 
TOKITA, Y., YUZURIHARA, M., SAKAGUCHI, M., SATOH, K. and KASE, Y., 2007. The 
pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal 
transit in rat postoperative ileus. Journal of pharm cological sciences, 104(4), pp. 303-310. 
TON, H., BRANDSNES, DALE, S., HOLTLUND, J., SKUIBINA, E., SCHJONSBY, H. and 
JOHNE, B., 2000. Improved assay for fecal calprotectin. Clinica Chimica Acta, 292(1-2), pp. 41-54. 
TORUNER, M., LOFTUS, E.V.,JR, HARMSEN, W.S., ZINSMEISTER, A.R., ORENSTEIN, R., 
SANDBORN, W.J., COLOMBEL, J.F. and EGAN, L.J., 2008. Risk factors for opportunistic 
infections in patients with inflammatory bowel disea . Gastroenterology, 134(4), pp. 929-936. 
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: 
Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian 
Journal of Gastroenterology, 19(suppl A), pp. 5-36. 
TOYODA, H., WANG, S.J., YANG, H.Y., REDFORD, A., MAGALONG, D., TYAN, D., 
MCELREE, C.K., PRESSMAN, S.R., SHANAHAN, F. and TARGAN, S.R., 1993. Distinct 
associations of HLA class II genes with inflammatory bowel disease. Gastroenterology, 104(3), pp. 
741-748. 
TRAUBE, M., BOCK, J.L. and BOYER, J.L., 1983. D-Lactic acidosis after jejunoileal bypass: 
identification of organic anions by nuclear magnetic resonance spectroscopy. Annals of Internal 
Medicine, 98(2), pp. 171-173. 
TRAVASSOS, L.H., CARNEIRO, L.A., RAMJEET, M., HUSSEY, S., KIM, Y.G., MAGALHAES, 
J.G., YUAN, L., SOARES, F., CHEA, E., LE BOURHIS, L., BONECA, I.G., ALLAOUI, A., 
JONES, N.L., NUNEZ, G., GIRARDIN, S.E. and PHILPOTT, D.J., 2010. Nod1 and Nod2 direct 
 
 408 
autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nature 
immunology, 11(1), pp. 55-62. 
TRAVIS, S.P., FARRANT, J.M., RICKETTS, C., NOLAN, D.J., MORTENSEN, N.M., 
KETTLEWELL, M.G. and JEWELL, D.P., 1996. Predicting outcome in severe ulcerative colitis. Gut, 
38(6), pp. 905-910. 
TRICKER, A.R., 1997. N-nitroso compounds and man: sources of exposure, endogenous formation 
and occurrence in body fluids. European journal of cancer prevention : the official journal of the 
European Cancer Prevention Organisation (ECP), 6(3)pp. 226-268. 
TRUELOVE, S.C. and WITTS, L.J., 1954. Cortisone in ulcerative colitis; preliminary report on a 
therapeutic trial. British medical journal, 2(4884), pp. 375-378. 
TSAI, H.H., DWARAKANATH, A.D., HART, C.A., MILTON, J.D. and RHODES, J.M., 1995. 
Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment. Gut, 
36(4), pp. 570-576. 
TWEEDDALE, H., NOTLEY-MCROBB, L. and FERENCI, T., 1998. Effect of slow growth on 
metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. 
Journal of Bacteriology, 180(19), pp. 5109-5116. 
TYSK, C., LINDBERG, E., JARNEROT, G. and FLODERUS-MYRHED, B., 1988. Ulcerative colitis 
and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of 
heritability and the influence of smoking. Gut, 29(7), pp. 990-996. 
ULLMAN, T.A. and ITZKOWITZ, S.H., 2011. Intestinal inflammation and cancer. Gastroenterology, 
140(6), pp. 1807-1816. 
UZA, N., NAKASE, H., YAMAMOTO, S., YOSHINO, T., TAKEDA, Y., UENO, S., INOUE, S., 
MIKAMI, S., MATSUURA, M., SHIMAOKA, T., KUME, N., MINAMI, M., YONEHARA, S., 
IKEUCHI, H. and CHIBA, T., 2011. SR-PSOX/CXCL16 plays a critical role in the progression of 
colonic inflammation. Gut, 60(11), pp. 1494-1505. 
VAISHNAVA, S., BEHRENDT, C.L., ISMAIL, A.S., ECKMANN, L. and HOOPER, L.V., 2008. 
Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial 
interface. Proceedings of the National Academy of Sciences of the United States of America, 105(52), 
pp. 20858-20863. 
VAN BUSKIRK, J.J., KIRSCH, W.M., KLEYER, D.L., BARKLEY, R.M. and KOCH, T.H., 1984. 
Aminomalonic acid: identification in Escherichia coli and atherosclerotic plaque. Proceedings of the 
National Academy of Sciences of the United States of America, 81(3), pp. 722-725. 
VAN DER SLUYS VEER, A., BIEMOND, I., VERSPAGET, H.W. and LAMERS, C.B., 1999. 
Faecal parameters in the assessment of activity in nflammatory bowel disease. Scandinavian Journal 
of Gastroenterology - Supplement, 230, pp. 106-110. 
VAN DER SLUYS VEER, A., BROUWER, J., BIEMOND, I., BOHBOUTH, G.E., VERSPAGET, 
H.W. and LAMERS, C.B., 1998. Fecal lysozyme in asses ment of disease activity in inflammatory 
bowel disease. Digestive Diseases & Sciences, 43(3), pp. 590-595. 
VAN DER VOORT, R., VAN LIESHOUT, A.W., TOONEN, L.W., SLOETJES, A.W., VAN DEN 
BERG, W.B., FIGDOR, C.G., RADSTAKE, T.R. and ADEMA, G.J., 2005. Elevated CXCL16 
expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis and 
Rheumatism, 52(5), pp. 1381-1391. 
VAN DIJK, A.P., MEIJSSEN, M.A., BROUWER, A.J., HOP, W.C., VAN BERGEIJK, J.D., 
FEYERABEND, C., WILSON, J.H. and ZIJLSTRA, F.J., 1998. Transdermal nicotine inhibits 
interleukin 2 synthesis by mononuclear cells derived from healthy volunteers. European journal of 
clinical investigation, 28(8), pp. 664-671. 
VAN RHEENEN, P.F., VAN DE VIJVER, E. and FIDLER, V., 2010. Faecal calprotectin for 
screening of patients with suspected inflammatory bwel disease: diagnostic meta-analysis. BMJ, 341, 
pp. 3369. 
VAN ZANTEN, G.C., SPARDING, N., MAJUMDER, A., LAHTINEN, S.J., SVENSSON, B. and 
JACOBSEN, S., 2015. The Differential Proteome of the Probiotic Lactobacillus acidophilus NCFM 
Grown on the Potential Prebiotic Cellobiose Shows Upregulation of Two beta -Glycoside Hydrolases. 
BioMed research international, 2015, pp. 347216. 
VARGA, C., HORVATH, K., BERKO, A., THURMOND, R.L., DUNFORD, P.J. and WHITTLE, 
B.J., 2005. Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. 
European journal of pharmacology, 522(1-3), pp. 130- 8. 
VARMA, S., BIRD, R., ESKIN, M., DOLENKO, B., RAJU, J. and BEZABEH, T., 2007. 
 
 409 
VASILIAUSKAS, E.A., PLEVY, S.E., LANDERS, C.J., BINDER, S.W., FERGUSON, D.M., 
YANG, H., ROTTER, J.I., VIDRICH, A. and TARGAN, S.R, 1996. Perinuclear antineutrophil 
cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology, 
110(6), pp. 1810-1819. 
VAZQUEZ-FRESNO, R., LLORACH, R., URPI-SARDA, M., LUPIANEZ-BARBERO, A., 
ESTRUCH, R., CORELLA, D., FITO, M., AROS, F., RUIZ-CANELA, M., SALAS-SALVADO, J. 
and ANDRES-LACUEVA, C., 2015. Metabolomic pattern analysis after mediterranean diet 
intervention in a nondiabetic population: a 1- and 3-year follow-up in the PREDIMED study. Journal 
of proteome research, 14(1), pp. 531-540. 
VELAZQUEZ, O.C., LEDERER, H.M. and ROMBEAU, J.L., 1997. Butyrate and the colonocyte. 
Production, absorption, metabolism, and therapeutic implications. Advances in Experimental 
Medicine and Biology, 427, pp. 123-134. 
VENTHAM, N.T., KENNEDY, N.A., NIMMO, E.R. and SATSANGI, J., 2013. Beyond gene 
discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology, 145(2), 
pp. 293-308. 
VERIOTTI, T. and SACKS, R., 2001. High-speed GC andGC/time-of-flight MS of lemon and lime 
oil samples. Analytical Chemistry, 73(18), pp. 4395-4402. 
VERMEIRE, S., PEETERS, M., VLIETINCK, R., JOOSSENS, S.  DEN HOND, E., BULTEEL, V., 
BOSSUYT, X., GEYPENS, B. and RUTGEERTS, P., 2001. Anti-Saccharomyces cerevisiae 
antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. 
Inflammatory bowel diseases, 7(1), pp. 8-15. 
VERMEIRE, S., VAN ASSCHE, G. and RUTGEERTS, P., 2004. C-reactive protein as a marker for 
inflammatory bowel disease. Inflammatory bowel diseases, 10(5), pp. 661-665. 
VERMEIRE, S., VAN ASSCHE, G. and RUTGEERTS, P., 2006. Laboratory markers in IBD: useful, 
magic, or unnecessary toys? Gut, 55(3), pp. 426-431. 
VERMEIRE, S., VERMEULEN, N., VAN ASSCHE, G., BOSSUYT, X. and RUTGEERTS, P., 2008. 
(Auto)Antibodies in Inflammatory Bowel Diseases. Gastroenterology clinics of North America, 37(2), 
pp. 429-438. 
VERNIA, P., CAPRILLI, R., LATELLA, G., BARBETTI, F., MAGLIOCCA, F.M. and CITTADINI, 
M., 1988. Fecal lactate and ulcerative colitis. Gastroenterology, 95(6), pp. 1564-1568. 
VERNIA, P., GNAEDINGER, A., HAUCK, W. and BREUER, R.I., 1988. Organic anions and the 
diarrhea of inflammatory bowel disease. Digestive Diseases & Sciences, 33(11), pp. 1353-1358. 
VIANT, M.R., 2007. Metabolomics of aquatic organisms: the new "omics" on the block. Marine 
Ecology Progress Series, 322, pp. 301-306. 
VIEIRA, E.L., LEONEL, A.J., SAD, A.P., BELTRAO, N.R., COSTA, T.F., FERREIRA, T.M., 
GOMES-SANTOS, A.C., FARIA, A.M., PELUZIO, M.C., CARA, D.C. and ALVAREZ-LEITE, J.I., 
2012. Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in 
experimental acute ulcerative colitis. The Journal of nutritional biochemistry, 23(5), pp. 430-436. 
VIGNEAU-CALLAHAN, K.E., SHESTOPALOV, A.I., MILBURY, P.E., MATSON, W.R. and 
KRISTAL, B.S., 2001. Characterization of diet-depend t metabolic serotypes: analytical and 
biological variability issues in rats. Journal of Nutrition, 131(3), pp. 924S-932S. 
VIJAY-KUMAR, M., AITKEN, J.D. and GEWIRTZ, A.T., 208. Toll like receptor-5: protecting the 
gut from enteric microbes. Seminars in immunopathology, 30(1), pp. 11-21. 
VIJAY-KUMAR, M., SANDERS, C.J., TAYLOR, R.T., KUMAR, A., AITKEN, J.D., 
SITARAMAN, S.V., NEISH, A.S., UEMATSU, S., AKIRA, S., WILLIAMS, I.R. and GEWIRTZ, 
A.T., 2007. Deletion of TLR5 results in spontaneous colitis in mice. The Journal of clinical 
investigation, 117(12), pp. 3909-3921. 
VIJAY-KUMAR, M., WU, H., AITKEN, J., KOLACHALA, V.L., NEISH, A.S., SITARAMAN, S.V. 
and GEWIRTZ, A.T., 2007. Activation of toll-like rec ptor 3 protects against DSS-induced acute 
colitis. Inflammatory bowel diseases, 13(7), pp. 856- 64. 
VILCEK, J., 2009. From IFN to TNF: a journey into realms of lore. Nature immunology, 10(6), pp. 
555-557. 
VINEIS, P. and PERERA, F., 2007. Molecular epidemiology and biomarkers in etiologic cancer 
research: the new in light of the old. Cancer epidemiology, biomarkers & prevention : a publication of 
the American Association for Cancer Research, cosponsored by the American Society of Preventive 
Oncology, 16(10), pp. 1954-1965. 
VOWINKEL, T., MORI, M., KRIEGLSTEIN, C.F., RUSSELL, J., SAIJO, F., BHARWANI, S., 
TURNAGE, R.H., DAVIDSON, W.S., TSO, P., GRANGER, D.N. and KALOGERIS, T.J., 2004. 
 
 410 
Apolipoprotein A-IV inhibits experimental colitis. The Journal of clinical investigation, 114(2), pp. 
260-269. 
VUCELIC, B., KORAC, B., SENTIC, M., MILICIC, D., HADZIC, N., JURESA, V., BOZIKOV, J., 
ROTKVIC, I., BULJEVAC, M. and KOVACEVIC, I., 1991a. Epidemiology of Crohn's disease in 
Zagreb, Yugoslavia: a ten-year prospective study. International journal of epidemiology, 20(1), pp. 
216-220. 
VUCELIC, B., KORAC, B., SENTIC, M., MILICIC, D., HADZIC, N., JURESA, V., BOZIKOV, J., 
ROTKVIC, I., BULJEVAC, M. and KOVACEVIC, I., 1991b. Ulcerative colitis in Zagreb, 
Yugoslavia: incidence and prevalence 1980-1989. International journal of epidemiology, 20(4), pp. 
1043-1047. 
WAGSATER, D., OLOFSSON, P.S., NORGREN, L., STENBERG, B. and SIRSJO, A., 2004. The 
chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth 
muscle cells and is induced by interferon gamma. Biochemical and biophysical research 
communications, 325(4), pp. 1187-1193. 
WAKEFIELD, A.J., MURCH, S.H., ANTHONY, A., LINNELL, J., CASSON, D.M., MALIK, M., 
BERELOWITZ, M., DHILLON, A.P., THOMSON, M.A., HARVEY, P., VALENTINE, A., 
DAVIES, S.E. and WALKER-SMITH, J.A., 1998. Ileal-lymphoid-nodular hyperplasia, non-specific 
colitis, and pervasive developmental disorder in children. Lancet, 351(9103), pp. 637-641. 
WAKEFIELD, A.J., PITTILO, R.M., SIM, R., COSBY, S.L, STEPHENSON, J.R., DHILLON, A.P. 
and POUNDER, R.E., 1993. Evidence of persistent measles virus infection in Crohn's disease. Journal 
of medical virology, 39(4), pp. 345-353. 
WAKEFIELD, A.J., SAWYERR, A.M., HUDSON, M., DHILLON, A.P. and POUNDER, R.E., 
1991. Smoking, the oral contraceptive pill, and Crohn's disease. Digestive diseases and sciences, 
36(8), pp. 1147-1150. 
WALKER, T.R., LAND, M.L., COOK, T.M., BOONE, J.H., LYERLY, D. and RUFO, P.A., 2004. 
Serial fecal lactoferrin measurements are useful in the interval assessment of patients with active and 
inactive inflammatory bowel disease. Gastroenterology, 126(4), pp. A215. 
WALMSLEY, R.S., AYRES, R.C., POUNDER, R.E. and ALLAN, R.N., 1998. A simple clinical 
colitis activity index. Gut, 43(1), pp. 29-32. 
WANG, H., YU, M., OCHANI, M., AMELLA, C.A., TANOVIC, M., SUSARLA, S., LI, J.H., 
WANG, H., YANG, H., ULLOA, L., AL-ABED, Y., CZURA, C.J. and TRACEY, K.J., 2003. 
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature, 
421(6921), pp. 384-388. 
WANG, K., BALDASSANO, R., ZHANG, H., QU, H.Q., IMIELINSKI, M., KUGATHASAN, S., 
ANNESE, V., DUBINSKY, M., ROTTER, J.I., RUSSELL, R.K., BRADFIELD, J.P., SLEIMAN, 
P.M., GLESSNER, J.T., WALTERS, T., HOU, C., KIM, C., FRACKELTON, E.C., GARRIS, M., 
DORAN, J., ROMANO, C., CATASSI, C., VAN LIMBERGEN, J., GUTHERY, S.L., DENSON, L., 
PICCOLI, D., SILVERBERG, M.S., STANLEY, C.A., MONOS, D., WILSON, D.C., GRIFFITHS, 
A., GRANT, S.F., SATSANGI, J., POLYCHRONAKOS, C. and HAKONARSON, H., 2010. 
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple 
loci with opposite effects. Human molecular genetics, 19(10), pp. 2059-2067. 
WANG, M.C., ZHANG, L.Y., HAN, W., SHAO, Y., CHEN, M., NI, R., WANG, G.N., WEI, F.X., 
ZHANG, Y.W., XU, X.D. and ZHANG, Y.C., 2014. PRISMA - Efficacy and Safety of Vedolizumab 
for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized 
Controlled Trials. Medicine, 93(28), pp. . doi:10.197/MD.0000000000000326. 
WANG, W., WU, Z., DAI, Z., YANG, Y., WANG, J. and WU, G., 2013. Glycine metabolism in 
animals and humans: implications for nutrition and health. Amino acids, 45(3), pp. 463-477. 
WASHINGTON, K., GREENSON, J.K., MONTGOMERY, E., SHYR, Y., CRISSINGER, K.D., 
POLK, D.B., BARNARD, J. and LAUWERS, G.Y., 2002. Histopathology of ulcerative colitis in 
initial rectal biopsy in children. American Journal of Surgical Pathology, 26(11), pp. 1441-1449. 
WATANABE, Y., NAGAI, F. and MOROTOMI, M., 2012. Char cterization of 
Phascolarctobacterium succinatutens sp. nov., an asaccharolytic, succinate-utilizing bacterium isolated 
from human feces. Applied and Environmental Microbiology, 78(2), pp. 511-518. 
WECKWERTH, W., 2003. Metabolomics in systems biology. Annual Review of Plant Biology, 54, 
pp. 669-689. 
WEGIEL, B. and OTTERBEIN, L.E., 2012. Go green: theanti-inflammatory effects of biliverdin 
reductase. Frontiers in pharmacology, 3, pp. 47. 
 
 411 
WEHKAMP, J., SALZMAN, N.H., PORTER, E., NUDING, S., WEICHENTHAL, M., PETRAS, 
R.E., SHEN, B., SCHAEFFELER, E., SCHWAB, M., LINZMEIER, R., FEATHERS, R.W., CHU, 
H., LIMA, H.,JR, FELLERMANN, K., GANZ, T., STANGE, E.F. and BEVINS, C.L., 2005. Reduced 
Paneth cell alpha-defensins in ileal Crohn's disease. Proceedings of the National Academy of Sciences 
of the United States of America, 102(50), pp. 18129- 8134. 
WEI, B., HUANG, T., DALWADI, H., SUTTON, C.L., BRUCKNER, D. and BRAUN, J., 2002. 
Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. 
Infection & Immunity, 70(12), pp. 6567-6575. 
WEI, S., SURYANI, Y., GOWDA, G.A., SKILL, N., MALUC IO, M. and RAFTERY, D., 2012. 
Differentiating hepatocellular carcinoma from hepatitis C using metabolite profiling. Metabolites, 
2(4), pp. 701-716. 
WEINSTOCK, P.H., BISGAIER, C.L., HAYEK, T., AALTO-SETALA, K., SEHAYEK, E., WU, L., 
SHEIFFELE, P., MERKEL, M., ESSENBURG, A.D. and BRESLOW, J.L., 1997. Decreased HDL 
cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV 
knockout mice. Journal of lipid research, 38(9), pp. 1782-1794. 
WEISSMAN, A.M., 2001. Themes and variations on ubiqitylation. Nature reviews.Molecular cell 
biology, 2(3), pp. 169-178. 
WELLCOME TRUST CASE CONTROL CONSORTIUM, 2007. Genome-wide association study of 
14,000 cases of seven common diseases and 3,000 shared controls. Nature, 447(7145), pp. 661-678. 
WELLS, A.D., MCMILLAN, I., PRICE, A.B., RITCHIE, J.K. and NICHOLLS, R.J., 1991. Natural 
history of indeterminate colitis. British Journal of Surgery, 78(2), pp. 179-181. 
WERNER, E., HEILIER, J.F., DUCRUIX, C., EZAN, E., JUNOT, C. and TABET, J.C., 2008. Mass 
spectrometry for the identification of the discriminating signals from metabolomics: current status and 
future trends. Journal of Chromatography B: Analytical Technologies in the Biomedical & Life 
Sciences, 871(2), pp. 143-163. 
WHITE, D.A., 1973. 
WILBANKS, A., ZONDLO, S.C., MURPHY, K., MAK, S., SOLER, D., LANGDON, P., ANDREW, 
D.P., WU, L. and BRISKIN, M., 2001. Expression cloning of the STRL33/BONZO/TYMSTRligand 
reveals elements of CC, CXC, and CX3C chemokines. Journal of immunology (Baltimore, Md.: 
1950), 166(8), pp. 5145-5154. 
WILKS, S. and MOXON, W., eds,  1875. Lectures on pathological anatomy. 2nd edn. Philadelphila: 
Lindsay and Blakiston. 
WILKS, S., 1859. The morbid appearance of the intestin  of Miss Banks. Medical Times and Gazette, 
2, pp. 264. 
WILLIAMS, H.R., COX, I.J., WALKER, D.G., COBBOLD, J.F., TAYLOR-ROBINSON, S.D., 
MARSHALL, S.E. and ORCHARD, T.R., 2010. Differences in gut microbial metabolism are 
responsible for reduced hippurate synthesis in Crohn's disease. BMC gastroenterology, 10, pp. 108-
230X-10-108. 
WILLIAMS, H.R., COX, I.J., WALKER, D.G., NORTH, B.V., PATEL, V.M., MARSHALL, S.E., 
JEWELL, D.P., GHOSH, S., THOMAS, H.J., TEARE, J.P., JAKOBOVITS, S., ZEKI, S., WELSH, 
K.I., TAYLOR-ROBINSON, S.D. and ORCHARD, T.R., 2009. Characterization of inflammatory 
bowel disease with urinary metabolic profiling. American Journal of Gastroenterology, 104(6), pp. 
1435-1444. 
WILLIAMS, R.E., EYTON-JONES, H.W., FARNWORTH, M.J., GALLAGHER, R. and PROVAN, 
W.M., 2002. Effect of intestinal microflora on the urinary metabolic profile of rats: a (1)H-nuclear 
magnetic resonance spectroscopy study. Xenobiotica, 32(9), pp. 783-794. 
WILLISON, H.J. and YUKI, N., 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain, 
125(Pt 12), pp. 2591-2625. 
WILSON, C.M., MCGILLIGAN, K. and THOMAS, D.W., 1988. Determination of fecal alpha 1-
antitrypsin concentration by radial immunodiffusion: two systems compared. Clinical chemistry, 
34(2), pp. 372-376. 
WINDEY, K., DE PRETER, V. and VERBEKE, K., 2012. Relevance of protein fermentation to gut 
health. Molecular nutrition & food research, 56(1), pp. 184-196. 
WITTMANN-LIEBOLD, B., GRAACK, H.R. and POHL, T., 206. Two-dimensional gel 
electrophoresis as tool for proteomics studies in combination with protein identification by mass 
spectrometry. Proteomics, 6(17), pp. 4688-4703. 
WOO, H.M., KIM, K.M., CHOI, M.H., JUNG, B.H., LEE, J., KONG, G., NAM, S.J., KIM, S., BAI, 
S.W. and CHUNG, B.C., 2009. Mass spectrometry based m tabolomic approaches in urinary 
 
 412 
biomarker study of women's cancers. Clinica chimica a t ; international journal of clinical chemistry, 
400(1-2), pp. 63-69. 
XIA, J., BROADHURST, D.I., WILSON, M. and WISHART, D.S., 2013. Translational biomarker 
discovery in clinical metabolomics: an introductory tutorial. Metabolomics : Official journal of the 
Metabolomic Society, 9(2), pp. 280-299. 
XU, S.Y., CARLSON, M., ENGSTROM, A., GARCIA, R., PET RSON, C.G. and VENGE, P., 1994. 
Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules 
of human neutrophils. Scandinavian Journal of Clinical & Laboratory Investigation, 54(5), pp. 365-
376. 
XUE, R., LIN, Z., DENG, C., DONG, L., LIU, T., WANG, J. and SHEN, X., 2008. A serum 
metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed 
by gas chromatography/mass spectrometry. Rapid communications in mass spectrometry : RCM, 
22(19), pp. 3061-3068. 
YAN, S.K., WEI, B.J., LIN, Z.Y., YANG, Y., ZHOU, Z.T. and ZHANG, W.D., 2008. A 
metabonomic approach to the diagnosis of oral squamo s cell carcinoma, oral lichen planus and oral 
leukoplakia. Oral oncology, 44(5), pp. 477-483. 
YANG, C., SINGH, P., SINGH, H., LE, M.L. and EL-MATARY, W., 2015. Systematic review: 
thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Alimentary 
Pharmacology & Therapeutics, 41(11), pp. 1079-1093. 
YANG, H., MCELREE, C., ROTH, M.P., SHANAHAN, F., TARGAN, S.R. and ROTTER, J.I., 
1993. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-
Jews. Gut, 34(4), pp. 517-524. 
YANG, J., SCHMELZER, K., GEORGI, K. and HAMMOCK, B.D , 2009. Quantitative profiling 
method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass 
spectrometry. Analytical Chemistry, 81(19), pp. 8085-8093. 
YANG, J., XU, G., ZHENG, Y., KONG, H., PANG, T., LV, S. and YANG, Q., 2004. Diagnosis of 
liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and 
hepatocirrhosis diseases. Journal of chromatography.B, Analytical technologies in the biomedical and 
life sciences, 813(1-2), pp. 59-65. 
YANG, Y., LU, N., CHEN, D., MENG, L., ZHENG, Y. and HUI, R., 2012. Effects of n-3 PUFA 
supplementation on plasma soluble adhesion molecules: a meta-analysis of randomized controlled 
trials. The American Journal of Clinical Nutrition, 95(4), pp. 972-980. 
YAP, L.M., AHMAD, T. and JEWELL, D.P., 2004. The contribution of HLA genes to IBD 
susceptibility and phenotype. Best practice & research.Clinical gastroenterology, 18(3), pp. 577-596. 
YASOJIMA, K., SCHWAB, C., MCGEER, E.G. and MCGEER, P.L., 2000. Human neurons generate 
C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain research, 887(1), pp. 80-
89. 
YASOJIMA, K., SCHWAB, C., MCGEER, E.G. and MCGEER, P.L., 2001. Generation of C-reactive 
protein and complement components in atherosclerotic plaques. American Journal of Pathology, 
158(3), pp. 1039-1051. 
YAU, Y., LEONG, R.W., ZENG, M. and WASINGER, V.C., 2013. Proteomics and metabolomics in 
inflammatory bowel disease. Journal of gastroenterology and hepatology, 28(7), pp. 1076-1086. 
YE, J.H. and RAJENDRAN, V.M., 2009. Adenosine: an immune modulator of inflammatory bowel 
diseases. World journal of gastroenterology, 15(36), pp. 4491-4498. 
YE, M.B. and LIM, B.O., 2010. Dietary pectin regulates the levels of inflammatory cytokines and 
immunoglobulins in interleukin-10 knockout mice. Journal of Agricultural and Food Chemistry, 
58(21), pp. 11281-11286. 
YU, A.P., CABANILLA, L.A., WU, E.Q., MULANI, P.M. and CHAO, J., 2008. The costs of Crohn's 
disease in the United States and other Western countries: a systematic review. Current Medical 
Research & Opinion, 24(2), pp. 319-328. 
YU, C.S., PEMBERTON, J.H. and LARSON, D., 2000. Ileal pouch-anal anastomosis in patients with 
indeterminate colitis: long-term results. Diseases of the Colon & Rectum, 43(11), pp. 1487-1496. 
YUI, S., NAKATANI, Y. and MIKAMI, M., 2003. Calprotectin (S100A8/S100A9), an inflammatory 
protein complex from neutrophils with a broad apoptosis-inducing activity. Biological & 
pharmaceutical bulletin, 26(6), pp. 753-760. 
ZAIKIN, V.G. and HALKET, J.M., 2003. Review: Derivatization in mass spectrometry--2. Acylation. 
European Journal of Mass Spectrometry, 9(5), pp. 421-434. 
 
 413 
ZEISEL, S.H., FREAKE, H.C., BAUMAN, D.E., BIER, D.M., BURRIN, D.G., GERMAN, J.B., 
KLEIN, S., MARQUIS, G.S., MILNER, J.A., PELTO, G.H. and RASMUSSEN, K.M., 2005. The 
nutritional phenotype in the age of metabolomics. Journal of Nutrition, 135(7), pp. 1613-1616. 
ZEISSIG, S., BURGEL, N., GUNZEL, D., RICHTER, J., MANKERTZ, J., WAHNSCHAFFE, U., 
KROESEN, A.J., ZEITZ, M., FROMM, M. and SCHULZKE, J.D., 2007. Changes in expression and 
distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active 
Crohn's disease. Gut, 56(1), pp. 61-72. 
ZEYTUN, A., CHAUDHARY, A., PARDINGTON, P., CARY, R. and GUPTA, G., 2010. Induction 
of cytokines and chemokines by Toll-like receptor signaling: strategies for control of inflammation. 
Critical reviews in immunology, 30(1), pp. 53-67. 
ZHANG, A.H., SUN, H. and WANG, X.J., 2013. Recent adv nces in metabolomics in neurological 
disease, and future perspectives. Analytical and bioanalytical chemistry, 405(25), pp. 8143-8150. 
ZHANG, H., KOVACS-NOLAN, J., KODERA, T., ETO, Y. and MINE, Y., 2015. gamma-Glutamyl 
cysteine and gamma-glutamyl valine inhibit TNF-alpha signaling in intestinal epithelial cells and 
reduce inflammation in a mouse model of colitis via allosteric activation of the calcium-sensing 
receptor. Biochimica et biophysica acta, 1852(5), pp. 792-804. 
ZHANG, Y., LIN, L., XU, Y., LIN, Y., JIN, Y. and ZHENG, C., 2013. 1H NMR-based spectroscopy 
detects metabolic alterations in serum of patients with early-stage ulcerative colitis. Biochemical and 
biophysical research communications, 433(4), pp. 547- 51. 
ZHAO, J., HONG, T., DONG, M., MENG, Y. and MU, J., 2013. Protective effect of myricetin in 
dextran sulphate sodium-induced murine ulcerative colitis. Molecular medicine reports, 7(2), pp. 565-
570. 
ZHOLUDEV, A., ZURAKOWSKI, D., YOUNG, W., LEICHTNER, A. and BOUSVAROS, A., 
2004. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with 
Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. 
American Journal of Gastroenterology, 99(11), pp. 2235-2241. 
ZHOU, J., XU, B., HUANG, J., JIA, X., XUE, J., SHI, X., XIAO, L. and LI, W., 2009. 1H NMR-
based metabonomic and pattern recognition analysis for detection of oral squamous cell carcinoma. 
Clinica chimica acta; international journal of clinical chemistry, 401(1-2), pp. 8-13. 
ZIJLSTRA, F.J., SRIVASTAVA, E.D., RHODES, M., VAN DIJK, A.P., FOGG, F., SAMSON, H.J., 
COPEMAN, M., RUSSELL, M.A., FEYERABEND, C. and WILLIAMS, G.T., 1994. Effect of 
nicotine on rectal mucus and mucosal eicosanoids. Gut, 35(2), pp. 247-251. 
ZITTERMANN, S.I. and ISSEKUTZ, A.C., 2006. Endothelial growth factors VEGF and bFGF 
differentially enhance monocyte and neutrophil recruitment to inflammation. Journal of leukocyte 
biology, 80(2), pp. 247-257. 
ZUGHAIER, S.M., ZIMMER, S.M., DATTA, A., CARLSON, R.W. and STEPHENS, D.S., 2005. 
Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling 











8.1 North of Scotland Ethic Committee Approved Study Documentation 
NRES Committees - North of Scotland  
Summerfield House 




Telephone: 01224 558474  
Facsimile: 01224 558609 
Email: nosres@nhs.net 
 
     
 
19 May 2011 
 
 
Mr Angus J M Watson 
Consultant General and Colorectal Surgeon 
NHS Highland 
Department of Surgery 
Raigmore Hospital 





Dear Mr Watson 
 
Study title: Metabolomics and inflammatory bowel disease 
REC reference: 11/AL/0238 
 
The Research Ethics Committee reviewed the above application at the meeting held on 




The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the 
start of the study (see “Conditions of the favourable opinion” below).  
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 




Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements. 
 
Guidance on applying for NHS permission for research is available in the 
Integrated Research Application System or at http://www.rdforum.nhs.uk.   
 
Other conditions specified by the REC 
 
• A6-2 – the Committee noted that the first approach to participants will be by 
the clinician responsible for the participant’s care or by the IBD specialist 
nurse.  Please confirm that the IBD specialist nurse will approach 
participants as part of the clinical team and not as part of the research team.  
  
• A21 – the Committee noted that participants would be in the study for 3 
years, however elsewhere in the paperwork it states 12 months.  Please 
clarify.  
  
• Participants Information Sheets – please remove ‘Please hand this to the 
reception staff at the clinic when you arrive for your appointment’ from all 
of the Information Sheets.  Please forward revised copies of the Information 
Sheets.  
   
• Participant Information Sheet – Controls – please remove the heading ‘Will 
my GP be informed?’ and the paragraph below as this is not required.  Please 
forward a copy of the amended Information Sheet to the Committee.  
 
• The Committee noted that in your paperwork, you are listed as Mr Angus 
Watson and Professor Angus Watson.  The Committee ask that you are 
consistent in your title.  Please forward copies of the amended documents. 
 
It is responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular 
site (as applicable). 
 
You should notify the REC in writing once all conditions have been met (except 
for site approvals from host organisations) and provide copies of any revised 
documentation with updated version numbers. Confirmation should also be 




The documents reviewed and approved at the meeting were: 
  
Document    Version    Date      
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Covering Letter    18 April 2011    
GP/Consultant Information Sheets: Sheet 1  2  7 April 2011    
Investigator CV: Angus Watson   20 April 2011*   
Letter of invitation to participant: Metabolomics and IBD 
Patient  
2  7 April 2011    
Other: Unfavourable Opinion Letter    16 March 
2011  
  
Other: Investigator CV: Diane Hildebrand    18 April 2011    
 
 
Document    Version    Date      
Other: Metabolomics and IBD Consultant Letter  2  7 April 2011    
Other: Consultant Information Sheet  2  7 April 2011    
Other: Metabolomics and IBD GP Letter  2  7 April 2011    
Other: Metabolomics and IBD GP Letter 2  2  7 April 2011    
Other: GP Information Sheet - Sheet 2  2  7 April 2011    
Other: Metabolomics and IBD GP Letter 3  1  7 April 2011    
Other: GP Information Sheet - Sheet 3  1  7 April 2011    
Participant Consent Form: Control  2  7 April 2011    
Participant Consent Form: IBD  2  7 April 2011    
Participant Information Sheet: IBD Quarterly  1  7 April 2011    
Participant Information Sheet: IBD Surgery  1  7 April 2011    
Participant Information Sheet: IBD Biological  1  7 April 2011    
Participant Information Sheet: Control  2  7 April 2011    
Protocol  2  7 April 2011    
REC application  79685/208112/1
/982  
21 April 2011    
* date received 
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on 
the attached sheet. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Service website > After Review. 
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You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure. If you wish to make 
your views known please use the feedback form available on the website. 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light 
of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
11/AL/0238 Please quote this number on all correspondence 
 












Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
“After ethical review – guidance for researchers”  
 
 
Copy to: Miss Frances Hines, NHS Highland 
 
North of Scotland Research Ethics Committee (2) 
 
Attendance at Committee meeting on 12 May 2011 
 
  
Committee Members:  
 
Name   Profession   Present    Notes      
Mr Stuart Bale  Lay Member - Retired HSE Manager - Shell  No      
Dr Jennifer Caldwell  Senior Lecturer in Occupational Therapy  No      
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Dr John Callender  Associate Medical Director  Yes      
Dr Sarah Christie  Lay Member - Reader in  Law  Yes      
Dr Medhat Ezzat  Consultant Neonatologist  Yes      
Dr Georgina Hold  Senior Lecturer - Gastroenterology  No      
Miss Rhoda MacKenzie  Clinical Teaching Fellow - Vascular Surgery  Yes      
Dr Mandy Moffat  Research Fellow - Psychology  Yes      
Dr Jeremy Morse  Manager of Clinical Skills  Yes      
Mr Alistair Ritchie  Lay Member - Retired Police Officer - 
Grampian Police  
Yes      
Dr Andy Schofield  Senior Lecturer in Surgery & Molecular & 
Cell Biology  
No      
Dr Ruth Stephenson  Chair and Consultant in Anaesthesia  No      
Mrs Juliette Watson  Quality & Training Manager  Yes      
Mrs Fiona Watson  Lay Member - Ex Company Director  No      
  
Also in attendance:  
 
Name   Position (or reason for attending)     
Mrs Irene Allan  Co-ordinator    
Mrs Carol Irvine  Ethics Co-ordinator    















Title   
Metabolomics and Inflammatory Bowel Disease 
 
Background 
Inflammatory bowel disease (IBD) is a common, chronic gastrointestinal disease 
comprised of two major subtypes, Crohn’s disease (CD) and ulcerative colitis (UC). 
Both disorders have complex multifactorial aetiologies involving an inadequately 
defined relationship between microbial population insult, genetic predisposition and 
altered intestinal barrier permeability1. CD is characterised by patchy transmural 
granulomatous inflammation, affecting any part of the gastrointestinal tract, whereas 
UC is characterised by diffuse superficial mucosal inflammation, limited to the colon 
and rectum without granulomata. 
 
Recent data suggests that the prevalence of IBD in the UK has exponentially 
increased to the current estimates of around 400 per 100,0002. Hospital statistics 
from England and Scotland also show that during the last two decades there is a 
significant increase in the hospitalisation rates for both diseases outlining the 
enormous economic impact to health services3. The age distribution is bimodal with 
a prominent first peak occurring in younger patients with CD and a more prominent 
second peak occurring in older patients with UCiii. This distribution has long ranging 
implications for the viable younger workforce and also the older dependant 
population. More importantly, the incidence rate of juvenile onset CD has risen by 
nearly 30% in Scotland over the last twenty years, which translates into a longer 
period of monitored healthcare for affected individuals4. 
 
Diagnostic and monitoring tools for IBD are currently inadequate.  Numerous faecal 
biomarkers including calprotectin and lactoferrin5,6 and serological biomarkers 
(ASCA, pANCA, anti-OmpC, anti-Cbir anti-I2 antibodies and anti-glycan antibodies) 
have been widely investigated within the last decade, but despite some promising 
studies, confirmation of their clinical validity and utility is awaited7.  
 
                                                        
1 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 
2007;448(7152):427-434. 
2 Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a 
cross sectional study from central England. Eur J Gastroenterol Hepatol 2003, 15:12751280. 
3 Sonnenberg A. Temporal changes in the age distribution of inflammatory bowel disease 
hospitalization: data from England and Scotland. Eur J Gastroenterol Hepatol, 22:95101. 
4 Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both juvenile onset 
Crohn's disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol 2001, 13:14391447. 
5 Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in 
inflammatory bowel disease. Inflammatory Bowel Diseases 2006;12(6):524-534. 
6 Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in 
the diagnosis of colitis. Diseases of the Colon & Rectum 2007;50(10):1697-1706. 
7 Seow CH, Stempak JM, Xu W, et al. Novel Anti-Glycan Antibodies Related to Inflammatory 




Genetic studies have identified variants in over thirty genes, which alter the risk for 
CD8,9 and genome wide association studies (GWAS) are now starting to unravel the 
genetic aetiology of UC10,11,12,13.  These studies have provided exciting insights into 
the pathogenesis of IBD.  However, each of these genetic variants only modestly 
increases the risk of disease and, either individually or in combination, they have 
limited clinical utility in aiding diagnosis of IBD, differentiating between UC and CD 
and predicting the natural history of disease.  Moreover, environmental effects are 
largely missed using GWAS and this is very important in defining the phenotype of 
the disease (since phenotype = genotype + environment). 
 
Metabolomics, and the associated metabonomics, are powerful scientific strategies 
which provide the investigation of low molecular weight (bio)chemicals (metabolites) 
present in the metabolome of a cell, tissue or organism14,15. Metabolomics focuses 
on the study of metabolism and the role of metabolites in regulatory processes 
including allosteric regulation and post-translational modifications. 
 
We were the first group to investigate serum metabolomic profiles in patients with 
IBD. During discovery and validation studies we were able to define important 
metabolomic differences between CD, UC and matched controls. Univariate 
analysis demonstrated greater than 50 metabolites that varied in their relative 
concentration when comparing CD or UC versus control patients, whilst only 6 
metabolites were shown to change when comparing CD versus UC. The greatest 
perturbation to metabolism was between healthy and disease subjects as would be 
expected, with a significantly lower level of differences observed between the two 
diseases. This may highlight similar pathophysiological mechanisms of both 
diseases with spatial differences in symptoms16.  
 
We now wish to interrogate these differences further by comparing metabolomic 
profiles of IBD patients during different phases of their disease. Metabolomic profiles 
will change with disease activity, anatomical distribution and therapy.  Studying 
these changes will enable us to gain a greater understanding of the pathogenesis of 
                                                        
8 Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with 
susceptibility to Crohn's disease. Nature 2001;411(6837):599-603. 
9 Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with 
susceptibility to Crohn's disease. Nature 2001;411(6837):603-606. 
10 Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies 
three new susceptibility loci, including the HNF4A region. Nature Genetics 2009;41(12):1330-
U99. 
11 Franke A, Balschun T, Sina C, et al. Genome-wide association study for ulcerative colitis 
identifies risk loci at 7q22 and 22q13 (IL17REL). Nature Genetics 2010:in press. 
12 McGovern DP, Gardet A, Törkvist L, et al. Genome-wide association identifies multiple 
ulcerative colitis susceptibility loci. Nature Genetics 2010:in press. 
13 Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 
12q15 found by genome-wide association study. Nature Genetics 2009;41(2):216-220. 
14 Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: 
acquiring and understanding global metabolite data. Trends in Biotechnology 2004;22(5):245-
252. 
15 Nicholson JK, Wilson ID. Understanding 'global' systems biology: Metabonomics and the 
continuum of metabolism. Nature Reviews Drug Discovery 2003;2(8):668-676. 
16 Johnston C, Dunn W, Broadhurst D, Brown M, Makin A, Campbell S, et al. Serum metabolite 









Principle Research Objectives 
1. Define the relationship between metabolomic profiles and disease activity. 
2. Examine how metabolomic profiles differ after surgery for inflammatory bowel 
disease. 
3. Establish how metabolomic profiles of drug naïve IBD patients differ and how 




Patients with inflammatory bowel disease in the Highlands and Islands of Scotland 
will be approached to take part in the study. We aim to recruit 40 drug naïve 
patients, 30 patients having surgery for IBD and 40 IBD patients receiving biological 
therapy.  In addition 40 patients with active IBD will be recruited for serial sample 
collection (samples collected every 3 months for 1 year).  
 
To recruit patients in the serial sampling group IBD patients will be sent 
metabolomics and IBD patient letter of invitation, version 3, and metabolomics 
participant information sheet 1 (IBD quarterly template), version 2, with routine clinic 
or endoscopy appointment letters. During their appointment they will be initially 
approached by the clinician in charge of their care regarding the study. Should they 
wish to gain more information they will then be seen by a member of the research 
team.  
 
It will be ensured that potential participants have a copy of metabolomics participant 
information sheet 1 (IBD quarterly template), version 2. Participants will read the 
information sheet and be given the opportunity to discuss the study with a member 
of the research team and ask any questions about the study. Patients will be given 
the length of time they deem necessary to decide whether or not they wish to 
participate. Therefore, patients who are ready to make a decision to take part in the 
outpatient clinic (having being provided with and read the patient information sheet 
and discussed the study with their clinician and the research fellow and/or research 
nurse) can do so at that time.  Alternatively patients can be followed up by a 
telephone call from the local recruitment officer/nurse to provide further information, 
if required, and consented to the study, if they are willing, when they next attend for 
a hospital appointment. 
After informed consent the patients will be phenotyped and will have disease scoring 
carried out by means of a short interview with one of the research team.  Blood 
(20ml) and urine (20ml) will be collected in the fasting state (>6 hours). In order to 
follow the relationship between disease activity and the metabolome (serum and 
urine), serial samples will be taken from consenting patients at three monthly 
intervals for a maximum duration of twelve months. The associated details of 
disease and drug activity will also be collated at these times. The timing of these 
samples will be correlated as far as possible with routine hospital appointments. 
 
We will recruit drug naïve patients from clinic, the endoscopy unit, and from the 
inpatient wards. They will initially be approached by the clinician in charge of their 
care. If they wish to consider the study they will be given participant information 
sheet 1 (IBD quarterly template), version 2, and will meet with a member of the 
research team. They will have the opportunity to read the information sheet and ask 
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any questions regarding the study. They will be given the length of time they deem 
necessary to decide whether or not they wish to participate. If they are an out patient 
they may take the information home to consider it and will be followed up and 
consented, if willing, as per the serial sampling group. If they are an inpatient they 
will be given the length of time they need to decide whether or not to participate in 
the study. This is likely to be over 24 hours in most cases, however if a patient is 
willing to give informed consent having read the information and discussed the study 
with their own clinician and the research team consent may be taken in less than 24 
hours. The reason for doing this would be to correlate fasting samples with routine 
morning blood samples that are taken after a night time fast. 
 
To enable us to examine the change in the metabolome after surgery we will recruit 
patients undergoing surgery for IBD from clinic and endoscopy as well as from the 
inpatient wards. Patients will initially be approached by the clinician in charge of their 
care. They will be given metabolomics participant information sheet 1 (IBD surgery 
template), version 2, and then will meet with the research team if they are 
agreeable. They will have the opportunity to ask and questions and discuss the 
study. If they are an outpatient they will be able to go home with the information 
sheet and if they wish to participate written informed consent will be taken on 
attendance at the pre-assessment clinic or on the inpatient ward when they attend 
for surgery.  
Those patients who are inpatients be given the length of time they need to decide 
whether or not to participate in the study. This is likely to be over 24 hours in most 
cases, however if a patient is willing to give informed consent having read the 
information and discussed the study with their own clinician and the research team 
consent may be taken in less than 24 hours. The reason for this would be if they 
required an urgent surgical procedure within 24 hours.  
Patients will be phenotyped, have disease severity scoring carried out, and samples 
of blood (20ml) and urine (20ml) will be taken immediately prior to surgery as the 
patient will already be in the fasting state. Post surgery samples (20ml blood and 
20ml urine) will be taken at a routine surgical clinic approximately 8 weeks post 
operatively. Disease severity scoring will be carried out at this time. 
 
Patients who will receive biological therapy will be recruited from clinic, the 
endoscopy unit or the inpatient wards. They will initially be approached by the 
clinician in charge of their care. They will be given metabolomics participant 
information sheet 1 (IBD biological template), version 2, and then will meet with the 
research team if they are agreeable. They will have the opportunity to ask and 
questions and discuss the study. If they are an outpatient they will be able to go 
home with the information sheet and if they wish to participate written informed 
consent will be taken on attendance at the inpatient ward when they attend for 
therapy.  
Those patients who are inpatients be given the length of time they need to decide 
whether or not to participate in the study. This is likely to be over 24 hours in most 
cases, however if a patient is willing to give informed consent having read the 
information and discussed the study with their own clinician and the research team 
consent may be taken in less than 24 hours. The reason for this would be if they 
required an urgent biological therapy within 24 hours.  
Patients will be phenotyped, have disease severity scoring carried out, and samples 
of blood (20ml) and urine (20ml) will be taken immediately prior to biological therapy. 
Post therapy samples (20ml blood and 20ml urine) will be taken 2 weeks after 
treatment, when the patient attends for their next dose. Disease severity scoring will 




It is potentially possible for one patient to be suitable for more than one of the 
groups. For example they may be in the serial sampling group but require biological 
therapy or surgery during the year of their participation in the study. Should this be 
the case they would be approached by their own clinician and shown the 
appropriate participant information sheet. If they wished further information they 
would meet with a member of the research team and have the opportunity to ask 
any questions about the study. They would then be consented and have their 
samples taken as previously described.  
 
Suitably matched control subjects will be recruited from patients attending for 
elective, non-colorectal procedures with no personal or family history of colorectal 
disease. They will initially be approached at clinic by the clinician in charge of their 
care. If they are agreeable they will be given metabolomics participant information 
sheet 2 (control template), version 3. They will be given the length of time they deem 
necessary to decide whether or not they wish to participate. Therefore, patients who 
are ready to make a decision to take part in the outpatient clinic (having been 
provided with and read the patient information sheet and discussed the study with 
their clinician and the research fellow and/or research nurse) can do so at that time.  
Alternatively patients can be followed up by a telephone call from the local 
recruitment officer/nurse to provide further information, if required, and consented to 
the study, if they are willing, when they next attend for their surgical procedure. They 
will be phenotyped and will have samples of blood (20ml) and urine (20ml) taken in 
the fasting state. Repeat samples are not required in the control group. 
 
During phenotyping the following patient specific and disease specific information 
will be collated during an interview with a member of the research team and by 
review of the medical notes: 
 
Patient Specific Information     
• Date of birth 
• Place of birth 
• Current postcode 
• Sex 
• Ethnicity 
• Age at diagnosis 
• Height / weight / BMI 
• Social history 
• Past medical history 
• Drug history 
• Past surgical history 
• Family history 
 
Disease Specific Information 
• Diagnosis (Crohn’s Disease / Ulcerative Colitis / Indeterminate Colitis) 
o Clinical / radiological / endoscopic / pathological 
• Disease location 
• Disease behaviour (nonstricturing nonpenetrating / fistulating / stenosing) 
 
Disease Severity Scoring 
• Harvey-Bradshaw Index (Crohn’s Disease) 
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o General wellbeing, abdominal pain, number of liquid stools / day, 
abdominal mass, complications of CD 
• Simple Clinical Colitis Activity Index (Ulcerative Colitis) 
o Bowel frequency (day / night), urgency of defaecation, blood in the 
stool, general wellbeing, extracolonic features 
  
Consent forms will be stored in a locked filing cabinet in a locked office in the Centre 
for Health Science, Raigmore Hospital, Inverness. 
All data will be stored on a secure database on an NHS computer. This computer is 
in the Centre for Health Science, Raigmore Hospital, Inverness, in an office that an 
access card is required to gain entry. 
 
During informed consent, the participants will be asked to consent to their GP being 
informed of their involvement in the study. All of the GPs within Highland will be 
informed of the study by means of metabolomics and IBD GP letter and information 
sheet 1, version 2. Should one of their patients with IBD enrol in the study the GP 
will be informed by means of metabolomics and IBD GP letter and information sheet 
2, version 2. If one of their patients is enrolled as a control the GP will be informed 
by means of metabolomics and IBD GP letter and information sheet 3, version 1. 
 
All blood samples will be allowed to clot for <120 minutes on ice at 4°C and serum 
samples will be obtained by centrifuging the samples at 2500g for 15 minutes at 
4°C. Urine will be put on ice for <120 minutes. Sam ples will then be stored in linked 
anonymised form in a -80°C freezer in the Centre fo r Health Science, Raigmore 
Hospital, Inverness.  
 
Samples of serum and urine will be transported to Manchester in liquid nitrogen 
using a specialist laboratory courier service. All metabolomic studies will be 
performed at the Manchester Integrative Biocentre under the supervision of 
Professor Roy Goodacre and Dr Warwick Dunn. Serum samples will be 
deproteinised in methanol and analysed using UPLC-MS (Waters AQUITY UPLC 
coupled to a ThermoFisher LTQ-Orbitrap MS). Urine samples will be processed with 
urease to remove urea and analysed using GC-MS (Agilent 6890N GC coupled to a 
Leco Pegasus III MS). Quality control samples will be intermittently analysed to 
provide quality assurance of the data acquired. Raw data will be processed using 
the XCMS software package (UPLC-MS) and Leco ChromaTof software package 
(GC-MS). Data analysis including univariate and multivariate statistics will combine 
analytical and clinical data to enable a greater understanding of the interactions 




A key collaboration has been established with Professor Roy Goodacre and Dr 
Warwick Dunn (University of Manchester) which was started whilst Mr Angus 
Watson worked at Manchester Royal Infirmary. Clinical metabolomics research in 
Manchester has an international reputation of excellence. The Manchester Centre 
for Integrative Systems Biology (www.mcisb.org), of which Professor Goodacre is a 
PI, provides the resources and expertise to perform this type of research.  
There are over 600 patients with inflammatory bowel disease in the Highlands & 
Islands of Scotland. The majority of specialist gastroenterology and surgical services 
are delivered at Raigmore Hospital in Inverness. Research activity is based in the 
Centre for Health Science (www.centreforhealthscience.com) and the Highland 




Miss Diane Hildebrand    Professor Angus Watson 
Clinical Research Fellow    Chief Investigator 
Centre for Health Science   Consultant Surgeon /  
Raigmore Hospital     Director of R&D 
Old Perth Road     Raigmore Hospital 
Inverness      Old Perth Road 
IV2 3UJ      Inverness 
       IV2 3UJ 
 
Email: dianehildebrand@nhs.net   angus.watson@nhs.net 





















        
 





Title of the Study:  Metabolomics and Inflammatory Bowel Disease (IBD)  
 
 
Dear Sir / Madam 
 
 
You have been scheduled for an outpatient appointment in the near future in 
Raigmore Hospital. I would like to draw your attention to an important study 
that is ongoing in Raigmore Hospital. This study involves taking samples of 
blood and urine from adults with IBD at three monthly intervals for one year, 
at the same time as assessing disease activity by means of a short interview. 
We will measure biochemicals in the samples and correlate them with 
disease activity. We hope that this will allow us to better diagnose and treat 
IBD in the future. 
 
I have included an information sheet with this letter for you to read. 
 
A member of the research team will be available to discuss this study with 
you in more detail and answer any questions you may have when you attend 
on the day of clinic. 
 
 





Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
 
 428 







Metabolomics Participant Information Sheet 
IBD Surgery Version 
 
Study title: Metabolomics and inflammatory bowel disease 
  
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether you wish to take part. Thank you 
for reading this. 
 
What is the purpose of the study? 
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases 
(IBD) of significant importance to both individual patients and the wider health 
economy. We are still uncertain as to what actually causes these diseases. We 
urgently need to develop techniques that will help us;  
1. uncover the causes of IBD, 
2. identify chemical markers of disease activity, 
3. measure responses to treatments. 
Metabolomics is a powerful new scientific technique that measures huge numbers of 
biochemicals. In pilot studies biochemicals have been identified which help tell apart 
IBD patients from normal subjects and to a lesser extent can differentiate between 
Crohn’s disease and ulcerative colitis. We now wish to build on these new findings 
and over the next 2 years we will collect samples of blood and urine from patients 
undergoing surgery, those having biological therapy and at 3 monthly intervals for 
those on medical treatment to analyse biochemical markers. 
 
Why have I been chosen? 
All patients with IBD having surgery in the Highlands and Islands will be approached 
to participate.  
We will also be recruiting control patients.  
 
Do I have to take part? 
No.  It is up to you to decide whether to take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part, you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or not to take part, will not affect the 
standard of care you receive. 
 
What will happen to me if I take part? 
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A member of the research team will discuss the study with you. You will be given 
this information sheet to keep, and will be able to ask any questions that you have 
regarding the study. If you are an out patient you will be able to go home and 
consider whether or not you wish to be involved. If you are an inpatient you will be 
given as much time as you require deciding whether or not you wish to participate. 
If you agree to take part you will be asked to sign a consent form and complete an 
interview with the researcher to allow us to gather demographic information and 
assess the current activity of your disease.  
We will ask for samples of 20ml (four teaspoons) of blood and 20ml of urine 
immediately prior to your surgical procedure, and approximately 8 weeks afterwards 
during a routine clinic visit.  At this time we will again assess the activity of your 
disease by a short interview. 
All samples must be taken in a fasting state, which  means you cannot eat or 
drink for 6 hours prior to the sample being taken.  
 
What are the possible disadvantages and risks of ta king part? 
A blood sample is required but often this is part of the normal care you would 
receive and most people tolerate it very well. 
 
What are the possible benefits of taking part? 
There will be no clinical benefit to you but from this research we hope to be able to 
discover new biochemical markers that may help us to diagnose and treat IBD in the 
future.  
 
What happens when the research study stops? 
Once the study is complete your data will be stored for 3 years, pending review. Any 
remaining samples will be stored for potential use in future studies. Any future work 
using stored tissue samples will be subject to approval from the local ethics 
committee. 
 
Will my taking part in this study be kept confident ial? 
All the information collected is confidential. On agreeing to donate samples for 
research, your name, along with other personal information, including date of birth 
and hospital number, will be entered into a file alongside a unique code number. The 
research team will store this file of personal information and codes securely on an 
NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of 
the code number only and will have no direct link to personal details, ensuring 
anonymity. 
 
Will my GP be informed? 
All GPs in Highland have been sent an information pack with the details of the study.  
We will ask for your permission to inform your own GP of your involvement. 
 
What will happen to the results of the research stu dy?  
The study will form the basis of an MD thesis, and results are likely to be published 
in a medical journal and presented at scientific / medical meetings. You would never 
be identified during any of these processes.  
 
Who is organising and funding the research?  
NHS Highland  
The doctor conducting the research is not being paid for conducting this study, but 




Who has reviewed the study? 
This study has been reviewed by the North of Scotland Research Ethics Committee. 
 
How to complain 
If you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal NHS 
complaints mechanisms are available to you. 
 
What next? 
If you are interested in participating in the study please complete the last page of 
this information sheet and hand it in to the reception staff at the clinic. A member of 
the research team can then meet with you to discuss your participation in the study 
in more detail. 
 
Thank you very much for taking the time to read this information sheet and 
considering taking part in this study. 
Contact for Further Information 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science,      Consultant Surgeon 
Raigmore Hospital,       Director of R&D 
Inverness       Raigmore Hospital 
IV2 3UJ       Inverness, IV2 3UJ 
Email: dianehildebrand@nhs.net     angus.watson@nhs.net  






I am interested in finding out more about the research study “Metabolomics and 















Date  ____/____/____ 
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Metabolomics Participant Information Sheet 
IBD Quarterly Version 
 
 
Study title: Metabolomics and inflammatory bowel disease 
  
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether you wish to take part. Thank you 
for reading this. 
 
What is the purpose of the study? 
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases 
(IBD) of significant importance to both individual patients and the wider health 
economy. We are still uncertain as to what actually causes these diseases. We 
urgently need to develop techniques that will help us;  
1. uncover the causes of IBD, 
2. identify chemical markers of disease activity, 
3. measure responses to treatments. 
Metabolomics is a powerful new scientific technique that measures huge numbers of 
biochemicals. In pilot studies biochemicals have been identified which help tell apart 
IBD patients from normal subjects and to a lesser extent can differentiate between 
Crohn’s disease and ulcerative colitis. We now wish to build on these new findings 
and over the next 2 years we will collect samples of blood and urine from patients 
from patients undergoing surgery, those having biological therapy and at 3 monthly 
intervals for those on medical treatment to analyse biochemical markers. 
 
Why have I been chosen? 
All patients with IBD in the Highlands and Islands will be approached to participate.  
We will also be recruiting control patients.  
 
Do I have to take part? 
No.  It is up to you to decide whether to take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part, you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part? 
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A member of the research team will discuss the study with you. You will be given 
this information sheet to keep, and will be able to ask any questions that you have 
regarding the study. If you are an out patient you will be able to go home and 
consider whether or not you wish to be involved. If you are an inpatient you will be 
given as much time as you require deciding whether or not you wish to participate. 
If you agree to take part you will be asked to sign a consent form and complete an 
interview with the researcher to allow us to gather demographic information and 
assess the current activity of your disease.  
We will ask for samples of 20ml (four teaspoons) of blood and 20ml of urine at 3 
monthly intervals for 1 year, as well as a short interview to assess the activity of your 
disease. 
All samples must be taken in a fasting state, which  means you cannot eat or 
drink for 6 hours prior to the sample being taken.  
As far as possible we aim to correlate samples with hospital visits and routine blood 
tests. 
 
What are the possible disadvantages and risks of ta king part? 
We require a commitment to 3 monthly samples of blood and urine.  
 
What are the possible benefits of taking part? 
There will be no clinical benefit to you but from this research we hope to be able to 
discover new biochemical markers that may help us to diagnose and treat IBD in the 
future.  
 
What happens when the research study stops? 
Once the study is complete your data will be stored for 3 years, pending review. Any 
remaining samples will be stored for potential use in future studies. Any future work 
using stored tissue samples will be subject to approval from the local ethics 
committee. 
 
Will my taking part in this study be kept confident ial? 
All the information collected is confidential. On agreeing to donate samples for 
research, your name, along with other personal information, including date of birth 
and hospital number, will be entered into a file alongside a unique code number. The 
research team will store this file of personal information and codes securely on an 
NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of 
the code number only and will have no direct link to personal details, ensuring 
anonymity. 
 
Will my GP be informed? 
All GPs in Highland have been sent an information pack with the details of the study.  
We will ask for your permission to inform your own GP of your involvement. 
 
What will happen to the results of the research stu dy?  
The study will form the basis of an MD thesis, and results are likely to be published 
in a medical journal and presented at scientific / medical meetings. You would never 
be identified during any of these processes.  
 
Who is organising and funding the research?  
NHS Highland  
The doctor conducting the research is not being paid for conducting this study, but 




Who has reviewed the study? 
This study has been reviewed by the North of Scotland Research Ethics Committee. 
 
How to complain 
If you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal NHS 
complaints mechanisms are available to you. 
 
What next? 
If you are interested in participating in the study please complete the last page of 
this information sheet and hand it in to the reception staff at the clinic. A member of 
the research team can then meet with you to discuss your participation in the study 




Thank you very much for taking the time to read this information sheet and 
considering taking part in this study. 
Contact for Further Information 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science,      Consultant Surgeon 
Raigmore Hospital,       Director of R&D 
Inverness       Raigmore Hospital 
IV2 3UJ       Inverness, IV2 3UJ 
Email: dianehildebrand@nhs.net     angus.watson@nhs.net  





I am interested in finding out more about the research study “Metabolomics and 




























Metabolomics Participant Information Sheet 
IBD Biological Version 
 
 
Study title: Metabolomics and inflammatory bowel disease 
  
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether you wish to take part. Thank you 
for reading this. 
 
What is the purpose of the study? 
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases 
(IBD) of significant importance to both individual patients and the wider health 
economy. We are still uncertain as to what actually causes these diseases. We 
urgently need to develop techniques that will help us;  
1. uncover the causes of IBD, 
2. identify chemical markers of disease activity, 
3. measure responses to treatments. 
Metabolomics is a powerful new scientific technique that measures huge numbers of 
biochemicals. In pilot studies biochemicals have been identified which help tell apart 
IBD patients from normal subjects and to a lesser extent can differentiate between 
Crohn’s disease and ulcerative colitis. We now wish to build on these new findings 
and over the next 2 years we will collect samples of blood and urine from patients 
undergoing surgery, those having biological therapy and at 3 monthly intervals for 
those on medical treatment to analyse biochemical markers. 
 
Why have I been chosen? 
All patients with IBD having biological therapy in the Highlands and Islands will be 
approached to participate.  
We will also be recruiting control patients.  
 
Do I have to take part? 
No.  It is up to you to decide whether to take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part, you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or not to take part, will not affect the 




What will happen to me if I take part? 
A member of the research team will discuss the study with you. You will be given 
this information sheet to keep, and will be able to ask any questions that you have 
regarding the study. If you are an out patient you will be able to go home and 
consider whether or not you wish to be involved. If you are an inpatient you will be 
given as much time as you require deciding whether or not you wish to participate. 
If you agree to take part you will be asked to sign a consent form and complete an 
interview with the researcher to allow us to gather demographic information and 
assess the current activity of your disease. We will ask for samples of 20ml (four 
teaspoons) of blood and 20ml of urine immediately prior to your biological therapy, 
and approximately 2 weeks afterwards during a routine hospital visit. At this time we 
will again assess the activity of your disease by a short interview.  
All samples must be taken in a fasting state, which  means you cannot eat or 
drink for 6 hours prior to the sample being taken.  
 
What are the possible disadvantages and risks of ta king part? 
A blood sample is required but often this is part of the normal care you would 
receive and most people tolerate it very well. 
 
What are the possible benefits of taking part? 
There will be no clinical benefit to you but from this research we hope to be able to 
discover new biochemical markers that may help us to diagnose and treat IBD in the 
future.  
 
What happens when the research study stops? 
Once the study is complete your data will be stored for 3 years, pending review. Any 
remaining samples will be stored for potential use in future studies. Any future work 
using stored tissue samples will be subject to approval from the local ethics 
committee. 
 
Will my taking part in this study be kept confident ial? 
All the information collected is confidential. On agreeing to donate samples for 
research, your name, along with other personal information, including date of birth 
and hospital number, will be entered into a file alongside a unique code number. The 
research team will store this file of personal information and codes securely on an 
NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of 
the code number only and will have no direct link to personal details, ensuring 
anonymity. 
 
Will my GP be informed? 
All GPs in Highland have been sent an information pack with the details of the study.  
We will ask for your permission to inform your own GP of your involvement. 
 
What will happen to the results of the research stu dy?  
The study will form the basis of an MD thesis, and results are likely to be published 
in a medical journal and presented at scientific / medical meetings. You would never 
be identified during any of these processes.  
 
Who is organising and funding the research?  
NHS Highland  
The doctor conducting the research is not being paid for conducting this study, but 




Who has reviewed the study? 
This study has been reviewed by the North of Scotland Research Ethics Committee. 
 
How to complain 
If you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal NHS 
complaints mechanisms are available to you. 
 
What next? 
If you are interested in participating in the study please complete the last page of 
this information sheet and hand it in to the reception staff at the clinic. A member of 
the research team can then meet with you to discuss your participation in the study 
in more detail. 
 
Thank you very much for taking the time to read this information sheet and 
considering taking part in this study. 
Contact for Further Information 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science,      Consultant Surgeon 
Raigmore Hospital,       Director of R&D 
Inverness       Raigmore Hospital 
IV2 3UJ       Inverness, IV2 3UJ 
Email: dianehildebrand@nhs.net     angus.watson@nhs.net  






I am interested in finding out more about the research study “Metabolomics and 















Date  ____/____/____ 
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Study title: Metabolomics and inflammatory bowel disease 
  
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with others if you wish.  Ask us if there is anything that is not clear or if you would 
like more information.  Take time to decide whether you wish to take part. Thank you 
for reading this. 
 
What is the purpose of the study? 
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases 
(IBD) of significant importance to both individual patients and the wider health 
economy. We are still uncertain as to what actually causes these diseases. We 
urgently need to develop techniques that will help us;  
1. uncover the causes of IBD, 
2. identify chemical markers of disease activity, 
3. measure responses to treatments. 
Metabolomics is a powerful new scientific technique that measures huge numbers of 
biochemicals. In pilot studies biochemicals have been identified which help tell apart 
IBD patients from normal subjects and to a lesser extent can differentiate between 
Crohn’s disease and ulcerative colitis. We now wish to build on these new findings 
and over the next 2 years we will collect samples of blood and urine from patients at 
3 monthly intervals to analyse biochemical markers. 
 
Why have I been chosen? 
All patients with IBD in the Highlands and Islands will be approached to participate.  
We will also be recruiting control patients from out patient clinics. These patients will 
be attending for elective non-colorectal procedures and must have no personal or 
family history of colorectal disease. 
 
Do I have to take part? 
No.  It is up to you to decide whether to take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part, you are still free to withdraw at any time and without giving a 
reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
What will happen to me if I take part? 
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At the out patient clinic a member of the research team will discuss the study with 
you. You will be given this information sheet to keep, and will be able to ask any 
questions that you have regarding the study. You will be able to go home and 
consider whether or not you wish to be involved. 
On the day that you attend for your elective surgical procedure you will be seen by a 
member of the research team. You will be able to ask any further questions and if 
you wish to participate you will be asked to sign a consent form and then to 
complete an interview with the researcher to allow us to gather demographic 
information.  
We will take a 20ml (four teaspoons) blood sample and a 20ml urine sample from 
you. 
The samples must be taken in a fasting state, which  means you cannot eat of 
drink anything for 6 hours prior to the sample bein g taken.  
 
What are the possible disadvantages and risks of ta king part? 
A blood sample is required but often this is part of the normal care you would 
receive and most people tolerate it very well. 
 
What are the possible benefits of taking part? 
There will be no clinical benefit to you but from this research we hope to be able to 
discover new biochemical markers that may help us to diagnose and treat IBD in the 
future.  
 
What happens when the research study stops? 
Once the study is complete your data will be stored for 3 years, pending review. Any 
remaining samples will be stored for potential use in future studies. Any future work 
using stored tissue samples will be subject to approval from the local ethics 
committee. 
 
Will my taking part in this study be kept confident ial? 
All the information collected is confidential. On agreeing to donate samples for 
research, your name, along with other personal information, including date of birth 
and hospital number, will be entered into a file alongside a unique code number. The 
research team will store this file of personal information and codes securely on an 
NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of 
the code number only and will have no direct link to personal details, ensuring 
anonymity. 
 
What will happen to the results of the research stu dy?  
The study will form the basis of an MD thesis, and results are likely to be published 
in a medical journal and presented at scientific / medical meetings. You would never 
be identified during any of these processes.  
 
Who is organising and funding the research?  
NHS Highland.  
The doctor conducting the research is not being paid for conducting this study, but 
continues to work for NHS Highland in the Department of General Surgery. 
 
Who has reviewed the study? 
This study has been reviewed by the North of Scotland Research Ethics Committee. 
 
How to complain 
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If you wish to complain or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal NHS 
complaints mechanisms are available to you. 
 
What next? 
If you are interested in participating in the study please complete the last page of 
this information sheet and hand it in to the reception staff at the clinic. A member of 
the research team can then meet with you to discuss your participation in the study 
in more detail. 
 
Thank you very much for taking the time to read this information sheet and 
considering taking part in this study. 
 
Contact for Further Information 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science,      Consultant Surgeon 
Raigmore Hospital,       Director of R&D 
Inverness       Raigmore Hospital 
IV2 3UJ       Inverness, IV2 3UJ 
Email: dianehildebrand@nhs.net     angus.watson@nhs.net  








I am interested in finding out more about the research study “Metabolomics and 















Date  ____/____/____ 
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Title of the Study:  Metabolomics and Inflammatory Bowel Disease (IBD)  
 
 
Dear Sir / Madam 
 
 
You have been scheduled for an outpatient appointment in the near future in 
Raigmore Hospital. I would like to draw your attention to an important study 
that is ongoing in Raigmore Hospital. This study involves taking samples of 
blood and urine from adults with IBD at three monthly intervals for one year, 
at the same time as assessing disease activity by means of a short interview. 
We will measure biochemicals in the samples and correlate them with 
disease activity. We hope that this will allow us to better diagnose and treat 
IBD in the future. 
 
I have included an information sheet with this letter for you to read. 
 
A member of the research team will be available to discuss this study with 
you in more detail and answer any questions you may have when you attend 
on the day of clinic. 
 
 






Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
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         << DATE >> 
 
 
Title of the Study:  Metabolomics and Inflammatory Bowel Disease (IBD)  
 
 
Dear Sir / Madam 
 
 
You have been scheduled for an elective operation in the near future in 
Raigmore Hospital. I would like to draw your attention to an important study 
that is ongoing in Raigmore Hospital. This study involves taking samples of 
blood and urine from adults with IBD. We will measure biochemicals in the 
samples and correlate them with disease activity. We hope that this will allow 
us to better diagnose and treat IBD in the future. 
 
We are currently recruiting healthy control patients to compare to the patients 
with IBD. This would involve giving a sample of blood and urine  
 
I have included an information sheet with this letter for you to read. 
 
Should you wish a member of the research team will be available to discuss 
this study with you in more detail and answer any questions you may have 
when you attend on the day of your procedure.  
 
 






Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
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Metabolomics and Inflammatory Bowel Disease  
 
I am writing to draw your attention to the above study that will be ongoing in 
Raigmore Hospital for the next two years, and will form the basis of my MD thesis. 
 
This is a study into metabolomics (biomarkers) in inflammatory bowel disease. Our 
aims are to: 
 
1. Define the relationship between metabolomic profiles and disease activity. 
2. Examine how metabolomic profiles differ after surgery for inflammatory 
bowel disease. 
3. Establish how metabolomic profiles of drug naïve IBD patients differ and how 
these alter after the introduction of medical therapy. 
 
As part of the study we require to enrol healthy controls from whom to obtain fasting 
samples of blood and urine. We will be recruiting from outpatient clinics. We aim to 
enrol patients who require elective, non-colorectal procedures with no personal or 
family history of colorectal disease.  
 
All aspects of the study including informed consent, and the collection of samples, 
which will be taken on the day of surgery, will be dealt with by the research team. At 
no point will this intrude on the care that you are providing. 
 
Please see overleaf for further information. Should you wish to discuss any aspect 
of our study or if you have any concerns regarding the potential recruitment of your 
patients please do not hesitate to contact me. 
 
Yours sincerely,  
 
 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
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 Metabolomics and Inflammatory Bowel Disease  
Consultant Information Sheet 
 
Title of project:   Metabolomics and Inflammatory Bowel Disease 
 
Background  
Crohn’s disease and ulcerative colitis are two types of inflammatory bowel disorders (IBD) of 
unknown aetiology that result in significant morbidity and health expenditure. Recent data 
suggests that the prevalence of IBD in the UK has exponentially increased to the current 
estimates of around 400 per 100,000. Hospital statistics from England and Scotland also 
show that during the last two decades there is a significant increase in the hospitalisation 
rates for both diseases outlining the enormous economic impact to health services. The age 
distribution is bimodal with a prominent first peak occurring in younger patients with Crohn's 
disease and a more prominent second peak occurring in older patients with ulcerative colitis. 
This distribution has long ranging implications for the viable younger workforce and also the 
older dependant population. More importantly, the incidence rate of juvenile onset Crohn’s 
disease has risen by nearly 30% in Scotland over the last twenty years, which translates into 
a longer period of monitored healthcare for affected individuals. 
Diagnostic and monitoring tools for IBD are currently inadequate. Numerous faecal 
biomarkers have been widely investigated within the last decade, but despite some 
promising studies, confirmation of their clinical validity and utility is awaited.  
Metabolomics, and the associated metabonomics, are powerful scientific strategies which 
provide the investigation of low molecular weight (bio)chemicals (metabolites) present in the 
metabolome of a cell, tissue or organism.  
Professor Watson was involved in the first group to investigate serum metabolomic profiles 
in patients with IBD. During discovery and validation studies it was possible to define 
important metabolomic differences between Crohn’s disease, ulcerative colitis and matched 
controls.  
We now wish to interrogate these differences further by comparing metabolomic profiles of 
IBD patients during different phases of their disease. Metabolomic profiles will change with 
disease activity, anatomical distribution and therapy.  Studying these changes will enable us 
to gain a greater understanding of the pathogenesis of the disease and may identify specific 
novel metabolic markers of disease identity and activity. 
 
Brief outline of the study 
Ethical approval has been granted for this study. 
Patients with inflammatory bowel disease in the Highlands and Islands of Scotland will be 
approached to take part in the study. After informed consent the patients will be phenotyped 
and their data stored on a secure database. Disease activity will be recorded using the 
Harvey Bradshaw and Simple Clinical Colitis activity indices. Serum and urine will be 
collected in the fasting state (>6 hours).  
To enable us to examine the change in the metabolome after surgery and the introduction of 
drug therapy, disease activity and phenotype will be recorded prior to the intervention. Urine 
and blood samples will also be collected at this time. This process will be repeated two 
months after surgery or after the start of medical therapy. 
In order to follow the relationship between disease activity and the metabolome (serum and 
urine), serial samples will be taken from consenting patients at three monthly intervals for a 
maximum duration of 12 months. The associated details of disease and drug activity will also 
be collated at these times. 
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Control subjects will be recruited from patients attending for elective, non-colorectal 
procedures with no personal or family history of colorectal disease. Written consent will be 
taken, phenotype collected and a single sample of blood (20ml) and urine (20ml) taken in the 
fasting state. 
All the data collected is confidential. Demographic data will be entered into a file alongside a 
unique code number. The research team will store this file of personal information and codes 
securely on an NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of the code 
number only and will have no direct link to personal details, ensuring anonymity. 











        
 
         << DATE >> 
 
 
Dear Dr  
 
 
Metabolomics and Inflammatory Bowel Disease  
 
 
I am writing to make you aware of the above study that will be taking place in 
Raigmore Hospital. 
 
This is a study into metabolomics (biomarkers) in inflammatory bowel disease. Our 
aims are to: 
 
1. Define the relationship between metabolomic profiles and disease activity. 
2. Examine how metabolomic profiles differ after surgery for inflammatory 
bowel disease. 
3. Establish how metabolomic profiles of drug naïve IBD patients differ and how 
these alter after the introduction of medical therapy. 
 
For further information please see overleaf. 
 
If any of your patients agree to participate we will write and inform you. We should 
not normally need to obtain any information from you.  
 
If you would like to discuss any aspect of our study, or require any further details, 
please do not hesitate to contact me at the email address given below. 
 
 




Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
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Metabolomics and Inflammatory Bowel Disease  
GP Information Sheet 
 
Title of project:   Metabolomics and Inflammatory Bowel Disease 
 
Background  
Crohn’s disease and ulcerative colitis are two types of inflammatory bowel disorders (IBD) of 
unknown aetiology that result in significant morbidity and health expenditure. Recent data 
suggests that the prevalence of IBD in the UK has exponentially increased to the current 
estimates of around 400 per 100,000. Hospital statistics from England and Scotland also 
show that during the last two decades there is a significant increase in the hospitalisation 
rates for both diseases outlining the enormous economic impact to health services. The age 
distribution is bimodal with a prominent first peak occurring in younger patients with Crohn's 
disease and a more prominent second peak occurring in older patients with ulcerative colitis. 
This distribution has long ranging implications for the viable younger workforce and also the 
older dependant population. More importantly, the incidence rate of juvenile onset Crohn’s 
disease has risen by nearly 30% in Scotland over the last twenty years, which translates into 
a longer period of monitored healthcare for affected individuals. 
Diagnostic and monitoring tools for IBD are currently inadequate. Numerous faecal 
biomarkers have been widely investigated within the last decade, but despite some 
promising studies, confirmation of their clinical validity and utility is awaited.  
Metabolomics, and the associated metabonomics, are powerful scientific strategies which 
provide the investigation of low molecular weight (bio)chemicals (metabolites) present in the 
metabolome of a cell, tissue or organism.  
Professor Watson was involved in the first group to investigate serum metabolomic profiles 
in patients with IBD. During discovery and validation studies it was possible to define 
important metabolomic differences between Crohn’s disease, ulcerative colitis and matched 
controls.  
We now wish to interrogate these differences further by comparing metabolomic profiles of 
IBD patients during different phases of their disease. Metabolomic profiles will change with 
disease activity, anatomical distribution and therapy.  Studying these changes will enable us 
to gain a greater understanding of the pathogenesis of the disease and may identify specific 
novel metabolic markers of disease identity and activity. 
 
Brief outline of the study 
Ethical approval has been granted for this study. 
Patients with inflammatory bowel disease in the Highlands and Islands of Scotland will be 
approached to take part in the study. After informed consent the patients will be phenotyped 
and their data stored on a secure database. Disease activity will be recorded using the 
Harvey Bradshaw and Simple Clinical Colitis activity indices. Serum and urine will be 
collected in the fasting state (>6 hours).  
To enable us to examine the change in the metabolome after surgery and the introduction of 
drug therapy, disease activity and phenotype will be recorded prior to the intervention. Urine 
and blood samples will also be collected at this time. This process will be repeated two 
months after surgery or after the start of medical therapy. 
In order to follow the relationship between disease activity and the metabolome (serum and 
urine), serial samples will be taken from consenting patients at three monthly intervals for a 
maximum duration of 12 months. The associated details of disease and drug activity will also 
be collated at these times. 
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Control subjects will be recruited from patients attending for elective, non-colorectal 
procedures with no personal or family history of colorectal disease. Written consent will be 
taken, phenotype collected and a single sample of blood (20ml) and urine (20ml) taken in the 
fasting state. 
All the data collected is confidential. Demographic data will be entered into a file alongside a 
unique code number. The research team will store this file of personal information and codes 
securely on an NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of the code 
number only and will have no direct link to personal details, ensuring anonymity. 










       
 







Dear Dr GPSName 
 
Metabolomics and Inflammatory Bowel Disease  
 
The above study is ongoing at Raigmore Hospital. One of you patients, (insert 
patient details), who has IBD has agreed to participate.  
 
This is a study into metabolomics (biomarkers) in inflammatory bowel disease. Our 
aims are to: 
 
1. Define the relationship between metabolomic profiles and disease activity. 
2. Examine how metabolomic profiles differ after surgery for inflammatory 
bowel disease. 
3. Establish how metabolomic profiles of drug naïve IBD patients differ and how 
these alter after the introduction of medical therapy. 
 
For further information please see overleaf. 
 
Samples of blood and urine have been taken. We should not normally need to 
obtain any information from you. However, we would be grateful if you could email 
dianehildebrand@nhs.net if your patient changes address, or dies.  
 
If you would like to discuss any aspect of our study, or require any further details, 
please do not hesitate to contact me at the above email address. 
 
Yours sincerely,  
 
 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
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Metabolomics and Inflammatory Bowel Disease  
GP Information Sheet 
 
Title of project:   Metabolomics and Inflammatory Bowel Disease 
 
Background  
Crohn’s disease and ulcerative colitis are two types of inflammatory bowel disorders (IBD) of 
unknown aetiology that result in significant morbidity and health expenditure. Recent data 
suggests that the prevalence of IBD in the UK has exponentially increased to the current 
estimates of around 400 per 100,000. Hospital statistics from England and Scotland also 
show that during the last two decades there is a significant increase in the hospitalisation 
rates for both diseases outlining the enormous economic impact to health services. The age 
distribution is bimodal with a prominent first peak occurring in younger patients with Crohn's 
disease and a more prominent second peak occurring in older patients with ulcerative colitis. 
This distribution has long ranging implications for the viable younger workforce and also the 
older dependant population. More importantly, the incidence rate of juvenile onset Crohn’s 
disease has risen by nearly 30% in Scotland over the last twenty years, which translates into 
a longer period of monitored healthcare for affected individuals. 
Diagnostic and monitoring tools for IBD are currently inadequate. Numerous faecal 
biomarkers have been widely investigated within the last decade, but despite some 
promising studies, confirmation of their clinical validity and utility is awaited.  
Metabolomics, and the associated metabonomics, are powerful scientific strategies which 
provide the investigation of low molecular weight (bio)chemicals (metabolites) present in the 
metabolome of a cell, tissue or organism.  
Professor Watson was involved in the first group to investigate serum metabolomic profiles 
in patients with IBD. During discovery and validation studies it was possible to define 
important metabolomic differences between Crohn’s disease, ulcerative colitis and matched 
controls.  
We now wish to interrogate these differences further by comparing metabolomic profiles of 
IBD patients during different phases of their disease. Metabolomic profiles will change with 
disease activity, anatomical distribution and therapy.  Studying these changes will enable us 
to gain a greater understanding of the pathogenesis of the disease and may identify specific 
novel metabolic markers of disease identity and activity. 
 
Brief outline of the study 
Ethical approval has been granted for this study. 
Patients with inflammatory bowel disease in the Highlands and Islands of Scotland will be 
approached to take part in the study. After informed consent the patients will be phenotyped 
and their data stored on a secure database. Disease activity will be recorded using the 
Harvey Bradshaw and Simple Clinical Colitis activity indices. Serum and urine will be 
collected in the fasting state (>6 hours).  
To enable us to examine the change in the metabolome after surgery and the introduction of 
drug therapy, disease activity and phenotype will be recorded prior to the intervention. Urine 
and blood samples will also be collected at this time. This process will be repeated two 
months after surgery or after the start of medical therapy. 
In order to follow the relationship between disease activity and the metabolome (serum and 
urine), serial samples will be taken from consenting patients at three monthly intervals for a 
maximum duration of 12 months. The associated details of disease and drug activity will also 
be collated at these times. 
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Control subjects will be recruited from patients attending for elective, non-colorectal 
procedures with no personal or family history of colorectal disease. Written consent will be 
taken, phenotype collected and a single sample of blood (20ml) and urine (20ml) taken in the 
fasting state. 
All the data collected is confidential. Demographic data will be entered into a file alongside a 
unique code number. The research team will store this file of personal information and codes 
securely on an NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of the code 
number only and will have no direct link to personal details, ensuring anonymity. 













        







Dear Dr GPSName 
 
Metabolomics and Inflammatory Bowel Disease  
 
The above study is ongoing at Raigmore Hospital. One of you patients (insert 
patient details) has agreed to participate as a control.  
 
This is a study into metabolomics (biomarkers) in inflammatory bowel disease. Our 
aims are to: 
 
1. Define the relationship between metabolomic profiles and disease activity. 
2. Examine how metabolomic profiles differ after surgery for inflammatory 
bowel disease. 
3. Establish how metabolomic profiles of drug naïve IBD patients differ and how 
these alter after the introduction of medical therapy. 
 
For further information please see overleaf. 
 
Samples of blood and urine have been taken. We should not normally need to 
obtain any information from you. However, we would be grateful if you could email 
dianehildebrand@nhs.net if your patient changes address, or dies.  
 
If you would like to discuss any aspect of our study, or require any further details, 
please do not hesitate to contact me at the above email address. 
 
Yours sincerely,  
 
 
Miss Diane Hildebrand     Professor Angus Watson 
Clinical Research Fellow     Chief Investigator 
Centre for Health Science    Consultant Surgeon /  
Raigmore Hospital      Director of R&D 
Old Perth Road      Raigmore Hospital 
Inverness       Old Perth Road 
IV2 3UJ       Inverness 
        IV2 3UJ 
 
Email: dianehildebrand@nhs.net    angus.watson@nhs.net 
Tel: 01463 279 575     01463 705 414 
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Metabolomics and Inflammatory Bowel Disease  
GP Information Sheet 
 
Title of project:   Metabolomics and Inflammatory Bowel Disease 
 
Background  
Crohn’s disease and ulcerative colitis are two types of inflammatory bowel disorders (IBD) of 
unknown aetiology that result in significant morbidity and health expenditure. Recent data 
suggests that the prevalence of IBD in the UK has exponentially increased to the current 
estimates of around 400 per 100,000. Hospital statistics from England and Scotland also 
show that during the last two decades there is a significant increase in the hospitalisation 
rates for both diseases outlining the enormous economic impact to health services. The age 
distribution is bimodal with a prominent first peak occurring in younger patients with Crohn's 
disease and a more prominent second peak occurring in older patients with ulcerative colitis. 
This distribution has long ranging implications for the viable younger workforce and also the 
older dependant population. More importantly, the incidence rate of juvenile onset Crohn’s 
disease has risen by nearly 30% in Scotland over the last twenty years, which translates into 
a longer period of monitored healthcare for affected individuals. 
Diagnostic and monitoring tools for IBD are currently inadequate. Numerous faecal 
biomarkers have been widely investigated within the last decade, but despite some 
promising studies, confirmation of their clinical validity and utility is awaited.  
Metabolomics, and the associated metabonomics, are powerful scientific strategies which 
provide the investigation of low molecular weight (bio)chemicals (metabolites) present in the 
metabolome of a cell, tissue or organism.  
Professor Watson was involved in the first group to investigate serum metabolomic profiles 
in patients with IBD. During discovery and validation studies it was possible to define 
important metabolomic differences between Crohn’s disease, ulcerative colitis and matched 
controls.  
We now wish to interrogate these differences further by comparing metabolomic profiles of 
IBD patients during different phases of their disease. Metabolomic profiles will change with 
disease activity, anatomical distribution and therapy.  Studying these changes will enable us 
to gain a greater understanding of the pathogenesis of the disease and may identify specific 
novel metabolic markers of disease identity and activity. 
 
Brief outline of the study 
Ethical approval has been granted for this study. 
Patients with inflammatory bowel disease in the Highlands and Islands of Scotland will be 
approached to take part in the study. After informed consent the patients will be phenotyped 
and their data stored on a secure database. Disease activity will be recorded using the 
Harvey Bradshaw and Simple Clinical Colitis activity indices. Serum and urine will be 
collected in the fasting state (>6 hours).  
To enable us to examine the change in the metabolome after surgery and the introduction of 
drug therapy, disease activity and phenotype will be recorded prior to the intervention. Urine 
and blood samples will also be collected at this time. This process will be repeated two 
months after surgery or after the start of medical therapy. 
In order to follow the relationship between disease activity and the metabolome (serum and 
urine), serial samples will be taken from consenting patients at three monthly intervals for a 
maximum duration of 12 months. The associated details of disease and drug activity will also 
be collated at these times. 
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Control subjects will be recruited from patients attending for elective, non-colorectal 
procedures with no personal or family history of colorectal disease. Written consent will be 
taken, phenotype collected and a single sample of blood (20ml) and urine (20ml) taken in the 
fasting state. 
All the data collected is confidential. Demographic data will be entered into a file alongside a 
unique code number. The research team will store this file of personal information and codes 
securely on an NHS computer. All samples collected will be stored and labelled with the code 
number only but no personal details. Thus, all laboratory work will involve the use of the code 
number only and will have no direct link to personal details, ensuring anonymity. 









Study Number: 11\AL\0238 




PARTICIPANT CONSENT FORM  
 
Title of Project:  Metabolomics and Inflammatory Bowel Disease 
 
Name of Researcher: Miss Diane Hildebrand, Clinical Research Fellow, Raigmore Hospital, 
Inverness 
Email: dianehildebrand@nhs.net   
Tel: 01463 279 575    
      
 Please initial box 
 
1 I confirm that I have read and understand the metabolomics participant 
information sheet 1 (IBD ………………template) version 2 dated 15/06/11 
for the above study.  I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
2 I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected. 
 
3 I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from NHS HIGHLAND, 
from regulatory authorities or from the NHS Board, where it is relevant to 
my taking part in this research.  I give permission for these individuals to 
have access to my records. 
 
4 I agree to my GP being informed of my participation in the study.  
5 I agree to my samples being stored and used in future research studies 
where ethical approval has been granted.  
 
6 I agree to take part in the above study.  
      
 
________________ _____________ _____________ 





________________ _____________ _____________ 
Name of Person taking consent Signature  Date  




________________ _____________ _____________ 




 1 for patient;  1 for researcher;  1 to be kept with hospital notes 
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Study Number: 11\AL\0238 




PARTICIPANT CONSENT FORM  
 
Title of Project:  Metabolomics and Inflammatory Bowel Disease 
 
Name of Researcher: Miss Diane Hildebrand, Clinical Research Fellow, Raigmore Hospital, 
Inverness 
Email: dianehildebrand@nhs.net   
Tel: 01463 279 575    
      
 Please initial box 
 
1 I confirm that I have read and understand the metabolomics participant 
information sheet 2 (control template) version 3 dated 15/06/11 for the 
above study.  I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. 
 
3 I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from NHS HIGHLAND, 
from regulatory authorities or from the NHS Board, where it is relevant to 
my taking part in this research.  I give permission for these individuals to 
have access to my records. 
 
4 I agree to my GP being informed of my participation in the study.  
5 I agree to my samples being stored and used in future research studies 
where ethical approval has been granted.  
 
6 I agree to take part in the above study.  
      
 
________________ _____________ _____________ 





________________ _____________ _____________ 
Name of Person taking consent Signature  Date  




________________ _____________ _____________ 
Researcher Signature  Date  
  
 




8.2 Clinical Metadata  
8.2.1 Healthy Controls 





DRH061 M 46 White British 1.7 90 31.1 normal never no no 
DRH062 M 49 White British 1.86 90 26.0 normal never no no 
DRH064 M 47 White British 1.78 82.8 26.1 normal never no no 
DRH065 M 54 White British 1.77 82.5 26.3 normal never no no 
DRH069 M 64 White British 1.7 94 32.5 normal ex no no 
DRH070 M 44 White British 1.85 97.9 28.6 normal ex no no 
DRH073 M 68 White British 1.82 81.2 24.5 normal never no no 
DRH076 M 54 White British 1.72 73.7 24.9 normal never no no 
DRH077 M 30 White British 1.76 81.2 26.2 normal ex no no 
DRH078 M 56 White British 1.86 81.2 23.5 normal never no no 
DRH080 F 41 White British 1.68 91 32.2 normal current no no 
DRH081 M 32 White British 1.73 76.7 25.6 normal never yes no 
DRH087 M 32 White British 1.95 78.9 20.7 normal never no no 
DRH088 M 42 White British 1.71 93.7 32.0 normal never no no 
DRH089 M 65 White British 1.78 101 31.9 normal never no no 
DRH092 M 40 White British 1.8 117 36.1 normal never no no 
DRH093 M 44 White British 1.6 67.5 26.4 normal never no no 
DRH094 M 49 White British 1.86 90 26.0 normal never no no 
DRH095 M 66 White British 1.8 79.6 24.6 normal current no no 
DRH100 F 37 White British 1.64 60.8 22.6 normal ex no no 
DRH101 F 30 Eastern European 1.71 57.2 19.6 normal current no no 
DRH103 F 30 White British 1.66 68 24.7 normal never no no 
DRH107 M 54 White British 1.9 105 29.1 normal ex no no 
DRH108 F 29 White British 1.66 62.8 22.8 normal never no no 
DRH109 M 75 White British 1.7 75 26.0 normal never no no 
IHC048 M 74 White British 1.75 79.4 25.9 normal never no no 
IHC049 M 72 White British 1.75 66 21.6 normal never no no 
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IHC054 M 28 White British 1.73 82.4 27.5 normal never no no 
IHC059 M 70 White British 1.8 70 21.6 normal never no no 
IHC061 M 47 White British 1.9 93 25.8 normal never no no 
IHC062 M 52 White British 1.66 79 28.7 normal never no no 
IHC072 M 32 White British 1.77 91 29.0 normal current no no 
IHC073 F 57 White British 1.62 114.4 43.6 normal never no no 
IHC102 M 49 White British 1.61 54 20.8 normal never no no 
IHC103 M 55 White British 1.86 81.3 23.5 normal never no no 
IHC104 M 56 White British 1.71 67 22.9 normal current no no 
IHC110 F 31 White British 1.57 71.4 29.0 normal ex no no 
IHC114 M 65 White British 1.74 78.5 25.9 normal never no no 
IHC115 M 31 White British 1.83 103.4 30.9 normal ex no no 
IHC116 M 58 White British 1.79 59.2 18.5 normal never no no 
IHC117 M 70 White British 1.74 99.8 33.0 normal never no no 
IHC120 M 59 White British 1.79 120 37.5 normal ex no no 
IHC121 M 57 White British 1.74 82.2 27.2 normal never no no 
IHC123 M 33 White British 1.79 112 35.0 normal never no no 
IHC124 M 60 White British 1.83 80.6 24.1 normal never no no 
IHC131 M 34 White British 1.77 71.4 22.8 normal current no no 
IHC138 F 56 White British 1.66 60 21.8 normal never no no 
IHC139 F 49 White British 1.69 73.2 25.6 normal current no no 
IHC140 F 30 White British 1.78 85.8 27.1 normal current no no 
IHC141 M 83 White British 1.73 71.6 23.9 normal never no no 
IHC142 F 42 White British 1.63 72 27.1 normal never no no 
IHC143 F 44 White British 1.63 89.6 33.7 normal never no no 
IHC144 F 39 White British 1.62 112.5 42.9 normal never no no 
IHC147 F 58 White British 1.67 62.2 22.3 normal never no no 
IHC148 M 53 White British 1.75 85.2 27.8 normal never no no 
IHC149 M 66 White British 1.78 99 31.2 normal never no no 
IHC150 M 60 White British 1.81 96.3 29.4 normal never no no 
IHC151 M 71 White British 1.69 86.6 30.3 normal never no no 
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IHC152 M 62 White British 1.69 76.5 26.8 normal ex no no 
IHC153 M 66 White British 1.78 84.5 26.7 normal never no no 
IHC177 M 51 White British 1.74 78.4 25.9 normal never no no 




8.2.2 IBD Patients 





diagnosis Dx Dx date 
Symptoms 
date Study Group 
DRH001A M 19/09/1953 58 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH001B M 19/09/1953 58 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH001C M 19/09/1953 59 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH001D M 19/09/1953 59 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH001E M 19/09/1953 59 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH001F M 19/09/1953 59 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH001G M 19/09/1953 59 White British 54 UC 08/07/2007 01/03/2007 B,L,S 
DRH002A F 10/11/1966 41 White British 43 UC 16/04/2009 01/06/2009 L 
DRH002B F 10/11/1966 45 White British 43 UC 16/04/2009 01/06/2009 L 
DRH002C F 10/11/1966 46 White British 43 UC 16/04/2009 01/06/2009 L 
DRH002D F 10/11/1966 46 White British 43 UC 16/04/2009 01/06/2009 L 
DRH003A M 04/02/1981 26 White British 29 UC 30/09/2010 01/03/2010 L 
DRH003B M 04/02/1981 30 White British 29 UC 30/09/2010 01/03/2010 L 
DRH003C M 04/02/1981 31 White British 29 UC 30/09/2010 01/03/2010 L 
DRH003D M 04/02/1981 31 White British 29 UC 30/09/2010 01/03/2010 L 
DRH004A F 22/02/1982 25 Australasian 29 UC 23/08/2011 01/01/2006 L 
DRH004B F 22/02/1982 29 Australasian 29 UC 23/08/2011 01/01/2006 L 
DRH004C F 22/02/1982 30 Australasian 29 UC 23/08/2011 01/01/2006 L 
DRH005A F 11/04/1969 38 White British 34 CD 01/01/2003 unknown B 
DRH005B F 11/04/1969 38 White British 34 CD 01/01/2003 unknown B 
DRH006A F 04/01/1980 27 White British 23 UC 18/12/2003 01/11/2003 L 
DRH006B F 04/01/1980 31 White British 23 UC 19/12/2003 02/11/2003 L 
DRH006C F 04/01/1980 32 White British 23 UC 20/12/2003 03/11/2003 L 
DRH006D F 04/01/1980 32 White British 23 UC 21/12/2003 04/11/2003 L 
DRH007A M 09/06/1961 46 White British 38 CD 03/11/1999 01/04/1999 L 
DRH007B M 09/06/1961 50 White British 38 CD 03/11/1999 01/04/1999 L 
DRH007C M 09/06/1961 51 White British 38 CD 03/11/1999 01/04/1999 L 
DRH007D M 09/06/1961 51 White British 38 CD 03/11/1999 01/04/1999 L 
DRH008A M 09/05/1989 22 White British 22 CD 29/08/2011 01/06/2011 L 
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DRH008BS M 09/05/1989 22 White British 22 CD 29/08/2011 01/06/2011 L 
DRH008BU M 09/05/1989 22 White British 22 CD 29/08/2011 01/06/2011 L 
DRH008C M 09/05/1989 23 White British 22 CD 29/08/2011 01/06/2011 L 
DRH008D M 09/05/1989 23 White British 22 CD 29/08/2011 01/06/2011 L 
DRH009A M 13/10/1988 23 White British 17 UC 29/03/2005 01/11/2004 L 
DRH009B M 13/10/1988 23 White British 17 UC 29/03/2005 01/11/2004 L 
DRH009C M 13/10/1988 24 White British 17 UC 29/03/2005 01/11/2004 L 
DRH009D M 13/10/1988 24 White British 17 UC 29/03/2005 01/11/2004 L 
DRH010A F 17/10/1949 58 White British 49 UC 07/07/1998 01/01/1990 L 
DRH010B F 17/10/1949 63 White British 49 UC 07/07/1998 01/01/1990 L 
DRH010C F 17/10/1949 63 White British 49 UC 07/07/1998 01/01/1990 L 
DRH010D F 17/10/1949 63 White British 49 UC 07/07/1998 01/01/1990 L 
DRH011A F 25/09/1991 16 White British 20 CD 25/08/2011 01/07/2011 L 
DRH011B F 25/09/1991 20 White British 20 CD 25/08/2011 01/07/2011 L 
DRH011C F 25/09/1991 21 White British 20 CD 25/08/2011 01/07/2011 L 
DRH011D F 25/09/1991 21 White British 20 CD 25/08/2011 01/07/2011 L 
DRH012A F 17/01/1965 42 White British 46 UC 02/02/2011 01/12/2010 L 
DRH012B F 17/01/1965 46 White British 46 UC 02/02/2011 01/12/2010 L 
DRH012C F 17/01/1965 47 White British 46 UC 02/02/2011 01/12/2010 L 
DRH012D F 17/01/1965 47 White British 46 UC 02/02/2011 01/12/2010 L 
DRH013A F 09/02/1952 55 White British 52 UC 06/05/2004 01/02/2004 L 
DRH013B F 09/02/1952 60 White British 52 UC 06/05/2004 01/02/2004 L 
DRH013C F 09/02/1952 60 White British 52 UC 06/05/2004 01/02/2004 L 
DRH013D F 09/02/1952 60 White British 52 UC 06/05/2004 01/02/2004 L 
DRH014A M 23/04/1960 47 White British 42 CD 01/01/200  unknown L,B 
DRH014B M 23/04/1960 47 White British 42 CD 01/01/200  unknown L,B 
DRH014C M 23/04/1960 51 White British 42 CD 01/01/200  unknown L,B 
DRH014D M 23/04/1960 52 White British 42 CD 01/01/200  unknown L,B 
DRH014E M 23/04/1960 52 White British 42 CD 01/01/200  unknown L,B 
DRH015A F 12/07/1945 62 White British 50 UC 28/03/1995 unknown L 
DRH015B F 12/07/1945 66 White British 50 UC 28/03/1995 unknown L 
DRH015C F 12/07/1945 67 White British 50 UC 28/03/1995 unknown L 
DRH015D F 12/07/1945 67 White British 50 UC 28/03/1995 unknown L 
DRH016A M 22/03/1939 68 White British 46 CD 01/01/1985 unknown L 
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DRH016B M 22/03/1939 73 White British 46 CD 01/01/1985 unknown L 
DRH016C M 22/03/1939 73 White British 46 CD 01/01/1985 unknown L 
DRH016D M 22/03/1939 73 White British 46 CD 01/01/1985 unknown L 
DRH017A F 20/11/1967 40 White British 37 CD 01/01/2004 unknown L,B 
DRH017B F 20/11/1967 40 White British 37 CD 01/01/2004 unknown L,B 
DRH017C F 20/11/1967 45 White British 37 CD 01/01/2004 unknown L,B 
DRH017D F 20/11/1967 45 White British 37 CD 01/01/2004 unknown L,B 
DRH017E F 20/11/1967 45 White British 37 CD 01/01/2004 unknown L,B 
DRH018A F 06/02/1976 31 White British 35 CD 30/03/2011 01/01/2008 L,B,S 
DRH018B F 06/02/1976 31 White British 35 CD 30/03/2011 01/01/2008 L,B,S 
DRH018C F 06/02/1976 36 White British 35 CD 30/03/2011 01/01/2008 L,B,S 
DRH018D F 06/02/1976 36 White British 35 CD 30/03/2011 01/01/2008 L,B,S 
DRH018E F 06/02/1976 37 White British 35 CD 30/03/2011 01/01/2008 L,B,S 
DRH019A F 10/04/1948 59 White British 62 UC 20/04/2010 unknown S 
DRH019B F 11/04/1948 63 White British 62 UC 20/04/2010 unknown S 
DRH020A M 15/09/1973 34 White British 31 CD 01/04/2004 01/04/2004 L 
DRH020B M 15/09/1973 39 White British 31 CD 01/04/2004 01/04/2004 L 
DRH020C M 15/09/1973 39 White British 31 CD 01/04/2004 01/04/2004 L 
DRH020D M 15/09/1973 39 White British 31 CD 01/04/2004 01/04/2004 L 
DRH021A F 15/06/1948 59 White British 63 UC 07/02/2011 unknown L,B 
DRH021B F 15/06/1948 59 White British 63 UC 07/02/2011 unknown L,B 
DRH022A F 01/12/1967 40 White British 40 CD 01/01/2007 unknown L 
DRH022B F 01/12/1967 45 White British 40 CD 01/01/2007 unknown L 
DRH022C F 01/12/1967 45 White British 40 CD 01/01/2007 unknown L 
DRH022D F 01/12/1967 45 White British 40 CD 01/01/2007 unknown L 
DRH023A M 23/09/1981 26 White British 25 UC 01/01/2006 unknown S 
DRH023B M 23/09/1981 31 White British 25 UC 01/01/2006 unknown S 
DRH024A M 14/02/1979 28 White British 25 CD 01/01/2004 unknown L,B 
DRH024B M 14/02/1979 32 White British 25 CD 01/01/2004 unknown L,B 
DRH024C M 14/02/1979 33 White British 25 CD 01/01/2004 unknown L,B 
DRH024D M 14/02/1979 33 White British 25 CD 01/01/2004 unknown L,B 
DRH024E M 14/02/1979 33 White British 25 CD 01/01/2004 unknown L,B 
DRH025A M 31/10/1962 45 White British 46 UC 21/05/2008 unknown L,B 
DRH025B M 31/10/1962 50 White British 46 UC 21/05/2008 unknown L,B 
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DRH025C M 31/10/1962 50 White British 46 UC 21/05/2008 unknown L,B 
DRH025D M 31/10/1962 50 White British 46 UC 21/05/2008 unknown L,B 
DRH025E M 31/10/1962 50 White British 46 UC 21/05/2008 unknown L,B 
DRH026A M 25/03/1952 55 White British 55 CD 01/01/2007 unknown L 
DRH026B M 25/03/1952 60 White British 55 CD 01/01/2007 unknown L 
DRH026C M 25/03/1952 60 White British 55 CD 01/01/2007 unknown L 
DRH026E M 25/03/1952 60 White British 55 CD 01/01/2007 unknown L 
DRH027A F 07/10/1981 26 White British 26 CD 25/03/2007 unknown L 
DRH027B F 07/10/1981 31 White British 26 CD 25/03/2007 unknown L 
DRH027C F 07/10/1981 31 White British 26 CD 25/03/2007 unknown L 
DRH027D F 07/10/1981 31 White British 26 CD 25/03/2007 unknown L 
DRH028A F 07/12/1978 33 White British 26 CD 01/01/2004 unknown S 
DRH028B F 07/12/1978 34 White British 26 CD 01/01/2004 unknown S 
DRH029A F 13/03/1988 23 White British 22 UC 18/02/2010 unknown L 
DRH029B F 13/03/1988 24 White British 22 UC 18/02/2010 unknown L 
DRH029C F 13/03/1988 24 White British 22 UC 18/02/2010 unknown L 
DRH029D F 13/03/1988 24 White British 22 UC 18/02/2010 unknown L 
DRH030A F 17/10/1952 59 White British 57 CD 30/10/2009 unknown L 
DRH030B F 17/10/1952 60 White British 57 CD 30/10/2009 unknown L 
DRH030C F 17/10/1952 60 White British 57 CD 30/10/2009 unknown L 
DRH030D F 17/10/1952 60 White British 57 CD 30/10/2009 unknown L 
DRH031A F 03/03/1954 57 White British 57 CD 07/05/2011 unknown L,B 
DRH031B F 03/03/1954 57 White British 57 CD 07/05/2011 unknown L,B 
DRH031C F 03/03/1954 58 White British 57 CD 07/05/2011 unknown L,B 
DRH031D F 03/03/1954 58 White British 57 CD 07/05/2011 unknown L,B 
DRH031E F 03/03/1954 58 White British 57 CD 07/05/2011 unknown L,B 
DRH032A F 04/03/1965 46 White British 42 CD 01/01/2007 unknown L 
DRH032B F 04/03/1965 47 White British 42 CD 01/01/2007 unknown L 
DRH032C F 04/03/1965 47 White British 42 CD 01/01/2007 unknown L 
DRH033A F 07/03/1969 42 White British 36 UC 01/01/2005 unknown L 
DRH033B F 07/03/1969 43 White British 36 UC 01/01/2005 unknown L 
DRH033C F 07/03/1969 43 White British 36 UC 01/01/2005 unknown L 
DRH033D F 07/03/1969 43 White British 36 UC 01/01/2005 unknown L 
DRH034A M 25/07/1959 52 White British 48 UC 08/05/2007 unknown L 
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DRH034B M 25/07/1959 53 White British 48 UC 08/05/2007 unknown L 
DRH034C M 25/07/1959 53 White British 48 UC 08/05/2007 unknown L 
DRH034D M 25/07/1959 53 White British 48 UC 08/05/2007 unknown L 
DRH035A F 07/04/1950 61 White British 31 CD 01/01/198  unknown L 
DRH035B F 07/04/1950 62 White British 31 CD 01/01/198  unknown L 
DRH035C F 07/04/1950 62 White British 31 CD 01/01/198  unknown L 
DRH035D F 07/04/1950 62 White British 31 CD 01/01/198  unknown L 
DRH036A F 30/09/1942 69 White British 65 UC 02/02/2007 unknown L 
DRH036B F 30/09/1942 70 White British 65 UC 02/02/2007 unknown L 
DRH036C F 30/09/1942 70 White British 65 UC 02/02/2007 unknown L 
DRH036D F 30/09/1942 70 White British 65 UC 02/02/2007 unknown L 
DRH037A F 01/03/1972 39 White British 33 UC 01/01/2005 unknown L 
DRH037B F 01/03/1972 40 White British 33 UC 01/01/2005 unknown L 
DRH037C F 01/03/1972 40 White British 33 UC 01/01/2005 unknown L 
DRH037D F 01/03/1972 40 White British 33 UC 01/01/2005 unknown L 
DRH038A F 11/12/1973 38 White British 37 UC 01/02/2010 unknown L 
DRH038B F 11/12/1973 39 White British 37 UC 01/02/2010 unknown L 
DRH038C F 11/12/1973 39 White British 37 UC 01/02/2010 unknown L 
DRH039A F 13/11/1959 52 White British 24 CD 01/01/1983 unknown L,B 
DRH039B F 13/11/1959 53 White British 24 CD 01/01/1983 unknown L,B 
DRH039C F 13/11/1959 53 White British 24 CD 01/01/1983 unknown L,B 
DRH039D F 13/11/1959 53 White British 24 CD 01/01/1983 unknown L,B 
DRH039E F 13/11/1959 54 White British 24 CD 01/01/1983 unknown L,B 
DRH039F F 13/11/1959 54 White British 24 CD 01/01/1983 unknown L,B 
DRH040A F 02/01/1983 28 White British 7 CD 02/05/1990 unknown S 
DRH040B F 02/01/1983 29 White British 7 CD 02/05/1990 unknown S 
DRH041A M 19/03/1953 58 White British 52 UC 01/01/2005 unknown L 
DRH041B M 19/03/1953 59 White British 52 UC 01/01/2005 unknown L 
DRH041C M 19/03/1953 59 White British 52 UC 01/01/2005 unknown L 
DRH041D M 19/03/1953 59 White British 52 UC 01/01/2005 unknown L 
DRH042A F 26/05/1973 38 White British 35 UC 01/01/2008 unknown L,S 
DRH042B F 26/05/1973 39 White British 35 UC 01/01/2008 unknown L,S 
DRH042C F 26/05/1973 39 White British 35 UC 01/01/2008 unknown L,S 
DRH042D F 26/05/1973 39 White British 35 UC 01/01/2008 unknown L,S 
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DRH042E F 26/05/1973 39 White British 35 UC 01/01/2008 unknown L,S 
DRH042F F 26/05/1973 40 White British 35 UC 01/01/2008 unknown L,S 
DRH043A F 22/05/1981 30 White British 29 UC 09/11/2010 unknown L 
DRH043B F 22/05/1981 31 White British 29 UC 09/11/2010 unknown L 
DRH043C F 22/05/1981 31 White British 29 UC 09/11/2010 unknown L 
DRH043D F 22/05/1981 32 White British 29 UC 09/11/2010 unknown L 
DRH044A M 01/06/1975 36 White British 32 CD 01/01/2007 unknown L,B 
DRH044B M 01/06/1975 37 White British 32 CD 01/01/2007 unknown L,B 
DRH045A F 23/12/1989 23 White British 20 UC 01/01/2009 unknown S 
DRH045B F 23/12/1989 23 White British 20 UC 01/01/2009 unknown S 
DRH046A F 15/02/1977 35 White British 35 CD 08/01/201  unknown Naïve to L, B 
DRH046B F 15/02/1977 35 White British 35 CD 08/01/201  unknown Naïve to L, B 
DRH047A F 15/05/1948 64 White British 52 UC 01/01/2000 unknown L 
DRH047B F 15/05/1948 64 White British 52 UC 01/01/2000 unknown L 
DRH047C F 15/05/1948 64 White British 52 UC 01/01/2000 unknown L 
DRH047D F 15/05/1948 64 White British 52 UC 01/01/2000 unknown L 
DRH048A F 15/02/1965 47 White British 37 CD 01/01/200  unknown S 
DRH048B F 15/02/1965 47 White British 37 CD 01/01/200  unknown S 
DRH049A F 07/03/1985 27 White British 26 CD 01/09/2011 unknown B,S 
DRH049B F 07/03/1985 27 White British 26 CD 01/09/2011 unknown B,S 
DRH049C F 07/03/1985 27 White British 26 CD 01/09/2011 unknown B,S 
DRH049D F 07/03/1985 28 White British 26 CD 01/09/2011 unknown B,S 
DRH050A M 02/10/1972 40 White British 38 CD 01/11/2010 unknown B 
DRH050B M 02/10/1972 40 White British 38 CD 01/11/2010 unknown B 
DRH051A M 30/10/1978 34 White British 22 CD 03/04/2000 unknown S 
DRH051B M 30/10/1978 34 White British 22 CD 03/04/2000 unknown S 
DRH052A F 07/01/1983 29 White British 26 UC 10/07/2009 unknown S 
DRH052B F 07/01/1983 29 White British 26 UC 10/07/2009 unknown S 
DRH053A F 09/06/1972 40 White British 10 CD 01/01/1982 unknown S 
DRH053B F 09/06/1972 40 White British 10 CD 02/01/1982 unknown S 
DRH054A F 16/07/1962 50 White British 50 CD 01/02/201  unknown S 
DRH055A M 12/11/1978 34 White British 33 UC 01/12/2011 unknown S 
DRH055B M 12/11/1978 34 White British 33 UC 01/12/2011 unknown S 
DRH056A F 26/12/1981 31 White British 28 UC 27/08/2009 unknown S 
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DRH057A F 20/06/1975 37 White British 24 CD 01/01/1999 unknown S 
DRH057B F 20/06/1975 37 White British 24 CD 01/01/1999 unknown S 
DRH058A M 01/05/1946 66 White British 65 CD 07/06/2011 unknown S 
DRH058B M 01/05/1946 66 White British 65 CD 07/06/2011 unknown S 
DRH059A F 06/01/1969 43 White British 43 UC 11/05/201  unknown Naïve to L 
DRH059B F 06/01/1969 43 White British 43 UC 11/05/201  unknown Naïve to L 
DRH060A F 21/09/1969 43 White British 22 UC 01/01/199  unknown B 
DRH060B F 21/09/1969 43 White British 22 UC 01/01/199  unknown B 
DRH063A M 09/01/1937 75 Southern European 68 UC 28/11/2005 unknown B 
DRH063B M 09/01/1937 75 Southern European 68 UC 28/11/2005 unknown B 
DRH066A M 05/01/1983 29 White British 29 CD 14/06/201  unknown S 
DRH066B M 05/01/1983 29 White British 29 CD 14/06/201  unknown S 
DRH067A M 09/01/1935 77 White British 77 UC 15/06/201  unknown S 
DRH068A F 18/02/1993 19 White British 17 UC 15/12/2010 unknown B 
DRH068B F 18/02/1993 19 White British 17 UC 15/12/2010 unknown B 
DRH071A F 18/03/1992 20 White British 20 CD 17/07/201  01/01/2008 Naïve to long 
DRH071B F 18/03/1992 20 White British 20 CD 17/07/201  01/01/2008 Naïve to long 
DRH071C F 18/03/1992 21 White British 20 CD 17/07/201  01/01/2008 Naïve to long 
DRH072A F 15/03/1977 35 White British 28 CD 01/01/2005 unknown S 
DRH072B F 15/03/1977 35 White British 28 CD 01/01/2005 unknown S 
DRH074A M 25/12/1953 59 White British 59 Diverticular fistula 13/08/2012 unknown Naïve to long 
DRH075A F 17/09/1943 69 White British 46 CD 01/01/1989 unknown S 
DRH075B F 17/09/1943 69 White British 46 CD 01/01/1989 unknown S 
DRH079A F 02/04/1966 46 White British 39 UC 01/01/2005 unknown S 
DRH079B F 02/04/1966 46 White British 39 UC 01/01/2005 unknown S 
DRH082A M 30/09/1984 28 White British 25 UC 01/01/2009 unknown S 
DRH082B M 30/09/1984 28 White British 25 UC 01/01/2009 unknown S 
DRH083A M 18/06/1952 60 White British 58 CD 24/11/2010 unknown B 
DRH083B M 18/06/1952 60 White British 58 CD 24/11/2010 unknown B 
DRH084A F 23/08/1971 41 White British 28 UC 01/01/1999 unknown B 
DRH084B F 23/08/1971 41 White British 28 UC 01/01/1999 unknown B 
DRH085A F 14/12/1959 53 White British 52 CD 01/01/2011 unknown S 
DRH085B F 14/12/1959 54 White British 52 CD 01/01/2011 unknown S 
DRH086A M 16/12/1947 65 White British 65 UC 31/10/21  unknown Naïve to long 
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DRH086B M 16/12/1947 66 White British 65 UC 31/10/21  unknown Naïve to long 
DRH090A M 05/02/1973 39 White British 39 CD 06/11/201  unknown Naïve to long 
DRH090B M 05/02/1973 40 White British 39 CD 06/11/201  unknown Naïve to long 
DRH091A F 03/08/1964 48 White British 33 UC 01/01/1997 unknown B 
DRH091B F 03/08/1964 48 White British 33 UC 01/01/1997 unknown B 
DRH096A F 16/05/1973 39 White British 35 UC 01/01/2008 unknown S 
DRH096B F 16/05/1973 40 White British 35 UC 01/01/2008 unknown S 
DRH097A M 05/08/1975 37 White British 26 CD 01/08/2001 unknown S 
DRH097B M 05/08/1975 38 White British 26 CD 01/08/2001 unknown S 
DRH098A F 19/01/1955 57 White British   UC unknown unknown B,S 
DRH098B F 19/01/1955 58 White British   UC unknown unknown B,S 
DRH098C F 19/01/1955 58 White British   UC unknown unknown B,S 
DRH099A F 30/01/1967 45 White British 29 CD 22/01/1996 unknown S 
DRH099B F 30/01/1967 45 White British 29 CD 22/01/1996 unknown S 
DRH102A M 07/06/1949 63 White British 46 CD 01/01/1995 unknown S 
DRH102B M 07/06/1949 64 White British 46 CD 01/01/1995 unknown S 
DRH104A F 29/11/1988 25 White British 8 CD 01/01/1996 unknown B 
DRH104B F 29/11/1988 25 White British 8 CD 01/01/1996 unknown B 
DRH105A F 18/08/1950 63 White British 47 UC 01/01/1997 unknown B 
DRH105B F 18/08/1950 63 White British 47 UC 01/01/1997 unknown B 
DRH106A M 30/07/1979 34 White British 26 CD 01/01/2005 unknown B 
DRH106B M 30/07/1979 34 White British 26 CD 01/01/2005 unknown B 
DRH200A M 25/10/1978 35 White British 31 CD 01/01/2009 unknown S 





8.2.2 IBD Patients cont… 
Label 
Sample 




(kg) BMI Diet Smoking 
Alcohol / wk 
(u) Drugs 
DRH001A 12/08/2011 1 1 1st long 1.69 71.2 24.9 normal ex 0 pred 15, 6mp 50 
DRH001B 15/11/2011 1 1 
2nd 
long 1.69 72 25.2 normal ex 0 pred 10, 6mp 50 
DRH001C 08/02/2012 1 1 
3rd 
long, 
pre bio 1.69 70 24.5 normal ex 0 pred 25, 6mp 75 
DRH001D 22/02/2012 1 1 post bio 1.69 73.5 25.7 normal ex 0 pred 25, 6mp 75 
DRH001E 10/05/2012 1 0 
4th 
long 1.69 67.5 23.6 normal ex 0 6mp 75, inflix 400 
DRH001F 19/06/2012 1 1 pre surg 1.69 66.3 23.2 normal ex 0 6mp 75, inflix 400 
DRH001G 31/08/2012 1 1 
post 




DRH002A 16/08/2007 1 1 Ist long 1.69 72.1 25.2 normal never 0 
6mp 75, Thyroxine 
75mg OD, Agnus 
Castus OD (for 
PMS), Multivit 
DRH002B 17/11/2011 1 1 
2nd 
long 1.69 71.1 24.9 normal never 0 
6mp 100, Thyroxine 
75mg OD, Agnus 




DRH002C 17/02/2012 1 1 
3rd 
long 1.69 73.6 25.8 normal never 0 
citalopram, 6mp 
100, Thyroxine 
75mg OD, Agnus 
Castus OD (for 
PMS), Multivit 
DRH002D 24/05/2012 1 1 
4th 
long 1.69 73 25.6 normal never 0 
citalopram, 6mp 75, 
Thyroxine 75mg 
OD, Agnus Castus 
OD (for PMS), 
Multivit 
DRH003A 22/08/2007 1 1 Ist long 1.7 73.4 25.4 normal never 10 
40 adalimumab 
every 2 weeks 
DRH003B 22/11/2011 1 1 
2nd 
long 1.7 71.4 24.7 normal never 10 
40 adalimumab 
every 2 weeks 
DRH003C 27/02/2012 1 1 
3rd 
long 1.7 71.6 24.8 normal never 10 
40 adalimumab 
every 2 weeks 
DRH003D 29/05/2012 1 1 
4th 
long 1.7 70.8 24.5 normal never 10 
40 adalimumab 
every 2 weeks 




2g po OD, Vit D 
/Calcium 2 tabs od, 
Alendronate 70mg 
weekly (tues), 
Nicotine patch in 
situ at present 
DRH004B 25/11/2011 1 1 
2nd 
long 1.7 84.7 29.3 normal current 0 6mp 75 
DRH004C 16/04/2012 1 1 
3rd 
long 1.7 84 29.1 normal current 0 













DRH006A 25/08/2007 1 1 Ist long 1.52 66 28.6 normal ex 0 
Movicol 1 sachet 
OD, methotrexate 
25mg weekly, folic 
acid 15mg weekly, 
pentasa supp 1g 
twice / wk 
DRH006B 25/11/2011 1 1 
2nd 
long 1.52 66.3 28.7 normal ex 0 
Movicol 1 sachet 
OD, methotrexate 
25mg weekly, folic 
acid 15mg weekly, 
pentasa supp 1g 
twice / wk 
DRH006C 02/03/2012 1 1 
3rd 
long 1.52 67 29.0 normal ex 0 
Movicol 1 sachet 
OD, methotrexate 
25mg weekly, folic 
acid 15mg weekly, 
pentasa supp 1g 
twice / wk, diazepam  
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DRH006D 01/06/2012 1 1 
4th 
long 1.52 65.6 28.4 normal ex 0 
Movicol 1 sachet 
OD, methotrexate 
25mg weekly, folic 
acid 15mg weekly, 
pentasa supp 1g 
twice / wk, 
antibiotics for ear 
infection (?what) 
DRH007A 29/08/2007 1 1 Ist long 1.81 65.3 20.0 normal current 0 
pred 35mg od, 
calcichew 
DRH007B 25/11/2011 1 1 
2nd 
long 1.81 74 22.6 normal current 0 
pred 30mg od, 
calcichew 
DRH007C 24/02/2012 1 1 
3rd 
long 1.81 72.5 22.16 normal current 0 
pred 15mg od, 
calcichew 
DRH007D 25/05/2012 1 1 
4th 
long 1.81 72.6 22.2 normal current 0 
pred 30mg od, 
calcichew 
DRH008A 30/08/3007 1 1 Ist long 1.85 75.4 22.0 normal ex 0 
hydrocortisone iv 
400mg/day, 
ranitidine 150mg po 
bd, enoxaparin 20mg 
sc od, pabrinex I+II 
bd iv, zopiclone 
7.5mg od po, peptac 
10ml po nocte, 
dihydrocodeine 
60mg nocte 













only 1.85 83.7 24.5 normal ex 0 
infliximab 400mg/8 
weeks 
DRH008C 28/03/2012 1 1 
3rd 
long 1.85 83 24.3 normal current 0 
infliximab 400mg/8 
weeks 
DRH008D 20/06/2012 1 1 
4th 
long 1.85 82.7 24.1636 normal current 0 
infliximab 400mg/8 
weeks 
DRH009A 01/09/2007 1 1 Ist long 1.74 80.4 26.6 normal never 0 6mp 50 
DRH009B 08/12/2011 1 1 
2nd 
long 1.74 84.5 28.0 normal never 0 6mp 50 
DRH009C 08/03/2012 1 1 
3rd 
long 1.74 83.8 27.7 normal never 0 6mp 50 
DRH009D 07/06/2012 1 1 
4th 
long 1.74 83.7 27.6 normal never 0 6mp 50 
DRH010A 05/09/2007 1 1 Ist long 1.68 70.6 25.0 normal never 0 
40mg adalimumab 2 
weekly 
DRH010B 10/01/2012 1 1 
2nd 
long 1.68 72 25.5 normal never 0 
40mg adalimumab 2 
weekly 
DRH010C 27/03/2012 1 1 
3rd 
long 1.68 72.5 25.7 normal never 0 
40mg adalimumab 2 
weekly 
DRH010D 22/06/2012 1 1 
4th 
long 1.68 74 26.2 normal never 0 
40mg adalimumab 2 
weekly 
DRH011A 07/09/2007 1 1 Ist long 1.66 78 28.3 normal never 0 
400mg infliximab, 
6mp 50, alcium, 
vitamin d, 
microgynon 30 
DRH011B 25/11/2011 1 1 
2nd 
long 1.66 80.9 29.4 normal never 0 
400mg infliximab, 





DRH011C 15/02/2012 1 1 
3rd 
long 1.66 86 31.2 normal never 0 
400mg infliximab, 
6mp 50, alcium, 
vitamin d, 
microgynon 31 
DRH011D 06/06/2012 1 1 
4th 
long 1.66 86 31.2 normal never 0 
400mg infliximab, 
6mp 50, alcium, 
vitamin d, 
microgynon 32 
DRH012A 07/09/2007 1 1 Ist long 1.54 56 23.6 normal ex 14 pred 30, 6mp 50 
DRH012B 14/12/2011 1 1 
2nd 
long 1.54 55.3 23.3 normal ex 14 
infliximab 300mg / 8 
weeks 
DRH012C 22/03/2012 1 1 
3rd 
long 1.54 54 22.8 normal ex 14 nil 
DRH012D 14/08/2012 1 1 
4th 
long 1.54 53.8 22.7 normal ex 14 nicotine gum 
DRH013A 08/09/2007 1 1 Ist long 1.58 64.4 25.8 normal ex 0 
pentasa 1g po BD, 
pentasa 1g supp 
every 2nd day, 
lansoprazole 30mg 








DRH013B 18/01/2012 1 1 
2nd 
long 1.58 66.4 26.6 normal ex 0 
pentasa 1g po BD, 
pentasa 1g supp 
every 2nd day, 
lansoprazole 30mg 




50mcg od, zopiclone 
7.5mg prn 
DRH013C 06/07/2012 1 1 
3rd 
long 1.58 65 26.0 normal ex 0 
pentasa 1g po BD, 
pentasa 1g supp 
every 2nd day, 
lansoprazole 30mg 




50mcg od, zopiclone 
7.5mg prn 
DRH013D 15/10/2012 1 1 
4th 
long 1.58 64.6 25.9 normal ex 0 
pentasa 1g po BD, 
pentasa 1g supp 
every 2nd day, 
lansoprazole 30mg 




50mcg od, zopiclone 
7.5mg prn 
DRH014A 19/09/2007 1 1 1st long 1.76 111.9 36.1 normal ex 30 
azathioprine 200mg 
od, amlodipine 5mg 
od, enoxaparin 20mg 
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DRH014B 05/10/2007 1 1 pre bio 1.76 111.9 36.1 normal ex 30 
azathioprine 200mg 
od, amlodipine 5mg 
od 
DRH014C 12/12/2011 1 1 
2nd 
long 1.76 113.4 36.6 normal ex 30 
azathioprine 200mg 
od, amlodipine 5mg 
od, inliximab 500mg 
8 weekly 
DRH014D 14/03/2012 1 1 
3rd 
long 1.76 110 35.5 normal ex 30 
azathioprine 200mg 
od, amlodipine 5mg 
od, infliximab 
500mg 8 weekly 
DRH014E 05/07/2012 1 1 
4th 
long 1.76 111.2 35.9 normal ex 30 
azathioprine 200mg 
od, amlodipine 5mg 
od 
DRH015A 26/09/2007 1 1 1st long 1.65 70.6 25.9 normal ex 0 
asacol 800mg po bd, 




inh prn, budesonide 
200mcg 2 puffs bd,  
DRH015B 14/12/2011 1 1 
2nd 
long 1.65 70.3 25.8 normal ex 0 
asacol 800mg po bd, 




inh prn, budesonide 
200mcg 2 puffs bd,  
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DRH015C 14/03/2012 1 1 
3rd 
long 1.65 68.6 25.2 normal ex 0 
asacol 800mg po bd, 




inh prn, budesonide 
200mcg 2 puffs bd,  
DRH015D 21/06/2012 1 1 
4th 
long 1.65 70.5 25.9 normal ex 0 
asacol 800mg po bd, 




inh prn, budesonide 
200mcg 2 puffs bd,  





DRH016B 09/01/2012 1 1 
2nd 





DRH016C 02/04/2012 1 1 
3rd 





DRH016D 09/07/2012 1 1 
4th 





DRH017A 03/10/2007 1 1 
1st 
long, 
pre bio 1.63 85 32.0 normal never 0 nil 
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DRH017B 17/10/2007 1 1 post bio 1.63 84 31.6 normal never 0 
400mg infliximab 2 
weeks ago 
DRH017C 11/01/2012 1 1 
2nd 
long 1.63 87 32.7 normal never 0 
400mg infliximab 8 
weekly, 200mg 
azathioprine 
DRH017D 03/04/2012 1 1 
3rd 
long 1.63 89 33.5 normal never 0 
400mg infliximab 8 
weekly, 200mg 
azathioprine 
DRH017E 22/08/2012 1 1 
4th 
long 1.63 85 32.0 normal never 0 
400mg infliximab 8 
weekly, 200mg 
azathioprine 
DRH018A 03/10/2007 1 1 
1st 
long, 





od, paracetamol iv,  





infliximab 250mg 2 
weeks ago 
DRH018C 01/02/2012 1 1 
2nd 


















infliximab 250mg 8 
weekly 









infliximab 250mg 8 
weekly 
DRH019A 11/10/2007 1 1 
pre 
surgery 1.57 64 26.0 normal current 10 loperamide prn 
DRH019B 02/12/2011 1 1 
post 
surgery 1.57 58.6 23.8 normal current 10 
preload at 1800/2200 
11/10/11, exoxapain 
at 17:00 11/10/11 
DRH020A 12/10/2007 1 1 1st long 1.79 69 21.5 normal never 5 Nil 
DRH020B 10/01/2012 1 1 
2nd 
long 1.79 69 21.5 normal never 5 Nil 
DRH020C 30/03/2012 1 1 
3rd 
long 1.79 66.2 20.7 normal never 5 Nil 
DRH020D 06/07/2012 1 1 
4th 
long 1.79 67.5 21.1 normal never 5 Nil 
DRH021A 17/10/2007 1 1 
1st 
long, 














300mg 2 weeks ago 
DRH022A 18/10/2007 1 1 1st long 1.65 50.5 18.5 normal current 5 
picolax x2, folic acid 
15mg od, 
omeprazole 20mg 
od, ascorbic acid, co-
codamol prn 
DRH022B 23/01/2012 1 1 
2nd 
long 1.65 50.2 18.4 normal current 5 
 folic acid 15mg od, 
omeprazole 20mg 
od, ascorbic acid, co-
codamol prn 
DRH022C 31/05/2012 1 1 
3rd 
long 1.65 50.8 18.7 normal current 5 
 folic acid 15mg od, 
omeprazole 20mg 
od, ascorbic acid, co-
codamol prn 
DRH022D 02/10/2012 1 1 
4th 
long 1.65 49.3 18.1 normal current 5 
 folic acid 15mg od, 
omeprazole 20mg 




DRH023A 25/10/2007 1 1 pre surg 1.78 75.2 23.7 normal never 0 
prednisolone 9mg. 
Azathioprine 125mg 
od, pentasa 2g bd, 
calcium and vit d 
supplements 1 tab 
bd, cocodamol prn, 
enoxaparin 40mg 
pre-op and preload 
10pm and 6am 
DRH023B 10/03/2012 1 1 
post 
surg 1.78 71 22.4 normal never 0   
DRH024A 01/11/2007 1 1 
1st 
long, 
pre bio 1.69 70 24.5 normal never 0 
folic acid 5mg / 
week, ibuprofen 
400mg prn.  
DRH024B 15/11/2011 1 1 post bio 1.69 70 24.5 normal never 0 
folic acid 5mg / 
week, ibuprofen 
400mg prn, 
infliximab 400mg 2 
weeks ago 
DRH024C 08/02/2012 1 1 
2nd 
long 1.69 70 24.5 normal never 0 
folic acid 5mg / 
week, ibuprofen 
400mg prn, 
infliximab 400mg 8 
weekly 
DRH024D 30/05/2012 1 1 
3rd 
long 1.69 66 23.1 normal never 0 
folic acid 5mg / 
week, ibuprofen 
400mg prn, 
infliximab 400mg 8 
weekly 
DRH024E 19/09/2012 1 1 
4th 
long 1.69 68 23.8 normal never 0 
folic acid 5mg / 
week, ibuprofen 
400mg prn, 








DRH025B 27/01/2012 1 1 
2nd 
long  1.75 80.4 26.3 normal ex 40 
mercaptopurine 
75mg od 
DRH025C 22/02/2012 1 1 pre bio 1.75 78 25.5 normal ex 40 
mercaptopurine 
75mg od 
DRH025D 07/03/2012 1 1 
post 
bio, 3rd 
long 1.75 76 24.8 normal current 40 
infliximab 400mg 2 
weeks ago 
DRH025E 30/05/2012 1 1 
4th 
long 1.75 76 24.8 normal current 40 
infliximab 400mg 8 
weekly 
DRH026A 03/11/2007 1 1 1st long 1.75 102 33.3 normal ex 70 
adalimumab 40mg 
every 2 weeks, 
tramadol 50mg prn, 
diclofenac 50mg prn, 
tadalifil prn, zydol xl 
prn,  
DRH026B 27/01/2012 1 1 
2nd 
long 1.75 102.5 33.5 normal ex 70 
adalimumab 80mg 
every 2 weeks 
DRH026C 02/05/2012 1 1 
3rd 
long 1.75 101.5 33.1 normal ex 70 
adalimumab 80mg 
every 2 weeks 
 
 481
DRH026E 15/08/2012 1 1 
4th 
long 1.75 103 33.6 normal ex 70 





tramadol 50mg prn, 
omeprazole, 
diclofenac 
DRH027A 06/11/2007 1 1 1st long 1.59 64.6 25.6 normal current 5 
adalimumab 40mg 
every 2 weeks 
DRH027B 30/01/2012 1 1 
2nd 
long 1.59 63.2 25.0 normal current 5 
adalimumab 40mg 
every 2 weeks 
DRH027C 09/05/2012 1 1 
3rd 
long 1.59 63.6 25.2 normal current 5 
adalimumab 40mg 
every 2 weeks 
DRH027D 21/09/2012 1 1 
4th 
long 1.59 61.8 24.4 normal ex 0 
adalimumab 40mg 
every 2 weeks 





200mg iv 4/10/11 
DRH028B 02/03/2012 1 1 
post 
surg 1.65 56.2 20.6 normal ex 0 
co-codamol prn, 
tramadol prn. 
DRH029A 08/11/2011 1 1 1st long 1.77 68.9 22.0 normal never 10 
adalimumab 40mg 2 
weekly 
DRH029B 01/03/2012 1 1 
2nd 
long 1.77 67 21.4 normal never 10 
adalimumab 40mg 2 
weekly 
DRH029C 29/06/2012 1 1 
3rd 
long 1.77 67.4 21.5 normal never 10 
adalimumab 40mg 2 
weekly 
DRH029D 28/12/2012 1 1 
4th 









DRH030B 08/02/2012 1 1 
2nd 




DRH030C 08/05/2012 1 1 
3rd 




DRH030D 20/08/2012 1 1 
4th 




DRH031A 08/11/2011 1 1 
1st 
long, 
pre bio 1.64 86.9 32.3 normal ex 0 
levothyroxine 
50mcg od, 
paroxetine 30mg od, 
bendroflumethiazide 
2.5mg od, ramipril 
10mg od, atenolol 
50mg of, metformin 
500mg bd, 
simvastatin 40mg 
od, novorapid as per 




DRH031B 23/11/2011 1 1 post bio 1.64 92.7 34.5 normal ex 0 
levothyroxine 
50mcg od, 
paroxetine 30mg od, 
bendroflumethiazide 
2.5mg od, ramipril 
10mg od, atenolol 
50mg of, metformin 
500mg bd, 
simvastatin 40mg 
od, novorapid as per 
BM, lantus as per 
BM, infliximab 
400mg 2 weeks ago. 
DRH031C 20/02/2012 1 1 
2nd 
long 1.64 86 32.0 normal ex 0 
levothyroxine 
50mcg od, 
paroxetine 30mg od, 
bendroflumethiazide 
2.5mg od, ramipril 
10mg od, atenolol 
50mg of, metformin 
500mg bd, 
simvastatin 40mg 
od, novorapid as per 
BM, lantus as per 
BM, infliximab 
400mg 8 weekly. 
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DRH031D 05/06/2012 1 1 
3rd 
long 1.64 94.4 35.1 normal ex 0 
levothyroxine 
50mcg od, 
paroxetine 30mg od, 
bendroflumethiazide 
2.5mg od, ramipril 
10mg od, atenolol 
50mg of, metformin 
500mg bd, 
simvastatin 40mg 
od, novorapid as per 
BM, lantus as per 
BM, infliximab 
400mg 8 weekly. 
DRH031E 02/10/2012 1 1 
4th 
long 1.64 94 34.9 normal ex 0 
levothyroxine 
50mcg od, 
paroxetine 30mg od, 
bendroflumethiazide 
2.5mg od, ramipril 
10mg od, atenolol 
50mg of, metformin 
500mg bd, 
simvastatin 40mg 
od, novorapid as per 
BM, lantus as per 
BM, picolax, 
infliximab 
DRH032A 15/11/2011 1 1 1st long 1.56 88 36.2 normal ex 0 
azathioprine150mg 
od, bisoprolol 5m od 
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DRH032B 14/02/2012 1 1 
2nd 
long 1.56 88 36.2 normal ex 2 
azathioprine150mg 
od, bisoprolol 5m od 
DRH032C 17/05/2012 1 1 
3rd 
long 1.56 89 36.6 normal ex 2 
azathioprine150mg 
od, bisoprolol 5m od 
DRH033A 15/11/2011 1 1 1st long 1.64 63.6 23.6 normal ex 2 
pentasa 1g bd, 
carbomazepine 
100mg  mane, 
200mg nocte, 
omeprazole 20mg 
od, movicol prn 
DRH033B 21/02/2012 1 1 
2nd 
long 1.64 63.4 23.6 normal ex 2 
pentasa 1g bd, 
carbomazepine 
100mg  mane, 
200mg nocte, 
omeprazole 20mg 
od, movicol prn 
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DRH033C 05/06/2012 1 1 
3rd 
long 1.64 61.3 22.8 normal ex 2 
pentasa 1g bd, 
carbomazepine 
100mg  mane, 
200mg nocte, 
omeprazole 20mg 
od, movicol prn, 
picolax 
DRH033D 28/08/2012 1 1 
4th 
long 1.64 62.1 23.1 normal ex 2 
pentasa 1g bd, 
carbomazepine 
100mg  mane, 
200mg nocte, 
omeprazole 20mg 
od, movicol prn 
DRH034A 17/11/2011 1 1 1st long 1.84 93.4 27.6 normal never 10 pentasa enemas prn 
DRH034B 13/02/2012 1 1 
2nd 
long 1.84 92.9 27.4 normal never 10 pentasa enemas prn 
DRH034C 14/05/2012 1 1 
3rd 
long 1.84 92.8 27.4 normal never 10 pentasa enemas prn 
DRH034D 31/08/2012 1 1 
4th 
long 1.84 95 28.1 normal never 10 pentasa enemas prn 




DRH035B 16/02/2012 1 1 
2nd 




DRH035C 18/05/2012 1 1 
3rd 




DRH035D 06/09/2012 1 1 
4th 






DRH036A 22/11/2011 1 1 1st long 1.58 62.5 25.0 normal ex 5 
mercaptopurine 
50mg od, thyroxine 
75mcg od. 
DRH036B 28/02/2012 1 1 
2nd 
long 1.58 62 24.8 normal ex 5 
mercaptopurine 
50mg od, thyroxine 
75mcg od. 
DRH036C 28/05/2012 1 1 
3rd 
long 1.58 61.3 24.6 normal ex 5 
mercaptopurine 
50mg od, thyroxine 
75mcg od. 
DRH036D 05/09/2012 1 1 
4th 
long 1.58 60.8 24.6 normal ex 5 
mercaptopurine 
50mg od, thyroxine 
75mcg od. 
DRH037A 23/11/2011 1 1 1st long 1.72 87 29.4 normal current 10 pentasa 2g od 
DRH037B 14/02/2012 1 1 
2nd 
long 1.72 88.6 30.0 normal current 5 pentasa 2g od 
DRH037C 15/05/2012 1 1 
3rd 
long 1.72 89 30.1 normal current 5 pentasa 2g od 
DRH037D 14/08/2012 1 1 
4th 
long 1.72 86.2 29.1 normal current 5 pentasa 2g od 
DRH038A 23/11/2011 1 1 1st long 1.59 84 33.2 vegetarian ex 0 pentasa supps prn 
DRH038B 20/02/2012 1 1 
2nd 
long 1.59 80.7 31.9 vegetarian ex 0 pentasa supps prn 
DRH038C 25/05/2012 1 1 
3rd 
long 1.59 81.4 32.2 vegetarian ex 0 pentasa supps prn 
DRH039A 28/11/2011 1 1 1st long 1.6 58.4 22.8 normal never 4 
mercaptopurine 
50mg od 
DRH039B 28/02/2012 1 1 
2nd 
long 1.6 60.2 23.5 normal never 4 
mercaptopurine 
50mg od 
DRH039C 28/06/2012 1 1 
3rd 





DRH039D 09/10/2012 1 1 
4th 
long 1.6 60 23.4 normal never 4 Nil 
DRH039E 17/01/2013 1 1 pre bio 1.6 60 23.4 normal never 4 Nil 
DRH039F 31/01/2013 1 1 post bio 1.6 59 23.0 normal never 4 
adalimumab 160mg 
2 weeks ago 
DRH040A 30/11/2011 1 1 pre surg 1.61 50 19.3 normal never 0 
adalimumab 40mg 
every 2 weeks 
DRH040B 02/03/2012 1 1 
post 
surg 1.61 50.2 19.4 normal never 0 
adalimumab 40mg 
every 2 weeks 
DRH041A 07/12/2011 1 1 1st long 1.74 77 25.4 normal ex 12 
prednisolone 35mg 
od, asacol 2.4g od 
DRH041B 13/03/2012 1 1 
2nd 
long 1.74 76.2 25.2 normal ex 12 
methotrexate 25mg 
weekly 
DRH041C 06/07/2012 1 1 
3rd 
long 1.74 77.4 25.6 normal ex 12 
methotrexate 25mg 
weekly 
DRH041D 25/10/2012 1 1 
4th 
long 1.74 76.6 25.3 normal ex 12 
methotrexate 25mg 
weekly 
DRH042A 12/12/2011 1 1 1st long 1.57 69.7 28.3 normal ex 1 
pentasa 2g bd, 
pentasa supps prn, 
mebeverine 135mg 
prn 
DRH042B 08/03/2012 1 1 
2nd 
long 1.57 70.6 28.6 normal ex 1 
pentasa 2g bd, 
pentasa supps prn, 
mebeverine 135mg 
prn 
DRH042C 08/06/2012 1 1 
3rd 






DRH042D 21/09/2012 1 1 
4th 
long 1.57 69.4 28.2 normal ex 1 
mercaptopurine 
75mg od, infliximab 
400mg every 8 
weeks 
DRH042E 12/12/2012 1 1 pre surg 1.57 70 28.4 normal ex 0 
mercaptopurine 
75mg od, infliximab 
400mg every 8 
weeks 
DRH042F 25/02/2013 1 1 
post 
surg 1.57 70 28.4 normal ex 0   
DRH043A 14/12/2011 1 1 1st long 1.73 73 24.4 normal never 14 
cocyprindiol(ocp), 
pentasa 1g supps as 
req,  
DRH043B 08/05/2012 1 1 
2nd 
long 1.73 72.6 24.3 normal never 14 
cocyprindiol(ocp), 
pentasa 1g supps as 
req,  
DRH043C 23/10/2012 1 1 
3rd 
long 1.73 70.6 23.6 normal never 14 
cocyprindiol(ocp), 
pentasa 1g supps as 
req,  
DRH043D 29/01/2013 1 1 
4th 
long 1.73 73.5 24.6 vegetarian never 14 
cocyprindiol(ocp), 
pentasa 1g supps as 
req, fluconase nasal 
spray + 
antihistamine 
DRH044A 15/12/2011 1 1 
1st 
long, 












300mg given 2 
weeks ago 
DRH045A 05/01/2012 1 1 pre surg 1.63 65 24.5 normal never 0 
mercaptopurine 
75mg / 50mg 
alternating days, 







paracetamol 1g, on 
iv 0.9%NaCl 
DRH045B 02/03/2012 1 1 
post 
surg 1.63 59.8 22.5 normal never 0 
ranitidine 150mg, 
paracetamol 1g 




pre bio 1.49 54.2 24.4 normal current 0   
DRH046B 02/02/2012 1 1 post bio 1.49 53.4 24.1 normal current 0 
prednisolone 20mg 
od, mercaptopurine 
75mg od, infliximab 
400mg 2 weeks ago 
DRH047A 10/01/2012 1 1 1st long 1.64 68.5 25.5 normal never 0 






DRH047B 08/05/2012 1 1 
2nd 
long 1.64 67 24.9 normal never 0 




DRH047C 20/08/2012 1 1 
3rd 
long 1.64 65.4 24.3 normal never 0 




DRH047D 29/11/2012 1 1 
4th 
long 1.64 65 24.2 normal never 0 












1mg 3 monthly, 
adcal d3 2 tabs od, 
diazepam 5mg tds, 
salbutamol inh, 
seretide inh, 
citalopram 40mg od, 
paracetamol 1g prn, 
zolpdem 10mg 
nocte, livial 2mg od. 
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DRH048B 05/04/2012 1 1 
post 








1mg 3 monthly, 
adcal d3 2 tabs od, 
diazepam 5mg tds, 
salbutamol inh, 
seretide inh, 
citalopram 40mg od, 
paracetamol 1g prn, 
zolpdem 10mg 
nocte, livial 2mg od. 
DRH049A 17/01/2012 1 1 pre bio 1.74 67.4 22.3 no red m at ex 2 
budesonide 9mg od, 
salbutamol inh, 
budesonide inh 
DRH049B 31/01/2012 1 1 post bio 1.74 67.7 22.4 no red meat ex 2 




2 weeks ago 
DRH049C 07/12/2012 1 1 pre surg 1.74 52.5 17.3 no red meat ex 0 
infliximab 400mg 8 
weekly, diazepam 






DRH049D 29/01/2013 1 1 
post 





DRH050A 18/01/2012 1 1 pre bio 1.75 88.2 28.8 normal ex 0 
methotrexate 25 mg 
/ week, folic acid 
15mg/wk 
DRH050B 01/02/2012 1 1 post bio 1.75 88 28.7 normal ex 0 
infliximab 400mg 2 
weeks ago, folic acid 
15mg/week 
DRH051A 19/01/2012 1 1 pre surg 1.78 78.3 24.7 normal never 6 
mercaptopurine 
50mg od, 
adalimumab 40mg 2 
weekly, questran 1 
sachet od 
DRH051B 23/03/2012 1 1 
post 
surg 1.78 76.2 24.1 normal never 6 
mercaptopurine 
50mg od, 
adalimumab 40mg 2 
weekly, questran 1 
sachet od 
DRH052A 07/02/2012 1 1 pre surg 1.61 62 23.9 normal never 0 
enoxaparin 40mg, 
sando k 2 tabs 
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DRH052B 02/05/2012 1 1 
post 






DRH053A 29/02/2012 1 1 pre surg 1.59 83.6 33.1 normal never 4 
paracetamol 1g qds, 
gentamicin 24/02/12, 
metronidazole 
21/2/12 - 2/3/12, 






prn, cyclizine 50mg 
prn 
DRH053B 04/04/2012 1 1 
post 
surg 1.59 82 32.4 normal never 4 
adalimumab 160mg 
2 weeks ago 
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DRH054A 29/01/2012 1 1 pre surg 1.62 87 33.2 normal current 0 





200mg iv 20/2/12, 
enoxaparin 40mg, 
paracetamol 1g qds, 
omeprazole 40mg 





tramadol 50mg prn, 
cyclizine 50mg prn, 
buscopan 20mg 
20/2/12 
DRH055A 20/03/2012 1 1 pre surg 1.88 66 18.7 normal ex 0 
mercaptopurine 
75mg od, infliximab 
400mg 8 weekly 
DRH055B 11/05/2012 1 1 
post 
surg 1.88 71.4 20.2 normal ex 0 Nil 




DRH057A 30/03/2012 1 1 pre surg 1.57 47 19.1 normal ex 0 prednisolone 2mg 
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DRH057B 25/05/2012 1 1 
post 
surg 1.57 47.2 19.1 gluten free ex 0 
dapsone 50mg od, 
antihistamine 







2011 - 09/02/2012 
(300mg) 
DRH058B 15/06/2012 1 1 
post 
surg 1.8 71.3 22.0 normal current 0 patient states nil? 
DRH059A 11/05/2012 1 1 
1st 
naïve to 
long 1.61 61.9 23.9 normal current 10 Nil 
DRH059B 26/10/2012 1 0 
2nd 
long 1.61 66.2 25.5 normal current 10 Nil 
DRH060A 23/05/2012 1 1 pre bio 1.68 97 34.4 normal ex 0 
prednisolone 25mg 
od, olsalazine 1g bd, 
omeprazole, predsol 
supps 
DRH060B 07/06/2012 1 1 post bio 1.68 105 37.2 normal ex 0 
infliximab 400mg 2 
weeks ago, 
olsalazine 1g bd, 
omeprazole, predsol 
supps 
DRH063A 06/06/2012 1 1 pre bio 1.62 98 37.3 normal ex 0 pentasa 1g bd 
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DRH063B 20/06/2012 1 1 post bio 1.62 98 37.3 normal ex 0 
infliximab 400mg 2 
weeks ago, pentasa 
1g bd 
DRH066A 27/06/2012 1 1 pre surg 1.91 79 21.7 normal current 20 Nil 
DRH066B 17/09/2012 1 1 
post 
surg 1.91 83 22.8 normal current 20 
omeprazole, 
paracetamol 
DRH067A 28/06/2012 1 1 pre surg 1.76 71 22.9 normal ex 7 
hydrocortisone 








DRH068B 18/07/2012 1 1 post bio 1.64 85 31.6 normal never 0 
prednisolone 10mg, 
mercaptopurine 
75mg od, infliximab 
400mg 2 weeks ago 
DRH071A 17/07/2012 1 1 
1st 
Naïve 
to long 1.66 59.8 21.7 normal never 0 
picolax x 2, 
diclofenac, 
paracetamol 
DRH071B 01/10/2012 1 1 
2nd 





DRH071C 18/01/2013 1 1 
3rd 
long 1.66 59.4 21.6 normal never 0 
mercaptopurine 
50mg od 
DRH072A 19/07/2012 1 1 pre surg 1.61 63.4 24.5 normal ex 0 enoxaparin 40mg 
DRH072B 01/11/2012 1 1 
post 
surg 1.61 61.7 23.8 normal ex 0 Nil 
DRH074A 14/08/2012 1 1 
1st 
naïve to 
long 1.77 105 33.5 normal current 0 
omeprazole 10mg, 
tazocin 




MST 10mg bd 
aspirin ec 75mg ) 
oramorph nifedipine 





diazepam 2mg folic 
acid 5mg GTN spray 
prn sulfasalazine 





DRH075B 27/11/2012 1 1 
post 




MST 10mg bd 
clopidogrel 75mg 
oramorph nifedipine 





diazepam 2mg folic 
acid 5mg GTN spray 
prn sulfasalazine 1g 
bd simvastatin 40mg 
amitriptyline 50mg  






DRH079B 14/09/2012 1 1 
post 






DRH082A 21/08/2012 1 1 pre surg 1.81 85 25.9 normal never 0 
infliximab 400mg 8 
weekly, tacroliomus 
5mg mane, 6mg 
nocte pentasa 2g bd 
enoxaparin 
DRH082B 29/10/2012 1 1 
post 
surg 1.81 86.6 26.4 normal never 10 Nil 
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DRH083A 28/08/2012 1 1 pre bio 1.79 79.3 24.7 normal never 0 
prednisolone 2mg, 
asacol 1.2g bd 
DRH083B 12/09/2012 1 1 post bio 1.79 78 24.3 normal never 0 
prednisolone 2mg, 
asacol 1.2g bd, 
adalimumab 160mg 
2 weeks ago 





od ompreazole 20mg 









od ompreazole 20mg 




infliximab 400mg 2 
weeks ago 
DRH085A 21/09/2012 1 1 pre surg 1.52 61.6 26.7 normal current 10 
azathioprine 125mg 
od 
DRH085B 17/01/2013 1 1 
post 





DRH086A 31/10/2012 1 1 
1st 
naïve to 





vit K 10mg iv 
DRH086B 12/02/2013 1 1 
2nd 





DRH090A 06/11/2012 1 1 
1st 
naïve to 
long 1.78 68 21.5 low residue diet never 2 Paracetamol 
DRH090B 19/01/2013 1 1 
2nd 




DRH091A 14/11/2012 1 1 pre bio 1.63 76.2 28.7 no red m at never 0 Nil 
DRH091B 28/11/2012 1 1 post bio 1.63 72 27.1 no red m at never 0 
infliximab 400mg 2 
weeks ago 
DRH096A 30/11/2012 1 1 pre surg 1.7 102.9 35.6 vegetarian ex 0 
azathioprine 200mg 





DRH096B 01/02/2013 1 1 
post 











preload 18:00 + 
22:00 10/12/12 
DRH097B 01/02/2013 1 1 
post 
surg 1.73 81.7 27.3 normal ex 0 vitamin tablets 
DRH098A 12/12/2012 1 1 pre bio 1.66 95 34.5 normal never 0 









prn, codeine 30mg 
prn, xyloprost 5% 
topical prep bd, 
paracetamol 1g qds, 
tramadol 100mg prn, 
iv hydrocortisone 




DRH098B 04/01/2013 1 1 
post 
bio, pre 
surg 1.66 92 33.4 normal never 0 
preload 18:00 + 
22:00, enoxaparin 








DRH098C 25/02/2013 1 1 
post 






codamol 30/500 prn 
DRH099A 20/04/2012 1 1 pre surg 1.59 79 31.2 normal never 0 Nil 
DRH099B 04/09/2012 1 1 
post 
surg 1.59 68.9 27.3 normal never 0 
warfarin, infliximab 








22:00, 10mg pred 
od, 50 mg aza bd, 
folic acid 5mg od, 
adcal d3 1.5g tds, 
pentasa 500mg tds, 
ascorbic acid 100mg 
od, codeine phos 




DRH102B 01/02/2013 1 1 
post 
surg 1.62 61.7 23.5 normal ex 0 





DRH104A 16/01/2013 1 1 pre bio 1.6 99 38.7 normal never 5 
mercaptopurine 
100mg od 
DRH104B 29/01/2013 1 1 post bio 1.6 97 37.9 normal never 5 
mercaptopurine 
100mg od, 
infliximab 500mg 2 
weeks ago  
DRH105A 16/01/2013 1 1 pre bio 1.73 76 25.4 normal ex 0 
prednisolone 10mg 
od 
DRH105B 30/01/2013 1 1 post bio 1.73 76 25.4 normal ex 0 
infliximab 400mg 2 
weeks ago 





DRH106B 31/01/2013 1 1 post bio 1.78 62 19.6 low residue diet never 10 
azathioprine 150mg 
od, infliximab 
400mg 2 weeks ago 
DRH200A 23/01/2013 1 1 pre surg 1.77 76.2 24.3 normal ex 4 
mercaptopurine 
75mg od, 
paracetamol 1g qds, 
dihydrocodeine 
30mg qds, oramorph 
10mg at 23:00 
22/1/13 
DRH200B 25/02/2013 1 1 
post 















nodosum uveitis paris sccai 
DRH001A 1 0 nil trace v well n n n n e2+ 1 
DRH001B 2 0 hurry nil poor n n n n e2+ 3 
DRH001C 2 1 hurry usually frank poor n n n n e2+ 7 
DRH001D 2 0 hurry occasionally frank slightly below par n n n n e2+ 4 
DRH001E 3 0 hurry occasionally frank poor n n n n e2+ 5 
DRH001F 3 0 hurry usually frank poor n n n n e2+ 6 
DRH001G stoma stoma stoma nil slightly below par n n n n n/a n/a (1) 
DRH002A 2 0 nil nil poor n n n n e4 2 
DRH002B 1 0 nil nil slightly below par n n n n e4 1 
DRH002C 1 0 nil nil poor n n n n e4 2 
DRH002D 3 0 nil nil slightly below par y n n n e4 2 
DRH003A 2 0 hurry nil slightly below par n n n n e4 2 
DRH003B 2 0 nil nil slightly below par n n n n e4 1 
DRH003C 1 0 nil nil v well n n n n e4 0 
DRH003D 1 0 nil nil v well n n n n e4 0 
DRH004A 3 0 nil nil slightly below par n n n n e2+ 1 
DRH004B 8 0 hurry occasionally frank slightly below par n n n n e2+ 6 
DRH004C 1 0 nil nil v well n n n n e2+ 0 
DRH005A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH005B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH006A 6 1 hurry occasionally frank poor y n n n e2 8 
DRH006B 2 0 nil n poor y n n n e2 3 
DRH006C 3 0 hurry n poor y n n n e2 4 
DRH006D 6 1 hurry n poor y n n n e4 6 
DRH007A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH007B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH007C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH007D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH008A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH008BS n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH008BU n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH008C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH008D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH009A 1 0 nil nil slightly below par n n n n e2 1 
DRH009B 1 0 nil nil v well n n n n e2 0 
DRH009C 1 0 nil nil slightly below par n n n n e2 1 
DRH009D 1 0 nil nil v well n n n n e2 0 
DRH010A 3 0 nil nil poor n n n n e2 2 
DRH010B 2 1 hurry occasionally frank poor n n n n e2 6 
DRH010C 1 0 nil occasionally frank slightly below par n n n n e2 3 
DRH010D 3 0 hurry occasionally frank slightly below par n n n n e2 4 
DRH011A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH011B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH011C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH011D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH012A 15 0 incontinent occasionally frank poor n n n n e2 10 
DRH012B 10 0 incontinent usually frank terrible n n n n e2 13 
DRH012C 2 0 hurry usually frank v poor n n n n e2 7 
DRH012D 1 0 nil nil slightly below par n n n n e2 1 
DRH013A 1 0 nil nil very well n n n n e1 0 
DRH013B 1 0 nil trace slightly below par n n n n e1 2 
DRH013C 1 0 nil trace slightly below par n n n n e1 2 
DRH013D 1 0 nil trace very well n n n n e1 1 
DRH014A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH014B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH014C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH014D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH014E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH015A 4 1 immediately nil poor n n n n e2 6 
DRH015B 3 0 hurry nil slightly below par n n n n e2 2 
DRH015C 4 0 hurry nil poor n n n n e2 4 
DRH015D 4 0 hurry nil poor n n n n e2 4 
DRH016A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH016B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH016C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH016D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH017A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH017B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH017C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH017D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH017E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH018A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH018B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH018C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH018D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH018E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH019A 6 1 incontinent nil poor n n n n e4 7 
DRH019B stoma stoma stoma nil slightly below par n n n n n/a 1 
DRH020A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH020B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH020C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH020D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH021A 2 3 hurry usually frank poor n n n n e2 7 
DRH021B 1 0 nil occasionally frank poor n n n n e2 4 
DRH022A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH022B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH022C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH022D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH023A 4 2 hurry nil slightly below par n n n n e2+ 4 
DRH023B                       
DRH024A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH024B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH024C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH024D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH024E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH025A 2 0 hurry nil slightly below par n n n n e2+ 2 
DRH025B 3 0 hurry occasionally frank slightly below par n n n n e4 4 
DRH025C 2 0 hurry occasionally frank slightly below par n n n n e4 4 
DRH025D 4 0 hurry usually frank poor n n n n e4 7 
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DRH025E 6 1 immediately usually frank very poor n n n n e4 10 
DRH026A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH026B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH026C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH026E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH027A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH027B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH027C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH027D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH028A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH028B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH029A 1 0 nil nil very well n n n n e4 0 
DRH029B 1 0 nil nil slightly below par n n n n e4 1 
DRH029C 6 0 hurry usually frank poor n n n n e4 7 
DRH029D 1 0 nil nil very well n n n n e4 0 
DRH030A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH030B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH030C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH030D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH031A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH031B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH031C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH031D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH031E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH032A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH032B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH032C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH033A 1 0 nil nil very well n n n n e2 0 
DRH033B 1 0 nil trace slightly below par n n n n e2 2 
DRH033C 1 0 nil nil poor n n n n e2 2 
DRH033D 0 0 nil nil slightly below par n n n n e2 1 
DRH034A 1 0 nil nil very well n n n n e2 0 
DRH034B 1 0 nil nil slightly below par n n n n e2 1 
DRH034C 1 0 nil nil very well n n n n e2 0 
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DRH034D 1 0 nil nil very well n n n n e2 0 
DRH035A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH035B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH035C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH035D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH036A 1 0 nil nil very well y n n n e1 1 
DRH036B 1 0 nil nil very well n n n n e1 0 
DRH036C 1 0 nil nil very well n n n n e1 0 
DRH036D 1 0 nil nil very well n n n n e1 0 
DRH037A 2 0 nil nil very well n n n n e4 0 
DRH037B 1 0 nil nil slightly below par n n n n e4 1 
DRH037C 1 0 nil nil very well n n n n e4 0 
DRH037D 1 0 nil nil very well n n n n e4 0 
DRH038A 2 0 nil nil slightly below par n n n n e1 1 
DRH038B 1 0 nil nil very well n n n n e1 0 
DRH038C 2 0 nil nil very well n n n n e1 0 
DRH039A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH039B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH039C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH039D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH039E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH039F n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH040A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH040B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH041A 1 0 nil nil slightly below par n n n n e2 1 
DRH041B 1 0 nil nil very well n n n n e2 0 
DRH041C 1 0 nil nil very well n n n n e2 0 
DRH041D 1 0 nil nil very well n n n n e2 0 
DRH042A 2 0 nil trace slightly below par n n n n e2 2 
DRH042B 7 4 immediately occasionally frank poor y n n n e2 11 
DRH042C 2 0 nil nil slightly below par n n n n e2 1 
DRH042D 8 1 immediately occasionally frank poor y n n n e2 10 
DRH042E 10 5 immediately trace poor n n n n e2 10 
DRH042F stoma stoma stoma nil very well n n n n n/a 0(stoma) 
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DRH043A 1 0 nil nil slightly below par n n n n e1 1 
DRH043B 1 0 nil nil very well n n n n e1 0 
DRH043C 1 0 hurry trace slightly below par n n n n e1 3 
DRH043D 1 4 nil usually frank slightly below par n n n n e1 4 
DRH044A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH044B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH045A 20 2 immediately trace terrible n n n n e4 11 
DRH045B stoma stoma stoma nil slightly below par n n n n n/a 1(stoma) 
DRH046A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH046B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH047A 1 0 nil nil slightly below par n n n n e4 1 
DRH047B 1 0 nil nil very well n n n n e4 0 
DRH047C 2 0 nil nil very well n n n n e4 0 
DRH047D 1 0 nil nil slightly below par n n n n e4 1 
DRH048A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH048B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH049A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH049B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH049C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH049D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH050A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH050B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH051A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH051B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH052A stoma stoma stoma nil very well n n n n n/a 0(stoma) 
DRH052B stoma stoma stoma nil slightly below par n n n n n/a 1(stoma) 
DRH053A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH053B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH054A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH055A 20 1 immediately occasionally frank terrible n n n n e4 12 
DRH055B stoma stoma stoma nil slightly below par n n n n n/a 1(stoma) 
DRH056A stoma stoma stoma nil very well n n n n n/a 0(stoma) 
DRH057A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH057B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH058A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH058B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH059A 3 2 immediately usually frank terrible n n n n e2+ 10 
DRH059B 6 0 hurry nil slightly below par n n n n e2+ 3 
DRH060A 8 0 hurry occasionally frank poor n n n n e1 7 
DRH060B 4 0 nil occasionally frank slightly below par n n n n e1 4 
DRH063A 5 0 immediately occasionally frank poor n n n n e4 7 
DRH063B 3 0 hurry nil slightly below par n n n n e4 2 
DRH066A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH066B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH067A 20 2 immediately usually frank very poor n n n n e4 12 
DRH068A 20 5 hurry occasionally frank very poor n n n n e4 11 
DRH068B 6 0 hurry nil slightly below par n n n n e4 3 
DRH071A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH071B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH071C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH072A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH072B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH074A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH075A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH075B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH079A stoma stoma stoma nil poor n n n n n/a 2(stoma) 
DRH079B stoma stoma stoma nil very well n n n n n/a 0(stoma) 
DRH082A 20 2 immediately usually frank very poor n n n n e2 12 
DRH082B stoma stoma stoma nil very well n n n n n/a 0(stoma) 
DRH083A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH083B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH084A 3 0 hurry trace poor n n n n e3 4 
DRH084B 2 0 hurry nil slightly below par n n n n e3 2 
DRH085A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH085B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH086A 10 5 immediately usually frank terrible n n n n e2+ 14 
DRH086B 10 2 immediately occasionally frank very poor n n n n e2+ 11 
DRH090A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH090B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH091A 8 2 hurry usually frank very poor y n n n e3 11 
DRH091B 3 0 hurry trace slightly below par y n n n e3 4 
DRH096A 10 10 immediately usually frank terrible y n n n e2 15 
DRH096B stoma stoma stoma nil poor n n n n n/a 2(stoma) 
DRH097A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH097B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH098A 15 5 incontinent usually frank very poor n n n n e2+ 14 
DRH098B 10 5 hurry occasionally frank very poor y n n n e2+ 12 
DRH098C stoma stoma stoma nil slightly below par n n n n n/a 1(stoma) 
DRH099A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH099B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH102A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH102B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH104A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH104B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH105A 6 0 hurry trace slightly below par n n n n e2 4 
DRH105B 2 0 hurry nil slightly below par n n n n e2 2 
DRH106A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH106B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH200A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 






























DRH001A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH001B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH001C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH001D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH001E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH001F n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH001G n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH002A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH002B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH002C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH002D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH003A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH003B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH003C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH003D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH004A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH004B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 





e 15 nil n n n n n n n 18 
DRH005B poor mild 10 nil n n n n n n n 13 
DRH006A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH006B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH006C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH006D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH007A poor 
moderat
e 1 nil n n n n n n y 6 
DRH007B 
slightly below 
par mild 3 nil y n n n n n n 6 
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DRH007C terrible severe 0 nil n n n n n n n 7 
DRH007D poor 
moderat
e 1 nil n n n n n n y 6 
DRH008A very poor mild 5 nil n n n n n n n 9 
DRH008B
S v well none 0 nil n n n n n n n 0 
DRH008B
U v well none 0 nil n n n n n n n 0 
DRH008C 
slightly below 
par none 2 nil n n n n n n n 3 
DRH008D v well none 1 nil n n n n n n n 1 
DRH009A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH009B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH009C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH009D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH010A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH010B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH010C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH010D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH011A 
slightly below 
par mild 2 nil n n n n n n n 4 
DRH011B 
slightly below 
par mild 8 nil n n n n n n n 10 
DRH011C poor mild 0 nil n n n n n n n 3 
DRH011D poor none 1 nil n n n n n n n 3 
DRH012A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH012B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH012C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH012D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH013A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH013B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH013C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH013D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 






par none 4 nil n n n n n n n 5 
DRH014C very poor mild 8 nil n n n n n n n 12 
DRH014D poor none 5 nil n n n n n n n 7 
DRH014E very poor 
moderat
e 6 nil n n n n n n n 11 
DRH015A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH015B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH015C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH015D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH016A very well none 2 nil y n n n n n n 3 
DRH016B 
slightly below 
par none 3 nil n n n n n n n 4 
DRH016C poor none 1 nil n n n n n n n 3 





e 1 nil n n n n n n n 4 
DRH017B very well none 0 nil n n n n n n n 0 
DRH017C very well none 0 nil n n n n n n n 0 
DRH017D very well none 0 nil n n n n n n n 0 
DRH017E very well none 0 nil n n n n n n n 0 
DRH018A very poor severe 1 nil n n n n n n n 7 
DRH018B poor mild 0 nil n n n n n n n 3 
DRH018C terrible mild 1 nil n n n n n n n 6 
DRH018D poor 
moderat
e 0 nil n n n n n n n 4 
DRH018E terrible severe 0 nil n n n n n n n 7 
DRH019A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH019B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH020A 
slightly below 





par none stoma nil n n n n n n n 1(stoma) 
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DRH020C very well none stoma nil n n n n n n n 0(stoma) 
DRH020D very well none stoma nil n n n n n n n 0(stoma) 
DRH021A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH021B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH022A 
slightly below 
par mild 4 nil y n n n n n n 7 
DRH022B poor mild 6 nil y n n n n n n 10 
DRH022C 
slightly below 
par mild 2 nil n n n n n n n 4 
DRH022D poor 
moderat
e 0 nil n n n n n n n 4 
DRH023A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH023B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH024A poor 
moderat
e 4 nil y n n n n n n 9 
DRH024B 
slightly below 
par none 4 nil n n n n n n n 5 
DRH024C 
slightly below 
par none 2 nil n n n n n n n 5 
DRH024D very well none 2 nil n n n n n n n 5 
DRH024E very well none 1 nil n n n n n n n 5 
DRH025A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH025B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH025C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH025D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH025E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH026A very well mild 7 nil n n n n n n n 8 
DRH026B 
slightly below 





e 0 nil n n n n n n n 3 
DRH026E poor 
moderat
e 6 nil y n n n n n n 11 










e 0 nil n n n n n n n 3 
DRH027D very poor 
moderat
e 10 nil y n n n n n n 16 
DRH028A very poor 
moderat
e stoma nil n n n n n n n 5(stoma) 
DRH028B 
slightly below 
par none stoma nil n n n n n n n 1(stoma) 
DRH029A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH029B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH029C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH029D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH030A very well mild 5 nil y n n n n n n 7 
DRH030B 
slightly below 
par none 6 nil n n n n n n n 7 
DRH030C very well none 0 nil n n n n n n n 0 
DRH030D very well none 2 nil n n n n n n n 2 
DRH031A 
slightly below 
par mild 6 nil n n n n n n n 8 
DRH031B 
slightly below 
par mild 2 nil n n n n n n n 4 
DRH031C poor mild 12 nil n n n n n n n 15 
DRH031D poor 
moderat
e 4 nil n n n n n n n 8 
DRH031E 
slightly below 
par mild 4 nil n n n n n n n 6 
DRH032A 
slightly below 
par none 0 nil n n n n n n n 1 
DRH032B poor none 0 nil n n n n n n n 2 
DRH032C very well none 0 nil n n n n n n n 0 
DRH033A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH033B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH033C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH033D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH034A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH034B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH034C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH034D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH035A 
slightly below 
par mild 2 nil y n n n n n n 5 
DRH035B 
slightly below 
par mild 3 nil n n n n n n n 5 
DRH035C very well  none 2 nil n n n n n n n 2 
DRH035D very well none 1 nil n n n n n n n 1 
DRH036A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH036B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH036C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH036D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH037A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH037B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH037C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH037D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH038A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH038B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH038C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH039A 
slightly below 
par none 2 nil y n n n n n n 4 
DRH039B 
slightly below 
par mild 2 nil n n n n n n n 4 
DRH039C poor mild 4 nil n n n n n n n 7 
DRH039D poor mild 4 nil y n n n n n n 8 
DRH039E poor 
moderat
e 2 nil n n n n n n n 6 
DRH039F 
slightly below 
par mild 2 nil n n n n n n n 4 






par mild stoma nil n n n n n n n 2(stoma) 
DRH041A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH041B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH041C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH041D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH042A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH042B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH042C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH042D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH042E n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH042F n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH043A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH043B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH043C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH043D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH044A terrible severe 2 dubious y n n n n n n 11 
DRH044B terrible 
moderat
e 0 nil n n n n n n n 6 
DRH045A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH045B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH046A terrible severe 20 nil n n n n n n n 27 
DRH046B very poor mild 4 nil n n n n n n n 8 
DRH047A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH047B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH047C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH047D n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH048A terrible severe 3 nil n n n n n n n 10 
DRH048B terrible 
moderat
e 0 nil n n n n n n n 6 
DRH049A terrible 
moderat
e 6 nil n n n n n n n 12 




DRH049C terrible mild 2 dubious n n n n n n n 8 
DRH049D terrible severe 2 nil n n n n n n n 9 
DRH050A poor none 2 nil n n n n n n n 4 
DRH050B 
slightly below 





e 0 nil n n n n n n n 3 
DRH051B 
slightly below 
par none 0 nil n n n n n n n 1 
DRH052A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH052B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH053A terrible none 0 nil n n n n n y y 6 
DRH053B very well none stoma nil n n n n n n n 0(stoma) 
DRH054A terrible severe 0 nil n n n n n n n 7 
DRH055A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH055B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH056A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH057A terrible severe 0 nil n n n n n n n 7 
DRH057B 
slightly below 
par none 10 nil n n n n n n n 11 
DRH058A very poor 
moderat
e 10 nil n y n n n n n 16 
DRH058B poor none stoma nil n n n n n n n 2(stoma) 
DRH059A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH059B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH060A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH060B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH063A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH063B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH066A very poor severe stoma dubious n n n n n n n 7(stoma) 
DRH066B very well none stoma nil n n n n n n n 0(stoma) 
DRH067A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH068A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH068B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH071A poor 
moderat
e 6 nil y n y n n n n 12 
DRH071B very poor 
moderat
e 4 nil n n n n n n n 9 
DRH071C very poor severe 8 nil n n n y n n n 15 
DRH072A very poor 
moderat
e 7 
tender and definate 
mass n n n n n n n 15 
DRH072B poor none 10 nil y n n n n n n 13 
DRH074A very poor severe 5 dubious y n n n n n n 13 
DRH075A terrible severe 0 nil n n n n n n n 7 
DRH075B poor 
moderat
e 10 nil n n n n n n n 14 
DRH079A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH079B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH082A                         
DRH082B                         
DRH083A poor 
moderat
e 2 nil y n n n n n n 7 
DRH083B 
slightly below 
par mild 2 nil n n n n n n n 4 
DRH084A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH084B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH085A poor 
moderat
e 2 nil y n n n n y n 8 
DRH085B very well none 1 nil n n n n n n n 1 
DRH086A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH086B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH090A very poor 
moderat
e 4 dubious n n n n n n n 10 
DRH090B 
slightly below 
par mild 3 nil n n n n n n n 5 
DRH091A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH091B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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DRH096A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH096B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH097A poor 
moderat
e 5 nil y n n n n n n 10 
DRH097B very well none stoma nil n n n n n n n 0(stoma) 
DRH098A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH098B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH098C n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH099A very poor 
moderat
e 10 nil n n n n n n n 15 
DRH099B 
slightly below 
par none stoma nil n n n n n n n 1(stoma) 
DRH102A poor 
moderat
e 2 nil n n n n n n n 6 
DRH102B poor 
moderat
e 0 nil n n n n n n n 4 
DRH104A poor 
moderat
e 4 nil n n n n n n n 8 
DRH104B very well none 0 nil n n n n n n n 0 
DRH105A n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH105B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
DRH106A poor 
moderat
e 3 nil n n n n n n n 7 
DRH106B poor mild 2 nil n n n n n n n 5 
DRH200A very poor severe 8 dubious n n n n n n n 15 
DRH200B poor 
moderat











(in study) reason for surgery 
DRH001
A n/a n/a n/a   
Perianal haematoma 
1990, rubber band 
ligation of haemorrhoids 
1990, mastectomy for 
gynaecomastia prior to 
1996 
19/06/2
012 colectomy chronic colitis 
DRH001
B n/a n/a n/a           
DRH001
C n/a n/a n/a           
DRH001
D n/a n/a n/a           
DRH001
E n/a n/a n/a           
DRH001
F n/a n/a n/a           
DRH001
G n/a n/a n/a           
DRH002
A n/a n/a n/a hypothyroid, fatigue 
tonsillectomy, c-section 
x 2, sterilistaion 
DRH002
B n/a n/a n/a hypothyroid, fatigue         
DRH002
C n/a n/a n/a hypothyroid, fatigue         
DRH002
D n/a n/a n/a hypothyroid, fatigue         
DRH003
A n/a n/a n/a   inguinal hernia aged 5 





C n/a n/a n/a           
DRH003
D n/a n/a n/a           
DRH004
A n/a n/a n/a   
3 x gynae laparoscopy 
for endometriosis 
DRH004
B n/a n/a n/a           
DRH004
C n/a n/a n/a           
DRH005
A L3 B1 A2   
right hemicolectomy for 
crohns 2006 
DRH005
B L3 B1 A2           
DRH006
A n/a n/a n/a           
DRH006
B n/a n/a n/a           
DRH006
C n/a n/a n/a           
DRH006
D n/a n/a n/a           
DRH007
A L3 B2p A2   
right hemicolectomy 
2003 for iatrogenic perf 
during stricture 
dilatation, open chole 
2003, i&d perianal 
abscess 2005, eua & 
fistulotomy 2007, EUA 
and i&d ischiorectal 
abscess 27/3/12 
DRH007
B L3 B2p A2           





D L3 B2p A2           
DRH008






BS L2  B1 A2           
DRH008
BU L2  B1 A2           
DRH008
C L2 B1p A2           
DRH008
D L2 B1p A2           
DRH009
A n/a n/a n/a           
DRH009
B n/a n/a n/a           
DRH009
C n/a n/a n/a           
DRH009
D n/a n/a n/a           
DRH010
A n/a n/a n/a   
lap chole 2010 
cholelithiasis       
DRH010
B n/a n/a n/a           
DRH010
C n/a n/a n/a           
DRH010
D n/a n/a n/a           
DRH011
A L2 B1 A2           
DRH011
B L2 B1 A2           





D L2 B1 A2           
DRH012
A n/a n/a n/a           
DRH012
B n/a n/a n/a           
DRH012
C n/a n/a n/a           
DRH012
D n/a n/a n/a           
DRH013
A n/a n/a n/a hypothyroid, vit B def         
DRH013
B n/a n/a n/a hypothyroid, vit B def         
DRH013
C n/a n/a n/a hypothyroid, vit B def         
DRH013
D n/a n/a n/a hypothyroid, vit B def         
DRH014
A L2 B1p A3   
20/9/2011 EUA, excision 
of fistula tract, insertion 
of seton suture       
DRH014
B L2 B1p A3   
20/9/2011 EUA, excision 
of fistula tract, insertion 
of seton suture       
DRH014
C L2 B1p A3   
20/9/2011 EUA, excision 
of fistula tract, insertion 
of seton suture       
DRH014
D L2 B1p A3   
20/9/2011 EUA, excision 
of fistula tract, insertion 
of seton suture       
DRH014
E L2 B1p A3   
20/9/2011 EUA, excision 
of fistula tract, insertion 
of seton suture       





B n/a n/a n/a   
Vaginal hysterectomy 
1998       
DRH015
C n/a n/a n/a   
Vaginal hysterectomy 
1999       
DRH015
D n/a n/a n/a   
Vaginal hysterectomy 
2000       
DRH016
A L1 B1 A3           
DRH016
B L1 B1 A3           
DRH016
C L1 B1 A3           
DRH016
D L1 B1 A3           
DRH017
A L1+4 B2 A2           
DRH017
B L1+4 B2 A2           
DRH017
C L1+4 B2 A2           
DRH017
D L1+4 B2 A2           
DRH017
E L1+4 B2 A2           
DRH018
A L2+4 B2 A2   
 appendicectomy 2005. 
gastrojejunostomy 
1/11/11  6/9/12 
small bowel 
resection for 4 
strictures   
DRH018
B L2+4 B2 A2         
DRH018
C L2+4 B2 A2         
DRH018




E L2+4 B2 A2         
DRH019
A n/a n/a n/a     
12/10/1
1 
 lap to open 
panproctocole
ctomy 
 chronic continuous 
disease 
DRH019
B n/a n/a n/a         
DRH020
A L2+4 B2p A2   





negative pressure therapy 
1/1/2009     
DRH020
B L2+4 B2p A2         
DRH020
C L2+4 B2p A2           
DRH020
D L2+4 B2p A2           
DRH021
A n/a n/a n/a           
DRH021
B n/a n/a n/a           
DRH022
A L3 B1 A2   
 Right hemicolectomy 
2007       
DRH022
B L3 B1 A2         
DRH022
C L3 B1 A2         
DRH022
D L3 B1 A2         
DRH023
A n/a n/a n/a     
26/10/1
1  colectomy  Acute disease 





A L2 B1 A2           
DRH024
B L2 B1 A2           
DRH024
C L2 B1 A2           
DRH024
D L2 B1 A2           
DRH024
E L2 B1 A2           
DRH025
A n/a n/a n/a           
DRH025
B n/a n/a n/a           
DRH025
C n/a n/a n/a           
DRH025
D n/a n/a n/a           
DRH025
E n/a n/a n/a           
DRH026
A L3 B1 A3    appendicectomy 1975       
DRH026
B L3 B1 A3           
DRH026
C L3 B1 A3           
DRH026
E L3 B1 A3         
DRH027
A L3 B1 A2           
DRH027
B L3 B1 A2           





D L3 B1 A2           
DRH028
A L2 B2 A2   
 Laparoscopic loop 
colostomy 30/11/10  7/11/11 
panproctocole
ctomy   Chronic disease 
DRH028
B L2 B2 A2           
DRH029
A n/a n/a n/a           
DRH029
B n/a n/a n/a           
DRH029
C n/a n/a n/a           
DRH029
D n/a n/a n/a           
DRH030
A L2 B1 A3           
DRH030
B L2 B1 A3           
DRH030
C L2 B1 A3           
DRH030
D L2 B1 A3           
DRH031
A L2 B1 A3           
DRH031
B L2 B1 A3           
DRH031
C L2 B1 A3           
DRH031
D L2 B1 A3           
DRH031
E L2 B1 A3           
DRH032 L2 B1 A3 cervical cancer  hysterectomy 1997,     
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A excision of cervix and 
pelvic lymphadenectomy 
for cervical ca 2010, 
laparoscopic incisional 
hernia repair 24/8/2011 
DRH032
B L2 B1 A3       
DRH032
C L2 B1 A3       
DRH033
A n/a n/a n/a           
DRH033
B n/a n/a n/a           
DRH033
C n/a n/a n/a           
DRH033
D n/a n/a n/a           
DRH034
A n/a n/a n/a           
DRH034
B n/a n/a n/a           
DRH034
C n/a n/a n/a           
DRH034
D n/a n/a n/a           
DRH035
A L2 B2p A2   
 appendicectomy 1970, 
perianal procedure 1981     
DRH035
B L2 B2p A2         
DRH035
C L2 B2p A2         
DRH035
D L2 B2p A2         
DRH036




B n/a n/a n/a           
DRH036
C n/a n/a n/a           
DRH036
D n/a n/a n/a           
DRH037
A n/a n/a n/a           
DRH037
B n/a n/a n/a           
DRH037
C n/a n/a n/a           
DRH037
D n/a n/a n/a           
DRH038
A n/a n/a n/a           
DRH038
B n/a n/a n/a           
DRH038
C n/a n/a n/a           
DRH039
A L2 B1 A2   
 right hemicolectomy 
1983, Total Abdominal 
Hysterectomy for 
fibroids 9/8/7     
DRH039
B L2 B1 A2           
DRH039
C L2 B1 A2           
DRH039
D L2 B1 A2           
DRH039
E L2 B1 A2           
DRH039
F L2 B1 A2           





B L3 B2 A1   
 panproctocolectomy 





resection  stricture 
DRH041
A n/a n/a n/a           
DRH041
B n/a n/a n/a           
DRH041
C n/a n/a n/a           
DRH041
D n/a n/a n/a           
DRH042
A n/a n/a n/a           
DRH042
B n/a n/a n/a           
DRH042
C n/a n/a n/a           
DRH042
D n/a n/a n/a           
DRH042
E n/a n/a n/a           
DRH042
F n/a n/a n/a     
12/12/1
2   colectomy 
 continuous chronic 
disease 
DRH043
A n/a n/a n/a 
CIN III, dislocated shoulder, UTIs 
/ pyelonephritis, erythema 
nodosum 07/10 
 arthroscopy right 
shoulder 2008, STOP 
2001     
DRH043
B n/a n/a n/a       
DRH043
C n/a n/a n/a       
DRH043
D n/a n/a n/a       
DRH044
A L2+4 B2 A2   
 small bowel resection 




B L2+4 B2 A2         
DRH045
A n/a n/a n/a     5/1/12  colectomy 
 acute on chronic 
disease 
DRH045
B n/a n/a n/a         
DRH046
A L2 B1 A2           
DRH046
B L2 B1 A2           
DRH047
A n/a n/a n/a  hypertension       
DRH047
B n/a n/a n/a         
DRH047
C n/a n/a n/a         
DRH047
D n/a n/a n/a         
DRH048
A L1 B2 A2  asthma, depression 
small bowel resection 
1/1/2, small bowe 
resection 1/1/4, small 
bowel resection 1/1/6, 
division of adhesions 




resection  strictures 
DRH048
B L1 B2 A2   .     
DRH049
A L1 B1 A2           
DRH049
B L1 B1 A2   
  laparoptomy 7/12/12 
looked like small bowel 
lymphoma  29/1/13 
. Laparotomy 
- excision of 
SB mass - 
path showed 
crohns  Abdo mass 
DRH049




D L1 B1 A2         
DRH050
A L2 B1 A2           
DRH050
B L2 B1 A2           
DRH051
A L3 B2p A2    right hemi 1/3/09 19/1/12 
 Anal 
dilatation   
DRH051
B L3 B2p A2         
DRH052
A n/a n/a n/a   
 colectomy 19/5/11 for 




of IPAA   
DRH052
B n/a n/a n/a         
DRH053
A L1 B1p A1   
 EUA 21/2/12, EUA and 
I&D horseshoe abscess 
22/2/12, insertion of 
seton suture 7/3/12 29/2/12 






 Perianal Crohn’s with 
sepsis 
DRH053
B L1 B1p A1         
DRH054
A L2 B2 A3    lap sterilisation 1995 29/2/12  
 right 
hemicolectom
y  obstructive symptoms 
DRH055
A n/a n/a n/a     20/3/12  colectomy  severe disease 
DRH055
B n/a n/a n/a         
DRH056
A n/a n/a n/a   
 colectomy for chronic 
severe disease 13/4/10 28/3/12 
 completion 
proctectomy  elective 
DRH057
A L1 B2p A2   
 right hemicolectomy 
1/1/2000, perianal 30/3/12 
 small bowel 
resection   strictures 
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abscess with fistula 
1/1/01, 
DRH057
B L1 B2p A2         
DRH058
A L2 B1 A3     30/3/12  colectomy  Chronic disease 
DRH058
B L2 B1 A3         
DRH059
A n/a n/a n/a           
DRH059
B n/a n/a n/a           
DRH060
A n/a n/a n/a           
DRH060
B n/a n/a n/a           
DRH063
A n/a n/a n/a           
DRH063
B n/a n/a n/a           
DRH066




 for CD fistulating 
into sigmoid 
DRH066
B L3 B3 A2         
DRH067
A n/a n/a n/a    28/6/12  colectomy severe disease  
DRH068
A n/a n/a n/a 
 Cardiac defect repair as 
a child       
DRH068
B n/a n/a n/a         
DRH071
A L3 B1 A2           
DRH071




C L3 B1 A2           
DRH072
A L3 B3 A2           
DRH072
B L3 B3 A2           
DRH074
A L1 B3 A3           
DRH075
A L3 B1 A3           
DRH075
B L3 B1 A3           
DRH079
A n/a n/a n/a 
asthma, dmII, hypothyroid, 
fibroids, parastomal / incisional 
herniae, fibromylagia colectomy 1/1/5   2/7/12 
 completion 
proctectomy  elective 
DRH079
B n/a n/a n/a       
DRH082
A          21/8/12  colectomy  severe disease 
DRH082
B               
DRH083
A L2 B1 A3           
DRH083
B L2 B1 A3           
DRH084
A n/a n/a n/a           
DRH084
B n/a n/a n/a           
DRH085




cystectomy  enterovesical fistula 
DRH085




A n/a n/a n/a           
DRH086
B n/a n/a n/a           
DRH090
A L3 B2 A2   
 appendicectomy 1/1/98 - 
? Crohns seen at terminal 
ileum at time of op but 
no treatment started       
DRH090
B L3 B2 A2         
DRH091
A n/a n/a n/a           
DRH091
B n/a n/a n/a           
DRH096
A n/a n/a n/a   
 30/11/1
2  colectomy  severe disease 
DRH096
B n/a n/a n/a         
DRH097
A L3 B1 A2   
right hemicolectomy 





proctectomy  elective 
DRH097
B L3 B1 A2         
DRH098
A n/a n/a n/a       4/1/13  colectomy  severe disease 
DRH098
B n/a n/a n/a       
DRH098
C n/a n/a n/a         
DRH099
A L3 B3 A2   
 right colonic resection 
1/1/93, sigmoid 




and repair of 3 
small bowel 





colon but SB 




B L4 B4 A3         
DRH102
A L1 B2 A3   
 13/12/1
2 
 small bowel 
resection for 
strictures   
DRH102
B L1 B2 A3         
DRH104
A L2 B1 A1           
DRH104
B L2 B1 A1           
DRH105
A n/a n/a n/a           
DRH105
B n/a n/a n/a           
DRH106
A L1 B2 A2   
right hemicolectomy 
1/1/5       
DRH106
B L1 B2 A2         
DRH200
A L1 B2 A2    23/1/13 
 ileo-caecal 
resection (lap 
assisted)  stricture 
DRH200




8.2.2 cont…  
Label  FHx Notes  Date of death  
DRH001A       
DRH001B       
DRH001C       
DRH001D       
DRH001E       
DRH001F       
DRH001G       
DRH002A       
DRH002B       
DRH002C       
DRH002D       
DRH003A brother (DRH009) sister (DRH006) and father ave UC     
DRH003B       
DRH003C       
DRH003D       
DRH004A father CD moved from sydney 2010   
DRH004B       
DRH004C       
DRH005A       
DRH005B       
DRH006A brothers(DRH003+009) and father have UC     
DRH006B       
DRH006C       
DRH006D       
DRH007A       
DRH007B       
DRH007C       
DRH007D       
DRH008A       
DRH008BS       
DRH008BU       
DRH008C       
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DRH008D       
DRH009A brother (DRH003) sister (DRH006) and father ave UC ankle fracture jan12   
DRH009B       
DRH009C       
DRH009D       
DRH010A       
DRH010B       
DRH010C       
DRH010D       
DRH011A       
DRH011B       
DRH011C       
DRH011D       
DRH012A   
trial tacrolimus april 2012 - no benefit therefore stopped, pt 
taking nicotine gum only   
DRH012B       
DRH012C       
DRH012D       
DRH013A       
DRH013B       
DRH013C       
DRH013D       
DRH014A   1st Sample taken pre EUA, fistulotomy and seton insertion   
DRH014B     
DRH014C     
DRH014D     
DRH014E     
DRH015A   2nd samples pre inflix - missed post inflix samples   
DRH015B       
DRH015C       
DRH015D       
DRH016A cousin colitis 
2/4/12 - recent flare requiring pred. finished at time of 
samples   
DRH016B       
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DRH016C       
DRH016D       
DRH017A       
DRH017B       
DRH017C       
DRH017D       
DRH017E       
DRH018A   DRH 018AS blood taken from c-line (no peripheral access)   
DRH018B   
DRH018BS blood taken from left radial artery (no peri heral 
access + c-line not bleeding)   
DRH018C   UGIE 12/10/2011 - duodenal ulceration improving on inflix   
DRH018D   2nd inflix (200mg hydrocortisome before) 19/10/2011 19:00   
DRH018E   01/02/2012 - severe upper gi disease   
DRH019A       
DRH019B       
DRH020A       
DRH020B       
DRH020C       
DRH020D       
DRH021A       
DRH021B   withdrew 16/1/12   
DRH022A   
previously had infliximab 2007, stopped methotrexat 09/11, 
normal colonoscopy 19/10/11   
DRH022B     
DRH022C     
DRH022D     
DRH023A     
DRH023B       
DRH024A   Methotrexate 25mg weekly stopped 20/10/11   
DRH024B     
DRH024C     
DRH024D     
DRH024E     
DRH025A       
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DRH025B       
DRH025C       
DRH025D       
DRH025E       
DRH026A       
DRH026B       
DRH026C       
DRH026E       
DRH027A Non-identical twin (other twin also has CD)     
DRH027B     
DRH027C     
DRH027D     
DRH028A       
DRH028B       
DRH029A brother has UC and PSC     
DRH029B flare end of feb requiring 30mg pred 1/52   
DRH029C     
DRH029D june 12 moved to ada 40mg / wk   
DRH030A 1st cousin CD + cousin's daughter CD     
DRH030B     
DRH030C     
DRH030D     
DRH031A       
DRH031B       
DRH031C       
DRH031D       
DRH031E       
DRH032A       
DRH032B       
DRH032C       
DRH033A       
DRH033B       
DRH033C       
DRH033D       
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DRH034A       
DRH034B       
DRH034C       
DRH034D       
DRH035A       
DRH035B       
DRH035C       
DRH035D       
DRH036A       
DRH036B       
DRH036C       
DRH036D       
DRH037A father CD     
DRH037B     
DRH037C     
DRH037D     
DRH038A       
DRH038B       
DRH038C   ? Pregnant, 4th set not taken as confirmed preg   
DRH039A       
DRH039B       
DRH039C       
DRH039D       
DRH039E       
DRH039F       
DRH040A       
DRH040B       
DRH041A       
DRH041B       
DRH041C       
DRH041D       
DRH042A       
DRH042B       
DRH042C       
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DRH042D       
DRH042E       
DRH042F       
DRH043A       
DRH043B       
DRH043C       
DRH043D       
DRH044A   
viral infection 2007 - unwell after protein losing enetropathy ? 
Cause. Died 3/2/12 03/02/12 
DRH044B   
viral infection 2007 - unwell after protein losing enetropathy ? 
Cause. Died 3/2/12 
DRH045A       
DRH045B       
DRH046A       
DRH046B       
DRH047A       
DRH047B       
DRH047C       
DRH047D       
DRH048A 170cm SB remains as well as large bowel     
DRH048B 170cm SB remains as well as large bowel     
DRH049A       
DRH049B       
DRH049C       
DRH049D       
DRH050A       
DRH050B       
DRH051A       
DRH051B       
DRH052A       
DRH052B       
DRH053A       
DRH053B       
DRH054A       
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DRH055A   
path indeterminate colitis (clinically more in keeping with UC 
but path ?CD)   
DRH055B       
DRH056A   
post-operatively deranged LFTs. Diagnosed with 
cholangiocarcinoma. Resection in edinburgh. Chemo. 
Community arrest - ct showed perforation of intra-abdo 
viscus with ? Ischaemia of liver, spleen, kidney, pancreas and 
right kidney with infarcts left kidney. 08/01/13 
DRH057A       
DRH057B       
DRH058A       
DRH058B       
DRH059A     
DRH059B   unable to contact after 2nd samples   
DRH060A       
DRH060B       
DRH063A   self catheterises   
DRH063B   self catheterises   
DRH066A       
DRH066B       
DRH067A   
PM - generalised acute peritonitis secondary to ileostomy 
ischaemia 02/08/12 
DRH068A       
DRH068B       
DRH071A   
4 yrs blood diarrhoea, 4 months erythema nodosum, 4 onths 
oligoarthritis   
DRH071B     
DRH071C     
DRH072A mother UC, pat aunt CD 
stopped pred 40mg / tacro 1mg / mesalazine 800mg bd / 
fluoxetine 3 weeks ago   
DRH072B mother UC, pat aunt CD     
DRH074A   
follow up colonoscopy - normal bowel ? Findings secondary 
to severe diverticular disease causing a fistula. Path from 
colonoscopy biopsies - normal   
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DRH075A   
admitted with ?obstruction - laparotomy and division of 
adhesions. Post op pelvic collection - perc drain.   
DRH075B     
DRH079A       
DRH079B       
DRH082A       
DRH082B       
DRH083A       
DRH083B       
DRH084A       
DRH084B       
DRH085A       
DRH085B       
DRH086A       
DRH086B       
DRH090A       
DRH090B       
DRH091A       
DRH091B       
DRH096A       
DRH096B       
DRH097A       
DRH097B       
DRH098A       
DRH098B       
DRH098C       
DRH099A   post op PE   
DRH099B     
DRH102A   previous inflix 04/12 - 10/12 (no response)   
DRH102B       
DRH104A       
DRH104B       
DRH105A       
DRH105B       
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DRH106A       
DRH106B       
DRH200A       
DRH200B       
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8.3 IBD Patient Sample Collection and Preparation Details 
Biofluid Sample Date Sample Label CollectionTime SpinTime FreezeTime FastedTime 
Serum 12-Aug-11 DRH001AS 08:40:00 09:50:00 10:25:00 overnight 
Urine 12-Aug-11 DRH001AU 09:10:00 09:35:00 10:25:00 overnight 
Serum 17-Aug-11 DRH002AS 09:00:00 10:05:00 10:40:00 overnight 
Urine 17-Aug-11 DRH002AU 09:05:00 09:40:00 10:40:00 overnight 
Serum 23-Aug-11 DRH003AS 08:40:00 09:50:00 10:20:00 overnight 
Urine 23-Aug-11 DRH003AU 08:45:00 09:30:00 10:20:00 overnight 
Serum 24-Aug-11 DRH004AS 06:40:00 08:35:00 09:25:00 overnight 
Urine 24-Aug-11 DRH004AU 07:20:00 08:25:00 09:25:00 overnight 
Serum 24-Aug-11 DRH005AS 10:05:00 11:50:00 12:15:00 overnight 
Urine 24-Aug-11 DRH005AU 10:00:00 11:35:00 12:15:00 overnight 
Serum 26-Aug-11 DRH006AS 09:50:00 11:10:00 11:35:00 overnight 
Urine 26-Aug-11 DRH006AU 09:55:00 10:55:00 11:35:00 overnight 
Serum 30-Aug-11 DRH007AS 14:05:00 15:35:00 16:00:00 overnight 
Urine 30-Aug-11 DRH007AU 14:10:00 15:20:00 16:00:00 overnight 
Serum 31-Aug-11 DRH008AS 08:10:00 10:10:00 10:40:00 overnight 
Urine 31-Aug-11 DRH008AU 08:30:00 09:10:00 10:40:00 overnight 
Serum 02-Sep-11 DRH009AS 09:05:00 10:25:00 10:50:00 overnight 
Urine 02-Sep-11 DRH009AU 09:30:00 10:05:00 10:50:00 overnight 
Serum 06-Sep-11 DRH010AS 08:50:00 10:05:00 10:35:00 overnight 
Urine 06-Sep-11 DRH010AU 09:00:00 09:40:00 10:35:00 overnight 
Serum 08-Sep-11 DRH011AS 10:20:00 12:00:00 13:05:00 overnight 
Urine 08-Sep-11 DRH011AU 10:45:00 12:25:00 13:05:00 overnight 
Serum 07-Sep-11 DRH005BS 15:05:00 16:10:00 16:50:00 6 hours 
Urine 07-Sep-11 DRH005BU 15:10:00 16:00:00 16:50:00 6 hours 
Serum 08-Sep-11 DRH012AS 16:40:00 18:35:00 19:05:00 6 hours 
Urine 08-Sep-11 DRH012AU 16:50:00 18:25:00 19:05:00 6 hours 
Serum 09-Sep-11 DRH013AS 09:15:00 10:35:00 11:10:00 overnight 
Urine 09-Sep-11 DRH013AU 09:20:00 10:20:00 11:10:00 overnight 
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Serum 20-Sep-11 DRH014AS 07:50:00 09:00:00 09:25:00 overnight 
Urine 20-Sep-11 DRH014AU 08:00:00 08:35:00 09:25:00 overnight 
Serum 27-Sep-11 DRH015AS 10:25:00 12:15:00 12:40:00 overnight 
Urine 27-Sep-11 DRH015AU 10:30:00 12:00:00 12:40:00 overnight 
Serum 03-Oct-11 DRH016AS 09:15:00 11:05:00 11:35:00 overnight 
Urine 03-Oct-11 DRH016AU 09:20:00 10:50:00 11:35:00 overnight 
Serum 04-Oct-11 DRH017AS 09:35:00 11:40:00 12:50:00 coffee with milk 
09:00 
Urine 04-Oct-11 DRH017AU 09:30:00 11:20:00 12:50:00 coffee with milk 
09:00 
Serum 04-Oct-11 DRH018AS 10:10:00 11:40:00 12:50:00 overnight 
Urine 04-Oct-11 DRH018AU 10:15:00 11:20:00 12:50:00 overnight 
Serum 06-Oct-11 DRH014BS 10:00:00 11:05:00 11:35:00 overnight 
Urine 06-Oct-11 DRH014BU 10:00:00 10:45:00 11:35:00 overnight 
Serum 12-Oct-11 DRH019AS 08:20:00 10:05:00 10:30:00 overnight 
Urine 12-Oct-11 DRH019AU 08:00:00 08:55:00 10:30:00 overnight 
Serum 13-Oct-11 DRH020AS 09:40:00 10:45:00 11:10:00 overnight 
Urine 13-Oct-11 DRH020AU 09:45:00 10:35:00 11:10:00 overnight 
Serum 18-Oct-11 DRH021AS 07:55:00 09:45:00 10:40:00 overnight 
Urine 18-Oct-11 DRH021AU 07:50:00 09:30:00 10:40:00 overnight 
Serum 18-Oct-11 DRH017BS 08:45:00 09:45:00 10:40:00 overnight 
Urine 18-Oct-11 DRH017BU 08:40:00 09:20:00 10:40:00 overnight 
Serum 19-Oct-11 DRH022AS 10:40:00 11:45:00 12:40:00 overnight 
Urine 19-Oct-11 DRH022AU 10:45:00 11:00:00 12:40:00 overnight 
Serum 20-Oct-11 DRH018BS 08:25:00 09:30:00 09:55:00 overnight 
Urine 20-Oct-11 DRH018BU 08:30:00 09:00:00 09:55:00 overnight 
Serum 26-Oct-11 DRH023AS 07:40:00 09:05:00 10:30:00 preload 06:00 
Urine 26-Oct-11 DRH023AU 07:35:00 08:50:00 10:20:00 preload 06:00 
Serum 02-Nov-11 DRH021BS 09:55:00 13:25:00 14:20:00 overnight 
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Urine 02-Nov-11 DRH021BU 09:50:00 13:10:00 14:20:00 overnight 
Serum 02-Nov-11 DRH024AS 11:20:00 13:25:00 14:50:00 tea with milk 07:30 
Urine 02-Nov-11 DRH024AU 11:25:00 14:05:00 14:20:00 tea with milk 07:40 
Serum 04-Nov-11 DRH025AS 07:20:00 08:20:00 08:50:00 overnight 
Urine 04-Nov-11 DRH025AU 07:25:00 08:00:00 08:50:00 overnight 
Serum 04-Nov-11 DRH026AS 11:10:00 12:20:00 13:05:00 overnight 
Urine 04-Nov-11 DRH026AU 11:15:00 12:10:00 13:05:00 overnight 
Serum 07-Nov-11 DRH027AS 09:15:00 10:25:00 11:00:00 overnight 
Urine 07-Nov-11 DRH027AU 09:30:00 10:05:00 11:00:00 overnight 
Serum 07-Nov-11 DRH028AS 08:00:00 10:25:00 11:00:00 overnight 
Urine 07-Nov-11 DRH028AU 08:15:00 09:55:00 11:00:00 overnight 
Serum 08-Nov-11 DRH029AS 08:10:00 11:10:00 11:50:00 overnight 
Urine 08-Nov-11 DRH029AU 08:15:00 11:00:00 11:50:00 overnight 
Serum 08-Nov-11 DRH030AS 09:35:00 11:10:00 11:50:00 overnight 
Urine 08-Nov-11 DRH030AU 09:40:00 11:00:00 11:50:00 overnight 
Serum 08-Nov-11 DRH031AS 13:15:00 14:30:00 15:55:00 breakfast 06:30, 
apple 11:00 
Urine 08-Nov-11 DRH031AU 13:20:00 14:20:00 15:55:00 breakfast 06:30, 
apple 11:00 
Serum 15-Nov-11 DRH032AS 08:10:00 10:55:00 11:45:00 overnight 
Urine 15-Nov-11 DRH032AU 08:15:00 10:20:00 11:45:00 overnight 
Serum 15-Nov-11 DRH033AS 09:00:00 10:55:00 11:50:00 overnight 
Urine 15-Nov-11 DRH033AU 09:05:00 10:35:00 11:50:00 overnight 
Serum 15-Nov-11 DRH001BS 08:45:00 10:55:00 11:45:00 overnight 
Urine 15-Nov-11 DRH001BU 08:50:00 10:20:00 11:45:00 overnight 
Serum 15-Nov-11 DRH024BS 13:05:00 14:25:00 14:50:00 6 hours 
Urine 15-Nov-11 DRH024BU 14:05:00 14:15:00 14:50:00 6 hours 
Serum 17-Nov-11 DRH002BS 09:15:00 11:40:00 12:45:00 overnight 
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Urine 17-Nov-11 DRH002BU 09:20:00 11:30:00 12:45:00 overnight 
Serum 17-Nov-11 DRH034AS 09:40:00 11:40:00 12:45:00 overnight 
Urine 17-Nov-11 DRH034BS 09:45:00 11:30:00 12:45:00 overnight 
Serum 21-Nov-11 DRH035AS 08:40:00 09:50:00 10:30:00 overnight 
Urine 21-Nov-11 DRH035AU 08:45:00 09:35:00 10:30:00 overnight 
Serum 22-Nov-11 DRH003BS 08:35:00 10:25:00 11:00:00 overnight 
Urine 22-Nov-11 DRH003BU 08:40:00 10:15:00 11:00:00 overnight 
Serum 22-Nov-11 DRH036AS 09:10:00 10:25:00 11:00:00 overnight 
Urine 22-Nov-11 DRH036AU 09:25:00 10:15:00 11:00:00 overnight 
Serum 23-Nov-11 DRH037AS 09:05:00 13:20:00 14:20:00 overnight 
Urine 23-Nov-11 DRH037AU 09:10:00 12:55:00 14:20:00 overnight 
Serum 23-Nov-11 DRH038AS 09:25:00 13:20:00 14:20:00 overnight 
Urine 23-Nov-11 DRH038AU 09:30:00 13:10:00 14:20:00 overnight 
Serum 23-Nov-11 DRH031BS 10:05:00 13:20:00 14:20:00 overnight 
Urine 23-Nov-11 DRH031BU 10:10:00 12:55:00 14:20:00 overnight 
Serum 23-Nov-11 DRH008BS 11:00:00 13:20:00 14:20:00 overnight 
Serum 25-Nov-11 DRH006BS 09:40:00 11:40:00 12:25:00 overnight 
Urine 25-Nov-11 DRH006BU 09:45:00 11:25:00 12:25:00 overnight 
Serum 25-Nov-11 DRH011BS 09:00:00 11:40:00 12:25:00 overnight 
Urine 25-Nov-11 DRH011BU 09:10:00 11:25:00 12:25:00 overnight 
Serum 25-Nov-11 DRH007BS 13:55:00 17:05:00 17:45:00 overnight 
Urine 25-Nov-11 DRH007BU 14:05:00 16:55:00 17:25:00 overnight 
Serum 25-Nov-11 DRH004BS 15:55:00 17:05:00 17:45:00 overnight 
Urine 25-Nov-11 DRH004BU 15:40:00 16:55:00 17:25:00 overnight 
Serum 28-Nov-11 DRH039AS 10:10:00 11:40:00 12:05:00 overnight 
Urine 28-Nov-11 DRH039AU 10:15:00 11:30:00 12:05:00 overnight 
Serum 30-Nov-11 DRH040AS 07:45:00 10:25:00 11:00:00 overnight 
Urine 30-Nov-11 DRH040AU 07:50:00 10:10:00 11:00:00 overnight 
Serum 02-Dec-11 DRH019BS 10:50:00 11:55:00 12:20:00 overnight 
Urine 02-Dec-11 DRH019BU 10:55:00 11:40:00 12:20:00 overnight 
Serum 07-Dec-11 DRH041AS 09:10:00 10:30:00 11:20:00 overnight 
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Urine 07-Dec-11 DRH041AU 09:15:00 10:45:00 11:10:00 overnight 
Serum 08-Dec-11 DRH009BS 09:05:00 10:30:00 11:00:00 overnight 
Urine 08-Dec-11 DRH009BU 09:10:00 10:10:00 11:00:00 overnight 
Serum 12-Dec-11 DRH014CS 08:55:00 10:30:00 11:00:00 overnight 
Urine 12-Dec-11 DRH014CU 09:00:00 10:10:00 11:00:00 overnight 
Serum 12-Dec-11 DRH042AS 09:15:00 10:30:00 11:00:00 overnight 
Urine 12-Dec-11 DRH042AU 09:20:00 10:20:00 11:00:00 overnight 
Serum 14-Dec-11 DRH043AS 09:10:00 12:05:00 12:45:00 overnight 
Urine 14-Dec-11 DRH043AU 09:15:00 11:40:00 12:45:00 overnight 
Serum 14-Dec-11 DRH015BS 10:05:00 12:05:00 13:45:00 cereal at 08:00 
Urine 14-Dec-11 DRH015BU 10:10:00 11:40:00 13:45:00 cereal at 08:00 
Serum 14-Dec-11 DRH012BS 10:25:00 12:05:00 12:45:00 overnight 
Urine 14-Dec-11 DRH012BU 10:30:00 11:50:00 12:45:00 overnight 
Urine 14-Dec-11 DRH008BU 16:20:00 17:20:00 18:35:00 6 hours 
Serum 15-Dec-11 DRH044AS 11:20:00 13:25:00 13:45:00 overnight 
Urine 15-Dec-11 DRH044AU 12:10:00 13:10:00 13:45:00 overnight 
Serum 04-Jan-12 DRH044BS 10:00:00 11:35:00 12:00:00 overnight 
Serum 05-Jan-12 DRH045AS 07:00:00 10:10:00 11:05:00 overnight 
Urine 05-Jan-12 DRH045AU 07:10:00 10:25:00 11:05:00 overnight 
Serum 08-Jan-12 DRH046AS 13:35:00 14:45:00 15:55:00 overnight 
Urine 08-Jan-12 DRH046AU 13:50:00 14:30:00 15:55:00 overnight 
Serum 09-Jan-12 DRH016BS 08:50:00 10:25:00 10:50:00 overnight 
Urine 09-Jan-12 DRH016BU 08:55:00 09:40:00 09:55:00 overnight 
Serum 10-Jan-12 DRH010BS 09:10:00 11:10:00 11:50:00 overnight 
Urine 10-Jan-12 DRH010BU 09:10:00 10:45:00 11:50:00 overnight 
Serum 10-Jan-12 DRH047AS 09:25:00 11:10:00 11:50:00 overnight 
Urine 10-Jan-12 DRH047AU 09:30:00 10:45:00 11:50:00 overnight 
Serum 10-Jan-12 DRH020BS 09:35:00 11:10:00 11:50:00 overnight 
Urine 10-Jan-12 DRH020BU 09:40:00 11:00:00 11:50:00 overnight 
Serum 11-Jan-12 DRH017CS 09:00:00 10:50:00 12:05:00 overnight 
 
 555
Urine 11-Jan-12 DRH017CU 08:55:00 10:40:00 12:05:00 overnight 
Serum 17-Jan-12 DRH048AS 08:35:00 10:10:00 10:40:00 overnight 
Urine 17-Jan-12 DRH048AU 08:45:00 10:00:00 10:40:00 overnight 
Serum 17-Jan-12 DRH049AS 14:05:00 15:10:00 15:35:00 overnight 
Urine 17-Jan-12 DRH049AU 14:10:00 14:40:00 15:35:00 overnight 
Serum 18-Jan-12 DRH050AS 09:40:00 12:00:00 12:40:00 overnight 
Urine 18-Jan-12 DRH050AU 09:35:00 11:50:00 12:40:00 overnight 
Serum 18-Jan-12 DRH013BS 10:30:00 12:00:00 12:40:00 overnight 
Urine 18-Jan-12 DRH013BU 10:40:00 11:50:00 12:40:00 overnight 
Serum 19-Jan-12 DRH051AS 12:35:00 14:00:00 14:25:00 6 hours 
Urine 19-Jan-12 DRH051AU 12:40:00 13:50:00 14:25:00 6 hours 
Serum 23-Jan-12 DRH022BS 09:05:00 10:45:00 11:10:00 overnight 
Urine 23-Jan-12 DRH022BU 09:10:00 10:35:00 11:10:00 overnight 
Serum 27-Jan-12 DRH025BS 07:20:00 08:30:00 08:55:00 overnight 
Urine 27-Jan-12 DRH025BU 07:25:00 08:20:00 08:55:00 overnight 
Serum 27-Jan-12 DRH026BS 11:05:00 12:20:00 13:00:00 overnight 
Urine 27-Jan-12 DRH026BU 11:10:00 12:10:00 13:00:00 overnight 
Serum 30-Jan-12 DRH027BS 09:45:00 10:50:00 11:15:00 overnight 
Urine 30-Jan-12 DRH027BU 09:50:00 10:40:00 11:15:00 overnight 
Serum 07-Feb-12 DRH052AS 08:10:00 09:30:00 10:25:00 overnight 
Urine 07-Feb-12 DRH052AU 08:15:00 09:20:00 10:25:00 overnight 
Serum 31-Jan-12 DRH049BS 14:15:00 15:25:00 16:10:00 6 hours 
Urine 31-Jan-12 DRH049BU 14:15:00 15:00:00 15:55:00 6 hours 
Serum 01-Feb-12 DRH018CS 09:40:00 11:40:00 12:10:00 overnight 
Urine 01-Feb-12 DRH018CU 09:10:00 11:00:00 12:10:00 overnight 
Serum 01-Feb-12 DRH050BS 10:10:00 11:40:00 12:10:00 overnight 
Urine 01-Feb-12 DRH050BU 10:00:00 11:00:00 12:10:00 overnight 
Serum 02-Feb-12 DRH046BS 09:55:00 11:05:00 11:30:00 overnight 
Urine 02-Feb-12 DRH046BU 09:40:00 10:10:00 11:30:00 overnight 
Serum 08-Feb-12 DRH001CS 08:55:00 11:20:00 12:00:00 overnight 
Urine 08-Feb-12 DRH001CU 09:05:00 10:50:00 12:00:00 overnight 
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Serum 08-Feb-12 DRH024CS 09:15:00 11:20:00 12:00:00 overnight 
Urine 08-Feb-12 DRH024CU 09:55:00 11:00:00 12:00:00 overnight 
Serum 08-Feb-12 DRH030BS 09:30:00 11:35:00 12:00:00 overnight 
Urine 08-Feb-12 DRH030BU 09:35:00 10:50:00 12:00:00 overnight 
Serum 13-Feb-12 DRH034BS 14:55:00 16:20:00 16:45:00 7.5 hours 
Urine 13-Feb-12 DRH034BU 15:00:00 16:10:00 16:45:00 7.5 hours 
Serum 14-Feb-12 DRH032BS 08:00:00 09:55:00 10:25:00 overnight 
Urine 14-Feb-12 DRH032BU 08:05:00 09:45:00 10:25:00 overnight 
Serum 14-Feb-12 DRH037BS 08:45:00 09:55:00 10:25:00 overnight 
Urine 14-Feb-12 DRH037BU 08:50:00 09:45:00 10:25:00 overnight 
Serum 15-Feb-12 DRH011CS 10:05:00 12:00:00 12:25:00 overnight 
Urine 15-Feb-12 DRH011CU 10:05:00 11:50:00 12:25:00 overnight 
Serum 16-Feb-12 DRH035BS 09:00:00 10:15:00 10:50:00 overnight 
Urine 16-Feb-12 DRH035BU 09:20:00 10:30:00 10:50:00 overnight 
Serum 17-Feb-12 DRH002CS 09:05:00 10:25:00 10:55:00 overnight 
Urine 17-Feb-12 DRH002CU 09:10:00 10:15:00 10:55:00 overnight 
Serum 20-Feb-12 DRH031CS 09:25:00 10:30:00 11:25:00 overnight 
Urine 20-Feb-12 DRH031CU 09:30:00 09:55:00 11:25:00 overnight 
Serum 20-Feb-12 DRH038BS 08:25:00 10:05:00 11:25:00 overnight 
Urine 20-Feb-12 DRH038BU 08:30:00 09:55:00 11:25:00 overnight 
Serum 21-Feb-12 DRH033BS 09:05:00 10:55:00 11:30:00 overnight 
Urine 21-Feb-12 DRH033BU 09:10:00 10:45:00 11:30:00 overnight 
Serum 22-Feb-12 DRH001DS 09:10:00 10:20:00 11:00:00 overnight 
Urine 22-Feb-12 DRH001DU 09:00:00 10:10:00 11:00:00 overnight 
Serum 22-Feb-12 DRH025CS 08:50:00 10:20:00 11:00:00 overnight 
Urine 22-Feb-12 DRH025CU 08:40:00 10:10:00 11:00:00 overnight 
Serum 24-Feb-12 DRH007CS 14:05:00 15:15:00 15:40:00 overnight 
Urine 24-Feb-12 DRH007CU 14:10:00 14:50:00 15:40:00 overnight 
Serum 27-Feb-12 DRH003CS 09:05:00 10:10:00 10:30:00 overnight 
Urine 27-Feb-12 DRH003CU 09:05:00 10:00:00 10:30:00 overnight 
Serum 28-Feb-12 DRH036BS 09:25:00 13:00:00 13:30:00 overnight 
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Urine 28-Feb-12 DRH036BU 09:30:00 12:50:00 13:30:00 overnight 
Serum 28-Feb-12 DRH039BS 11:10:00 13:00:00 13:30:00 overnight 
Urine 28-Feb-12 DRH039BU 11:15:00 12:50:00 13:30:00 overnight 
Serum 29-Feb-12 DRH053AS 07:10:00 10:15:00 11:30:00 overnight 
Urine 29-Feb-12 DRH053AU 07:00:00 10:00:00 11:30:00 overnight 
Serum 29-Feb-12 DRH054AS 07:30:00 10:15:00 11:30:00 overnight 
Urine 29-Feb-12 DRH054AU 07:25:00 10:00:00 11:30:00 overnight 
Serum 01-Mar-12 DRH029BS 08:55:00 10:15:00 10:40:00 overnight 
Urine 01-Mar-12 DRH029BU 09:00:00 10:00:00 10:40:00 overnight 
Serum 02-Mar-12 DRH006CS 09:20:00 12:35:00 13:10:00 overnight 
Urine 02-Mar-12 DRH006CU 09:25:00 12:25:00 13:10:00 overnight 
Serum 02-Mar-12 DRH028BS 10:25:00 13:20:00 13:50:00 overnight 
Urine 02-Mar-12 DRH028BU 10:20:00 12:55:00 13:50:00 overnight 
Serum 02-Mar-12 DRH040BS 11:45:00 13:20:00 13:50:00 overnight 
Urine 02-Mar-12 DRH040BU 11:40:00 12:55:00 13:50:00 overnight 
Serum 02-Mar-12 DRH045BS 09:50:00 12:35:00 13:10:00 overnight 
Urine 02-Mar-12 DRH045BU 09:00:00 12:25:00 13:10:00 overnight 
Serum 07-Mar-12 DRH025DS 08:45:00 10:30:00 10:55:00 overnight 
Urine 07-Mar-12 DRH025DU 08:40:00 10:20:00 10:55:00 overnight 
Serum 08-Mar-12 DRH009CS 08:40:00 10:25:00 10:50:00 overnight 
Urine 08-Mar-12 DRH009CU 08:40:00 10:15:00 10:50:00 overnight 
Serum 08-Mar-12 DRH042BS 09:05:00 10:25:00 10:50:00 overnight 
Urine 08-Mar-12 DRH042BU 09:10:00 10:15:00 10:50:00 overnight 
Serum 10-Mar-12 DRH023BS 09:05:00 10:30:00 11:00:00 overnight 
Urine 10-Mar-12 DRH023BU 09:20:00 10:10:00 11:00:00 overnight 
Serum 13-Mar-12 DRH041BS 09:10:00 10:15:00 10:40:00 overnight 
Urine 13-Mar-12 DRH041BU 09:15:00 10:05:00 10:40:00 overnight 
Serum 14-Mar-12 DRH014DS 09:15:00 11:15:00 11:50:00 overnight 
Urine 14-Mar-12 DRH014DU 08:55:00 10:50:00 11:50:00 overnight 
Serum 14-Mar-12 DRH015CS 10:15:00 11:15:00 11:50:00 overnight 
Urine 14-Mar-12 DRH015CU 10:20:00 10:50:00 11:50:00 overnight 
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Serum 20-Mar-12 DRH055AS 09:10:00 12:10:00 12:40:00 overnight 
Urine 20-Mar-12 DRH055AU 09:15:00 12:00:00 12:40:00 overnight 
Serum 22-Mar-12 DRH012CS 14:30:00 15:40:00 16:00:00 6 hours 
Urine 22-Mar-12 DRH012CU 14:20:00 15:30:00 16:00:00 6 hours 
Serum 23-Mar-12 DRH051BS 12:20:00 13:55:00 14:15:00 6 hours 
Urine 23-Mar-12 DRH051BU 12:15:00 13:45:00 14:15:00 6 hours 
Serum 27-Mar-12 DRH010CS 09:15:00 10:20:00 11:45:00 overnight 
Urine 27-Mar-12 DRH010CU 09:20:00 10:10:00 11:45:00 overnight 
Serum 28-Mar-12 DRH008CS 09:00:00 10:10:00 11:50:00 overnight 
Urine 28-Mar-12 DRH008CU 09:05:00 10:00:00 11:50:00 overnight 
Serum 28-Mar-12 DRH056AS 05:50:00 08:35:00 09:15:00 overnight 
Urine 28-Mar-12 DRH056AU 05:55:00 08:20:00 09:15:00 overnight 
Serum 29-Mar-12 DRH058AS 15:00:00 16:05:00 16:30:00 6 hours 
Urine 30-Mar-12 DRH058AU 08:55:00 11:20:00 12:30:00 overnight 
Serum 30-Mar-12 DRH057AS 08:10:00 11:55:00 12:30:00 overnight 
Urine 30-Mar-12 DRH057AU 08:30:00 11:20:00 12:30:00 overnight 
Serum 30-Mar-12 DRH020CS 09:30:00 11:55:00 12:30:00 overnight 
Urine 30-Mar-12 DRH020CU 09:35:00 11:30:00 12:30:00 overnight 
Serum 02-Apr-12 DRH016CS 09:05:00 10:10:00 10:30:00 overnight 
Urine 02-Apr-12 DRH016CU 09:10:00 09:40:00 10:30:00 overnight 
Serum 03-Apr-12 DRH017DS 08:45:00 09:50:00 10:40:00 overnight 
Urine 03-Apr-12 DRH017DU 08:40:00 09:40:00 10:40:00 overnight 
Serum 04-Apr-12 DRH053BS 15:55:00 16:55:00 17:15:00 6 hours 
Urine 04-Apr-12 DRH053BU 15:50:00 16:20:00 17:15:00 6 hours 
Serum 20-Apr-12 DRH099AS 12:30:00 14:40:00 14:50:00 6 hours 
Urine 20-Apr-12 DRH099AU 12:20:00 14:30:00 15:10:00 6 hours 
Serum 05-Apr-12 DRH048BS 16:10:00 17:15:00 17:45:00 6 hours 
Urine 05-Apr-12 DRH048BU 16:50:00 17:15:00 17:30:00 6 hours 
Serum 26-Apr-12 DRH070S 13:10:00 14:15:00 14:45:00 overnight 
Urine 26-Apr-12 DRH070U 13:10:00 13:55:00 14:45:00 overnight 
Serum 16-Apr-12 DRH004CS 15:00:00 16:10:00 16:45:00 6 hours 
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Urine 16-Apr-12 DRH004CU 14:40:00 15:50:00 16:45:00 6 hours 
Serum 02-May-12 DRH052BS 06:35:00 11:00:00 11:45:00 overnight 
Urine 02-May-12 DRH052BU 06:40:00 10:45:00 11:45:00 overnight 
Serum 02-May-12 DRH026CS 10:05:00 11:20:00 11:45:00 overnight 
Urine 02-May-12 DRH026CU 10:15:00 10:45:00 11:45:00 overnight 
Serum 08-May-12 DRH030CS 09:45:00 10:50:00 11:15:00 overnight 
Urine 08-May-12 DRH030CU 09:40:00 10:20:00 11:15:00 overnight 
Serum 08-May-12 DRH047BS 09:00:00 10:30:00 11:15:00 overnight 
Urine 08-May-12 DRH047BU 09:05:00 10:20:00 11:15:00 overnight 
Serum 08-May-12 DRH043BS 11:45:00 12:45:00 13:10:00 overnight 
Urine 08-May-12 DRH043BU 11:50:00 12:25:00 13:10:00 overnight 
Serum 09-May-12 DRH027CS 10:00:00 11:10:00 11:35:00 overnight 
Urine 09-May-12 DRH027CU 10:05:00 11:00:00 11:35:00 overnight 
Serum 10-May-12 DRH001ES 08:35:00 11:10:00 11:35:00 overnight 
Serum 11-May-12 DRH059AS 08:00:00 09:40:00 10:00:00 just ate roll / jam / 
coffee 
Urine 11-May-12 DRH059AU 07:50:00 09:30:00 10:00:00 overnight 
Serum 12-May-12 DRH055BS 11:40:00 13:00:00 13:25:00 overnight 
Urine 12-May-12 DRH055BU 12:35:00 12:45:00 13:25:00 overnight 
Serum 14-May-12 DRH034CS 09:00:00 10:55:00 12:00:00 overnight 
Urine 14-May-12 DRH034CU 09:05:00 11:40:00 12:00:00 overnight 
Serum 15-May-12 DRH037CS 09:00:00 11:05:00 11:25:00 overnight 
Urine 15-May-12 DRH037CU 09:05:00 10:55:00 11:25:00 overnight 
Serum 17-May-12 DRH032CS 08:00:00 09:35:00 10:15:00 overnight 
Urine 17-May-12 DRH032CU 07:55:00 09:25:00 10:15:00 overnight 
Serum 18-May-12 DRH035CS 08:55:00 10:50:00 11:15:00 overnight 
Urine 18-May-12 DRH035CU 09:00:00 10:40:00 11:15:00 overnight 
Serum 23-May-12 DRH060AS 09:30:00 10:35:00 11:00:00 overnight 
Urine 23-May-12 DRH060AU 09:15:00 10:20:00 11:00:00 overnight 
Serum 24-May-12 DRH002DS 09:15:00 10:25:00 10:50:00 overnight 
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Urine 24-May-12 DRH002DU 09:20:00 10:15:00 10:50:00 overnight 
Serum 25-May-12 DRH038CS 08:35:00 10:05:00 10:25:00 overnight 
Urine 25-May-12 DRH038CU 08:40:00 09:55:00 10:25:00 overnight 
Serum 25-May-12 DRH057BS 11:55:00 13:05:00 13:35:00 6 hours 
Urine 25-May-12 DRH057BU 12:00:00 12:55:00 13:35:00 6 hours 
Serum 25-May-12 DRH007DS 13:55:00 15:55:00 16:25:00 overnight 
Urine 25-May-12 DRH007DU 14:00:00 15:45:00 16:25:00 overnight 
Serum 28-May-12 DRH036CS 08:55:00 10:20:00 10:45:00 overnight 
Urine 28-May-12 DRH036CU 09:00:00 10:10:00 10:45:00 overnight 
Serum 29-May-12 DRH003DS 08:55:00 12:30:00 13:00:00 overnight 
Urine 29-May-12 DRH003DU 09:00:00 12:20:00 13:00:00 overnight 
Serum 29-May-12 DRH061S 08:35:00 12:30:00 13:00:00 overnight 
Urine 29-May-12 DRH061U 08:55:00 12:20:00 13:00:00 overnight 
Serum 30-May-12 DRH025ES 08:55:00 11:05:00 11:50:00 overnight 
Urine 30-May-12 DRH025EU 08:45:00 10:55:00 11:50:00 overnight 
Serum 30-May-12 DRH024DS 10:20:00 11:20:00 11:50:00 overnight 
Urine 30-May-12 DRH024DU 10:10:00 10:55:00 11:50:00 overnight 
Serum 31-May-12 DRH022CS 11:40:00 12:45:00 13:10:00 overnight 
Urine 31-May-12 DRH022CU 11:45:00 12:20:00 13:10:00 overnight 
Serum 01-Jun-12 DRH006DS 08:40:00 10:00:00 10:20:00 overnight 
Urine 01-Jun-12 DRH006DU 08:45:00 09:50:00 10:20:00 overnight 
Serum 05-Jun-12 DRH033CS 08:50:00 10:55:00 11:15:00 overnight 
Urine 05-Jun-12 DRH033CU 08:55:00 10:45:00 11:15:00 overnight 
Serum 05-Jun-12 DRH031DS 11:45:00 12:55:00 13:20:00 6 hours 
Urine 05-Jun-12 DRH031DU 11:50:00 12:45:00 13:20:00 6 hours 
Serum 26-May-12 DRH062S 08:30:00 09:30:00 09:55:00 overnight 
Urine 26-May-12 DRH062U 08:40:00 09:10:00 09:55:00 overnight 
Serum 06-Jun-12 DRH063AS 09:15:00 10:25:00 11:05:00 overnight 
Urine 06-Jun-12 DRH063AU 09:00:00 10:15:00 11:05:00 overnight 
Serum 07-Jun-12 DRH009DS 09:00:00 10:55:00 11:40:00 overnight 
Urine 07-Jun-12 DRH009DU 09:05:00 09:55:00 11:40:00 overnight 
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Serum 07-Jun-12 DRH060BS 09:25:00 10:55:00 11:40:00 overnight 
Urine 07-Jun-12 DRH060BU 09:15:00 09:55:00 11:40:00 overnight 
Serum 07-Jun-12 DRH064S 12:45:00 15:10:00 15:35:00 6 hours 
Urine 07-Jun-12 DRH064U 13:50:00 14:55:00 15:35:00 6 hours 
Serum 06-Jun-12 DRH011DS 13:30:00 14:35:00 15:15:00 6 hours 
Urine 06-Jun-12 DRH011DU 13:25:00 14:00:00 15:15:00 6 hours 
Serum 08-Jun-12 DRH042CS 09:00:00 10:50:00 11:15:00 overnight 
Urine 08-Jun-12 DRH042CU 09:05:00 10:40:00 11:15:00 overnight 
Serum 08-Jun-12 DRH065S 13:10:00 14:15:00 14:40:00 6 hours 
Urine 08-Jun-12 DRH065U 13:05:00 13:45:00 14:40:00 6 hours 
Serum 15-Jun-12 DRH058BS 10:00:00 10:50:00 11:40:00 overnight 
Urine 15-Jun-12 DRH058BU 09:55:00 11:05:00 11:40:00 overnight 
Serum 19-Jun-12 DRH001FS 09:15:00 14:55:00 15:15:00 preload 06:15 
Urine 19-Jun-12 DRH001FU 09:40:00 14:45:00 15:15:00 preload 06:15 
Serum 21-Jun-12 DRH015DS 10:15:00 12:50:00 13:15:00 overnight 
Urine 21-Jun-12 DRH015DU 10:20:00 12:40:00 13:15:00 overnight 
Serum 22-Jun-12 DRH010DS 10:20:00 11:30:00 11:50:00 overnight 
Urine 22-Jun-12 DRH010DU 10:25:00 11:20:00 11:50:00 overnight 
Serum 27-Jun-12 DRH066AS 06:30:00 10:45:00 11:10:00 overnight 
Urine 27-Jun-12 DRH066AU 06:35:00 10:30:00 11:10:00 overnight 
Serum 28-Jun-12 DRH067AS 08:05:00 09:30:00 09:50:00 overnight 
Urine 28-Jun-12 DRH067AU 08:10:00 09:20:00 09:50:00 overnight 
Serum 28-Jun-12 DRH039CS 15:05:00 17:00:00 17:25:00 6 hours 
Urine 28-Jun-12 DRH039CU 15:10:00 16:50:00 17:25:00 6 hours 
Serum 29-Jun-12 DRH029CS 09:05:00 10:35:00 11:00:00 overnight 
Urine 29-Jun-12 DRH029CU 09:10:00 10:25:00 11:00:00 overnight 
Serum 02-Jul-12 DRH079AS 06:40:00 09:30:00 10:20:00 overnight 
Urine 02-Jul-12 DRH079AU 06:10:00 09:50:00 10:20:00 overnight 
Urine 05-Jul-12 DRH068AU 07:00:00 09:00:00 09:45:00 overnight 
Serum 05-Jul-12 DRH068AS 07:00:00 09:10:00 09:45:00 overnight 
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Serum 05-Jul-12 DRH014ES 10:55:00 12:20:00 12:45:00 overnight 
Urine 05-Jul-12 DRH014EU 11:00:00 12:10:00 12:45:00 overnight 
Serum 06-Jul-12 DRH013CS 10:45:00 12:10:00 13:05:00 overnight 
Urine 06-Jul-12 DRH013CU 10:50:00 11:40:00 13:05:00 overnight 
Serum 06-Jul-12 DRH020DS 09:15:00 12:10:00 13:05:00 overnight 
Urine 06-Jul-12 DRH020DU 09:20:00 11:30:00 13:05:00 overnight 
Serum 06-Jul-12 DRH041CS 10:45:00 12:10:00 13:15:00 overnight 
Urine 06-Jul-12 DRH041CU 10:50:00 11:40:00 13:05:00 overnight 
Serum 06-Jul-12 DRH069S 10:45:00 12:10:00 13:15:00 overnight 
Urine 06-Jul-12 DRH069U 10:40:00 11:55:00 13:05:00 overnight 
Serum 20-Jun-12 DRH008DS 15:15:00 16:25:00 16:50:00 6 hours 
Urine 20-Jun-12 DRH008DU 16:00:00 16:05:00 16:50:00 6 hours 
Serum 20-Jun-12 DRH063BS 09:05:00 10:15:00 11:00:00 overnight 
Urine 20-Jun-12 DRH063BU 09:15:00 09:35:00 11:00:00 overnight 
Serum 09-Jul-12 DRH016DS 09:10:00 11:55:00 12:15:00 overnight 
Urine 09-Jul-12 DRH016DU 09:20:00 11:40:00 12:15:00 overnight 
Serum 17-Jul-12 DRH071AS 09:05:00 11:05:00 11:30:00 overnight 
Urine 17-Jul-12 DRH071AU 09:10:00 10:55:00 11:30:00 overnight 
Serum 18-Jul-12 DRH068BS 10:10:00 11:15:00 11:40:00 overnight 
Urine 18-Jul-12 DRH068BU 10:00:00 10:25:00 11:40:00 overnight 
Serum 19-Jul-12 DRH072AS 06:05:00 07:10:00 07:35:00 overnight 
Urine 19-Jul-12 DRH072AU 06:10:00 06:50:00 07:35:00 overnight 
Serum 19-Jul-12 DRH073S 12:55:00 14:30:00 14:50:00 6 hours 
Serum 14-Aug-12 DRH037DS 09:10:00 10:50:00 11:20:00 overnight 
Urine 14-Aug-12 DRH037DU 09:15:00 10:40:00 11:20:00 overnight 
Serum 14-Aug-12 DRH012DS 13:10:00 14:50:00 15:35:00 6 hours 
Urine 14-Aug-12 DRH012DU 13:15:00 14:40:00 15:35:00 6 hours 
Serum 14-Aug-12 DRH074AS 12:30:00 14:50:00 15:35:00 overnight 
Urine 14-Aug-12 DRH074AU 12:35:00 14:40:00 15:35:00 overnight 
Serum 15-Aug-12 DRH026DS 10:10:00 11:35:00 12:00:00 overnight 
Urine 15-Aug-12 DRH026DU 10:15:00 11:10:00 12:00:00 overnight 
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Serum 15-Aug-12 DRH075AS 06:35:00 10:55:00 12:00:00 overnight 
Urine 15-Aug-12 DRH075AU 06:40:00 10:40:00 12:00:00 overnight 
Serum 17-Aug-12 DRH076S 08:25:00 11:25:00 12:35:00 overnight 
Urine 17-Aug-12 DRH076U 08:20:00 11:15:00 12:35:00 overnight 
Serum 17-Aug-12 DRH077S 08:50:00 11:25:00 12:35:00 overnight 
Urine 17-Aug-12 DRH077U 08:35:00 11:15:00 12:35:00 overnight 
Serum 17-Aug-12 DRH080S 10:55:00 12:10:00 12:35:00 overnight 
Urine 17-Aug-12 DRH080U 10:50:00 12:00:00 12:35:00 overnight 
Serum 17-Aug-12 DRH078S 13:10:00 16:20:00 16:50:00 6 hours 
Urine 17-Aug-12 DRH078U 13:50:00 16:05:00 16:50:00 6 hours 
Serum 17-Aug-12 DRH081S 12:45:00 16:20:00 16:50:00 overnight 
Urine 17-Aug-12 DRH081U 12:50:00 15:55:00 16:50:00 overnight 
Serum 20-Aug-12 DRH047CS 09:05:00 11:10:00 11:40:00 overnight 
Serum 20-Aug-12 DRH030DS 09:35:00 11:10:00 11:40:00 overnight 
Urine 20-Aug-12 DRH030DU 09:40:00 11:00:00 11:40:00 overnight 
Serum 21-Aug-12 DRH082AS 05:50:00 08:50:00 09:20:00 overnight 
Urine 21-Aug-12 DRH082AU 05:55:00 08:40:00 09:20:00 overnight 
Serum 22-Aug-12 DRH017ES 09:10:00 10:25:00 11:00:00 overnight 
Urine 22-Aug-12 DRH017EU 09:05:00 10:40:00 11:00:00 overnight 
Serum 28-Aug-12 DRH033DS 08:00:00 09:05:00 09:30:00 overnight 
Urine 28-Aug-12 DRH033DU 08:05:00 08:45:00 09:30:00 overnight 
Urine 20-Aug-12 DRH047CU 10:52:00 15:52:00 17:05:00 overnight 
Serum 28-Aug-12 DRH083AS 14:00:00 15:35:00 16:00:00 6 hours 
Urine 28-Aug-12 DRH083AU 13:55:00 15:25:00 16:00:00 6 hours 
Serum 31-Aug-12 DRH034DS 09:05:00 13:35:00 14:30:00 overnight 
Urine 31-Aug-12 DRH034DU 09:10:00 13:25:00 14:30:00 overnight 
Serum 31-Aug-12 DRH001GS 13:00:00 14:05:00 14:30:00 overnight 
Urine 31-Aug-12 DRH001GU 11:25:00 13:25:00 14:30:00 overnight 
Serum 04-Sep-12 DRH099BS 09:05:00 11:55:00 12:20:00 overnight 
Urine 04-Sep-12 DRH099BU 09:10:00 11:40:00 12:20:00 overnight 
Serum 05-Sep-12 DRH036DS 09:15:00 10:55:00 11:35:00 overnight 
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Urine 05-Sep-12 DRH036DU 09:20:00 10:45:00 11:35:00 overnight 
Serum 06-Sep-12 DRH018DS 10:35:00 12:25:00 14:35:00 overnight 
Urine 06-Sep-12 DRH018DU 10:35:00 12:00:00 12:40:00 overnight 
Serum 06-Sep-12 DRH035DS 08:30:00 12:10:00 12:40:00 overnight 
Urine 06-Sep-12 DRH035DU 08:35:00 12:00:00 12:40:00 overnight 
Serum 12-Sep-12 DRH083BS 14:55:00 16:20:00 16:45:00 6 hours 
Urine 12-Sep-12 DRH083BU 15:00:00 16:10:00 16:45:00 6 hours 
Serum 14-Sep-12 DRH079BS 12:50:00 14:20:00 14:40:00 6 hours 
Urine 14-Sep-12 DRH079BU 13:00:00 14:10:00 14:40:00 6 hours 
Serum 17-Sep-12 DRH066BS 14:40:00 15:45:00 16:20:00 6 hours 
Urine 17-Sep-12 DRH066BU 14:45:00 15:15:00 16:20:00 6 hours 
Serum 19-Sep-12 DRH024ES 09:00:00 11:25:00 12:25:00 overnight 
Urine 19-Sep-12 DRH024EU 09:05:00 11:10:00 12:25:00 overnight 
Serum 20-Sep-12 DRH084AS 09:05:00 11:25:00 12:00:00 overnight 
Urine 20-Sep-12 DRH084AU 09:00:00 11:15:00 12:00:00 overnight 
Serum 21-Sep-12 DRH085AS 08:20:00 11:45:00 12:15:00 overnight 
Urine 21-Sep-12 DRH085AU 08:15:00 11:35:00 12:15:00 overnight 
Serum 21-Sep-12 DRH027DS 10:05:00 12:15:00 12:45:00 overnight 
Urine 21-Sep-12 DRH027DU 10:20:00 12:05:00 12:45:00 overnight 
Serum 21-Sep-12 DRH042DS 09:10:00 12:15:00 12:45:00 overnight 
Urine 21-Sep-12 DRH042DU 09:15:00 12:05:00 12:45:00 overnight 
Serum 01-Oct-12 DRH071BS 14:40:00 15:50:00 16:15:00 6 hours 
Urine 01-Oct-12 DRH071BU 14:45:00 15:40:00 16:15:00 6 hours 
Serum 02-Oct-12 DRH022DS 09:00:00 10:30:00 11:00:00 overnight 
Urine 02-Oct-12 DRH022DU 09:05:00 10:20:00 11:00:00 overnight 
Serum 02-Oct-12 DRH031ES 11:55:00 13:25:00 13:55:00 6 hours 
Urine 02-Oct-12 DRH031EU 11:50:00 13:10:00 13:55:00 6 hours 
Serum 04-Oct-12 DRH084BS 09:00:00 11:30:00 12:10:00 overnight 
Urine 04-Oct-12 DRH084BU 08:55:00 11:20:00 12:10:00 overnight 
Serum 15-Oct-12 DRH013DS 08:55:00 10:15:00 10:45:00 overnight 
Urine 15-Oct-12 DRH013DU 09:00:00 10:05:00 10:45:00 overnight 
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Serum 09-Oct-12 DRH039DS 09:30:00 10:40:00 11:00:00 overnight 
Urine 09-Oct-12 DRH039DU 08:55:00 09:55:00 11:00:00 overnight 
Serum 23-Oct-12 DRH043CS 12:20:00 13:30:00 13:55:00 overnight 
Urine 23-Oct-12 DRH043CU 12:25:00 13:15:00 13:55:00 overnight 
Serum 25-Oct-12 DRH041DS 09:05:00 10:40:00 11:05:00 overnight 
Urine 25-Oct-12 DRH041DU 09:10:00 10:30:00 11:05:00 overnight 
Serum 26-Oct-12 DRH059BS 12:55:00 14:25:00 14:50:00 6 hours 
Serum 29-Oct-12 DRH082BS 14:00:00 15:05:00 15:30:00 6 hours 
Urine 29-Oct-12 DRH082BU 14:05:00 14:55:00 15:30:00 6 hours 
Serum 31-Oct-12 DRH086AS 06:05:00 08:40:00 09:25:00 overnight 
Urine 31-Oct-12 DRH086AU 06:30:00 08:30:00 09:25:00 overnight 
Serum 01-Nov-12 DRH072BS 15:05:00 18:00:00 18:25:00 6 hours 
Urine 01-Nov-12 DRH072BU 14:30:00 17:50:00 18:25:00 6 hours 
Serum 02-Nov-12 DRH087S 08:50:00 10:10:00 10:55:00 overnight 
Urine 02-Nov-12 DRH087U 09:45:00 11:35:00 12:35:00 overnight 
Serum 02-Nov-12 DRH088S 10:05:00 12:05:00 12:35:00 overnight 
Urine 02-Nov-12 DRH088U 10:10:00 11:35:00 12:35:00 overnight 
Serum 02-Nov-12 DRH089S 10:40:00 12:05:00 12:35:00 overnight 
Urine 02-Nov-12 DRH089U 10:45:00 11:45:00 12:35:00 overnight 
Serum 06-Nov-12 DRH090AS 09:20:00 10:50:00 11:15:00 overnight 
Urine 06-Nov-12 DRH090AU 08:50:00 10:40:00 11:15:00 overnight 
Serum 14-Nov-12 DRH091AS 09:00:00 10:15:00 10:35:00 overnight 
Urine 14-Nov-12 DRH091AU 08:55:00 09:40:00 10:35:00 overnight 
Serum 16-Nov-12 DRH092S 08:30:00 12:15:00 12:40:00 overnight 
Urine 16-Nov-12 DRH092U 08:35:00 12:05:00 12:40:00 overnight 
Serum 16-Nov-12 DRH093S 08:40:00 12:15:00 12:40:00 overnight 
Urine 16-Nov-12 DRH093U 08:45:00 12:05:00 12:40:00 overnight 
Serum 16-Nov-12 DRH094S 10:30:00 14:05:00 14:55:00 overnight 
Urine 16-Nov-12 DRH094U 10:35:00 13:55:00 14:55:00 overnight 
Serum 16-Nov-12 DRH095S 10:55:00 14:05:00 14:55:00 overnight 
Urine 16-Nov-12 DRH095U 11:00:00 13:55:00 14:55:00 overnight 
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Serum 27-Nov-12 DRH075BS 10:05:00 12:15:00 12:45:00 overnight 
Urine 27-Nov-12 DRH075BU 10:30:00 12:05:00 12:45:00 overnight 
Serum 28-Nov-12 DRH091BS 09:15:00 11:40:00 12:10:00 overnight 
Urine 28-Nov-12 DRH091BU 09:05:00 11:30:00 12:10:00 overnight 
Serum 29-Nov-12 DRH047DS 09:10:00 10:30:00 11:20:00 overnight 
Urine 29-Nov-12 DRH047DU 09:15:00 10:40:00 11:20:00 overnight 
Serum 30-Nov-12 DRH096AS 12:15:00 15:20:00 15:40:00 6 hours 
Urine 30-Nov-12 DRH096AU 14:50:00 15:10:00 15:40:00 8 hours 
Serum 07-Dec-12 DRH049CS 12:55:00 15:25:00 15:50:00 5.5 hours 
Urine 07-Dec-12 DRH049CU 13:00:00 15:15:00 15:50:00 5.5 hours 
Serum 11-Dec-12 DRH097AS 07:35:00 10:35:00 11:40:00 overnight 
Urine 11-Dec-12 DRH097AU 07:40:00 10:00:00 11:40:00 overnight 
Serum 12-Dec-12 DRH098AS 07:00:00 09:25:00 10:25:00 overnight 
Urine 12-Dec-12 DRH098AU 06:10:00 08:55:00 10:25:00 overnight 
Serum 12-Dec-12 DRH100S 08:00:00 09:25:00 10:25:00 overnight 
Urine 12-Dec-12 DRH100U 08:05:00 08:55:00 10:25:00 overnight 
Serum 12-Dec-12 DRH101S 08:15:00 09:25:00 10:40:00 overnight 
Urine 12-Dec-12 DRH101U 08:10:00 09:05:00 10:40:00 overnight 
Serum 12-Dec-12 DRH042ES 16:15:00 17:25:00 17:45:00 6 hours 
Urine 12-Dec-12 DRH042EU 16:00:00 17:15:00 17:45:00 6 hours 
Serum 13-Dec-12 DRH102AS 05:55:00 09:00:00 09:50:00 overnight 
Urine 13-Dec-12 DRH102AU 06:00:00 09:20:00 09:50:00 overnight 
Serum 18-Dec-12 DRH103S 09:40:00 11:40:00 12:40:00 overnight 
Urine 18-Dec-12 DRH103U 09:45:00 11:15:00 12:40:00 overnight 
Serum 28-Dec-12 DRH029DS 09:00:00 10:05:00 10:30:00 overnight 
Urine 28-Dec-12 DRH029DU 09:05:00 09:55:00 10:30:00 overnight 
Serum 04-Jan-13 DRH098BS 06:00:00 08:30:00 08:55:00 overnight 
Urine 04-Jan-13 DRH098BU 05:55:00 08:20:00 08:55:00 overnight 
Serum 09-Jan-13 IHC141S 12:10:00 13:15:00 14:00:00 overnight 
Urine 09-Jan-13 IHC141U 12:30:00 13:00:00 14:00:00 overnight 
Serum 16-Jan-13 DRH104AS 10:00:00 12:20:00 13:05:00 overnight 
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Urine 16-Jan-13 DRH104AU 09:55:00 12:55:00 13:05:00 overnight 
Serum 16-Jan-13 DRH105AS 11:00:00 12:20:00 13:05:00 overnight 
Urine 16-Jan-13 DRH105AU 11:30:00 12:55:00 13:05:00 overnight 
Serum 17-Jan-13 DRH106AS 09:05:00 11:40:00 13:05:00 overnight 
Urine 17-Jan-13 DRH106AU 09:00:00 11:30:00 13:05:00 overnight 
Serum 17-Jan-13 DRH039ES 10:05:00 11:40:00 13:05:00 overnight 
Urine 17-Jan-13 DRH039EU 10:00:00 11:30:00 13:05:00 overnight 
Serum 17-Jan-13 DRH085BS 14:40:00 16:10:00 16:45:00 6 hours 
Urine 17-Jan-13 DRH085BU 14:35:00 15:55:00 16:45:00 6 hours 
Serum 18-Jan-13 DRH071CS 10:35:00 12:50:00 13:30:00 overnight 
Urine 18-Jan-13 DRH071CU 10:40:00 12:35:00 13:30:00 overnight 
Serum 19-Jan-13 DRH090BS 10:10:00 11:15:00 11:30:00 overnight 
Urine 19-Jan-13 DRH090BU 10:00:00 10:40:00 11:30:00 overnight 
Serum 23-Jan-13 DRH200AS 06:25:00 09:45:00 10:45:00 overnight 
Urine 23-Jan-13 DRH200AU 06:30:00 09:30:00 10:45:00 overnight 
Serum 29-Jan-13 DRH104BS 09:10:00 11:00:00 11:45:00 overnight 
Urine 29-Jan-13 DRH104BU 09:00:00 10:45:00 11:45:00 overnight 
Serum 29-Jan-13 DRH049DS 07:40:00 11:00:00 11:45:00 overnight 
Urine 29-Jan-13 DRH049DU 07:50:00 10:45:00 11:45:00 overnight 
Serum 29-Jan-13 DRH043DS 12:25:00 14:30:00 15:20:00 6 hours 
Urine 29-Jan-13 DRH043DU 12:30:00 14:40:00 15:20:00 6 hours 
Serum 30-Jan-13 DRH105BS 10:35:00 12:45:00 13:20:00 overnight 
Urine 30-Jan-13 DRH105BU 10:00:00 12:30:00 13:20:00 overnight 
Serum 31-Jan-13 DRH106BS 10:10:00 12:45:00 13:20:00 overnight 
Urine 31-Jan-13 DRH106BU 10:00:00 12:35:00 13:20:00 overnight 
Serum 31-Jan-13 DRH039FS 11:05:00 12:45:00 13:20:00 overnight 
Urine 31-Jan-13 DRH039FU 11:00:00 12:35:00 13:20:00 overnight 
Serum 01-Feb-13 DRH108S 08:30:00 13:10:00 13:35:00 overnight 
Urine 01-Feb-13 DRH108U 08:35:00 13:00:00 13:35:00 overnight 
Serum 01-Feb-13 DRH107S 08:25:00 13:10:00 13:35:00 overnight 
Urine 01-Feb-13 DRH107U 08:10:00 13:00:00 13:35:00 overnight 
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Serum 01-Feb-13 DRH097BS 09:45:00 13:40:00 14:20:00 overnight 
Urine 01-Feb-13 DRH097BU 09:50:00 13:25:00 14:20:00 overnight 
Serum 01-Feb-13 DRH096BS 12:05:00 14:05:00 15:35:00 eating mint sweets 
Urine 01-Feb-13 DRH096BU 12:10:00 13:55:00 15:35:00 eating mint sweets 
Serum 01-Feb-13 DRH102BS 11:55:00 14:05:00 15:35:00 overnight 
Urine 01-Feb-13 DRH102BU 11:50:00 13:55:00 15:35:00 overnight 
Serum 12-Feb-13 DRH086BS 11:00:00 12:10:00 overnight 
Urine 12-Feb-13 DRH086BU 11:10:00 12:10:00 overnight 
Serum 08-Feb-13 DRH018ES 09:00:00 10:30:00 overnight 
Urine 08-Feb-13 DRH018EU 10:00:00 10:30:00 overnight 
Serum 25-Feb-13 DRH200BS 13:50:00 15:10:00 16:10:00 6 hours 
Urine 25-Feb-13 DRH200BU 13:50:00 14:45:00 16:10:00 6 hours 
Serum 25-Feb-13 DRH098CS 14:00:00 15:10:00 16:10:00 6 hours 
Urine 25-Feb-13 DRH098CU 14:05:00 14:45:00 16:10:00 6 hours 
Serum 25-Feb-13 DRH042FS 13:40:00 15:10:00 16:10:00 6 hours 





8.4 Complete Metabolite List 
Name Compound Class Description 
(+/-)-1-Phenylethylmercaptan HMDB32467 Benzene and substituted derivates Food additive 
(+/-)-Dihydromintlactone HMDB32219 Not classified A food additive 
(±)-(E)-3-Methyl-4-decen-1-yl acetate HMDB32792 Fatty acyls Found in herbs and spices 
(±)-2-(3,4-Dihydroxyphenyl)-1,3-
benzodioxole-5-carboxaldehyde 
HMDB33088 Benzodioxoles Found in herbs and spices 
(±)-Glycerol 1-monophosphate K salt (1:2) HMDB40362 Not classified Food additive 
(±)-Glycerol 1-monophosphate Mg salt 
(1:1) 
HMDB40363 Not classified Food additive 
(±)-Sphaerosin HMDB38128 Not classified Found in the common bean 
(1RS,2RS)-Guaiacylglycerol 1-glucoside HMDB33300 Not classified From Scotch pine needles 
(1x,2x)-Guaiacylglycerol 2-glucoside HMDB33301 Not classified From Scotch pine needles 
(1x,2x)-Guaiacylglycerol 3-glucoside HMDB40600 Not classified From Scotch pine needles 
(2E,4Z,7Z)-2,4,7-Tridecatrienal HMDB33545 Fatty acyls Found in animal foods 
(2E,4Z,7Z)-2,4,7-Tridecatrienal HMDB33545 Fatty acyls Found in animal foods 
(2R,3R,4R)-2-Amino-4-hydroxy-3-
methylpentanoic acid 
HMDB29449 Fatty acyls Found in herbs and spices 
(3beta,5alpha,6beta,7alpha,22E,24R)-
Ergosta-8,22-diene-3,5,6,7-tetrol 
HMDB32107 Steroids and steroid derivatives Found in mushrooms 




HMDB38736 Not classified Found in herbs and spices 
(3xi,5Z)-1,5-Octadien-3-ol HMDB30966 Fatty acyls Found in crustaceans 
(9xi,10xi,12xi)-9,10-Dihydroxy-12-
octadecenoic acid 
HMDB31679 Fatty Acyls Found in fruits 
(E)-5,8-Megastigmadien-4-one HMDB34671 Carbonyl comp unds Found in fruits 
(E)-5,8-Megastigmadien-4-one HMDB34671 Carbonyl comp unds Found in fruit 
 
 570
(R)-(E)-4,7-Megastigmadien-9-one HMDB35753 Prenol lipids Flavouring agent 
(R)-(E)-4,7-Megastigmadien-9-one HMDB35753 Prenol lipids Found in essential oils 
(R)-3',7-Dihydroxy-2',4'-
dimethoxyisoflavan 
HMDB30717 Isoflavanoids Found in the common bean 
(R)C(R)S-S-Propylcysteine sulfoxide HMDB29442 Carboxylic acids and derivatives Found in onion family vegetables 
(R,S)-Norlaudanosoline HMDB12486 Not classified A key intermediate in the synthesis of the 
benzylisoquinoline alkaloids 
(S,E)-Filbertone HMDB35242 Not classified Found in nuts 
[12]-Gingerol HMDB36356 Benzene and substituted derivatives Found in ginger 
1-(2,4,5-Trimethoxyphenyl)-1,2-
propanedione 




HMDB39249 Not classified Found in herbs and spices 
1-(4-Methoxyphenyl)-2-nitroethylene HMDB32595 Benzee and substituted derivatives Used for the control of rice blast disease 
1,1-Diethoxy-2,6-nonadiene HMDB38078 Ethers A flavouring ingredient 
1,2,3,4-Tetrahydro-beta-carboline HMDB12488 Indoles and derivatives Found in chocolate and cocoa 
1,2,3,4-Tetrahydro-beta-carboline HMDB12488 Indoles and derivatives A potential neuroactive alkaloid found in chocolate 
and cocoa 
1,2-Benzisothiazol-3(2H)-one HMDB34413 Benzothiazoles An industrial biocide 
1,2-Bis(1-ethoxyethoxy)propane HMDB37163 Ethers A flavouring agent 
1,2-Epoxy-1,2,7,7',8,8',11',12'-octahydro-
psi,psi-carotene 
HMDB29854 Not classified Found in tomatoes 
1,4'-Bipiperidine-1'-carboxylic acid HMDB60336 Piperidines A piperidinecarboxylic acid 
11-alpha-O-beta-D-Glucopyranosyl-
16alpha-O-methylneoquassin 
HMDB39773 Prenol lipids Aconstituent of Quassia amara 
12,13-DHOME HMDB04705 Fatty Acyls The epoxide hydrolase metabolite of the 
leukotoxin12,13-EpOME 









HMDB35273 Fatty acyls Found in fruits 
1D-Myo-inositol 1,3,4,6-tetrakisphosphate HMDB01187 Alcohols and polyols A substrate for Tyrosine-protein kinase BTK and 
Inositol polyphosphate multikinase 
1D-Myo-inositol 1,4,5,6-tetrakisphosphate HMDB04527 Alcohols and polyols Regulates chloride transport 
1-Ethylhexyl tiglate HMDB37626 Fatty acyls A flavouring ingredient 
1-Hydroxy-3,6,7-trimethoxy-2,8-
diprenylxanthone 
HMDB36597 Benzopyrans Found in fruits 
1-Penten-3-one HMDB31607 Carbonyl compounds Found in an mal foods 
2,3-Diaminopropionic acid HMDB02006 Carboxylic acids and derivatives A non-proteogenic amino acid found in antibiotics 
2,3-Diethylpyrazine HMDB41253 Diazines Found in cereals and cereal products 
2,3-Dihydrothiophene HMDB33875 Dihydrothiophenes A Maillard product 
2,3-Octanedione HMDB01568 Carbonyl compounds Found in coffee and coffee products 
2,4,4-Trimethylcyclopentanone HMDB31197 Carbonyl comp unds Found in fats and oils 
2,4-Diaminobutyric acid HMDB02362 Carboxylic acids and derivatives A non-physiological, cationic amino acid 
analogue, used in glioma treatment 
2,4-Diisopropyl-3-methylphenol HMDB29824 Benzene and substituted derivatives Found in herbs and spices 
2,4-Diisopropyl-3-methylphenol HMDB29824 Benzene and substituted derivatives Found in herbs and spices 
2,4-Diisopropyl-5-methylphenol HMDB29823 Prenol lipids Found in herbs and spices 
2,4-Diisopropyl-5-methylphenol HMDB29823 Prenol lipids Found in herbs and spices 
2,5-Dichloro-4-oxohex-2-enedioate HMDB60363 Keto acids and derivatives Medium chain keto acid 
2,5-Diethylpyrazine HMDB36808 Diazines Found in coffee and coffee products 
2,5-Diisopropyl-3-methylphenol HMDB29822 Prenol lipids Found in herbs and spices 
2,5-Diisopropyl-3-methylphenol HMDB29822 Prenol lipids Found in herbs and spices 
2,6-Diisopropylnaphthalene HMDB59902 Naphthalenes Plant growth regulator 
2,6-Dimethoxy-4-phenanthrenol HMDB32890 Phenanthrenes and derivatives Found in poppy seeds, and opium extracts 
2,6-Dimethylbenzenethiol HMDB32019 Benzene and substit ted derivates Food additive 
2',7-Dihydroxy-4',6-dimethoxyisoflavan HMDB33996 Isoflavanoids Found in pulses 
2-[(2-Furanylmethyl)thio]-6-methylpyrazine HMDB36187 Thioethers Present in pumpkin seed oil 
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23-trans-p-Coumaroyloxytormentic acid HMDB40682 Prenol lipids Found in fruits 
28-Glucosylpomolate HMDB38452 Prenol lipids Found i herbs and spices 
2-Arachidonylglycerol HMDB11549 Glycerolipids A monacylglyceride and endogenous ligand for 
the cannabinoid receptors 
2-Carboxy-4-dodecanolide HMDB30987 Not classified Found in milk and milk products 
2-Carboxy-5,7-dimethyl-4-octanolide HMDB30986 Lactones Found in milk and milk products 
2-Ethyl-3,(5 or 6)-dimethylpyrazine HMDB32276 Diazines Found in coffee and coffee products 
2-Ethylbenzenethiol HMDB41361 Benzene and substituted derivates Flavouring ingredient in coffee 
2-Ethylglutaric acid HMDB59738 Not classified A fatty acid containing a branched chain 
2-Hexenyl acetate HMDB40212 Carboxylic acids and derivatives Found in fruits 
2-Hydroxy-22-methyltetracosanoic acid HMDB40909 Fatty cyls Found in lanolin wool fat 
2-Methyl-3 or 5 or 6-(furfurylthio)pyrazine 
(mixture of isomers) 
HMDB32414 Thioethers Food additive 
2-Methylbutyroylcarnitine HMDB00378 Fatty acyls Not usually detected in normal individuals and its 
elevation suggests a deficiency of a dehydrogenase 
specific for isobutyryl-CoA 
2-Methylbutyrylglycine HMDB00339 Carboxylic acids and derivatives An acyl glycine, normally a minor metabolite of 
fatty acids 
2-Octen-4-one HMDB31301 Carbonyl compounds Found in cereal and cereal products 
2-Octenal HMDB30961 Carbonyl compounds A flavouring i redient 
2-Octenoic acid HMDB00392 Fatty acyls Medium chain f tty acid 
2-Propylsuccinic acid HMDB61239 Not classified Dicarboxylic acid 
3,3',4,4'-Tetrachloroazobenzene HMDB32856 Azobenzenes An environmental pollutant arising from the soil 
degradation of DXZ32-P and related herbicides 
3,4,5-Trimethoxycinnamic acid HMDB02511 Cinnamic acids and derivatives Found in pepper 
3,4-Diethylthiophene HMDB40236 Heteroaromatic compounds Found in garden onion 
3-Dehydrocarnitine HMDB12154 Keto acids and derivatives An intermediate in carnitine degradation 
3'-Deoxyoleacein HMDB37494 Benzene and substituted derivatives Found in fats and oils 




3-Hydroxy-4-aminopyridine HMDB60741 Pyridines and derivatives A metabolite of dalfampridine, used in the
management of multiple sclerosis 
3-keto-2-Methylbutyrate HMDB29172 Not classified Used in the diagnosis of beta-ketothiolase 
deficiency 
3-Methoxy-4,5-methylenedioxybenzoic acid HMDB30800 Benzene and substituted derivatives Found in green v getables 
3-Methoxymorphinan HMDB14045 Morphinans A metabolite of dextromethorphan 
3-Methyladipic acid HMDB00555 Fatty acyls A metabolite of the catabolism of phytanic acid 
3'-O-Methyl-(-)-epicatechin-7-O-sulphate HMDB29177 Flavanoids A urinary and gut-derived metabolite of 
epicatechin 
3-Phenylpropyl hexanoate HMDB36390 Fatty acyls A flavouring ingredient 
3-Succinoylpyridine HMDB00992 Keto acids and derivati es The byproduct of tobacco-specific N-nitrosamines 
generated by the enzyme cytochrome P 450 which 
catalyzes methylnitrosaminopyridylbutanone 
hydroxylation 
3-Sulfodeoxycholic acid HMDB02504 Steroids and steroid deivatives Sulfated steroid, a sterol lipid contai ing a sulfate 
group 
3-trans-Caffeoyltormentic acid HMDB40650 Prenol lipids Found in fruits 
4-(2,6,6-Trimethylcyclohex-1-enyl)but-2-
en-4-one 
HMDB32541 Carbonyl compounds Found in tea 
4-(2,6,6-Trimethylcyclohex-1-enyl)but-2-
en-4-one 
HMDB32541 Carbonyl compounds Found in tea 
4-(3-Hydroxybutyl)-3,3,5-
trimethylcyclohexanone 
HMDB39805 Prenol lipids Found in alcoholic beverages 
4,10-Longipinanedione HMDB32081 Prenol lipids Found i  herbs and spices 
4',5-Dihydroxy-7-methoxy-6-methylflavone HMDB29512 Flavonoids Found in beverages 
4-Hydroxy-benzenepropanedioate HMDB59809 Benzene and substituted derivatives An aromatic compound containing a benzene ring 
substituted by a hydroxyl group and an ester group 
4-Hydroxystachydrine HMDB29230 Carboxylic acids and derivatives Biomarker of citrus consumption found i  urine 
4-Methylphenyl octanoate HMDB37710 Benzene and substit ted derivatives Flavouring ingredient 
4-Phosphopantothenoylcysteine HMDB01117 Carboxylic acids and derivatives An intermediate in the biosynthetic pathway that 




4-Thiocyanatophenol HMDB40578 Benzene and substituted derivatives From fruits and vegetables 
4-Thiocyanatophenol HMDB40578 Benzene and substituted derivatives Found in fruits 
5,6,8-Trihydroxy-2-
methylbenzo[g]chromen-4-one 
HMDB33911 Naphthopyrans Found in coffee and coffee products 
5a-Cholest-8-en-3b-ol HMDB06841 Steroids and steroid derivatives An intermediate of cholesterol synthesis 
5alpha-Cholestanone HMDB00871 Steroids and steroid derivatives An oxidation product of coprosterol 
5-Aminoimidazole HMDB03929 Azoles An intermediate in the formation of purines 
5-beta-Cholestan-3-one HMDB59604 Steroids and steroid derivatives Part of the Primary bile acid biosynthesis, and 
steroid hormone biosynthesis pathways 
5beta-Cholestanone HMDB11182 Steroids and steroid derivatives An oxidation product of coprosterol 
5-Decanoyl-2-nonylpyridine HMDB35516 Carbonyl compound Found in herbs and spices 
5-Methyl-5-hepten-2-one HMDB31591 Carbonyl compounds Found in root vegetables 
5-Octen-2-one HMDB35390 Carbonyl compounds Found in citrus 
6-Hydroxy-2,6-dimethyl-2,7-octadien-4-one HMDB34670 Prenol lipids Found in citrus 
6-Mercaptopurine riboside HMDB61269 Imidazopyrimidines A metabolite of mercaptopurine 
6-Octenal HMDB39769 Carbonyl compounds Food additive 
6-Thioinosinic acid HMDB60791 Carbohydrates and carbohydrate conjugates A metabolite of azathioprine 
6-trans-Leukotriene B4 HMDB05087 Fatty Acyls An enzymatic metabolite of leukotriene 
B4(LTB4). 
7(14)-Bisabolene-2,3,10,11-tetrol HMDB35918 Not classified A mycotoxin of Fusarium sambucinum 
7,9-Illudadiene-3,14-diol HMDB38795 Not classified Found in mushrooms 
7-Aminoflunitrazepam HMDB41818 Benzodiazepines A pharmacologically-active metabolite of 
flunitrazepam 
7-Hydroxycostal HMDB35202 Not classified Found in potato 
8,15-Isopimaradien-18-oic acid HMDB35692 Prenol lipids Found in pine tree resin 
8-Hydroxyguanosine HMDB02044 Purine nucleosides A marker for measuring the rate of oxidative 
damage to nucleic acids and lipids 
8-Hydroxyhesperetin 7-[6-acetylglucosyl-
(1->2)-glucoside] 
HMDB41232 Flavonoids Found in tea 
9,10-DHOME HMDB04704 Fatty Acyls A derivative of linoleic acid diol 
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Acetamide HMDB31645 Carboxylic acids and derivatives Found in red beetroot 
Acetyl-N-formyl-5-methoxykynurenamine HMDB04259 Benzene and substituted derivatives Results from the oxidative cleavage of the pyrrole 
ring during melatonin oxidation by 
myeloperoxidase 
Adouetine Y HMDB34101 Not classified Found in tea 
Adrenochrome HMDB12884 Not classified A pigment obtained by the oxidation of adrenaline 
Alfafuran HMDB38677 2-arylbenzofuran flavonoids Found in pulses 
Alfalone HMDB38811 Isoflavonoids Found in alfalfa 
Alpha-Carboxy-delta-decalactone HMDB30985 Lactones Found in milk and milk products 
alpha-Damascone HMDB36027 Not classified Found in tea 
alpha-Damascone HMDB36027 Not classified Found in tea 
alpha-Methylstyrene HMDB59899 Benzene and substituted derivatives Used in the manufacture of plasticisers, resins and 
polymers 
Alpha-N-Phenylacetyl-L-glutamine HMDB06344 Carboxylic acids and derivatives A product formed by the conjugation of 
phenylacetate and glutamine 
Alternariol HMDB30831 Coumarins and derivatives A mycotoxin produced by Alternaria fungi 
Alternariol HMDB30831 Coumarins and derivatives Found in mushrooms 
Ambenonium HMDB15254 Carboxylic acids and derivatives A cholinesterase inhibitor used in the management 
of myasthenia gravis 
Aminomalonic acid HMDB01147 Carboxylic acids and derivatives Isolated from proteins of E.coli and atherosclerotic 
plaque 
Ammonium peroxydisulfate HMDB37638 Non-metal oxoanionic compounds A strong oxidising agent 
Anguidol HMDB35846 Prenol lipids Produced by Fusarium roseum, Fusarium equiseti 
and Fusarium sporotrichiella 
Apigenin 7-sulfate HMDB37851 Flavonoids Isolated from Bixa orellana 
Arginyl-Phenylalanine HMDB28716 Carboxylic acids and derivatives An incomplete breakdown product of protein 
digestion or protein catabolism 
Artabsinolide D HMDB34941 Prenol lipids Found in alcoholic beverages 
Artocarpetin B HMDB33148 Flavanoids Found in fruits 
Artonol D HMDB30495 Not classified Found in breadfruit 
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Ascochitine HMDB30145 Benzene and substituted derivates Causes rot in broad bean 
Austalide C HMDB34075 Benzopyrans A metabolite of Aspergillus ustus 
Benzyl methyl sulfide HMDB31314 Benzene and substituted derivates Found in animal foods 
Beta-Citryl-L-glutamic acid HMDB13220 Carboxylic acids and derivatives A derivative of glutamic acid 
Betahistine HMDB15644 Amines An anti-vertigo drug 
Biliverdin HMDB01008 Tetrapyrroles and derivatives A byproduct of hemoglobin breakdown 
Bisbynin HMDB41324 Not classified Found in cereals nd cereal products 
Bn-NCC-2 HMDB38230 Tetrapyrroles and derivatives Found in brassicas 
Butyl (S)-3-hydroxybutyrate [arabinosyl-(1-
>6)-glucoside] 
HMDB39214 Not classified Found in fruits 
Butyl 1-(methylthio)propyl disulfide HMDB33049 Organic disulfides Found in onion family vegetables 
Butyl 1-(methylthio)propyl disulfide HMDB33049 Organic disulphides From fruits and vegetables 
Calystegine A3 HMDB38593 Tropane alkaloids Found in alcoholic beverages 
Calystegine A6 HMDB31345 Tropane alkaloids Found in coffee 
Calystegine A7 HMDB36384 Not classified An alkaloid from the roots of Lycium chinense 
Canescein HMDB29313 Steroids and steroid derivatives Isolated from Convallaria majalis 
Canesceol HMDB34084 Steroids and steroid derivatives Isolated from Convallaria majalis 
Casomorphin HMDB59787 Not classified A protein found i  the milk of mammals 
Ceanothine C HMDB29340 Carboxylic acids and derivatives Found in tea 
Ceanothine D HMDB29341 Carboxylic acids and derivatives Found in tea 
Ceanothine E HMDB29342 Not classified Found in tea 
Cefuroxime HMDB15244 Lactams A broad-spectrum cephalosporin antibiotic 
resistant to beta-lactamase 
Cellobiose HMDB00055 Carbohydrates and carbohydrate conjugates Obtained from the partial hydrolysis of cellulose 
Cerebroside B HMDB35990 Sphingolipids Found in mushrooms 
Chlophedianol HMDB15585 Benzene and substituted derivatives Centrally acting cough suppressant 
Chlordiazepoxide HMDB14618 Benzodiazepines An anxiolytic benzodiazepine derivative 
Chloromethyl methyl ether HMDB31332 Ethers used to modify ion-exchange membranes used in 
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the production of grapefruit juice 
Chlorprothixene HMDB15369 Benzothiopyrans An antipsychotic medication 
Chlorprothixene HMDB15369 Benzothiopyrans An antipsychotic drug of the thioxanthene 
(tricyclic) class 
Cholesterol HMDB00067 Steroids and steroid derivatives A sterol (a combination steroid and alcohol) and  
lipid found in the cell membranes of all body 
tissues, and transported in the blood plasma of all 
animals 
Cinncassiol D2 glucoside HMDB34679 Prenol lipids Found in herbs and spices 
cis-3-Hexenyl acetate HMDB40215 Carboxylic acids and derivatives Found in dill, green tea and fruit volatiles 
Citalopram N-oxide HMDB60654 Not classified Metabolite of citalopram 
Citalopram propionic acid HMDB60463 Not classified A metabolite of citalopram 
Citric acid HMDB00094 Carboxylic acids and derivaties A weak acid that is formed in the tricarboxylic 
acid cycle or that may be introduced with diet 
Citronellyl propionate HMDB37226 Fatty acyls Found i  garden tomato 
Coniferan HMDB31741 Not classified A food additive 
CPA(18:2(9Z,12Z)/0:0) HMDB07007 Lineolic acid and derivatives A cyclic phosphatidic acid or cyclic 
lysophosphatidic acid 
Cyclamic acid HMDB31340 Sulfamic acid derivatives An artificial sweetening agent 
Cycloartanyl ferulate HMDB36295 Not classified Found i  cereal and cereal products 
Cyclohexaneacetic acid HMDB31403 Carboxylic acids and derivatives Flavouring ingredient 
Cynaratriol HMDB34983 Prenol lipids Found in cardoon 
Cyromazine HMDB29862 Triazines An insect growth regulator 
Cysteinyl-Methionine HMDB28781 Carboxylic acids and derivatives A dipeptide composed of cysteine and methionine 
Dambonitol HMDB33942 Alcohols and polyols Latex used for manufacture of chewing gum 
Delavirdine HMDB14843 Diazinanes A non-nucleoside reverse transcriptase inhibitor 
with activity specific for HIV-1 
Desmethyl frovatriptan HMDB60815 Indoles and derivatives A metabolite of frovatriptan, used in the trea ment 
of migraine 
Desvenlafaxine HMDB15646 Not classified Metabolite of venlafaxine 
 
 578
Dextrorphan HMDB60552 Morphinans A metabolite of dextromethorphan 
Dezocine HMDB15340 Tetralins A partial opiate drug 
Dhurrin HMDB60471 Carbohydrates and carbohydrate conjugates Found in plants 
Di-2-propenyl tetrasulfide HMDB33202 Sulfenyl compounds Found in onion family vegetables 
Dibutyl decanedioate HMDB41220 Fatty Acyls Used in fruit flavouring 
Difluorodeoxyuridine monophosphate HMDB61204 Pyrimidine nucleosides Metabolite of gemcitabine 
Dihydro-5-Hydroxyrofecoxib HMDB61182 Dihydrothiophines Found in animal foods 
Dihydromethysticin HMDB30791 Not classified Found in beverages 
Dihydrophaseic acid HMDB38660 Prenol lipids Found i coconut and French beans 
Dihydroxybutanoic acid HMDB00360 Fatty acyls An organic acid that is a major component of CSF 
di-Hydroxymelatonin HMDB61136 Indoles and derivatives Metabolite of melatonin 
Dimethadione HMDB61093 Azolines aAmetabolite of trimethadione, an 
oxazolidinedione anticonvulsant 
Dimethyl sulfoxide HMDB02151 Sulfoxides A key dipolar aprotic solvent 
Dimethylprotoporphyrin IX dimethyl ester HMDB00810 Tetrapyrroles and derivatives The hepatic pigment accumulated as a 
consequence of the self-catalyzed destruction of 
cytochrome P-450 by norethisterone 
Diphenhydramine N-glucuronide HMDB60897 Carbohydrates and carbohydrate conjugates A metabolite of diphenhydramine 
Divinyl sulfide HMDB33922 Thioethers Found in onion family vegetables 
D-Myo-inositol 3,4,5,6-tetrakisphosphate HMDB03848 Alcohols and polyols Has a direct biphasic (activation/inhibition) effect 
on an epithelial calcium-activated chloride channel 
Doristerol HMDB29815 Steroids and steroid derivatives Found in root vegetables 
Doxepin HMDB15273 Benzoxepines Tricyclic antidepressant 
Dutasteride HMDB15258 Steroids and steroid derivatives 5-alpha-reductase inhibitor 
Edulan I HMDB34959 Benzopyrans Flavour constituent in purple passion fruit 
Edulan I HMDB34959 Benzopyrans Found in fruit 
Eicosane HMDB59909 Alkanes Acyclic hydrocarbon 
ent-8(17),13(16),14-Labdatrien-18-oic acid HMDB39486 Prenol lipids Found in fruits 
Epidihydrophaseic acid HMDB38661 Prenol lipids Found i  pulses 
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Erythritol HMDB02994 Carbohydrates and carbohydrate conjugates Found in wine, sake, beer, water melon, pear, 
grape and soy sauce 
Etamiphylline HMDB41889 Not available (Super Class Alkaloids and 
derivatives) 
Agent for the treatment of asthma 
Ethyl (±)-2-methyl-4-pentenoate HMDB29761 Fatty acyls Flavouring agent 
Ethyl 1-(propylthio)propyl disulfide HMDB33048 Organic disulphides From fruits and vegetables 
Ethyl 1-(propylthio)propyl disulfide HMDB33048 Organic disulfides Found in fruits 
Ethyl 10-undecenoate HMDB34286 Fatty acyls Found in alcoholic beverages 
Ethyl 2E-hexenoate HMDB32268 Fatty acyls Flavouring agent 
Ethyl beta-D-glucopyranoside HMDB29968 Carbohydrates and carbohydrate conjugates Found in pulses 
Eucaglobulin HMDB36742 Saccharolipids A constituent of Eucalyptus globulus 
Fagomine HMDB33453 Piperidines Found in fruits 
Ferrocytochrome HMDB12947 Not classified A cytochrome containing reduced iron 
Fluorescein HMDB14831 Benzopyrans A phthalic indicator dye that appears yellow-green 
in normal tear film and bright green in a more 
alkaline medium 
Fluvoxamine HMDB14322 Benzene and substituted derivatives An antidepressant which functions 
pharmacologically as a selective serotonin 
reuptake inhibitor 
Fructose HMDB00660 Carbohydrates and carbohydrate conjugates A simple monosaccharide found in fruits and 
berries 
Galactose HMDB00143 Carbohydrates and carbohydrate conjugates An energy-providing nutrient 
Gentisin HMDB31760 Benzopyrans Found in alcoholic beverages 
Germacrone 4,5-epoxide HMDB35889 Prenol lipids Found in tumeric 
Glucuronic acid HMDB00127 Carbohydrates and carbohydrate conjugates Synthesised in the uronic acid pathway 
Glycerol HMDB00131 Carbohydrates and carbohydrate conjugates An important component of triglycerides and
phospholipids 
Glycyrin HMDB33712 Isoflavanoids Found in root vegetables 
Goshonoside F1 HMDB38539 Not classified Found in fruits 
Goshonoside F2 HMDB38540 Not classified Found in fruits 
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Guanethidine HMDB15301 Guanidines An antihypertensive agent 
Gyromitrin HMDB33952 Hydrazines and derivatives Found in mushrooms 
Hippuric acid HMDB00714 Benzene and substituted derivatives An acyl glycine formed by the conjugation f 
benzoic acid with glycine 
Hordatine B HMDB30459 2-arylbenzofuran flavonoids Found in barley 
Hydroxy-alpha-sanshool HMDB29567 Alcohols and polyols Found in herbs and spices 
Hydroxylamine HMDB03338 Homogenous other non-metal compounds Used in organic synthesis and as a reducing agent 
Imidazole-4-acetaldehyde HMDB03905 Azoles Aldehyde metabolite of histamine 
Imidazole-4-acetaldehyde HMDB03905 Azoles A metabolite of histamine 
Imidazoleacetic acid riboside HMDB02331 Imidazole ribonucleosides and 
ribonucleotides 
A metabolite of imidazoleacetic acid, histamine's 
oxidative metabolite 
Indane HMDB59837 Indanes A hydrocarbon petrochemical compound 
Inositol 1,3,4,5-tetraphosphate HMDB01059 Alcohols and polyols A common regulator in calcium homeostasi  
Isogentisin HMDB30871 Benzopyrans Found in alcoholic beverages 
Isomucronulatol HMDB33189 Not classified Found in the common bean 
Isospirene HMDB36022 Dihydrofurans A fragrance ingredient 
Isospirene HMDB36022 Dihydrofurans Fragrance ingredient 
Isotridecanol Not classified Not classified Fatty alcohol 
Kanokoside A HMDB35635 Not classified Found in fats nd oils 
Kanzonol G HMDB40613 Isoflavanoids Found in herbs and spices 
Kanzonol O HMDB41102 Not classified Found in herbs and spices 
L-2,4-diaminobutyric acid HMDB06284 Carboxylic acids and derivatives a component of branched-chain amio acid 
biosynthesis and metabolism 
Lactose HMDB00186 Carbohydrates and carbohydrate conjugates The major sugar present in milk 
Lathosterol HMDB01170 Steroids and steroid derivatives A sterol (a combination steroid and alcohol) and  
lipid found in the cell membranes of all body 
tissues, and transported in the blood plasma of all 
animals 
Levorphanol HMDB14992 Morphinans A narcotic analgesic 
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Licoricone HMDB29515 Isoflavanoids Found in herbs and spices 
Lisdexamfetamine HMDB15385 Carboxylic acids and derivatives Agent for the treatment of attention deficit 
hyperactivity disorder 
Lithocholate 3-O-glucuronide HMDB02513 Steroids and steroid derivatives Found in bile 
Loratadine HMDB05000 Benzocyclohepatapyridines Tricycli  antihistamine 
Lucyoside Q HMDB29621 Prenol lipids Found in fruits 
Luteolin 4'-sulfate HMDB38471 Flavonoids Found in carrot 
LysoPE(0:0/24:6(6Z,9Z,12Z,15Z,18Z,21Z)) HMDB11499 Glycerophospholipids A lysophospholipid 
LysoPE(24:6(6Z,9Z,12Z,15Z,18Z,21Z)/0:0) HMDB11529 Glycerophospholipids A lysophospholipid 
Lysyl-Proline HMDB28959 Carboxylic acids and derivat es An incomplete breakdown product of protein 
digestion or protein catabolism 
Lysyl-Valine HMDB28964 Carboxylic acids and derivati es A dipeptide composed of lysine and valine 
Malonic acid HMDB00691 Carboxylic acids and derivati es Acts against succinate dehydrogenase (complex II) 
in the respiratory electron transport chain 
Marasmene HMDB36035 Furofurans Found in mushrooms 
Maslinic acid 3-O-b-D-glucoside HMDB29606 Not classified Found in fruits 
Matricarin HMDB35790 Prenol lipids Found in fats and oils 
Medicanine HMDB38625 Carboxylic acids and derivatives Found in pulses 
Mesoporphyrin IX HMDB02379 Tetrapyrroles and derivati es Porphyrin that inhibits interferon-gamma and 
interleukin-6 production 
Methionyl-Cysteine HMDB28970 Carboxylic acids and derivatives A dipeptide composed of methionine and cysteine 
Methoxypyrazine HMDB33156 Diazines A flavouring agent 
Methyl (E)-2-dodecenoate HMDB31028 Fatty acyls Found in pomes 
Methyl acrylate-divinylbenzene, completely 
hydrolyzed, copolymer 
HMDB32389 Pyridines and derivatives Used as a food ad itive 
Methyl n-formylanthranilate HMDB32398 Benzene and substituted derivatives A food additive 
Methyl propenyl ketone HMDB01184 Carbonyl compounds A volatile organic compound 
Methyl salicylate O-[rhamnosyl-(1->6)-
glucoside] 
HMDB33138 Carbohydrates and carbohydrate conjugates Found in fruits 
Methyltestosterone HMDB15655 Steroids and steroid derivatives Anabolic sterois 
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MG(0:0/20:4(8Z,11Z,14Z,17Z)/0:0) HMDB11549 Glycerolipids A monoacylglyceride 
MG(20:4(5Z,8Z,11Z,14Z)/0:0/0:0) HMDB11578 Glycerolipids A monoacylglyceride 
MG(20:4(8Z,11Z,14Z,17Z)/0:0/0:0) HMDB11579 Glycerolipids A monoacylglyceride 
Mianserin HMDB15620 Benzazepines A tetracyclic compund with antidepressant effects 
Momordicin II HMDB35966 Steroids and steroid derivat es Found in bitter gourd 
Momordicoside L HMDB35917 Prenol lipids Found in bitter gourd 
Mono-methyl-adipate HMDB59722 Fatty acyls Medium-chain fatty acids 
Moreollin HMDB30795 Not classified Found in fruits 
Musabalbisiane B HMDB38681 Prenol lipids Found in fruits 
Myo-inositol HMDB00211 Alcohols and polyols A product of glycerophospholipid metabolism 
Myricetin 3,3'-digalactoside HMDB37850 Not classified Found in herbs and spices 
N-(1-Deoxy-1-fructosyl)methionine HMDB37841 Carbohydrates and carbohydrate conjugates Food additive 
N-(2-Hydroxyethyl)-morpholine N-oxide HMDB61157 Oxazinanes A metabolite of mycophenylate mofetil 
N4-Acetylsulfamethoxazole HMDB13854 Benzene and substituted derivatives A metabolite of Sulfamethoxazole 
N-Acetylglutamine HMDB06029 Carboxylic acids and derivatives From fruits and vegetables 
N-Acetylvaline HMDB11757 Carboxylic acids and derivati es A derivative of valine 
N-Acryloylglycine HMDB01843 Carboxylic acids and derivatives An acyl glycine, normally a minor metabolite of 
fatty acids 
N-Desmethylvenlafaxine HMDB13892 Not classified Metabolite of venlafaxine 
N-Nitroso-pyrrolidine HMDB31642 Pyrrolidines Found in animal foods 
Noroxymorphone HMDB61073 Morphinans A metabolite of oxymorphone 
NTP HMDB60500 c-glycosyl compounds Provides energy and a phosphate group for 
phosphorylations 
Octadecanedioic acid HMDB00782 Fatty Acyls A long-chain dicarboxylic acid 
Octanoic acid HMDB59831 Fatty acyls A carboxylic ester derivative of a fatty acid 
O-Desmethylvenlafaxine HMDB60532 Not classified Metabolite of venlafaxine 
Oleic acid HMDB00207 Fatty acyls An unsaturated fatty cid that is the most widely 
distributed and abundant fatty acid in nature 
 
 583
Oltipraz HMDB41967 Diazines A dithiole derivative and a schistosomicide 
Ortho-hydroxyatorvastatin HMDB61015 Not classified A metabolite of atorvastatin 
Oxacyclotetradecan-2-one HMDB40451 Macrolides and analogues Found in fats and oils 
Oxaprozin HMDB15126 Azoles An anti-inflammatory medication 
Oxytetracycline HMDB14733 Tetracyclines Isolated from the actinomycete streptomyces 
rimosus, used as an antibiotic 
Para-hydroxyatorvastatin HMDB61014 Not classified A metabolite of atorvastatin 
PC(14:0/18:0) HMDB07871 Glycerophospholipids A glycerophospholipid in which a 
phosphorylcholine moiety occupies a glycerol 
substitution site 
PC(16:0/16:0) HMDB00564 Glycerophospholipids A glycerophospholipid in which a 
phosphorylcholine moiety occupies a glycerol 
substitution site 
PC(18:0/14:0) HMDB08031 Glycerophospholipids A glycerophospholipid in which a 
phosphorylcholine moiety occupies a glycerol 
substitution site 
p-Chlorobenzene sulfonyl urea HMDB14026 Benzene and substituted derivatives Found in individuals that ve used or taken 
chlorpropamide, used in diabetes mellitus 
treatment 
PE(15:0/20:0) HMDB08899 Glycerophospholipids A glycerophospholipid in which a 
phosphorylethanolamine moiety occupies a 
glycerol substitution site 
PE(20:0/15:0) HMDB09219 Glycerophospholipids A glycerophospholipid in which a 
phosphorylethanolamine moiety occupies a 
glycerol substitution site 
PE(20:4(8Z,11Z,14Z,17Z)/P-18:1(9Z)) HMDB09447 Glycerophospholipids A glycerophospholipid in which a 
phosphorylethanolamine moiety occupies a 
glycerol substitution site 
PE(22:5(4Z,7Z,10Z,13Z,16Z)/P-16:0) HMDB09642 Glycerophospholipids A glycerophospholipid in which a 
phosphorylethanolamine moiety occupies a 
glycerol substitution site 
PE(P-16:0/22:5(4Z,7Z,10Z,13Z,16Z)) HMDB11359 Glycerophospholipids A glycerophospholipid in which a 
phosphorylethanolamine moiety occupies a 
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glycerol substitution site 
PE(P-18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) HMDB11451 Glycerophospholipids A glycerophospholipid in which a 
phosphorylethanolamine moiety occupies a 
glycerol substitution site 
Pentanoic acid HMDB00892 Fatty Acyls Straight chain f tty acid 
Peroxynitrite HMDB02179 Non-metal oxoanionic compounds A potent oxidant synthesised by the cell during its 
normal metabolism 
Persenone A HMDB36568 Not classified Found in fruits 
Phenelzine HMDB14918 Benzene and substituted derivatives An irreversible non-selective inhibitor of 
monoamine oxidase, used in depression 
Phenylalanyl-Arginine HMDB28989 Not classified An incomplete breakdown product of protein 
digestion or protein catabolism 
Phosphate HMDB01429 Non-metal oxoanionic compounds A salt of phosphoric acid 
p-HPEA-EDA HMDB29305 Benzene and substituted derivatives Found in olive 
Phytoene 1,2-epoxide HMDB36875 Prenol lipids Found in tomatoes 
Pimelic acid HMDB00857 Fatty acyls A group of compounds that are derivatives of 
heptanedioic acid with the general formula R-
C7H11O4 
Pipermethystine HMDB33486 Benzene and substituted derivatives An alkaloid from the leaves of kava 
Pivaloylcarnitine HMDB41993 Fatty acyls An acyl carnitine 
Porric acid C HMDB31898 Benzofurans Found in onion-family vegetables 
Prolyl-Lysine HMDB29022 Not classified An incomplete breakdown product of protein 
digestion or protein catabolism 
Propanetricarboxylic acid HMDB31193 Carboxylic acids and derivatives Found in corn 
Protoporphyrinogen IX HMDB01097 Tetrapyrroles and derivatives An intermediate in heme synthesis 
Ptelatoside A HMDB32600 Not classified Found in green vegetables 
Pyridoxamine HMDB01431 Pyridines and derivatives The 4-aminomethyl form of vitamin B6 
Pyroglutamic acid HMDB00267 Carboxylic acids and derivatives A cyclised derivative of L-glutamic acid 
Pyrrolidonecarboxylic acid HMDB00805 Carboxylic acids and derivatives A cyclic derivative of glutamic acid 
Quercetin 3-(3'',6''-di-p-coumarylglucoside) HMDB37373 Not classified Found in Scotch pine 
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Retinyl ester HMDB03598 Prenol lipids The storage form of vitamin A 
Rhazidigenine Nb-oxide HMDB30263 Indoles and derivatives An alkaloid from the bark of Aspidosperma 
quebracho-blanco 
Rhodinyl propionate HMDB37187 Fatty acyls A flavouring ingredient 
Rishitinol HMDB38190 Not classified Found in alcoholic beverages 
Roxatidine acetate HMDB15695 Piperidines A drug metabolite 
S-Acetyldihydrolipoamide HMDB01526 Fatty acyls An intermediate in alanine, aspartate and pyruvate 
metabolism and glycolysis/gluconeogenesis 
S-Acetyldihydrolipoamide-E HMDB06878 Fatty acyls The acetyl thioester of the reduced lipoyllysine 
residue in dihydrolipoyllysine-residue 
acetyltransferase 
S-aminomethyldihydrolipoamide HMDB06239 Fatty acyls An intermediate in the glycine, serine, threonine 
metabolism pathway 
Sayanedin HMDB30718 Isoflavonoids Found in the common pea 
Scorzonoside HMDB38718 2-arylbenzofuran flavonoids Found in coffee and coffee products 
Serine HMDB00187 Carboxylic acids and derivatives A non-essential amino acid derived from glycine 
S-Furanopetasitin HMDB36131 Prenol lipids Found in herbaceous plants 
Sibutramine HMDB15237 Benzene and substituted derivatives Agent for the treatment of obesity 
Soyasapogenol B 3-O-b-D-glucuronide HMDB39329 Not classified Formed by acid or alkaline hydrolysis of 
soyasaponins 
Spirapril HMDB15438 Carboxylic acids and derivatives An ACE inhibitor antihypertensive drug used to 
treat hypertension 
Sudachiin B HMDB39087 Flavanoids Found in citrus 
Sudachiin C HMDB39088 Not classified Found in citrus 
Sugeonol HMDB41036 Prenol lipids Found in root vegetables 
Sulcatone HMDB35915 Carbonyl compounds Found in citrus 
Sumatriptan HMDB05037 Indoles and derivatives Used in the treatment of migraine to stabilise 
serotonin levels in the brain 
Taxiphyllin HMDB30704 Carbohydrates and carbohydrate conjugates Found in plants 
Teniposide catechol derivative HMDB61336 Lignan lactones A semisynthetic derivative of podophyllotoxin 
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Tenofovir Monophosphate HMDB61280 Imidazopyimidines Belongs to a class of antiretroviral drugs known as 
nucleotide analogue reverse transcriptase inhibitors 
Tetrahydro-2,5-furan-diacetic acid HMDB59767 Dicarboxylic acids and derivatives A dicarboxylic acid 
TG(14:0/14:1(9Z)/18:4(6Z,9Z,12Z,15Z)) HMDB42295 Not classified A dimyristoleic acid triglyceride 
TG(14:0/18:4(6Z,9Z,12Z,15Z)/14:1(9Z)) HMDB42788 Not classified A dimyristoleic acid triglyceride 
TG(14:1(9Z)/14:0/18:4(6Z,9Z,12Z,15Z)) HMDB47741 Not classified A dimyristoleic acid triglyceride 
TG(14:1(9Z)/14:1(9Z)/18:3(6Z,9Z,12Z)) HMDB47894 Not classified A dimyristoleic acid triglyceride 
TG(14:1(9Z)/14:1(9Z)/18:3(9Z,12Z,15Z)) HMDB47901 Not classified A dimyristoleic acid triglyceride 
TG(14:1(9Z)/18:3(6Z,9Z,12Z)/14:1(9Z)) HMDB48092 Not classified A dimyristoleic acid triglyceride 
TG(14:1(9Z)/18:3(9Z,12Z,15Z)/14:1(9Z)) HMDB48253 Not classified A dimyristoleic acid triglyceride 
Thiabendazole HMDB14868 Benzimidazoles Treatment against nematodes 
Threonine HMDB00167 Fatty acyls Essential amino acid 
Tiludronate HMDB15265 Organic phosphonic acids and derivatives A bisphosphonate medication 
Trabectedin metabolite M8b (ET-729) HMDB61254 Benzene and substituted derivatives A marine derived antitumoral agent 
Tracheloside HMDB30557 Not classified Found in fats nd oils 
Tramadol HMDB14339 Benzene and substituted derivatives Narcotic analgesic 
trans-2-Octenoic acid HMDB01568 Fatty acyl Medium chain fatty acid 
Turicine HMDB29409 Carboxylic acids and derivatives A constituent of jack bean 
Urea HMDB00294 Organic carbonic acids and derivatives Formed in the liver from ammonia 
Uric acid HMDB00289 Not available (Super Class Alkanoids and 
derivative) 
A heterocyclic purine derivative that is the final 
oxidation product of purine metabolism 
Valerylcarnitine HMDB13128 Fatty acyls An acyl carniti e 
Valerylglycine HMDB00927 Carboxylic acids and derivati es An acyl glycine, normally a minor metabolite of 
fatty acids 
Valproic acid glucuronide HMDB00901 Carbohydrates and carbohydrate conjugates The glucuronidation product of valproic acid 
Valpronic acid beta-O-glucuronide HMDB60889 O-glucuronides The glucuronidation product of valproic acid 
Valyl-Lysine HMDB29132 Not classified A dipeptide composed of valine and lysine 
Vignatic acid A HMDB33599 Carboxylic acids and derivat ves Found in pulses 
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xi-Tetrahydro-3-propyl-2H-pyran-2-one HMDB37630 Lactones Found in fruits 
Yucalexin A16 HMDB36775 Prenol lipids Found in root vegetables 
Yucalexin B14 HMDB36709 Prenol lipids Found in root vegetables 
Zerumbone oxide HMDB36466 Carbonyl compounds Found in herbs and spices 
Zileuton sulfoxide HMDB13969 Not classified Drug metabolite used in the treatment of asthma 
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